PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Capturing genes	SCIENCE			English	Article																		Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297	1	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2143	2143						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432724				2022-12-28	WOS:A1997YM23500059
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Cell shocked	SCIENCE			English	Article																		Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077	2	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2143	&						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432724				2022-12-28	WOS:A1997YM23500060
J	Raghunathan, PL; Guthrie, C				Raghunathan, PL; Guthrie, C			A spliceosomal recycling factor that reanneals U4 and U6 small nuclear ribonucleoprotein particles	SCIENCE			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; SPLICING MUTANTS; SNRNP PROTEIN; TRI-SNRNP; YEAST; BINDING; STEP; U2	The spliceosome removes introns from pre-messenger RNAs by a mechanism that entails extensive remodeling of RNA structure, The most conspicuous rearrangement involves disruption of 24 base pairs between U4 and U6 small nuclear RNAs (snRNAs). Here, the yeast RNA binding protein Prp24 is shown to reanneal these snRNAs, When Prp24 is absent, unpaired U4 and U6 small nuclear ribonucleoprotein particles (snRNPs) accumulate; with time, splicing becomes inhibited. Addition of purified Prp24 protein regenerates duplex U4/U6 snRNPs for new rounds of splicing. The reannealing reaction catalyzed by Prp24 proceeds more efficiently with snRNPs than with deproteinized snRNAs.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Guthrie, C (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	guthrie@cgl.ucsf.edu			NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; ELLEDGE SJ, GENE, V70, P303; FORTNER DM, 1994, GENE DEV, V8, P221, DOI 10.1101/gad.8.2.221; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; GHETTI A, 1995, RNA, V1, P132; Guthrie C, 1991, GUIDE YEAST GENETICS; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; LI ZR, 1993, NUCLEIC ACIDS RES, V21, P4645, DOI 10.1093/nar/21.19.4645; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; Moore M., 1993, RNA WORLD, P303; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; RAGHUNATHAN PL, UNPUB; RAGHUNATHAN PL, 1997, THESIS U SAN FRANCIS; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571	40	119	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					857	860		10.1126/science.279.5352.857	http://dx.doi.org/10.1126/science.279.5352.857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452384				2022-12-28	WOS:000071923500042
J	Korzus, E; Torchia, J; Rose, DW; Xu, L; Kurokawa, R; McInerney, EM; Mullen, TM; Glass, CK; Rosenfeld, MG				Korzus, E; Torchia, J; Rose, DW; Xu, L; Kurokawa, R; McInerney, EM; Mullen, TM; Glass, CK; Rosenfeld, MG			Transcription factor-specific requirements for coactivators and their acetyltransferase functions	SCIENCE			English	Article							YEAST PUTATIVE ADAPTERS; CREB-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; CO-REPRESSOR; ACTIVATION; CBP; P300; IDENTIFICATION; COMPLEX	Different classes of mammalian transcription factors-nuclear receptors, cyclic adenosine 3',5'-monophosphate-regulated enhancer binding protein (CREB), and signal transducer and activator of transcription-1 (STAT-1)-functionally require distinct com ponents of the coactivator complex, including CREB-binding protein (CBP/p300), nuclear receptor coactivators (NCoAs), and p300/CBP-associated factor (p/CAF), based on their platform or assembly properties. Retinoic acid receptor, CREB, and STAT-1 also require different histone acetyltransferase (HAT) activities to activate transcription. Thus, transcription factor-specific differences in configuration and content of the coactivator complex dictate requirements for specific acetyltransferase activities, providing an explanation, at least in part, for the presence of multiple HAT components of the complex.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; MULLEN, Tina-Marie/0000-0001-6150-8084				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Candau R, 1996, MOL CELL BIOL, V16, P593; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HONG M, 1997, MOL CELL BIOL, V17, P2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KORZUS E, UNPUB; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHERTY OD, 1997, CELL, V89, P349; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Moore DD, 1995, GLOB MOB SURV; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	54	542	551	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					703	707		10.1126/science.279.5351.703	http://dx.doi.org/10.1126/science.279.5351.703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445475				2022-12-28	WOS:000071731500036
J	Chan, JM; Stampfer, MJ; Giovannucci, E; Gann, PH; Ma, J; Wilkinson, P; Hennekens, CH; Pollak, M				Chan, JM; Stampfer, MJ; Giovannucci, E; Gann, PH; Ma, J; Wilkinson, P; Hennekens, CH; Pollak, M			Plasma insulin-like growth factor I and prostate cancer risk: A prospective study	SCIENCE			English	Article							BODY-MASS INDEX; BINDING-PROTEINS; HORMONE; SEX; ADOLESCENTS; CHILDREN; ANTIGEN; CELLS; STAGE; AGE	Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells. To investigate associations between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' Health Study was conducted on prospectively collected plasma from 152 cases and 152 controls. A strong positive association was observed between IGF-I levels and prostate cancer risk. Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 percent confidence interval 1.8 to 10.6) compared with men in the lowest quartile. This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Oncol,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Northwestern University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chan, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	jmlchan@hsph.harvard.edu	Wilkinson, Peter/AAK-6426-2020; Pollak, Michael/G-9094-2011	Wilkinson, Peter/0000-0002-1365-0470; Pollak, Michael/0000-0003-3047-0604; Chan, June/0000-0002-7620-569X	NATIONAL CANCER INSTITUTE [R01CA058684, T32CA009001, R01CA042182] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09001-20, CA-42182, CA-58684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson SO, 1997, JNCI-J NATL CANCER I, V89, P385, DOI 10.1093/jnci/89.5.385; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Giovannucci E, 1997, CANCER EPIDEM BIOMAR, V6, P557; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Hebert PR, 1997, CANCER CAUSE CONTROL, V8, P591, DOI 10.1023/A:1018442329319; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; LAVECCHIA C, 1990, INT J CANCER, V45, P275, DOI 10.1002/ijc.2910450212; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P82; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; TIBLJIN G, 1995, EPIDEMIOLOGY, V6, P423; ZARANDI M, 1994, P NATL ACAD SCI USA, V91, P12298, DOI 10.1073/pnas.91.25.12298	28	1640	1729	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					563	566		10.1126/science.279.5350.563	http://dx.doi.org/10.1126/science.279.5350.563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438850				2022-12-28	WOS:000071616000047
J	Hirokawa, N				Hirokawa, N			Kinesin and dynein superfamily proteins and the mechanism of organelle transport	SCIENCE			English	Review							ANTEROGRADE AXONAL-TRANSPORT; MICROTUBULE-BASED MOTILITY; CYTOPLASMIC MOTOR ENZYME; BOVINE BRAIN KINESIN; HEAVY-CHAIN; MEMBRANOUS ORGANELLES; C-ELEGANS; PLUS-END; IN-VIVO; HETEROTRIMERIC KINESIN	Cells transport and sort proteins and lipids, after their synthesis, to various destinations at appropriate velocities in membranous organelles and protein complexes. Intracellular transport is thus fundamental to cellular morphogenesis and functioning. Microtubules serve as a rail on which motor proteins, such as kinesin and dynein superfamily proteins, convey their cargoes. This review focuses on the molecular mechanism of organelle transport in cells and describes kinesin and dynein superfamily proteins.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Hongo 7-3-1, Tokyo, Japan.	hirokawa@m.u-tokyo.ac.jp						AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; BLOOM GS, 1993, J CELL BIOL, V120, P467, DOI 10.1083/jcb.120.2.467; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; COLE DG, 1992, J CELL SCI, V101, P291; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DAVARAJAN P, 1996, J CELL BIOL, V133, P819; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; ENDOW SA, 1991, P NATL ACAD SCI USA, V88, P4424, DOI 10.1073/pnas.88.10.4424; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GIBBONS BH, 1994, MOL BIOL CELL, V5, P57, DOI 10.1091/mbc.5.1.57; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hanlon DW, 1997, NEURON, V18, P439, DOI 10.1016/S0896-6273(00)81244-1; Harada A., UNPUB; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; HOLZBAUER ELF, 1994, ANN REV CELL BIOL, V10, P338; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1992, J CELL SCI, V101, P125; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; Muresan V, 1996, J CELL BIOL, V135, P383, DOI 10.1083/jcb.135.2.383; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; PESAVENTO PA, 1994, J CELL BIOL, V127, P1041, DOI 10.1083/jcb.127.4.1041; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RASHID DJ, 1995, J MOL BIOL, V252, P157, DOI 10.1006/jmbi.1995.0484; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; SatoHarada R, 1996, CELL STRUCT FUNCT, V21, P283, DOI 10.1247/csf.21.283; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; SHROER TA, 1989, CELL, V56, P937; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singer RH, 1996, TRENDS CELL BIOL, V6, P486, DOI 10.1016/0962-8924(96)84947-6; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; TANAKA Y, 1995, J CELL SCI, V108, P1883; Terada S, 1996, SCIENCE, V273, P784, DOI 10.1126/science.273.5276.784; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VALLEE RB, 1995, COLD SPRING HARB SYM, V60, P87969; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; WANG SZ, 1995, J CELL BIOL, V128, P761, DOI 10.1083/jcb.128.5.761; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; Wedaman KP, 1996, J CELL BIOL, V132, P371, DOI 10.1083/jcb.132.3.371; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Yang ZH, 1997, GENOMICS, V45, P123, DOI 10.1006/geno.1997.4901; YONEKAWA Y, UNPUB; YU H, 1992, J BIOL CHEM, V267, P20457; ZHANG ZZ, 1993, P NATL ACAD SCI USA, V90, P7928, DOI 10.1073/pnas.90.17.7928	123	1327	1367	7	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					519	526		10.1126/science.279.5350.519	http://dx.doi.org/10.1126/science.279.5350.519			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438838				2022-12-28	WOS:000071616000035
J	Kodish, E; Wiesner, GL; Mehlman, M; Murray, T				Kodish, E; Wiesner, GL; Mehlman, M; Murray, T			Genetic testing for cancer risk - How to reconcile the conflicts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; BREAST-CANCER; BRCA1; MUTATIONS		Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Law Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Ctr Biomed Eth, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Ctr Human Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Law Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Ctr Biomed Eth, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Kodish, E (corresponding author), Rainbow Babies & Childrens Hosp, 11100 Euclid Ave,RBC 310, Cleveland, OH 44106 USA.							BAKER SG, 1995, J NATL CANCER I, V87, P1137, DOI 10.1093/jnci/87.15.1137; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Khoury MJ, 1996, AM J PUBLIC HEALTH, V86, P1717, DOI 10.2105/AJPH.86.12.1717; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1996, Oncology (Williston Park), V10, P191; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Mehlman MJ, 1996, AM J HUM GENET, V58, P393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peters J A, 1996, Oncology (Williston Park), V10, P159; RICCARDI VA, 1996, HUMAN GENOME PROJECT, P21; Rimer Barbara K., 1997, P619; ROTHSTEIN MA, 1995, MONOGRAPH NCI, V17, P87; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *US DEP HHS, 1997, UND GEN TEST	25	26	26	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					179	181		10.1001/jama.279.3.179	http://dx.doi.org/10.1001/jama.279.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438721				2022-12-28	WOS:000071460700001
J	McCall, K; Steller, H				McCall, K; Steller, H			Requirement for DCP-1 caspase during Drosophila oogenesis	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; NUCLEAR LAMIN ISOFORMS; NONMUSCLE MYOSIN-II; DNA FRAGMENTATION; EGG CHAMBER; APOPTOSIS; GENE; INTERCONVERSION; EMBRYOGENESIS; DEGRADATION	Caspases, a class of cysteine proteases, are an essential component of the apoptotic cell death program. During Drosophila oogenesis, nurse cells transfer their cytoplasmic contents to developing oocytes and then die. Loss of function for the dcp-l gene, which encodes a caspase, caused female sterility by inhibiting this transfer. dcp-1(-) nurse cells were defective in the cytoskeletal reorganization and nuclear breakdown that normally accompany this process. The dcp-1(-) phenotype suggests that the cytoskeletal and nuclear events in the nurse cells make use of the machinery normally associated with apoptosis and that apoptosis of the nurse cells is a necessary event for oocyte development.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Dept Biol, 31 Ames St,68-430, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou TB, 1996, GENETICS, V144, P1673; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; COTTER TG, 1992, CANCER RES, V52, P997; DeFelici M, 1997, CELL DEATH DIFFER, V4, P169, DOI 10.1038/sj.cdd.4400237; Edwards KA, 1996, DEVELOPMENT, V122, P1499; FOLEY KM, UNPUB; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; GUTZEIT HO, 1986, J CELL SCI, V80, P159; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King R. C., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Moir RD, 1995, INT REV CYTOL, V162B, P141; NEAMATI N, 1995, J IMMUNOL, V154, P3788; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OKADA E, 1959, J EMBRYOL EXP MORPH, V7, P583; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; RIEMER D, 1995, J CELL SCI, V108, P3189; RUBY JR, 1969, J MORPHOL, V127, P307, DOI 10.1002/jmor.1051270304; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SMITH DE, 1989, J CELL BIOL, V108, P255, DOI 10.1083/jcb.108.2.255; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; Song Z., UNPUB; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TOURMENTE S, 1990, BIOL CELL, V68, P119, DOI 10.1016/0248-4900(90)90296-F; VERHEYEN E, 1994, METHOD CELL BIOL, V44, P545, DOI 10.1016/S0091-679X(08)60931-0; WHEATLEY S, 1995, DEVELOPMENT, V121, P1937; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276; [No title captured]	53	142	145	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					230	234		10.1126/science.279.5348.230	http://dx.doi.org/10.1126/science.279.5348.230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422696				2022-12-28	WOS:000071408100043
J	Adrogue, HJ; Madias, NE				Adrogue, HJ; Madias, NE			Management of life-threatening acid-base disorders - Second of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC RESPIRATORY ALKALOSIS; METABOLIC ALKALOSIS; CHRONIC HYPOCAPNIA; HYPOKALEMIA; EQUILIBRIUM; H+		New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Vet Affairs Med Ctr, Renal Sect, Houston, TX 77030 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Tufts University; Tufts Medical Center	Madias, NE (corresponding author), New England Med Ctr, Div Nephrol, Box 172,750 Washington St, Boston, MA 02111 USA.							BUSHINSKY DA, 1978, ANN INTERN MED, V89, P632, DOI 10.7326/0003-4819-89-5-632; COHEN JJ, 1976, J CLIN INVEST, V57, P1483, DOI 10.1172/JCI108418; COLUSSI G, 1994, AM J NEPHROL, V14, P127, DOI 10.1159/000168701; Gennari FJ, 1982, ACID BASE, P349; HARRINGTON JT, 1986, KIDNEY INT, V30, P43, DOI 10.1038/ki.1986.148; HARRINGTON JT, 1982, ACID BASE, P227; HENE RJ, 1987, AM J KIDNEY DIS, V9, P200, DOI 10.1016/S0272-6386(87)80055-0; HILDEN SA, 1989, AM J PHYSIOL, V257, pF615, DOI 10.1152/ajprenal.1989.257.4.F615; KNUTSEN OH, 1983, LANCET, V1, P953; KRAPF R, 1991, NEW ENGL J MED, V324, P1394, DOI 10.1056/NEJM199105163242003; MADIAS NE, 1983, AM J MED, V74, P155, DOI 10.1016/0002-9343(83)91133-6; MADIAS NE, 1990, AM J PHYSIOL, V258, pF479, DOI 10.1152/ajprenal.1990.258.3.F479; MADIAS NE, 1979, NEW ENGL J MED, V300, P1421, DOI 10.1056/NEJM197906213002507; Rimmer JM, 1987, J INTENSIVE CARE MED, V2, P137; SHIRES GT, 1989, PRINCIPLES SURG, P69; VINCI JM, 1978, J CLIN INVEST, V61, P1671, DOI 10.1172/JCI109088; WEIL MH, 1986, NEW ENGL J MED, V315, P153, DOI 10.1056/NEJM198607173150303	17	101	104	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					107	111		10.1056/NEJM199801083380207	http://dx.doi.org/10.1056/NEJM199801083380207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420343				2022-12-28	WOS:000071341300007
J	Stelfox, HT; Chua, G; O'Rourke, K; Detsky, AS				Stelfox, HT; Chua, G; O'Rourke, K; Detsky, AS			Conflict of interest in the debate over calcium-channel antagonists	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; GASTROINTESTINAL HEMORRHAGE; ARTERY DISEASE; BLOCKERS; NIFEDIPINE; HYPERTENSION; MORTALITY; RISK; SAFE	Background Physicians' financial relationships with the pharmaceutical industry are controversial because such relationships may pose a conflict of interest. It is unknown to what extent industry support of medical education and research influences the opinions and behavior of clinicians and researchers. The recent debate over the safety of calcium-channel antagonists provided an opportunity to examine the effect of financial conflicts of interest. Methods We searched the English-language medical literature published from March 1995 through September 1996 for articles examining the controversy about the safety of calcium-channel antagonists. Articles were reviewed and classified as being supportive, neutral, or critical with respect to the use of calcium-channel antagonists. The authors of the articles were asked about their financial relationships with bath manufacturers of calcium-channel antagonists and manufacturers of competing products (i.e., beta-blockers, angiotensin-converting-enzyme inhibitors, diuretics, and nitrates). We examined the authors' published positions on the safety of calcium-channel antagonists according to their financial relationships with pharmaceutical companies. Results Authors who supported the use of calcium-channel antagonists were significantly more likely than neutral or critical authors to have financial relationships with manufacturers of calcium-channel antagonists (96 percent, vs. 60 percent and 37 percent, respectively; P<0.001). Supportive authors were also more likely than neutral or critical authors to have financial relationships with any pharmaceutical manufacturer, irrespective of the product (100 percent, vs. 67 percent and 43 percent, respectively; P<0.001). Conclusions Our results demonstrate a strong association between authors' published positions on the safety of calcium-channel antagonists and their financial relationships with pharmaceutical manufacturers. The medical profession needs to develop a more effective policy on conflict of interest. We support complete disclosure of relationships with pharmaceutical manufacturers for clinicians and researchers who write articles examining pharmaceutical products. (C) 1998, Massachusetts Medical Society.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Adm, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Toronto Hosp, Dept Med, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, Rm 427,600 Univ Ave, Toronto, ON M5G 1X5, Canada.			Stelfox, Henry/0000-0003-1231-1490				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Angeli M, 1996, NEW ENGL J MED, V335, P1055, DOI 10.1056/NEJM199610033351410; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Barlow, 1972, STAT INFERENCE ORDER; Barnett AA, 1996, LANCET, V347, P313; Blandino DA, 1996, JAMA-J AM MED ASSOC, V275, P516; BROWN MJ, 1995, LANCET, V346, P768; Buring JE, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.1996.03530310021017; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Cooper RS, 1996, JAMA-J AM MED ASSOC, V275, P515, DOI 10.1001/jama.1996.03530310021014; COOPER RS, 1995, LANCET, V346, P961; Cox DR., 1989, ANAL BINARY DATA; Dargie HJ, 1996, LANCET, V348, P488, DOI 10.1016/S0140-6736(05)64663-6; DARGIE HJ, 1996, LANCET, V348, P694; ELLIOTT HL, 1995, LANCET, V346, P1421, DOI 10.1016/S0140-6736(95)92433-7; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; FAGAN TC, 1995, ARCH INTERN MED, V155, P2145, DOI 10.1001/archinte.155.20.2145; Feeman WE, 1996, JAMA-J AM MED ASSOC, V275, P515, DOI 10.1001/jama.1996.03530310021013; FERRARI D, 1996, AM J CARDIOL, V77, pD22; Frohlich E D, 1995, J La State Med Soc, V147, P343; Frohlich ED, 1996, HYPERTENSION, V27, P317, DOI 10.1161/01.HYP.27.3.317; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, J AM GERIATR SOC, V43, P1309, DOI 10.1111/j.1532-5415.1995.tb07411.x; FURBERG CD, 1995, ARCH INTERN MED, V155, P2157, DOI 10.1001/archinte.155.20.2157; Furberg CD, 1996, EUR HEART J, V17, P1142; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Furberg CD, 1996, CIRCULATION, V93, P1473; Furberg CD, 1996, CIRCULATION, V93, P1474; Ghali WA, 1996, ANN INTERN MED, V125, P518, DOI 10.7326/0003-4819-125-6-199609150-00029; GIFFORD RW, 1995, CLEV CLIN J MED, V62, P348, DOI 10.3949/ccjm.62.6.348; GOODMAN S, 1996, UPDATE CALCIUM ANTAG; Gordon RD, 1996, LANCET, V347, P1056, DOI 10.1016/S0140-6736(96)90269-X; HABIB GB, 1995, CHEST, V108, P3, DOI 10.1378/chest.108.1.3; Hardell L, 1996, LANCET, V348, P542, DOI 10.1016/S0140-6736(05)64695-8; HORTON R, 1995, LANCET, V346, P891, DOI 10.1016/S0140-6736(95)92717-4; HORTON R, 1995, LANCET, V346, P770; HORTON R, 1995, LANCET, V346, P586, DOI 10.1016/S0140-6736(95)91429-3; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023019; Kaplan NM, 1996, LANCET, V348, P541, DOI 10.1016/S0140-6736(96)24034-6; Kaplan NM, 1996, AM J CARDIOL, V77, P81, DOI 10.1016/S0002-9149(97)89139-4; KLONER RA, 1995, CIRCULATION, V92, P1074, DOI 10.1161/01.CIR.92.5.1074; LICHTLEN PR, 1995, LANCET, V346, P962; Lichtlen PR, 1996, CIRCULATION, V93, P1472; Lip GYH, 1996, LANCET, V347, P1761; LUCAS BD, 1995, ANN PHARMACOTHER, V29, P629, DOI 10.1177/106002809502900615; MacCarthy EP, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023020; MACDONALD G, 1995, LANCET, V346, P768; Mancia G, 1996, J HYPERTENS, V14, P13; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P423, DOI 10.1001/jama.275.6.423; MARWICK C, 1996, JAMA-J AM MED ASSOC, V275, P1638; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; Mehta JL, 1996, CIRCULATION, V93, P1472; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; MESSERLI FH, 1995, LANCET, V346, P767, DOI 10.1016/S0140-6736(95)91526-5; Messerli FH, 1996, ANN INTERN MED, V125, P519, DOI 10.7326/0003-4819-125-6-199609150-00031; Messerli FH, 1996, J AM COLL CARDIOL, V28, P12, DOI 10.1016/0735-1097(96)00171-4; Messerli Franz H., 1996, Journal of the American College of Cardiology, V27, p319A; MONGE JC, 1996, SAFETY ANTIHYPERTENS; OPIE LH, 1995, CIRCULATION, V92, P1068, DOI 10.1161/01.CIR.92.5.1068; OPIE LH, 1995, LANCET, V346, P961; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Pahor M, 1996, LANCET, V348, P541, DOI 10.1016/S0140-6736(05)64694-6; Parmley WW, 1996, J AM COLL CARDIOL, V27, P1820; Parmley WW, 1996, J AM COLL CARDIOL, V27, P510, DOI 10.1016/0735-1097(95)00601-X; PHILLIPS BG, 1995, AM J HEALTH-SYST PH, V52, P1460, DOI 10.1093/ajhp/52.13.1460; Pilotto A, 1996, LANCET, V347, P1761; PooleWilson PA, 1996, EUR HEART J, V17, P1131; POOLEWILSON PA, 1995, LANCET, V346, P769; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BM, 1996, LANCET, V347, P1761, DOI 10.1016/S0140-6736(96)90837-5; Psaty BM, 1996, JAMA-J AM MED ASSOC, V275, P516, DOI 10.1001/jama.1996.03530310021016; Psaty BM, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023021; Rafflenbeul W, 1996, EUR HEART J, V17, P1147; RAFFLENBEUL W, 1996, CIRCULATION, V493, P1473; Ryden L, 1996, EUR HEART J, V17, P1; SCHUBERT T, 1995, LANCET, V346, P961, DOI 10.1016/S0140-6736(95)91580-X; Smith G N, 1996, J Fam Pract, V42, P30; *STAT SCI, 1995, S PLUS GUID STAT MAT; Stryer DB, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.275.7.517; Tierney WM, 1996, ANN INTERN MED, V125, P519, DOI 10.7326/0003-4819-125-6-199609150-00030; Tijssen JGP, 1996, EUR HEART J, V17, P1152; Walker AM, 1996, LANCET, V348, P489, DOI 10.1016/S0140-6736(05)64664-8; Walker AM, 1996, AM J CARDIOL, V78, P380; YUSUF S, 1995, CIRCULATION, V92, P1079, DOI 10.1161/01.CIR.92.5.1079; 1996, LANCET, V348, P487	89	441	457	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					101	106		10.1056/NEJM199801083380206	http://dx.doi.org/10.1056/NEJM199801083380206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420342	Bronze			2022-12-28	WOS:000071341300006
J	Korenman, SG; Berk, R; Wenger, NS; Lew, V				Korenman, SG; Berk, R; Wenger, NS; Lew, V			Evaluation of the research norms of scientists and administrators responsible for academic research integrity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCIENCE; PERCEPTIONS; MISCONDUCT	Context.-The professional integrity of scientists is important to society as a whole and particularly to disciplines such as medicine that depend heavily on scientific advances for their progress. Objective.-To characterize the professional norms of active scientists and compare them with those of individuals with institutional responsibility for the conduct of research. Design.-A mailed survey consisting of 12 scenarios in 4 domains of research ethics. Respondents were asked whether an act was unethical and, if so, the degree to which they considered it unethical and to select responses and punishments for the act. Participants.-A total of 924 National Science Foundation research grantees in 1993 or 1994 in molecular or cellular biology and 140 representatives from the researchers' institutions to the US Department of Health and Human Services Office of Research Integrity. Main Outcome Measures.-Percentage of respondents considering an act unethical and the mean malfeasance rating on a scale of 1 to 10. Results.-A total of 606 research grantees and 91 institutional representatives responded to the survey (response rate of 69% of those who could be contacted). Respondents reported a hierarchy of unethical research behaviors. The mean malfeasance rating was unrelated to the characteristics of the investigator performing the hypothetical act or to its consequences. Fabrication, falsification, and plagiarism received malfeasance ratings higher than 8.6, and virtually all thought they were unethical. Deliberately misleading statements about a paper or failure to give proper attribution received ratings between 7 and 8. Sloppiness, oversights, conflicts of interest, and failure to share were less serious still, receiving malfeasance ratings between 5 and 6. Institutional representatives proposed more and different interventions and punishments than the scientists. Conclusions.-Surveyed scientists and institutional representatives had strong and similar norms of professional behavior, but differed in their approaches to an unethical act.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Korenman, SG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 52-242 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.							ANDERSON MS, 1994, RES HIGH EDUC, V35, P273, DOI 10.1007/BF02496825; BERK RA, 1995, CLIMATIC CHANGE, V29, P1, DOI 10.1007/BF01091637; BORQUE LB, 1989, DEFINING RAPE; Bryk A. S., 1992, HIERARCHICAL LINEAR; Buzzelli DE, 1996, SCIENCE, V272, P937; COHEN J, 1995, SCIENCE, V268, P1715, DOI 10.1126/science.7792594; COURNAND A, 1977, SCIENCE, V198, P699, DOI 10.1126/science.910153; Grinnell F, 1996, SCIENCE, V272, P333, DOI 10.1126/science.272.5260.333; Guenin LM, 1996, ACAD MED, V71, P595, DOI 10.1097/00001888-199606000-00010; HAMILTON DP, 1992, SCIENCE, V255, P1636, DOI 10.1126/science.11642983; HOX JJ, 1991, SOCIOL METHOD RES, V19, P493, DOI 10.1177/0049124191019004003; KALICHMAN MW, 1992, ACAD MED, V67, P769, DOI 10.1097/00001888-199211000-00015; Merton Robert K., 1942, J LEGAL POLITICAL SO, V1, P115; Miller D.J., 1992, RES FRAUD BEHAV BIOM; *MIT, 1995, FOST AC INT; *OFF SCI INT REV, 1992, DRAFT STAND RESP CON; Rossi P. H., 1982, MEASURING SOCIAL JUD; ROSSI PH, 1985, AM SOCIOL REV, V50, P333, DOI 10.2307/2095543; ROSSI PH, 1997, JUST PUNISHMENT; RYAN KJ, 1995, COMMUNICATION   1015; RYAN KJ, 1995, INTEGRITY MISCONDUCT; *US DEP HHS, 1986, NIH GUIDE GRANTS CON, V15, P1; US Public Health Service, 1989, Fed Regist, V54, P32446; Wenger NS, 1997, J INVEST MED, V45, P371; WONG GY, 1985, J AM STAT ASSOC, V80, P513, DOI 10.2307/2288464; 1992, RESPONSIBLE SCI ENSU; 1995, BEING SCI RESPONSIBL; 1991, FED REG, V56, P22286	28	42	42	1	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					41	47		10.1001/jama.279.1.41	http://dx.doi.org/10.1001/jama.279.1.41			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YP607	9424042				2022-12-28	WOS:000071295100033
J	Weiss, HB; Friedman, DI; Coben, JH				Weiss, HB; Friedman, DI; Coben, JH			Incidence of dog bite injuries treated in emergency departments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Pennsylvania-Public-Health-Association Annual Meeting	OCT   01, 1996	PITTSBURGH, PENNSYLVANIA	Penn Public Hlth Assoc			CHILDREN	Context.-Dog bites that result in injuries occur frequently, but how frequently dog bite injuries necessitate medical attention at a hospital or hospital admission is unknown. Objective.-To describe the incidence and characteristics of dog bite injuries treated in US emergency departments (EDs). Design.-Emergency department survey from the National Center for Health Statistics National Hospital Ambulatory Medical Care Survey for 1992 to 1994. Patients.-National probability sample of patients visiting EDs. Main Outcome Measure.-Incidence of dog bites treated in EDs, defined as a cause of injury recorded as the E-code E906.0. Results.-The 3-year annualized, adjusted, and weighted estimate of new dog bite-related injury visits to US EDs was 333 687, a rate of 12.9 per 10 000 persons (95% confidence interval [CI], 10.5-15.4). This represents approximately 914 new dog bite injuries requiring ED visits per day. The median age of patients bitten was 15 years, with children, especially boys aged 5 to 9 years, having the highest incidence rate (60.7 per 10 000 persons for boys aged 5 to 9 years). Children seen in EDs were more likely than older persons to be bitten on the face, neck, and head (73% vs 30%). We estimated that for each US dog bite fatality there are about 670 hospitalizations and 16000 ED visits. Conclusions.-Dog bite injuries are an important source of injury in the US population, especially among children. Improved surveillance and prevention of dog bite-related injuries, particularly among children, are needed.	Univ Pittsburgh, Ctr Injury Res & Control, Dept Emergency Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weiss, HB (corresponding author), Allegheny Univ Hlth Sci, Ctr Violence & Injury Control, Dept Emergency Med, 1 Allegheny Ctr,Suite 510,320 E North Ave, Pittsburgh, PA 15212 USA.		Weiss, Hank/D-1052-2010		PHS HHS [MCH-424002-01-0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGHABABIAN RV, 1980, ANN EMERG MED, V9, P79, DOI 10.1016/S0196-0644(80)80335-0; AVNER JR, 1991, PEDIATRICS, V88, P55; BECK AM, 1975, PUBLIC HEALTH REP, V90, P262; BECK AM, 1985, PUBLIC HEALTH REP, V100, P315; BROGAN TV, 1995, PEDIATRICS, V96, P947; BURT CW, 1995, ADV DATA VITAL HLTH, V261; CHIN Y, 1982, PEDIATRICS, V69, P119; DAVIS SJM, 1978, NATURE, V276, P608, DOI 10.1038/276608a0; GERSHMAN KA, 1994, PEDIATRICS, V93, P913; KIZER KW, 1979, JACEP-J AM COLL EMER, V8, P134, DOI 10.1016/S0361-1124(79)80339-1; LANGLEY J, 1992, NEW ZEAL MED J, V105, P33; MCCAIG LF, 1994, ADV DATA VITAL HLTH, V245; PEEL MM, 1993, PATHOLOGY, V25, P379, DOI 10.3109/00313029309090863; Pickney LE, 1982, PEDIATRICS, V69, P193; Sacks J J, 1996, Inj Prev, V2, P52, DOI 10.1136/ip.2.1.52; SACKS JJ, 1989, JAMA-J AM MED ASSOC, V262, P1489, DOI 10.1001/jama.262.11.1489; Sacks JJ, 1996, PEDIATRICS, V97, P891; Scarcella J V, 1969, Ohio State Med J, V65, P25; SOKOL AB, 1971, CLIN PEDIATR, V10, P336, DOI 10.1177/000992287101000616; STUSSMAN BJ, 1996, ADV DATA VITAL HLTH, V271; *US CONS PROD SAF, 1992, 009207 US CONS PROD; WISE JK, 1994, J AM VET MED ASSOC, V204, P1166; 1996, CONSUMER PRODUCT SUM, V1, P5	23	274	285	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					51	53		10.1001/jama.279.1.51	http://dx.doi.org/10.1001/jama.279.1.51			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424044				2022-12-28	WOS:000071295100035
J	Goldman, A				Goldman, A			ABC of palliative care - Special problems of children	BRITISH MEDICAL JOURNAL			English	Review									Great Ormond St Hosp Children, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Goldman, A (corresponding author), Great Ormond St Hosp Children, Great Ormond St, London WC1N 3JH, England.							*ACT ROYAL COLL PR, 1997, HLTH GUID DEV CHILDR; *ROYAL COLL PAED C, 1997, PREV CONTR PAIN CHIL	2	53	54	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					49	52		10.1136/bmj.316.7124.49	http://dx.doi.org/10.1136/bmj.316.7124.49			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451269	Green Published			2022-12-28	WOS:000071377900027
J	Doppman, JL; Oldfield, EH; Nieman, LK				Doppman, JL; Oldfield, EH; Nieman, LK			Bilateral sampling of the internal jugular vein to distinguish between mechanisms of adrenocorticotropic hormone-dependent Cushing syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							INFERIOR PETROSAL SINUS; CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; CAVERNOUS SINUS; ACTH; OVERNIGHT	Background: Bilateral sampling of the petrosal sinuses to distinguish Cushing disease from the ectopic adrenocorticotropic hormone (ACTH) syndrome is accurate but technically demanding and risky. Bilateral sampling of the internal jugular vein is simpler and safer. Objective: To compare bilateral internal jugular vein sampling with bilateral inferior petrosal sinus sampling for distinguishing patients with Cushing disease from those with the ectopic ACTH syndrome. Setting: Tertiary referral hospital. Patients: 20 patients with surgically proven Cushing disease and 1 patient with proven ectopic ACTH syndrome. Intervention: All patients underwent petrosal sinus sampling and jugular vein sampling before and after administration of corticotropin-releasing hormone (CRH) on separate days. Measurements: Ratios of central ACTH to peripheral ACTH in petrosal sinus samples and jugular vein samples were calculated before and after administration of CRH. Results: Ratios of central to peripheral ACTH were diagnostic for Cushing disease (>2 before administration of CRH and >3 after administration of CRH) in jugular vein samples from 16 of 20 patients with surgically proven Cushing disease (sensitivity, 80% [95% CI, 56% to 96%]). Ten of these 16 patients (63%) had diagnostic results only after CRH was administered. The average ratio of central to peripheral ACTH in jugular vein samples was 2.7 before CRH and 7.7 after CRH. Ratios of central to peripheral ACTH were diagnostic in petrosal sinus samples from 19 of 20 patients with surgically proven Cushing disease (sensitivity, 95% [CI, 75% to 99%]). Samples from all 19 patients had diagnostic ratios before and after administration of CRH. The average ratio of central to peripheral ACTH in petrosal sinus samples was 17.7 before CRH and 90.0 after CRH. In the patient with the ectopic ACTH syndrome, ratios of central to peripheral ACTH were negative in jugular vein samples and petrosal sinus samples before and after CRH (<2 and <3, respectively). Conclusions: Jugular vein sampling correctly identified ACTH-secreting pituitary adenomas in 80% of patients with proven Cushing disease. Administration of CRH was essential for diagnostic results in 63% of the patients. Jugular vein sampling is less invasive than petrosal sinus sampling. Negative results on jugular vein sampling should be confirmed by petrosal sinus sampling.	NINDS, Warren Grant Magnuson Clin Ctr, Dept Diagnost Radiol, Bethesda, MD 20892 USA; NINDS, Neurol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Doppman, JL (corresponding author), NINDS, Warren Grant Magnuson Clin Ctr, Dept Diagnost Radiol, Bldg 10,Room 1C660,10 Ctr Dr,MSC 1182, Bethesda, MD 20892 USA.							Avgerinos PC, 1996, CLIN ENDOCRINOL, V45, P483, DOI 10.1046/j.1365-2265.1996.8170827.x; CORRIGAN DF, 1977, NEW ENGL J MED, V296, P861, DOI 10.1056/NEJM197704142961508; DICHEK HL, 1994, J CLIN ENDOCR METAB, V78, P418, DOI 10.1210/jc.78.2.418; DOPPMAN JL, 1995, J CLIN ENDOCR METAB, V80, P2485, DOI 10.1210/jc.80.8.2485; FINDLING JW, 1981, ANN INTERN MED, V94, P647, DOI 10.7326/0003-4819-94-5-647; MAGIAKOU MA, 1994, NEW ENGL J MED, V331, P629, DOI 10.1056/NEJM199409083311002; Mamelak AN, 1996, J CLIN ENDOCR METAB, V81, P475, DOI 10.1210/jc.81.2.475; MILLER DL, 1993, AM J NEURORADIOL, V14, P1075; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; MILLER DL, 1991, RADIOLOGY, V178, P37, DOI 10.1148/radiology.178.1.1845785; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; TERAMOTO A, 1993, J CLIN ENDOCR METAB, V76, P637, DOI 10.1210/jc.76.3.637; YANOVSKI JA, 1994, ENDOCRINOLOGIST, V4, P245, DOI 10.1097/00019616-199407000-00004	14	47	49	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					33	36		10.7326/0003-4819-128-1-199801010-00006	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424979				2022-12-28	WOS:000071158000006
J	Herman, J				Herman, J			Phantom limb: From medical knowledge to folk wisdom and back	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PAIN		Assia Community Hlth Ctr, IL-80200 Netivot, Israel		Herman, J (corresponding author), 24 Megadim St, IL-96185 Jerusalem, Israel.							BARON R, 1995, PAIN, V60, P223, DOI 10.1016/0304-3959(94)00188-K; BURR AR, 1929, W MITCHELL HIS LIFE; ENGEL GL, 1971, ANN INTERN MED, V74, P771, DOI 10.7326/0003-4819-74-5-771; Gallinek A, 1939, AM J PSYCHIAT, V96, P413, DOI 10.1176/ajp.96.2.413; HENDERSON WR, 1948, J NEUROL NEUROSUR PS, V11, P88, DOI 10.1136/jnnp.11.2.88; Herman J, 1997, SLEEP, V20, P577, DOI 10.1093/sleep/20.7.577; JENSEN TS, 1985, PAIN, V21, P267, DOI 10.1016/0304-3959(85)90090-9; JHEAD H, 1920, STUDIES NEUROLOGY, P606; KATZ J, 1992, J NEUROL NEUROSUR PS, V55, P811, DOI 10.1136/jnnp.55.9.811; KOLB LC, 1959, AM HDB PSYCHIAT, V66, P749; MELVILLE H, 1942, MOBY DICK, P435; MELZACK R, 1992, SCI AM, V266, P120, DOI 10.1038/scientificamerican0492-120; MICHAELS L, 1966, BRIT HEART J, V28, P258; Mitchell S. Weir, 1871, LIPPINCOTTS MAGAZINE, P563; MITCHELL SW, 1990, AUTOBIOGRAPHY QUACK, P115; Nikolajsen L, 1996, PAIN, V67, P69, DOI 10.1016/0304-3959(96)03080-1; PARE A, 1840, OEUVRES COMPLETES, V2, P221; Riddoch G, 1941, BRAIN, V64, P197, DOI 10.1093/brain/64.4.197; Romberg M.H., 1853, MANUAL NERVOUS DIS M, V1 and 2; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; SPRAGUE HB, 1966, ARCH ENVIRON HEALTH, V13, P4, DOI 10.1080/00039896.1966.10664500; STRONG JP, 1986, JAMA-J AM MED ASSOC, V256, P2863, DOI 10.1001/jama.256.20.2863; Taylor J, 1958, SELECTED WRITINGS JH; WASSERSTEIN AG, 1988, ANN INTERN MED, V109, P440, DOI 10.7326/0003-4819-109-5-440; 1993, COLUMBIA ENCY, P1975	25	14	14	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					76	78		10.7326/0003-4819-128-1-199801010-00029	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00029			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424997				2022-12-28	WOS:000071158000029
J	Gradia, S; Acharya, S; Fishel, R				Gradia, S; Acharya, S; Fishel, R			The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch	CELL			English	Article							NONPOLYPOSIS COLON-CANCER; HUMAN MSH2 PROTEIN; HETERODUPLEX REPAIR; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; NUCLEAR EXTRACTS; RAS SUPERFAMILY; TUMOR-CELLS; DNA; HETERODIMER	The mechanism of DNA mismatch repair has been modeled upon biochemical studies of the E. coli DNA adenine methylation-instructed pathway where the initial recognition of mismatched nucleotides is performed by the MutS protein. MutS homologs (MSH) have been identified based on a highly conserved region containing a Walker-A adenine nucleotide binding motif. Here we show that adenine nucleotide binding and hydrolysis by the human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. The hMSH2-hMSH6 complex is ON (binds mismatched nucleotides) in the ADP-bound form and OFF in the ATP-bound form. These results suggest a new model for the function of MutS proteins during mismatch repair in which the switch determines the timing of downstream events.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA067007, R01CA056542] Funding Source: NIH RePORTER; NCI NIH HHS [CA56542, R01 CA067007, CA67007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHI NW, 1994, J BIOL CHEM, V269, P29984; Dixon M., 1979, ENZYMES, Vthird; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL RA, 1988, P NATL ACAD SCI USA, V85, P36, DOI 10.1073/pnas.85.1.36; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Laalami S, 1996, BIOCHIMIE, V78, P577, DOI 10.1016/S0300-9084(96)80004-6; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Meyers M, 1997, CANCER RES, V57, P206; MILLER LK, 1976, P NATL ACAD SCI USA, V73, P3073, DOI 10.1073/pnas.73.9.3073; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WILSON TM, 1995, CANCER RES, V55, P5146; WOODWARDGRAVES KL, 1996, J BIOL CHEM, V271, P13629; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O	49	300	307	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					995	1005		10.1016/S0092-8674(00)80490-0	http://dx.doi.org/10.1016/S0092-8674(00)80490-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428522	Bronze			2022-12-28	WOS:000071281400016
J	Martin, KC; Casadio, A; Zhu, HX; E, YP; Rose, JC; Chen, M; Bailey, CH; Kandel, ER				Martin, KC; Casadio, A; Zhu, HX; E, YP; Rose, JC; Chen, M; Bailey, CH; Kandel, ER			Synapse-specific, long-form facilitation of Aplysia sensory to motor synapses: A function for local protein synthesis in memory storage	CELL			English	Article							TERM FACILITATION; HETEROSYNAPTIC FACILITATION; STRUCTURAL-CHANGES; MESSENGER-RNA; CELL-CULTURE; NEURONS; DENDRITES; SENSITIZATION; LOCALIZATION; HABITUATION	The requirement for transcription during long-lasting synaptic plasticity has raised the question of whether the cellular unit of synaptic plasticity is the soma and its nucleus or the synapse. To address this question, we cultured a single bifurcated Apylsia sensory neuron making synapses with two spatially separated motor neurons. By perfusing serotonin onto the synapses made onto one motor neuron, we found that a single axonal branch can undergo long-term branch-specific facilitation. This branch-specific facilitation depends on CREB-mediated transcription and involves the growth of new synaptic connections exclusively at the treated branch. Branch-specific long-term facilitation requires local protein synthesis in the presynaptic but not the postsynaptic cell. In fact, presynaptic sensory neuron axons deprived of their cell bodies are capable of protein synthesis, and this protein synthesis is stimulated 3-fold by exposure to serotonin.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, 722 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRUNET JF, 1991, SCIENCE, V252, P856, DOI 10.1126/science.1840700; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Crispino M, 1997, J NEUROSCI, V17, P7694; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; FEIG S, 1993, J NEUROSCI, V13, P1010; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; RAYPORT SG, 1986, J NEUROSCI, V6, P759; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; Schuman EM, 1997, NEURON, V18, P339, DOI 10.1016/S0896-6273(00)81234-9; Sossin WS, 1996, TRENDS NEUROSCI, V19, P215; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STIRPE F, 1980, J BIOL CHEM, V255, P6947; TRUDEAU LE, 1995, J NEUROSCI, V15, P1275; VanMinnen J, 1997, NEUROSCIENCE, V80, P1; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	42	580	594	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					927	938		10.1016/S0092-8674(00)80484-5	http://dx.doi.org/10.1016/S0092-8674(00)80484-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428516	hybrid			2022-12-28	WOS:000071281400010
J	Eagles, JM; Rhind, GB				Eagles, JM; Rhind, GB			Increasing handicaps in hospital medicine: two point cross sectional study of golfing activity among doctors	BRITISH MEDICAL JOURNAL			English	Article									Royal Cornhill Hosp, Aberdeen AB25 2ZH, Scotland; Roodlands Hosp, Haddington EH41 3PF, Scotland		Eagles, JM (corresponding author), Royal Cornhill Hosp, Aberdeen AB25 2ZH, Scotland.							FITZGERALD L, 1991, INT J SPORTS MED S1, V12, P5; FRY RW, 1991, SPORTS MED, V12, P32, DOI 10.2165/00007256-199112010-00004; KIRWAN M, 1995, BRIT J GEN PRACT, V45, P259; MCDANIEL KD, 1989, NEUROLOGY, V39, P192, DOI 10.1212/WNL.39.2.192; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1656	1657		10.1136/bmj.315.7123.1656	http://dx.doi.org/10.1136/bmj.315.7123.1656			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448531	Green Published			2022-12-28	WOS:000071149400014
J	Elwyn, GJ				Elwyn, GJ			So many precious stories: a reflective narrative of patient based medicine in general practice, Christmas 1996	BRITISH MEDICAL JOURNAL			English	Article							PROSTATE-SPECIFIC ANTIGEN; CONSULTATIONS; CANCER		Univ Wales Coll Med, Sch Postgrad Studies, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Med, Dept Gen Practice, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University	Elwyn, GJ (corresponding author), Univ Wales Coll Med, Sch Postgrad Studies, Cardiff CF4 4XN, S Glam, Wales.		Elwyn, Glyn/B-4798-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; 				Baker R, 1996, BRIT J GEN PRACT, V46, P601; BALINT M, 1957, DOCTOR PATIENT HIS I; *BRIT THOR SOC, 1997, THORAX S1, V52; Cochrane A.L., 1971, EFFECTIVENESS EFFICI; Coulter A, 1997, J Health Serv Res Policy, V2, P112; Cromarty I, 1996, BRIT J GEN PRACT, V46, P525; Dawes MG., 1996, BMJ EVID-BASED MED, V1, P68; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; EDDY DM, 1982, JUDGEMENT UNCERTAINT; ELWYN GJ, 1994, BRIT MED J, V309, P576, DOI 10.1136/bmj.309.6954.576; Fleming C, 1993, JAMA, V269, P2650; GREENHALGH P, 1996, BRIT MED J, V313, P957; Hamm RM, 1988, PROFESSIONAL JUDGEME; Howie J G, 1972, J R Coll Gen Pract, V22, P310; Howie JGR, 1996, BRIT J GEN PRACT, V46, P479; Illich I, 1975, LIMITS MED; Kai J, 1996, BRIT MED J, V313, P983; KATZ J, 1988, PROFESSIONAL JUDGMEN; Kernick DP, 1997, BRIT J GEN PRACT, V47, P95; Kleinman A., 1988, ILLNESS NARRATIVES; McWhinney IR, 1996, BRIT J GEN PRACT, V46, P433; MCWHINNEY IR, 1972, NEW ENGL J MED, V287, P384, DOI 10.1056/NEJM197208242870805; *NHS CTR REV DISS, 1995, EFF HLTH CAR B, P5; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; PRICE R, 1994, WHOLE NEW LIFE ILLNE; PROEHASKA J, 1992, AM PSYCHOL, V47, P1102; REES J, 1995, ABC ASTHMA; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; Stott N C, 1979, J R Coll Gen Pract, V29, P201; STOTT NCH, 1983, PRIMARY HLTH CARE BR; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1; Tuckett D., 1985, M EXPERTS APPROACH S; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107; Zeldin Theodor, 1994, INTIMATE HIST HUMANI	36	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1659	1663		10.1136/bmj.315.7123.1659	http://dx.doi.org/10.1136/bmj.315.7123.1659			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448533	Green Published			2022-12-28	WOS:000071149400017
J	Fetz, EE				Fetz, EE			Neuroscience - Temporal coding in neural populations?	SCIENCE			English	Editorial Material							COOPERATIVE FIRING ACTIVITY; PRIMATE MOTOR CORTEX; MOVEMENT; NEURONS; DIRECTION; DYNAMICS				Fetz, EE (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ABELES M, 1993, BRAIN THEORY, P149; Abeles M., 1991, CORTICONICS; Aertsen A, 1996, J PHYSIOLOGY-PARIS, V90, P243, DOI 10.1016/S0928-4257(97)81432-5; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Buszaki G, 1994, TEMPORAL CODING BRAI; Davis J., 1994, LARGE SCALE NEURONAL; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; GERSTEIN GL, 1985, J NEUROPHYSIOL, V54, P1513, DOI 10.1152/jn.1985.54.6.1513; Lindsey BG, 1997, J NEUROPHYSIOL, V78, P1714, DOI 10.1152/jn.1997.78.3.1714; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; RIECKE F, 1997, SPIKES; RIEHLE A, 1950, SCIENCE, V278; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1993, ANN REV PHYSL, V55, P201; Taira M, 1996, EXP BRAIN RES, V109, P367; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; ZHANG K, IN PRESS J NEUROPHYS	25	47	50	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1901	1902		10.1126/science.278.5345.1901	http://dx.doi.org/10.1126/science.278.5345.1901			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417639				2022-12-28	WOS:A1997YL00200021
J	Ahmad, W; Haque, WFU; Brancolini, V; Tsou, HC; Haque, SU; Lam, H; Aita, VM; Owen, J; deBlaquiere, M; Frank, J; Cserhalmi-Friedman, PB; Leask, A; McGrath, JA; Peacocke, M; Ahmad, M; Ott, J; Christiano, AM				Ahmad, W; Haque, WFU; Brancolini, V; Tsou, HC; Haque, SU; Lam, H; Aita, VM; Owen, J; deBlaquiere, M; Frank, J; Cserhalmi-Friedman, PB; Leask, A; McGrath, JA; Peacocke, M; Ahmad, M; Ott, J; Christiano, AM			Alopecia universalis associated with a mutation in the human hairless gene	SCIENCE			English	Article							GROWTH CYCLE; NUDE LOCUS; MOUSE; EXPRESSION; MICE; MECHANISMS; FOLLICLE; PROTEIN; RAT	There are several forms of hereditary human hair loss, known collectively as alopecias, the molecular bases of which are entirely unknown. A kindred with a rare, recessively inherited type of alopecia universalis was used to search for a locus by homozygosity mapping, and linkage was established in a B-centimorgan interval on chromosome 8p12 (the logarithm of the odds favoring linkage score was 6.19). The human homolog of a murine gene, hairless, was localized in this interval by radiation hybrid mapping, and a missense mutation was found in affected individuals. Human hairless encodes a putative single zinc finger transcription factor protein with restricted expression in the brain and skin.	Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Quaid I Azam Univ, Dept Biol Sci, Islamabad, Pakistan; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Res Genet Inc, Huntsville, AL 35801 USA; Fibrogen Inc, San Francisco, CA 94080 USA; St Thomas Hosp, Inst Dermatol, London SE1 7EH, England	Columbia University; Columbia University; Quaid I Azam University; Rockefeller University; FibroGen; Guy's & St Thomas' NHS Foundation Trust	Christiano, AM (corresponding author), Columbia Univ, Dept Dermatol, 630 W 168 St,VC-15-526, New York, NY 10032 USA.	amc65@columbia.edu	Leask, Andrew/G-5217-2015; Ahmad, Wasim/GSD-8904-2022; Ahmad, Wasim/E-9713-2015; McGrath, John/N-3529-2019; Leask, Andy/ABH-9433-2020; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Brancolini, Valeria/0000-0003-0871-537X	NHGRI NIH HHS [HG-00008] Funding Source: Medline; NIAMS NIH HHS [P30AR44535] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BERGFELD WF, 1995, AM J MED, V98, pS95, DOI 10.1016/S0002-9343(99)80065-5; BROOKE HC, 1924, J HERED, V15, P173; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Engelkamp D, 1996, CURR OPIN GENET DEV, V6, P334, DOI 10.1016/S0959-437X(96)80011-6; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; MORRISSEY PJ, 1980, J IMMUNOL, V125, P1558; MULLER HK, 1980, BRIT J DERMATOL, V102, P609, DOI 10.1111/j.1365-2133.1980.tb07664.x; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; ROOK A, 1991, DIS HAIR SCALP, P136; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SEMENZA GL, 1994, HUM MUTAT, V3, P180, DOI 10.1002/humu.1380030304; SHEFFIELD VC, 1995, CURR OPIN GENET DEV, V5, P335, DOI 10.1016/0959-437X(95)80048-4; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; Thompson CC, 1996, J NEUROSCI, V16, P7832; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	27	322	352	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					720	724		10.1126/science.279.5351.720	http://dx.doi.org/10.1126/science.279.5351.720			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445480				2022-12-28	WOS:000071731500041
J	Maria, G; Cassetta, E; Gui, D; Brisinda, G; Bentivoglio, AR; Albanese, A				Maria, G; Cassetta, E; Gui, D; Brisinda, G; Bentivoglio, AR; Albanese, A			A comparison of botulinum toxin and saline for the treatment of chronic anal fissure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATERAL INTERNAL SPHINCTEROTOMY; GLYCERYL TRINITRATE; THERAPY	Background Chronic anal fissure is a tear in the lower half of the anal canal that is maintained by contraction of the internal anal sphincter. Sphincterotomy, the most widely used treatment, is a surgical procedure that permanently weakens the internal sphincter and may lead to anal deformity and incontinence. Methods We conducted a double-blind, placebo-controlled study of botulinum toxin for the treatment of chronic anal fissure in 30 consecutive symptomatic adults. All the patients received two injections (total volume, 0.4 ml) into the internal anal sphincter; the treated group (15 patients) received 20 U of botulinum toxin A, and the control group (15 patients) received saline. Success was defined as healing of the fissure (formation of a scar), and symptomatic improvement was defined as the presence of a persistent fissure without symptoms. Results After two months, 11 patients in the treated group and 2 in the control group had healed fissures (P=0.003); 13 in the treated group and 4 in the control group had symptomatic relief (P = 0.003). The maximal voluntary pressures were similar to those at base line in both groups, and the resting anal pressure was reduced by 25 percent in the treated group but not in the control group. Three patients in the control group later underwent sphincterotomy, and 10 received botulinum-toxin injections (20 U). Of the latter, seven had healed fissures after two months; the other three left the study and underwent surgery. Four patients in the treated group were later re-treated (with 25 U of botulinum toxin); all had healed fissures after two months. One patient in the control group had temporary flatus incontinence after treatment with botulinum toxin. No relapses occurred during an average of 16 months of follow-up. Conclusions Local infiltration of botulinum toxin into the internal anal sphincter is an effective treatment for chronic anal fissure. (C) 1998, Massachusetts Medical Society.	Univ Cattolica Sacro Cuore, Ist Neurol, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Ist Clin Chirurg, I-00168 Rome, Italy; Assoc Fatebenefraatelli Ric, Ist Ricovero & Cura Carattere Sci, Ctr S Giovanni di Dio, Brescia, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Albanese, A (corresponding author), Univ Cattolica Sacro Cuore, Ist Neurol, Largo Argostino Gemelli 8, I-00168 Rome, Italy.		Brisinda, Giuseppe/G-6436-2010; Bentivoglio, Anna Rita/K-3752-2018; Albanese, Alberto/K-7396-2016	Brisinda, Giuseppe/0000-0001-8820-9471; Albanese, Alberto/0000-0002-5864-0006; Cassetta, Emanuele/0000-0003-1442-1458; Bentivoglio, Anna Rita/0000-0002-9663-095X				ABCARIAN H, 1982, DIS COLON RECTUM, V25, P525, DOI 10.1007/BF02564159; Albanese A, 1995, ALIMENT PHARM THERAP, V9, P599; ASHTON AC, 1988, J NEUROCHEM, V50, P1808, DOI 10.1111/j.1471-4159.1988.tb02482.x; Dixon WJ., 1983, INTRO STAT ANAL; GORDON PH, 1985, CAN J SURG, V28, P228; GORFINE SR, 1995, NEW ENGL J MED, V333, P1156, DOI 10.1056/NEJM199510263331718; GUI D, 1994, LANCET, V344, P1127, DOI 10.1016/S0140-6736(94)90633-5; JOST WH, 1994, DIS COLON RECTUM, V37, P1321, DOI 10.1007/BF02257805; LOCKHARTMUMMERY JP, 1934, DIS RECTUM COLON; Lund JN, 1996, BRIT J SURG, V83, P776, DOI 10.1002/bjs.1800830615; Lund JN, 1996, BRIT J SURG, V83, P1335, DOI 10.1002/bjs.1800831006; MAZIER WP, 1994, SURG CLIN N AM, V74, P1277; NOTARAS MJ, 1988, SURG CLIN N AM, V68, P1427; OH C, 1995, DIS COLON RECTUM, V38, P378, DOI 10.1007/BF02054225; PEDERSEN IK, 1989, BRIT J SURG, V76, P69, DOI 10.1002/bjs.1800760121; PERNIKOFF BJ, 1994, DIS COLON RECTUM, V37, P1291, DOI 10.1007/BF02257799; PESCATORI M, 1989, COLOPROCTOLOGY, V11, P120; PESCI AD, 1995, ASTROPART PHYS, V3, P29, DOI 10.1016/0927-6505(94)00034-Z; Schouten WR, 1996, BRIT J SURG, V83, P63, DOI 10.1002/bjs.1800830120; Simons AJ, 1996, LANCET, V348, P491, DOI 10.1016/S0140-6736(05)64667-3; Watson SJ, 1996, BRIT J SURG, V83, P771, DOI 10.1002/bjs.1800830614	21	237	244	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					217	220		10.1056/NEJM199801223380402	http://dx.doi.org/10.1056/NEJM199801223380402			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435326				2022-12-28	WOS:000071594100002
J	O'Connor, PG; Kosten, TR				O'Connor, PG; Kosten, TR			Rapid and ultrarapid opioid detoxification techniques	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NONINVASIVE OPIATE DETOXIFICATION; WITHDRAWAL SYMPTOMS; MEDICAL LITERATURE; SUBSTANCE-ABUSE; USERS GUIDES; NALTREXONE; CLONIDINE; NALOXONE; ADDICTION; METHADONE	Objective.-To review the scientific literature on the effectiveness of rapid opioid detoxification (RD) (opioid withdrawal precipitated by naloxone hydrochloride or naltrexone) and ultrarapid opioid detoxification (URD) (opioid withdrawal precipitated by naloxone or naltrexone under anesthesia or heavy sedation) techniques. Data Sources.-The MEDLINE database was searched from 1966 through 1997 using the indexing terms naloxone, naltrexone, substance dependence, and substance withdrawal syndrome, Additional data sources included bibliographies of papers identified on MEDLINE and bibliographies in textbooks on substance abuse. Study Selection.-Inclusion criteria were studies of RD or URD, pharmacologic protocols specified, and clinical outcomes specified and reported. Exclusion criteria were unpublished data, data not in peer-reviewed journals, abstract-only publications, and review articles. Data Extraction.-The methodologic characteristics of studies were extracted by the authors and summarized according to key components of research design concerning subject characteristics, therapy allocation, and outcomes assessed. Data Synthesis.-A qualitative analysis was performed on the 12 studies of RD and the 9 studies of URD identified in our search, The RD studies enrolled 641 subjects (range for individual studies, 1-162): 7 were inpatient studies, and the protocols varied considerably, as did the outcomes assessed. Three RD studies included a control group, 2 used a randomized design, and 3 reported outcomes beyond 12 days, The URD studies enrolled 424 subjects (range for individual studies, 6-300): all were inpatient studies, the detoxification and anesthesia protocols varied, 3 included a control group, 2 used a randomized design, and 2 reported outcomes for URD beyond 7 days. Conclusions.-The existing literature on RD and URD is limited in terms of the number of subjects evaluated, the variation in protocols studied, lack of randomized design and use of control groups, and the short-term nature of the outcomes reported, Further research is needed using more rigorous research methods, longer-term outcomes, and comparisons with other methods of treatment for opioid dependence.	Yale Univ, Sch Med, Primary Care Ctr, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA	Yale University; Yale University	O'Connor, PG (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, Dept Med, 333 Cedar St, New Haven, CT 06520 USA.							Ball J.C., 2012, EFFECTIVENESS METHAD; BREWER C, 1988, BRIT J PSYCHIAT, V153, P340, DOI 10.1192/bjp.153.3.340; BROWN DL, 1992, RISK OUTCOME ANESTHE, P1; CAPONE T, 1986, J CLIN PSYCHOL, V42, P825, DOI 10.1002/1097-4679(198609)42:5<825::AID-JCLP2270420526>3.0.CO;2-B; CHARNEY DS, 1981, ARCH GEN PSYCHIAT, V38, P1273; CHARNEY DS, 1986, AM J PSYCHIAT, V143, P831; COOK CCH, 1987, BRIT J HOSP MED, V38, P79; DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002; FARRELL M, 1994, ADDICTION, V89, P1471, DOI 10.1111/j.1360-0443.1994.tb03745.x; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; GERRA G, 1995, J SUBST ABUSE TREAT, V12, P35, DOI 10.1016/0740-5472(94)00077-8; GOLD MS, 1993, PSYCHIAT CLIN N AM, V16, P61; GONZALEZ JP, 1988, DRUGS, V35, P192, DOI 10.2165/00003495-198835030-00002; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HOLMAN PW, 1985, CLIN PHARMACY, V4, P100; KLEBER HD, 1987, AM J DRUG ALCOHOL AB, V13, P1, DOI 10.3109/00952998709001497; Kosten TR, 1996, AM J ADDICTION, V5, P58; KOSTEN TR, 1984, AM J DRUG ALCOHOL AB, V10, P249, DOI 10.3109/00952998409002784; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEGARDA JJ, 1994, DRUG ALCOHOL DEPEN, V35, P91, DOI 10.1016/0376-8716(94)90115-5; LOIMER N, 1991, AM J PSYCHIAT, V148, P933; LOIMER N, 1988, BRIT J PSYCHIAT, V153, P851, DOI 10.1192/bjp.153.6.851b; LOIMER N, 1989, J PSYCHIAT RES, V23, P81, DOI 10.1016/0022-3956(89)90020-4; LOIMER N, 1990, BRIT J PSYCHIAT, V157, P748, DOI 10.1192/bjp.157.5.748; LOIMER N, 1991, AM J DRUG ALCOHOL AB, V17, P307; LOIMER N, 1993, AM J PSYCHIAT, V150, P839; MASINI E, 1981, CLIN TOXICOL, V18, P1021, DOI 10.3109/15563658108990332; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; O'Connor P. G., 1997, JGIM, V12, P78; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OCONNOR PG, 1995, J GEN INTERN MED, V10, P255, DOI 10.1007/BF02599882; OConnor PG, 1997, ANN INTERN MED, V127, P526, DOI 10.7326/0003-4819-127-7-199710010-00004; OCONNOR PG, 1994, PRINCIPLES ADDICTION, P1; PRESSLICH O, 1989, J TOXICOL-CLIN TOXIC, V27, P263, DOI 10.3109/15563658908994422; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; RESNICK RB, 1977, CLIN PHARMACOL THER, V21, P409; RIORDAN CE, 1980, LANCET, V1, P1079; SAN L, 1995, AM J PSYCHIAT, V152, P956; Seivewright NA, 1996, LANCET, V347, P373, DOI 10.1016/S0140-6736(96)90542-5; Seoane A, 1997, BRIT J PSYCHIAT, V171, P340, DOI 10.1192/bjp.171.4.340; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P363, DOI 10.1001/jama.277.5.363; TAFT RH, 1983, ANESTHESIOLOGY, V59, P576; VINING E, 1988, BRIT J ADDICT, V83, P567; WARNER MA, 1993, JAMA-J AM MED ASSOC, V270, P1437, DOI 10.1001/jama.270.12.1437; WINICK C, 1997, SUBSTANCE ABUSE COMP, P10; WODAK A, 1994, DRUGS, V47, P446, DOI 10.2165/00003495-199447030-00005	48	118	121	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					229	234		10.1001/jama.279.3.229	http://dx.doi.org/10.1001/jama.279.3.229			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR124	9438745				2022-12-28	WOS:000071460700035
J	Goldenberg, DL				Goldenberg, DL			Septic arthritis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; NEISSERIA-GONORRHOEAE; RHEUMATOID-ARTHRITIS; GONOCOCCAL ARTHRITIS; BACTERIAL ARTHRITIS; JOINT INFECTIONS; ARTHROPLASTY; BONE; EXPERIENCE; DIAGNOSIS		Newton Wellesley Hosp, Newton, MA 02162 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Newton Wellesley Hospital; Tufts University	Goldenberg, DL (corresponding author), Newton Wellesley Hosp, Newton, MA 02162 USA.							Abdelnour A, 1997, SCAND J IMMUNOL, V45, P301, DOI 10.1046/j.1365-3083.1997.d01-401.x; BAKER DG, 1993, NEW ENGL J MED, V329, P1013, DOI 10.1056/NEJM199309303291407; BAYER AS, 1979, SEMIN ARTHRITIS RHEU, V8, P200, DOI 10.1016/S0049-0172(79)80008-6; BRANCOS MA, 1991, SEMIN ARTHRITIS RHEU, V21, P81, DOI 10.1016/0049-0172(91)90041-W; Canvin JMG, 1997, BRIT J RHEUMATOL, V36, P203; CHANTLER JK, 1982, LANCET, V1, P1323; CUCKLER JM, 1991, ORTHOP CLIN N AM, V22, P523; Cunningham R, 1996, J MED MICROBIOL, V44, P157, DOI 10.1099/00222615-44-3-157; DUBOST JJ, 1993, MEDICINE, V72, P296, DOI 10.1097/00005792-199309000-00002; FINK CW, 1986, CLIN RHEUM DIS, V12, P423; FITZGERALD RH, 1992, ORTHOP CLIN N AM, V23, P259; Forrester DM, 1996, SEMIN ROENTGENOL, V31, P239, DOI 10.1016/S0037-198X(96)80032-0; GARDNER GC, 1990, AM J MED, V88, P503, DOI 10.1016/0002-9343(90)90430-L; Gilbert MS, 1996, CLIN ORTHOP RELAT R, P54; GOLDENBERG DL, 1985, NEW ENGL J MED, V312, P764, DOI 10.1056/NEJM198503213121206; GOLDENBERG DL, 1991, RHEUM DIS CLIN N AM, V17, P149; GOLDENBERG DL, 1989, ARTHRITIS RHEUM, V32, P496, DOI 10.1002/anr.1780320422; Goldenberg Don L., 1993, P2025; GRANFORS K, 1989, NEW ENGL J MED, V320, P216, DOI 10.1056/NEJM198901263200404; GRAVALLESE EM, 1995, ARTHRITIS RHEUM, V38, P1315, DOI 10.1002/art.1780380920; Hamed KA, 1996, CLIN PHARMACOKINET, V31, P156, DOI 10.2165/00003088-199631020-00006; HEDSTROM SA, 1994, RHEUMATOLOGY; HO G, 1993, J RHEUMATOL, V20, P2001; HOOSEN AA, 1994, BRIT J RHEUMATOL, V33, P840; HUGHES RA, 1992, BRIT J RHEUMATOL, V31, P381; Ilahi OA, 1996, ORTHOPEDICS, V19, P613; Kaandorp CJE, 1995, ARTHRITIS RHEUM, V38, P1819, DOI 10.1002/art.1780381215; Kaandorp CJE, 1997, ARTHRITIS RHEUM-US, V40, P884, DOI 10.1002/art.1780400516; Klein DM, 1997, CLIN ORTHOP RELAT R, P153; LeDantec L, 1996, REV RHUM, V63, P103; LIEBLING MR, 1994, ARTHRITIS RHEUM, V37, P702, DOI 10.1002/art.1780370514; MIKHAIL IS, 1993, RHEUM DIS CLIN N AM, V19, P311; Morgan DS, 1996, EPIDEMIOL INFECT, V117, P423, DOI 10.1017/S0950268800059070; MUNOZFERNANDEZ S, 1993, ANN RHEUM DIS, V52, P570, DOI 10.1136/ard.52.8.570; Nilsson IM, 1996, INFECT IMMUN, V64, P4438, DOI 10.1128/IAI.64.11.4438-4443.1996; OBRIEN JP, 1983, MEDICINE, V62, P395, DOI 10.1097/00005792-198311000-00005; PARISIEN JS, 1992, CLIN ORTHOP RELAT R, P243; PETERS RHJ, 1992, CLIN RHEUMATOL, V11, P351, DOI 10.1007/BF02207192; PINALS RS, 1994, NEW ENGL J MED, V330, P769, DOI 10.1056/NEJM199403173301108; PITKIN AD, 1993, J INFECTION, V27, P297, DOI 10.1016/0163-4453(93)92242-O; ROMPALO AM, 1987, ARCH INTERN MED, V147, P281, DOI 10.1001/archinte.147.2.281; Ryan MJ, 1997, BRIT J RHEUMATOL, V36, P370; RYNES RI, 1991, RHEUM DIS CLIN N AM, V17, P79; Sakiniene E, 1996, ARTHRITIS RHEUM, V39, P1596, DOI 10.1002/art.1780390921; Sapico FL, 1996, CLIN INFECT DIS, V22, P783, DOI 10.1093/clinids/22.5.783; Saraux A, 1997, BRIT J RHEUMATOL, V36, P333; Schurman D J, 1987, Orthop Rev, V16, P241; SCOPELITIS E, 1993, RHEUM DIS CLIN N AM, V19, P363; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SMITH RL, 1987, J BONE JOINT SURG AM, V69A, P1063, DOI 10.2106/00004623-198769070-00015; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; STUDAHL M, 1994, SCAND J INFECT DIS, V26, P85, DOI 10.3109/00365549409008595; TIGGES S, 1993, RADIOLOGY, V189, P485, DOI 10.1148/radiology.189.2.8210377; WISE CM, 1994, ARCH INTERN MED, V154, P2690, DOI 10.1001/archinte.1994.00420230077009; WYMENGA AB, 1992, ACTA ORTHOP SCAND, V63, P665, DOI 10.1080/17453679209169732; YU LP, 1992, SCAND J RHEUMATOL, V21, P142, DOI 10.3109/03009749209095087; Zimmermann B, 1996, SEMIN ARTHRITIS RHEU, V26, P592, DOI 10.1016/S0049-0172(96)80010-2	57	305	310	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	1998	351	9097					197	202		10.1016/S0140-6736(97)09522-6	http://dx.doi.org/10.1016/S0140-6736(97)09522-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449882				2022-12-28	WOS:000071616300041
J	Crameri, A; Raillard, SA; Bermudez, E; Stemmer, WPC				Crameri, A; Raillard, SA; Bermudez, E; Stemmer, WPC			DNA shuffling of a family of genes from diverse species accelerates directed evolution	NATURE			English	Article							BETA-LACTAMASE; MOLECULAR EVOLUTION; IN-VITRO; SEQUENCE; RECOMBINATION; PROTEIN; PLASMID	DNA shuffling is a powerful process for directed evolution, which generates diversity by recombination(1,2), combining useful mutations from individual genes. Libraries of chimaeric genes can be generated by random frag;mentation of a pool of related genes, followed by reassembly of the fragments in a self-priming polymerase reaction. Template switching causes crossovers in areas of sequence homology. Our previous studies used single genes and random point mutations as the source of diversity(3-6). An alternative source of diversity is naturally occurring homologous genes, which provide 'functional diversity.' To evaluate whether natural diversity could accelerate the evolution process, we compared the efficiency of obtaining moxalactamase activity from four cephalosporinase genes evolved separately with that from a mixed pool of the four genes. A single cycle of shuffling yielded eightfold improvements from the four separately evolved genes, versus a 270- to 540-fold improvement from the four genes shuffled together, a 50-fold increase per cycle of shuffling. The best clone contained eight segments from three of the four genes as well as 33 amino-acid point mutations, Molecular breeding by shuffling can efficiently mix sequences from different species, unlike traditional breeding techniques, The power of family shuffling may arise from sparse sampling of a larger portion of sequence space.	Maxygen Inc, Santa Clara, CA 95051 USA		Stemmer, WPC (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.							Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1997, NAT BIOTECHNOL, V15, P436, DOI 10.1038/nbt0597-436; Eigen M, 1992, STEPS LIFE PERSPECTI; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; Kauffman S. A., 1993, ORIGINS ORDER; LEIZA MG, 1994, ANTIMICROB AGENTS CH, V38, P2150; LINDBERG F, 1986, EUR J BIOCHEM, V156, P441, DOI 10.1111/j.1432-1033.1986.tb09601.x; LOBKOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257, DOI 10.1073/pnas.90.23.11257; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; SEOANE A, 1992, ANTIMICROB AGENTS CH, V36, P1049, DOI 10.1128/AAC.36.5.1049; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	16	618	1129	6	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					288	291		10.1038/34663	http://dx.doi.org/10.1038/34663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440693				2022-12-28	WOS:000071484400052
J	Crick, F; Koch, C				Crick, F; Koch, C			Constraints on cortical and thalamic projections: The no-strong-loops hypothesis	NATURE			English	Article							LATERAL GENICULATE NEURONS; PRIMARY VISUAL-CORTEX; INDETERMINATE ORGANIZATION; SQUIRREL-MONKEY; STRIATE CORTEX; CONNECTIONS; PULVINAR; SYSTEM; TERMINATIONS; NETWORKS	The many distinct cortical areas of the macaque monkey visual system can be arranged hierarchically, but not in a unique way, We suggest that the connections between these cortical areas never form strong, directed loops. For connections between the visual cortex and particular thalamic nuclei, we predict that certain types of connections will not be found, If strong, directed loops were to exist, we suggest that the cortex would go into uncontrolled oscillations.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	Salk Institute; California Institute of Technology	Crick, F (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Koch, Christof/0000-0001-6482-8067				BAKER FH, 1977, EXP BRAIN RES, V29, P433; BOURASSA J, 1995, NEUROSCIENCE, V66, P253, DOI 10.1016/0306-4522(95)00009-8; CALLWAY EM, IN PRESS ANN REV NEU; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DOUGLAS RJ, 1995, SCIENCE, V269, P891; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Guillery R W, 1971, Vision Res, VSuppl 3, P211; Guillery RW, 1995, J ANAT, V187, P583; Gutierrez C, 1995, J COMP NEUROL, V363, P545, DOI 10.1002/cne.903630404; HENDRY SHC, 1994, SCIENCE, V264, P575, DOI 10.1126/science.8160015; Hilgetag CC, 1996, SCIENCE, V271, P776, DOI 10.1126/science.271.5250.776; HIRSCH MW, 1989, NEURAL NETWORKS, V2, P331, DOI 10.1016/0893-6080(89)90018-X; Jones EG, 1985, THALAMUS; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; KUAN CM, 1994, NEURAL COMPUT, V6, P420, DOI 10.1162/neco.1994.6.3.420; LEVITT JB, 1995, EXP BRAIN RES, V104, P419; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; MATHERS LH, 1972, J COMP NEUROL, V146, P43, DOI 10.1002/cne.901460104; MATHERS LH, 1972, J COMP NEUROL, V146, P15, DOI 10.1002/cne.901460103; MIGNARD M, 1991, SCIENCE, V251, P1249, DOI 10.1126/science.1848727; OJIMA H, 1994, CEREB CORTEX, V4, P646, DOI 10.1093/cercor/4.6.646; PETERS A, 1994, CEREB CORTEX, V4, P215, DOI 10.1093/cercor/4.3.215; Robinson D. F., 1980, DIGRAPHS THEORY TECH; ROBINSON DL, IN PRESS THALAMUS, V2; ROCKLAND KS, 1994, NEUROREPORT, V5, P1865, DOI 10.1097/00001756-199410000-00006; Rockland KS, 1996, J COMP NEUROL, V368, P57, DOI 10.1002/(SICI)1096-9861(19960422)368:1<57::AID-CNE5>3.0.CO;2-J; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; ROCKLAND KS, IN PRESS J COMP NEUR; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; VanEssen DC, 1996, SCIENCE, V271, P777; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470	34	232	235	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					245	250		10.1038/34584	http://dx.doi.org/10.1038/34584			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440687				2022-12-28	WOS:000071484400039
J	Reichard, O; Norkrans, G; Fryden, A; Braconier, JH; Sonnerborg, A; Weiland, O				Reichard, O; Norkrans, G; Fryden, A; Braconier, JH; Sonnerborg, A; Weiland, O		Swedish Study Group	Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C	LANCET			English	Article							VIRUS-RNA LEVELS; NON-B-HEPATITIS; CHRONIC NON-A; COMBINATION THERAPY; SUSTAINED RESPONSE; ALFA THERAPY; PROBE ASSAY; RECOMBINANT; REGIMENS	Background Pilot studies suggested that more patients with chronic hepatitis C virus (HCV) infection had a sustained virological response when treated with the combination of interferon alpha-2b and ribavirin than with interferon alpha-2b alone. We investigated the biochemical and virological responses and safety of treatment with interferon alpha-2b and ribavirin compared with interferon alpha-2b alone. Methods In this double-blind trial 100 patients were randomly assigned to treatment with interferon alpha-2b (3 MU three times a week) in combination with ribavirin (1000 or 1200 mg per day) or placebo for 24 weeks and then followed up for a further 24 weeks. A further followup was done 1 year after active treatment stopped. The primary endpoint was the sustained virological response, defined as no detectable HCV RNA by PCR at both week 24 and week 48. Retrospectively, the baseline HCV-RNA load was analysed as a predictor of a sustained virological response. Data were analysed by intention to treat. Findings 18 (36%) of the 50 patients in the interferon alpha-2b and ribavirin group had a sustained virological response compared with nine (18%) of the 50 patients in the interferon alpha-2b and placebo group (p=0.047). At the 1 year follow-up the proportion of patients with virological response was greater in the interferon alpha-2b and ribavirin group than the interferon alpha-2b and placebo group (42 vs 20%, p=0.03), respectively. More patients with baseline HCV-RNA concentrations greater than 3x10(6) genome equivalents (Eq) per mL had a sustained response with interferon alpha-2b and ribavirin than with interferon alpha-2b and placebo (12/29 vs 1/26, p=0.009), whereas the sustained response did not differ between the two treatment groups for HCV-RNA amounts less than 3x10(6) Eq per mt (6/21 vs 8/24, p=0.67), respectively. Interpretation More patients with chronic hepatitis C have a sustained virological response with interferon alpha-2b and ribavirin than with only interferon alpha-2b treatment. We suggest that patients with high HCV-RNA loads should be treated with interferon alpha-2b and ribavirin.	Karolinska Inst, Huddinge Univ Hosp, Dept Infect Dis, Stockholm, Sweden; Karolinska Inst, Huddinge Univ Hosp, Dept Virol, Stockholm, Sweden; Karolinska Inst, Danderyd Hosp, Stockholm, Sweden; East Hosp, S-41685 Gothenburg, Sweden; Univ Hosp, Linkoping, Sweden; Univ Lund Hosp, S-22185 Lund, Sweden	Karolinska Institutet; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Lund University; Skane University Hospital	Weiland, O (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, S-14186 Huddinge, Sweden.		Sönnerborg, Anders/W-2011-2019	Sönnerborg, Anders/0000-0001-8928-3374; Weiland, Ola/0000-0002-6934-9724				BARDELLI F, 1995, CLIN DRUG INVEST, V9, P239, DOI 10.2165/00044011-199509050-00001; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; BRACONIER JH, 1995, SCAND J INFECT DIS, V27, P325, DOI 10.3109/00365549509032725; Brillanti S., 1996, Hepatology, V24, p395A; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; CAMPS J, 1993, J HEPATOL, V19, P408, DOI 10.1016/S0168-8278(05)80550-1; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; Chemello L, 1995, J HEPATOL, V23, P8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1995, ANN INTERN MED, V123, P897, DOI 10.7326/0003-4819-123-12-199512150-00001; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; Dusheiko G, 1996, J HEPATOL, V25, P591, DOI 10.1016/S0168-8278(96)80225-X; Hawkins A, 1997, J CLIN MICROBIOL, V35, P187, DOI 10.1128/JCM.35.1.187-192.1997; *INT GROUP, 1977, LANCET, V2, P914; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LIN R, 1995, J HEPATOL, V23, P487, DOI 10.1016/0168-8278(95)80052-2; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; PATTERSON JL, 1990, REV INFECT DIS, V12, P1132; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REICHARD O, 1994, HEPATOLOGY, V19, P280; REICHARD O, 1993, J MED VIROL, V41, P99, DOI 10.1002/jmv.1890410203; REICHARD O, 1991, LANCET, V337, P1058, DOI 10.1016/0140-6736(91)91707-2; Reichard O, 1996, DIGEST DIS SCI, V41, pS109, DOI 10.1007/BF02087885; Schalm SW, 1997, J HEPATOL, V26, P961, DOI 10.1016/S0168-8278(97)80103-1; Schvarcz R, 1995, J HEPATOL, V23, P17; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TONG MJ, IN PRESS HEPATOLOGY; Toyoda H, 1996, J MED VIROL, V48, P354, DOI 10.1002/(SICI)1096-9071(199604)48:4<354::AID-JMV9>3.0.CO;2-6; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502; YUN ZB, 1994, SCAND J INFECT DIS, V26, P263, DOI 10.3109/00365549409011794	33	588	607	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					83	87		10.1016/S0140-6736(97)06088-1	http://dx.doi.org/10.1016/S0140-6736(97)06088-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439491				2022-12-28	WOS:000071591900008
J	Braman, GN				Braman, GN			Wacker revisited	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Braman, GN (corresponding author), 6142 Delafield Ave, Bronx, NY 10471 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					69	69		10.7326/0003-4819-128-1-199801010-00012	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424985				2022-12-28	WOS:000071158000012
J	Huang, HJ; Liao, J; Cohen, SN				Huang, HJ; Liao, J; Cohen, SN			Poly(A)- and poly(U)-specific RNA 3 ' tail shortening by E-coli ribonuclease E	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ANTISENSE RNAI; DEGRADATION; REPLICATION; PROTEINS; CLEAVES; BINDING; COMPLEX; ENZYME	Ribonuclease (RNase) E is an extensively studied enzyme from Escherichia coli whose site-specific endoribonuclease activity on single-stranded RNA has a central role in the processing of ribosomal RNA, the degradation of messenger RNA and the control of replication of ColE1-type plasmids (for recent reviews, see refs 1-3). Here we report a previously undetected activity of RNase E: the ability to shorten 3' poly(A)- and poly(U)-homopolymer tails on RNA molecules. This activity, which leaves a 6-nucleotide adenylate or a 1-nucleotide uridylate remnant on primary transcripts, resides in the amino-terminal region of RNase E and does not require other protein cofactors. Addition of a 3'-terminal phosphate group prevents both removal of the poly(A) tail and endonucleolytic cleavage within primary transcripts, but has no effect on the cleavage of transcripts with tails that have already been truncated. The ability of RNase E to shorten poly(A) tails, together with the effect of tail length on endonucleolytic cleavage within primary transcripts, suggests a mechanism by which RNase E may exercise overall control over RNA decay.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.							Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; ClaverieMartin F, 1997, J BIOL CHEM, V272, P13823, DOI 10.1074/jbc.272.21.13823; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; EHRETSMANN CP, 1992, FASEB J, V6, P318; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JACOBSON A, 1996, COLD SPRING HARBOR M, V30, P451; Kaberdin VR, 1996, J BIOL CHEM, V271, P13103, DOI 10.1074/jbc.271.22.13103; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; KLEE CB, 1968, J BIOL CHEM, V243, P923; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, V15, P517; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NOSSAL NG, 1968, J BIOL CHEM, V243, P913; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; Sarkar N, 1996, MICROBIOL-UK, V142, P3125, DOI 10.1099/13500872-142-11-3125; SINGER MF, 1965, BIOCHEMISTRY-US, V4, P1319, DOI 10.1021/bi00883a016; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	28	68	70	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					99	102		10.1038/34219	http://dx.doi.org/10.1038/34219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422514				2022-12-28	WOS:000071326100058
J	Simmonds, RE; Ireland, H; Lane, DA; Zoller, B; de Frutos, PG; Dahlback, B				Simmonds, RE; Ireland, H; Lane, DA; Zoller, B; de Frutos, PG; Dahlback, B			Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect	ANNALS OF INTERNAL MEDICINE			English	Article						protein S deficiency; thrombophlebitis; heterozygote; mutation; hereditary diseases	C4B-BINDING PROTEIN; C DEFICIENCY; PLASMA-LEVELS; FACTOR-X; THROMBOPHILIA; ORGANIZATION; COMPLEX; DISEASE; OUTPATIENTS; RESISTANCE	Background: Protein S is an important regulatory protein of the coagulation cascade. The risk for venous thrombosis associated with protein S deficiency has been uncertain because all previous risk estimates used phenotypic evaluation alone, which can be ambiguous. Objective: To quantitate the risk for thrombosis associated with a characterized protein S gene mutation that causes a Gly295-->Val substitution and protein S deficiency. Design: Retrospective study of a single extended family. Setting: University hospital referral center. Participants: A 122-member protein S-deficient family, in which 44 members had a recently characterized gene defect. Measurements: Comprehensive history of thrombosis, history of exposure to acquired risk factors for thrombosis, levels of total and free protein S antigen, and genotype for the mutation causing the Gly295-->Val substitution. Results: Kaplan-Meier analysis of thrombosis-free survival showed that the probability of remaining free of thrombosis at 30 years of age is 0.5 (95% CI, 0.33 to 0.66) for carriers of the Gly295-->Val mutation compared with 0.97 (CI, 0.93 to 1.0) for normal family members (P < 0.001). In a multivariate Cox regression model that included smoking and obesity, the mutation was a strong independent risk factor for thrombosis (hazard ratio, 11.5 [CI, 4.33 to 30.6]; P < 0.001). For free (but not total) protein S antigen levels, the distributions of persons with and persons without the mutation did not overlap. Conclusions: Protein S deficiency, as defined by the presence of a causative gene mutation or a reduced level of free protein S antigen; is a strong independent risk factor for venous thrombosis in a clinically affected family.	Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, London W6 8RP, England; Univ Lund Hosp, Dept Internal Med, S-22185 Lund, Sweden; Lund Univ, Dept Clin Chem, S-20502 Malmo, Sweden	Imperial College London; Lund University; Skane University Hospital; Lund University	Simmonds, RE (corresponding author), Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, St Dunstans Rd, London W6 8RP, England.		Ireland, Helen A/B-9868-2008; Zöller, Bengt/M-3217-2019; de Frutos, Pablo García/B-8594-2011; Zöller, Bengt/H-8856-2012; Simmonds, Rachel E/M-7122-2016	Ireland, Helen A/0000-0002-7980-548X; Zöller, Bengt/0000-0002-8250-5613; de Frutos, Pablo García/0000-0003-1547-1190; Zöller, Bengt/0000-0002-8250-5613; Simmonds, Rachel E/0000-0003-4843-8266; Lane, David/0000-0003-4283-3695; Dahlback, Bjorn/0000-0003-1546-0328				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BENTAL O, 1989, THROMB HAEMOSTASIS, V61, P50; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; EDENBRANDT CM, 1990, BIOCHEMISTRY-US, V29, P7861, DOI 10.1021/bi00486a012; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; Gandrille S, 1997, THROMB HAEMOSTASIS, V77, P1201; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1992, BLOOD, V79, P3203; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HENKENS CMA, 1995, THROMB HAEMOSTASIS, V74, P1271; Hille ETM, 1997, BLOOD, V89, P1963, DOI 10.1182/blood.V89.6.1963; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOPPELMAN SJ, 1995, BLOOD, V86, P1062; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; MAHASANDANA C, 1990, LANCET, V335, P61, DOI 10.1016/0140-6736(90)90201-F; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P441; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; Rosendaal FR, 1997, THROMB HAEMOSTASIS, V78, P1; SCHMIDEL DK, 1990, BIOCHEMISTRY-US, V29, P7845, DOI 10.1021/bi00486a010; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCOTT BD, 1991, AM HEART J, V122, P76, DOI 10.1016/0002-8703(91)90761-6; Simmonds RE, 1996, BLOOD, V88, P4195; Simmonds RE, 1997, BLOOD, V89, P4364, DOI 10.1182/blood.V89.12.4364; TABERNERO MD, 1991, AM J HEMATOL, V36, P249, DOI 10.1002/ajh.2830360405; VANAMSTEL HKP, 1990, BIOCHEMISTRY-US, V29, P7853, DOI 10.1021/bi00486a011; VANBOVEN HH, 1994, BLOOD, V84, P4209, DOI 10.1182/blood.V84.12.4209.bloodjournal84124209; vanBoven HH, 1997, THROMB HAEMOSTASIS, V77, P452; ZOLLER B, 1993, THROMB HAEMOSTASIS, V69, P1256; ZOLLER B, 1995, BLOOD, V85, P3524, DOI 10.1182/blood.V85.12.3524.bloodjournal85123524; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	38	76	77	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					8	+		10.7326/0003-4819-128-1-199801010-00002	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424998				2022-12-28	WOS:000071158000002
J	Martin, LA; Vile, R; Lemoine, NR; Sikora, K; Pandha, HS				Martin, LA; Vile, R; Lemoine, NR; Sikora, K; Pandha, HS			Genetic prodrug activation therapy	LANCET			English	Editorial Material									Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, London W12 0NN, England	Cancer Research UK; Imperial College London	Martin, LA (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, London W12 0NN, England.							Cosset FL, 1996, GENE THER, V3, P946; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; HARRIS JD, 1994, GENE THER, V1, P170; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; Martin LA, 1996, CANCER METAST REV, V15, P301, DOI 10.1007/BF00046344; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Ring CJA, 1997, GENE THER, V4, P1045, DOI 10.1038/sj.gt.3300510; VILE RG, 1993, CANCER RES, V53, P3860	8	5	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1793	1794		10.1016/S0140-6736(05)63633-1	http://dx.doi.org/10.1016/S0140-6736(05)63633-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428248				2022-12-28	WOS:000071102500005
J	Ronsmans, C; Vanneste, AM; Chakraborty, J; van Ginneken, J				Ronsmans, C; Vanneste, AM; Chakraborty, J; van Ginneken, J			Decline in maternal mortality in Matlab, Bangladesh: a cautionary tale	LANCET			English	Article							HEALTH-SERVICES; CARE PROGRAM; IMPACT; CHILD	Background A study in Matlab, Bangladesh, has provided evidence favouring a community-based maternity-care delivery system, 3 years of this programme coincided with a significant reduction in direct obstetric mortality compared with the 3 years before the programme, We have examined whether the effects of the programme are sustained over time. Methods Using data from the continuing demographic surveillance system and from special investigations into the rates and causes of maternal mortality during 1976-93, we compared the trends in direct obstetric maternal mortality ratios in the Maternal and Child Health and Family Planning (MCH-FP) area (which has received extensive services in health and family planning since 1977) with those in the comparison area (with no such intensive health inputs), We divided the areas and time periods into discrete groups;hat best represented the effects of the introduction of the maternity-care programme. Findings Direct obstetric mortality declined by 3% per year (rate ratio 0.97 per year [95% CI 0.95-0.99]); there was no difference between the MCH-FP and comparison areas (1.00 [0.96-1.05]), Direct obstetric mortality halved between 1976-86 and 1987-89 in the northern MCH-FP area, where the maternity-care programme was initiated in 1987 (0.50 [0.22-0.99]), hut showed no change in the southern MCH-FP area, which had no such intervention at that time (1.07 [0.64-1.72]). After 1990, when the programme was expanded throughout the MCH-FP area, the southern part showed a downward (non-significant) trend in direct obstetric mortality (0.68 [0.35-1.32]). However, direct obstetric mortality also declined between 1987 and 1989 in the southern comparison area (0.48 [0.26-0.83]) in the absence of an intense maternity-care programme, and remained stable thereafter. In the north ern comparison area, there was no such decline in direct obstetric mortality (0.78 [0 40-1.40]). Interpretation Although the introduction of the maternity-care programme coincided with declining trends in direct obstetric mortality in the areas covered by the programme, a decline also occurred in one of the areas not receiving any such interventions, Caution is required in the interpretation of short-term trends in one indicator in studies designed without random allocation of interventions into treatment and control groups.	Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; London Sch Hyg & Trop Med, Maternal & Child Epidemiol Unit, London WC1, England; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh	Institute of Tropical Medicine (ITM); University of London; London School of Hygiene & Tropical Medicine; International Centre for Diarrhoeal Disease Research (ICDDR)	Ronsmans, C (corresponding author), Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.	cronsmans@itg.be						*COMM MAT CHILD CA, 1964, GUID MAT DEATH STUD; DEGRAFF DS, 1986, STUD FAMILY PLANN, V17, P228, DOI 10.2307/1966972; FAUVEAU V, 1991, LANCET, V338, P1183, DOI 10.1016/0140-6736(91)92041-Y; FAUVEAU V, 1988, HEALTH POLICY PLANN, V3, P271; Fauveau V., 1994, MATLAB WOMEN CHILDRE; Foord Frances, 1995, World Health Statistics Quarterly, V48, P18; Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16; GREENWOOD AM, 1990, J TROP MED HYG, V93, P58; HAYES R, 1995, AIDS, V9, P919, DOI 10.1097/00002030-199508000-00014; HOGBERG U, 1986, INT J GYNECOL OBSTET, V24, P251, DOI 10.1016/0020-7292(86)90081-0; KOBLINSKY M, IN PRESS LANCET; KOENIG MA, 1988, STUD FAMILY PLANN, V19, P69, DOI 10.2307/1966492; KOENIG MA, 1994, MATLAB WOMEN CHILDRE, P285; LAMB WH, 1984, LANCET, V2, P912; LOUDON I, 1992, BRIT MED J, V305, P1557, DOI 10.1136/bmj.305.6868.1557; Maine D, 1996, STUD FAMILY PLANN, V27, P179, DOI 10.2307/2137952; Maine D, 1991, SAFE MOTHERHOOD PROG; MIRZA T, 1993, 84 ICDDRB; MOSTAFA G, 1996, 77 INT CTR DIARRH DI; RONSMANS C, IN PRESS INT J EPIDE; Rooney C., 1992, ANTENATAL CARE MATER; RUZICKA LT, 1987, 9 INT CTR DIARRH DIS, V1; TRUSSELL J, 1984, STUD FAMILY PLANN, V15, P267, DOI 10.2307/1966071; WHO, 1991, ESS EL OBST CAR 1 RE	24	78	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	1997	350	9094					1810	1814		10.1016/S0140-6736(97)08012-4	http://dx.doi.org/10.1016/S0140-6736(97)08012-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YM803	9428252				2022-12-28	WOS:000071102500010
J	Roberts, J				Roberts, J			Transcription - Control of the supply line	SCIENCE			English	Editorial Material							RIBOSOMAL-RNA SYNTHESIS; ESCHERICHIA-COLI; FEEDBACK-REGULATION; EXPRESSION; OPERONS; PPGPP				Roberts, J (corresponding author), CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853, USA.							BARACCHINI E, 1991, J BIOL CHEM, V266, P11753; BREMER H, 1996, CELLULAR MOL BIOL, V2, P1553; Cashell M, 1996, CELLULAR MOL BIOL, V1, P1458; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; HERNANDEZ VJ, 1993, J BIOL CHEM, V268, P10851; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; KEENER J, 1996, CELLULAR MOL BIOL, V1, P1417; LIU J, 1994, J BACTERIOL, V176, P2938, DOI 10.1128/JB.176.10.2938-2945.1994; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335	13	14	14	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2073	2074		10.1126/science.278.5346.2073	http://dx.doi.org/10.1126/science.278.5346.2073			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432720				2022-12-28	WOS:A1997YM23500040
J	Burn, J; Dennis, M; Bamford, J; Sandercock, P; Wade, D; Warlow, C				Burn, J; Dennis, M; Bamford, J; Sandercock, P; Wade, D; Warlow, C			Epileptic seizures after a first stroke: the Oxfordshire community stroke project	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; INTRACEREBRAL HEMORRHAGE; POPULATION; CLASSIFICATION; DEMOGRAPHY; FREQUENCY; ONSET	Objective: To describe the immediate and long term risk of epileptic seizures after a first ever stroke. Design: Cohort study following up stroke survivors for 2 to 6.5 years; comparison with age specific incidence rates of epileptic seizures in the general population. Setting: Community based stroke register. Subjects: 675 patients with a first stroke, followed up for a minimum of 2 years. Main outcome measures: Occurrence of single and recurrent seizures. Results: 52 patients had one or more post stroke seizures; in 25 the seizures were recurrent The 5 year actuarial risk of a post stroke seizure in survivors (excluding 19 patients with a history of epilepsy and 3 patients in whom the seizure occurred shortly before death from another cause) was 11.5% (95% confidence interval 4.8% to 18.2%). The relative risk of seizures, in comparison with the general population, was estimated at 35.2 in the first year after stroke and 19.0 in year 2. The risk of seizures was increased in survivors of subarachnoid and intracerebral haemorrhage (hazard ratio for intracranial haemorrhage v cerebral infarction 10.2 (3.7 to 27.9)), The risk of seizures after ischaemic stroke was substantial only in patients presenting with severe strokes due to total anterior circulation infarction. Only 9 of 295 patients (3%) independent one month after stroke suffered a seizure between 1 month and 5 years (actuarial risk 4.2% (0.1% to 8.3%)). Conclusion: Stroke patients hare about an 11.5% risk of single or recurrent seizures in the first 5 years after a stroke, Patients with more severe strokes or haemorrhagic strokes are at higher risk.	Southampton Gen Hosp, Rehabil Res Unit, Southampton SO9 4XY, Hants, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; St James Univ Hosp, Dept Neurol, Leeds LS9 7TF, W Yorkshire, England; Rivermead Rehabil Ctr, Oxford OX1 4XD, England	University of Southampton; University of Edinburgh; Saint James's University Hospital	Burn, J (corresponding author), Southampton Gen Hosp, Rehabil Res Unit, Southampton SO9 4XY, Hants, England.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021; Ritter, Stefanie L/D-9312-2012	sandercock, peter/0000-0001-8484-0135; Wade, Derick/0000-0002-1188-8442				ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; AVRAHAMI E, 1988, J NEUROL, V235, P472, DOI 10.1007/BF00314250; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BAQUIS GD, 1985, STROKE, V16, P444, DOI 10.1161/01.STR.16.3.444; BAROLIN GS, 1971, FORTSCHR NEUROL P I, V39, P199; DAVALOS A, 1988, J NEUROL NEUROSUR PS, V51, P1464, DOI 10.1136/jnnp.51.11.1464; DECAROLIS P, 1984, J NEUROL NEUROSUR PS, V47, P1345, DOI 10.1136/jnnp.47.12.1345; DODGE PR, 1954, BRAIN, V77, P610, DOI 10.1093/brain/77.4.610; EVANS JH, 1963, NEUROLOGY, V13, P207, DOI 10.1212/WNL.13.3.207; FAUGHT E, 1984, EPILEPSIA, V25, P666; FRENCH JD, 1956, ARCH NEURO PSYCHIATR, V75, P260, DOI 10.1001/archneurpsyc.1956.02330210040005; Gardner M. J., 1989, STAT CONFIDENCE; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; HALL G C, 1988, Pharmaceutical Medicine (London), V2, P345; HAUSER WA, 1984, EPILEPSIA, V25, P666; Jennet B, 1975, EPILEPSY NONMISSILE; KASE CS, 1989, STROKE, V20, P850, DOI 10.1161/01.STR.20.7.850; KILPATRICK CJ, 1990, ARCH NEUROL-CHICAGO, V47, P157, DOI 10.1001/archneur.1990.00530020053014; MOSKOWITZ E, 1972, ARCH PHYS MED REHAB, V53, P167; OLSEN TS, 1987, NEUROLOGY, V37, P1209, DOI 10.1212/WNL.37.7.1209; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; REITH J, 1996, EUR J N EUROL S2, V3, P93; ROBERTS MA, 1982, AGE AGEING, V11, P24, DOI 10.1093/ageing/11.1.24; ROBERTS RC, 1988, EPILEPSIA, V29, P190, DOI 10.1111/j.1528-1157.1988.tb04418.x; ROPPER AH, 1988, NEUROLOGY, V38, P1500, DOI 10.1212/WNL.38.9.1500-a; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; SHINTON RA, 1987, LANCET, V1, P11; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; STARKEY IR, 1987, LANCET, V1, P742; SUNG CY, 1989, J NEUROL NEUROSUR PS, V52, P1273, DOI 10.1136/jnnp.52.11.1273; TALLIS R, 1991, AGE AGEING, V20, P442, DOI 10.1093/ageing/20.6.442; VIITANEN M, 1988, EUR NEUROL, V28, P227, DOI 10.1159/000116272	39	274	286	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1582	1587		10.1136/bmj.315.7122.1582	http://dx.doi.org/10.1136/bmj.315.7122.1582			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437276	Green Published			2022-12-28	WOS:000071021900023
J	Oakley, C				Oakley, C			Clinical review - Aetiology, diagnosis, investigation, and management of the cardiomyopathies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TUMOR-NECROSIS-FACTOR; HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; HEART-FAILURE; MYOCARDITIS; MORTALITY	A molecular pathogenesis for dilated and hypertrophic cardiomyopathy is beginning to be elucidated. More than half of patients with hypertrophic cardiomyopathy and a quarter of patients with dilated cardiomyopathy have familial disease. Known genetic mutations occur in only about a half of families affected by hypertrophic cardiomyopathy and considerable genetic diversity may give rise to similar phenotypes Differences in phenotype expression within affected families may reflect other modifying genetic or environmental factors Diagnosis of hypertrophic cardiomyopathy is based on the echocardiographic finding of unexplained thickening of parr or all of the left ventricular wall with a normal or small sized cavity. Within affected families, however, electrocardiography is more sensitive than echocardiography in detecting the disorder. Diagnosis of dilated cardiomyopathy is based on echocardiographic recognition of left ventricular dilatation and reduced contractile function after exclusion of valvular or coronary disease.			Oakley, C (corresponding author), HAMMERSMITH HOSP, IMPERIAL COLL, LONDON W12 0NN, ENGLAND.							Basso C, 1996, CIRCULATION, V94, P983, DOI 10.1161/01.CIR.94.5.983; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; DEL GW, 1994, NEW ENGL J MED, V331, P1564; DILENARDA A, 1994, BRIT HEART J, V72, pS46; FAY WP, 1990, J AM COLL CARDIOL, V16, P821, DOI 10.1016/S0735-1097(10)80328-6; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Habib FM, 1996, LANCET, V347, P1151, DOI 10.1016/S0140-6736(96)90610-8; Hawkins PN, 1997, J ROY COLL PHYS LOND, V31, P552; HOSENPUD JD, 1994, J HEART LUNG TRANSPL, V13, P561; JULIAN DG, 1996, DIS HEART; Kappenberger L, 1997, EUR HEART J, V18, P1249; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KEELING PJ, 1994, BRIT HEART J, V72, pS25; MESTRONI L, 1994, BRIT HEART J, V72, pS35; Mittal SR, 1995, INT J CARDIOL, V52, P1, DOI 10.1016/0167-5273(95)02429-Z; Monson JP, 1997, HEART, V77, P1; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; OAKLEY CM, 1993, CARDIOVASCULAR DISOR, P210; OLDFORS A, 1994, BRIT HEART J, V72, P344; PACKER M, 1995, CIRCULATION, V92, P1379, DOI 10.1161/01.CIR.92.6.1379; POHTANA L, 1996, JAMA-J AM MED ASSOC, V275, P1335; POLLICK C, 1988, AM J CARDIOL, V62, P1248, DOI 10.1016/0002-9149(88)90268-8; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; RICKENBACHER PR, 1994, AM HEART J, V127, P1318, DOI 10.1016/0002-8703(94)90051-5; RIZEQ MN, 1994, AM J CARDIOL, V74, P474, DOI 10.1016/0002-9149(94)90906-7; Robbins RC, 1996, J THORAC CARDIOV SUR, V111, P586, DOI 10.1016/S0022-5223(96)70310-0; RYAN MP, 1995, AM J CARDIOL, V76, P689, DOI 10.1016/S0002-9149(99)80198-2; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; SPIRITO P, 1994, BRIT HEART J, V72, pS10; STEVENSON WG, 1995, CURR OPIN CARDIOL, V10, P274, DOI 10.1097/00001573-199505000-00007; Tavazzi L, 1997, EUR HEART J, V18, P4; TEARE D, 1958, BRIT HEART J, V20, P1; Yusuf S, 1997, EUR HEART J, V18, P1685; Zarembski DG, 1996, AM J CARDIOL, V77, P1247, DOI 10.1016/S0002-9149(96)00175-0	35	6	6	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 6	1997	315	7121					1520	1524		10.1136/bmj.315.7121.1520	http://dx.doi.org/10.1136/bmj.315.7121.1520			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420497	Green Published			2022-12-28	WOS:A1997YK98600029
J	Reed, J; Lyne, M				Reed, J; Lyne, M			The quality of health care in prison: results of a year's programme of semistructured inspections	BRITISH MEDICAL JOURNAL			English	Article							MENTAL DISORDER; PREVALENCE; ENGLAND	Objectives: To assess, as part of wider inspect-ions by HM Inspectorate of Pri Design: Inspections based on a set of ''expectations'' derived mainly from existing healthcare quality standards published by the prison service and existing ethical guidelines; questionnaire survey of prisoners. Subjects: 19 prisons in England and Wales, 1996-7. Main outcome measures: Appraisals of needs assessment and the commissioning and delivery of health care against the inspectorate's expectations. Results: The quality of health care varied greatly. A few prisons provided health care broadly equivalent to NHS care, but in many the health, care was of low quality, some doctors were not adequately trained to do the work they faced, and some care failed to meet proper ethical standards. Little professional support was available to healthcare staff. Conclusions: The current policy for improving health care in prisons is not likely to achieve its objectives and is potentially wasteful. The prison service needs to recognise that expertise in the commissioning and delivery of health care is overwhelmingly based in the NHS. The current review of the provision of health care in prisons offers an opportunity to ensure that prisoners are not excluded from high quality health care.			Reed, J (corresponding author), HM INSPECTORATE PRISONS, HOME OFF, LONDON SW1H 9AT, ENGLAND.			Lyne, Michael/0000-0002-4530-1195				Beech BAL, 1996, BRIT MED J, V312, P256; Bellis MA, 1997, BRIT MED J, V315, P30, DOI 10.1136/bmj.315.7099.30; Birmingham L, 1997, BRIT MED J, V315, P65, DOI 10.1136/bmj.315.7099.65a; Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; BRIDGWOOD A, 1994, SURVEY PHYSICAL HLTH; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; *COMM PREV TORT IN, 1991, REP UK GOV VIS UK; *DEP HLTH HOM OFF, 1997, GOV RESP ADV COMM ME; Dillner L, 1996, BRIT MED J, V312, P200; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; Hall JM, 1997, BRIT MED J, V314, P302, DOI 10.1136/bmj.314.7076.302; *HM, 1964, ORG PRIS MED SERV; *HM INSP PRIS, 1997, PAT PRIS; *HM INSP PRIS, 1996, EXP AV QUAL HLTH CAR; *HM PRIS SERV, 1994, STAND ORD 13 HLTH CA; *HM PRIS SERV DIR, 1996, HLTH CAR STAND PRIS; *HOM OFF, 1991, CUST CAR JUST WAY AH; Home Office, 1990, REP EFF SCRUT PRIS M; Mason D, 1997, BRIT MED J, V315, P18, DOI 10.1136/bmj.315.7099.18; May J., 1979, REPORT COMMITTEE INQ; MITCHISON S, 1994, MED SCI LAW, V34, P324, DOI 10.1177/002580249403400410; Smith R, 1997, BRIT MED J, V314, P164, DOI 10.1136/bmj.314.7075.164; SMITH R, 1997, BRIT MED J, V315, P1; Smith Richard, 1984, PRISON HLTH CARE; *STAT OFF, 1997, PRIS SERV REP DIR HL; STOCKDALE E, 1983, BRIT J CRIMINOL, V23, P209; *UN, 1981, DECL PRINC MED ETH	27	41	41	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1420	1424		10.1136/bmj.315.7120.1420	http://dx.doi.org/10.1136/bmj.315.7120.1420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418090	Green Published			2022-12-28	WOS:A1997YJ67200026
J	Pauly, D; Christensen, V; Dalsgaard, J; Froese, R; Torres, F				Pauly, D; Christensen, V; Dalsgaard, J; Froese, R; Torres, F			Fishing down marine food webs	SCIENCE			English	Article							FISHERIES	The mean trophic level of the species groups reported in Food and Agricultural Organization global fisheries statistics declined from 1950 to 1994. This reflects a gradual transition in landings from long-lived, high trophic level, piscivorous bottom fish toward short-lived, low trophic level invertebrates and planktivorous pelagic fish. This effect, also found to be occurring in inland fisheries, is most pronounced in the Northern? Hemisphere. Fishing down food webs (that is, at lower trophic levels) leads at first to increasing catches, then to a phase transition associated with stagnating or declining catches. These results indicate that present exploitation patterns are unsustainable.	Univ British Columbia, Fisheries Ctr, Vancouver, BC V6T 1Z4, Canada; Int Ctr Living Aquat Resources Management, Makati 0718, Philippines	University of British Columbia; CGIAR; Worldfish	Pauly, D (corresponding author), Univ British Columbia, Fisheries Ctr, 2204 Main Mall, Vancouver, BC V6T 1Z4, Canada.	pauly@fisheries.com	Langhamer, Olivia/J-3425-2012; Torres, Filipa/G-9742-2016; Pauly, Daniel Marc/AAY-2316-2021; Froese, Rainer/C-9687-2009	Froese, Rainer/0000-0001-9745-636X; Pauly, Daniel/0000-0003-3756-4793; Dalsgaard, Anne Johanne Tang/0000-0001-8723-566X				Alcala A. C., 1990, J CONS INT EXPLOR ME, V46, P40; Beddington J.R., 1982, Scientific American, V247, P42; CARR MH, 1993, CAN J FISH AQUAT SCI, V50, P2019, DOI 10.1139/f93-226; Christensen V, 1996, REV FISH BIOL FISHER, V6, P417, DOI 10.1007/BF00164324; CHRISTENSEN V, 1992, ECOL MODEL, V61, P169, DOI 10.1016/0304-3800(92)90016-8; CHRISTENSEN V, 1995, DANA, V11; Christensen V., 1993, C P; DALZELL P, 1989, NETHERLANDS J SEA RE, V24, P641; DUGAN JE, 1993, CAN J FISH AQUAT SCI, V50, P2029, DOI 10.1139/f93-227; *FAO, 1996, FISHSTAT PC DAT RETR; FROESE R, 1997, FISHBASE 97 CONCEPTS; Garcia SM, 1997, AM FISH S S, V20, P3; Gjosaeter J., 1980, REV WORLD RESOURCES; Grainger RJR, 1996, 359 FAO, P51; JARRE A, 1991, ICES MAR SC, V193, P171; Jones R., 1982, ICLARM C P, V9, P195; Longhurst AR, 1987, ECOLOGY TROPICAL OCE; Mark Freeberg J.G.Pope, 1994, GLOBAL ASSESSMENT FI; PARRISH R, 1989, C P, V18; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; PAULY D, 1993, LARGE MARINE ECOSYSTEMS, P148; PIMM SL, 1982, FOOD WEBS; POWER ME, 1992, ECOLOGY, V73, P733, DOI 10.2307/1940153; Rice J, 1996, ICES J MAR SCI, V53, P1214, DOI 10.1006/jmsc.1996.0146; ROBB AP, 1980, J FISH BIOL, V16, P199, DOI 10.1111/j.1095-8649.1980.tb03699.x; ROBERTS CM, 1993, CAN J FISH AQUAT SCI, V6, P363; RYTHER JH, 1969, SCIENCE, V166, P72, DOI 10.1126/science.166.3901.72; SILVESTRE G, 1997, C P, V53; URSIN E, 1982, Dana, V2, P51; [No title captured]	31	3018	3226	11	1053	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					860	863		10.1126/science.279.5352.860	http://dx.doi.org/10.1126/science.279.5352.860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452385				2022-12-28	WOS:000071923500043
J	McLaughlin, VV; Genthner, DE; Panella, MM; Rich, S				McLaughlin, VV; Genthner, DE; Panella, MM; Rich, S			Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; REGISTRY; VESSELS	Background Primary (idiopathic) pulmonary hypertension is a progressive, fatal disease. Conventional therapy with anticoagulant and vasodilator drugs may improve symptoms and survival among selected patients, but there is no evidence that the disease can be reversed. Methods We evaluated the effects of long-term thera py (i.e., for more than one year) with intravenous epoprostenol (prostacyclin) in patients with advanced primary pulmonary hypertension. The base-line evaluation included an assessment of pulmonary vascular dilation in response to intravenous adenosine. The epoprostenol dose was increased monthly to the maximum tolerated. Long-term therapy was evaluated by measuring improvement in symptoms, exercise capacity, and hemodynamic variables. Results We evaluated 27 patients with primary pulmonary hypertension over a mean (+/-SD) period of 16.7+/-5.2 months. Intravenous adenosine had a variable effect on pulmonary vascular resistance (mean reduction, 27 percent; range, 0 to 56; P<0.001). Epoprostenol therapy was initiated and the rate of infusion was increased by an average of 2.4 ng per kilogram of body weight per minute each month. Twenty-six of the 27 patients had improvement in symptoms and hemodynamic measures, and overall, pulmonary vascular resistance declined by 53 percent to 7.9+/-3.8 resistance units (P<0.001) at the time of restudy. The long-term effects of epoprostenol exceeded the short-term pulmonary vasodilator response to adenosine in all but one patient. Seven of the eight patients who had minimal pulmonary vasodilation in response to adenosine (mean reduction in resistance units, <20 percent) still had a significant reduction in pulmonary vascular resistance when treated with epoprostenol (mean, 39+/-14 percent; P=0.002). Conclusions In primary pulmonary hypertension, long-term therapy with epoprostenol lowers pulmonary vascular resistance beyond the level achieved in the short term with intravenous adenosine. Epoprostenol appears to have sustained efficacy in this disorder. (C) 1998, Massachusetts Medical Society.	Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Cardiol Sect, Chicago, IL 60612 USA	Rush University	Rich, S (corresponding author), Rush Presbyterian St Lukes Med Ctr, Ctr Pulm Heart Dis, Rush Heart Inst, 1725 W Harrison St,Suite 020, Chicago, IL 60612 USA.							BARST RJ, 1986, CHEST, V89, P497, DOI 10.1378/chest.89.4.497; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; HIGENBOTTAM T, 1984, LANCET, V1, P1046; JONES DA, 1995, MOL PHARMACOL, V48, P890; NOOTENS M, 1995, CHEST, V107, P54, DOI 10.1378/chest.107.1.54; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RUBIN LJ, 1983, ANN INTERN MED, V99, P433, DOI 10.7326/0003-4819-99-4-433; Shapiro SM, 1997, J AM COLL CARDIOL, V30, P343, DOI 10.1016/S0735-1097(97)00187-3; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WAGENVOORT CA, 1985, MINN MED, V68, P45; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623	17	490	511	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					273	277		10.1056/NEJM199801293380501	http://dx.doi.org/10.1056/NEJM199801293380501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445406	Bronze			2022-12-28	WOS:000071665200001
J	Kim, JJ; Krupa, DJ; Thompson, RF				Kim, JJ; Krupa, DJ; Thompson, RF			Inhibitory cerebello-olivary projections and blocking effect in classical conditioning	SCIENCE			English	Article							NICTITATING-MEMBRANE RESPONSE; INFERIOR OLIVE; US LOCUS; LESIONS; RABBIT; RAT; ACQUISITION; EYEBLINK; STIMULI; CAT	The behavioral phenomenon of blocking indicates that the informational relationship between the conditioned stimulus and the unconditioned stimulus is essential in classical conditioning. The eyeblink conditioning paradigm is used to describe a neural mechanism that mediates blocking, Disrupting inhibition of the inferior olive, a structure that conveys unconditioned stimulus information (airpuff) to the cerebellum prevented blocking in rabbits. Recordings of cerebellar neuronal activity show that the inferior olive input to the cerebellum becomes suppressed as learning occurs. These results suggest that the inferior olive becomes functionally inhibited by the cerebellum during conditioning, and that this negative feedback process might be the neural mechanism mediating blocking.	Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA	University of Southern California	Kim, JJ (corresponding author), Yale Univ, Dept Psychol, 2 Hillhouse Ave, New Haven, CT 06520 USA.	jeansok.kim@yale.edu			ACF HHS [AF05142] Funding Source: Medline	ACF HHS		ANDERSON G, 1988, BRAIN RES, V472, P450; ANGAUT P, 1987, NEUROSCI LETT, V83, P227, DOI 10.1016/0304-3940(87)90090-5; ANGAUT P, 1989, BRAIN RES, V479, P361, DOI 10.1016/0006-8993(89)91641-7; Angaut P, 1996, NEUROSCI RES, V26, P345, DOI 10.1016/S0168-0102(96)01116-9; Betts SL, 1996, ANIM LEARN BEHAV, V24, P459, DOI 10.3758/BF03199017; DICKINSON A, 1979, J EXP PSYCHOL ANIM B, V5, P162, DOI 10.1037/0097-7403.5.2.162; DONEGAN NH, 1989, COMPUTATIONAL MODELS, P108; FREDETTE BJ, 1991, ANAT EMBRYOL, V184, P225, DOI 10.1007/BF01673258; GIBSON AR, 1987, J COMP NEUROL, V260, P362, DOI 10.1002/cne.902600304; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HAWKINS RD, 1984, PSYCHOL REV, V91, P375, DOI 10.1037/0033-295X.91.3.375; Hesslow G, 1996, EXP BRAIN RES, V110, P36; Kamin L. J., 1968, MIAMI S PREDICTION B, P9; Katz DB, 1997, LEARN MEMORY, V4, P88, DOI 10.1101/lm.4.1.88; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; MACKINTOSH NJ, 1975, PSYCHOL REV, V82, P276, DOI 10.1037/h0076778; MARCHANT HG, 1973, J EXP PSYCHOL, V101, P155; MAUK MD, 1986, P NATL ACAD SCI USA, V83, P5349, DOI 10.1073/pnas.83.14.5349; MCCORMICK DA, 1985, BRAIN RES, V359, P120, DOI 10.1016/0006-8993(85)91419-2; MOORE JW, 1997, LEARN MEM COLD SPRIN, V3, P116; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SEARS LL, 1991, BRAIN RES, V545, P114, DOI 10.1016/0006-8993(91)91276-7; STICKNEY KJ, 1983, ANIM LEARN BEHAV, V11, P60, DOI 10.3758/BF03212308; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; TURKER KS, 1984, BRAIN RES BULL, V13, P229, DOI 10.1016/0361-9230(84)90121-7; TURKER KS, 1986, BRAIN RES, V363, P376; VONEIDA TJ, 1990, J NEUROSCI, V10, P3583; Wagner A.R., 1981, P5; WAGNER AR, 1989, PSYCHOL LEARN MOTIV, V23, P157; YEO CH, 1991, ANN NY ACAD SCI, V627, P292; YEO CH, 1986, EXP BRAIN RES, V63, P81	34	155	157	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					570	573		10.1126/science.279.5350.570	http://dx.doi.org/10.1126/science.279.5350.570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YT527	9438852				2022-12-28	WOS:000071616000049
J	Zhao, DY; Feng, JL; Huo, QS; Melosh, N; Fredrickson, GH; Chmelka, BF; Stucky, GD				Zhao, DY; Feng, JL; Huo, QS; Melosh, N; Fredrickson, GH; Chmelka, BF; Stucky, GD			Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores	SCIENCE			English	Article							MOLECULAR-SIEVES; MCM-41; MECHANISM; TEMPLATES; BEHAVIOR; PHASES	Use of amphiphilic triblock copolymers to direct the organization of polymerizing silica species has resulted in the preparation of well-ordered hexagonal mesoporous silica structures (SBA-15) with uniform pore sizes up to approximately 300 angstroms, The SBA-15 materials are synthesized in acidic media to produce highly ordered, two-dimensional hexagonal (space group p6mm) silica-block copolymer mesophases, Calcination at 500 degrees C gives porous structures with unusually large interlattice d spacings of 74.5 to 320 angstroms between the (100) planes, pore sizes from 46 to 300 angstroms, pore volume fractions up to 0.85, and silica wall thicknesses of 31 to 64 angstroms. SBA-15 can be readily prepared over a wide range of uniform pore sizes and pore wall thicknesses at low temperature (35 degrees to 80 degrees C), using a variety of poly(alkylene oxide) triblock copolymers and by the addition of cosolvent organic molecules, The block copolymer species can be recovered for reuse by solvent extraction with ethanol or removed by heating at 140 degrees C for 3 hours, in both cases, yielding a product that is thermally stable in boiling water.	Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Ctr Quantized Elect Struct, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Chmelka, BF (corresponding author), Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA.		, 赵东元/E-5796-2010	, 赵东元/0000-0002-1642-2510				Aksay IA, 1996, SCIENCE, V273, P892, DOI 10.1126/science.273.5277.892; Antonelli DM, 1996, CURR OPIN COLLOID IN, V1, P523, DOI 10.1016/S1359-0294(96)80122-1; Antonelli DM, 1996, ANGEW CHEM INT EDIT, V35, P426, DOI 10.1002/anie.199604261; ATONIETTI M, 1997, ANGEW CHEM INT EDIT, V36, P910; ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0; BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242; BECK JC, 1993, Patent No. 5156829; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BRANTON PJ, 1994, J CHEM SOC FARADAY T, V90, P2965, DOI 10.1039/ft9949002965; CHEN CY, 1993, MICROPOROUS MATER, V2, P17, DOI 10.1016/0927-6513(93)80058-3; Chu B., 1996, SURF SCI SERIES, V60, P67; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; Firouzi A, 1997, J AM CHEM SOC, V119, P9466, DOI 10.1021/ja971267+; Firouzi A, 1997, J AM CHEM SOC, V119, P3596, DOI 10.1021/ja963007i; GOTLNER CG, 1997, ADV MATER, V9, P431; Hillmyer MA, 1997, J AM CHEM SOC, V119, P2749, DOI 10.1021/ja963622m; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1995, SCIENCE, V268, P1324, DOI 10.1126/science.268.5215.1324; HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016; Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h; KHUSHALANI D, 1995, ADV MATER, V7, P842, DOI 10.1002/adma.19950071005; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lim MH, 1997, J AM CHEM SOC, V119, P4090, DOI 10.1021/ja9638824; MATSEN MW, 1995, MACROMOLECULES, V28, P5765, DOI 10.1021/ma00121a011; Matsen MW, 1996, CURR OPIN COLLOID IN, V1, P329, DOI 10.1016/S1359-0294(96)80128-2; McGrath KM, 1997, SCIENCE, V277, P552, DOI 10.1126/science.277.5325.552; Prouzet E, 1997, ANGEW CHEM INT EDIT, V36, P516, DOI 10.1002/anie.199705161; Ryoo R, 1996, J PHYS CHEM-US, V100, P17718, DOI 10.1021/jp9620835; Ryoo R, 1997, J PHYS CHEM B, V101, P317, DOI 10.1021/jp962500d; Sayari A, 1996, CHEM MATER, V8, P1840, DOI 10.1021/cm950585+; SCHMIDT R, 1995, J AM CHEM SOC, V117, P4049, DOI 10.1021/ja00119a021; TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865; Tanev PT, 1996, SCIENCE, V271, P1267, DOI 10.1126/science.271.5253.1267; Tolbert SH, 1997, SCIENCE, V278, P264, DOI 10.1126/science.278.5336.264; WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016; Zana R, 1997, COLLOID SURFACE A, V123, P27, DOI 10.1016/S0927-7757(96)03788-0; Zhao D., UNPUB; [No title captured]	38	10693	11317	119	4466	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					548	552		10.1126/science.279.5350.548	http://dx.doi.org/10.1126/science.279.5350.548			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438845				2022-12-28	WOS:000071616000042
J	van Enk, SJ; Cirac, JI; Zoller, P				van Enk, SJ; Cirac, JI; Zoller, P			Photonic channels for quantum communication	SCIENCE			English	Article								A general photonic channel for quantum communication is defined. By means of local quantum computing with a few auxiliary atoms, this channel can be reduced to one with effectively less noise. A scheme based on quantum interference is proposed that iteratively improves the fidelity of distant entangled particles.	Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria	University of Innsbruck	van Enk, SJ (corresponding author), Univ Innsbruck, Inst Theoret Phys, Technikerstr 25, A-6020 Innsbruck, Austria.		Zoller, Peter/O-1639-2014; Cirac, J. Ignacio/A-9105-2017	Zoller, Peter/0000-0003-4014-1505; Cirac, J. Ignacio/0000-0003-3359-1743				BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Bennett CH, 1997, PHYS REV LETT, V78, P3217, DOI 10.1103/PhysRevLett.78.3217; BENNETT CH, 1995, PHYS TODAY, V48, P24, DOI 10.1063/1.881452; Bennett CH, 1996, PHYS REV LETT, V76, P722, DOI 10.1103/PhysRevLett.76.722; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Cirac JI, 1996, SCIENCE, V273, P1207, DOI 10.1126/science.273.5279.1207; Ekert A, 1996, PHYS REV LETT, V77, P2585, DOI 10.1103/PhysRevLett.77.2585; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; Steane AM, 1996, PHYS REV LETT, V77, P793, DOI 10.1103/PhysRevLett.77.793; vanEnk SJ, 1997, PHYS REV LETT, V78, P4293, DOI 10.1103/PhysRevLett.78.4293; WOOTTERS WK, 1982, NATURE, V299, P802, DOI 10.1038/299802a0	13	183	185	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					205	208		10.1126/science.279.5348.205	http://dx.doi.org/10.1126/science.279.5348.205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422688				2022-12-28	WOS:000071408100035
J	Iacoviello, L; Di Castelnuovo, A; de Knijff, P; D'Orazio, A; Amore, C; Arboretti, R; Kluft, C; Donati, MB				Iacoviello, L; Di Castelnuovo, A; de Knijff, P; D'Orazio, A; Amore, C; Arboretti, R; Kluft, C; Donati, MB			Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; REPEAT POLYMORPHISM; HEMOSTATIC FUNCTION; HEALTHY-MEN; F7; IDENTIFICATION; FIBRINOGEN; MUTATION; ANTIGEN; REGION	Background High blood levels of coagulation factor VII are associated with a risk of ischemic vascular disease. Although factor VI levels may be genetically determined, the relation between genetic polymorphisms of factor VII, factor VII blood levels, and the risk of myocardial infarction has not been established. Methods We performed a case-control study of 165 patients with familiar myocardial infarction (mean [+/-SD] age, 55+/-9 years) and 225 controls without a personal or family history of cardiovascular disease (mean age, 56+/-8 years). The polymorphisms involving R353Q and hypervariable region 4 of the factor VI gene were studied. Factor VII clotting activity and antigen levels were also measured. Results Patients with the QQ or H7H7 genotype had a decreased risk of myocardia[ infarction (odds ratios, 0.08 [95 percent confidence interval, 0.01 to 0.9] and 0.22 [95 percent confidence interval, 0.08 to 0.63], respectively). For the R353Q polymorphism, the RR genotype was associated with the highest risk, followed by the RQ genotype and then by the QQ genotype (P<0.001). For the polymorphism involving hypervariable region 4, the combined H7H5 and H6H5 genotypes were associated with the highest risk, followed in descending order by the H6H6, H6H7, and H7H7 genotypes (P<0.001). Patients with the OQ or H7H7 genotype had lower levels of both factor VI[ antigen and factor VII clotting activity than those with the RR or H6H6 genotype. Patients with the fewest level of factor VII clotting activity had a lower risk of myocardial infarction than those with the highest level (odds ratio, 0.13; 95 percent confidence interval, 0.05 to 0.34). Conclusions Our findings suggest that certain polymorphisms of the factor VII gene may influence the risk of myocardial infarction. It is possible that this effect may be mediated by alterations in factor VII levels. (C) 1998. Massachusetts Medical Society.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud,Dept Vasc Med & Pharm, Angela Valenti Lab Thrombosis Pharmacol, Unit Genet Vasc Risk Factors, I-66030 Santa Maria Imbaro, Italy; Ist Ric Farmacol Mario Negri, Dept Clin Pharmacol & Epidemiol, Lab Drug Epidemiol, I-66030 Santa Maria Imbaro, Italy; Leiden Univ, Gaubius Lab, Leiden, Netherlands; Leiden Univ, Dept Human Genet, Ctr Genet Med, NL-2300 RA Leiden, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Iacoviello, L (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud,Dept Vasc Med & Pharm, Angela Valenti Lab Thrombosis Pharmacol, Unit Genet Vasc Risk Factors, I-66030 Santa Maria Imbaro, Italy.		Di Castelnuovo, Augusto Filippo/AAC-2436-2022; de Knijff, Peter/Y-2519-2018; Arboretti, Rosa/AAY-6499-2020; Iacoviello, Licia/K-4676-2016; Donati, Maria Benedetta/K-6606-2016; Iacoviello, Licia/AGX-7071-2022; Siani, Alfonso/B-7925-2015	Di Castelnuovo, Augusto Filippo/0000-0001-9767-7998; de Knijff, Peter/0000-0002-0899-771X; Iacoviello, Licia/0000-0003-0514-5885; Donati, Maria Benedetta/0000-0003-1747-5443; Iacoviello, Licia/0000-0003-0514-5885; ARBORETTI GIANCRISTOFARO, ROSA/0000-0003-1263-0440				[Anonymous], 1990, LANCET, V336, P65; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; BERNARDI F, 1993, HUM GENET, V92, P446, DOI 10.1007/BF00216448; Bernardi F, 1996, ARTERIOSCL THROM VAS, V16, P72; CORTELLARO M, 1992, ARTERIOSCLER THROMB, V12, P1063, DOI 10.1161/01.ATV.12.9.1063; DEKNIJFF P, 1994, HUM MOL GENET, V3, P384; deMaat MPM, 1997, ARTERIOSCL THROM VAS, V17, P1918, DOI 10.1161/01.ATV.17.10.1918; DICASTELNUOVO A, 1997, THROMB HAEMOST S, V77, P390; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P1392; Heywood DM, 1997, STROKE, V28, P816, DOI 10.1161/01.STR.28.4.816; HOFFMAN CJ, 1992, ARTERIOSCLER THROMB, V12, P267, DOI 10.1161/01.ATV.12.3.267; HUMPHRIES SE, 1994, ARTERIOSCLER THROMB, V14, P193, DOI 10.1161/01.ATV.14.2.193; Lane A, 1996, ATHEROSCLEROSIS, V119, P119, DOI 10.1016/0021-9150(95)05638-6; MARCHETTI G, 1992, HUM GENET, V89, P497; MARCHETTI G, 1991, NUCLEIC ACIDS RES, V19, P4570, DOI 10.1093/nar/19.16.4570-a; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; *SAS I, 1989, SAS STAT US GUID VER; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; TERWILLINGER JD, 1994, HDB HUMAN GENETIC LI, P278; VAZIRI ND, 1992, AM J MED, V93, P651, DOI 10.1016/0002-9343(92)90198-K; Wang XL, 1997, ARTERIOSCL THROM VAS, V17, P246, DOI 10.1161/01.ATV.17.2.246; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623; 1989, INT J EPIDEMIOL S1, V18, pS1	28	265	278	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					79	85		10.1056/NEJM199801083380202	http://dx.doi.org/10.1056/NEJM199801083380202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420338				2022-12-28	WOS:000071341300002
J	Leeuw, T; Wu, CL; Schrag, JD; Whiteway, M; Thomas, DY; Leberer, E				Leeuw, T; Wu, CL; Schrag, JD; Whiteway, M; Thomas, DY; Leberer, E			Interaction of a G-protein beta-subunit with a conserved sequence in Ste20/PAK family protein kinases	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; GAMMA-SUBUNITS; YEAST; PHOSPHORYLATION; ASSOCIATION; FAR1	Serine/threonine protein kinases of the Ste20/PAK family have been implicated in the signalling from heterotrimeric G proteins to mitogen-activated protein (MAP) kinase cascades(1,2). in the yeast Saccharomyces cerevisiae, Ste20 is involved in transmitting the mating-pheromone signal from the beta gamma-subunits (encoded by the STE4 and STE18 genes, respectively) of a heterotrimeric G protein to a downstream MAP kinase cascade(1). We have identified a binding site for the G-protein beta-subunit (G beta) in the non-catalytic carboxy-terminal regions of Ste20 and its mammalian homologues, the p21-activated protein kinases (PAKs). Association of G beta with this site in Ste20 was regulated by binding of pheromone to the receptor. Mutations in G beta and Ste20 that prevented this association blocked activation of the MAP kinase cascade. Considering the high degree of structural and functional conservation of Ste20/PAK family members and G-protein subunits, our results provide a possible model for a role of these kinases in G beta gamma-mediated signal transduction in organisms ranging from yeast to mammals.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Macromol Struct Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; National Research Council Canada; McGill University; McGill University; McGill University	Leberer, E (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	Ekkehard.Leberer@nrc.ca	Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787	20	179	180	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					191	195		10.1038/34448	http://dx.doi.org/10.1038/34448			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428767				2022-12-28	WOS:000071380900055
J	David, TJ				David, TJ			Ethical debate - Child sexual abuse: when a doctor's duty to report abuse conflicts with a duty of confidentiality to the victim	BRITISH MEDICAL JOURNAL			English	Article								Fifteen years after she has been admitted to hospital with unexplained bruising, a woman asks to see her paediatric medical records. Professor TJ David describes the dilemma surrounding her allegations of sexual abuse, and a general practitioner, lawyer, and community paediatrician offer their opinions.	Univ Manchester, Booth Hall Childrens Hosp, Dept Child Hlth, Manchester M9 7AA, Lancs, England	Royal Manchester Children's Hospital; University of Manchester	David, TJ (corresponding author), Univ Manchester, Booth Hall Childrens Hosp, Dept Child Hlth, Manchester M9 7AA, Lancs, England.								0	6	6	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					55	55		10.1136/bmj.316.7124.55	http://dx.doi.org/10.1136/bmj.316.7124.55			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451272	Green Published			2022-12-28	WOS:000071377900030
J	McDonagh, TA; Robb, SD; Murdoch, DR; Morton, JJ; Ford, I; Morrison, CE; Tunstall-Pedoe, H; McMurray, JJV; Dargie, HJ				McDonagh, TA; Robb, SD; Murdoch, DR; Morton, JJ; Ford, I; Morrison, CE; Tunstall-Pedoe, H; McMurray, JJV; Dargie, HJ			Biochemical detection of left-ventricular systolic dysfunction	LANCET			English	Article							BRAIN NATRIURETIC PEPTIDE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; IN-VITRO; ECHOCARDIOGRAPHY; COMMUNITY; INDICATOR; ACCURACY	Background In previous studies on the use of natriuretic peptides to detect left-ventricular systolic dysfunction, a higher rate of cardiac disorders in the control groups than in the study groups could have led to bias. We investigated the effectiveness of plasma N-terminal atrial natriuretic peptide (NT-ANP) and brain natriuretic peptide (BNP) concentrations to show left-ventricular systolic dysfunction in a random sample of the general population. Methods We randomly selected 2000 participants aged 25-74 years from family physicians' lists in Glasgow, UK. We sent all participants questionnaires, 1653 respondents underwent echocardiography and electrocardiography. We took a left-ventricular ejection fraction of 30% or less to show left-ventricular systolic dysfunction. NT-ANP and BNP were measured in plasma by RIAs. Findings 1252 participants had analysable electrocardiograms and echocardiograms, completed available blood samples. Median and BNP were significantly higher in participants with left-ventricular systolic dysfunction (2.8 ng/mL [IQR 1.8-4.6] and 24.0 pg/mL [18.0-33.0]) than in those without (1.3 ng/mL [0.9-1.8] and 7.7 pg/mL [3.4-13.0]; each p<0.001). Among participants with left-ventricular systolic dysfunction, both symptomatic and asymptomatic subgroups had raised NT-ANP and BNP concentrations, A BNP concentration of 17.9 pg/mL or more gave a sensitivity of 77% and specificity of 87% in all participants, and 92% and 72% in participants aged 55 years or older, NT-ANP Interpretation Measurement of BNP could be a cost-effective method of screening for left-ventricular systolic dysfunction in the general population, especially if its use were targeted to individuals at high risk.	Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, MRC, Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland; Glasgow Royal Infirm, Scottish Monica Project, Glasgow, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow	McDonagh, TA (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.		Ford, Ian/ABE-6145-2020; mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				CHOY AMJ, 1994, BRIT HEART J, V72, P16; DAVIDSON NC, 1995, CIRCULATION, V91, P1276; DAVIS M, 1994, LANCET, V343, P40; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GLENBOTSKI CC, 1988, J BIOL CHEM, V263, P16073; HALL C, 1995, CIRCULATION, V91, P911; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEUBLEIN D M, 1989, Journal of the American College of Cardiology, V13, p9A; Jacobsen SJ, 1996, ARCH INTERN MED, V156, P2462, DOI 10.1001/archinte.156.21.2462; LAND CC, 1991, J HYPERTENS, V9, P779; LERMAN A, 1993, LANCET, V341, P1105, DOI 10.1016/0140-6736(93)93125-K; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P781; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; ROSE GA, WHO MONOGRAPH SERIES, V56; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SUNDSFJORD JA, 1988, J CLIN ENDOCR METAB, V66, P605, DOI 10.1210/jcem-66-3-605; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; WHEELDON NM, 1993, Q J MED, V86, P17; YAMAMOTO K, 1996, J AM COLL CARDIOL A, V69, P723; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	27	801	862	2	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					9	13		10.1016/S0140-6736(97)03034-1	http://dx.doi.org/10.1016/S0140-6736(97)03034-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433422				2022-12-28	WOS:000071253100009
J	Braun, AR; Balkin, TJ; Wesensten, NJ; Gwadry, F; Carson, RE; Varga, M; Baldwin, P; Belenky, G; Herscovitch, P				Braun, AR; Balkin, TJ; Wesensten, NJ; Gwadry, F; Carson, RE; Varga, M; Baldwin, P; Belenky, G; Herscovitch, P			Dissociated pattern of activity in visual cortices and their projections during human rapid eye movement sleep	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; HUMAN BRAIN; REM-SLEEP; CORTEX; IMAGERY; WAVES; PET	Positron emission tomography was used to measure cerebral activity and to evaluate regional interrelationships within visual cortices and their projections during rapid eye movement (REM) sleep in human subjects. REM sleep was associated with selective activation of extrastriate visual cortices, particularly within the ventral processing stream, and an unexpected attenuation of activity in the primary visual cortex; increases in regional cerebral blood flow in extrastriate areas were significantly correlated with decreases in the striate cortex. Extrastriate activity was also associated with concomitant activation of limbic and paralimbic regions, but with a marked reduction of activity in frontal association areas including lateral orbital and dorsolateral prefrontal cortices. This pattern suggests a model for brain mechanisms subserving REM sleep where visual association cortices and their paralimbic projections may operate as a closed system dissociated from the regions at either end of the visual hierarchy that mediate interactions with the external world.	NIDOCD, Voice Speech & Language Branch, Language Sect, NIH, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Neurobiol & Behav, Div Neuropsychiat, Washington, DC 20307 USA; NIH, Ctr Clin, PET Imaging Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Braun, AR (corresponding author), NIDOCD, Voice Speech & Language Branch, Language Sect, NIH, Bethesda, MD 20892 USA.		Carson, Richard E/H-3250-2011	Carson, Richard E/0000-0002-9338-7966				ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BROOKS DC, 1968, EXP NEUROL, V22, P603, DOI 10.1016/0014-4886(68)90152-0; CALLAWAY CW, 1987, CELL MOL NEUROBIOL, V7, P105, DOI 10.1007/BF00711551; Chavis D, 1974, Trans Am Neurol Assoc, V99, P192; DEMENT W, 1958, J EXP PSYCHOL, V55, P543, DOI 10.1037/h0040031; DEMENT W, 1957, J EXP PSYCHOL, V53, P339, DOI 10.1037/h0048189; EFRON B, 1982, SIAM MONOGR, V381; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GOLDENBERG G, 1995, NEUROPSYCHOLOGIA, V33, P1373, DOI 10.1016/0028-3932(95)00070-J; GOODENOUGH DR, 1965, J NERV MENT DIS, V140, P365, DOI 10.1097/00005053-196505000-00005; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Hobson J. Allan, 1988, DREAMING BRAIN; HOBSON JA, 1969, BRAIN RES, V14, P607, DOI 10.1016/0006-8993(69)90202-9; Hobson JA, 1996, ENDEAVOUR, V20, P86; HONG CCH, 1995, SLEEP, V18, P570; KASAMATSU T, 1973, BRAIN RES, V55, P323, DOI 10.1016/0006-8993(73)90298-9; KOSSLYN SM, 1995, NATURE, V378, P496, DOI 10.1038/378496a0; KOSSLYN SM, 1994, TRENDS NEUROSCI, V17, P290, DOI 10.1016/0166-2236(94)90059-0; MADSEN PL, 1991, J CEREBR BLOOD F MET, V11, P502, DOI 10.1038/jcbfm.1991.94; MANLY BFJ, 1990, RANDOMIZATION MONTE; Maquet P, 1996, NATURE, V383, P163, DOI 10.1038/383163a0; MCCARLEY RW, 1983, BRAIN RES, V274, P359, DOI 10.1016/0006-8993(83)90719-9; PAUS T, 1995, J NEUROPHYSIOL, V74, P2179, DOI 10.1152/jn.1995.74.5.2179; PIVIK TERRY, 1966, SCIENCE, V153, P1282, DOI 10.1126/science.153.3741.1282; RECHTSCHAFFEN A, 1978, SLEEP, V1, P97, DOI 10.1093/sleep/1.1.97; RECHTSCHAFFEN A, 1963, Can Psychiatr Assoc J, V8, P409; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; ROLAND PE, 1995, CEREB CORTEX, V5, P79, DOI 10.1093/cercor/5.1.79; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; Talairach I., 1988, COPLANAR STEREOTACTI; VERDONE P, 1965, PERCEPT MOTOR SKILL, V20, P1253, DOI 10.2466/pms.1965.20.3c.1253; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WEISKRANTZ L, 1995, P NATL ACAD SCI USA, V92, P6122, DOI 10.1073/pnas.92.13.6122; WILLIAMS RL, 1974, ELECTROENEPHALOGRAPH; ZEKI S, 1991, J NEUROSCI, V11, P641; Zeki S., 1993, VISION BRAIN	39	315	324	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					91	95		10.1126/science.279.5347.91	http://dx.doi.org/10.1126/science.279.5347.91			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417032				2022-12-28	WOS:000071323900047
J	Majeti, R; Bilwes, AM; Noel, JP; Hunter, T; Weiss, A				Majeti, R; Bilwes, AM; Noel, JP; Hunter, T; Weiss, A			Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; CD45; PHOSPHORYLATION; KINASES; MATURATION; ACTIVATION; EXPRESSION; MICE	The function and regulation of the receptorlike transmembrane protein tyrosine phosphatases (RPTPs) are not well understood. Ligand-induced dimerization inhibited the function of the epidermal growth factor receptor (EGFR)-RPTP CD45 chimera (EGFR-CD45) in T cell signal transduction. Properties of mutated EGFR-CD45 chimeras supported a general model for the regulation of RPTPs, derived from the crystal structure of the RPTP alpha membrane-proximal phosphatase domain, The phosphatase domain apparently forms a symmetrical dimer in which the catalytic site of one molecule is blocked by specific contacts with a wedge from the other.	Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Salk Institute; Salk Institute	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA.		Noel, Joseph P/A-9459-2009	Bilwes Crane, Alexandrine/0000-0001-9922-0692				Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; MARVEL J, 1991, EUR J IMMUNOL, V21, P195, DOI 10.1002/eji.1830210129; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MITTLER RS, 1994, J IMMUNOL, V153, P84; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	23	211	220	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					88	91		10.1126/science.279.5347.88	http://dx.doi.org/10.1126/science.279.5347.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417031				2022-12-28	WOS:000071323900046
J	Harlow, T				Harlow, T			Do overweight people remove their shoes before being weighed by a doctor? Consecutive study of patients in general practice	BRITISH MEDICAL JOURNAL			English	Article									Coll Surg, Cullompton EX15 1TG, Devon, England		Harlow, T (corresponding author), Coll Surg, Cullompton EX15 1TG, Devon, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1663	1663		10.1136/bmj.315.7123.1663	http://dx.doi.org/10.1136/bmj.315.7123.1663			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448534	Green Published			2022-12-28	WOS:000071149400018
J	Smith, GD; Egger, M; Phillips, AN				Smith, GD; Egger, M; Phillips, AN			Meta-analysis - Beyond the grand mean?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIALS; SUBGROUP ANALYSES; RISK; MORTALITY; HYPERTENSION; METAANALYSIS; OVERVIEWS; BENEFITS		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat, London NW3 2PF, England	University of Bristol; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1987, Eur Heart J, V8, P1056; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BAILEY KR, 1994, CONTROL CLIN TRIALS, V15, P15, DOI 10.1016/0197-2456(94)90024-8; BOISSEL JP, 1990, AM J CARDIOL, V66, P251, DOI 10.1016/0002-9149(90)90831-K; BUYSE ME, 1989, CONTROL CLIN TRIALS, V10, pS187; EFRON B, 1977, SCI AM, V236, P119, DOI 10.1038/scientificamerican0577-119; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; EGGER M, 1994, LANCET, V343, P1355, DOI 10.1016/S0140-6736(94)92490-2; EGGER M, 1995, J HYPERTENS, V13, P813, DOI 10.1097/00004872-199507000-00014; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; HOES AW, 1995, J HYPERTENS, V13, P805; Holme I, 1996, CONTROL CLIN TRIALS, V17, P13, DOI 10.1016/0197-2456(95)00083-6; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEIZOROVICZ A, 1988, EUR HEART J, V9, P8; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1990, AM J CARDIOL, V66, P771, DOI 10.1016/0002-9149(90)91149-Z; Peto R, 1982, TREATMENT CANC; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; SCHRODER R, 1985, Z KARDIOL, V74, P165; SCHRODER R, 1984, EUR HEART J, V5, P189; Sharp SJ, 1996, BRIT MED J, V313, P735; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; Smith GD, 1997, EUR HEART J, V18, P6; SMITH GD, IN PRESS BMJ; THOMPSON SG, IN PRESS STAT MED; WITTES RE, 1987, STAT MED, V6, P269, DOI 10.1002/sim.4780060312; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; ZELEN M, 1983, NEW ENGL J MED, V308, P593	37	121	123	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 13	1997	315	7122					1610	1614		10.1136/bmj.315.7122.1610	http://dx.doi.org/10.1136/bmj.315.7122.1610			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437284	Green Published			2022-12-28	WOS:000071021900037
J	Hegde, RS; Mastrianni, JA; Scott, MR; DeFea, KA; Tremblay, P; Torchia, M; DeArmond, SJ; Prusiner, SB; Lingappa, VR				Hegde, RS; Mastrianni, JA; Scott, MR; DeFea, KA; Tremblay, P; Torchia, M; DeArmond, SJ; Prusiner, SB; Lingappa, VR			A transmembrane form of the prion protein in neurodegenerative disease	SCIENCE			English	Article							STRAUSSLER-SCHEINKER SYNDROME; CREUTZFELDT-JAKOB-DISEASE; FATAL FAMILIAL INSOMNIA; TRANSGENIC MICE; PRP GENE; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; SCRAPIE; TRANSMISSION; BIOGENESIS	At the endoplasmic reticulum membrane, the prion protein (PrP) can be synthesized in several topological forms. The role of these different forms was explored with transgenic mice expressing PrP mutations that alter the relative ratios of the topological forms, Expression of a particular transmembrane form (termed (Ctm)PrP) produced neurodegenerative changes in mice similar to those of some genetic prion diseases, Brains from these mice contained (Cim)PrP but not PrP(Sc), the PrP isoform responsible for transmission of prion diseases, Furthermore, in one heritable prion disease of humans, brain tissue contained (Ctm)PrP but not PrP(Sc), Thus, aberrant regulation of protein biogenesis and topology at the endoplasmic reticulum can result in neurodegeneration.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	vrl@itsa.ucsf.edu		Hegde, Ramanujan/0000-0001-8338-852X; Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; HAYWARD PAR, 1994, NEUROPATH APPL NEURO, V20, P375, DOI 10.1111/j.1365-2990.1994.tb00983.x; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HEGDE RI, UNPUB; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; MASTRIANNI JA, UNPUB; Mathieu ME, 1996, BIOCHEMISTRY-US, V35, P4084, DOI 10.1021/bi952924i; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1991, J IMMUNOL, V147, P3568; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SCOTT MR, 1997, PROTEIN SCI S1, V6, P84; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TATEISHI J, 1992, E H S NEURO, P129; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Weissmann C, 1995, PROG BRAIN RES, V105, P15; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	52	594	613	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					827	834		10.1126/science.279.5352.827	http://dx.doi.org/10.1126/science.279.5352.827			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452375				2022-12-28	WOS:000071923500033
J	De Strooper, B; Saftig, P; Craessaerts, K; Vanderstichele, H; Guhde, G; Annaert, W; Von Figura, K; Van Leuven, F				De Strooper, B; Saftig, P; Craessaerts, K; Vanderstichele, H; Guhde, G; Annaert, W; Von Figura, K; Van Leuven, F			Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; BETA-PROTEIN; MUTATIONS; PEPTIDE; CELLS	Point mutations in the presenilin-1 gene (PS1) are a major cause of familial Alzheimer's disease, They result in a selective increase in the production of the amyloidogenic peptide amyloid-beta(1-42) by proteolytic processing of the amyloid precursor protein (APP)(1-4). Here we investigate whether PS1 is also involved in normal APP processing in neuronal cultures derived from PS1-deficient mouse embryos. Cleavage by alpha- and beta-secretase(5) of the extracellular domain of APP was not affected by the absence of PS1, whereas cleavage by gamma-secretase of the transmembrane domain of APP was prevented, causing carboxyl-terminal fragments of APP to accumulate and a fivefold drop in the production of amyloid peptide. Pulse-chase experiments indicated that PS1 deficiency specifically decreased the turnover of the membrane-associated fragments of APP. As in the regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor(6), PS1 appears to facilitate a proteolytic activity that cleaves the integral membrane domain of APP. Our results indicate that mutations in PS1 that manifest clinically cause a gain of function and that inhibition of PS1 activity is a potential target for anti-amyloidogenic therapy in Alzheimer's disease.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Louvain, Belgium; Innogenet NV, B-9057 Ghent, Belgium; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	Flanders Institute for Biotechnology (VIB); KU Leuven; Innogenetics NV; University of Gottingen	Saftig, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Louvain, Belgium.	Saftig@uni-bc2.gwdg.de	de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010; Vanderstichele, Hugo/AAD-2601-2019	De Strooper, Bart/0000-0001-5455-5819; 				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Baumeister R, 1997, Genes Funct, V1, P149; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LI X, 1996, NEURON, V17, P1017; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Simons M, 1996, J NEUROSCI, V16, P899; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; VANDERSTICHELE H, IN PRESS PROGR ALZHE; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	29	1518	1562	1	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					387	390		10.1038/34910	http://dx.doi.org/10.1038/34910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450754				2022-12-28	WOS:000071604200054
J	Winkler, C; Modi, W; Smith, MW; Nelson, GW; Wu, XY; Carrington, M; Dean, M; Honjo, T; Tashiro, K; Yabe, D; Buchbinder, S; Vittinghoff, E; Goedert, JJ; O'Brien, TR; Jacobson, LP; Detels, R; Donfield, S; Willoughby, A; Gomperts, E; Vlahov, D; Phair, J; O'Brien, SJ				Winkler, C; Modi, W; Smith, MW; Nelson, GW; Wu, XY; Carrington, M; Dean, M; Honjo, T; Tashiro, K; Yabe, D; Buchbinder, S; Vittinghoff, E; Goedert, JJ; O'Brien, TR; Jacobson, LP; Detels, R; Donfield, S; Willoughby, A; Gomperts, E; Vlahov, D; Phair, J; O'Brien, SJ		ALIVE Study; Hemophilia Growth Dev Study; Multicenter AIDS Cohort Study; Multicenter Hemophilia Cohort Study; San Francisco City Cohort	Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; TYPE-1 INFECTION; PROGRESSION; RECEPTORS; RESISTANCE; INDIVIDUALS; COFACTOR; DISEASE; ENTRY	Stromal-derived factor (SDF-1) is the principal ligand for CXCR4, a coreceptor with CD4 for T lymphocyte cell line-tropic human immunodeficiency virus-type 1 (HIV-1). A common polymorphism, SDF1-3'A, was identified in an evolutionarily conserved segment of the 3' untranslated region of the SDF-1 structural gene transcript. In the homozygous state, SDF1-3'A/3'A delays the onset of acquired immunodeficiency syndrome (AIDS), according to a genetic association analysis of 2857 patients enrolled in five AIDS cohort studies. The recessive protective effect of SDF1-3'A was increasingly pronounced in individuals infected with HIV-1 for longer periods, was twice as strong as the dominant genetic restriction of AIDS conferred by CCR5 and CCR2 chemokine receptor variants in these populations, and was complementary with these mutations in delaying the onset of AIDS.	NCI, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Sci Applicat Int Corp, Frederick, MD 21702 USA; Kyoto Univ, Dept Med Chem, Kyoto 606, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto 606, Japan; Dept Publ Hlth, AIDS Off, San Francisco, CA 94102 USA; NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, CAMACS, Baltimore, MD 21205 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Rho Inc, Chapel Hill, NC 27514 USA; NICHHD, Ctr Res Mothers & Children, Bethesda, MD 20892 USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Northwestern Univ, Sch Med, Comprehens AIDS Ctr, Chicago, IL 60611 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Kyoto University; Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; University of California System; University of California Los Angeles; Rho; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Children's Hospital Los Angeles; Northwestern University	O'Brien, SJ (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.		Dean, Michael/R-7501-2019; Smith, Michael/B-5341-2012; Honjo, Tasuku/N-4470-2016; OBRIEN, STEPHEN/ABD-1346-2020; Yabe, Daisuke/J-6682-2014; Dean, Michael C/G-8172-2012	Yabe, Daisuke/0000-0002-5334-7687; Dean, Michael C/0000-0003-2234-0631; Jacobson, Lisa P./0000-0003-1722-6826; OBRIEN, STEPHEN/0000-0001-7857-0757				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ASJO B, 1986, LANCET, V2, P660; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; BLUEL CC, 1996, J EXP MED, V184, P1101; BLUEL CC, 1996, NATURE, V382, P829; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cohen OJ, 1997, J CLIN INVEST, V100, P1581, DOI 10.1172/JCI119682; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P36; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DETELS R, 1994, J ACQ IMMUN DEF SYND, V7, P1263; Detels R, 1996, AIDS, V10, P102, DOI 10.1097/00002030-199601000-00016; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HILGARTNER MW, 1993, AM J PEDIAT HEMATOL, V15, P208; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KUBE D, 1995, CYTOKINE, V7, P107; LEDERMAN MM, 1995, J INFECT DIS, V172, P228, DOI 10.1093/infdis/172.1.228; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; MARUBINI E, 1995, ANAL SURVIVAL DATA C, P160; McNicholl JM, 1997, EMERG INFECT DIS, V3, P261, DOI 10.3201/eid0303.970302; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MOGOWAN KM, 1997, J BIOL CHEM, V272, P1331; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PRMACK BA, 1996, NAT MED, V2, P1174; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Theodorou I, 1997, LANCET, V349, P1219; Tsai KC, 1997, J NEUROSCI, V17, P1950; *US CDC, 1987, MORB MORTAL WKLY S1, V36; *US CDC, 1992, MORB MORTAL WKLY S1, V41; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	62	612	642	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					389	393		10.1126/science.279.5349.389	http://dx.doi.org/10.1126/science.279.5349.389			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430590				2022-12-28	WOS:000071570800048
J	Burge, MR; Schmitz-Fiorentino, K; Fischette, C; Qualls, CR; Schade, DS				Burge, MR; Schmitz-Fiorentino, K; Fischette, C; Qualls, CR; Schade, DS			A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSULIN-INDUCED HYPOGLYCEMIA; ADRENERGIC-MECHANISMS; EPINEPHRINE; SERUM; GLIBENCLAMIDE; HYPERGLYCEMIA; RECOVERY; THERAPY; AGENTS; NIDDM	Context.-Retrospective studies have identified oral sulfonylureas, age, and fasting as major risk factors for hypoglycemia in patients with type 2 diabetes. Sulfonylureas may be withheld from elderly patients out of concern for hypoglycemia. Objective.-To evaluate the hypoglycemic effects of maximum doses of once-daily second-generation sulfonylureas administered to fasting elderly patients. Design.-A prospective, randomized, double-blind clinical trial. Setting.-The University of New Mexico General Clinical Research Center. Patients.-Fifty-two sulfonylurea-treated subjects with type 2 diabetes with a mean (SD) age of 65.1 (5.7) years. Interventions.-Subjects were randomly assigned to glyburide or glipizide gastrointestinal therapeutic system (GITS). Each subject participated in three 23-hour fasting studies after the sequential administration of 1 week of placebo and 1 week of 10 mg and 1 week of 20 mg of the assigned sulfonylurea. Main Outcome Measures.-Occurrence of hypoglycemia (defined as plasma glucose level <3.33 mmol/L [60 mg/dL]) and hormonal parameters during the final 9 hours of the 23-hour fast in patients who had taken sulfonylureas vs placebo. Results.-No hypoglycemia was observed during 156 fasting studies. Plasma glucose level was decreased (nadir, 4.9 mmol/L [88 mg/dL] for a 20-mg dose of glyburide vs 8.3 mmol/L [150 mg/dL] for placebo; nadir, 5.8 mmol/L [105 mg/dL] for a 20-mg dose of glipizide GITS vs 8.7 mmol/L [157 mg/dL] for placebo), and serum insulin was increased in the sulfonylurea studies compared with placebo (P<.001). Plasma glucose parameters did not differ between the 2 sulfonylureas, but C peptide concentrations were increased in the glyburide group compared with glipizide GITS in the 20-mg study (P=.05). Concentrations of epinephrine were increased in the sulfonylurea studies compared with placebo (P<.001). Epinephrine secretion increased when glucose concentration fell below the mean (SD) level of 9.10 (2.66) mmol/L (164 [48] mg/dL) in the 10-mg study and 8.77 (2.83) mmol/L (158 [51] mg/dL) in the 20-mg study. Conclusions.-Fasting was well tolerated among these elderly patients with type 2 diabetes treated with sulfonylureas. Older age should not be considered a contraindication to sulfonylurea treatment for diabetes. Stimulation of epinephrine secretion at normal or elevated plasma glucose levels appears to be the primary mechanism of protection against hypoglycemia in this study.	Univ New Mexico, Sch Med, Dept Med Endocrinol, Albuquerque, NM 87131 USA; Univ New Mexico, Gen Clin Res Ctr, Computerized Database Management & Anal Syst, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico	Burge, MR (corresponding author), Univ New Mexico, Sch Med, Dept Med Endocrinol, 5ACC, Albuquerque, NM 87131 USA.				NCRR NIH HHS [5MO1-RR00997] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM DIAB ASS, 1997, DIABETES CARE S1, V20, pS59; ASPLUND K, 1983, DIABETOLOGIA, V24, P412; BODEN G, 1983, DIABETES, V32, P1055, DOI 10.2337/diabetes.32.11.1055; BORG WP, 1994, J CLIN INVEST, V93, P1677, DOI 10.1172/JCI117150; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; CLUTTER WE, 1980, J CLIN INVEST, V66, P94, DOI 10.1172/JCI109840; ENSINCK JW, 1983, GLUCAGON HDB EXPT PH, P66; GARBER AJ, 1976, J CLIN INVEST, V58, P7, DOI 10.1172/JCI108460; GERICH J, 1979, AM J PHYSIOL, V236, pE380, DOI 10.1152/ajpendo.1979.236.4.E380; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GLIPIZIDE GIT, 1996, PHYSICIANS DESK REFE; GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/diacare.15.6.737; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; JENNINGS AM, 1989, DIABETES CARE, V12, P203, DOI 10.2337/diacare.12.3.203; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; MITRAKOU T, 1991, AM J PHYSIOL, V260, pE67; MOKAN M, 1994, DIABETES CARE, V17, P1397, DOI 10.2337/diacare.17.12.1397; NAKAGAWA S, 1973, DIABETES, V22, P590, DOI 10.2337/diab.22.8.590; POPP DA, 1982, J CLIN INVEST, V69, P315, DOI 10.1172/JCI110455; Riddle MC, 1997, DIABETES CARE, V20, P992, DOI 10.2337/diacare.20.6.992; RYDBERG T, 1991, J CHROMATOGR-BIOMED, V564, P223, DOI 10.1016/0378-4347(91)80084-P; SANTIAGO JV, 1984, AM J PHYSIOL, V247, pE215, DOI 10.1152/ajpendo.1984.247.2.E215; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1135; SELTZER HS, 1989, ENDOCRIN METAB CLIN, V18, P163, DOI 10.1016/S0889-8529(18)30395-5; SHAH SD, 1985, J LAB CLIN MED, V106, P624; SIEGEL JS, 1980, DHHS NIH PUBLICATION; TURNER RC, 1995, DIABETES, V44, P1249; WAHLINBOLL E, 1979, J CHROMATOGR, V164, P541, DOI 10.1016/S0378-4347(00)81560-1	28	49	51	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					137	143		10.1001/jama.279.2.137	http://dx.doi.org/10.1001/jama.279.2.137			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440664	Bronze			2022-12-28	WOS:000071338900031
J	Davies, SW; Beardsall, K; Turmaine, M; DiFiglia, M; Aronin, N; Bates, GP				Davies, SW; Beardsall, K; Turmaine, M; DiFiglia, M; Aronin, N; Bates, GP			Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?	LANCET			English	Article							SPINOCEREBELLAR ATAXIA TYPE-2; BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; CAG REPEAT; HYALINE INCLUSIONS; DISEASE; DEGENERATION; CLONING	Neuronal intranuclear inclusions have been found in the brain of a transgenic mouse model of Huntington's disease and in necropsy brain tissue of patients with Huntington's disease, We suggest that neuronal intranuclear inclusions are the common neuropathology for all inherited diseases caused by expansion of polyglutamine repeats, We also suggest that patients with a pathological diagnosis of neuronal intranuclear hyaline inclusion disease may also have polyglutamine repeat expansions.	UCL, Dept Anat & Dev Biol, London WC1E 6JJ, England; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA; Univ Med & Dent New Jersey, Guys Hosp, Div Med & Mol Genet, London, England	University of London; University College London; Harvard University; Harvard Medical School; Massachusetts General Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Davies, SW (corresponding author), UCL, Dept Anat & Dev Biol, Rockefeller Bldg, London WC1E 6JJ, England.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305				[Anonymous], ADV NEUROL; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; GILLES D, 1997, NAT GENET, V17, P65; Heintz N, 1997, NAT GENET, V16, P325, DOI 10.1038/ng0897-325; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; JANOTA I, 1979, NEUROPATH APPL NEURO, V5, P311, DOI 10.1111/j.1365-2990.1979.tb00630.x; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LINDENBERG R, 1968, ACTA NEUROPATHOL, V10, P54, DOI 10.1007/BF00690510; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MUNOZGARCIA D, 1986, NEUROLOGY, V36, P785, DOI 10.1212/WNL.36.6.785; NAKAMURA M, 1993, ANN NEUROL, V34, P261; NAKAMURA Y, 1994, RHODIUM EX, V6, P14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PARKER JC, 1983, J NEUROPATH EXP NEUR, V42, P352, DOI 10.1097/00005072-198305000-00149; PATEL H, 1985, J NEUROL SCI, V67, P57, DOI 10.1016/0022-510X(85)90022-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; ROBITAILLE Y, 1997, BRAIN PATHOL, V7, P877; Ross CA, 1997, BRAIN PATHOL, V7, P1003, DOI 10.1111/j.1750-3639.1997.tb00898.x; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Sathasivam K, 1997, HUM GENET, V99, P692, DOI 10.1007/s004390050432; SCHALLING M, 1993, NAT GENET, V4, P136; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHUFFLER MD, 1978, GASTROENTEROLOGY, V75, P889; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SLOANE AE, 1994, PEDIATR NEUROL, V10, P61, DOI 10.1016/0887-8994(94)90070-1; SOFFER D, 1985, ACTA NEUROPATHOL, V65, P322, DOI 10.1007/BF00687016; SUNG JH, 1980, J NEUROPATH EXP NEUR, V39, P107, DOI 10.1097/00005072-198003000-00001; SUNG JH, 1980, ACTA NEUROPATHOL, V50, P115, DOI 10.1007/BF00692861; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; YOUNG AB, 1977, HUNTINGTONS DIS OTHE; ZHUCHENKO S, 1997, NAT GENET, V15, P622	39	146	148	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					131	133		10.1016/S0140-6736(97)08360-8	http://dx.doi.org/10.1016/S0140-6736(97)08360-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439509				2022-12-28	WOS:000071591900045
J	Salisbury, DM				Salisbury, DM			Association between oral poliovaccine and Guillain-Barre syndrome?	LANCET			English	Editorial Material							CAMPAIGN		Dept Hlth, London SE1 8UG, England		Salisbury, DM (corresponding author), Dept Hlth, London SE1 8UG, England.							daSilveira CM, 1997, LANCET, V349, P14, DOI 10.1016/S0140-6736(96)07408-9; Howson CP, 1991, ADVERSE EFFECTS PERT; Hughes R, 1996, BRIT MED J, V312, P1475; KINNUNEN E, 1989, NEUROLOGY, V39, P1034, DOI 10.1212/WNL.39.8.1034; Kinnunen E, 1998, AM J EPIDEMIOL, V147, P69; Olive JA, 1997, J INFECT DIS, V175, pS160, DOI 10.1093/infdis/175.Supplement_1.S160; Stratton K.R., 1994, ADVERSE EVENTS ASS C; UHARI M, 1989, LANCET, V2, P440	8	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					79	80		10.1016/S0140-6736(05)78156-3	http://dx.doi.org/10.1016/S0140-6736(05)78156-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439487				2022-12-28	WOS:000071591900004
J	Bartalena, L; Marcocci, C; Bogazzi, F; Manetti, L; Tanda, ML; Dell'Unto, E; Bruno-Bossio, G; Nardi, M; Bartolomei, MP; Lepri, A; Rossi, G; Martino, E; Pinchera, A				Bartalena, L; Marcocci, C; Bogazzi, F; Manetti, L; Tanda, ML; Dell'Unto, E; Bruno-Bossio, G; Nardi, M; Bartolomei, MP; Lepri, A; Rossi, G; Martino, E; Pinchera, A			Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIOIODINE THERAPY; NECK IRRADIATION; DISEASE; THYROIDECTOMY; METHIMAZOLE; SMOKING	Background The chief clinical characteristics of Graves' disease are hyperthyroidism and ophthalmopathy. The relation between the two and the effect of treatment for hyperthyroidism on ophthalmopathy are unclear. Methods We studied 443 patients with Graves' hyperthyroidism and slight or no ophthalmopathy who were randomly assigned to receive radioiodine, radioiodine followed by a 3-month course of prednisone, or methimazole for 18 months. The patients were evaluated for changes in the function and appearance of the thyroid and progression of ophthalmopathy at intervals of 1 to 2 months for 12 months. Hypothyroidism and persistent hyperthyroidism were promptly corrected. Results Among the 150 patients treated with radioiodine, ophthalmopathy developed or worsened in 23 (15 percent) two to six months after treatment. The change was transient in 15 patients, but it persisted in 8 (5 percent), who subsequently required treatment for their eye disease. None of the 55 other patients in this group who had ophthalmopathy at base line had improvement in their eye disease. Among the 145 patients treated with radioiodine and prednisone, 50 (67 percent) of the 75 with ophthalmopathy at base line had improvement, and no patient had progression. The effects of radioiodine on thyroid function were similar in these two groups. Among the 148 patients treated with methimazole, 3 (2 percent) who had ophthalmopathy at base line improved, 4 (3 percent) had worsening of eye disease, and the remaining 141 had no change. Conclusions Radioiodine therapy for Graves' hyperthyroidism is followed by the appearance or worsening of ophthalmopathy more often than is therapy with methimazole. Worsening of ophthalmopathy after radioiodine therapy is often transient and can be prevented by the administration of prednisone. (C) 1998, Massachusetts Medical Society.	Univ Pisa, Ist Endocrinol, Pisa, Italy; Univ Pisa, Clin Oculist, Pisa, Italy; Natl Res Council, Ist Fisiol Clin, Reparto Epidemiol & Biostat, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; University of Pisa	Bartalena, L (corresponding author), Univ Pisa, Osped Cisanello, Ist Endocrinol, Via Paradisa 3, I-56122 Pisa, Italy.		Manetti, Luca/K-9022-2016; Tanda, Maria Laura/AAD-4071-2020; BOGAZZI, FAUSTO/I-2087-2012	Manetti, Luca/0000-0001-9911-5366; BOGAZZI, FAUSTO/0000-0001-5975-4411; tanda, maria laura/0000-0001-7551-1751; nardi, marco/0000-0003-3422-9498				ARONROSA D, 1973, MOD PROBL OPHTHAL, V14, P432; Bartalena L, 1996, THYROID, V6, P345, DOI 10.1089/thy.1996.6.345; BARTALENA L, 1989, J ENDOCRINOL INVEST, V12, P733, DOI 10.1007/BF03350047; BARTALENA L, 1995, EUR J ENDOCRINOL, V133, P507, DOI 10.1530/eje.0.1330507; BARTALENA L, 1989, NEW ENGL J MED, V321, P1349, DOI 10.1056/NEJM198911163212001; BARTH A, 1991, J ENDOCRINOL INVEST, V14, P209, DOI 10.1007/BF03346790; Bartley GB, 1996, AM J OPHTHALMOL, V121, P426, DOI 10.1016/S0002-9394(14)70439-8; BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; CALISSENDORFF BM, 1986, ACTA OPHTHALMOL, V64, P698; GWINUP G, 1982, JAMA-J AM MED ASSOC, V247, P2135, DOI 10.1001/jama.247.15.2135; HERZEL BS, 1968, AUSTRALAS ANN MED, V17, P307; JACKSON R, 1979, CANCER TREAT REP, V63, P1393; KARLSSON F, 1989, LANCET, V2, P691; KUNG AWC, 1994, J CLIN ENDOCR METAB, V79, P542, DOI 10.1210/jc.79.2.542; MARCOCCI C, 1990, J ENDOCRINOL INVEST, V13, P513, DOI 10.1007/BF03348615; MARCOCCI C, 1992, THYROID, V2, P171, DOI 10.1089/thy.1992.2.171; MOURITS MP, 1989, BRIT J OPHTHALMOL, V73, P639, DOI 10.1136/bjo.73.8.639; PRUMMEL MF, 1990, ARCH INTERN MED, V150, P1098, DOI 10.1001/archinte.150.5.1098; SANCHEZ JRF, 1993, BRIT J SURG, V80, P1134; SRIDAMA V, 1989, AM J MED, V87, P70, DOI 10.1016/S0002-9343(89)80485-1; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; TALLSTEDT L, 1994, EUR J ENDOCRINOL, V130, P494, DOI 10.1530/eje.0.1300494; VASQUEZCHAVEZ C, 1992, REV INVEST CLIN, V44, P241; VESTERGAARD H, 1989, LANCET, V2, P47; Vitti P, 1997, THYROID, V7, P369, DOI 10.1089/thy.1997.7.369; WASNICH RD, 1973, J CLIN ENDOCR METAB, V37, P703, DOI 10.1210/jcem-37-5-703; WIERSINGA W, 1995, J CLIN ENDOCR METAB, V80, P345, DOI 10.1210/jcem.80.2.7852487; WINSA B, 1995, EUR J ENDOCRINOL, V132, P406, DOI 10.1530/eje.0.1320406	28	458	490	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					73	78		10.1056/NEJM199801083380201	http://dx.doi.org/10.1056/NEJM199801083380201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420337				2022-12-28	WOS:000071341300001
J	Gow, AJ; Stamler, JS				Gow, AJ; Stamler, JS			Reactions between nitric oxide and haemoglobin under physiological conditions	NATURE			English	Article							HEMOGLOBIN; NO; BLOOD; NITROSYLATION; BINDING; CELLS	The tenet of high-affinity nitric oxide (NO) binding to a haemoglobin (Hb) has shaped our view of haem proteins and of small diffusible signaling molecules. Specifically, NO binds rapidly to haem iron in Hb (k approximate to 10(7) M-1 s(-1)) (refs 1, 2) and once bound, the NO activity is largely irretrievable (K-d approximate to 10(-5) s(-1)) (refs 3-10); the binding is purportedly so tight as to be unaffected by O-2 or CO. However, these general principles do not consider the allosteric state of Hb or the nature of the allosteric effector,and they mostly derive from the functional behaviour of fully nitrosylated Hb, whereas Hb is only partially nitrosylated in vivo(11-16). Here we show that oxygen drives the conversion of nitrosylhaemoglobin in the 'tense' T (or partially nitrosylated, deoxy) structure to S-nitrosohaemoglobin in the 'relaxed' R (or ligand-bound, oxy) structure. In the absence of oxygen, nitroxyl anion(NO-) is liberated in a reaction producing methaemoglobin. The yields of both S-nitrosohaemoglobin and methaemoeglobin are dependent on the NO/Hb ratio. These newly discovered reactions elucidate mechanisms underlying NO function in the respiratory cycle, and provide insight into the aetiology of S-nitrosothiols, methaemoglobin and its related valency hybrids. Mechanistic re-examination of NO interactions with other haem proteins containing allosteric-site thiols may be warranted.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of Pennsylvania	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Gow, Andrew/N-8566-2013; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572				ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V32, P272; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kagan VE, 1996, NATURE, V383, P30, DOI 10.1038/383030b0; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P39; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; KRUSZYNA R, 1987, J PHARMACOL EXP THER, V241, P307; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MARLETTA M A, 1990, Biofactors, V2, P219; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Motterlini R, 1996, TRANSFUS MED REV, V10, P77, DOI 10.1016/S0887-7963(96)80084-8; Perutz MF, 1996, NATURE, V380, P205, DOI 10.1038/380205b0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; RIGGS A, 1961, J BIOL CHEM, V236, P1948; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TAKETA F, 1978, J BIOL CHEM, V253, P5448; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680	30	490	508	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					169	173		10.1038/34402	http://dx.doi.org/10.1038/34402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428761				2022-12-28	WOS:000071380900049
J	Hosenpud, JD; Bennett, LE; Keck, BM; Edwards, EB; Novick, RJ				Hosenpud, JD; Bennett, LE; Keck, BM; Edwards, EB; Novick, RJ			Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; REDUCTION SURGERY APPROPRIATE; QUALITY-OF-LIFE; EMPHYSEMA; RECIPIENTS; PROGNOSIS	Background Although certain forms of end-stage lung disease are debilitating, whether the associated mortality rate exceeds that of transplantation is unclear. We undertook analysis to clarify the survival benefit of lung transplantation for various types of end-stage lung disease. Methods We analysed data for all patients listed for transplantation in the USA for emphysema, cystic fibrosis, or interstitial pulmonary fibrosis in the years 1992-94. The numbers of patients entered on the waiting list, posttransplantation, died waiting, and currently waiting were: emphysema group 1274, 843, 143, and 165; cystic fibrosis group 664, 318, 193, and 59; interstitial pulmonary fibrosis group 481, 230, 160, and 48, A time-dependent non-proportional hazard analysis was used to assess the risk of mortality after transplantation relative to that for patients an the waiting list. Findings The dearest survival benefit from lung transplantation occurred in the cystic fibrosis group, The relative risks of transplantation compared with waiting were 0.87, 0.61, and 0.61 at 1 month, 6 months, and 1 year (p=0.008), respectively. For interstitial pulmonary fibrosis, the corresponding relative risks were 2.09, 0.71, and 0.67 (p=0.09). No survival benefit was apparent in the emphysema group, The risks of transplantation relative to waiting were 2.76, 1.12, and 1.10 at 1 month, 6 months, and 1 year, respectively, and the relative risk did not decrease to below 1.0 during 2 years of follow-up. Interpretation These findings suggest that lung transplantation does not confer a survival benefit in patients with end-stage emphysema by 2 years of follow-up, Other benefits not accounted for in this analysis such as improved quality of life, however, may justify lung transplantation for these patients.	Int Soc Heart & Lung Transplantat Thorac Registry, Joint United Network Organ Sharing, Richmond, VA USA	United Network for Organ Sharing	Hosenpud, JD (corresponding author), Med Coll Wisconsin, Div Cardiovasc Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.		Bennett, Louise/AAA-8266-2020	Bennett, Louise/0000-0001-9421-4410				[Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; ANTHONISEN NR, 1989, AM REV RESPIR DIS, V140, pS95, DOI 10.1164/ajrccm/140.3_Pt_2.S95; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; Cooper JD, 1996, AM J RESP CRIT CARE, V153, P1201, DOI 10.1164/ajrccm.153.4.8616541; COX DR, 1984, ANAL SURVIVAL DATA, P137; GROSS CR, 1995, CHEST, V108, P1587, DOI 10.1378/chest.108.6.1587; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; Lynch JP, 1996, MED CLIN N AM, V80, P657, DOI 10.1016/S0025-7125(05)70459-4; Make BJ, 1996, AM J RESP CRIT CARE, V153, P1205, DOI 10.1164/ajrccm.153.4.8616542; Naunheim KS, 1996, ANN THORAC SURG, V62, P601, DOI 10.1016/0003-4975(96)00428-6; ONOFRIO JM, 1992, MED CLIN N AM, V76, P1207, DOI 10.1016/S0025-7125(16)30319-4; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; RAMSEY SD, 1995, J HEART LUNG TRANSPL, V14, P870; RAMSEY SD, 1995, CHEST, V108, P1594, DOI 10.1378/chest.108.6.1594; SUNDARESAN S, 1995, ANN THORAC SURG, V60, P1341, DOI 10.1016/0003-4975(95)00751-6; ZENATI M, 1995, ANN THORAC SURG, V59, P1581, DOI 10.1016/0003-4975(95)00082-V	18	351	352	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	1998	351	9095					24	27		10.1016/S0140-6736(97)06405-2	http://dx.doi.org/10.1016/S0140-6736(97)06405-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433425				2022-12-28	WOS:000071253100012
J	Pal, DK; Das, T; Chaudhury, G; Johnson, AL; Neville, BGR				Pal, DK; Das, T; Chaudhury, G; Johnson, AL; Neville, BGR			Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India	LANCET			English	Article							ANTIEPILEPTIC DRUG-TREATMENT; FEBRILE SEIZURES; CARBAMAZEPINE; RECURRENCE; CHILDREN; ECUADOR; PROGRAM	Background The use of phenobarbital for childhood epilepsy is controversial because of reported behavioural side-effects; however, whether this research can validly be extrapolated to developing countries is not clear. We undertook randomised comparison of phenobarbital and phenytoin to assess the acceptability and efficacy of phenobarbital as monotherapy for childhood epilepsy in rural India. Methods Between August, 1995, and February, 1996, 109 unselected children aged 2-18 years with partial and generalised tonic-clonic epilepsy were identified by population screening. 15 families declined to take part. 94 children were randomly allocated treatment with phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily; n=47) or phenytoin (2.5 mg/kg daily then 5.0 mg/kg daily; n=47). Children were followed up for 12 months. The primary outcome measure was the frequency of behavioural side-effects; behaviour was assessed by the Conners parent rating scale for children aged 6 years and older, and by the preschool behaviour screening questionnaire (BSQ) for those aged 2-5 years, at 12 months or at withdrawal from treatment. Analysis was by intention to treat. Findings The mean log-transformed scores on the behaviour rating scales did not differ significantly between the phenobarbital and phenytoin groups (Conners 2.64 [SD 0.71] vs 2.65 [0.89], p=0.97; n=32 in each group: BSQ 2.12 [1.31] vs 2.18 [1.02], p=0.94; n=4 vs 3). The odds ratio for behavioural problems (phenobarbital vs phenytoin) was 0.51 (95% CI 0.16-1.59). There was no excess in parental reports of side-effects for phenobarbital. We found no difference in efficacy between the study drugs (adjusted hazard ratio for time to first seizure from randomisation 0.97 [0.28-3.30]). Interpretation This evidence supports the acceptability of phenobarbital as a first-line drug for childhood epilepsy in rural settings in developing countries.	UCL, Inst Child Hlth, Neurosci Unit, Wolfson Ctr, London WC1N 2AP, England; SANCHAR AROD, Pailan, W Bengal, India; Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; Child Need Inst, Daulutpur, W Bengal, India	University of London; University College London; MRC Biostatistics Unit; University of Cambridge	Pal, DK (corresponding author), UCL, Inst Child Hlth, Neurosci Unit, Wolfson Ctr, London WC1N 2AP, England.	d.pal@ucl.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson JC, 1996, LANCET, V348, P73, DOI 10.1016/S0140-6736(05)64598-9; CAMFIELD PR, 1980, J PEDIATR-US, V97, P16, DOI 10.1016/S0022-3476(80)80122-3; DEKKER N, 1993, TROP GEOGR MED, V45, P248; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; FEKSI AT, 1991, LANCET, V337, P406, DOI 10.1016/0140-6736(91)91176-U; FEKSI AT, 1991, EPILEPSY RES, V8, P252, DOI 10.1016/0920-1211(91)90072-N; Garcia FO, 1984, AN ESP PEDIATR, V20, P763; GASTAUT H, 1976, EPILEPSIA, V17, P355, DOI 10.1111/j.1528-1157.1976.tb04445.x; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; KSHIRSAGAR NA, 1992, RECENT ADV EPILEPSY, P159; MITCHELL WG, 1987, EPILEPSIA, V28, P56, DOI 10.1111/j.1528-1157.1987.tb03623.x; Pillai A M, 1995, J Indian Med Assoc, V93, P120; PLACENCIA M, 1992, NEUROEPIDEMIOLOGY, V11, P74, DOI 10.1159/000110915; PLACENCIA M, 1993, EPILEPSY RES, V14, P237, DOI 10.1016/0920-1211(93)90048-C; Richman N, 1982, PRESCHOOL SCH BEHAV; Rutter M, 1970, NEUROPSYCHIATRIC STU; SENANAYAKE N, 1994, TROP GEOGR MED, V46, P6; SHORVON S, 1986, BRIT MED J, V292, P1666, DOI 10.1136/bmj.292.6536.1666-a; Shorvon SD, 1988, EPILEPSIA S1, V29, P36; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; VINING EPG, 1987, PEDIATRICS, V80, P165; *WHO, 1990, IN SUPP PEOPL EP; WOLF SM, 1978, PEDIATRICS, V61, P728	24	103	103	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					19	23		10.1016/S0140-6736(97)06250-8	http://dx.doi.org/10.1016/S0140-6736(97)06250-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433424				2022-12-28	WOS:000071253100011
J	Chen, R; Amoui, M; Zhang, ZH; Mardon, G				Chen, R; Amoui, M; Zhang, ZH; Mardon, G			Dachshund and eyes absent proteins form a complex and function synergistically to induce ectopic eye development in Drosophila	CELL			English	Article							HOMEOBOX-CONTAINING GENE; VISUAL-SYSTEM; EYELESS GENE; ENCODES; DIFFERENTIATION; MORPHOGENESIS; ANIRIDIA; DPP; MELANOGASTER; PROPAGATION	The eyeless, dachshund, and eyes absent genes encode conserved, nuclear proteins that are essential for eye development in Drosophila. Misexpression of eyeless or dachshund is also sufficient to induce the formation of ectopic compound eyes. Here we show that the dachshund and eyes absent genes act synergistically to induce ectopic retinal development and positively regulate the expression of each other. Moreover, we show that the Dachshund and Eyes Absent proteins can physically interact through conserved domains, suggesting a molecular basis for the genetic synergy observed and that a similar complex may function in mammals. We propose that a conserved regulatory network, rather than a linear hierarchy, controls retinal specification and involves multiple protein complexes that function during distinct steps of eye development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mardon, G (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011232] Funding Source: NIH RePORTER; NEI NIH HHS [EY07001, R01 EY11232-01] Funding Source: Medline; NICHD NIH HHS [P30 HD24064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BONINI NM, 1995, CURR OPIN GENET DEV, V5, P507, DOI 10.1016/0959-437X(95)90056-M; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chanut F, 1997, DEVELOPMENT, V124, P559; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Glardon S, 1997, DEVELOPMENT, V124, P817; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARPER JW, 1993, CELL, V75, P805; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HILL RE, 1992, NATURE, V355, P750, DOI 10.1038/355750a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Oliver G, 1995, DEVELOPMENT, V121, P4045; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Pignoni F, 1997, DEVELOPMENT, V124, P271; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Shen WP, 1997, DEVELOPMENT, V124, P45; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; THAKER HM, 1992, GENETICS, V131, P883; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; Wolff Tanya, 1993, P1277; Xu PX, 1997, DEVELOPMENT, V124, P219; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	44	314	323	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					893	903		10.1016/S0092-8674(00)80481-X	http://dx.doi.org/10.1016/S0092-8674(00)80481-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428513	Bronze			2022-12-28	WOS:000071281400007
J	Yaffe, MB; Rittinger, K; Volinia, S; Caron, PR; Aitken, A; Leffers, H; Gamblin, SJ; Smerdon, SJ; Cantley, LC				Yaffe, MB; Rittinger, K; Volinia, S; Caron, PR; Aitken, A; Leffers, H; Gamblin, SJ; Smerdon, SJ; Cantley, LC			The structural basis for 14-3-3 : phosphopeptide binding specificity	CELL			English	Article							PROTEIN-KINASE-C; BIOSPECIFIC INTERACTION ANALYSIS; MULTIPLE SIGNALING PATHWAYS; MIDDLE TUMOR-ANTIGEN; 14-3-3 PROTEIN; T-CELLS; 14-3-3-PROTEINS; ASSOCIATION; INHIBITION; ACTIVATION	The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Using phosphoserine-oriented peptide libraries to probe all mammalian and yeast 14-3-3s, we identified two different binding motifs, RSXpSXP and RXY/FXpSXP, present in nearly all known 14-3-3 binding proteins. The crystal structure of 14-3-3 zeta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 Angstrom resolution. The bound peptide is in an extended conformation, with a tight turn created by the pS +2 Pro in a cia conformation. Sites of peptide-protein interaction in the complex rationalize the peptide library results. Finally, we show that the 14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and CbI.	Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Vertex Pharmaceut, Cambridge, MA 02139 USA; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Rigshosp, Dept Growth, DK-2100 Copenhagen, Denmark; Rigshosp, Reprod Sect GR5064, DK-2100 Copenhagen, Denmark	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; MRC National Institute for Medical Research; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Yaffe, MB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, HIM 1018,330 Brookline Ave, Boston, MA 02215 USA.		Volinia, Stefano/A-3029-2010; Cantley, Lewis C/D-1800-2014; Volinia, Stefano/AAA-9264-2019; Rittinger, Katrin/N-3344-2019; Rittinger, Katrin/D-2586-2014	Volinia, Stefano/0000-0003-0910-3893; Cantley, Lewis C/0000-0002-1298-7653; Volinia, Stefano/0000-0003-0910-3893; Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Smerdon, Stephen/0000-0001-5688-8465; Gamblin, Steve/0000-0001-5331-639X	NIGMS NIH HHS [GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; Craparo A, 1997, J BIOL CHEM, V272, P11663; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Meller N, 1996, MOL CELL BIOL, V16, P5782; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rommel C, 1996, ONCOGENE, V12, P609; Schulz G. E., 1979, PRINCIPLES PROTEIN S; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; WheelerJones CPD, 1996, BIOCHEM J, V315, P41, DOI 10.1042/bj3150041; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	1320	1378	9	101	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					961	971		10.1016/S0092-8674(00)80487-0	http://dx.doi.org/10.1016/S0092-8674(00)80487-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428519	Bronze			2022-12-28	WOS:000071281400013
J	Debbie, JG; Trimarchi, CV				Debbie, JG; Trimarchi, CV			Prophylaxis for suspected exposure to bat rabies	LANCET			English	Editorial Material							EPIDEMIOLOGY		New York State Dept Hlth, Albany, NY 12201 USA	State University of New York (SUNY) System	Debbie, JG (corresponding author), New York State Dept Hlth, Albany, NY 12201 USA.							*CDC, 1997, MMWR-MORBID MORTAL W, V46, P770; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; Feder HM, 1997, LANCET, V350, P1300, DOI 10.1016/S0140-6736(05)62479-8; LAFON M, 1986, LANCET, V2, P515; SCATTERDAY JE, 1954, VET MED, V49, P133; Smith JS, 1996, CLIN MICROBIOL REV, V9, P166, DOI 10.1128/CMR.9.2.166; Whitby JE, 1996, VET REC, V139, P491, DOI 10.1136/vr.139.20.491; *WHO, 1992, WHO TECH REP SER, V824, P21	8	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1790	1791		10.1016/S0140-6736(97)22051-9	http://dx.doi.org/10.1016/S0140-6736(97)22051-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428245				2022-12-28	WOS:000071102500002
J	Chen, CT; Wagner, H; Still, WC				Chen, CT; Wagner, H; Still, WC			Fluorescent, sequence-selective peptide detection by synthetic small molecules	SCIENCE			English	Article							2-ARMED RECEPTORS; BINDING; DESIGN; CHEMOSENSOR; LIBRARIES; WATER; ZINC; ACID	Small organic sensor molecules were prepared that bind and signal the presence of unlabeled tripeptides in a sequence-selective manner. Sequence-selective peptide binding is a difficult problem because small peptides are highly flexible acid there are no clear rules for designing peptide-binding molecules as there are for the nucleic acids. The signaling system involved the application of fluorescence energy transfer and provided large, real-time fluorescence increases (300 to 500 percent) upon peptide binding. With it, these sensors were sensitive enough to detect unlabeled cognate peptides both in organic solution and in the solid state at low micromolar concentrations.	Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University	Still, WC (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.							ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERT JS, 1995, J AM CHEM SOC, V117, P1143, DOI 10.1021/ja00108a037; AOKI I, 1992, J CHEM SOC CHEM COMM, P730, DOI 10.1039/c39920000730; BELL TW, 1995, SCIENCE, V269, P671, DOI 10.1126/science.7624796; BOYCE R, 1994, J AM CHEM SOC, V116, P7955, DOI 10.1021/ja00096a086; Cheng YA, 1996, J AM CHEM SOC, V118, P1813, DOI 10.1021/ja952976v; CZARNIK AW, 1995, CHEM BIOL, V2, P423, DOI 10.1016/1074-5521(95)90257-0; CZARNIK AW, 1992, ACS S SER, V538; DESVERGNE JP, 1997, NATO ASI SER C; FABBRIZZI L, 1995, CHEM SOC REV, P197; Godwin HA, 1996, J AM CHEM SOC, V118, P6514, DOI 10.1021/ja961184d; GOODMAN MS, 1995, J AM CHEM SOC, V117, P11610, DOI 10.1021/ja00151a039; HEALEY BG, 1995, SCIENCE, V269, P1078, DOI 10.1126/science.7652555; Ikeda H, 1997, J ORG CHEM, V62, P1411, DOI 10.1021/jo960425x; Iorio EJ, 1996, BIOORG MED CHEM LETT, V6, P2673, DOI 10.1016/S0960-894X(96)00500-8; JAMES TD, 1995, NATURE, V374, P345, DOI 10.1038/374345a0; KUHN MA, 1993, ACS SYM SER, V538, P147; LABRENZ SR, 1995, J AM CHEM SOC, V117, P3887; Mortellaro MA, 1996, J AM CHEM SOC, V118, P7414, DOI 10.1021/ja961323r; Nestler HP, 1996, MOL DIVERS, V2, P35, DOI 10.1007/BF01718698; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Pan ZY, 1996, TETRAHEDRON LETT, V37, P8699, DOI 10.1016/S0040-4039(96)02040-0; Peczuh MW, 1997, J AM CHEM SOC, V119, P9327, DOI 10.1021/ja970951l; Shao YF, 1996, J ORG CHEM, V61, P6086, DOI 10.1021/jo960775j; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; TORNEIRO M, 1995, J AM CHEM SOC, V117, P5887, DOI 10.1021/ja00126a043; Torneiro M, 1997, TETRAHEDRON, V53, P8739, DOI 10.1016/S0040-4020(97)90388-4; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Walkup GK, 1996, J AM CHEM SOC, V118, P3053, DOI 10.1021/ja9538501; WENNEMERS H, 1995, J ORG CHEM, V60, P1108, DOI 10.1021/jo00110a007; YOON J, 1992, J AM CHEM SOC, V114, P5874, DOI 10.1021/ja00040a067	31	121	127	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					851	853		10.1126/science.279.5352.851	http://dx.doi.org/10.1126/science.279.5352.851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452382				2022-12-28	WOS:000071923500040
J	Kurokawa, R; Kalafus, D; Ogliastro, MH; Kioussi, C; Xu, L; Torchia, J; Rosenfeld, MG; Glass, CK				Kurokawa, R; Kalafus, D; Ogliastro, MH; Kioussi, C; Xu, L; Torchia, J; Rosenfeld, MG; Glass, CK			Differential use of CREB binding protein coactivator complexes	SCIENCE			English	Article							TRANSCRIPTIONAL COACTIVATOR; NUCLEAR RECEPTORS; P300; CBP; ACTIVATION; E1A	CREB binding protein (CBP) functions as an essential coactivator of transcription factors that are inhibited by the adenovirus early gene product E1A. Transcriptional activation by the signal transducer and activator of transcription-1 (STAT1) protein requires the C/H3 domain in CBP, which is the primary target of E1A inhibition, Here it was found that the C/H3 domain is not required for retinoid acid receptor (RAR) function, nor is it involved in E1A inhibition, Instead, E1A inhibits RAR function by preventing the assembly of CBP-nuclear receptor coactivator complexes, revealing differences in required CBP domains for transcriptional activation by RAR and STAT1.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Kioussi, Chrissa/0000-0001-8226-9908				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, UNPUB; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NEVINS JR, 1992, SCIENCE, V258, P442; ONATE SA, 1995, SCIENCE, V270, P1354; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	32	189	190	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					700	703		10.1126/science.279.5351.700	http://dx.doi.org/10.1126/science.279.5351.700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445474				2022-12-28	WOS:000071731500035
J	Muskin, PR				Muskin, PR			The request to die - Role for a psychodynamic perspective on physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT REQUESTS; PRIMARY-CARE; VOLUNTARY EUTHANASIA; WASHINGTON-STATE; ATTITUDES; DEPRESSION; MANAGEMENT; LIFE; PAIN; PSYCHIATRISTS	Published reports indicate that 2.5% of deaths in the Netherlands are the result of euthanasia or physician-assisted suicide, It is not known how many patients make these requests in the United States, but the issue has gained considerable attention, including that of the Supreme Court. The focus of the writing and discussion regarding the request to die has been on a patient's capacity. There has not been an adequate focus on the possible meanings contained within the request to die, A patient's request to die is a situation that requires the physician to engage in a dialogue to understand what the request means, including whether the request arises from a clinically significant depression or inadequately treated pain. This article outlines some of the thoughts and emotions that could underlie the patient's request to die. Recommendations are made regarding the role of the primary care physician and the role of the psychiatric consultant in the exploration of the meaning of the request.	Columbia Univ Coll Phys & Surg, Columbia Presbyterian Med Ctr, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Psychoanalyt Ctr Training & Res, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University	Muskin, PR (corresponding author), Columbia Univ Coll Phys & Surg, Columbia Presbyterian Med Ctr, Dept Psychiat, 622 W 168th St,Mailbox 427, New York, NY 10032 USA.							ADMIRAAL P, COMMUNICATION; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P326; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; Battin M P, 1991, Crisis, V12, P73; BECK AT, 1985, AM J PSYCHIAT, V142, P559; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; BREITBART W, 1990, ADV PAIN RES THER, V16, P399; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; CAVANAUGH S, 1984, MANUAL PSYCHIATRIC C, P211; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Cleeland C S, 1987, Oncology (Williston Park), V1, P19; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; DRUSS RG, 1995, PSYCHOL ILLNESS; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; Eissler K., 1955, PSYCHIAT DYING PATIE; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; Ganzini L, 1996, AM J PSYCHIAT, V153, P1469; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; GOLDSTEIN WN, 1991, AM J PSYCHIAT, V148, P153; HELIG S, 1988, SAN FRANCISCO MED, V61, P24; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; HENDIN H, 1997, SEDUCED DEATH DOCTOR; HUYSE FJ, 1993, HOSP COMMUNITY PSYCH, V44, P733; Jacox A, 1994, AHCPR PUBLICATION; Kohut H., 1971, ANAL SELF SYSTEMATIC; Kohut H., 1977, RESTORATION SELF; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Leiser RJ, 1996, NEW ENGL J MED, V335, P972; LO B, 1988, W J MED, V49, P211; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MASSIE MJ, 1987, MED CLIN N AM, V71, P243, DOI 10.1016/S0025-7125(16)30868-9; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; McKeogh M, 1997, NEW ENGL J MED, V337, P56, DOI 10.1056/NEJM199707033370118; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; Muskin Philip R., 1995, P69; NIETZSCHE F, 1993, COLUMBIA DICT QUOTAT; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; Roberts LW, 1997, PSYCHOSOMATICS, V38, P459, DOI 10.1016/S0033-3182(97)71423-3; Roter D L, 1994, JAMA, V271, P80, DOI 10.1001/jama.271.1.80; Roter D.L., 1992, DOCTORS TALKING PATI; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SHERBOURNE CD, 1994, AM J PSYCHIAT, V151, P1777; Sontag S., 1978, ILLNESS METAPHOR; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	56	80	80	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					323	328		10.1001/jama.279.4.323	http://dx.doi.org/10.1001/jama.279.4.323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT472	9450720				2022-12-28	WOS:000071607000043
J	Han, JW; Luby-Phelps, K; Das, B; Shu, XD; Xia, Y; Mosteller, RD; Krishna, UM; Falck, JR; White, MA; Broek, D				Han, JW; Luby-Phelps, K; Das, B; Shu, XD; Xia, Y; Mosteller, RD; Krishna, UM; Falck, JR; White, MA; Broek, D			Role of substrates and products of PI3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav	SCIENCE			English	Article							PROTEIN; TRANSFORMATION; EFFECTORS; EXCHANGE; DISTINCT; DOMAIN; DBL	Mitogen stimulation of cytoskeletal changes and c-jun amino-terminal kinases is mediated by Rac small guanine nucleotide-binding proteins, Vav, a guanosine diphosphate (GDP)-guanosine triphosphate (GTP) exchange factor for Rac that stimulates the exchange of bound GDP for GTP, bound to and was directly controlled by substrates and products of phosphoinositide (PI) 3-kinase, The PI 3-kinase substrate phosphatidylinositol-4,5-bisphosphate inhibited activation of Vav by the tyrosine kinase Lck, whereas the product phosphatidylinositol-3,4,5-trisphosphate enhanced phosphorylation and activation of Vav by Lck. Control of Vav in response to mitogens by the products of PI 3-kinase suggests a mechanism for Ras-dependent activation of Rac.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Broek, D (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.	broek@zygote.hsc.usc.edu		Falck, John/0000-0002-9219-7845; Luby-Phelps, Katherine/0000-0002-8378-1409	NATIONAL CANCER INSTITUTE [R01CA071443, R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NCI NIH HHS [CA71443, CA50261] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSTELO XR, 1994, ONCOGENE, V9, P2405; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Han J., UNPUB; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REDDY KK, 1995, J ORG CHEM, V60, P3385, DOI 10.1021/jo00116a023; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	23	687	697	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					558	560		10.1126/science.279.5350.558	http://dx.doi.org/10.1126/science.279.5350.558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438848				2022-12-28	WOS:000071616000045
J	Glaser, B; Kesavan, P; Heyman, M; Davis, E; Cuesta, A; Buchs, A; Stanley, CA; Thornton, PS; Permutt, MA; Matschinsky, FM; Herold, KC				Glaser, B; Kesavan, P; Heyman, M; Davis, E; Cuesta, A; Buchs, A; Stanley, CA; Thornton, PS; Permutt, MA; Matschinsky, FM; Herold, KC			Familial hyperinsulinism caused by an activating glucokinase mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SULFONYLUREA RECEPTOR GENE; INSULIN-SECRETION; DIABETES-MELLITUS; GLUCOSE SENSOR; HYPOGLYCEMIA; INFANCY; PROTEIN; FORM		Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Endocrinol & Metab, IL-91010 Jerusalem, Israel; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Diabet Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp, Natl Metab Unit, Dublin, Ireland; Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO USA; Univ Illinois, Dept Internal Med, Chicago, IL USA	Hebrew University of Jerusalem; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Trinity College Dublin; Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Glaser, B (corresponding author), Hadassah Univ Hosp, Dept Endocrinol & Metab, IL-91120 Jerusalem, Israel.		Glaser, Benjamin/F-8411-2017	Glaser, Benjamin/0000-0003-4711-5000; STANLEY, CHARLES/0000-0003-4881-9392	NCRR NIH HHS [RR-00240] Funding Source: Medline; NIDDK NIH HHS [DK19525, DK16746] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016746, R01DK016746, P30DK019525] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUCHS A, 1995, ENDOCRINOLOGY, V136, P4224, DOI 10.1210/en.136.10.4224; CHIU KC, 1993, DIABETES, V42, P579, DOI 10.2337/diabetes.42.4.579; FABER OK, 1978, DIABETES, V27, P170, DOI 10.2337/diab.27.1.S170; Froguel P, 1997, DIABETES REV, V5, P123; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HARTLING SG, 1986, CLIN CHIM ACTA, V156, P289, DOI 10.1016/0009-8981(86)90072-0; Kesavan P, 1997, BIOCHEM J, V322, P57, DOI 10.1042/bj3220057; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIANG Y, 1995, BIOCHEM J, V309, P167, DOI 10.1042/bj3090167; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; PILKIS SJ, 1994, J BIOL CHEM, V269, P21925; POLONSKY KS, 1984, DIABETES, V33, P1112, DOI 10.2337/diabetes.33.11.1112; POLONSKY KS, 1988, J CLIN INVEST, V81, P435, DOI 10.1172/JCI113338; Stanley C A, 1976, Adv Pediatr, V23, P315; STANLEY CA, 1997, DIABETES, V46, pA217; TANIZAWA Y, 1993, DIABETOLOGIA, V36, P409, DOI 10.1007/BF00402276; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; Thomas PM, 1996, AM J HUM GENET, V59, P510; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, IN PRESS J PEDIAT; TURNER RC, 1996, OXFORD TXB MED, V2, P1505; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; Weinzimer SA, 1997, J PEDIATR-US, V130, P661, DOI 10.1016/S0022-3476(97)70256-7; Zammarchi E, 1996, METABOLISM, V45, P957, DOI 10.1016/S0026-0495(96)90262-0	30	441	492	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					226	230		10.1056/NEJM199801223380404	http://dx.doi.org/10.1056/NEJM199801223380404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435328	Bronze			2022-12-28	WOS:000071594100004
J	Glinka, A; Wu, W; Delius, H; Monaghan, AP; Blumenstock, C; Niehrs, C				Glinka, A; Wu, W; Delius, H; Monaghan, AP; Blumenstock, C; Niehrs, C			Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction	NATURE			English	Article							HOMEOBOX GENE; XENOPUS-EMBRYOS; SPEMANN ORGANIZER; WNT GENES; EXPRESSION; MESODERM; HOMOLOG; LAEVIS; RECEPTOR; SEQUENCE	The Spemann organizer in amphibian embryos is a tissue with potent head-inducing activity, the molecular nature of which is unresolved. Here we describe dickkopf-1 (dkk-1), which encodes Dkk-1, a secreted inducer of Spemann's organizer in Xenopus and a member of a new protein family. Injections of mRNA and antibody Indicate that dkk-1 is sufficient and necessary to cause head induction. dkk-1 is a potent antagonist of Wnt signalling, suggesting that dkk genes encode a family of secreted Wnt inhibitors.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumorvirol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							BallyCuif L, 1997, BIOESSAYS, V19, P127, DOI 10.1002/bies.950190207; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUI YZ, 1995, DEVELOPMENT, V121, P2177; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Fagotto F, 1997, DEVELOPMENT, V124, P453; GAMMIL LS, 1996, DEVELOPMENT, V124, P471; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERHART J, 1991, BOD MAR LAB, P57; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Itoh K, 1995, DEVELOPMENT, V121, P3979; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PANNESE M, 1995, DEVELOPMENT, V121, P707; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	46	1302	1409	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					357	362		10.1038/34848	http://dx.doi.org/10.1038/34848			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450748				2022-12-28	WOS:000071604200044
J	Shetty, AK; Steele, RW; Silas, V; Dehne, R				Shetty, AK; Steele, RW; Silas, V; Dehne, R			A boy with a limp	LANCET			English	Article									Louisiana State Univ, Med Ctr, Dept Paediat Orthopaed, New Orleans, LA 70118 USA; Childrens Hosp New Orleans, New Orleans, LA 70118 USA	Louisiana State University System; Children's Hospital of New Orleans	Shetty, AK (corresponding author), Louisiana State Univ, Med Ctr, Dept Paediat Orthopaed, New Orleans, LA 70118 USA.		Steele, Russell/A-6075-2011					Barlow T, 1883, Med Chir Trans, V66, P159; GARTY B, 1989, INT PEDIAT, V4, P280; Lind J., 1753, TREATISE SCURVY 3 PA; MASTERS R, 1986, NEW ENGL J MED, V315, P503; SHETTY AK, 1988, J RHEUMATOL, V15, P1878	5	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					182	182		10.1016/S0140-6736(97)10235-5	http://dx.doi.org/10.1016/S0140-6736(97)10235-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449874				2022-12-28	WOS:000071616300013
J	Xu, L; Eu, JP; Meissner, G; Stamler, JS				Xu, L; Eu, JP; Meissner, G; Stamler, JS			Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation	SCIENCE			English	Article							FROG SKELETAL-MUSCLE; PROTEIN-KINASE-C; NITRIC-OXIDE; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; CA-2+ RELEASE; CA2+ RELEASE; OXIDATION; SULFHYDRYLS; MECHANISM	Several ion channels are reportedly redox responsive, but the molecular basis for the changes in activity is not known. The mechanism of nitric oxide action on the cardiac calcium release channel (ryanodine receptor) (CRC) in canines was explored. This tetrameric channel contains similar to 84 free thiols and is S-nitrosylated in vivo. S-Nitrosylation of up to 12 sites (3 per CRC subunit) led to progressive channel activation that was reversed by denitrosylation. In contrast, oxidation of 20 to 24 thiols per CRC (5 or 6 per subunit) had no effect on channel function. Oxidation of additional thiols (or of another class of thiols) produced irreversible activation. The CRC thus appears to be regulated by poly-S-nitrosylation (multiple covalent attachments), whereas oxidation can lead to loss of control. These results reveal that ion channels can differentiate nitrosative from oxidative signals and indicate that: the CRC is regulated by posttranslational chemical modification(s) of sulfurs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Physiol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Pulm, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Cardiovasc Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.			Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL59130, HL52529, HL-27430] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, R01HL059130, P01HL027430] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; AOKI T, 1985, CAN J PHYSIOL PHARM, V63, P1070, DOI 10.1139/y85-175; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CHIAMVIMONVAT N, 1995, CIRC RES, V76, P325, DOI 10.1161/01.RES.76.3.325; DOU YM, 1994, J BIOL CHEM, V269, P20410; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GATH I, IN PRESS NITRIC OXID; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P246; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LEE HB, 1994, J BIOL CHEM, V269, P13305; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OBA T, 1985, PFLUG ARCH EUR J PHY, V405, P354, DOI 10.1007/BF00595688; OBA T, 1992, BIOPHYS J, V63, P1416, DOI 10.1016/S0006-3495(92)81704-6; OTSU K, 1990, J BIOL CHEM, V265, P13472; Pinsky DJ, 1997, CIRC RES, V81, P372, DOI 10.1161/01.RES.81.3.372; PRABHU SD, 1990, ARCH BIOCHEM BIOPHYS, V282, P275, DOI 10.1016/0003-9861(90)90117-H; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467; XU L, 1993, CARDIOVASC RES, V27, P1815, DOI 10.1093/cvr/27.10.1815; Xu L, 1996, CIRC RES, V79, P1100, DOI 10.1161/01.RES.79.6.1100	55	810	832	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					234	237		10.1126/science.279.5348.234	http://dx.doi.org/10.1126/science.279.5348.234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422697				2022-12-28	WOS:000071408100044
J	Silverman, IE; Flynn, JA				Silverman, IE; Flynn, JA			Ivory vertebra	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Johns Hopkins Hosp, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Silverman, IE (corresponding author), Johns Hopkins Hosp, Baltimore, MD 21287 USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					100	100		10.1056/NEJM199801083380205	http://dx.doi.org/10.1056/NEJM199801083380205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420341				2022-12-28	WOS:000071341300005
J	Kivela, T; Pelkonen, R; Oja, M; Heiskanen, O				Kivela, T; Pelkonen, R; Oja, M; Heiskanen, O			Diabetes insipidus and blindness caused by a suprasellar tumor - Pieter Pauw's observations from the 16th century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RATHKES CLEFT CYSTS; MANAGEMENT; FEATURES	Tumors in the suprasellar region may cause both visual and endocrinologic symptoms. This association, well known to modern physicians, was established during the 19th century. However, we have identified a 16th-century autopsy report, written by the Dutch professor of anatomy Pieter Pauw (1564-1617), which describes an 18-year-old girl who developed marked polyuria and subsequently became totally blind from a cystic tumor compressing the optic chiasm. Based on prevailing theories on the nature of diabetes, Pauw attributed the disease to the kidneys. Undoubtedly, however, his lucid report is the earliest known account of diabetes insipidus caused by an arachnoid cyst, the Rathke cleft cyst, or craniopharyngioma in the region of the pouch of Rathke. The description also gives insights into the role of anatomic dissections in late 16th-century northern Europe.	Univ Helsinki, Cent Hosp, Dept Ophthalmol, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Internal Med, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, FIN-00290 Helsinki, Finland; Univ Helsinki, Language Ctr, Helsinki, Finland; Univ Helsinki, Fac Educ, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki	Kivela, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Ophthalmol, Haartmaninkatu 4 C, FIN-00290 Helsinki, Finland.		Kivelä, Tero/C-9241-2009	Kivelä, Tero/0000-0003-1198-4394				ALLAN FN, 1953, DIABETES, V2, P74, DOI 10.2337/diab.2.1.74; BANNA M, 1976, BRIT J RADIOL, V49, P206, DOI 10.1259/0007-1285-49-579-206; BARTHOLINUS T, 1657, HIST ANATOMICARUM RA, P5; BECH SV, 1979, DANSK BIOGRAFISK LEK, V1, P476; DANKMEIJER J, 1957, PETITE HIST ANATOMIE, P1; DUKEELDER S, 1971, SYSTEM OPHTHALMOLOGY, V12, P371; DUNPHY E B, 1964, Trans Am Acad Ophthalmol Otolaryngol, V68, P249; Erdheim J, 1904, SITZUNGSBERICHTE K 3, V113, P537; FRANK L L, 1957, Am J Gastroenterol, V27, P76; HIRSCH A, 1929, BIOGRAPHISCHES LEXIK, V4, P535; HIRSCHBERG J, 1911, GRAEFESAEMISCH HDB G, V14, P480; HOFFMAN HJ, 1982, J NEUROSURG, V57, P597, DOI 10.3171/jns.1982.57.5.0597; KENNEDY HB, 1975, BRIT J OPHTHALMOL, V59, P689, DOI 10.1136/bjo.59.12.689; KING LS, 1973, AM J PATHOL, V73, P514; KUCHARCZYK W, 1987, RADIOLOGY, V165, P491, DOI 10.1148/radiology.165.2.3659372; MEDVEI VC, 1993, HIST CLIN ENDOCRINOL, P97; MILLER DC, 1994, PEDIATR NEUROSURG, V21, P11, DOI 10.1159/000120855; Moro F, 1989, Metab Pediatr Syst Ophthalmol (1985), V12, P7; Murdoch R, 1969, Scott Med J, V14, P39; PARK K, 1995, J HIST MED ALL SCI, V50, P111, DOI 10.1093/jhmas/50.1.111; POST KD, 1987, ENDOCRIN METAB CLIN, V16, P609, DOI 10.1016/S0889-8529(18)30466-3; RAO GP, 1995, AM J OPHTHALMOL, V119, P86, DOI 10.1016/S0002-9394(14)73818-8; ROSS DA, 1992, NEUROSURGERY, V30, P173, DOI 10.1227/00006123-199202000-00004; Rostotskaia V I, 1986, Zh Vopr Neirokhir Im N N Burdenko, P12; TERAMOTO A, 1994, RADIOLOGY, V193, P161, DOI 10.1148/radiology.193.1.8090885; van der Aa A. J., 1969, BIOGRAPHISCH WOORDEN; VOELKER JL, 1991, J NEUROSURG, V74, P535, DOI 10.3171/jns.1991.74.4.0535	27	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					48	50		10.1001/jama.279.1.48	http://dx.doi.org/10.1001/jama.279.1.48			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424043				2022-12-28	WOS:000071295100034
J	Nightingale, SL				Nightingale, SL			Irradiation of meat approved for pathogen control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-28	WOS:000071295100005
J	Banner, AS				Banner, AS			Non-steroidal anti-inflammatory therapy for bronchial asthma	LANCET			English	Editorial Material									Vet Affairs Med Ctr, Manchester, NH 03104 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University	Banner, AS (corresponding author), Vet Affairs Med Ctr, Manchester, NH 03104 USA.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; FISH JE, 1997, AM J RESP CARE MED, V156; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; KANE GC, 1994, CLIN PULM MED, V1, P69; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Spahn JD, 1996, ALLERGY ASTHMA PROC, V17, P341, DOI 10.2500/108854196778606365; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; Spahn JD, 1997, J ASTHMA, V34, P177, DOI 10.3109/02770909709068188	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					5	7		10.1016/S0140-6736(05)78098-3	http://dx.doi.org/10.1016/S0140-6736(05)78098-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433419				2022-12-28	WOS:000071253100005
J	Bielinsky, AK; Gerbi, SA				Bielinsky, AK; Gerbi, SA			Discrete start sites for DNA synthesis in the yeast ARS1 origin	SCIENCE			English	Article							REPLICATION ORIGINS; RECOGNITION COMPLEX; S-PHASE; SIMIAN VIRUS-40; CELL-CYCLE; INITIATION; ORC; CHROMOSOMES; CEREVISIAE; SEQUENCE	Sites of DNA synthesis initiation have been detected at the nucleotide level in a yeast origin of bidirectional replication with the use of replication initiation point mapping. The ARS1 origin of Saccharomyces cerevisiae showed a transition from discontinuous to continuous DNA synthesis in an 18-base pair region (nucleotides 828 to 845) from within element B1 toward B2, adjacent to the binding site for the origin recognition complex, the putative initiator protein.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA	Brown University	Gerbi, SA (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA.			Bielinsky, Anja/0000-0003-1783-619X	NIGMS NIH HHS [GM 35929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035929] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1977, BIOCHEMISTRY-US, V16, P4990, DOI 10.1021/bi00642a009; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HENDRICKSON EA, 1987, EMBO J, V6, P2011, DOI 10.1002/j.1460-2075.1987.tb02465.x; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lin S, 1997, MOL CELL BIOL, V17, P5473, DOI 10.1128/MCB.17.9.5473; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NETHANEL T, 1988, J VIROL, V62, P2867, DOI 10.1128/JVI.62.8.2867-2873.1988; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; YAMAGUCHI M, 1985, MOL CELL BIOL, V5, P1170, DOI 10.1128/MCB.5.5.1170; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	30	124	126	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					95	98		10.1126/science.279.5347.95	http://dx.doi.org/10.1126/science.279.5347.95			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417033				2022-12-28	WOS:000071323900048
J	Po, ALW; Zhang, WY				Po, ALW; Zhang, WY			Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol	BRITISH MEDICAL JOURNAL			English	Article							ORAL-SURGERY PAIN; ACETAMINOPHEN PLUS CODEINE; POSTOPERATIVE PAIN; PROPOXYPHENE HYDROCHLORIDE; CLINICAL-TRIALS; 1000 MG; EFFICACY; COMBINATION; RELIEF; PLACEBO	Objective: To evaluate the comparative efficacy and tolerability of paracetamol-dextropropoxyphene combination and paracetamol through a systematic overview of randomised controlled trials. Design: Systematic retrieval of trials of paracetamol-dextropropoxyphene, paracetamol, and placebo to allow pooling of results from head to head comparison trials and single active placebo controlled trials. Subjects: 2231 patients with postsurgical pain, arthritis, and musculoskeletal pain reported in 26 randomised controlled trials. Main outcome measures: Sum of difference in pain intensity; response rate ratio and difference in response rate with response defined as moderate to excellent pain relief; and rate ratio and rate difference of side effects. Results: The difference in pain intensity between paracetamol-dextropropoxyphene and paracetamol was 7.3% (95% confidence interval -0.2 to 14.9). The response rate ratio for the combination and paracetamol was 1.05 (0.8 to 1.3) on the basis of the head to head trials. Indirect comparisons produced quantitatively consistent results. Compared with placebo, the combination produced more dizziness (3.1; 1.1 to 8.9) whereas paracetamol resulted in more drowsiness (1.8; 1.1 to 2.9). Conclusion: On the basis of data on analgesic efficacy and acute safely in both head to head and indirect comparisons, there is little objective evidence to support prescribing a combination of paracetamol and dextropropoxyphene in preference to paracetamol alone in moderate pain such as that after surgery.	Univ Nottingham, Dept Pharmaceut Sci, Ctr Evidence Based Pharmacotherapy, Nottingham NG7 2RD, England	University of Nottingham	Po, ALW (corresponding author), Univ Nottingham, Dept Pharmaceut Sci, Ctr Evidence Based Pharmacotherapy, Univ Pk, Nottingham NG7 2RD, England.			Zhang, Weiya/0000-0003-1142-1460				BEAVER WT, 1987, CLIN PHARMACOL THER, V41, P180; BEAVER WT, 1978, CLIN PHARMACOL THER, V23, P108; BEAVER WT, 1984, HUM TOXICOL, V3, P191; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BLOOMFIELD SS, 1981, CURR THER RES, V30, P139; BUCK ME, 1978, CURR MED RES OPIN, V5, P548, DOI 10.1185/03007997809108999; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; COOPER S A, 1991, Journal of Clinical Dentistry, V2, P70; Cooper S A, 1986, Compend Contin Educ Dent, V7, P580; COOPER SA, 1981, J ORAL SURG, V39, P21; deCraen AJM, 1996, BRIT MED J, V313, P321, DOI 10.1136/bmj.313.7053.321; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIONNE RA, 1994, J ORAL MAXIL SURG, V52, P919, DOI 10.1016/S0278-2391(10)80068-0; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; EVANS PJD, 1982, BRIT J ANAESTH, V54, P927, DOI 10.1093/bja/54.9.927; FORBES JA, 1984, CLIN PHARMACOL THER, V35, P843, DOI 10.1038/clpt.1984.123; FORBES JA, 1984, PHARMACOTHERAPY, V4, P221; FORBES JA, 1982, PHARMACOTHERAPY, V2, P43; FORBES JA, 1983, CLIN PHARMACOL THER, V33, P196; Gobel H, 1996, NERVENARZT, V67, P672, DOI 10.1007/s001150050040; Haigh S, 1996, LANCET, V347, P1840, DOI 10.1016/S0140-6736(96)91665-7; HONIG S, 1981, J CLIN PHARMACOL, V21, P443, DOI 10.1002/j.1552-4604.1981.tb01747.x; HOPKINSON JH, 1974, CURR THER RES CLIN E, V16, P194; HOPKINSON JH, 1973, J CLIN PHARMACOL, V13, P251, DOI 10.1002/j.1552-4604.1973.tb00265.x; HOPKINSON JH, 1976, CURR THER RES CLIN E, V19, P622; HUSKISSON EC, 1974, BMJ-BRIT MED J, V4, P196, DOI 10.1136/bmj.4.5938.196; JAIN AK, 1986, CLIN PHARMACOL THER, V39, P295, DOI 10.1038/clpt.1986.42; LIASHEK P, 1987, J ORAL MAXIL SURG, V45, P99, DOI 10.1016/0278-2391(87)90398-3; MELZACK R, 1983, CURR THER RES CLIN E, V34, P929; MESSICK RT, 1979, J CLIN PHARMACOL, V19, P227, DOI 10.1002/j.1552-4604.1979.tb01656.x; MILLER RR, 1970, J AMER MED ASSOC, V213, P996, DOI 10.1001/jama.213.6.996; PERRIER D, 1973, J CLIN PHARMACOL, V12, P449; PETTI A, 1985, CLIN THER, V8, P126; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P177; SEYMOUR RA, 1981, PAIN, V10, pS248; SUNSHINE A, 1989, J CLIN PHARMACOL, V29, P660, DOI 10.1002/j.1552-4604.1989.tb03397.x; SUNSHINE A, 1993, CLIN PHARMACOL THER, V54, P546, DOI 10.1038/clpt.1993.187; SUNSHINE A, 1986, AM J MED, V80, P50, DOI 10.1016/0002-9343(86)90111-7; SUNSHINE A, 1992, CLIN PHARMACOL THER, V51, P740, DOI 10.1038/clpt.1992.86; Sykes JV, 1996, LANCET, V348, P408, DOI 10.1016/S0140-6736(05)65028-3; TERRENCE CF, 1983, CLIN NEUROPHARMACOL, V6, P241, DOI 10.1097/00002826-198309000-00006; WALL R, 1980, BRIT MED J, V1, P1213; WEBER B, 1990, CONTRACEPT FERTIL S, V18, P1073; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YOUNG RES, 1979, J MED, V10, P239; Zhang WY, 1996, J CLIN PHARM THER, V21, P261, DOI 10.1111/j.1365-2710.1996.tb01148.x	46	66	66	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1565	1571		10.1136/bmj.315.7122.1565	http://dx.doi.org/10.1136/bmj.315.7122.1565			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437273	Green Published			2022-12-28	WOS:000071021900020
J	Egger, M; Smith, GD; Phillips, AN				Egger, M; Smith, GD; Phillips, AN			Meta-analysis: Principles and procedures	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; CLINICAL-TRIALS; SYSTEMATIC REVIEWS; QUALITY; CHECKLISTS; BIAS	Meta-analysis should be as carefully planned as any other research project, with a detailed written protocol being prepared in advance. The a priori definition of eligibility criteria for studies to be included and a comprehensive search for such studies are central to high quality meta-analysis. The graphical display of results from individual studies on a common scale is an important intermediate step, which allows a visual examination of the degree of heterogeneity between studies Different statistical methods exist for combining the data, but there is no single ''correct'' method. A thorough sensitivity analysis is essential to assess the robustness of combined estimates to different assumptions and inclusion criteria.	ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Egger, M (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Franzeck, Fabian C/B-5055-2011; Davey Smith, George/A-7407-2013; Phillips, Andrew N/B-4427-2008	Davey Smith, George/0000-0002-1407-8314; Phillips, Andrew N/0000-0003-2384-4807; Egger, Matthias/0000-0001-7462-5132				BAILEY KR, 1987, STAT MED, V6, P351, DOI 10.1002/sim.4780060327; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; CARLIN JB, 1992, STAT MED, V11, P141, DOI 10.1002/sim.4780110202; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; Chatellier G, 1996, BRIT MED J, V312, P426; *COCHR CONTR TRIAL, 1977, COCHR LIB; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DICKERSIN K, 1985, CONTROL CLIN TRIALS, V6, P306, DOI 10.1016/0197-2456(85)90106-0; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Eddy DM, 1992, METAANALYSIS CONFIDE; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; GREEN SJ, 1987, STAT MED, V6, P361, DOI 10.1002/sim.4780060329; Greenhalgh T, 1997, BRIT MED J, V315, P180, DOI 10.1136/bmj.315.7101.180; Huque MF, 1988, PROC BIOPHARM SECT A, V2, P28; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Lilford RJ, 1996, BRIT MED J, V313, P603; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; PRENDIVILLE W, 1988, BRIT J OBSTET GYNAEC, V95, P3, DOI 10.1111/j.1471-0528.1988.tb06475.x; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	30	1346	1360	6	102	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 6	1997	315	7121					1533	1537		10.1136/bmj.315.7121.1533	http://dx.doi.org/10.1136/bmj.315.7121.1533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9432252	Green Published			2022-12-28	WOS:A1997YK98600035
J	Heinemann, LAJ; Lewis, MA; Thorogood, M; Spitzer, WO; GuggenmoosHolzmann, I; Bruppacher, R; Bergman, U; Breckwoldt, M; Kemper, F; LeLorier, J; MacLeod, S; MacRae, K; Ray, W; Schlesselman, J; Concin, H; Stark, G; Pfeiffer, K; Weitgasser, R; Begaud, B; Boissel, B; Haerting, J; Lautenschlaeger, F; Puschel, K; Hoffmann, F; Robra, BP; Lustermann, M; Schulzki, I; Boethig, S; Gutzwiller, F; deCaestecker, L; McCollum, C; Hannaford, P; Mann, R; KuhlHabich, D; Klindworth, C; Assmann, A				Heinemann, LAJ; Lewis, MA; Thorogood, M; Spitzer, WO; GuggenmoosHolzmann, I; Bruppacher, R; Bergman, U; Breckwoldt, M; Kemper, F; LeLorier, J; MacLeod, S; MacRae, K; Ray, W; Schlesselman, J; Concin, H; Stark, G; Pfeiffer, K; Weitgasser, R; Begaud, B; Boissel, B; Haerting, J; Lautenschlaeger, F; Puschel, K; Hoffmann, F; Robra, BP; Lustermann, M; Schulzki, I; Boethig, S; Gutzwiller, F; deCaestecker, L; McCollum, C; Hannaford, P; Mann, R; KuhlHabich, D; Klindworth, C; Assmann, A			Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women	BRITISH MEDICAL JOURNAL			English	Article							3RD-GENERATION	Objective: To determine the influence of oral contraceptives (particularly those containing modern progestins) on the risk for ischaemic stroke in women aged 16-44 years, Design: Matched case-control study, Setting: 16 centres in the United Kingdom, Germany, France, Switzerland, and Austria, Subjects: Cases were 220 women aged 16-44 who had an incident ischaemic stroke, Controls were 775 women( at least one hospital and one community control per case) unaffected by stroke who were matched with the corresponding case for 5 year age band and for hospital or community setting, Information on exposure and confounding variables were collected in a face to face interview. Main outcome measures: Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding, Results: Adjusted odds ratios (95% confidence intervals) for ischaemic stroke (unmatched analysis) were 4.4 (2.0 to 9.9), 3.4 (2.1 to 5.5), and 3.9 (2.3 to 6.6) for current use of first second, and third generation oral contraceptives, respectively. The risk ratio for third versus second generation was 1.1 (0.7 to 2.0) and was similar in the United Kingdom and other European countries, The risk estimates were lower if blood pressure was checked before prescription, Conclusion: Although there is a small relative risk of occlusive stroke for women of reproductive age who currently use oral contraceptives, the attributable risk is very small because the incidence in this age range is very low. There is no difference between the risk of oral contraceptives of the third and second generation; only first generation oral contraceptives seem to be associated with a higher risk, This small increase in risk may be further reduced by efforts ta control cardiovascular risk factors, particularly high blood pressure.	EPES EPIDEMIOL PHARMACOEPIDEMIOL & SYST RES,D-12165 BERLIN,GERMANY; UNIV LONDON LONDON SCH HYG & TROP MED,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Heinemann, LAJ (corresponding author), ZEG,CTR EPIDEMIOL & HLTH RES,D-16341 ZEPERNICK,GERMANY.		Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002				HEINEMANN L, 1989, SAFETY REQUIREMENTS, P113; Lewis MA, 1996, BRIT MED J, V312, P88; Spitzer WO, 1996, BRIT MED J, V312, P83; Spitzer WO, 1993, PHARMACOEPIDEM DR S, V2, P21; *STAT, 1995, STAT SOFTW PACK VERS; *WHO COLL STUD CAR, 1995, J CLIN EPIDEMIOL, V48, P1513; *WHO COLL STUD CAR, 1996, LANCET, V348, P498	7	70	71	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1502	1504		10.1136/bmj.315.7121.1502	http://dx.doi.org/10.1136/bmj.315.7121.1502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420491	Green Published			2022-12-28	WOS:A1997YK98600020
J	Volmink, J; Garner, P				Volmink, J; Garner, P			Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPROVE ADHERENCE; THERAPY; INTERVENTIONS; EDUCATION; PROGRAM; RATES	Objective: To determine the effectiveness of strategies to promote adherence t Identification: Searches in Medline (1966 to August 1996), the Cochrane trials register (up to October 1996), and LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud) (1982 to September 1996); screening of references in articles on compliance and adherence; contact with experts in research on tuberculosis and adherence. Inclusion criteria: Randomised or pseudorandomised controlled trials of interventions to promote adherence with curative or preventive treatment for tuberculosis, with at least one measure of adherence. Main outcome measure: Relative risks and 95% confidence intervals for estimates of effect for categorical outcomes. Results: Five trials met the inclusion criteria. The relative risk for tested reminder cards sent to patients who defaulted on treatment was 1.2 (95% confidence interval 1.1 to 1.4), for help given to patients by lay health workers 1.4 (1.1 to 1.8), for monetary incentives offered to patients 1.6 (1.3 to 2.0), for health education 1.2 (1.1 to 1.4), for a combination of a patient incentive and health education 2.4 (1.5 to 3.7) or 1.1 (1.0 to 1.2), and for intensive supervision of staff in tuberculosis clinics 1.2 (1.1 to 1.3). There were no completed trials of directly observed treatment All of the interventions tested improved adherence. On current evidence it is unclear whether health education by itself leads to better adherence to treatment Conclusions: Reliable evidence is available to show some specific strategies improve adherence to tuberculosis treatment, and these should be adopted in health systems, depending on their appropriateness to practice circumstances. Further innovations require testing to help find specific approaches that will be useful in low income countries. Randomised controlled trials evaluating the independent effects of directly observed treatment are awaited.	UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, INT HLTH DIV, LIVERPOOL L3 5QA, MERSEYSIDE, ENGLAND	Liverpool School of Tropical Medicine; University of Liverpool	Volmink, J (corresponding author), S AFRICAN MRC, S AFRICAN COCHRANE CTR, BOX 19070, ZA-7505 TYGERBERG, CAPE TOWN, SOUTH AFRICA.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941				ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; CUNEO WD, 1989, CLIN CHEST MED, V10, P375; DICKERSON K, 1995, SYSTEMATIC REV; FOX W, 1983, BRIT MED J, V287, P33, DOI 10.1136/bmj.287.6384.33; Garner P, 1997, LANCET, V350, P666, DOI 10.1016/S0140-6736(05)63361-2; Haynes RB, 1996, LANCET, V348, P383; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; JIN BW, 1993, TUBERCLE LUNG DIS, V74, P267, DOI 10.1016/0962-8479(93)90053-Z; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; MORISKY DE, 1990, HEALTH EDUC QUART, V17, P253, DOI 10.1177/109019819001700303; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; Neher A, 1996, TUBERCLE LUNG DIS, V77, P302, DOI 10.1016/S0962-8479(96)90093-3; Paramasivan R, 1993, INDIAN J TUBERCULOSI, V40, P185; Pilote L, 1996, ARCH INTERN MED, V156, P161, DOI 10.1001/archinte.156.2.161; SANMARTI LS, 1993, TUBERCLE LUNG DIS, V74, P28, DOI 10.1016/0962-8479(93)90065-6; Sbarbaro J A, 1994, Semin Respir Infect, V9, P120; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; VOLMINK J, 1997, INFECT DIS MODULE CO; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; 1997, COMPUTER PROGRAMME V; 1993, MMWR-MORBID MORTAL W, V42, P81; 1993, MMWR-MORBID MORTAL W, V42, P74	25	94	100	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	1997	315	7120					1403	1406		10.1136/bmj.315.7120.1403	http://dx.doi.org/10.1136/bmj.315.7120.1403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418086	Green Published			2022-12-28	WOS:A1997YJ67200022
J	Egger, M; Smith, GD				Egger, M; Smith, GD			Meta-analysis - Potentials and promise	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MOLECULAR-WEIGHT HEPARIN; MYOCARDIAL-INFARCTION; TRIALS; METAANALYSIS; BIAS; CHOLESTEROL; SCIENCE; STATE; DRUGS				Egger, M (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132; s, hema/0000-0002-3440-9475				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, LANCET, V340, P944; [Anonymous], 1997, LANCET, V350, P675; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; Chalmers I, 1989, EFFECTIVE CARE PREGN; Chalmers I, 1995, SYSTEMATIC REV; Chalmers I., 1979, PERINATAL MED, P260; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; COLLINS R, 1992, BRIT MED J, V304, P1689, DOI 10.1136/bmj.304.6843.1689; COOPER HM, 1980, PSYCHOL BULL, V87, P442, DOI 10.1037/0033-2909.87.3.442; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1997, IN PRESS BMJ; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; Freiman J.A., 1992, MED USES STAT, P357, DOI [10.1201/9780429187445, DOI 10.1201/9780429187445]; GELBER RD, 1987, STAT MED, V6, P371, DOI 10.1002/sim.4780060331; General Accounting Office, 1992, CROSS DES SYNTH NEW; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GOTZSCHE PC, 1992, J CLIN EPIDEMIOL, V45, P587, DOI 10.1016/0895-4356(92)90130-F; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; *GRUPP IT STUD STR, 1986, LANCET, P397; Huque MF, 1988, PROC BIOPHARM SECT A, V2, P28; JENICEK M, 1989, J CLIN EPIDEMIOL, V42, P35, DOI 10.1016/0895-4356(89)90023-1; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MITCHELL JRA, 1981, BRIT MED J, V282, P1565, DOI 10.1136/bmj.282.6276.1565; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; MURPHY DJ, 1994, ARCH INTERN MED, V154, P505, DOI 10.1001/archinte.154.5.505; Naylor CD, 1997, BMJ-BRIT MED J, V315, P617, DOI 10.1136/bmj.315.7109.617; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Oakes M. W., 1986, STAT INFERENCE COMME; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Rosenthal R, 1990, FUTURE METAANALYSIS, P123; Simpson RJS, 1904, BRIT MED J, V1904, P1243; SMITH GD, 1997, IN PRESS BMJ; TEAGARDEN JR, 1989, PHARMACOTHERAPY, V9, P274; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	44	384	403	1	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1371	1374		10.1136/bmj.315.7119.1371	http://dx.doi.org/10.1136/bmj.315.7119.1371			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9432250	Green Published			2022-12-28	WOS:A1997YJ21800033
J	Bindschadler, R; Vornberger, P				Bindschadler, R; Vornberger, P			Changes in the West Antarctic ice sheet since 1963 from declassified satellite photography	SCIENCE			English	Article							STREAM-C; STAGNATION	Comparison of declassified satellite photography taken in 1963 with more recent satellite imagery reveals that large changes have occurred in the region where an active ice stream enters the Ross Ice Shelf. Ice stream B has widened by 4 kilometers, at a rate much faster than suggested by models, and has decreased in speed by 50 percent. The ice ridge between ice streams B and C has eroded 14 kilometers. These changes, along with changes in the crevassing around Crary Ice Rise, imply that this region's velocity field shifted during this century.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Gen Sci Corp, Laurel, MD 20727 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Bindschadler, R (corresponding author), NASA, Goddard Space Flight Ctr, Code 971, Greenbelt, MD 20771 USA.							ALLEY RB, 1994, ANN GLACIOL, V20, P187, DOI 10.3189/172756494794587032; ALLEY RB, 1991, SCIENCE, V254, P959, DOI 10.1126/science.254.5034.959; BINDSCHADLER R, 1993, J GLACIOL, V39, P538, DOI 10.3189/S0022143000016439; BINDSCHADLER RA, 1988, 100708 NASA; BINDSCHADLER RA, 1988, ANN GLACIOL, V11, P8, DOI DOI 10.3189/S0260305500006248; CLARKE T, COMMUNICATION; ECHELMEYER K, COMMUNICATION; HALL B, 1997, THESIS U MAINE; Houghton J., 1996, SCI CLIMATE CHANGE; JACOBSON P, IN PRESS J GEOPHYS R; RETZLAFF R, 1993, J GLACIOL, V39, P553, DOI 10.3189/S0022143000016440; STEPHENSON SN, 1988, NATURE, V334, P695, DOI 10.1038/334695a0; Stuiver M., 1981, LAST GREAT ICE SHEET, P319; Thomas R., 1988, ANN GLACIOL, V11, P165; Thomas R. H., 1984, ROSS ICE SHELF GLACI, V42, P21; [No title captured]	16	101	103	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					689	692		10.1126/science.279.5351.689	http://dx.doi.org/10.1126/science.279.5351.689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445471				2022-12-28	WOS:000071731500032
J	Ioannidis, JPA				Ioannidis, JPA			Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CLINICAL-TRIALS; CUBIC MILLIMETER; HIV-INFECTION; DOUBLE-BLIND; BIAS; METAANALYSIS; AIDS; ZIDOVUDINE; DISEASE	Context.-Medical evidence may be biased over time if completion and publication of randomized efficacy trials are delayed when results are not statistically significant. Objective.-To evaluate whether the time to completion and the time to publication of randomized phase 2 and phase 3 trials are affected by the statistical significance of results and to describe the natural history of such trials. Design.-Prospective cohort of randomized efficacy trials conducted by 2 trialist groups from 1986 to 1996. Setting.-Multicenter trial groups in human immunodeficiency virus infection sponsored by the National Institutes of Health. Patients.-A total of 109 efficacy trials (total enrollment, 43 708 patients). Main Outcome Measures.-Time from start of enrollment to completion of follow-up and time from completion of follow-up to peer-reviewed publication assessed with survival analysis. Results.-The median time from start of enrollment to publication was 5.5 years and was substantially longer for negative trials than for results favoring an experimental arm (6.5 vs 4.3 years, respectively; P<.001; hazard ratio for time to publication for positive vs negative trials, 3.7; 95% confidence interval [CI], 1.8-7.7). This difference was mostly attributable to differences in the time from completion to publication (median, 3.0 vs 1.7 years for negative vs positive trials; P<.001). On average, trials with significant results favoring any arm completed follow-up slightly earlier than trials with nonsignificant results (median, 2.3 vs 2.5 years; P=.045), but long-protracted trials often had low event rates and failed to reach statistical significance, while trials that were terminated early had significant results. Positive trials were submitted for publication significantly more rapidly after completion than were negative trials (median, 1.0 vs 1.6 years; P=.001) and were published more rapidly after submission (median, 0.8 vs 1.1 years; P=.04). Conclusion.-Among randomized efficacy trials, there is a time lag in the publication of negative findings that occurs mostly after the completion of the trial follow-up.	NIAID, HIV Res Branch, Therapeut Res Program, Div Aids,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ioannidis, JPA (corresponding author), NIAID, HIV Res Branch, Therapeut Res Program, Div Aids,NIH, Solar Bldg 2C31,6003 Execut Blvd, Bethesda, MD 20892 USA.	ji24m@nih.gov	Ioannidis, John P. A./G-9836-2011					[Anonymous], 1993, AIDS Res Hum Retroviruses, V9, P83; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DeMets DL, 1995, CONTROL CLIN TRIALS, V16, P408, DOI 10.1016/S0197-2456(95)00073-9; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; HERSH EM, 1991, JAMA-J AM MED ASSOC, V265, P1538, DOI 10.1001/jama.265.12.1538; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; Ioannidis JPA, 1996, LANCET, V348, P756, DOI 10.1016/S0140-6736(05)65647-4; Ioannidis JPA, 1997, CONTROL CLIN TRIALS, V18, P431, DOI 10.1016/S0197-2456(97)00097-4; Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2; Ioannidis JPA, 1996, AM J EPIDEMIOL, V144, P1074, DOI 10.1093/oxfordjournals.aje.a008881; KOREN G, 1989, LANCET, V2, P1440; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1762; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; SELIGMANN M, 1994, LANCET, V343, P871; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YOULE MS, 1994, AIDS, V8, P641, DOI 10.1097/00002030-199405000-00010	30	439	444	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					281	286		10.1001/jama.279.4.281	http://dx.doi.org/10.1001/jama.279.4.281			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450711				2022-12-28	WOS:000071607000034
J	McEllistrem, M; Allgeier, M; Boland, JJ				McEllistrem, M; Allgeier, M; Boland, JJ			Dangling bond dynamics on the silicon (100)-2x1 surface: Dissociation, diffusion, and recombination	SCIENCE			English	Article							HYDROGEN-ATOMS; DESORPTION; KINETICS; ADSORPTION; SI(100)2X1; CHLORINE; SI(001); DIMERS; SI2H6	The dynamics of dangling bond (DB) diffusion Was studied after deuterium desorption from the silicon (100)-2 x 1 surface. At elevated temperatures, paired DB sites produced after desorption unpaired as deuterium atoms hopped from adjacent dimers. Below 620 kelvin, the unpaired configuration most commonly observed corresponded to two DBs on adjacent silicon dimers. At higher temperatures, unpaired DBs executed one-dimensional walks along the dimer rows, and recombination was observed with the same partner after walks lasting many minutes. The frequency and extent of these excursions increased with temperature. Above 660 kelvin, complete dissociation was observed and was sometimes followed by recombination by means of partner exchange. The implications for low-temperature materials growth are discussed.	Univ N Carolina, Dept Chem, Venable & Kenan Labs, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Boland, JJ (corresponding author), Univ N Carolina, Dept Chem, Venable & Kenan Labs, CB 3290, Chapel Hill, NC 27599 USA.		Boland, John/AAB-8498-2022; Boland, John J/P-9740-2016	Boland, John/0000-0002-3229-8038; Boland, John J/0000-0002-3229-8038				BOLAND JJ, 1993, SCIENCE, V262, P1703, DOI 10.1126/science.262.5140.1703; BOLAND JJ, 1993, ADV PHYS, V42, P129, DOI 10.1080/00018739300101474; BOLAND JJ, 1991, PHYS REV LETT, V67, P1593; DEVELYN MP, 1993, J CHEM PHYS, V98, P3560, DOI 10.1063/1.464078; deWijs GA, 1996, PHYS REV LETT, V77, P881, DOI 10.1103/PhysRevLett.77.881; FOLEY ET, IN PRESS PHYS REV LE; GATES SM, 1988, SURF SCI, V195, P307, DOI 10.1016/0039-6028(88)90798-4; HAMERS RJ, 1989, J VAC SCI TECHNOL A, V7, P2854, DOI 10.1116/1.576158; HOFER U, 1992, PHYS REV B, V45, P9485, DOI 10.1103/PhysRevB.45.9485; JASINSKI JM, 1987, ANNU REV PHYS CHEM, V38, P109, DOI 10.1146/annurev.physchem.38.1.109; MCELLISTREM MT, UNPUB; NACHTIGALL P, 1991, J CHEM PHYS, V95, P8652, DOI 10.1063/1.461245; Owen JHG, 1996, PHYS REV B, V54, P14153, DOI 10.1103/PhysRevB.54.14153; SHEN TC, 1995, SCIENCE, V268, P1590, DOI 10.1126/science.268.5217.1590; SUDA Y, 1990, J VAC SCI TECHNOL A, V8, P61, DOI 10.1116/1.576356; VITTADINI A, 1994, PHYS REV B, V49, P11191, DOI 10.1103/PhysRevB.49.11191; WU CJ, 1992, PHYS REV B, V46, P4651, DOI 10.1103/PhysRevB.46.4651	17	57	58	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					545	548		10.1126/science.279.5350.545	http://dx.doi.org/10.1126/science.279.5350.545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438844				2022-12-28	WOS:000071616000041
J	Carson, JL; Duff, A; Berlin, JA; Lawrence, VA; Poses, RM; Huber, EC; O'Hara, DA; Noveck, H; Strom, BL				Carson, JL; Duff, A; Berlin, JA; Lawrence, VA; Poses, RM; Huber, EC; O'Hara, DA; Noveck, H; Strom, BL			Perioperative blood transfusion and postoperative mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORBIDITY; DISEASE; SYSTEM; RISK	Context.-The risks of blood transfusion have been studied extensively but the benefits and the hemoglobin concentration at which patients should receive a transfusion have not. Objective.-To determine the effect of perioperative transfusion on 30- and 90-day postoperative mortality. Design.-Retrospective cohort study. Setting.-A total of 20 US hospitals between 1983 and 1993. Participants.-A total of 8787 consecutive hip fracture patients, aged 60 years or older, who underwent surgical repair. Main Outcome Measures.-Primary outcome was 30-day postoperative mortality; secondary outcome was 90-day postoperative mortality. The "trigger" hemoglobin level was defined as the lowest hemoglobin level prior to the first transfusion during the time period or, for patients in the nontranfused group, as the lowest hemoglobin level during the time period. Results.-Overall 30-day mortality was 4.6% (n=402; 95% confidence interval [CI], 4.1%-5.0%); overall 90-day mortality was 9.0% (n=788; 95% CI, 8.4%-9.6%). A total of 42% of patients (n=3699) received a postoperative transfusion. Among patients with trigger hemoglobin levels between 80 and 100 g/L (8.0 and 10.0 g/dL), 55.6% received a transfusion, while 90.5% of patients with hemoglobin levels less than 80 g/L (8.0 g/dL) received postoperative transfusions. Postoperative transfusion did not influence 30- or 90-day mortality after adjusting for trigger hemoglobin level, cardiovascular disease, and other risk factors for death: for 30-day mortality, the adjusted odds ratio (OR) was 0.96 (95% CI, 0.74-1.26); for 90-day mortality, the adjusted hazard ratio was 1.08 (95% CI, 0.90-1.29). Similarly, 30-day mortality after surgery did not differ between those who received a preoperative transfusion and those who did not (adjusted OR, 1.23; 95% CI, 0.81-1.89). Conclusions.-Perioperative transfusion in patients with hemoglobin levels 80 g/L (8.0 g/dL) or higher did not appear to influence the risk of 30- or 90-day mortality in this elderly population, At hemoglobin concentrations of less than 80 g/L (8.0 g/dL), 90.5% of patients received a transfusion, precluding further analysis of the association of transfusion and mortality.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Anesthesia, New Brunswick, NJ 08903 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, Div Gen Med, San Antonio, TX USA; Univ Texas, Dept Med, San Antonio, TX 78285 USA; Brown Univ, Sch Med, Dept Med, Div Gen Internal Med, Providence, RI 02912 USA; Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Gen Internal Med, Richmond, VA 23298 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; Brown University; Brown University; Virginia Commonwealth University	Carson, JL (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, 125 Paterson St, New Brunswick, NJ 08903 USA.	carson@umdnj.edu			AHRQ HHS [1R01HS07322] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON HT, 1978, SURGERY, V84, P8; [Anonymous], 1990, SAS STAT US GUID VER; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P142; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; FEINBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; Geha A S, 1978, World J Surg, V2, P645; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; HERBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUNN JN, 1970, BRIT MED J, V3, P71, DOI 10.1136/bmj.3.5714.71; MANTEL N, 1959, J NATL CANCER I, V22, P719; Rawstron R E, 1970, Aust N Z J Surg, V39, P425, DOI 10.1111/j.1445-2197.1970.tb05389.x; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; TOPLEY E, 1956, BR J CLIN PRACT, V1, P770; WEISEL RD, 1992, J THORAC CARDIOVASC, V104, P308; WILKERSON DK, 1988, SURGERY, V103, P665; YOSHIKAWA H, 1973, AM J CARDIOL, V32, P670, DOI 10.1016/S0002-9149(73)80061-X	27	297	306	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					199	205		10.1001/jama.279.3.199	http://dx.doi.org/10.1001/jama.279.3.199			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438739	Bronze			2022-12-28	WOS:000071460700029
J	McEwen, BS				McEwen, BS			Protective and damaging effects of stress mediators	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AMBULATORY BLOOD-PRESSURE; DEPENDENT DIABETES-MELLITUS; IMMUNE CELL DISTRIBUTION; CORONARY HEART-DISEASE; CHRONIC SOCIAL STRESS; PSYCHOLOGICAL STRESS; CARDIOVASCULAR-RESPONSES; SOCIOECONOMIC-STATUS; ALZHEIMERS-DISEASE; CORTISOL-LEVELS		Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendocri, New York, NY 10021 USA	Rockefeller University	McEwen, BS (corresponding author), Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendocri, Box 165,1230 York Ave, New York, NY 10021 USA.		McEwen, Bruce/Z-1630-2019					ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Albeck DS, 1997, J NEUROSCI, V17, P4895; BAUM A, 1993, PSYCHOSOM MED, V55, P274, DOI 10.1097/00006842-199305000-00005; BERG K, 1983, PROG MED GENET, V5, P35; BERNADET P, 1995, J CARDIOVASC PHARM, V25, pS3, DOI 10.1097/00005344-199525001-00003; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; BLANCHARD DC, 1993, BEHAV BRAIN RES, V58, P113, DOI 10.1016/0166-4328(93)90096-9; Bobak M, 1996, BRIT MED J, V312, P421; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; BOYAR RM, 1977, NEW ENGL J MED, V296, P190, DOI 10.1056/NEJM197701272960403; BRINDLEY DN, 1989, CLIN SCI, V77, P453, DOI 10.1042/cs0770453; Brunner E, 1996, HLTH SOCIAL ORG, P272; BuskeKirschbaum A, 1997, PSYCHOSOM MED, V59, P419, DOI 10.1097/00006842-199707000-00012; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Cohen S, 1997, JAMA-J AM MED ASSOC, V277, P1940; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; COHEN S, 1992, PSYCHOL SCI, V3, P301, DOI 10.1111/j.1467-9280.1992.tb00677.x; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; Dhabhar F. S., 1996, Society for Neuroscience Abstracts, V22, P1350; DHABHAR FS, 1994, BRAIN BEHAV IMMUN, V8, P66, DOI 10.1006/brbi.1994.1006; Dhabhar FS, 1996, J IMMUNOL, V157, P1638; Dhabhar FS, 1996, J IMMUNOL, V156, P2608; DHABHAR FS, 1995, J IMMUNOL, V154, P5511; DHABHAR FS, 1996, STRESS INDUCED ENHAN; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; Everson SA, 1997, BRIT MED J, V314, P553, DOI 10.1136/bmj.314.7080.553; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; GERIN W, 1995, J HYPERTENS, V13, P603, DOI 10.1097/00004872-199506000-00005; GOULD E, 1990, J NEUROSCI, V10, P996; Hadid R, 1996, NEUROIMMUNOMODULAT, V3, P62, DOI 10.1159/000097228; HAGGLOF B, 1991, DIABETOLOGIA, V34, P579, DOI 10.1007/BF00400277; HANDA RJ, 1994, PHYSIOL BEHAV, V55, P117, DOI 10.1016/0031-9384(94)90018-3; HEIM C, IN PRESS PSYCHOSOM M; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JAYO JM, 1993, INT J OBESITY, V17, P597; JURASKA JM, 1985, BRAIN RES, V333, P73, DOI 10.1016/0006-8993(85)90125-8; KAPLAN JR, 1991, CIRCULATION, V84, P23; KERR DS, 1991, J NEUROSCI, V11, P1316; KERR DS, 1992, P NATL ACAD SCI USA, V89, P8527, DOI 10.1073/pnas.89.18.8527; KIMURA D, 1992, Scientific American, V267, P118; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P468, DOI 10.1097/00006842-199509000-00009; LARSSON BO, 1989, APPETITE, V13, P37, DOI 10.1016/0195-6663(89)90025-1; Lazarus RS., 1984, STRESS APPRAISAL COP; Ledoux Joseph E., 1995, P1049; LEHMAN CD, 1991, BEHAV NEUROSCI, V105, P241, DOI 10.1037/0735-7044.105.2.241; LOUCKS AB, 1989, J CLIN ENDOCR METAB, V68, P402, DOI 10.1210/jcem-68-2-402; LOWY MT, 1995, J NEUROCHEM, V65, P268; LUPIEN S, 1994, J NEUROSCI, V14, P2893, DOI 10.1523/jneurosci.14-05-02893.1994; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863; MANUCK SB, 1988, HEALTH PSYCHOL, V7, P113, DOI 10.1037/0278-6133.7.2.113; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATTHEWS KA, 1992, PSYCHOSOM MED, V54, P686, DOI 10.1097/00006842-199211000-00009; MATTSON MP, 1992, EXP GERONTOL, V27, P29, DOI 10.1016/0531-5565(92)90027-W; MCCARTY R, 1985, J AUTONOM NERV SYST, V12, P15, DOI 10.1016/0165-1838(85)90037-2; McEwen BS, 1997, ANN NY ACAD SCI, V821, P271, DOI 10.1111/j.1749-6632.1997.tb48286.x; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093; MCEWEN BS, 1992, PROG BRAIN RES, V93, P365; McEwen BS, 1995, VITAM HORM, V51, P371, DOI 10.1016/S0083-6729(08)61045-6; MCKITTRICK CR, 1995, BIOL PSYCHIAT, V37, P383, DOI 10.1016/0006-3223(94)00152-S; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1994, SEMIN NEUROSCI, V6, P247; MELIN B, IN PRESS J ORG PSYCH; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; MILLER AH, 1994, ENDOCRINOLOGY, V135, P1934, DOI 10.1210/en.135.5.1934; MILLS LR, 1990, NEURON, V4, P149, DOI 10.1016/0896-6273(90)90451-K; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; Moyer A E, 1994, Obes Res, V2, P255; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Pickering TG, 1996, J HYPERTENS, V14, pS179; PLOMIN R, 1990, SCIENCE, V248, P183, DOI 10.1126/science.2183351; POTELIAKHOFF A, 1981, J PSYCHOSOM RES, V25, P91, DOI 10.1016/0022-3999(81)90095-7; Pugh CR, 1997, BEHAV NEUROSCI, V111, P503, DOI 10.1037/0735-7044.111.3.503; Raikkonen K, 1996, METABOLISM, V45, P1533, DOI 10.1016/S0026-0495(96)90184-5; Raikkonen K, 1996, ARTERIOSCL THROM VAS, V16, P363, DOI 10.1161/01.ATV.16.3.363; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; RICHARDSON JL, 1990, J CLIN ONCOL, V8, P356, DOI 10.1200/JCO.1990.8.2.356; ROOF RL, 1993, BRAIN RES, V610, P148, DOI 10.1016/0006-8993(93)91228-K; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/edrv-7-3-284; SAPOLSKY RM, 1990, SCI AM, V262, P116, DOI 10.1038/scientificamerican0190-116; Sapolsky RM, 1992, STRESS AGING BRAIN M; SCHNALL PL, 1992, HYPERTENSION, V19, P488, DOI 10.1161/01.HYP.19.5.488; SCHULKIN J, 1994, NEUROSCI BIOBEHAV R, V18, P385, DOI 10.1016/0149-7634(94)90051-5; SCHULZ P, IN PRESS STRESS MED; Seeman TE, 1997, ARCH INTERN MED, V157, P2259; Seeman TE, 1997, J CLIN ENDOCR METAB, V82, P2458, DOI 10.1210/jc.82.8.2458; SEEMAN TE, 1994, ENDOCR REV, V15, P233, DOI 10.1210/er.15.2.233; Seeman TE, 1996, PSYCHOSOM MED, V58, P459, DOI 10.1097/00006842-199609000-00008; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; SPIEGEL D, 1989, LANCET, V2, P888; Sterling P., 1988, HDB LIFE STRESS COGN, P629, DOI DOI 10.1016/0005-7967(90)90076-U; STERN Y, 1995, NEUROLOGY, V45, P55, DOI 10.1212/WNL.45.1.55; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; UNO H, 1989, J NEUROSCI, V9, P1705, DOI 10.1523/jneurosci.09-05-01705.1989; UR E, 1992, EUR ARCH PSY CLIN N, V241, P317, DOI 10.1007/BF02195983; VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468; VERDECCHIA P, 1995, J HYPERTENS, V13, P1209, DOI 10.1097/00004872-199510000-00016; WILINSON CW, 1997, NEUROENDOCRINOLOGY, V65, P79; YEHUDA R, 1991, BIOL PSYCHIAT, V30, P1031, DOI 10.1016/0006-3223(91)90123-4; Yehuda R, 1996, BIOL PSYCHIAT, V40, P79, DOI 10.1016/0006-3223(95)00451-3	113	4042	4115	14	642	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					171	179		10.1056/NEJM199801153380307	http://dx.doi.org/10.1056/NEJM199801153380307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ414	9428819				2022-12-28	WOS:000071384500007
J	De Koninck, P; Schulman, H				De Koninck, P; Schulman, H			Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; HIPPOCAMPAL SLICES; CALMODULIN KINASE; AUTOPHOSPHORYLATION; EXPRESSION; MECHANISM; MEMORY; ACTIVATION	The transduction of many cellular stimuli results in oscillations in the intracellular concentration of calcium ions (Ca2+). Although information is thought to be encoded in the frequency of such oscillations, no frequency decoder has been identified. Rapid superfusion of immobilized Ca2+ - and calmodulin-dependent protein kinase II (CaM kinase II) in vitro showed that the enzyme can decode the frequency of Ca2+ spikes into distinct amounts of kinase activity. The frequency response of CaM kinase II was modulated by several factors, including the amplitude and duration of individual spikes as well as the subunit composition and previous state of activation of the kinase. These features should provide specificity in the activation of this multifunctional enzyme by distinct cellular stimuli and may underlie its pivotal role in activity-dependent forms of synaptic plasticity.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600, R01GM030179, R37GM030179] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30179, GM40600] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Deisseroth K, 1995, CURR BIOL, V5, P1334, DOI 10.1016/S0960-9822(95)00262-4; DEKONINCK P, UNPUB; Dosemeci A, 1996, BIOPHYS J, V70, P2493, DOI 10.1016/S0006-3495(96)79821-1; ESTEP RP, 1989, CURR TOP CELL REGUL, V31, P161; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER P, 1994, BIOCHEM J, V298, P757, DOI 10.1042/bj2980757; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MICHELSON S, 1994, J THEOR BIOL, V171, P281, DOI 10.1006/jtbi.1994.1231; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Skene J H, 1990, Neurosci Res Suppl, V13, pS112, DOI 10.1016/0921-8696(90)90040-A; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175	37	1004	1019	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					227	230		10.1126/science.279.5348.227	http://dx.doi.org/10.1126/science.279.5348.227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422695				2022-12-28	WOS:000071408100042
J	Andrews, L; Nelkin, D				Andrews, L; Nelkin, D			Whose body is it anyway? Disputes over body tissue in a biotechnology age	LANCET			English	Article							GENES		Chicago Kent Coll Law, Chicago, IL 60661 USA; Amer Bar Fdn, Chicago, IL USA; NYU, Dept Sociol, New York, NY 10003 USA; NYU, Sch Law, New York, NY 10003 USA	New York University; New York University	Andrews, L (corresponding author), Chicago Kent Coll Law, 565 W Adams St, Chicago, IL 60661 USA.							[Anonymous], 1996, B MED ETHICS; BOWCOCK A, 1991, GENOMICS, V11, P191; BOYLE R, 1772, WORKS, V5, P236; BURROWS B, 1994, BOYCOTT Q        SPR, P20; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; Douglas Mary, 1966, PURITY DANGER; Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; FOX R, 1992, SPARE PARTS 206; FOX RC, 1993, TRANSPLANT P, V25, P55; HAMEER D, 1995, SCI DESIRE; Jasper J., 1992, ANIMAL RIGHTS CRUSAD; *JOHNPAUL II, 1996, FAMILY RESOURCE  WIN; KELNER K, 1994, SCIENCE, V264, P1685; Kimbrell, 1994, HUMAN BODY SHOP ENG; KIMBRELL A, 1993, HUMAN BODY SHOP, P284; LAPPE M, 1994, BROKEN CODE 80; LASTER K, 1995, INT J SOCIOL LAW, V24, P21; LASTER K, 1995, INT J SOCIOL LAW, V24, P29; LINDEE MS, 1999, IN PRESS OSIRIS; LOCK M, 1993, ENCOUNTERS AGING, P370; MELKIN D, 1995, DANGEROUS DIAGNOSTIC; Mitchell P, 1997, LANCET, V349, P1232, DOI 10.1016/S0140-6736(05)62436-1; RAPP R, 1997, SCI TECHNOLOGY H FAL; RICHARDSON R, 1996, ORGAN TRANSPLANTATIO, V82; ROSE S, 1995, NATURE, V373, P380, DOI 10.1038/373380a0; ROSE S, 1995, NATURE, V372, P390; Stern D.N., 1985, INTERPERSONAL WORLD; STONE R, 1995, SCIENCE, V268, P1126, DOI 10.1126/science.7761825; Turner V., 1967, FOREST SYMBOLS; *WORLD COUNC IND P, RES HGDP; 1995, GENE HUNTERS; 1995, NEW SCI         0708, P34	32	53	54	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					53	57		10.1016/S0140-6736(05)78066-1	http://dx.doi.org/10.1016/S0140-6736(05)78066-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433437				2022-12-28	WOS:000071253100045
J	Chambers, JC; McGregor, A; Jean-Marie, J; Kooner, JS				Chambers, JC; McGregor, A; Jean-Marie, J; Kooner, JS			Acute hyperhomocysteinaemia and endothelial dysfunction	LANCET			English	Article							DILATATION		Hammersmith Hosp, Imperial Coll Sch Med, Natl Heart & Lung Inst, London W12 0NN, England; Ealing Hosp, Dept Cardiol, Ealing, Middx, England	Imperial College London	Kooner, JS (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Natl Heart & Lung Inst, London W12 0NN, England.							Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403	5	188	193	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					36	37		10.1016/S0140-6736(05)78090-9	http://dx.doi.org/10.1016/S0140-6736(05)78090-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433433				2022-12-28	WOS:000071253100020
J	Rozwarski, DA; Grant, GA; Barton, DHR; Jacobs, WR; Sacchettini, JC				Rozwarski, DA; Grant, GA; Barton, DHR; Jacobs, WR; Sacchettini, JC			Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; MYCOLIC ACID SYNTHESIS; RESISTANT STRAINS; DRUG-RESISTANCE; ENOYL REDUCTASE; OXIDATION; KATG; MUTATIONS; DNA; IDENTIFICATION	The preferred antitubercular drug isoniazid specifically targets a long-chain enoyl-acyl carrier protein reductase (InhA), an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Despite the widespread use of this drug for more than 40 years, its precise mode of action has remained obscure. Data from x-ray crystallography and mass spectrometry reveal that the mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of nicotinamide adenine dinucleotide bound within the active site of InhA.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36849] Funding Source: Medline; NIGMS NIH HHS [GM-45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRUNGER AT, 1992, XPLOR VERSOIN 3 1 SY; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; COLE ST, 1995, EUR RESPIR J, V8, pS701; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; Heym B, 1996, CURR TOP MICROBIOL, V215, P49; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; LEWIN E, 1955, AM REV TUBERC PULM, V71, P732; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; MUSSER JH, COMMUNICATION; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; OBRIEN RJ, 1993, LUNG BIOL HLTH DISEA, V66, P207; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAOLETTI F, 1990, CHEM-BIOL INTERACT, V76, P3, DOI 10.1016/0009-2797(90)90030-Q; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P408, DOI 10.1128/AAC.27.3.408; SINHA BK, 1983, J BIOL CHEM, V258, P796; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; WANG L, 1975, ANTIMICROB AGENTS CH, V16, P308; Wheeler PR, 1996, BIOCHEM J, V318, P451, DOI 10.1042/bj3180451; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1959, BIOCHEM J, V73, P500, DOI 10.1042/bj0730500; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1994, J ANTIMICROB CHEMOTH, V34, P313, DOI 10.1093/jac/34.3.313; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	53	573	593	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					98	102		10.1126/science.279.5347.98	http://dx.doi.org/10.1126/science.279.5347.98			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417034				2022-12-28	WOS:000071323900049
J	Jiang, CY; Ting, AT; Seed, B				Jiang, CY; Ting, AT; Seed, B			PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; PROLIFERATOR-ACTIVATED RECEPTORS; ADIPOCYTE DIFFERENTIATION; RHEUMATOID-ARTHRITIS; 3T3-L1 CELLS; FACTOR-ALPHA; EXPRESSION; LIGAND; J(2); BETA	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor family of transcription factors, a large and diverse group of proteins that mediate ligand-dependent transcriptional activation and repression(1,2). Expression of PPAR-gamma is an early and pivotal event in the differentiation of adipocytes(3-6). Several agents that promote differentiation of fibroblast lines into adipocytes have been shown to be PPAR-gamma agonists(7-10), including several prostanoids, of which 15-deoxy-Delta(12,14)-prostaglandin J(2) is the most potent(8,9), as well as members of a new class of oral antidiabetic agents, the thiazolidinediones(7), and a variety of non-steroidal anti-inflammatory drugs (NSAIDs)(10). Here we show that PPAR-gamma agonists suppress monocyte elaboration of inflammatory cytokines at agonist concentrations similar to those found to be effective for the promotion of adipogenesis. Inhibition of cytokine production may help to explain the incremental therapeutic benefit of NSAIDs observed in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are required to inhibit prostaglandin G/H synthase (cyclooxygenase).	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Seed, B (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.							BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brennan FM, 1996, CURR OPIN IMMUNOL, V8, P872, DOI 10.1016/S0952-7915(96)80018-5; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Firestein GS, 1997, NEW ENGL J MED, V337, P195, DOI 10.1056/NEJM199707173370310; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Greene M. E., 1995, Gene Expression, V4, P281; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LAU CS, 1993, BRIT J RHEUMATOL, V32, P982; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; MCEVOY GK, 1997, AHFS 97 DRUG INFORMA; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	28	2551	2706	3	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					82	86		10.1038/34184	http://dx.doi.org/10.1038/34184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422509				2022-12-28	WOS:000071326100053
J	Barrett, K; Leptin, M; Settleman, J				Barrett, K; Leptin, M; Settleman, J			The rho GTPase and a putative RhoGEF mediate a signaling pathway for the cell shape changes in Drosophila gastrulation	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; GENE; CDC42; RAS; ENCODES; EMBRYO; DOMAIN; TRANSFORMATION	The Rho GTPases mediate actin rearrangements that are likely to be required for the numerous cell shape changes in a developing embryo. In a genetic screen for Rho signaling pathway components in Drosophila, we identified a gene, DRhoGEF2, that encodes a predicted Rho-specific guanine nucleotide exchange factor. Embryos lacking DRhoGEF2 fail to gastrulate due to a defect in cell shape changes required for tissue invagination, and expression of a dominant-negative Rho GTPase in early embryos results in similar defects. Evidence is also presented that DRhoGEF2 mediates these specific cell shape changes in response to the extracellular ligand, Fog. Together, these results establish a Rho-mediated signaling pathway that is essential for the major morphogenetic events in Drosophila gastrulation.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Cologne, Inst Genet, D-5000 Cologne, Germany	Harvard University; Massachusetts General Hospital; Harvard University; University of Cologne	Settleman, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.							BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dutartre H, 1996, J CELL SCI, V109, P367; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Leptin M, 1995, ANNU REV CELL DEV BI, V11, P189; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SWEETON D, 1991, DEVELOPMENT, V112, P775; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Werner LA, 1997, GENE, V187, P107, DOI 10.1016/S0378-1119(96)00732-9; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YOUNG PE, 1991, DEVELOPMENT, V111, P1; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	57	306	309	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					905	915		10.1016/S0092-8674(00)80482-1	http://dx.doi.org/10.1016/S0092-8674(00)80482-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428514	Bronze			2022-12-28	WOS:000071281400008
J	Levchenko, I; Smith, CK; Walsh, NP; Sauer, RT; Baker, TA				Levchenko, I; Smith, CK; Walsh, NP; Sauer, RT; Baker, TA			PDZ-like domains mediate binding specificity in the Clp/Hsp100 family of chaperones and protease regulatory subunits	CELL			English	Article							BACTERIOPHAGE-MU REPRESSOR; DEPENDENT CLP PROTEASE; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; TRANSPOSASE TETRAMER; MOLECULAR CHAPERONE; SERINE-PROTEASE; MESSENGER-RNA; HSP104; COMPONENT	ClpX, a molecular chaperone and the regulatory subunit of the ClpXP protease, is shown to contain tandem modular domains that bind to the C-terminal sequences of target proteins in a manner that parallels functional specificity Nuclear magnetic resonance studies show that these C-terminal sequences are displayed as disordered peptides on the surface of otherwise folded proteins. The ClpX substrate-binding domains are homologous to sequences in other Clp/Hsp100 proteins and are related more distantly to PDZ domains, which also mediate C-terminal specific protein-protein interactions. Conservation of these binding domains indicates that the mode of substrate recognition characterized here for ClpX will be a conserved feature among Clp/Hsp100 family members and a distinguishing characteristic between this chaperone family and the Hsp70 chaperones.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Baker, TA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CAMPBELL ID, 1975, FEBS LETT, V57, P96, DOI 10.1016/0014-5793(75)80160-8; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GEUSKENS V, 1991, J BACTERIOL, V173, P6578, DOI 10.1128/jb.173.20.6578-6585.1991; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MILLA ME, 1993, PROTEIN SCI, V2, P2198, DOI 10.1002/pro.5560021219; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Ponting CP, 1997, PROTEIN SCI, V6, P464; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P890, DOI 10.1021/bi00377a033; Welty DJ, 1997, J MOL BIOL, V272, P31, DOI 10.1006/jmbi.1997.1193; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	47	102	105	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					939	947		10.1016/S0092-8674(00)80485-7	http://dx.doi.org/10.1016/S0092-8674(00)80485-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428517	Bronze			2022-12-28	WOS:000071281400011
J	Hooper, E				Hooper, E			Sailors and star-bursts, and the arrival of HIV	BRITISH MEDICAL JOURNAL			English	Article							AIDS; VIRUS; ZAIRE; INFECTION; SEQUENCE				Hooper, E (corresponding author), POB 4087, Worthing BN14 7LQ, England.							AGUT H, 1992, LANCET, V340, P682; BarreSinoussi F, 1996, LANCET, V348, P31, DOI 10.1016/S0140-6736(96)09058-7; Bryceson A, 1988, Lancet, V2, P221; BYGBJERG IC, 1983, LANCET, V1, P925; Centers for Disease Control (CDC), 1981, MMWR-MORBID MORTAL W, V30, P250; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; CONNOR S, 1994, INDEPENDENT SUN 0403; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CRIBB J, 1996, WHITE DEATH; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; GARRETT L, 1994, COMING PLAGUE NEWLY, P378; Hooper E, 1996, LANCET, V348, P1363, DOI 10.1016/S0140-6736(96)07063-8; Jonassen TO, 1997, VIROLOGY, V231, P43, DOI 10.1006/viro.1997.8510; LEGUENNO B, 1989, T ROY SOC TROP MED H, V83, P847, DOI 10.1016/0035-9203(89)90350-7; LI WH, 1988, MOL BIOL EVOL, V5, P313; Mauclere P, 1997, AIDS, V11, P445, DOI 10.1097/00002030-199704000-00007; MYERS G, 1994, AIDS RES HUM RETROV, V10, P1317, DOI 10.1089/aid.1994.10.1317; NAHMIAS AJ, 1986, LANCET, V1, P1279; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; *NUFF COUNC BIOETH, 1996, AN TO HUM TRANSPL ET; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; QUERAT G, 1990, VIROLOGY, V175, P434, DOI 10.1016/0042-6822(90)90428-T; SARAGOSTI S, 1994, C CENT GARDS, V9, P109; Sharp P.M., 1994, AIDS S1, V8, pS27; Songok EM, 1996, LANCET, V347, P1700, DOI 10.1016/S0140-6736(96)91533-0; SONNET J, 1987, SCAND J INFECT DIS, V19, P511, DOI 10.3109/00365548709032415; STERRY W, 1983, LANCET, V1, P924; *UNAIDS WHO WORK G, 1997, REP GLOB HIV AIDS EP; WINSLOW CEA, 1980, CONQUEST EPIDEMIC DI, P271; ZHU TF, 1995, NATURE, V374, P503, DOI 10.1038/374503a0	31	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1689	1691		10.1136/bmj.315.7123.1689	http://dx.doi.org/10.1136/bmj.315.7123.1689			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448543	Green Published			2022-12-28	WOS:000071149400029
J	Wasserberg, J; Barlow, P				Wasserberg, J; Barlow, P			Lesson of the week - Lumbar puncture still has an important role in diagnosing subarachnoid haemorrhage	BRITISH MEDICAL JOURNAL			English	Review							HEMORRHAGE; ANEURYSM; CT		So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Wasserberg, J (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.		Wasserberg, Jonathan/AAB-7099-2020	Wasserberg, Jonathan/0000-0002-3782-0390				ADAMS HP, 1983, NEUROLOGY, V33, P981, DOI 10.1212/WNL.33.8.981; DUFFY GP, 1982, BRIT MED J, V285, P1163, DOI 10.1136/bmj.285.6349.1163; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; PATEL MK, 1986, POSTGRAD MED J, V62, P1021, DOI 10.1136/pgmj.62.733.1021; Sames TA, 1996, ACAD EMERG MED, V3, P16, DOI 10.1111/j.1553-2712.1996.tb03296.x; TEDDY PJ, 1983, BRIT MED J, V286, P143, DOI 10.1136/bmj.286.6359.143; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365	8	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1598	1599		10.1136/bmj.315.7122.1598	http://dx.doi.org/10.1136/bmj.315.7122.1598			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437281	Green Published			2022-12-28	WOS:000071021900029
J	King, M; Elliott, C				King, M; Elliott, C			To the point of farce: a Martian view of the Hardinian taboo - the silence that surrounds population control	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CB2 1TJ,ENGLAND	University of Leeds; University of Cambridge								CASSEN R, 1994, POPULATION POLICY NE; HARDIN G, 1993, LIVING LIMITS; King M, 1996, NATL MED J INDIA, V9, P130; KING MH, 1995, BRIT MED J, V313, P995; KING MH, AWAY HARDINIAN TABOO; MCINTOSH CA, 1995, POPUL DEV REV, V21, P223, DOI 10.2307/2137493; 1997, LANCET, V349, P1530	7	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1441	1443		10.1136/bmj.315.7120.1441	http://dx.doi.org/10.1136/bmj.315.7120.1441			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418096	Green Published			2022-12-28	WOS:A1997YJ67200032
J	Campbell, JJ; Hedrick, J; Zlotnik, A; Siani, MA; Thompson, DA; Butcher, EC				Campbell, JJ; Hedrick, J; Zlotnik, A; Siani, MA; Thompson, DA; Butcher, EC			Chemokines and the arrest of lymphocytes rolling under flow conditions	SCIENCE			English	Article							T-CELL ADHESION; ENDOTHELIAL-CELLS; CHEMOATTRACTANT; MOLECULES; PROTEINS; MIP-1-BETA; MIGRATION; INTEGRINS; RECEPTOR; MEMORY	Circulating lymphocytes are recruited from the blood to the tissue by railing along the endothelium until being stopped by a signaling event linked to the G(i) alpha subunit of a heterotrimeric GTP-binding protein; that event then triggers rapid integrin-dependent adhesion. Four chemokines are now shown to induce such adhesion tb intercellular adhesion molecule-1 and to induce arrest of rolling cells within 1 second under flow conditions similar to those of blood. SDF-1 (also called PBSF), 6-C-kine (also called Exodus-2), and MIP-3 beta (also called ELC or Exodus-3) induced adhesion of most circulating lymphocytes, including most CD4(+) T cells; and MIP-3 alpha (also called LARC or Exodus-1) triggered adhesion of memory, but not nai ve, CD4(+) T cells. Thus, chemokines can regulate the arrest of lymphocyte subsets under flawing conditions, which may allow them to control lymphocyte-endothelial cell recognition and lymphocyte recruitment in vivo.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Ctr Digest Dis, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; Gryphon Sci, San Francisco, CA 94080 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Campbell, JJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Zlotnik, Albert/C-3791-2011	Campbell, James/0000-0003-4252-5182; Thompson, Darren/0000-0002-3725-7112	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037734, R37GM037734] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA090302] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BARGATZE R, 1994, THESIS MONTANA STATE; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; CARLOS TM, 1994, BLOOD, V84, P2068; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Hedrick JA, 1997, J IMMUNOL, V159, P1589; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HONDA S, 1994, J IMMUNOL, V152, P4026; Hromas R, 1997, BLOOD, V89, P3315; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Lloyd AR, 1996, J IMMUNOL, V156, P932; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Rossi DL, 1997, J IMMUNOL, V158, P1033; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WARNOCK RA, IN PRESS J EXP MED; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	41	792	822	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					381	384		10.1126/science.279.5349.381	http://dx.doi.org/10.1126/science.279.5349.381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430588				2022-12-28	WOS:000071570800046
J	Bezzi, P; Carmignoto, G; Pasti, L; Vesce, S; Rossi, D; Rizzini, BL; Pozzan, T; Volterra, A				Bezzi, P; Carmignoto, G; Pasti, L; Vesce, S; Rossi, D; Rizzini, BL; Pozzan, T; Volterra, A			Prostaglandins stimulate calcium-dependent glutamate release in astrocytes	NATURE			English	Article							ARACHIDONIC-ACID; SYNAPTIC TRANSMISSION; GLIAL-CELLS; HIPPOCAMPAL; NEURONS; CULTURES; INHIBITION; RECEPTORS; RESPONSES; TETANUS	Astrocytes in the brain form an intimately associated network with neurons. They respond to neuronal activity and synaptically released glutamate by raising intracellular calcium concentration ([Ca2+](i))(1,2), which could represent the start of back-signalling to neurons(3-5). Here we show that coactivation of the AMPA/kainate and metabotropic glutamate receptors (mGluRs) on astrocytes stimulates these cells to release glutamate through a Ca2+-dependent process mediated by prostaglandins. Pharmacological inhibition of prostaglandin synthesis prevents glutamate release, whereas application of prostaglandins (in particular PGE(2)) mimics and occludes the releasing action of GluR agonists. PGE(2) promotes Ca2+-dependent glutamate release from cultured astrocytes and also from acute brain slices under conditions that suppress neuronal exocytotic release. When applied to the CA1 hippocampal region, PGE(2) induces increases in [Ca2+](i) both in astrocytes and in neurons. The [Ca2+](i) increase in neurons is mediated by glutamate released from astrocytes, because it is abolished by GluR antagonists. Our results reveal a new pathway of regulated transmitter release from astrocytes and outline the existence of an integrated glutamatergic cross-talk between neurons and astrocytes in situ that may play critical roles in synaptic plasticity and in neurotoxicity.	Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Univ Padua, Dept Expt Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Biomembranes, I-35121 Padua, Italy	University of Milan; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Volterra, A (corresponding author), Univ Milan, Inst Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		Carmignoto, Giorgio/A-8375-2018; Rossi, Daniela Maria/AAA-3401-2021; Bezzi, Paola/AAP-2440-2020	Carmignoto, Giorgio/0000-0003-3063-6774; Rossi, Daniela Maria/0000-0002-3346-1327; Volterra, Andrea/0000-0003-1069-1602	Telethon [845, 586] Funding Source: Medline	Telethon(Fondazione Telethon)		BARAN H, 1987, BRAIN RES, V404, P107, DOI 10.1016/0006-8993(87)91360-6; CALABRESI P, 1989, NEUROSCIENCE, V30, P663, DOI 10.1016/0306-4522(89)90159-0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; ERIKSSON PS, 1992, NEUROSCI LETT, V143, P195, DOI 10.1016/0304-3940(92)90264-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; Jeftinija SD, 1997, BRAIN RES, V750, P41, DOI 10.1016/S0006-8993(96)00610-5; JEFTINIJA SD, 1996, J NEUROCHEM, V66, P674; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; Mennerick S, 1996, J NEUROSCI, V16, P55; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; OBanion MK, 1996, J NEUROCHEM, V66, P2532; OOMAGARI K, 1991, EUR J NEUROSCI, V3, P928, DOI 10.1111/j.1460-9568.1991.tb00028.x; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Porter JT, 1996, J NEUROSCI, V16, P5073; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; STELLA N, 1994, J NEUROSCI, V14, P568; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Volterra A, 1996, EUR J NEUROSCI, V8, P2019, DOI 10.1111/j.1460-9568.1996.tb01345.x	29	929	963	1	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					281	285		10.1038/34651	http://dx.doi.org/10.1038/34651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440691				2022-12-28	WOS:000071484400050
J	Boccaccio, C; Ando, M; Tamagnone, L; Bardelli, A; Michieli, P; Battistini, C; Comoglio, PM				Boccaccio, C; Ando, M; Tamagnone, L; Bardelli, A; Michieli, P; Battistini, C; Comoglio, PM			Induction of epithelial tubules by growth factor HGF depends on the STAT pathway	NATURE			English	Article							SCATTER FACTOR-RECEPTOR; C-FOS PROMOTER; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; MET RECEPTOR; PROTEIN; EXPRESSION; CELLS; TRANSFORMATION; MORPHOGENESIS	Hepatocyte growth factor (HGF) induces a three-phase response leading-to the formation of branched tubular structures in epithelial cells(1,2). The HGF receptor tyrosine kinase works through a Src homology (SH2) docking site that can activate several signalling pathways(3). The first phase of the response (scattering), which results from cytoskeletal reorganization, loss of intercellular junctions and cell migration(4), is depdent on phosphatidylinositol-3-OH kinase and Rac activation(5,6). The second phase (growth) requires stimulation of the Ras-MAP kinase cascade(7). Here we show that the third phase (tubulogenesis) is dependent on the STAT pathway. HGF stimulates recruitment of Stat-3 to the receptor, tyrosine phosphorylation, nuclear translocation and binding to the specific promoter element SIE. Electroporation of a tyrosine-phosphorylated peptide, which interferes with both the association of STAT to the receptor and STAT dimerization, inhibits tubule formation in vitro without affecting either HGF-induced 'scattering' or growth. The same result is obtained using a specific 'decoy' oligonucleotide that prevents STAT from binding to DNA and affecting the expression of genes involved in cell-cycle regulation (c-fos and waf-1). Activation of signal transducers that directly control transcription is therefore required for morphogenesis.	Univ Turin, Sch Med, Inst Canc Res, I-10060 Candiolo, Italy; Pharmacia & Upjohn Inc, Preclin Res, I-20014 Nerviano, Italy	University of Turin; Pfizer	Boccaccio, C (corresponding author), Univ Turin, Sch Med, Inst Canc Res, Str Prov 142, I-10060 Candiolo, Italy.	cboccaccio@hal.ircc.polito.it	Michieli, Paolo/A-2588-2011; Tamagnone, Luca/J-8948-2018; Boccaccio, Carla/AHE-7875-2022; Battistini, Carlo/AAJ-1193-2020; BARDELLI, Alberto/J-9721-2018	Michieli, Paolo/0000-0002-3093-8871; Tamagnone, Luca/0000-0002-2884-7946; Boccaccio, Carla/0000-0003-2620-9083; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gambarotta G, 1996, ONCOGENE, V13, P1911; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; IHLE JN, 1996, CELL, V84, P221; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STOCKER M, 1987, NATURE, V327, P239; TEKEDA K, 1997, P NATL ACAD SCI USA, V94, P3801; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	30	436	457	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					285	288		10.1038/34657	http://dx.doi.org/10.1038/34657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440692				2022-12-28	WOS:000071484400051
J	Papanicolaou, DA; Wilder, RL; Manolagas, SC; Chrousos, GP				Papanicolaou, DA; Wilder, RL; Manolagas, SC; Chrousos, GP			The pathophysiologic roles of interleukin-6 in human disease	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PITUITARY-ADRENAL AXIS; C-REACTIVE PROTEIN; SYSTEMIC LUPUS-ERYTHEMATOSUS; SOLUBLE IL-6 RECEPTOR; ACUTE-PHASE PROTEINS; ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; CORTICOTROPIN-RELEASING HORMONE; STIMULATORY FACTOR-II; NF-KAPPA-B; RHEUMATOID-ARTHRITIS	Interleukin-6, an inflammatory cytokine, is characterized by pleiotropy and redundancy of action. Apart from its hematologic, immune, and hepatic effects, it has many endocrine and metabolic actions. Specifically, it is a potent stimulator of the hypothalamic-pituitary-adrenal axis and is under the tonic negative control of glucocorticoids. It acutely stimulates the secretion of growth hormone, inhibits thyroid-stimulating hormone secretion, and decreases serum lipid concentrations. Furthermore, it is secreted during stress and is positively controlled by catecholamines. Administration of interleukin-6 results in fever, anorexia, and fatigue. Elevated levels of circulating interleukin-6 have been seen in the steroid withdrawal syndrome and in the severe inflammatory, infectious, and traumatic states potentially associated with the inappropriate secretion of vasopressin. Levels of circulating interleukin-6 are also elevated in several inflammatory diseases, such as rheumatoid arthritis. Interleukin-6 is negatively controlled by estrogens and androgens, and it plays a central role in the pathogenesis of the osteoporosis seen in conditions characterized by increased bone resorption, such as sex-steroid deficiency and hyperparathyroidism. Overproduction of interleukin-6 may contribute to illness during aging and chronic stress. Finally, administration of recombinant human interleukin-6 may serve as a stimulation test for the integrity of the hypothalamic-pituitary-adrenal axis.	NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Internal Med, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Papanicolaou, DA (corresponding author), NICHHD, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr MSC 1862, Bethesda, MD 20892 USA.							AKIRA S, 1992, CHEM IMMUNOL, V51, P299; AMATRUDA TT, 1965, J CLIN ENDOCR METAB, V25, P1207, DOI 10.1210/jcem-25-9-1207; BATAILLE R, 1992, ARTHRITIS RHEUM-US, V35, P982, DOI 10.1002/art.1780350824; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BAYLIS PH, 1990, PRINCIPLES PRACTICE, P241; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BOELEN A, 1993, J CLIN ENDOCR METAB, V77, P1695, DOI 10.1210/jcem.77.6.8263160; BOOCKFOR FR, 1994, ENDOCRINOLOGY, V134, P2150, DOI 10.1210/en.134.5.2150; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; BREUNINGER LM, 1993, CLIN IMMUNOL IMMUNOP, V69, P205, DOI 10.1006/clin.1993.1171; Brugada R, 1996, CARDIOLOGY, V87, P194, DOI 10.1159/000177086; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CHEN JT, 1995, J BONE MINER RES, V10, pS347; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; Crofford LJ, 1997, J CLIN ENDOCR METAB, V82, P1279, DOI 10.1210/jc.82.4.1279; Culley FJ, 1996, J IMMUNOL, V156, P4691; DALRYMPLE SA, 1995, INFECT IMMUN, V63, P2262, DOI 10.1128/IAI.63.6.2262-2268.1995; DEBENEDETTI F, 1994, J CLIN INVEST, V93, P2114, DOI 10.1172/JCI117206; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; Devlin RD, 1996, J CLIN ENDOCR METAB, V81, P1893, DOI 10.1210/jc.81.5.1893; DONALD RA, 1994, J ENDOCRINOL INVEST, V17, P263, DOI 10.1007/BF03348973; DRENTH JPH, 1995, J APPL PHYSIOL, V79, P1497, DOI 10.1152/jappl.1995.79.5.1497; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; ERSHLER WB, 1993, LYMPHOKINE CYTOK RES, V12, P225; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; FELTEN DL, 1985, J IMMUNOL, V135, pS755; GABAY C, 1993, J RHEUMATOL, V20, P815; GAULDIE J, 1992, RES IMMUNOL, V143, P755, DOI 10.1016/0923-2494(92)80018-G; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GIRASOLE G, 1995, J BONE MINER RES, V10, pS160; Gold PW, 1995, ANN NY ACAD SCI, V771, P716, DOI 10.1111/j.1749-6632.1995.tb44723.x; Grey A, 1996, J CLIN ENDOCR METAB, V81, P3450, DOI 10.1210/jc.81.10.3450; HAGER K, 1994, NEUROBIOL AGING, V15, P771, DOI 10.1016/0197-4580(94)90066-3; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KAMEDA T, 1990, PLACENTA, V11, P205, DOI 10.1016/S0143-4004(05)80266-8; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1991, BLOOD, V78, P1198; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kopf M, 1995, ANN NY ACAD SCI, V762, P308; Kotake S, 1996, J BONE MINER RES, V11, P88; LAKATOS P, 1994, J BONE MINER RES  S1, V9, pS139; Langub MC, 1996, KIDNEY INT, V50, P515, DOI 10.1038/ki.1996.343; LIBERT C, 1994, EUR J IMMUNOL, V24, P2237, DOI 10.1002/eji.1830240945; LIN SC, 1997, J CLIN INVEST, V100, pS160; LINKERISRAELI M, 1992, CLIN IMMUNOL IMMUNOP, V63, P10, DOI 10.1016/0090-1229(92)90084-2; LINKERISRAELI M, 1991, J IMMUNOL, V147, P117; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; LYSON K, 1991, NEUROENDOCRINOLOGY, V54, P262, DOI 10.1159/000125884; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Manolagas Stavros C., 1996, P701; Masi AT, 1997, ANN RHEUM DIS, V56, P1, DOI 10.1136/ard.56.1.1; MASTORAKOS G, 1994, J CLIN ENDOCR METAB, V79, P934, DOI 10.1210/jc.79.4.934; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCGEE DW, 1993, J IMMUNOL, V151, P970; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MIYASAKA N, 1989, CLIN IMMUNOL IMMUNOP, V52, P238, DOI 10.1016/0090-1229(89)90175-X; NAITOH Y, 1988, BIOCHEM BIOPH RES CO, V155, P1459, DOI 10.1016/S0006-291X(88)81305-6; Papanicolaou D.A, 1996, 10 INT C END ICE 96, P346; Papanicolaou DA, 1996, AM J PHYSIOL-ENDOC M, V271, pE601; Papanicolaou DA, 1996, J CLIN ENDOCR METAB, V81, P2303, DOI 10.1210/jc.81.6.2303; Papanicolaou DA, 1996, J INVEST MED, V44, pA266; PAPANICOLAOU DA, 1996, 10 INT C END 12 15 J, P901; PAPANICOLAOU DA, 1997, CURR OPIN ENDOCRINOL, V4, P194; PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822; PELTON GH, 1995, P ANN M AM COLL NEUR, P122; PERRELLA O, 1992, J NEUROL, V239, P387; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; RAY A, 1994, J BIOL CHEM, V269, P12940; REICHLIN S, 1997, WILLIAMS TXB ENDOCRI, P135; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROCK CS, 1992, SURGERY, V112, P467; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; ROTHWELL NJ, 1994, CRIT REV NEUROBIOL, V8, P1; ROTHWELL NJ, 1993, INT J OBESITY, V17, pS98; ROTHWELL NJ, 1993, INT J OBES RELAT S3, V17, pS115; RUSINKO R, 1995, J BONE MINER RES, V10, pS500; Salvi M, 1996, J CLIN ENDOCR METAB, V81, P2976, DOI 10.1210/jc.81.8.2976; SCHINDLER R, 1990, BLOOD, V75, P40; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; Soszynski D, 1996, NEUROENDOCRINOLOGY, V63, P459, DOI 10.1159/000127072; SPRONK PE, 1992, CLIN EXP IMMUNOL, V90, P106; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; SWAAK AJG, 1989, RHEUMATOL INT, V8, P263, DOI 10.1007/BF00270982; TANABE M, 1994, J RHEUMATOL, V21, P830; Tsigos C, 1997, NEUROENDOCRINOLOGY, V66, P54, DOI 10.1159/000127219; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; VANGOOL J, 1990, CLIN IMMUNOL IMMUNOP, V57, P200, DOI 10.1016/0090-1229(90)90034-N; VANKELECOM H, 1989, NEUROENDOCRINOLOGY, V49, P102, DOI 10.1159/000125097; VANLEEUWEN MA, 1995, ANN RHEUM DIS, V54, P674, DOI 10.1136/ard.54.8.674; Vgontzas AN, 1997, J CLIN ENDOCR METAB, V82, P1313, DOI 10.1210/jc.82.5.1313; VIZI ES, 1995, NEUROSCIENCE, V68, P1263, DOI 10.1016/0306-4522(95)00215-5; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WENDLING D, 1993, J RHEUMATOL, V20, P259; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; Wilder RL, 1996, J RHEUMATOL, V23, P10; Wolbink GJ, 1996, J IMMUNOL, V157, P473; WOOD JA, 1993, BRAIN RES, V629, P245, DOI 10.1016/0006-8993(93)91327-O; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; WORTEL CH, 1993, SURGERY, V114, P564; Yamamoto T, 1996, J CLIN INVEST, V98, P30, DOI 10.1172/JCI118773; YANG YC, 1988, J CELL PHYSIOL, V134, P292, DOI 10.1002/jcp.1041340217; YANOVSKI JA, 1993, JAMA-J AM MED ASSOC, V269, P2232, DOI 10.1001/jama.269.17.2232	116	890	956	0	40	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					127	137		10.7326/0003-4819-128-2-199801150-00009	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441573				2022-12-28	WOS:000071470800008
J	van Veen, HW; Callaghan, R; Soceneantu, L; Sardini, A; Konings, WN; Higgins, CF				van Veen, HW; Callaghan, R; Soceneantu, L; Sardini, A; Konings, WN; Higgins, CF			A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene	NATURE			English	Article							DRUG TRANSPORT; CELLS; BINDING; MDR1; VINBLASTINE; MEMBRANE; PROTEIN	Bacteria have developed many fascinating antibiotic-resistance mechanisms(1,2). A protein in Lactococcus lactis, LmrA, mediates antibiotic resistance by extruding amphiphilic compounds from the inner leaflet of the cytoplasmic membrane(3,4). Unlike other known bacterial multidrug-resistance proteins, LmrA is an ATP-binding cassette (ABC) transporter(5). The human multidrug-resistance P-glycoprotein(6), encoded by the MDR1 gene, is also an ABC transporter, overexpression of which is one of the principal causes of resistance of human cancers to chemotherapy(7,8). We expressed ImrA in human lung fibroblast cells. Surprisingly, LmrA was targeted to the plasma membrane and conferred typical multidrug resistance on these human cells. The pharmacological characteristics of LmrA and P-glycoprotein-expressing lung fibroblasts were very similar, and the affinities of both proteins for vinblastine and magnesium-ATP were indistinguishable. Blockers of P-glycoprotein-mediated multidrug resistance also inhibited LmrA-dependent drug resistance. Kinetic analysis of drug dissociation from LmrA expressed in plasma membranes of insect cells revealed the presence of two allosterically linked drug-binding sites indistinguishable from those of P-glycoprotein. These findings have implications for the reversal of antibiotic resistance in pathogenic microorganisms. Taken together, they demonstrate that bacterial LmrA and human P-glycopiotein are functionally interchangeable and that this type of multidrug-resistance efflux pump is conserved from bacteria to man.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Oxford, John Radcliffe Hosp, Inst Mol Med,Nuffield Dept Clin Biochem, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med,Nuffield Dept Clin Biochem, Canc Res Campaign,Drug Resistance Grp, Oxford OX3 9DS, England; Univ London Kings Coll, Dept Physiol, London WC2R 2LS, England	University of Groningen; Cancer Research UK; University of Oxford; University of Oxford; University of London; King's College London	van Veen, HW (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Konings, Wilhelmus N./C-7063-2013; van Veen, Hendrik W./A-4162-2008; Callaghan, Richard/ABG-1638-2020; Callaghan, Richard/B-7032-2012	van Veen, Hendrik W./0000-0002-9658-8077; Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532				Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Ferry D. R, 1994, NEW MOL TARGETS CANC, P177; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Kostenis E, 1996, TRENDS PHARMACOL SCI, V17, P280, DOI 10.1016/0165-6147(96)10034-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVER JE, 1977, J BIOL CHEM, V252, P1990; MALKHANDI J, 1994, EUR J PHARM-MOLEC PH, V288, P105, DOI 10.1016/0922-4106(94)90015-9; Martin C, 1997, BRIT J PHARMACOL, V122, P765, DOI 10.1038/sj.bjp.0701429; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shao YM, 1997, BBA-MOL BASIS DIS, V1360, P30, DOI 10.1016/S0925-4439(96)00065-8; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; TAMAI I, 1991, J BIOL CHEM, V266, P16796; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanVeen HW, 1997, BIOL CHEM, V378, P769; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213	29	213	217	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					291	295		10.1038/34669	http://dx.doi.org/10.1038/34669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440694				2022-12-28	WOS:000071484400053
J	Gannon, PJ; Holloway, RL; Broadfield, DC; Braun, AR				Gannon, PJ; Holloway, RL; Broadfield, DC; Braun, AR			Asymmetry of chimpanzee planum temporale: Humanlike pattern of Wernicke's brain language area homolog	SCIENCE			English	Article							CEREBRAL LATERALIZATION; BIOLOGICAL MECHANISMS; RHESUS-MONKEYS; ASSOCIATIONS; HYPOTHESIS; PATHOLOGY; PROGRAM; ORGANIZATION; REGION	The anatomic pattern and left hemisphere size predominance of the planum temporale, a language area of the human brain, are also present in chimpanzees (Pan troglodytes). The left planum temperate was significantly larger in 94 percent (17 of 18) of chimpanzee brains examined. It is widely accepted that the planum temporale is a key component of Wernicke's receptive language area, which is also implicated in human communication-related disorders such as schizophrenia and in normal variations such as musical talent. However, anatomic hemispheric asymmetry of this cerebrocortical site is clearly not unique to humans, as is currently thought. The evolutionary origin of human language may have been founded on this basal anatomic substrate, which was already lateralized to the left hemisphere in the common ancestor of chimpanzees and humans 8 million years ago.	CUNY Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; Columbia Univ, Dept Anthropol, New York, NY 10027 USA; CUNY, Dept Anthropol, New York, NY 10036 USA; Natl Inst Deafness & Other Commun Disorders, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Gannon, PJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Otolaryngol, Box 1189,5th Ave & 100th St, New York, NY 10029 USA.	P_Gannon@smtplink.mssm.edu						ANNETT M, 1992, NEUROPSYCHOLOGIA, V30, P951, DOI 10.1016/0028-3932(92)90048-Q; Bailey P, 1950, ISOCORTEX CHIMPANZEE; Binder JR, 1996, BRAIN, V119, P1239, DOI 10.1093/brain/119.4.1239; Calvert GA, 1997, SCIENCE, V276, P593, DOI 10.1126/science.276.5312.593; Crow TJ, 1997, TRENDS NEUROSCI, V20, P339; DDEWAAL F, 1997, DISCOVER, V18, P50; DEACON TW, 1992, EVOLUTION HUMAN LANG, V11, P49; FALK D, 1986, FOLIA PRIMATOL, V46, P98, DOI 10.1159/000156242; FOUNDAS AL, 1994, NEUROPSYCHOLOGIA, V32, P1225, DOI 10.1016/0028-3932(94)90104-X; FOUNDAS AL, 1995, ARCH NEUROL-CHICAGO, V52, P501, DOI 10.1001/archneur.1995.00540290091023; GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312; GALABURDA AM, 1993, ARCH NEUROL-CHICAGO, V50, P457, DOI 10.1001/archneur.1993.00540050011007; GALABURDA AM, 1978, ARCH NEUROL-CHICAGO, V35, P812, DOI 10.1001/archneur.1978.00500360036007; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GANNON PJ, 1995, THESIS CITY U NEW YO; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P521, DOI 10.1001/archneur.1985.04060060019009; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P634, DOI 10.1001/archneur.1985.04060070024012; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; GREENFIELD PM, 1993, J CHILD LANG, V20, P1, DOI 10.1017/S0305000900009090; HABIB M, 1995, BRAIN LANG, V48, P238, DOI 10.1006/brln.1995.1011; Harasty J, 1997, ARCH NEUROL-CHICAGO, V54, P171, DOI 10.1001/archneur.1997.00550140045011; HEILBRONER PL, 1988, AM J PHYS ANTHROPOL, V76, P39, DOI 10.1002/ajpa.1330760105; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; HOLLOWAY RL, 1980, AM J PHYS ANTHROPOL, V53, P285, DOI 10.1002/ajpa.1330530213; Just MA, 1996, SCIENCE, V274, P114, DOI 10.1126/science.274.5284.114; KIOYASHI H, 1997, NATURE, V387, P767; LEMAY M, 1975, BRAIN BEHAV EVOLUT, V11, P48, DOI 10.1159/000123623; LEMAY M, 1976, ANN NY ACAD SCI, V280, P349, DOI 10.1111/j.1749-6632.1976.tb25499.x; Lynch MP, 1996, BEHAV BRAIN SCI, V19, P788, DOI 10.1017/S0140525X00044071; Ojemann G A, 1993, Adv Neurol, V63, P155; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; PETTY RG, 1995, AM J PSYCHIAT, V152, P715; PFEIFER RA, 1936, HDB NEUROLOGIE, V6, P533; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; ROSSI A, 1994, BRAIN LANG, V47, P89, DOI 10.1006/brln.1994.1043; SAVAGERUMBAUGH ES, 1993, MONOGR SOC RES CHILD, V58, pR5; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; STEINMETZ H, 1991, ANN NEUROL, V29, P315, DOI 10.1002/ana.410290314; STEINMETZ H, 1989, J COMPUT ASSIST TOMO, V13, P996, DOI 10.1097/00004728-198911000-00011; STEKIIS HD, 1979, NEUROBIOLOGY SOCIAL; STEKLIS HD, COMMUNICATION; TOBIAS PV, 1987, J HUM EVOL, V16, P741, DOI 10.1016/0047-2484(87)90022-4; Vauclair J, 1997, TRENDS COGN SCI, V1, P35, DOI 10.1016/S1364-6613(97)01004-8; von Economo C, 1930, Z GESAMTE NEUROL PSY, V130, P678; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WITELSON SF, 1991, PSYCHONEUROENDOCRINO, V16, P131, DOI 10.1016/0306-4530(91)90075-5; YENIKOMSHIAN GH, 1976, SCIENCE, V192, P387, DOI 10.1126/science.816005; [No title captured]	50	339	343	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					220	222		10.1126/science.279.5348.220	http://dx.doi.org/10.1126/science.279.5348.220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YQ636	9422693				2022-12-28	WOS:000071408100040
J	van Leeuwen, FW; de Kleijn, DPV; van den Hurk, HH; Neubauer, A; Sonnemans, MAF; Sluijs, JA; Koycu, S; Ramdjielal, RDJ; Salehi, A; Martens, GJM; Grosveld, FG; Burbach, JPH; Hol, EM				van Leeuwen, FW; de Kleijn, DPV; van den Hurk, HH; Neubauer, A; Sonnemans, MAF; Sluijs, JA; Koycu, S; Ramdjielal, RDJ; Salehi, A; Martens, GJM; Grosveld, FG; Burbach, JPH; Hol, EM			Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; HUMAN-BRAIN; DOWNS-SYNDROME; DISEASE; GENE; MUTATIONS; IDENTIFICATION; TRANSCRIPTS; DESTRUCTION; PEPTIDES	The cerebral cortex of Alzheimer's and Down syndrome patients is characterized by the presence of protein deposits in neurofibrillary tangles, neuritic plaques, and neuropil threads. These structures were shown to contain forms of beta amyloid precursor protein and ubiquitin-B that are aberrant(+1 proteins) in the carboxyl terminus. The +1 proteins were not found in young control patients, whereas the presence of ubiquitin-B+1 in elderly control patients may indicate early stages of neurodegeneration. The two species of +1 proteins displayed cellular colocalization, suggesting a common origin, operating at the transcriptional level or by posttranscriptional editing of RNA. This type of transcript mutation is likely an important factor in the widely occurring nonfamilial early- and late-onset forms of Alzheimer's disease.	Netherlands Inst Brain Res, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands; Univ Nijmegen, Dept Mol Anim Physiol, NL-6525 ED Nijmegen, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Radboud University Nijmegen; Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center	van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.		Martens, Gerard JM/D-1925-2010; Salehi, Ahmad/H-2746-2019; Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019; Salehi, Ahmad/A-1148-2007	Salehi, Ahmad/0000-0001-8257-3280; Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; Salehi, Ahmad/0000-0001-8257-3280				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALIKHAN Z, 1992, NEUROSCI LETT, V139, P24, DOI 10.1016/0304-3940(92)90849-3; BAKER RT, 1987, NUCLEIC ACIDS RES, V15, P443, DOI 10.1093/nar/15.2.443; Braak H, 1996, J NEURAL TRANSM, V103, P455, DOI 10.1007/BF01276421; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Glisic S, 1996, TRENDS GENET, V12, P391, DOI 10.1016/S0168-9525(96)90094-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harrison PJ, 1996, NEURODEGENERATION, V5, P409, DOI 10.1006/neur.1996.0055; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; JIN LW, 1994, J NEUROSCI, V14, P5461; Johnston JA, 1996, MOL BRAIN RES, V43, P85, DOI 10.1016/S0169-328X(96)00161-1; KWAK S, 1991, NEUROSCI LETT, V128, P21, DOI 10.1016/0304-3940(91)90751-E; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OYAMA F, 1994, J NEUROCHEM, V62, P1062; PERRY G, 1989, J NEUROCHEM, V52, P1523, DOI 10.1111/j.1471-4159.1989.tb09203.x; PHILIPPE B, 1993, NEUROREPORT, V5, P289, DOI 10.1097/00001756-199312000-00027; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STRACHAN T, 1997, HUMAN MOL GENETICS; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Terry Robert D., 1994, P179; VANBROECKHOVEN CL, 1995, EUR NEUROL, V35, P8, DOI 10.1159/000117083; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417; VANLEEUWEN FXR, UNPUB; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	31	465	478	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					242	247		10.1126/science.279.5348.242	http://dx.doi.org/10.1126/science.279.5348.242			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422699				2022-12-28	WOS:000071408100046
J	Addolorato, G; Cibin, M; Caprista, E; Beghe, F; Gessa, G; Stefanini, GF; Gasbarrini, G				Addolorato, G; Cibin, M; Caprista, E; Beghe, F; Gessa, G; Stefanini, GF; Gasbarrini, G			Maintaining abstinence from alcohol with gamma-hydroxybutyric acid	LANCET			English	Article									Univ Cattolica Sacro Cuore, Inst Internal Med, I-00168 Rome, Italy; Neuropsychotoxicol Unit, Dolo, Italy; Pharmacol & Clin Res Unit Piertommaso Tessitore, San Remo, Italy; Univ Cagliari, Bb Brodie Dept Neurosci, I-09124 Cagliari, Italy; Civ Hosp Osped Infermi, Dept Internal Med, Faenza, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Cagliari	Addolorato, G (corresponding author), Univ Cattolica Sacro Cuore, Inst Internal Med, I-00168 Rome, Italy.			Addolorato, Giovanni/0000-0002-1522-9946				Addolorato G, 1996, ALCOHOL ALCOHOLISM, V31, P341; ADDOLORATO G, 1997, ADDICTION, V92, P1041; FERRARA SD, 1992, BRIT J CLIN PHARMACO, V34, P231, DOI 10.1111/j.1365-2125.1992.tb04129.x; GALLIMBERTI L, 1992, ALCOHOL CLIN EXP RES, V16, P673, DOI 10.1111/j.1530-0277.1992.tb00658.x; GALLIMBERTI L, 1989, LANCET, V2, P787	5	52	55	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					38	38		10.1016/S0140-6736(05)78088-0	http://dx.doi.org/10.1016/S0140-6736(05)78088-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433435				2022-12-28	WOS:000071253100022
J	Garred, P				Garred, P			Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis?	LANCET			English	Editorial Material							INFECTION; INDIVIDUALS; PROGRESSION; RESISTANCE; ALLELE; ENTRY; GENE		Rigshosp, Dept Clin Immun, Tissue Typing Lab, DK-2200 Copenhagen N, Denmark	Rigshospitalet	Garred, P (corresponding author), Rigshosp, Dept Clin Immun, Tissue Typing Lab, DK-2200 Copenhagen N, Denmark.			Garred, Peter/0000-0002-2876-8586				AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hoffman TL, 1997, J INFECT DIS, V176, P1093, DOI 10.1086/516519; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MEYER L, 1997, AIDS, V11, P73; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; 1997, NAT MED, V3, P1051	18	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					2	3		10.1016/S0140-6736(98)22001-0	http://dx.doi.org/10.1016/S0140-6736(98)22001-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433416				2022-12-28	WOS:000071253100002
J	Kippelen, B; Marder, SR; Hendrickx, E; Maldonado, JL; Guillemet, G; Volodin, BL; Steele, DD; Enami, Y; Sandalphon; Yao, YJ; Wang, JF; Rockel, H; Erskine, L; Peyghambarian, N				Kippelen, B; Marder, SR; Hendrickx, E; Maldonado, JL; Guillemet, G; Volodin, BL; Steele, DD; Enami, Y; Sandalphon; Yao, YJ; Wang, JF; Rockel, H; Erskine, L; Peyghambarian, N			Infrared photorefractive polymers and their applications for imaging	SCIENCE			English	Article							STATE; GAIN	Photorefractive polymers with high diffraction efficiency in the visible and near-infrared regions of the electromagnetic spectrum have been developed, These polymers, which have a large dynamic range because of their high orientational birefringence, incorporate a dye designed to have a large dipole moment and a high linear polarizability anisotropy, Such polymers have enabled demonstrations of imaging through scattering media, using a holographic time-gating technique at a wavelength that is compatible with the transparency of biological tissues and with the emission of low-cost semiconductor laser diodes.	Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Arizona; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kippelen, B (corresponding author), Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA.		Maldonado, Jose-Luis/L-6884-2017; Kippelen, Bernard/I-4058-2013; Enami, Yasufumi/E-4273-2016; Marder, Seth/GRR-9990-2022	Maldonado, Jose-Luis/0000-0003-3601-7464; Kippelen, Bernard/0000-0002-8417-7051; Enami, Yasufumi/0000-0002-0303-2695; 				ABRAMSON NH, 1989, APPL OPTICS, V28, P1834, DOI 10.1364/AO.28.001834; ASHKIN A, 1966, APPL PHYS LETT, V9, P72, DOI 10.1063/1.1754607; DONCKERS MCJM, 1993, OPT LETT, V18, P1044, DOI 10.1364/OL.18.001044; DUCHARME S, 1991, PHYS REV LETT, V66, P1846, DOI 10.1103/PhysRevLett.66.1846; Gayen S. K., 1996, OPT PHOTONICS NEWS, V7, P16; GrunnetJepsen A, 1997, SCIENCE, V277, P549, DOI 10.1126/science.277.5325.549; GUNTER P, 1988, PHOTOREFRACTIVE MAT, V1; GUNTER P, 1989, PHOTOREFRACTIVE MAT, V2; Hendrickx E, 1997, APPL PHYS LETT, V71, P1159, DOI 10.1063/1.119612; Huignard J. P., 1988, PHOTOREFRACTIVE MAT; HYDE SCW, 1995, OPT LETT, V20, P1331, DOI 10.1364/OL.20.001331; Kippelen B, 1997, J AM CHEM SOC, V119, P4559, DOI 10.1021/ja9643477; Kippelen B, 1996, APPL PHYS LETT, V68, P1748, DOI 10.1063/1.116653; KIPPELEN B, 1997, NONLINEAR OPTICS ORG, P465; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; KUZYK MG, 1990, J OPT SOC AM B, V7, P842, DOI 10.1364/JOSAB.7.000842; LIPHARDT M, 1994, SCIENCE, V263, P367, DOI 10.1126/science.263.5145.367; Lundquist PM, 1996, SCIENCE, V274, P1182, DOI 10.1126/science.274.5290.1182; MEERHOLZ K, 1994, NATURE, V371, P497, DOI 10.1038/371497a0; MOERNER WE, 1994, J OPT SOC AM B, V11, P320, DOI 10.1364/JOSAB.11.000320; MOERNER WE, 1994, CHEM REV, V94, P127, DOI 10.1021/cr00025a005; OUDAR JL, 1977, J CHEM PHYS, V66, P2664, DOI 10.1063/1.434213; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; STEELE DD, IN PRESS OPT LETT; Volodin BL, 1996, NATURE, V383, P58, DOI 10.1038/383058a0; WILLIAMS DJ, 1987, NONLINEAR OPTICAL PR, V1; WU JW, 1991, J OPT SOC AM B, V8, P142, DOI 10.1364/JOSAB.8.000142; Zhang Y, 1996, ADV MATER, V8, P111, DOI 10.1002/adma.19960080203	28	235	243	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					54	57		10.1126/science.279.5347.54	http://dx.doi.org/10.1126/science.279.5347.54			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417020				2022-12-28	WOS:000071323900035
J	Escalante, CR; Yie, JM; Thanos, D; Aggarwal, AK				Escalante, CR; Yie, JM; Thanos, D; Aggarwal, AK			Structure of IRF-1 with bound DNA reveals determinants of interferon regulation	NATURE			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; PROTEINS; RECOGNITION; COMPLEX; BINDING; IFN; EXPRESSION; DOMAIN; GENES	The family of interferon regulatory factor (IRF) transcription factors is important in the regulation of interferons in response to infection by virus and in the regulation of interferon-inducible genes(1,2). The IRF family is characterized by a unique 'tryptophan cluster' DNA-binding region. Here we report the crystal structure of the IRF-1 region bound to the natural positive regulatory domain I (PRD I) DNA element from the interferon-beta promoter(1). The structure provides the first three-dimensional view of a member of the growing IRF family, revealing a new helix-turn-helix motif that latches onto DNA through three of the five conserved tryptophans. The moth selects a short GAAA core sequence through an obliquely angled recognition helix, with an accompanying bending of the DNA axis in the direction of the protein. Together, these features suggest a basis for the occurrence of GAAA repeats within IRF response elements and provide clues to the assembly of the higher-order interferon-beta enhancesome.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University	Aggarwal, AK (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.		Thanos, Dimitris/AAE-5720-2019					AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1997, FEBS LETT, V414, P219, DOI 10.1016/S0014-5793(97)00996-4; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FUREY W, 1993, PHASES PROGRAM PACKA; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1993; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEGAKI K, 1995, FEBS LETT, V359, P184, DOI 10.1016/0014-5793(95)00040-G; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315	30	308	321	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					103	106		10.1038/34224	http://dx.doi.org/10.1038/34224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422515				2022-12-28	WOS:000071326100059
J	McFarland, J; Menitove, J; Kagen, L; Braine, H; Kickler, T; Ness, P; Fuller, A; Slichter, S; Gernsheimer, T; Townsend-McCall, D; Kao, KJ; Noyes, W; Weiner, R; Hudson, S; Waldman-Slone, A; Schiffer, C; Lee, E; Norris, D; McCullough, J; Enright, H; Lennon, S; Clay, M; Woodson, R; Meisch, M; Noordsij, P; Davis, K; Mickel, M; Gillespie, MJ; Ng, G; Parker, S; Corley, S; Rodey, G; Kao, KJ; Sell, J; Nemo, G; Follmann, D; Hernandez, M; Hollingsworth, C; Klein, H; Dutcher, J; Fratantoni, J; Kruskall, M; Macklin, R; Strauss, R; Wittes, J				McFarland, J; Menitove, J; Kagen, L; Braine, H; Kickler, T; Ness, P; Fuller, A; Slichter, S; Gernsheimer, T; Townsend-McCall, D; Kao, KJ; Noyes, W; Weiner, R; Hudson, S; Waldman-Slone, A; Schiffer, C; Lee, E; Norris, D; McCullough, J; Enright, H; Lennon, S; Clay, M; Woodson, R; Meisch, M; Noordsij, P; Davis, K; Mickel, M; Gillespie, MJ; Ng, G; Parker, S; Corley, S; Rodey, G; Kao, KJ; Sell, J; Nemo, G; Follmann, D; Hernandez, M; Hollingsworth, C; Klein, H; Dutcher, J; Fratantoni, J; Kruskall, M; Macklin, R; Strauss, R; Wittes, J		Trial Reduce Alloimmunization Platelets Study	Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOSORBENT-ASSAY; PACKED RED-CELLS; HLA-ALLOIMMUNIZATION; THROMBOCYTOPENIC PATIENTS; BLOOD COMPONENTS; SINGLE-DONOR; DELAYED ALLOIMMUNIZATION; LYMPHOCYTOTOXIC ANTIBODY; GLYCOPROTEIN-IIIA; RANDOMIZED TRIAL	Background We conducted a multi-institutional, randomized, blinded trial to determine whether the use of platelets from which leukocytes had been removed by a filter or that had been treated with ultraviolet B irradiation would prevent the formation of antiplatelet alloantibodies and refractoriness to platelet transfusions. Methods Patients who were receiving induction chemotherapy for acute myeloid leukemia were randomly assigned to receive one of four types of platelet transfusions: unmodified, pooled platelet concentrates from random donors (control); filtered, pooled platelet concentrates from random donors (F-PC); ultraviolet B-irradiated, pooled platelet concentrates from random donors (UVB-PC); or filtered platelets obtained by apheresis from single random donors (F-AP). All patients received transfusions of filtered, leukocyte-reduced red cells. Results Of 530 patients with no alloantibodies at base line, 13 percent of those in the control group produced lymphocytotoxic antibodies and their thrombocytopenia became refractory to platelet transfusions, as compared with 3 percent in the F-PC group, 5 percent in the UVB-PC group, and 4 percent in the F-AP group (P less than or equal to 0.03 for each treated group as compared with the controls; there were no significant differences among the treated groups). Lymphocytotoxic antibodies were found in 45 percent of the controls, as compared with 17 to 21 percent in the treated groups (P<0.001 for each treated group as compared with the controls; there were no significant differences among the treated groups). Antibodies against platelet glycoproteins developed in 6 to 11 percent of the patients, with no significant differences among the four groups. Conclusions Reduction of leukocytes by filtration and ultraviolet B irradiation of platelets are equally effective in preventing alloantibody-mediated refractoriness to platelets during chemotherapy for acute myeloid leukemia. Platelets obtained by apheresis from single random donors provided no additional benefit as compared with pooled platelet concentrates from random donors. (C) 1997, Massachusetts Medical Society.	Puget Sound Blood Ctr, Div Res & Educ, Seattle, WA 98104 USA	Puget Sound Blood Center	Slichter, S (corresponding author), Puget Sound Blood Ctr, Div Res & Educ, 921 Terry Ave, Seattle, WA 98104 USA.			Corley, Scott/0000-0001-5288-9188	NHLBI NIH HHS [U01 HL42805, U01 HL42802, U01 HL42799] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL042805, U01HL042799, U01HL042802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREU G, 1990, TRANSFUSION, V30, P401, DOI 10.1046/j.1537-2995.1990.30590296370.x; ANDREU G, 1988, BLOOD, V72, P964; Andreu Georges, 1994, V60, P29; BISHOP JF, 1988, BLOOD, V71, P383; BLAJCHMAN MA, 1991, SEMIN HEMATOL, V28, P14; Blundell EL, 1996, TRANSFUSION, V36, P296, DOI 10.1046/j.1537-2995.1996.36496226140.x; BOWDEN RA, 1995, BLOOD, V86, P3598, DOI 10.1182/blood.V86.9.3598.bloodjournal8693598; BRAND A, 1988, VOX SANG, V54, P160, DOI 10.1111/j.1423-0410.1988.tb03892.x; BRAND A, 1978, BLOOD, V51, P781; CLAAS FHJ, 1981, EXP HEMATOL, V9, P84; COLLINS J, 1987, VOX SANG, V53, P157, DOI 10.1111/j.1423-0410.1987.tb04941.x; CORASH L, 1994, BLOOD, V84, pA530; CURTIS BR, 1994, BLOOD, V84, P176, DOI 10.1182/blood.V84.1.176.bloodjournal841176; DUQUESNOY RJ, 1977, AM J HEMATOL, V2, P219, DOI 10.1002/ajh.2830020303; Fish D., 1995, Blood, V86, p541A; FRIEDBERG RC, 1993, BLOOD, V81, P3428; FULLER TC, 1982, TRANSPLANTATION, V34, P24, DOI 10.1097/00007890-198207000-00005; FURIHATA K, 1987, J CLIN INVEST, V80, P1624, DOI 10.1172/JCI113250; GMUR J, 1983, BLOOD, V62, P473; Grass J., 1995, Blood, V86, p542A; GRIJZENHOUT MA, 1994, BRIT J HAEMATOL, V87, P598, DOI 10.1111/j.1365-2141.1994.tb08319.x; GRIJZENHOUT MA, 1994, BLOOD, V84, P3524; HOGGE DE, 1983, AM J HEMATOL, V14, P363, DOI 10.1002/ajh.2830140407; HOLOHAN TV, 1981, BLOOD, V58, P122; HOWE SE, 1984, TRANSFUSION, V24, P348, DOI 10.1046/j.1537-2995.1984.24484275580.x; KAO KJ, 1989, TRANSFUSION, V29, P774, DOI 10.1046/j.1537-2995.1989.29990070180.x; KAO KJ, 1995, TRANSFUSION, V35, P13, DOI 10.1046/j.1537-2995.1995.35195090653.x; KEKOMAKI R, 1991, J CLIN INVEST, V88, P847, DOI 10.1172/JCI115386; KICKLER T, 1990, TRANSFUSION, V30, P622, DOI 10.1046/j.1537-2995.1990.30790385520.x; KICKLER TS, 1985, TRANSFUSION, V25, P385, DOI 10.1046/j.1537-2995.1985.25485273823.x; KOOY MV, 1991, BLOOD, V77, P201; KRIPKE ML, 1984, IMMUNOL REV, V80, P87, DOI 10.1111/j.1600-065X.1984.tb00496.x; LEE EJ, 1987, BLOOD, V70, P1727; LINDAHLK.K, 1971, INT ARCH ALLER A IMM, V41, P670, DOI 10.1159/000230559; LUTZ P, 1993, TRANSFUSION, V33, P409, DOI 10.1046/j.1537-2995.1993.33593255602.x; MURPHY MF, 1986, BRIT J HAEMATOL, V62, P529, DOI 10.1111/j.1365-2141.1986.tb02965.x; Murphy S, 1996, TRANSFUSION, V36, P751, DOI 10.1046/j.1537-2995.1996.36896374382.x; NOROL F, 1994, BRIT J HAEMATOL, V86, P125, DOI 10.1111/j.1365-2141.1994.tb03262.x; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OKSANEN K, 1991, TRANSFUSION, V31, P588, DOI 10.1046/j.1537-2995.1991.31791368333.x; PAMPHILON DH, 1990, BRIT J HAEMATOL, V75, P240, DOI 10.1111/j.1365-2141.1990.tb02656.x; RUBINSTEIN LV, 1981, J CHRON DIS, V34, P469, DOI 10.1016/0021-9681(81)90007-2; SCHIFFER CA, 1983, BLOOD, V61, P311; SCHIFFER CA, 1986, BLOOD, V67, P1591; SCHIFFER CA, 1983, BLOOD, V62, P815; SHERMAN L, 1992, TRANSFUSION, V32, P402, DOI 10.1046/j.1537-2995.1992.32592327711.x; SINTNICOLAAS K, 1995, BLOOD, V85, P824, DOI 10.1182/blood.V85.3.824.bloodjournal853824; SINTNICOLAAS K, 1981, LANCET, V1, P750; SNIECINSKI I, 1988, BLOOD, V71, P1402; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103; VISENTIN GP, 1990, TRANSFUSION, V30, P694, DOI 10.1046/j.1537-2995.1990.30891020326.x; WILLIAMSON LM, 1994, BLOOD, V83, P3028, DOI 10.1182/blood.V83.10.3028.3028	52	569	577	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1861	1869						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9417523				2022-12-28	WOS:000071128200001
J	Iglehart, JK				Iglehart, JK			Medicare and graduate medical education	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE		Off Hlth Affairs, Bethesda, MD USA		Iglehart, JK (corresponding author), Off Hlth Affairs, Bethesda, MD USA.							*ASS AM MED COLL, 1997, 979 ASS AM MED COLL; CHU BK, 1997, INFORMATION TRADING; *COUNC GRAD MED ED, 1998, 10 REP PHYS WORKF DE; *COUNC GRAD MED ED, 1998, 11 REP PHYS WORKF IN; FEIN O, 1997, INFORMATION TRADING; FISHMAN LE, 1996, MEDICARE PAYMENT ED; FOREMAN S, 1997, COMMUNICATION   0312; GOLDSTEIN A, 1997, WASHINGTON POST 1120, pA1; Guterman S, 1998, HEALTH AFFAIR, V17, P159, DOI 10.1377/hlthaff.17.1.159; HARRIS JF, 1997, WASH POST       0205, pA1; *I MED, 1996, NAT PHYS WORKF OPT B; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; Iglehart JK, 1996, NEW ENGL J MED, V334, P1679, DOI 10.1056/NEJM199606203342521; Mick SS, 1997, HEALTH AFFAIR, V16, P141, DOI 10.1377/hlthaff.16.4.141; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; *NY STAT DEP HLTH, 1995, NEW DIR HLTH NEW YOR; ONEILL J, 1997, COMMUNICATION   0502; *PEW HLTH PROF COM, 1995, REF GRAD MED ED REP; Rosenbaum S, 1998, HEALTH AFFAIR, V17, P75, DOI 10.1377/hlthaff.17.1.75; WHITCOMB ME, 1995, JAMA-J AM MED ASSOC, V274, P696, DOI 10.1001/jama.274.9.696; 1997, DALLAS MORNING  0829, pA24	21	33	33	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					402	407		10.1056/NEJM199802053380620	http://dx.doi.org/10.1056/NEJM199802053380620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449736				2022-12-28	WOS:000071822200032
J	Trapp, BD; Peterson, J; Ransohoff, RM; Rudick, R; Mork, S; Bo, L				Trapp, BD; Peterson, J; Ransohoff, RM; Rudick, R; Mork, S; Bo, L			Axonal transection in the lesions of multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; AMYLOID PRECURSOR PROTEIN; MONOCLONAL-ANTIBODIES DISTINGUISH; MYELIN-ASSOCIATED GLYCOPROTEIN; DISEASE PROGRESSION; N-ACETYLASPARTATE; NERVOUS-SYSTEM; CALIBER; BRAIN; NEUROFILAMENTS	Background Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy, most patients have progressive neurologic deterioration that may reflect axonal loss. We conducted pathological studies of brain tissues to define the changes in axons in patients with multiple sclerosis. Methods Brain tissue was obtained at autopsy from 11 patients with multiple sclerosis and 4 subjects without brain disease. Fourteen active multiple-sclerosis lesions, 33 chronic active lesions, and samples of normal-appearing white matter were examined for demyelination, inflammation, and axonal pathologic changes by immunohistochemistry and confocal microscopy. Axonal transection, identified by the presence of terminal axonal ovoids, was detected in all 47 lesions and quantified in 18 lesions. Results Transected axons were a consistent feature of the lesions of multiple sclerosis, and their frequency was related to the degree of inflammation within the lesion. The number of transected axons per cubic millimeter of tissue averaged 11,236 in active lesions, 3138 at the hypocellular edges of chronic active lesions, 875 in the hypocellular centers of chronic active lesions, and less than 1 in normal-appearing white matter from the control brains. Conclusions Transected axons are common in the; lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease. (C) 1998, Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Res, Cleveland, OH 44195 USA; Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Bergen; Haukeland University Hospital	Trapp, BD (corresponding author), Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Mörk, Sverre Jarl/AAW-1330-2020		NINDS NIH HHS [R01NS35058] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035058] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARBUTHNOTT ER, 1980, J PHYSIOL-LONDON, V308, P125, DOI 10.1113/jphysiol.1980.sp013465; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; Bo L, 1996, J NEUROPATH EXP NEUR, V55, P1060, DOI 10.1097/00005072-199655100-00006; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BORNSTEI.MB, 1965, SCIENCE, V148, P1242, DOI 10.1126/science.148.3674.1242; CHARCOT M, 1868, GAZ HOSP, P557; CHARCOT M, 1868, GAZ HOSP, P141; COCHRAN E, 1991, AM J PATHOL, V139, P485; Davie CA, 1995, BRAIN, V118, P1583, DOI 10.1093/brain/118.6.1583; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Hsieh S-T, 1993, BRAIN PATHOL, V3, P307; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jm C., 1868, GAZ HOPITAUX, P554; LEE VMY, 1986, J NEUROSCI, V6, P850; LEE VMY, 1987, J NEUROSCI, V7, P3474; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Losseff NA, 1996, BRAIN, V119, P2009, DOI 10.1093/brain/119.6.2009; Matthews PM, 1996, BRAIN, V119, P715, DOI 10.1093/brain/119.3.715; MCDONALD WI, 1994, J NEUROPATH EXP NEUR, V53, P338, DOI 10.1097/00005072-199407000-00003; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; Narayanan S, 1997, ANN NEUROL, V41, P385, DOI 10.1002/ana.410410314; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PRINEAS JW, 1981, ANN NEUROL, V10, P149, DOI 10.1002/ana.410100205; PRINEAS JW, 1984, ANN NY ACAD SCI, V436, P11, DOI 10.1111/j.1749-6632.1984.tb14773.x; PRINEAS JW, 1985, HDB CLIN NEUROLOGY, V47, P213; RAINE CS, 1989, LAB INVEST, V60, P714; RUDICK RA, 1996, ANN NEUROL, V40, P516; Sanchez I, 1996, J NEUROSCI, V16, P5095; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Weinshenker BG, 1996, NEUROL CLIN, V14, P291, DOI 10.1016/S0733-8619(05)70257-7; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; WINDEBANK AJ, 1985, J NEUROSCI, V5, P1563	54	3171	3248	3	161	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					278	285		10.1056/NEJM199801293380502	http://dx.doi.org/10.1056/NEJM199801293380502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445407				2022-12-28	WOS:000071665200002
J	New, JH; Sugiyama, T; Zaitseva, E; Kowalczykowski, SC				New, JH; Sugiyama, T; Zaitseva, E; Kowalczykowski, SC			Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; ESCHERICHIA-COLI; REPAIR; GENES; RECA; FILAMENT; BINDING; REPEAT	The generation of a double-strand break in the Saccharomyces cerevisiae genome is a potentially catastrophic event that can induce cell-cycle arrest or ultimately result in loss of cell viability. The repair of such lesions is strongly dependent on proteins encoded by the RAD52 epistasis group of genes (RAD50-55, RAD57, MRE11, XRS2)(1,2), as well as the RFA1(3,4) and RAD59 genes(5). rad52 mutants exhibit the most severe phenotypic defects in double-strand break repair(2), but almost nothing is known about the biochemical role of Rad52 protein. Rad51 protein promotes DNA strand exchange(6-8) and acts similarly to RecA protein(9). Yeast Rad52 protein interacts with Rad51 protein(10,11), binds single-stranded DNA and stimulates annealing of complementary single-stranded DNA(12). We find that Rad52 protein stimulates DNA strand exchange by targeting Rad51 protein to a complex of replication protein A (RPA) with single-stranded DNA. Rad52 protein affects an early step in the reaction, presynaptic filament formation, by overcoming the inhibitory effects of the competitor, RPA. Furthermore, stimulation is dependent on the concerted action of both Rad51 protein and RPA, implying that specific protein-protein interactions between Rad52 protein, Rad51 protein and RPA are required.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.			Sugiyama, Tomohiko/0000-0003-2942-3667				Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; JIANG H, 1993, J BIOL CHEM, V268, P7904; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RATTRAY AJ, 1994, GENETICS, V138, P587; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, 1992, CELL, V71, P180; SMITH J, 1995, MOL CELL BIOL, V15, P1632; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; WLD MS, 1997, ANN REV BIOCH, V66, P61; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	24	484	506	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					407	410		10.1038/34950	http://dx.doi.org/10.1038/34950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450760				2022-12-28	WOS:000071604200060
J	Rhodes, M; Sussman, L; Cohen, L; Lewis, MP				Rhodes, M; Sussman, L; Cohen, L; Lewis, MP			Randomised trial of laparoscopic exploration of common bile duct versus postoperative endoscopic retrograde cholangiography for common bile duct stones	LANCET			English	Article							CHOLECYSTECTOMY; SPHINCTEROTOMY; CHOLEDOCHOLITHIASIS; MANAGEMENT	Background The management of stones in the common bile duct in the laparoscopic era is controversial. The three major options are preoperative endoscopic retrograde cholangiography (ERCP), laparoscopic exploration of the common bile duct (LECBD), or postoperative ERCP. Methods Between August, 1995, and August, 1997, 471 laparoscopic cholecystectomies were done in our department. In 427 (91%), satisfactory peroperative cholangiography was obtained. In 80 (17%) of these cases there were stones in the common bile duct. 40 patients were randomised to LECBD and 40 to postoperative ERCP. If LECBD failed, patients had either open exploration of the common bile duct or postoperative ERCP. If one postoperative ERCP failed, the procedure was repeated until the common bile duct was cleared of stones or an endoprosthesis was placed to prevent stone impaction. The primary endpoints were duct-clearance rates, morbidity, operating time, and hospital stay, Analyses were by intention to treat. Findings Age and sex distribution of patients was similar in the randomised groups, Duct clearance after the first intervention was 75% in both groups. By the end of treatment, duct clearance was 100% in the laparoscopic group compared with 93% in the ERCP group, Duration of treatment was a median of 90 min (range 25-310) in the laparoscopic group (including ERCPs for failed LECBD) compared with 105 min (range 60-255) in the postoperative ERCP group (p=0.1, 95% CI for difference -5 to 40). Hospital stay was a median of 1 day (range 1-26) in the laparoscopic group compared with 3.5 days (range 1-11) in the ERCP group (p=0.0001, 95% CI 1-2). Interpretation LECBD is as effective as ERCP in clearing the common bile duct of stones. There is a non-significant trend to shorter time in the operating theatre and a significantly shorter hospital stay in patients treated by LECBD.	Norfolk & Norwich NHS Trust Hosp, Dept Surg, Gastrointestinal Unit, Norwich NR1 3SR, Norfolk, England		Rhodes, M (corresponding author), Norfolk & Norwich NHS Trust Hosp, Dept Surg, Gastrointestinal Unit, Norwich NR1 3SR, Norfolk, England.			Lewis, Michael Philip N/0000-0002-6913-6454				COX MR, 1995, BRIT J SURG, V82, P257, DOI 10.1002/bjs.1800820240; CURET MJ, 1995, ANN SURG, V221, P149, DOI 10.1097/00000658-199502000-00004; CUSCHIERI A, 1996, GUT               S1, V39, pA43; FLETCHER DR, 1993, AUST NZ J SURG, V63, P673, DOI 10.1111/j.1445-2197.1993.tb00488.x; GOMPERTZ RHK, 1992, BRIT J SURG, V79, P233, DOI 10.1002/bjs.1800790315; HAINSWORTH PJ, 1994, GUT, V35, P991, DOI 10.1136/gut.35.7.991; Khoo DE, 1996, BRIT J SURG, V83, P341, DOI 10.1002/bjs.1800830314; Kirkwood B., 1988, BR K ESSENTIALS MED; Kullman E, 1996, BRIT J SURG, V83, P171, DOI 10.1046/j.1365-2168.1996.02190.x; LAMBERT ME, 1991, BRIT J SURG, V78, P473, DOI 10.1002/bjs.1800780427; MARTIN I, 1997, SURG ENDOSC-ULTRAS, V11, P516; PERISSAT J, 1994, BRIT J SURG, V81, P799, DOI 10.1002/bjs.1800810606; RHODES M, 1995, BRIT J SURG, V82, P666, DOI 10.1002/bjs.1800820533; Rhodes M, 1995, ENDOSCOPY, V27, P676, DOI 10.1055/s-2007-1005786; RIJNA H, 3 INT C NEW TECHN AD, P1005; TRAVERSO LW, 1993, AM J SURG, V165, P581, DOI 10.1016/S0002-9610(05)80439-8; VAIRA D, 1989, LANCET, V2, P431	17	340	358	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					159	161		10.1016/S0140-6736(97)09175-7	http://dx.doi.org/10.1016/S0140-6736(97)09175-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449869				2022-12-28	WOS:000071616300008
J	Biervert, C; Schroeder, BC; Kubisch, C; Berkovic, SF; Propping, P; Jentsch, TJ; Steinlein, OK				Biervert, C; Schroeder, BC; Kubisch, C; Berkovic, SF; Propping, P; Jentsch, TJ; Steinlein, OK			A potassium channel mutation in neonatal human epilepsy	SCIENCE			English	Article							CONVULSIONS; GENE; CHROMOSOME-20; K(V)LQT1; PROTEINS; MYOKYMIA; SUBUNIT; CLONING; ATAXIA; FORM	Benign familial neonatal convulsions (BFNC) is an autosomal dominant epilepsy of infancy, with loci mapped to human chromosomes 20q13.3 and 8q24. By positional cloning, a potassium channel gene (KCNQ2) located on 20q13.3 was isolated and found to be expressed in brain. Expression of KCNQ2 in frog (Xenopus laevis) oocytes led to potassium-selective currents that activated slowly with depolarization. In a large pedigree with BFNC, a five-base pair insertion would delete more than 300 amino acids from the KCNQ2 carboxyl terminus. Expression of the mutant channel did not yield measurable currents. Thus, impairment of potassium-dependent repolarization is likely to cause this age-specific epileptic syndrome.	Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Univ Melbourne, Dept Med Neurol, Melbourne, Vic, Australia	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn; University of Melbourne	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de; steinlein@snphysio2.wilhelm.uni-bonn.de	jiang, yu/HGU-0029-2022; Kubisch, Christian/F-1893-2011	Kubisch, Christian/0000-0003-4220-0978; Berkovic, Samuel/0000-0003-4580-841X; Jentsch, Thomas/0000-0002-3509-2553				Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BERKOVIC SF, 1994, ARCH NEUROL-CHICAGO, V51, P1125, DOI 10.1001/archneur.1994.00540230063014; Berkovic SF, 1997, BRAIN DEV-JPN, V19, P13, DOI 10.1016/S0387-7604(96)00060-5; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BRUNT ERP, 1990, BRAIN, V113, P1361, DOI 10.1093/brain/113.5.1361; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHROEDER BC, UNPUB; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; STEINLEIN O, 1994, GENOMICS, V22, P493, DOI 10.1006/geno.1994.1420; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	27	859	910	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					403	406		10.1126/science.279.5349.403	http://dx.doi.org/10.1126/science.279.5349.403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430594				2022-12-28	WOS:000071570800052
J	Norabuena, E; Leffler-Griffin, L; Mao, AL; Dixon, T; Stein, S; Sacks, IS; Ocola, L; Ellis, M				Norabuena, E; Leffler-Griffin, L; Mao, AL; Dixon, T; Stein, S; Sacks, IS; Ocola, L; Ellis, M			Space geodetic observations of Nazca-South America convergence across the central Andes	SCIENCE			English	Article							GLOBAL POSITIONING SYSTEM; CURRENT PLATE MOTIONS; CRUSTAL DEFORMATION; STRAIN ACCUMULATION; ACTIVE TECTONICS; SUBDUCTION ZONES; MODEL; EARTHQUAKE; RATES; SEISMICITY	Space geodetic data recorded rates and directions of motion across the convergent boundary zone between the oceanic Nazca and continental South American plates in Peru and Bolivia. Roughly half of the overall convergence, about 30 to 40 millimeters per year, accumulated on the locked plate interface and can be released in future earthquakes. About 10 to 15 millimeters per year of crustal shortening occurred inland at the sub-Andean foreland fold and thrust belt, indicating that the Andes are continuing to build. Little (5 to 10 millimeters per year) along-trench motion of coastal forearc slivers was observed, despite the oblique convergence.	Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Inst Geofis Peru, Lima 100, Peru; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; Univ Memphis, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA	Northwestern University; University of Miami; Carnegie Institution for Science; University of Memphis	Stein, S (corresponding author), Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA.		Norabuena, Edmundo O/I-5486-2013; Norabuena, Edmundo O./M-8772-2019; Ellis, Michael Alexander A/M-4505-2018; Ellis, Michael/AAP-2039-2020	Ellis, Michael Alexander A/0000-0002-6613-3565; Ellis, Michael/0000-0002-6613-3565; Norabuena, Edmundo/0000-0002-1865-8922				Abdrakhmatov KY, 1996, NATURE, V384, P450, DOI 10.1038/384450a0; Allmendinger RW, 1997, ANNU REV EARTH PL SC, V25, P139, DOI 10.1146/annurev.earth.25.1.139; ARGUS DF, 1995, GEOPHYS RES LETT, V22, P1973, DOI 10.1029/95GL02006; ARGUS DF, 1991, GEOPHYS RES LETT, V18, P2039, DOI 10.1029/91GL01532; Barrientos SE, 1995, GEOPHYS RES LETT, V22, P3541, DOI 10.1029/95GL03316; BECK ME, 1991, PHYS EARTH PLANET IN, V68, P1, DOI 10.1016/0031-9201(91)90002-Y; BECK ME, 1994, TECTONICS, V13, P215, DOI 10.1029/93TC02398; BEVIS M, 1995, NATURE, V374, P249, DOI 10.1038/374249a0; Bilham R, 1997, NATURE, V386, P61, DOI 10.1038/386061a0; BOUCHER C, 1996, 20 IERS; CAZENAVE A, 1992, J GEOPHYS RES-SOL EA, V97, P7109, DOI 10.1029/91JB03128; CHASE CG, 1972, GEOPHYS J ROY ASTR S, V29, P117, DOI 10.1111/j.1365-246X.1972.tb02202.x; CIFUENTES IL, 1989, J GEOPHYS RES-SOLID, V94, P643, DOI 10.1029/JB094iB01p00643; DeMets C, 1995, GEOPHYS RES LETT, V22, P3545, DOI 10.1029/95GL03323; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; DEWEY JF, 1992, TECTONOPHYSICS, V205, P79, DOI 10.1016/0040-1951(92)90419-7; DIXON TH, 1995, TECTONICS, V14, P755, DOI 10.1029/95TC00931; Dixon TH, 1997, GEOPHYS RES LETT, V24, P535, DOI 10.1029/97GL00284; Dixon TH, 1997, J GEOPHYS RES-SOL EA, V102, P12017, DOI 10.1029/96JB03902; DIXON TH, 1991, REV GEOPHYS, V29, P249, DOI 10.1029/91RG00152; DIXON TH, 1993, GEOPHYS RES LETT, V20, P2167, DOI 10.1029/93GL02415; FEIGL KL, 1993, J GEOPHYS RES-SOL EA, V98, P21677, DOI 10.1029/93JB02405; Freymueller J, 1996, GEOPHYS RES LETT, V23, P3107, DOI 10.1029/96GL02518; FREYMUELLER JT, 1993, J GEOPHYS RES-SOL EA, V98, P21853, DOI 10.1029/93JB00520; FUKAO Y, 1989, J GEOPHYS RES, V94, P3876; GELLER RJ, 1976, B SEISMOL SOC AM, V66, P1501; GOMBERG J, 1994, J GEOPHYS RES-SOL EA, V99, P20299, DOI 10.1029/94JB00039; GORDON RG, 1992, SCIENCE, V256, P333, DOI 10.1126/science.256.5055.333; Heki K, 1997, NATURE, V386, P595, DOI 10.1038/386595a0; ISACKS BL, 1988, J GEOPHYS RES-SOLID, V93, P3211, DOI 10.1029/JB093iB04p03211; JACKSON J, 1994, GEOPHYS RES LETT, V21, P2849, DOI 10.1029/94GL02734; JACKSON J, 1995, J GEOPHYS RES-SOL EA, V100, P15205, DOI 10.1029/95JB01294; JAMES DE, 1971, GEOL SOC AM BULL, V82, P3325, DOI 10.1130/0016-7606(1971)82[3325:PTMFTE]2.0.CO;2; Kanamori H., 1974, Physics of the Earth and Planetary Interiors, V9, P128, DOI 10.1016/0031-9201(74)90029-6; KANAMORI H, 1977, TRENCHES BACK ARC BA, P163; King RW, 1997, GEOLOGY, V25, P179, DOI 10.1130/0091-7613(1997)025<0179:GMOCMI>2.3.CO;2; Larson KM, 1997, J GEOPHYS RES-SOL EA, V102, P9961, DOI 10.1029/97JB00514; Leffler L, 1997, GEOPHYS RES LETT, V24, P1031, DOI 10.1029/97GL00770; MCCAFFREY R, 1992, J GEOPHYS RES-SOL EA, V97, P8905, DOI 10.1029/92JB00483; McCaffrey R, 1997, B SEISMOL SOC AM, V87, P1069; MCNALLY KC, 1981, J GEOPHYS RES, V86, P4949, DOI 10.1029/JB086iB06p04949; MEGARD F, 1987, ANATOMY MOUNTAIN RAN, P179; MINSTER JB, 1974, GEOPHYS J ROY ASTR S, V36, P541, DOI 10.1111/j.1365-246X.1974.tb00613.x; NISHENKO SP, 1991, PURE APPL GEOPHYS, V135, P169, DOI 10.1007/BF00880240; PACHECO JF, 1993, J GEOPHYS RES-SOL EA, V98, P14133, DOI 10.1029/93JB00349; PETERSON ET, 1984, J GEOPHYS RES, V89, P233, DOI 10.1029/JB089iB12p10233; Pollitz FF, 1997, J GEOPHYS RES-SOL EA, V102, P17921, DOI 10.1029/97JB01277; ROBBINS J, 1993, SPACE GEODESY GEODYN, P21; ROEDER D, 1988, TECTONICS, V7, P23, DOI 10.1029/TC007i001p00023; RYDELEK PA, 1990, GEOPHYS J INT, V100, P39, DOI 10.1111/j.1365-246X.1990.tb04566.x; SAVAGE JC, 1983, J GEOPHYS RES, V88, P4984, DOI 10.1029/JB088iB06p04984; SCHMITZ M, 1994, TECTONICS, V13, P484, DOI 10.1029/93TC02232; SEBRIER M, 1988, TECTONICS, V7, P895, DOI 10.1029/TC007i004p00895; SEMPERE T, 1990, GEOLOGY, V18, P946, DOI 10.1130/0091-7613(1990)018<0946:LOEMMT>2.3.CO;2; SHEFFELS BM, 1990, GEOLOGY, V18, P812, DOI 10.1130/0091-7613(1990)018<0812:LBOTAO>2.3.CO;2; SMITH DE, 1990, J GEOPHYS RES-SOLID, V95, P22013, DOI 10.1029/JB095iB13p22013; STEIN S, 1992, NATURE, V356, P387, DOI 10.1038/356387a0; STEIN S, 1986, GEOPHYS RES LETT, V13, P713, DOI 10.1029/GL013i008p00713; STEIN S, 1993, SPACE GEODESY GEODYN, P5; SUAREZ G, 1983, J GEOPHYS RES, V88, P403, DOI 10.1029/JB088iB12p10403; THATCHER W, 1990, J GEOPHYS RES-SOLID, V95, P2609, DOI 10.1029/JB095iB03p02609; TICHELAAR BW, 1991, J GEOPHYS RES-SOLID, V96, P11997, DOI 10.1029/91JB00200	63	201	205	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					358	362		10.1126/science.279.5349.358	http://dx.doi.org/10.1126/science.279.5349.358			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430582				2022-12-28	WOS:000071570800040
J	Zhang, HM; Forde, BG				Zhang, HM; Forde, BG			An Arabidopsis MADS box gene that controls nutrient-induced changes in root architecture	SCIENCE			English	Article							NITRATE; PLANTS; GROWTH; PRODUCTIVITY; EXPRESSION; RESPONSES; THALIANA; ROLES	The development of plant root systems is sensitive to the availability and distribution of nutrients within the soil. For example, lateral roots proliferate preferentially within nitrate (NO3-)-rich soil patches. A NO3--inducible Arabidopsis gene (ANR1), was identified that encodes a member of the MADS box family of transcription factors. Transgenic plants in which ANR1 was repressed had an altered sensitivity to NO3- and no longer responded to NO3--rich zones by lateral root proliferation, indicating that ANR1 is a key determinant of developmental plasticity in Arabidopsis roots.	IACR Rothamsted, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Forde, BG (corresponding author), IACR Rothamsted, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England.		Forde, Brian G/C-6554-2009	Forde, Brian G/0000-0001-7973-7280				AGREN GI, 1987, PLANT CELL ENVIRON, V10, P579, DOI 10.1111/j.1365-3040.1987.tb01838.x; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; DREW MC, 1973, J EXP BOT, V24, P1189, DOI 10.1093/jxb/24.6.1189; FITTER AH, 1991, NEW PHYTOL, V118, P383, DOI 10.1111/j.1469-8137.1991.tb00019.x; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GRANATO TC, 1989, J EXP BOT, V40, P263, DOI 10.1093/jxb/40.2.263; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; HACKETT C, 1972, AUST J BIOL SCI, V25, P1169, DOI 10.1071/BI9721169; HUTCHINGS MJ, 1994, ADV ECOL RES, V25, P159, DOI 10.1016/S0065-2504(08)60215-9; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; LYNCH J, 1995, PLANT PHYSIOL, V109, P7, DOI 10.1104/pp.109.1.7; REDINBAUGH MG, 1991, PHYSIOL PLANTARUM, V82, P640, DOI 10.1111/j.1399-3054.1991.tb02958.x; ROBINSON D, 1994, NEW PHYTOL, V127, P635, DOI 10.1111/j.1469-8137.1994.tb02969.x; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SATTELMACHER B, 1988, PLANT ROOTS THEIR EN, P149; Scheible WR, 1997, PLANT J, V11, P671, DOI 10.1046/j.1365-313X.1997.11040671.x; SCHIEFELBEIN JW, 1991, PLANT CELL, V3, P1147, DOI 10.1105/tpc.3.11.1147; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/BF02337521; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREWAVAS AJ, 1983, INTERACTIONS NITROGE, P97; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL DA, 1995, REV GENET, V29, P19; WIERSUM L. K., 1958, ACTA BOT NEERLANDICA, V7, P174; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Zachgo S, 1997, PLANT J, V11, P1043, DOI 10.1046/j.1365-313X.1997.11051043.x; ZHANG H, UNPUB	26	893	1017	13	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					407	409		10.1126/science.279.5349.407	http://dx.doi.org/10.1126/science.279.5349.407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430595				2022-12-28	WOS:000071570800053
J	Reed, RR				Reed, RR			Opening the window to odor space	SCIENCE			English	Article							C-ELEGANS; RECEPTORS; CLONING; ENCODES; FAMILY; MEMBER		Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Reed, RR (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.							BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	8	6	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					193	193		10.1126/science.279.5348.193	http://dx.doi.org/10.1126/science.279.5348.193			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9446227				2022-12-28	WOS:000071408100031
J	Kuehn, MJ; Herrmann, JM; Schekman, R				Kuehn, MJ; Herrmann, JM; Schekman, R			COPII-cargo interactions direct protein sorting into ER-derived transport vesicles	NATURE			English	Article							AMINO-ACID PERMEASES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; COATED VESICLES; YEAST; COMPONENT; COMPLEX; TRANSLOCATION; COATOMER; FAMILY	Vesicles coated with coat protein complex II (COPII) selectively transport molecules (cargo) and vesicle fusion proteins from the endoplasmic reticulum (ER) to the Golgi complex(1-3). We have investigated the role of coat proteins in cargo selection and recruitment. We isolated integral membrane and soluble cargo proteins destined for transport from the ER in complexes formed in the presence of Sar1 and Sec23/24, a subset of the COPII components, and GTP or GMP-PNP. Vesicle fusion proteins of the vSNARE family and Emp24, a member of a putative cargo carrier family(4), were also found in COPII complexes. The inclusion of amino-acid permease molecules into the complex depended on the presence of Shr3, a protein required for the permease to leave the ER3,5. Resident ER proteins Sec61, BiP (Kar2) and Shr3 were not included in the complexes, indicating that the COPII components bound specifically to vesicle cargo. COPII-cargo complexes and putative cargo adaptor-cargo complexes were also isolated from COPII vesicles. Our results indicate that cargo packaging signals and soluble cargo adaptors are recognized by a recruitment complex comprising Sar1-GTP and Sec23/24.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Barker Hall, Berkeley, CA 94720 USA.		Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019				BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	19	319	326	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					187	190		10.1038/34438	http://dx.doi.org/10.1038/34438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428766				2022-12-28	WOS:000071380900054
J	Picciotto, MR; Zoli, M; Rimondini, R; Lena, C; Marubio, LM; Pich, EM; Fuxe, K; Changeux, JP				Picciotto, MR; Zoli, M; Rimondini, R; Lena, C; Marubio, LM; Pich, EM; Fuxe, K; Changeux, JP			Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine	NATURE			English	Article							VENTRAL TEGMENTAL AREA; H-3 DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; AUTORADIOGRAPHIC ANALYSIS; RAT-BRAIN; INVITRO; MODULATION; PITUITARY; STRIATUM; SYSTEM	Release of the neurotransmitter dopamine in the mesolimbic system of the brain mediates the reinforcing properties of several drugs of abuse, including nicotine(1). Here we investigate the contribution of the high-affinity neuronal nicotinic acetylcholine receptor(2) to the effects of nicotine on the mesolimbic dopamine system in mice lacking the beta 2 subunit of this receptor(3). We found that nicotine stimulates dopamine release in the ventral striatum of wild-type mice but not in the ventral striatum of beta 2-mutant mice. Using patch-clamp recording, we show that mesencephalic dopaminergic neurons from mice without the beta 2 subunit no longer respond to nicotine, and that self-administration of nicotine is attenuated in these mutant mice. Our results strongly support the idea that the beta 2-containing neuronal nicotinic acetycholine receptor is involv ed in mediating the reinforcing properties of nicotine.	Inst Pasteur, CNRS, UA D128, F-75724 Paris, France; Karolinska Inst, Dept Histol, S-10401 Stockholm, Sweden; Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); Karolinska Institutet; GlaxoSmithKline	Changeux, JP (corresponding author), Inst Pasteur, CNRS, UA D128, 28 Rue Dr Roux, F-75724 Paris, France.		, clement/ADN-8076-2022; Léna, Clément/P-6929-2019; Léna, Clément/ABE-4862-2021; Zoli, Michele/C-8899-2016; Picciotto, Marina R./F-8747-2012; Rimondini, Roberto/B-2500-2010	Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Zoli, Michele/0000-0002-8034-2849; Picciotto, Marina R./0000-0002-4404-1280; Rimondini, Roberto/0000-0003-4099-513X; Fuxe, Kjell/0000-0001-8491-4288				Blaha CD, 1996, J NEUROSCI, V16, P714; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CLARKE PBS, 1988, J PHARMACOL EXP THER, V246, P701; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; DAWSON TM, 1986, J NEUROSCI, V6, P2352; GRACE AA, 1989, J NEUROSCI, V9, P3463; GRADY S, 1992, J NEUROCHEM, V59, P848, DOI 10.1111/j.1471-4159.1992.tb08322.x; GRAHAME NJ, 1995, PHARMACOL BIOCHEM BE, V51, P827, DOI 10.1016/0091-3057(95)00047-Z; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P887, DOI 10.1016/0091-3057(83)90099-0; IZENWASSER S, 1991, J NEUROCHEM, V56, P603, DOI 10.1111/j.1471-4159.1991.tb08192.x; KAUFMAN MJ, 1991, SYNAPSE, V9, P177, DOI 10.1002/syn.890090304; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LUETJE CW, 1991, J NEUROSCI, V11, P837; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MEMO M, 1986, J NEUROCHEM, V47, P1689, DOI 10.1111/j.1471-4159.1986.tb13075.x; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Pich EM, 1997, SCIENCE, V275, P83; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; REAVILL C, 1990, NEUROPHARMACOLOGY, V29, P619, DOI 10.1016/0028-3908(90)90022-J; RHEINLAND JE, 1986, LIFE SCI, V39, P2185; RIMONDINI R, 1994, NEUROSCI LETT, V177, P53, DOI 10.1016/0304-3940(94)90043-4; RISINGER FO, 1995, PHARMACOL BIOCHEM BE, V51, P457, DOI 10.1016/0091-3057(95)00007-J; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; STOLERMAN IP, 1995, MED RES REV, V15, P47, DOI 10.1002/med.2610150105; TESSARI M, 1995, PSYCHOPHARMACOLOGY, V121, P282, DOI 10.1007/BF02245640	29	1030	1052	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					173	177		10.1038/34413	http://dx.doi.org/10.1038/34413			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428762				2022-12-28	WOS:000071380900050
J	Wilson, SB; Kent, SC; Patton, KT; Orban, T; Jackson, RA; Exley, M; Porcelli, S; Schatz, DA; Atkinson, MA; Balk, SP; Strominger, JL; Hafler, DA				Wilson, SB; Kent, SC; Patton, KT; Orban, T; Jackson, RA; Exley, M; Porcelli, S; Schatz, DA; Atkinson, MA; Balk, SP; Strominger, JL; Hafler, DA			Extreme Th1 bias of invariant V alpha 24J alpha Q T cells in type 1 diabetes	NATURE			English	Article							FIRST-DEGREE RELATIVES; MICE; LYMPHOCYTES; AUTOIMMUNITY; EXPRESSION; RESPONSES; SEARCH; GENES; MOUSE; IDDM	Type 1 diabetes (insulin-dependent diabetes-mellitus, IDDM) is a disease controlled by the major histocompatibility complex (MHC) which results from T-cell-mediated destruction of pancreatic beta-cells(1). The incomplete concordance in identical twins and the presence of autoreactive T cells and autoantibodies in individuals who do not develop diabetes suggest that other abnormalities must occur in the immune system for disease to result(2,3). We therefore investigated a series of at-risk non-progressors and type 1 diabetic patients (including five identical twin/tripiet sets discordant for disease). The diabetic siblings had lower frequencies of CD4(-)CD8(-)V alpha 24J alpha Q(+) T cells compared with their non-diabetic sibling, All 56 V alpha 24J alpha Q(+) clones isolated from the diabetic twins/triplets secreted only interferon (IFN)-gamma upon stimulation; in contrast, 76 of 79 clones from the at-risk non-progressors and normals secreted both interleukin (IL)-4 and IFN-gamma. Half of the at-risk non-progressors had high serum levels of IL-4 and IFN-gamma. These results support a model for IDDM in which Th1-cell-mediated tissue damage is initially regulated by V alpha 24J alpha Q(+) T cells producing both cytokines; the loss of their capacity to secrete IL-4 is correlated with IDDM.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Immunol Sect, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Lymphocyte Biol Sect, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Florida, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Dept Pediat, Gainesville, FL 32610 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hafler, DA (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.			Exley, Mark/0000-0002-5088-1032				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVODEAU E, 1997, J IMMUNOL, V158, P5603; Denkers EY, 1996, J EXP MED, V184, P131, DOI 10.1084/jem.184.1.131; EXLEY M, 1997, J EXP MED, V186, P1; Fox CJ, 1997, J IMMUNOL, V158, P2414; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Gombert JM, 1996, INT IMMUNOL, V8, P1751, DOI 10.1093/intimm/8.11.1751; Kallmann BA, 1997, DIABETES, V46, P237, DOI 10.2337/diabetes.46.2.237; LANIER LL, 1994, J IMMUNOL, V153, P2417; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Mieza MA, 1996, J IMMUNOL, V156, P4035; Mueller R, 1996, J EXP MED, V184, P1093, DOI 10.1084/jem.184.3.1093; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; PUGLIESE A, 1995, DIABETES, V44, P608, DOI 10.2337/diabetes.44.6.608; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; Roep BO, 1996, DIABETES, V45, P1147, DOI 10.2337/diabetes.45.9.1147; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; VERGE CF, 1995, DIABETES, V44, P1176, DOI 10.2337/diabetes.44.10.1176; Vicari AP, 1996, IMMUNOL TODAY, V17, P71, DOI 10.1016/0167-5699(96)80582-2; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531	27	547	564	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					177	181		10.1038/34419	http://dx.doi.org/10.1038/34419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428763				2022-12-28	WOS:000071380900051
J	Balas, EA; Kretschmer, RAC; Gnann, W; West, DA; Boren, SA; Centor, RM; Nerlich, M; Gupta, M; West, TD; Soderstrom, NS				Balas, EA; Kretschmer, RAC; Gnann, W; West, DA; Boren, SA; Centor, RM; Nerlich, M; Gupta, M; West, TD; Soderstrom, NS			Interpreting cost analyses of clinical interventions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIALS; MYOCARDIAL-INFARCTION; ECONOMIC-EVALUATION; HEALTH-CARE; ASTHMA; RECOMMENDATIONS; REHABILITATION; INFORMATION; GUIDELINES; MEDICINE	Objective.-In the present era of cost containment, physicians need reliable data about specific interventions. The objectives of this study were to assist practitioners in interpretation of economic analyses and estimation of their own costs of implementing recommended interventions. Data Sources.-MEDLINE search from 1966 through 1995 using the text words cost or expense and medical subject heading (MeSH) terms costs and cost analysis, cost control, cost of illness, cost savings, or cost-benefit analysis. Study Selection.-The 4 eligibility criteria were clinical trial with random assignment; health care quality improvement intervention tested; effects measured on the process or outcome of care; and cost calculation mentioned in the report. Data Extraction.-After independent abstraction and after consensus development, financial data were entered into a costing protocol to determine which costs related to the intervention were provided. Data Synthesis.-Of 181 articles, 97 (53.6%) included actual numbers on the costs of the intervention. Of 97 articles analyzed, the most frequently reported cost figures were in the category of operating expenses (direct cost, 61.9%; labor, 42.3%; and supplies, 32.0%). General overhead was not presented in 91 (93.8%) of the 97 studies. Only 14 (14.4%) of the 97 studies mentioned start-up costs. The text word $ in the abstract and the most useful MeSH index term of cost-benefit analysis appeared with nearly equal frequency in the articles that included actual cost data (37.1% vs 35.1%). Two thirds of articles indexed with the MeSH term cost control did not include cost figures. Conclusions.-Statements regarding cost without substantiating data are made habitually in reports of clinical trials. In clinical trial reports presenting data on expenditures, start-up costs and general overhead are frequently disregarded. Practitioners can detect missing information by placing cost data in a standardized protocol. The costing protocol of this study can help bridge care delivery and economic analyses.	Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO 65211 USA; Univ Missouri, Sch Business & Publ Adm, Columbia, MO USA; Univ Missouri, Columbia, MO USA; Univ Regensburg, Sch Med, D-8400 Regensburg, Germany; Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA; Washington Univ, Sch Business, St Louis, MO USA; Iowa State Univ, Coll Business, Ames, IA 50011 USA; Univ Washington, Sch Business, Seattle, WA 98195 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Regensburg; University of Alabama System; University of Alabama Tuscaloosa; Washington University (WUSTL); Iowa State University; University of Washington; University of Washington Seattle	Balas, EA (corresponding author), Univ Missouri, Sch Med, Dept Hlth Management & Informat, 324 Clark Hall, Columbia, MO 65211 USA.		Boren, Suzanne Austin/M-6589-2014	Boren, Suzanne Austin/0000-0003-4727-399X; Kretschmer, Rainer A.C./0000-0002-5280-7362; Soderstrom, Naomi/0000-0001-7602-9182; Balas, Andrew/0000-0003-3535-8822	NATIONAL LIBRARY OF MEDICINE [R01LM005545] Funding Source: NIH RePORTER; NLM NIH HHS [LM05545] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; Atkinson AA., 1995, MANAGEMENT ACCOUNTIN; BALAS EA, 1995, MED CARE, V33, P687, DOI 10.1097/00005650-199507000-00005; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; BALAS EA, 1995, J AM MED INFORM ASSN, V2, P307, DOI 10.1136/jamia.1995.96073833; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cooper R., 1992, ACCOUNT HORIZ, P12; DOR A, 1992, MED CARE, V30, P879, DOI 10.1097/00005650-199210000-00001; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; FACKLER ML, 1994, ANN INTERN MED, V121, P894, DOI 10.7326/0003-4819-121-11-199412010-00015; Fleiss JL, 1981, STAT METHODS RATES P, P218; GARRISON RH, 1997, MANAGERIAL ACCOUNTIN, P178; Gold MR, 1996, COST EFFECTIVENESS H; HUGHES SL, 1990, MED CARE, V28, P135, DOI 10.1097/00005650-199002000-00004; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levit K R, 1991, Health Care Financ Rev, V13, P29; MASON J, 1995, HEALTH ECON, V4, P85, DOI 10.1002/hec.4730040202; Neumann PJ, 1996, HEALTH AFFAIR, V15, P54, DOI 10.1377/hlthaff.15.3.54; ODDONE E, 1995, J CLIN EPIDEMIOL, V48, P1011, DOI 10.1016/0895-4356(94)00229-J; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; ROBINSON R, 1993, BMJ-BRIT MED J, V307, P670, DOI 10.1136/bmj.307.6905.670; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SPENCER DC, 1994, FAMILY MED PRINCIPLE, P1028; Stempel DA, 1996, ARCH FAM MED, V5, P36, DOI 10.1001/archfami.5.1.36; STRAUSS MJ, 1993, EUR J CANCER, V29A, pS3, DOI 10.1016/0959-8049(93)90608-I; TAITEL MS, 1995, J ALLERGY CLIN IMMUN, V95, P672, DOI 10.1016/S0091-6749(95)70171-0; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TUCKER MA, 1984, BRIT MED J, V289, P1209, DOI 10.1136/bmj.289.6453.1209; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253	36	30	30	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					54	57		10.1001/jama.279.1.54	http://dx.doi.org/10.1001/jama.279.1.54			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424045				2022-12-28	WOS:000071295100036
J	Bonneux, L; Barendregt, JJ; Nusselder, WJ; Van der Maas, PJ				Bonneux, L; Barendregt, JJ; Nusselder, WJ; Van der Maas, PJ			Preventing fatal diseases increases healthcare costs: cause elimination life table approach	BRITISH MEDICAL JOURNAL			English	Article							COMPRESSION; MORBIDITY	Objectives: To examine whether elimination of fatal diseases will increase healthcare costs. Design: Mortality data from vital statistics combined with healthcare spending in a cause elimination life table. Costs were allocated to specific diseases through the various healthcare registers. Setting and subjects: The population of the Netherlands, 1988. Main outcome measures: Healthcare costs of a synthetic life table cohort, expressed as life time expected costs. Results: The life time expected healthcare costs for 1988 in the Netherlands were pound 56 600 for men and pound 80 900 for women. Elimination of fatal diseases-such as coronary heart disease, cancer, or chronic obstructive lung disease-increases healthcare costs. Major savings will be achieved only by elimination of non-fatal disease-such as musculoskeletal diseases and mental disorders. Conclusion: The aim of prevention is to spare people from avoidable misery and death not to save money on the healthcare system. Ln countries with low mortality, elimination of fatal diseases by successful prevention increases healthcare spending because of the medical expenses during added life years.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Bonneux, L (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Barendregt, Jan J/F-6895-2010					DOLL R, 1981, J NATL CANCER I, V66, P1270; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Koopmanschap M, 1994, EUR J PUB HLTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KOOPMANSCHAP MA, 1991, COST ILLNESS NETHERL; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; NAMBOODIRI K, 1987, LIFE TABLE TECHNIQUE, P92; Nusselder WJ, 1996, AM J PUBLIC HEALTH, V86, P187, DOI 10.2105/AJPH.86.2.187; ROSE G, 1992, STRATEGY PREVENTIVE, P4; RUSSELL L, 1986, IS PREVENTION BETTER, P116; SHRYOCK HS, 1976, LIFE TABLE METHODS M, P249; *STAT NETH, DEATHS CAUSES DEATHS; van Roijen L, 1992, Ned Tijdschr Geneeskd, V136, P74; World Health Organization, 1977, INT STAT CLASS DIS I	14	57	57	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					26	29		10.1136/bmj.316.7124.26	http://dx.doi.org/10.1136/bmj.316.7124.26			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451262	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071377900019
J	Quillent, C; Oberlin, E; Braun, J; Rousset, D; Gonzalez-Canali, G; Metais, P; Montagnier, L; Virelizier, JL; Arenzana-Seisdedos, F; Beretta, A				Quillent, C; Oberlin, E; Braun, J; Rousset, D; Gonzalez-Canali, G; Metais, P; Montagnier, L; Virelizier, JL; Arenzana-Seisdedos, F; Beretta, A			HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene	LANCET			English	Article							CHEMOKINE RECEPTOR GENE; HIV-1 INFECTION; INDIVIDUALS; PROGRESSION; MIP-1-ALPHA; RESISTANCE; MIP-1-BETA; COFACTOR; CLONING; ALLELE	Background Despite multiple exposures to HIV-1, some individuals remain uninfected, and their peripheral-blood mononuclear cells (PBMC) are resistant to in-vitro infection by primary HIV-1 isolates. Such resistance has been associated with a homozygous 32-base-pair deletion (Delta 32) in the C-C chemokine receptor gene CCR5. We examined other mutations of the CCR5 gene that could be associated with resistance to HIV-1 infection. Methods We assessed the susceptibility of PBMC to in-vitro infection by HIV-1 isolates that use the CCR5 as the major coreceptor for Viral entry in 18 men who had frequent unprotected sexual intercourse with a seropositive partner. We also did genotypic analysis of CCR5 alleles. One of the 18 exposed bur uninfected men (who we refer to as ExU2) showed total resistance to in-vitro infection by CCR5-dependent viruses, and was found to carry a CCR5 Delta 32 allele and a single point mutation (T-->A) at position 303 on the other allele, To find out whether the CCR5 mutation was restricted to ExU2's family or existed in the general population, we did genetic analyses of the CCR5 genotype in ExU2's father and sister and also in 209 healthy blood donors who were not exposed to HIV-1. Findings The m303 mutation found in ExU2 introduced a premature stop codon and prevented the expression of a functional coreceptor. The family studies revealed that the m303 mutant allele was inherited as a single mendelian trait. Genotype analysis showed that three of the 209 healthy blood donors were heterozygous for the mutant allele. Interpretation We characterise a new CCR5 gene mutation, present in the general population, that prevents expression of functional coreceptors from the abnormal allele and confers resistance to HIV-1 infection when associated to the Delta 32 CCR5 mutant gene.	Hop St Joseph, Ctr Integre Rech Bioclin SIDA, F-75014 Paris, France; Inst Pasteur, Unite Immunol Virale, Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France	Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Beretta, A (corresponding author), Hop St Joseph, Ctr Integre Rech Bioclin SIDA, F-75014 Paris, France.		Oberlin, Estelle/M-4915-2018; Arenzana-Seisdedos, Fernando/E-5835-2016; Rousset, Dominique/A-4209-2009; Rousset, Dominique/S-5400-2019	Oberlin, Estelle/0000-0002-8200-9548; Rousset, Dominique/0000-0002-1473-3147				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DORANZ BJ, 1996, CELL, V85, P1159; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodorou I, 1997, LANCET, V349, P1219; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	25	218	226	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					14	18		10.1016/S0140-6736(97)09185-X	http://dx.doi.org/10.1016/S0140-6736(97)09185-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433423				2022-12-28	WOS:000071253100010
J	Granata, AV; Hillman, AL				Granata, AV; Hillman, AL			Competing practice guidelines: Using cost-effectiveness analysis to make optimal decisions	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE; PHYSICIANS; QUALITY; EXPENDITURES; PRESCRIPTION; SERVICES; ADOPTION	In this paper, cost and effectiveness data for six clinical interventions are applied simultaneously to a hypothetical population of 100 000 patients to show how selecting guidelines to maximize overall population benefit compares with selecting the best guidelines for individual patients. By entering effectiveness (added survival) and cost information from recent prevention, screening, diagnostic, and therapeutic guidelines into a computer-based optimization model, the options that maximized overall population effectiveness while keeping additional cost within varying specified constraints were identified. In 57% of selection opportunities, the clusters of guidelines that yielded maximum population benefit differed from those that maximized benefit for individual patients. Some choices were more stable than others over ranges of cost constraints. Clinical practice guidelines chosen to maximize cost-effectiveness for individual patients often do not maximize cost-effectiveness for populations of patients. To allocate resources as efficiently as possible, decision makers should consider other sources of information in addition to the recommendations of specific practice guidelines. "Robust" guidelines that simultaneously address both individual and societal health benefit should be sought.	Univ Penn, Leonard Davis Inst Hlth Econ, Sch Med, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, New Haven, CT USA; Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA	University of Pennsylvania; Yale University; University of Pennsylvania	Granata, AV (corresponding author), Oxford Hlth Plans, 48 Monroe Turnpike, Trumbull, CT 06611 USA.							[Anonymous], 1980, CANCER; [Anonymous], 1992, MANUAL ASSESSING HLT; [Anonymous], 1992, EC REPORT PRESIDENT; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DOUBILET P, 1986, NEW ENGL J MED, V314, P253, DOI 10.1056/NEJM198601233140421; Drummond M F, 1990, Int J Technol Assess Health Care, V6, P77; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; GAFNI A, 1993, CAN MED ASSOC J, V148, P913; GOULD FJ, 1988, QUANTITATIVE CONCEPT; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hayward R S, 1993, Ann Intern Med, V118, P731; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KEENEY RL, 1994, NEW ENGL J MED, V331, P193, DOI 10.1056/NEJM199407213310311; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; Kissick W.L., 1994, MED DILEMMAS INFINIT; Koepke M D, 1992, QRB Qual Rev Bull, V18, P480; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KUPPERMANN M, 1990, CIRCULATION, V81, P91, DOI 10.1161/01.CIR.81.1.91; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; *OFF QUAL ASS, 1993, DIR PRACT PAR; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RAPHAEL C, 1992, PHYS MED BIOL, V37, P1293, DOI 10.1088/0031-9155/37/6/007; Rudowski R, 1996, INT J CLIN MONIT COM, V13, P157, DOI 10.1023/A:1016952525892; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1205, DOI 10.1136/bmj.305.6863.1205; THEWS O, 1992, INT J ARTIF ORGANS, V15, P447, DOI 10.1177/039139889201500801; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; *US DEP COMM, 1993, STAT ABSTR US; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; Weinstein M C, 1990, Int J Technol Assess Health Care, V6, P93; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC, 1980, CLIN DECISION ANAL; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1991, MMWR MORB MORTAL WKL, V40, P1; 1979, CAN MED ASS J, V121, P1193	44	47	47	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					56	63		10.7326/0003-4819-128-1-199801010-00009	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424982				2022-12-28	WOS:000071158000009
J	Nurse, P				Nurse, P			Checkpoint pathways come of age	CELL			English	Review							DNA-DAMAGE CHECKPOINT; FISSION YEAST; PROTEIN-KINASE		Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Nurse, P (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.							BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; KHARBANDA S, 1994, CANCER RES, V54, P1412; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182	15	189	213	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					865	867		10.1016/S0092-8674(00)80476-6	http://dx.doi.org/10.1016/S0092-8674(00)80476-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428508	Bronze			2022-12-28	WOS:000071281400002
J	Gilson, L; Mkanje, R; Grosskurth, H; Mosha, F; Picard, J; Gavyole, A; Todd, J; Mayaud, P; Swai, R; Fransen, L; Mabey, D; Mills, A; Hayes, R				Gilson, L; Mkanje, R; Grosskurth, H; Mosha, F; Picard, J; Gavyole, A; Todd, J; Mayaud, P; Swai, R; Fransen, L; Mabey, D; Mills, A; Hayes, R			Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RURAL TANZANIA; RISK-FACTORS; TRANSMISSION; FEMALE; IMPACT; TRIAL	Background A community-randomised trial was undertaken to assess the impact, cost, and cost-effectiveness of averting HIV-1 infection through improved management of sexually transmitted diseases (STDs) by primary-health-care workers in Mwanza Region, Tanzania. Methods The impact of improved treatment services for STDs on HIV-1 incidence was assessed by comparison of six intervention communities with six matched communities. We followed up a random cohort of 12 537 adults aged 15-54 years for 2 years to record incidence of HIV-1 infection. The total and incremental costs of the intervention were estimated (ingredients approach) and used to calculate the total cost per case treated, the incremental cost per HIV-1 infection averted, and the incremental cost per disability-adjusted life-year (DALY) saved. Findings During 2 years of follow-up, 11 632 cases of STDs were treated in the intervention health units. The baseline prevalence of HIV-1 infection was 4%. The incidence of HIV-1 infection during the 2 years was 1.16% in the intervention communities and 1.86% in the comparison communities, An estimated 252 HIV-1 infections were averted each year. The total annual cost of the intervention was US$59 060 (1993 prices), equivalent to $0.39 per head of population served. The cost for STD case treated was $10.15, of which the drug cost was $2.11. The incremental annual cost of the intervention was $54 839, equivalent to $217.62 per HIV-1 infection averted and $10.33 per DALY saved (based on Tanzanian life expectancy) or $9.45 per DALY saved (based on the assumptions of the World Development Report). In a sensitivity analysis of factors influencing cost-effectiveness, cost per DALY saved ranged from $2.51 to $47.86. Interpretation Improved management of STDs in rural health units reduced the incidence of HIV-1 infection in the general population by about 40%. The estimated cost-effectiveness of this intervention ($10 per DALY) compares favourably with that of, for example, childhood immunisation programmes ($12-17 per DALY). Cost-effectiveness should be further improved when the intervention is applied on a larger scale. Resources should be made available for this highly cost-effective HIV control strategy.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; African Med & Res Fdn, Mwanza, Tanzania; Natl Inst Med Res, Mwanza, Tanzania; Minist Hlth, Dar Es Salaam, Tanzania; European Union, AIDS Task Force, Brussels, Belgium	University of London; London School of Hygiene & Tropical Medicine; African Medical & Research Foundation (AMREF); National Institute of Medical Research	Grosskurth, H (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.		Gilson, Lucy/R-8846-2019	Gilson, Lucy/0000-0002-2775-7703; Hayes, Richard/0000-0002-1729-9892; Grosskurth, Heiner/0000-0001-9960-7280; MAYAUD, Philippe/0000-0001-5730-947X; Mabey, David/0000-0002-0031-8276; Todd, Jim/0000-0001-5918-4914; Mills, Anne/0000-0001-9863-9950				CAMERON DW, 1989, LANCET, V2, P403; GOLD MR, 1996, COST EFFECTIVENESS H, P233; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Ham C., 1996, HLTH POLICY SYSTEMS, P25; HAYES R, 1995, AIDS, V9, P919, DOI 10.1097/00002030-199508000-00014; *INT MON FUND, 1995, INT FIN STAT YB; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; Levin H. M., 1983, COST EFFECTIVENESS P; MULDER DW, 1996, EPIDEMIOLOGY HIV 1 R, P108; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Over M, 1993, DIS CONTROL PRIORITI, P455; OVER M, 1988, GLOBAL IMPACT AIDS; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SODERLUND N, 1993, B WORLD HEALTH ORGAN, V71, P595; *UNAIDS, 1996, STAT TRENDS GLOB HIV; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; *WHO, 1996, WEEKLY EPIDEMIOL REC, V71, P207; *WORLD BANK, 1993, WORLD DEV REP 1993 I	18	129	129	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1805	1809		10.1016/S0140-6736(97)08222-6	http://dx.doi.org/10.1016/S0140-6736(97)08222-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428251				2022-12-28	WOS:000071102500009
J	Grimbacher, B; Wenger, B; Deibert, P; Ness, T; Koetter, I; Peter, HH				Grimbacher, B; Wenger, B; Deibert, P; Ness, T; Koetter, I; Peter, HH			Loss of vision and diarrhoea	LANCET			English	Article							BEHCETS-DISEASE; INVOLVEMENT		Univ Hosp Freiburg, Dept Med, Div Clin Immunol & Rheumatol, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Dept Med, Div Gastroenterol, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Dept Ophthalmol, D-79106 Freiburg, Germany; Univ Tubingen Hosp, Dept Med, Div Rheumatol & Immunol, Tubingen, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Peter, HH (corresponding author), Univ Hosp Freiburg, Dept Med, Div Clin Immunol & Rheumatol, D-79106 Freiburg, Germany.		Deibert, Peter/AAE-4623-2020; Koetter, Ina/O-3121-2019	Koetter, Ina/0000-0002-9262-005X				ALPSOY E, 1994, J AM ACAD DERMATOL, V31, P617, DOI 10.1016/S0190-9622(94)70226-8; FERON EJ, 1994, LANCET, V343, P1428, DOI 10.1016/S0140-6736(94)92549-6; KASAHARA Y, 1981, DIS COLON RECTUM, V24, P103, DOI 10.1007/BF02604297; KOETTER I, 1996, ARTHRITIS RHEUM, V39, P227; Yurdakul S, 1996, ANN RHEUM DIS, V55, P208, DOI 10.1136/ard.55.3.208	5	12	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1818	1818		10.1016/S0140-6736(97)10114-3	http://dx.doi.org/10.1016/S0140-6736(97)10114-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428254				2022-12-28	WOS:000071102500012
J	Tesmer, JJG; Sunahara, RK; Gilman, AG; Sprang, SR				Tesmer, JJG; Sunahara, RK; Gilman, AG; Sprang, SR			Crystal structure of the catalytic domains of adenylyl cyclase in a complex with G(s alpha).GTP gamma S	SCIENCE			English	Article							GUANYLATE-CYCLASE; GS-ALPHA; STEREOCHEMICAL COURSE; MOLECULAR-CLONING; ESCHERICHIA-COLI; GTP HYDROLYSIS; G-PROTEIN; MECHANISM; EXPRESSION; DIVERSITY	The crystal structure of a soluble, catalytically active form of adenylyl cyclase in a complex with its stimulatory heterotrimeric G protein alpha subunit (G(S alpha)) and forskolin was determined to a resolution of 2.3 angstroms. When P-site inhibitors were soaked into native crystals of the complex, the active site of adenylyl cyclase was located and structural elements important for substrate recognition and catalysis were identified. On the basis of these and other structures, a molecular mechanism is proposed for the activation of adenylyl cyclase by G(S alpha).	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK46371, DK38828] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN SZ, 1997, J BIOL CHEM, V272, P18849; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CHINKERS M, 1991, ANN REV BIOCH, V60, P563; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GERLT JA, 1980, J BIOL CHEM, V255, P331; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITOH H, 1991, J BIOL CHEM, V266, P16226; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SENTER PD, 1983, J BIOL CHEM, V258, P6741; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SRTYMIUK PJ, 1997, NATURE, V388, P33; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, PROTEIN SCI, V6, P903; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	52	635	649	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1907	1916		10.1126/science.278.5345.1907	http://dx.doi.org/10.1126/science.278.5345.1907			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417641				2022-12-28	WOS:A1997YL00200024
J	Mannheim, K				Mannheim, K			Possible production of high-energy gamma rays from proton acceleration in the extragalactic radio source Markarian 501	SCIENCE			English	Article							ACTIVE GALACTIC NUCLEI; COSMIC-RAYS; SHOCK ACCELERATION; MAXIMUM ENERGY; EMISSION; QUASARS; BLAZARS; WAVES	The active galaxy Markarian 501 was discovered with air-Cerenkov telescopes at photon energies of 10 tera-electron volts, Such high energies may indicate that the gamma rays from Markarian 501 are due to the acceleration of protons rather than electrons, Furthermore, the observed absence of gamma ray attenuation due to electron-positron pair production in collisions with cosmic infrared photons implies a limit of 2 to 4 nanowatts per square meter per steradian for the energy flux of an extragalactic infrared radiation background at a wavelength of 25 micrometers, This limit provides important clues about the epoch of galaxy formation.	Univ Sternwarte, D-37083 Gottingen, Germany	University of Gottingen	Mannheim, K (corresponding author), Univ Sternwarte, Geismarlandstr 11, D-37083 Gottingen, Germany.	kmannhe@uni-sw.gwdg.de	Mannheim, Karl/F-6705-2012					Aharonian F, 1997, ASTRON ASTROPHYS, V327, pL5; Bednarz J, 1996, MON NOT R ASTRON SOC, V283, P447, DOI 10.1093/mnras/283.2.447; BIERMANN PL, 1987, ASTROPHYS J, V322, P643, DOI 10.1086/165759; Bradbury SM, 1997, ASTRON ASTROPHYS, V320, pL5; Catanese M, 1997, ASTROPHYS J, V487, pL143, DOI 10.1086/310899; Cawley M. F., 1995, Experimental Astronomy, V6, P7, DOI 10.1007/BF00421124; Dar R, 1997, ASTROPHYS J, V478, pL5, DOI 10.1086/310544; deJager OC, 1996, ASTROPHYS J, V457, P253, DOI 10.1086/176726; DERMER CD, 1992, SCIENCE, V257, P1642, DOI 10.1126/science.257.5077.1642; FRANCESCHINI A, 1991, ASTRON ASTROPHYS SUP, V89, P285; FRANCESCHINI A, IN PRESS EUROPEAN SP, V401; Gaisser T. K., 1995, Physics Reports, V258, P173, DOI 10.1016/0370-1573(95)00003-Y; GHISELLINI G, 1993, ASTROPHYS J, V407, P65, DOI 10.1086/172493; HARRIS DE, 1994, NATURE, V367, P713, DOI 10.1038/367713a0; Hayashida N, 1996, PHYS REV LETT, V77, P1000, DOI 10.1103/PhysRevLett.77.1000; Impey C, 1996, ASTRON J, V112, P2667, DOI 10.1086/118211; JOKIPII JR, 1987, ASTROPHYS J, V313, P842, DOI 10.1086/165022; KNIFFEN DA, 1996, ASTRON ASTROPHYS S, V120, P615; KOYAMA K, 1995, NATURE, V378, P255, DOI 10.1038/378255a0; Krennrich F, 1997, ASTROPHYS J, V481, P758, DOI 10.1086/304090; LAGAGE PO, 1983, ASTRON ASTROPHYS, V125, P249; Macminn D, 1996, SPACE SCI REV, V75, P413, DOI 10.1007/BF00195049; Madau P, 1996, MON NOT R ASTRON SOC, V283, P1388, DOI 10.1093/mnras/283.4.1388; Mannheim K, 1996, ASTRON ASTROPHYS, V315, P77; MANNHEIM K, 1993, ASTRON ASTROPHYS, V269, P67; MANNHEIM K, 1991, ASTRON ASTROPHYS, V251, P723; PADOVANI P, 1993, MON NOT R ASTRON SOC, V260, pL21, DOI 10.1093/mnras/260.1.L21; PETRY D, 1997, IN PRESS P 25 INT CO; PLAN E, IN PRESS ASTROPHYS J; Protheroe RJ, 1996, ASTROPART PHYS, V5, P215, DOI 10.1016/0927-6505(96)00042-4; Quinn J, 1996, ASTROPHYS J, V456, pL83, DOI 10.1086/309878; RACHEN JP, 1993, ASTRON ASTROPHYS, V273, P377; Reynolds SP, 1996, ASTROPHYS J, V459, pL13, DOI 10.1086/309936; SOIFER BT, 1991, ASTRON J, V101, P354, DOI 10.1086/115691; STANEV T, UNPUB; STANEY T, 1995, PHYS REV LETT, V75, P3065; STECKER FW, IN PRESS ASTROPHYS J; URRY CM, 1995, PUBL ASTRON SOC PAC, V107, P803, DOI 10.1086/133630; WIEBELSOOTH B, IN PRESS ASTRON ASTR	39	76	77	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					684	686		10.1126/science.279.5351.684	http://dx.doi.org/10.1126/science.279.5351.684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445469				2022-12-28	WOS:000071731500030
J	Rowe, T; Dascher, C; Bannykh, S; Plutner, H; Balch, WE				Rowe, T; Dascher, C; Bannykh, S; Plutner, H; Balch, WE			Role of vesicle-associated syntaxin 5 in the assembly of pre-Golgi intermediates	SCIENCE			English	Article							STOMATITIS-VIRUS GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; CELL-SURFACE; ALPHA-SNAP; FUSION; DOCKING; COPII; ACTIVATION; EXOCYTOSIS	Syntaxins are thought to function during vesicular transport as receptors on the target membrane and to contribute to the specificity of membrane docking and fusion by interacting with vesicle-associated receptors. Here, syntaxin 5 (Syn5) was shown to be an integral component of endoplasmic reticulum-derived transport vesicles. This pool, but not the target, Golgi-associated Syn5 pool, was essential for the assembly of vesicular-tubular pre-Golgi intermediates and the delivery of cargo to the Golgi. The requirement for vesicle-associated Syn5 in transport suggests a reevaluation of the basis for operation of the early secretory pathway.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	webalch@scripps.edu			NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Fleischer S, 1974, Methods Enzymol, V31, P6; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, UNPUB; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; TANG BL, 1995, EUR J CELL BIOL, V68, P397; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	42	98	98	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					696	700		10.1126/science.279.5351.696	http://dx.doi.org/10.1126/science.279.5351.696			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445473				2022-12-28	WOS:000071731500034
J	Wang, YD; DuBois, JL; Hedman, B; Hodgson, KO; Stack, TDP				Wang, YD; DuBois, JL; Hedman, B; Hodgson, KO; Stack, TDP			Catalytic galactose oxidase models: Biomimetic Cu(II)-phenoxyl-radical reactivity	SCIENCE			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; COPPER; COMPLEXES; OXIDATION; ALCOHOLS; SYSTEM	Biomimetic functional models of the mononuclear copper enzyme galactose oxidase are presented that catalytically oxidize benzylic and allylic alcohols to aldehydes with O-2 under mild conditions, The mechanistic fidelity between the models and the natural system is pronounced. Modest structural mimicry proves sufficient to transfer an unusual ligand-based radical mechanism, previously unprecedented outside the protein matrix, to a simple chemical system.	Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University	Hedman, B (corresponding author), Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA.			Wang, Yadong/0000-0003-2067-382X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050730, R01GM050730] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01209] Funding Source: Medline; NIGMS NIH HHS [GM50730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; COOKSON PG, 1975, J ORGANOMET CHEM, V99, pC31, DOI 10.1016/S0022-328X(00)88466-1; DuBois JL, 1997, J AM CHEM SOC, V119, P8578, DOI 10.1021/ja9717673; FILIPPONI A, 1991, SOLID STATE COMMUN, V78, P265, DOI 10.1016/0038-1098(91)90194-Z; Groves John T., 1995, P3; GROVES JT, 1988, STUD ORG CHEM AMSTER, V33, P541; Halfen JA, 1997, J AM CHEM SOC, V119, P8217, DOI 10.1021/ja9700663; Hamilton G., 1973, OXIDASES RELATED RED, V1, P103; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KARLIN KD, 1994, J AM CHEM SOC, V116, P1324, DOI 10.1021/ja00083a018; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KITAJIMA N, 1986, J CHEM SOC CHEM COMM, P1504, DOI 10.1039/c39860001504; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOWLES PF, 1995, INORG CHEM, V34, P3895, DOI 10.1021/ic00119a010; KOCH WO, 1996, ANGEW CHEM INT EDIT, V34, P2671; LEE SC, 1993, INORG CHEM, V32, P4745, DOI 10.1021/ic00074a016; MARADUFU A, 1971, CAN J CHEMISTRY, V49, P3429, DOI 10.1139/v71-575; Marko IE, 1996, SCIENCE, V274, P2044, DOI 10.1126/science.274.5295.2044; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; REGLIER M, 1990, J CHEM SOC CHEM COMM, P1752, DOI 10.1039/c39900001752; Sokolowski A, 1997, J AM CHEM SOC, V119, P8889, DOI 10.1021/ja970417d; SOKOLOWSKI A, 1996, J CHEM SOC CHEM COMM, P1671; SOLOMON EI, 1984, COMMENTS INORG CHEM, V0003, P00227; Wachter RM, 1996, J AM CHEM SOC, V118, P2782, DOI 10.1021/ja9519896; Wang YD, 1996, J AM CHEM SOC, V118, P13097, DOI 10.1021/ja9621354; WESTRE TE, 1995, J AM CHEM SOC, V117, P1566, DOI 10.1021/ja00110a012; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; WOLFE WC, 1962, ANAL CHEM, V34, P1328, DOI 10.1021/ac60190a040; Zondervan C, 1997, CHEM COMMUN, P419, DOI 10.1039/a607779j	32	419	421	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					537	540		10.1126/science.279.5350.537	http://dx.doi.org/10.1126/science.279.5350.537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438841				2022-12-28	WOS:000071616000038
J	O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW				O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW			PAPNET-assisted rescreening of cervical smears - Cost and accuracy compared with a 100% manual rescreening strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY ASSURANCE; NEGATIVE SMEARS; TESTING SYSTEM; BENEFITS; INCREASE; EFFICACY; CYTOLOGY	Context.-The Food and Drug Administration has recently approved several devices that use computerized image analysis to rescreen Papanicolaou (Pap) smears that have already been examined by cytotechnologists. Physicians and laboratories must decide whether the utility of these devices justifies the cost. Objective.-To determine the effectiveness and cost of PAPNET-assisted rescreening in identifying cervical abnormalities not identified by manual rescreening. Design.-PAPNET-assisted rescreening of 5478 Pap smears obtained in 1994 and 1995 previously identified as "within normal limits" or "benign changes" on both initial and random screening. Patients.-Female service members and dependents aged 12 to 88 years. Setting.-Air Force clinics in the United States and Japan. Intervention.-Rescreening of Pap smears by PAPNET, followed by reevaluation of abnormal smears by the consensus panel, consisting of 3 cytotechnologists and 3 pathologists. Main Outcome Measures.-Proportion of Pap smears initially screened as normal identified as abnormal by both PAPNET and consensus panel; costs of rescreening. Results.-PAPNET screening identified 1614 (29%) slides requiring additional microscopic review, On further review, 448 (8% of total) had possibly abnormal cells, Ultimately, 11 of these cases were reviewed by the consensus panel for potentially atypical cells, Of these 11 cases, 5 were reclassified as atypical squamous cells of undetermined significance (ASCUS) and 1 as atypical glandular cells of undetermined significance (AGUS). No additional squamous intraepithelial neoplasia (SIL) was identified in these smears; the patient with a diagnosis of AGUS on rescreening was diagnosed as having a low-grade SIL (LSIL) on follow-up, Costs were $5825 to $33 781 for each additional ASCUS or AGUS diagnosis, A cost of $17 475 to $101 343 is expected for each case of LSIL identified by PAPNET-assisted rescreening and not by traditional manual rescreening. Conclusions.-PAPNET-assisted rescreening identified a few more cases of ASCUS than did manual rescreening, but at a relatively high cost, The costs of rescreening should be carefully compared with the expected efficacy in reducing cervical cancer mortality.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	O'Leary, TJ (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, 14th St & Alaska Ave NW, Washington, DC 20306 USA.	tjo@afip.mil	Oleary, Timothy/AAE-5219-2021; Oleary, Timothy/AAF-2829-2021	O'LEARY, TIMOTHY/0000-0002-2435-9136				ASHFAQ R, 1995, DIAGN CYTOPATHOL, V13, P31, DOI 10.1002/dc.2840130108; BOON ME, 1993, DIAGN CYTOPATHOL, V9, P411, DOI 10.1002/dc.2840090408; BOON ME, 1994, MODERN PATHOL, V7, P957; Boon ME, 1996, ACTA CYTOL, V40, P1109; CRANE M, 1996, MED ECON, P177; HENDEE WR, 1989, JAMA-J AM MED ASSOC, V262, P1672; HUSAIN OAN, 1994, ANAL CELL PATHOL, V6, P157; Hutchinson ML, 1996, ACTA CYTOL, V40, P4; KAMINSKY FC, 1995, ACTA CYTOL, V39, P232; Kok MR, 1996, CANCER, V78, P112, DOI 10.1002/(SICI)1097-0142(19960701)78:1<112::AID-CNCR16>3.0.CO;2-2; KOSS LG, 1994, AM J CLIN PATHOL, V101, P220, DOI 10.1093/ajcp/101.2.220; Mango LJ, 1996, ACTA CYTOL, V40, P138; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; OUWERKERKNOORDAM E, 1994, CYTOPATHOLOGY, V5, P211, DOI 10.1111/j.1365-2303.1994.tb00422.x; Patten SF, 1996, ACTA CYTOL, V40, P45; Rosenthal DL, 1996, ACTA CYTOL, V40, P120; Ryan MR, 1996, AM J CLIN PATHOL, V105, P711; SCHWARZ PJ, 1981, PUBLIC HEALTH REP, V96, P547; SHERMAN ME, 1994, MODERN PATHOL, V7, P578; SLAGEL DD, 1995, DIAGN CYTOPATHOL, V13, P26, DOI 10.1002/dc.2840130107; Vooijs GP, 1996, ACTA CYTOL, V40, P14; Vuong P. N., 1995, Archives d'Anatomie et de Cytologie Pathologiques, V43, P147; Waugh N, 1996, CYTOPATHOLOGY, V7, P249, DOI 10.1046/j.1365-2303.1996.40182401.x; Wied GL, 1996, ACTA CYTOL, V40, P1; Wilbur DC, 1996, ACTA CYTOL, V40, P127	25	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					235	237		10.1001/jama.279.3.235	http://dx.doi.org/10.1001/jama.279.3.235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438746	Bronze			2022-12-28	WOS:000071460700036
J	Leach, JP; Brodie, MJ				Leach, JP; Brodie, MJ			Tiagabine	LANCET			English	Article							GABA UPTAKE INHIBITOR; NEWLY-DIAGNOSED EPILEPSY; ANTIEPILEPTIC DRUGS; THERAPY; PHARMACOKINETICS; CARBAMAZEPINE; MONOTHERAPY; TRANSPORTER; VIGABATRIN; POTENT		Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland.	martin.j.brodie@clinmed.gla.ac.uk	Leach, John Paul/AGZ-0356-2022; Leach, John Paul/AGU-8942-2022	Leach, John Paul/0000-0003-2086-9937				BenMenachem E, 1995, EPILEPSIA, V36, pS14, DOI 10.1111/j.1528-1157.1995.tb06010.x; BITON V, 1996, EPILEPSIA S4, V37, P40; BOPP BA, 1995, EPILEPSIA, V36, pS159; BORDEN LA, 1994, EUR J PHARM-MOLEC PH, V269, P219, DOI 10.1016/0922-4106(94)90089-2; Brodie M.J, 1997, EPILEPSIA S2, V38, pS23; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; Brodie MJ, 1996, LANCET, V347, P777, DOI 10.1016/S0140-6736(96)90863-6; Brodie MJ, 1995, EPILEPSIA, V36, pS7, DOI 10.1111/j.1528-1157.1995.tb06015.x; CLARK JA, 1994, MOL PHARMACOL, V46, P550; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Dodrill CB, 1997, NEUROLOGY, V48, P1025, DOI 10.1212/WNL.48.4.1025; FINKJENSEN A, 1992, EUR J PHARMACOL, V220, P197, DOI 10.1016/0014-2999(92)90748-S; GUSTAVSON LE, 1995, EPILEPSIA, V36, P605, DOI 10.1111/j.1528-1157.1995.tb02575.x; Gustavson LE, 1997, NEUROLOGY, V48, P1032, DOI 10.1212/WNL.48.4.1032; JOHNSTON GAR, 1996, PHARMACOL THERAPEUT, P173; KALVIAINEN R, 1995, ARCH NEUROL-CHICAGO, V52, P989, DOI 10.1001/archneur.1995.00540340081016; Kalviainen R, 1996, EPILEPSY RES, V25, P291, DOI 10.1016/S0920-1211(96)00084-8; KALVIAINEN R, IN PRESS EPILEPSY RE; LASSEN LC, 1994, PHASE 2 STUDY TIAGAB; Lau AH, 1997, EPILEPSIA, V38, P445, DOI 10.1111/j.1528-1157.1997.tb01734.x; Leach JP, 1996, SEIZURE-EUR J EPILEP, V5, P229, DOI 10.1016/S1059-1311(96)80041-0; LEACH JP, 1995, SEIZURE-EUR J EPILEP, V4, P155, DOI 10.1016/S1059-1311(95)80098-0; Leppik IE, 1995, EPILEPSIA, V36, pS10, DOI 10.1111/j.1528-1157.1995.tb06009.x; MARSON AG, 1996, BRIT MED J, V13, P1169; MCKEE PJW, 1994, NEW ANTICONVULSANTS, P1; MELDRUM BS, 1995, EPILEPSIA, V36, pS30; MENGEL HB, 1994, J PHARM MED, V4, P141; NIELSEN EB, 1991, EUR J PHARMACOL, V196, P257, DOI 10.1016/0014-2999(91)90438-V; OSTERGAARD LH, 1995, POTENTIAL ANTIEPILEP, P1057; Perucca E, 1996, BRIT J CLIN PHARMACO, V42, P531, DOI 10.1111/j.1365-2125.1996.tb00107.x; Petroff OAC, 1996, ANN NEUROL, V40, P908, DOI 10.1002/ana.410400613; RICHENS A, 1995, EPILEPSY RES, V21, P37, DOI 10.1016/0920-1211(95)00006-V; Sachdeo RC, 1997, ARCH NEUROL-CHICAGO, V54, P595, DOI 10.1001/archneur.1997.00550170069016; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; SCHACHTER S, 1995, EPILEPSIA S3, V36, P148; Schachter SC, 1995, EPILEPSIA, V36, pS2, DOI 10.1111/j.1528-1157.1995.tb06011.x; SCHMIDT D, 1995, CNS DRUGS, V3, P194, DOI 10.2165/00023210-199503030-00005; So EL, 1995, EPILEPSY RES, V22, P221, DOI 10.1016/0920-1211(95)00048-8; SUZDAK PD, 1995, EPILEPSIA, V36, P612, DOI 10.1111/j.1528-1157.1995.tb02576.x; Sveinbjornsdottir S, 1994, Seizure, V3, P29, DOI 10.1016/S1059-1311(05)80160-8; ULDALL P, 1995, EPILEPSIA, V36, pS147; UTHMAN BM, IN PRESS ARCH NEUROL; WILSON EA, 1996, MODERN MANAGEMENT EP, P723	44	82	83	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 17	1998	351	9097					203	207		10.1016/S0140-6736(97)05035-6	http://dx.doi.org/10.1016/S0140-6736(97)05035-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449883				2022-12-28	WOS:000071616300042
J	Ahsan, H; Neugut, AI				Ahsan, H; Neugut, AI			Radiation therapy for breast cancer and increased risk for esophageal carcinoma	ANNALS OF INTERNAL MEDICINE			English	Article							LUNG-CANCER; TUMORS; CHEMOTHERAPY	Background: Several case reports have suggested an association between radiation therapy for breast cancer and the subsequent occurrence of esophageal carcinomas. Objective: To examine the association between radiation therapy for breast cancer and subsequent esophageal squamous-cell carcinomas and adenocarcinomas. Design: Population-based retrospective cohort study. Setting: Population-based U.S. cancer registries. Patients: 220 806 women in whom breast cancer was diagnosed between 1 January 1973 and 31 December 1993; 1 216 853 person-years of follow-up. Measurements: Age- and period-adjusted standardized incidence ratio as a measure of relative risk for the second primary cancer. Results: In women who had received radiation therapy for breast cancer, the relative risk for esophageal squamous-cell carcinoma increased to 5.42 (95% CI, 2.33 to 10.68) and the relative risk for esophageal adenocarcinoma increased to 4.22 (CI, 0.47 to 15.25) 10 or more years after radiation therapy. No increased risk was seen for either type of carcinoma among patients with breast cancer who did not receive radiation therapy. Conclusion: The risk for esophageal carcinoma is increased in women who receive radiation therapy for breast cancer.	Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Oncol, New York, NY 10032 USA	Columbia University; Columbia University	Ahsan, H (corresponding author), Columbia Univ, Sch Publ Hlth, Div Epidemiol, 600 W 168th St, New York, NY 10032 USA.							Ahsan H, 1997, CANCER EPIDEM BIOMAR, V6, P779; AHSAN H, 1995, J CLIN ONCOL, V13, P2931, DOI 10.1200/JCO.1995.13.12.2931; BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; Cartei G, 1996, EUR J CANCER PREV, V5, P400; DAVIS FG, 1989, CANCER RES, V49, P6130; DOLL R, 1981, BRIT J RADIOL, V54, P179, DOI 10.1259/0007-1285-54-639-179; Fekete F, 1994, Dysphagia, V9, P289; GATES O, 1968, AM J PATHOL, V53, P667; GOFFMAN TE, 1983, CANCER, V52, P1808, DOI 10.1002/1097-0142(19831115)52:10<1808::AID-CNCR2820521008>3.0.CO;2-W; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HARRIS JR, 1988, INT J RADIAT ONCOL, V15, P497, DOI 10.1016/S0360-3016(98)90034-7; INSKIP PD, 1994, J NATL CANCER I, V86, P983, DOI 10.1093/jnci/86.13.983; Kelsey JL., 1996, METHODS OBSERVATIONA; *NAT AC SCI, 1980, BIOL EFF ION RAD EFF, P431; NEUGUT AI, 1993, CANCER, V71, P3054, DOI 10.1002/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N; Neugut AI, 1997, CANCER, V79, P1600, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0; OCONNELL EW, 1984, GASTROINTEST RADIOL, V9, P287, DOI 10.1007/BF01887853; SHERRILL DJ, 1984, CANCER, V54, P726, DOI 10.1002/1097-0142(1984)54:4<726::AID-CNCR2820540422>3.0.CO;2-X; SHIMIZU T, 1990, JPN J SURG, V20, P97, DOI 10.1007/BF02470720; *SURV EP END RES S, 1996, PROGR PUBL US DAT 19; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; VANAGUNAS A, 1990, AM J GASTROENTEROL, V85, P808; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519	23	74	74	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					114	117		10.7326/0003-4819-128-2-199801150-00007	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441571				2022-12-28	WOS:000071470800006
J	Gill, TM; Robison, JT; Tinetti, ME				Gill, TM; Robison, JT; Tinetti, ME			Difficulty and dependence: Two components of the disability continuum among community-living older persons	ANNALS OF INTERNAL MEDICINE			English	Article						activities of daily living; aged; disabled persons; independent living; geriatric assessment	PHYSICAL-DISABILITY; FUNCTIONAL STATUS; ADULTS; PREDICTORS; ELDERS; HEALTH; POPULATIONS; IMPAIRMENT; DESIGN; FALLS	Background: Although most epidemiologic studies have defined disability in basic activities of daily living (BADLs) as dependence, some investigators have argued that BADL disability should be defined as degree of difficulty. Objective: To determine whether the responses to questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than the response to either question alone. Setting: General community. Participants: 1065 persons 72 years of age and older. Measurements: On the basis of self-reported information collected at baseline, participants were categorized into three BADL groups: independent without difficulty, independent with difficulty, and dependent. Additional baseline information was collected on several measures of higher-level function and physical performance. Follow-up information was collected on regular home care visits and BADL function at 1 and 3 years and on hospitalizations, admissions to skilled-nursing facilities, and deaths over a 4-year period. Results: In a cross-sectional analysis, the proportion of participants with poor higher-level function and physical performance increased substantially across the three BADL groups. In a longitudinal analysis, the rates of hospitalization and regular home care visits for the independent without difficulty group, the independent with difficulty group, and the dependent group were 46%, 57%, and 72% (P < 0.001) and 17%, 30%, and 49% (P < 0.001), respectively; survival curves for admission to a skilled-nursing facility and death differed significantly for each pair-wise comparison. Among persons who were BADL independent, those with difficulty were significantly more likely to develop BADL dependence over a 3-year period than those without difficulty (31% compared with 18%; P < 0.001). Conclusions: In the assessment of BADL function in older persons, questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than either question alone.	Yale Univ, Sch Med, Genet Program, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Genet Program, Room 17B-TMP,POB 208025, New Haven, CT 06504 USA.		Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NATIONAL INSTITUTE ON AGING [R01AG007449, T32AG000153, P60AG010469] Funding Source: NIH RePORTER; NIA NIH HHS [5T32-AG00153, P60 AG-10469, R01 AG-07449] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENVENUTI F, 1995, J AM GERIATR SOC, V43, P479, DOI 10.1111/j.1532-5415.1995.tb06092.x; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crawford SL, 1997, J AM GERIATR SOC, V45, P338, DOI 10.1111/j.1532-5415.1997.tb00950.x; DIPIETRO L, 1993, MED SCI SPORT EXER, V25, P628; DUNN JE, 1992, AM J PUBLIC HEALTH, V82, P395, DOI 10.2105/AJPH.82.3.395; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FERRUCCI L, 1991, J GERONTOL, V46, pM52, DOI 10.1093/geronj/46.2.M52; Ferrucci L, 1996, J CLIN EPIDEMIOL, V49, P1089, DOI 10.1016/0895-4356(96)00231-4; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fried LP, 1996, J GERONTOL A-BIOL, V51, pM206, DOI 10.1093/gerona/51A.5.M206; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X; JETTE AM, 1985, J CHRON DIS, V38, P59, DOI 10.1016/0021-9681(85)90008-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEIL JE, 1989, J CLIN EPIDEMIOL, V42, P521, DOI 10.1016/0895-4356(89)90148-0; Kempen GIJM, 1996, SOC SCI MED, V43, P1601, DOI 10.1016/S0277-9536(96)00057-3; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; REUBEN DB, 1995, J AM GERIATR SOC, V43, P936, DOI 10.1111/j.1532-5415.1995.tb05540.x; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; WIENER JM, 1990, J GERONTOL, V45, pS229, DOI 10.1093/geronj/45.6.S229	35	184	184	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					96	+		10.7326/0003-4819-128-2-199801150-00004	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR200	9441588				2022-12-28	WOS:000071470800003
J	Willner, IR; Uhl, MD; Howard, SC; Williams, EQ; Riely, CA; Waters, B				Willner, IR; Uhl, MD; Howard, SC; Williams, EQ; Riely, CA; Waters, B			Serious hepatitis A: An analysis of patients hospitalized during an urban epidemic in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							A VIRUS-INFECTION; TYPE-1	Background: Memphis and Shelby County, Tennessee, experienced an epidemic of hepatitis A in 1994 and 1995. More than 1700 cases were reported. Objective: To characterize the clinical features of patients hospitalized during a large urban epidemic of hepatitis A. Design: Retrospective chart review. Setting: 15 acute care hospitals in Shelby County, Tennessee. Patients: 256 patients hospitalized with acute hepatitis A. Measurements: Laboratory findings (such as prothrombin time and bilirubin level), complications, and mortality. Results: The median patient age was 26 years. Thirty-nine complications occurred in 35 patients. Twenty patients (8%) had extrahepatic complications, and 5 (2%) died. Patients 40 years of age and older were more likely to have serious complications, including death (P = 0.014). Sixty-seven patients (26%) presented with coagulopathy (prothrombin time greater than or equal to 3 seconds prolonged). Fifty-four patients (21%) had a bilirubin level greater than 170 mu mol/L (10 mg/dL). Conclusions: During this epidemic, hepatitis A caused serious illness and death. Complications were more frequent in patients 40 years of age and older, but young, healthy persons were also at risk for severe complications.	Univ Tennessee, Memphis, TN USA	University of Tennessee System; University of Tennessee Health Science Center	Willner, IR (corresponding author), Med Univ S Carolina, Div Gastroenterol, Liver Serv, 916 Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA.							*ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P1; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; Dalton CB, 1996, ARCH INTERN MED, V156, P1013, DOI 10.1001/archinte.156.9.1013; Faust RL, 1996, AM J GASTROENTEROL, V91, P369; FORBES A, 1990, BRIT MED BULL, V46, P303, DOI 10.1093/oxfordjournals.bmb.a072400; HUPPERTZ HI, 1995, J HEPATOL, V23, P204, DOI 10.1016/0168-8278(95)80336-X; INMAN RD, 1986, ANN INTERN MED, V105, P700, DOI 10.7326/0003-4819-105-5-700; KOFF RS, 1995, J INFECT DIS, V171, pS19, DOI 10.1093/infdis/171.Supplement_1.S19; KOFF RS, 1992, VACCINE, V10, pS15, DOI 10.1016/0264-410X(92)90533-P; MELNICK JL, 1995, J INFECT DIS, V171, pS2, DOI 10.1093/infdis/171.Supplement_1.S2; MOURANI S, 1994, ANN INTERN MED, V120, P398, DOI 10.7326/0003-4819-120-5-199403010-00008; Muraoka H, 1990, Nihon Shokakibyo Gakkai Zasshi, V87, P1383; SHAPIRO CN, 1992, VACCINE, V10, pS59, DOI 10.1016/0264-410X(92)90545-U; SHAW FE, 1986, AM J EPIDEMIOL, V123, P1057, DOI 10.1093/oxfordjournals.aje.a114334; Skinner J T, 1995, J Tenn Med Assoc, V88, P468; TONG MJ, 1995, J INFECT DIS, V171, pS15, DOI 10.1093/infdis/171.Supplement_1.S15; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; Vento S, 1996, AM J GASTROENTEROL, V91, P2618; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; 1995, J ARK MED SOC, V92, P345	20	170	175	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					111	114		10.7326/0003-4819-128-2-199801150-00006	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441570				2022-12-28	WOS:000071470800005
J	Blunt, J; Savulescu, J; Watson, AJM				Blunt, J; Savulescu, J; Watson, AJM			Meeting the challenges facing research ethics committees: some practical suggestions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL RESEARCH; SCIENTIFIC FRAUD; STRUCK; TRIALS		Oxford Radcliffe Hosp, Oxford OX3 9RP, England; Univ Manchester, Hope Hosp, Dept Med, Salford M6 8HD, Lancs, England	University of Oxford; University of Manchester	Blunt, J (corresponding author), 53 Hawkstone Ave, Manchester M45 7PR, Lancs, England.							ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; BENDALL C, 1994, STANDARD OPERATING P; BENDALL CH, 1994, USING STANDARDS LOCA; BROCK P, 1996, FRAUD MISCONDUCT MED, P61; Carnall D, 1996, BRIT MED J, V312, P400; CHALMERS I, 1996, EVIDENCE BASED MED, V1, P39; Commission of the European Communities, 1991, CPMP WORK PART EFF M; *DEP HLTH, 1991, HSG915 DEP HLTH; *DEP HLTH, 1997, HSG9723 DEP HLTH; DYER O, 1995, BRIT MED J, V310, P1554, DOI 10.1136/bmj.310.6994.1554a; Dyer O, 1996, BRIT MED J, V312, P798; EICHLER HG, 1995, LANCET, V346, P1115, DOI 10.1016/S0140-6736(95)91796-9; FOSTER C, 1995, J ROY COLL PHYS LOND, V29, P315; FOSTER C, 1996, MANUAL RES ETHICS CO; Freedman Benjamin, 1994, IRB, V16, P1, DOI 10.2307/3563572; GARFIELD P, 1995, BRIT MED J, V311, P660, DOI 10.1136/bmj.311.7006.660; GARRITY M, 1993, THESIS U MANCHESTER, P15; HARRIES UJ, 1994, J ROY COLL PHYS LOND, V28, P150; HOSIE J, 1996, FRAUD MISCONDUCT MED, P46; HOTOPF M, 1995, J ROY SOC MED, V88, P31; HUSSON JM, 1996, FRAUD MISCONDUCT MED, P208; *INT C HARM TECHN, 1996, TRIP GUID GOOD CLIN; JACOBSEN G, 1995, J ROY COLL PHYS LOND, V29, P405; *LEIGH BARR CONS L, 1994, STAND LOC ETH COMM F; LOCK S, 1995, BRIT MED J, V310, P1547, DOI 10.1136/bmj.310.6994.1547; LOCK S, 1996, FRAUD MISCONDUCT MED, pR11; MEADE TW, 1994, J ROY COLL PHYS LOND, V28, P102; MIDDLE C, 1995, BRIT MED J, V311, P659, DOI 10.1136/bmj.311.7006.659; NEUBERGER J, 1992, 47 KINGS FUND I; OLIVER S, 1995, CRITICAL APPRAISAL S; PEARN J, 1995, BRIT MED J, V310, P1313, DOI 10.1136/bmj.310.6990.1313; PEARN J, 1996, NEW SCI         0106, P40; PENN ZJ, 1995, BRIT J OBSTET GYNAEC, V102, P1, DOI 10.1111/j.1471-0528.1995.tb09015.x; RIPPERE V, 1995, BRIT MED J, V311, P262, DOI 10.1136/bmj.311.6999.262a; *ROYAL COLL PHYS L, 1996, GUID PRACT ETH COMM; *ROYAL COLL PHYS L, 1991, FRAUD MISC MED RES C; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SHAPIRO M, 1996, FRAUD MISCONDUCT MED, P175; Smith R, 1996, BRIT MED J, V312, P789; WEIJER C, 1995, CAN MED ASSOC J, V152, P1973; WELLS F, 1996, FRAUD MISCONDUCT MED, P91; WHILE AE, 1995, BRIT MED J, V311, P661, DOI 10.1136/bmj.311.7006.661; Wise J, 1997, BRIT MED J, V314, P1145; Wise P, 1996, BRIT MED J, V313, P1245, DOI 10.1136/bmj.313.7067.1245; 1996, LANCET, V347, P843; 1980, LANCET, V1, P1061	47	32	33	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	1998	316	7124					58	61		10.1136/bmj.316.7124.58	http://dx.doi.org/10.1136/bmj.316.7124.58			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451273	Green Published			2022-12-28	WOS:000071377900034
J	Brahams, D				Brahams, D			Designating parents in surrogate pregnancies	LANCET			English	Editorial Material									Old Sq Chambers, London WC1R 5LQ, England		Brahams, D (corresponding author), Old Sq Chambers, London WC1R 5LQ, England.							CONNOR S, 1997, SUNDAY TIMES    1130; Simini B, 1997, LANCET, V350, P1307, DOI 10.1016/S0140-6736(05)63858-5; 1997, LANCET, V349, P1487	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					8	8		10.1016/S0140-6736(05)78096-X	http://dx.doi.org/10.1016/S0140-6736(05)78096-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433421				2022-12-28	WOS:000071253100007
J	Jackson, A; Wilkinson, C; Ranger, M; Pill, R; August, P				Jackson, A; Wilkinson, C; Ranger, M; Pill, R; August, P			Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; EARLY DIAGNOSIS; PRIMARY-CARE; EDUCATION CAMPAIGN; NEVUS COUNTS; CANCER	Objectives: To establish whether a questionnaire incorporating MacKie's risk factor flow chart can identify patients at high risk for melanoma so that they can be targeted for primary and secondary prevention. To validate the risk score derived fr om the questionnaire and test the feasibility of self completion by comparing patients' self reported skin characteristics with a skin examination performed by an experienced general practitioner. Design. Prospective questionnaire survey followed by a comparative study. Setting: 16 randomly selected group practices in a health district in Cheshire, United Kingdom. Subjects: Questionnaire survey-3105 consecutive patients aged 16 years and over attending for a primary care consultation; comparative study-a self selected subsample of 388 of the 3105 patients. Main outcome measures: MacKie risk group for melanoma. Comparison of high risk skin characteristics reported by patients and those noted during a skin examination by a doctor (ic statistic). Results: 4.3% of patients (87% women) were in the highest risk group and 4.4% (79% men) were in the second highest risk group, as defined by the MacKie score. Agreement between patients' self appraisal of skin characteristics and clinical skin examinations was reflected in kappa values of 0.67 for freckles, 0.60 for moles, and 0.43 for atypical naevi. Conclusion: This questionnaire helped to identify a group at high risk for melanoma. Furthermore, good agreement was found when the patient's risk scores were compared with results of the clinical skin examination. This risk score is potentially useful in targeting primary and secondary prevention of melanoma through general practice.	Maelfa Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales; Leighton Hosp, Dept Dermatol, Crewe CW1 4QJ, Cheshire, England		Jackson, A (corresponding author), Holmes Chapel Hlth Ctr, London Rd, Holmes Chapel CW4 7BB, Cheshire, England.							AUSTOKER J, 1994, BRIT MED J, V308, P1682, DOI 10.1136/bmj.308.6945.1682; BYLES JE, 1994, BRIT J DERMATOL, V130, P51, DOI 10.1111/j.1365-2133.1994.tb06882.x; COCKERELL CJ, 1993, SOUTH MED J, V86, P1325, DOI 10.1097/00007611-199312000-00001; COLEMAN MP, 1993, IARC SCI PUBLICATION, V12; DIFFEY BL, 1992, BRIT MED J, V304, P1175; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; Elwood J M, 1994, J Med Screen, V1, P22; ENGLISH JSC, 1988, BRIT J DERMATOL, V118, P641, DOI 10.1111/j.1365-2133.1988.tb02564.x; GELLER AC, 1992, J GEN INTERN MED, V7, P154, DOI 10.1007/BF02598004; GRAHAMBROWN RAC, 1990, BRIT J DERMATOL, V122, P53, DOI 10.1111/j.1365-2133.1990.tb08239.x; HIGGINS E, 1991, BRIT J CLIN PRACT, V45, P109; JACKSON A, 1995, BRIT J GEN PRACT, V45, P97; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; LITTLE P, 1995, BRIT MED J, V310, P912, DOI 10.1136/bmj.310.6984.912; LOWITT MH, 1995, BRIT MED J, V311, P1616; MACKIE RM, 1989, LANCET, V2, P487; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; MacKie RM, 1997, BRIT MED J, V315, P1117, DOI 10.1136/bmj.315.7116.1117; MALLETT RB, 1993, BRIT J DERMATOL, V129, P689, DOI 10.1111/j.1365-2133.1993.tb03332.x; MORRIS J, 1997, J MED SCREENING, V1, P2; NICHOLS S, 1988, BRIT MED J, V296, P1526; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; *SECR STAT HLTH, 1992, CMND1986; WHITEHEAD SM, 1989, BRIT J CANCER, V60, P421, DOI 10.1038/bjc.1989.298; Wilson JMG, 1968, 34 WHO PUBL HLTH, V34	25	37	37	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					34	38		10.1136/bmj.316.7124.34	http://dx.doi.org/10.1136/bmj.316.7124.34			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451264	Green Published			2022-12-28	WOS:000071377900021
J	Koonin, SE				Koonin, SE			An independent perspective on the human genome project	SCIENCE			English	Article									CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Koonin, SE (corresponding author), CALTECH, Pasadena, CA 91125 USA.							COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; *MITRE CORP, 1997, JSR97315 MITRE CORP; Rowen L, 1997, SCIENCE, V278, P605, DOI 10.1126/science.278.5338.605	3	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					36	37		10.1126/science.279.5347.36	http://dx.doi.org/10.1126/science.279.5347.36			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9441408				2022-12-28	WOS:000071323900027
J	Heilbron, JL; Bynum, WF				Heilbron, JL; Bynum, WF			Eighteen-ninety-eight and all that	NATURE			English	Editorial Material									Univ Oxford Worcester Coll, Oxford OX1 2HB, England; Wellcome Inst Hist Med Sci, London NW1 2BE, England	University of Oxford; University of London; University College London	Heilbron, JL (corresponding author), Univ Oxford Worcester Coll, Oxford OX1 2HB, England.							JENNER E, INQUIRY CAUSES EFFEC; Malthus T. R., 1798, ESSAY PRINCIPLE POPU; RUMFORD C, ENQUIRY SOURCE HEAT; WHETSTONE G, CURES DIS REMOTE REG	4	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					13	16		10.1038/34022	http://dx.doi.org/10.1038/34022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422498				2022-12-28	WOS:000071326100017
J	Melbye, M; Wohlfahrt, J; Westergaard, T; Jensen, AKV; Koch, A; Hjalgrim, H; Kristensen, A; Aaby, P				Melbye, M; Wohlfahrt, J; Westergaard, T; Jensen, AKV; Koch, A; Hjalgrim, H; Kristensen, A; Aaby, P		Christmas Paper Study Grp	Births at Christmas are different: population based survey of 2 million deliveries	BRITISH MEDICAL JOURNAL			English	Article									Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol, DK-2300 Copenhagen S, Denmark	Aarhus University; Statens Serum Institut	Melbye, M (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol, Artillerivej 5, DK-2300 Copenhagen S, Denmark.		Hjalgrim, Henrik/AAG-4973-2021	melbye, mads/0000-0001-8264-6785; Koch, Anders/0000-0001-9205-1048; Aaby, Peter/0000-0001-8331-1389				Westergaard T, 1997, BMJ-BRIT MED J, V314, P775, DOI 10.1136/bmj.314.7083.775	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1654	1655		10.1136/bmj.315.7123.1654	http://dx.doi.org/10.1136/bmj.315.7123.1654			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448529	Green Published			2022-12-28	WOS:000071149400012
J	Margolis, P; Gadomski, A				Margolis, P; Gadomski, A			Does this infant have pneumonia?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY RATE; CHILDHOOD PNEUMONIA; PEDIATRIC PRACTICE; CLINICAL SIGNS; CHILDREN; CHEST; BACTERIAL; PULMONARY; DIAGNOSIS; ACCURACY	Acute lower respiratory tract illness is common among children seen in primary care. We reviewed the accuracy and precision of the clinical examination in detecting pneumonia in children. Although most cases are viral, it is important to identify bacterial pneumonia to provide appropriate therapy. Studies were identified by searching MEDLINE from 1982 to 1995, reviewing reference lists, reviewing a published compendium of studies of the clinical examination, and consulting experts. Observer agreement is good for most signs on the clinical examination. Each study was reviewed by 2 observers and graded for methodologic quality. There is better agreement about signs that can be observed leg, use of accessory muscles, color, attentiveness; kappa, 0.48-0.66) than signs that require auscultation of the chest leg, adventitious sounds; kappa, 0.3). Measurements of the respiratory rate are enhanced by counting for 60 seconds. The best individual finding for ruling out pneumonia is the absence of tachypnea. Chest indrawing, and other signs of increased work of breathing, increases the likelihood of pneumonia. If all clinical signs (respiratory rate, auscultation, and work of breathing) are negative, the chest x-ray findings are unlikely to be positive. Studies are needed to assess the value of clinical findings when they are used together.	Univ N Carolina, Sch Med, Div Community Pediat, Chapel Hill, NC 27599 USA; Bassett Hlth Care, Cooperstown, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Margolis, P (corresponding author), Univ N Carolina, Sch Med, Div Community Pediat, CB 7225,Wing C, Chapel Hill, NC 27599 USA.							[Anonymous], P INT WORKSH AC RESP; ASHTON R, 1971, DEV MED CHILD NEUROL, V13, P180; BERMAN S, 1991, ARCH DIS CHILD, V66, P81, DOI 10.1136/adc.66.1.81; BETTENAY FAL, 1988, PEDIATR RADIOL, V18, P453, DOI 10.1007/BF00974077; CAMPBELL EJ, 1969, THORAX, V24, P1, DOI 10.1136/thx.24.1.1; CENTOR R, 1992, 2 2 ANAL; COURTOY I, 1989, CLIN PEDIATR, V28, P261, DOI 10.1177/000992288902800604; CRAIN EF, 1991, PEDIATRICS, V88, P821; DAI YH, 1995, PEDIATR INFECT DIS J, V14, P48, DOI 10.1097/00006454-199501000-00010; DAVIS GM, 1987, CLIN PERINATOL, V14, P551, DOI 10.1016/S0095-5108(18)30750-4; FINER NN, 1975, PEDIATR RES, V9, P365; FORBES J, 1935, TREATISE DIS CHEST M; FORGACS P, 1978, LUNG SOUNDS, P44; GADOMSKI A, 1993, B WORLD HEALTH ORGAN, V17, P523; GADOMSKI AM, 1994, J CLIN EPIDEMIOL, V47, P1043, DOI 10.1016/0895-4356(94)90120-1; GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018; HALL CB, 1988, J PEDIATR-US, V113, P266; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; HENDERSON FW, 1989, AM REV RESPIR DIS, V140, P197, DOI 10.1164/ajrccm/140.1.197; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; Hoover CF, 1920, J AMER MED ASSOC, V75, P1626; HOPPENBROUWERS T, 1978, PEDIATR RES, V12, P120, DOI 10.1203/00006450-197802000-00011; ILIFF ALBERTA, 1952, CHILD DEVELOPMENT, V23, P237, DOI 10.2307/1126031; ISAACS D, 1989, PEDIATR INFECT DIS J, V8, P143; KENDIG E, 1983, DISORDERS RESP TRACT, P62; KIRCHNER SG, 1985, PEDIATR CLIN N AM, V32, P1363; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; KORPPI M, 1993, ACTA PAEDIATR, V82, P360, DOI 10.1111/j.1651-2227.1993.tb12697.x; LEHRER S, 1984, UNDERSTANDING BREATH, P85; LEVENTHAL J, 1992, CLIN PEDIATR, V21, P730; LOZANO JM, 1994, ARCH DIS CHILD, V71, P323, DOI 10.1136/adc.71.4.323; MARGOLIS PA, 1994, J PEDIATR-US, V124, P552, DOI 10.1016/S0022-3476(05)83133-6; MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101; MCCONNOCHIE KM, 1988, AM J PUBLIC HEALTH, V78, P34, DOI 10.2105/AJPH.78.1.34; MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z; MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004; MURPHY R, 1980, BASICS RESP DIS, P1; POOLE SR, 1995, PEDIATR EMERG CARE, V11, P158, DOI 10.1097/00006565-199506000-00004; REDD SC, 1994, T ROY SOC TROP MED H, V88, P307, DOI 10.1016/0035-9203(94)90092-2; REDD SC, 1994, B WORLD HEALTH ORGAN, V72, P113; RICHARDS J, 1984, PEDIATRICS, V5, P763; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; SIMOES EAF, 1991, ARCH DIS CHILD, V66, P1199, DOI 10.1136/adc.66.10.1199; SIMPSON W, 1974, PEDIATR RADIOL, V2, P155, DOI 10.1007/BF00972727; SWISCHUK LE, 1986, PEDIATR RADIOL, V16, P278, DOI 10.1007/BF02386862; TAYLOR JA, 1995, ARCH PEDIAT ADOL MED, V149, P283, DOI 10.1001/archpedi.1995.02170150063011; WAFULA EM, 1989, E AFR MED J, V66, P678; WANG EEL, 1992, AM REV RESPIR DIS, V145, P106, DOI 10.1164/ajrccm/145.1.106; *WHO, 1991, PROGR CONTR AC RESP; *WHO, 1993, PROGRAMME CONTROL AC, P173; WILDIN SR, 1988, AM J DIS CHILD, V142, P43, DOI 10.1001/archpedi.1988.02150010053020; ZUKIN DD, 1986, ANN EMERG MED, V15, P792	52	107	115	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					308	313		10.1001/jama.279.4.308	http://dx.doi.org/10.1001/jama.279.4.308			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450716				2022-12-28	WOS:000071607000039
J	Benson, FE; Baumann, P; West, SC				Benson, FE; Baumann, P; West, SC			Synergistic actions of Rad51 and Rad52 in recombination and DNA repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; COMPLEX; MOUSE; RECA; GENE; UVSY; BACTERIOPHAGE-T4; HOMOLOGS	In the yeast Saccharomyces cerevisiae, mutations in the genes RAD51 or RAD52 result in severe defects in genetic recombination and the repair of double-strand DNA breaks, These genes, and others of the RAD52 epistasis group (RAD50, RAD54, RAD55 RAD57, RAD59 MRE11 and XRS2), were first identified by their sensitivity to X-rays(1). They were subsequently shown to be required for spontaneous and induced mitotic recombination, meiotic recombination, and mating-type switching (reviewed in ref, 2), Human homologues of RAD50, RAD51, RAD52 RAD54 and MRE11 have been identified(3-6). Targeted disruption of the murine RAD51 gene results in an embryonic lethal phenotype, indicating that Rad51 protein is required during cell proliferation(7,8). Biochemical studies have shown that human RAD51 encodes a protein of relative molecular mass 36,966 (hRad51) that promotes ATP-dependent homologous pairing and DNA strand exchange(9-11), As a structural and functional homologue of the RecA protein from Escherichia coli(3,9,12), hRad51 is thought to play a central role in recombination, Yeast Rad51 has been shown to interact with Rad52 protein(13-15), as does the human homologue(16), Here we show that hRad52 stimulates homologous pairing by hRad51. The DNA-binding properties of hRad52 indicate that Rad52 is involved in an early stage of Rad51-mediated recombination.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			West, Stephen/0000-0001-8848-9418; Benson, Fiona Elizabeth/0000-0002-3918-7015; Baumann, Peter/0000-0003-4892-1485				Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baumann P, 1997, MUTAT RES-DNA REPAIR, V384, P65, DOI 10.1016/S0921-8777(97)00028-1; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KODADEK T, 1989, J BIOL CHEM, V264, P16451; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	26	320	342	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					401	404		10.1038/34937	http://dx.doi.org/10.1038/34937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450758				2022-12-28	WOS:000071604200058
J	Carithers, RL				Carithers, RL			Effect of interferon on hepatitis B	LANCET			English	Editorial Material							ETIOLOGY; VIRUS		Univ Washington, Med Ctr, Dept Med, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle	Carithers, RL (corresponding author), Univ Washington, Med Ctr, Dept Med, Seattle, WA 98105 USA.							BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Evans AA, 1997, J INFECT DIS, V176, P845, DOI 10.1086/516538; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Lau G. K. K., 1997, Hepatology, V26, p259A; LOK ASF, 1990, J HEPATOL, V10, P29, DOI 10.1016/0168-8278(90)90069-4; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	7	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					157	157						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449867				2022-12-28	WOS:000071616300006
J	Koehler, CM; Jarosch, E; Tokatlidis, K; Schmid, K; Schweyen, RJ; Schatz, G				Koehler, CM; Jarosch, E; Tokatlidis, K; Schmid, K; Schweyen, RJ; Schatz, G			Import of mitochondrial carriers mediated by essential proteins of the intermembrane space	SCIENCE			English	Article							ADP-ATP CARRIER; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; INNER MEMBRANE; TRANSLOCATION; MUTAGENESIS; CONTAINS; STEPS	In order to reach the inner membrane of the mitochondrion, multispanning carrier proteins must cross the aqueous intermembrane space. Two essential proteins of that space, Tim10p and Tim12p, were shown to mediate import of multispanning carriers into the inner membrane. Both proteins formed a complex with the inner membrane protein Tim22p. Tim10p readily dissociated from the complex and was required to transport carrier precursors across the outer membrane; Tim12p was firmly bound to Tim22p and mediated the insertion of carriers into the inner membrane. Neither protein was required for protein import into the other mitochondrial compartments. Both proteins may function as intermembrane space chaperones for the highly insoluble carrier proteins.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Univ Vienna, Inst Mikrobiol & Genet, A-1030 Vienna, Austria	University of Basel; University of Vienna	Schatz, G (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Tokatlidis, Kostas/0000-0001-6295-8183; Jarosch, Ernst/0000-0002-5897-3492				ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; [Anonymous], 1991, Methods Enzymol, V194, P1; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEITZ RD, 1991, YEAST, V7, P253; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KOEHLER CM, UNPUB; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; STAPLES RR, 1993, GENETICS, V135, P981; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780	32	258	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					369	373		10.1126/science.279.5349.369	http://dx.doi.org/10.1126/science.279.5349.369			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430585				2022-12-28	WOS:000071570800043
J	[Anonymous]				[Anonymous]			Needle exchange programmes in the USA: time to act now	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	1998	351	9096					75	75						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439484				2022-12-28	WOS:000071591900001
J	Bloom, BR				Bloom, BR			The highest attainable standard: Ethical issues in AIDS vaccines	SCIENCE			English	Article							CONTROLLED TRIAL; PERTUSSIS		Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Bloom, BR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA.	bloom@aecom.yu.edu						Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CIOMS WHO, 1982, INT ETH GUID BIOM RE; CJ Murray, 1996, GLOBAL BURDEN DIS CO, VI; Council of Europe, 1997, CONV PROT HUM RIGHTS; deWachter MAM, 1997, HASTINGS CENT REP, V27, P13, DOI 10.2307/3528021; Dommel FW, 1997, KENNEDY INST ETHIC J, V7, P259, DOI 10.1353/ken.1997.0023; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; MELLORS JW, 1997, ANN INTERN MED, V126, P12946; *NAT COMM PROT HUM, 1988, BELM REP ETH PRINC G; RIIS P, COMMUNICATION; *UNAIDS, 1997, P M HELD 23 24 SEPT; *US PHS, 1990, CONS INT COLL HUM IM; VanHeyningen WE, 1983, CHOLERA AM SCI EXPER; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Medical Association, 1964, DECL HELS	20	55	56	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					186	188		10.1126/science.279.5348.186	http://dx.doi.org/10.1126/science.279.5348.186			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9446225				2022-12-28	WOS:000071408100027
J	Ge, NH; Wong, CM; Lingle, RL; McNeill, JD; Gaffney, KJ; Harris, CB				Ge, NH; Wong, CM; Lingle, RL; McNeill, JD; Gaffney, KJ; Harris, CB			Femtosecond dynamics of electron localization at interfaces	SCIENCE			English	Article							2-PHOTON PHOTOEMISSION; POLARONS; CRYSTALS	The dynamics of two-dimensional smalt-polaron formation at ultrathin alkane layers on a silver(111) surface have been studied with femtosecond time-and angle-resolved two-photon photoemission spectroscopy. Optical excitation creates interfacial electrons in quasi-free states fbr motion parallel to the interface, These initially delocalized electrons self-trap as small polarons in a localized state within a few hundred femtoseconds. The localized electrons then decay back to the metal within picoseconds by tunneling through the adlayer potential barrier, The energy dependence of the self-trapping rate has been measured and modeled with a theory analogous to electron transfer theory. This analysis determines the inter-and intramolecular vibrational modes of the overlayer responsible for self-trapping as well as the relaxation energy of the overlayer molecular lattice. These results for a model interface contribute to the fundamental picture of electron behavior in weakly bonded solids and can lead to better understanding of carrier dynamics in many different systems, including organic light-emitting diodes.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Harris, CB (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	harris@socrates.berkeley.edu	McNeill, Jason/E-5389-2011; Gaffney, Kelly/AAG-7136-2020; Gaffney, Kelly J/N-1597-2017	Gaffney, Kelly J/0000-0002-0525-6465; Ge, Nien-Hui/0000-0002-0011-0790				BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; BURNS AR, 1993, DESORPTION INDUCED E; ECHENIQUE PM, 1989, PROG SURF SCI, V32, P111, DOI 10.1016/0079-6816(89)90015-4; EFRIMA S, 1976, CHEM PHYS, V13, P447, DOI 10.1016/0301-0104(76)87014-0; EMIN D, 1976, PHYS REV LETT, V36, P323, DOI 10.1103/PhysRevLett.36.323; FAUSTER T, 1995, PHOTONIC PROBES SURF, P347; FIRMENT LE, 1978, J CHEM PHYS, V69, P3940, DOI 10.1063/1.437132; FISHER AJ, 1989, J PHYS-CONDENS MAT, V1, P5567, DOI 10.1088/0953-8984/1/33/001; GIESEN K, 1985, PHYS REV LETT, V55, P300, DOI 10.1103/PhysRevLett.55.300; GILBERT TL, 1966, UNPUB LECT NOTES NAT; Hayes W., 1985, DEFECTS DEFECT PROCE; Hofer U, 1997, SCIENCE, V277, P1480, DOI 10.1126/science.277.5331.1480; HOLSTEIN T, 1959, ANN PHYS-NEW YORK, V8, P325, DOI 10.1016/0003-4916(59)90002-8; HOLSTEIN T, 1959, ANN PHYS-NEW YORK, V8, P343, DOI 10.1016/0003-4916(59)90003-X; Landau L. D., 1933, PHYS Z SOWJETUNION, V3, P664; LINGLE RL, 1994, PHYS REV LETT, V72, P2243, DOI 10.1103/PhysRevLett.72.2243; Lingle RL, 1996, CHEM PHYS, V205, P191, DOI 10.1016/0301-0104(95)00375-4; Lingle RL, 1996, CHEM PHYS, V208, P297, DOI 10.1016/0301-0104(96)00136-X; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MIHAILOVIC D, 1995, ANHARMONIC PROPERTIE; PADOWITZ DF, 1992, PHYS REV LETT, V69, P3583, DOI 10.1103/PhysRevLett.69.3583; RASHBA EI, 1957, OPT SPEKTROSK+, V2, P75; SHLUGER AL, 1993, J PHYS-CONDENS MAT, V5, P3049, DOI 10.1088/0953-8984/5/19/007; Silinsh E. A., 1994, ORGANIC MOL CRYSTALS; SNYDER RG, 1967, J CHEM PHYS, V47, P1316, DOI 10.1063/1.1712087; Song K. S., 1993, SELF TRAPPED EXCITON; STUCHEBRUKHOV AA, 1994, J CHEM PHYS, V101, P9354, DOI 10.1063/1.468444; SUMI H, 1995, P SOC PHOTO-OPT INS, V2362, P108, DOI 10.1117/12.200939; TOYOZAWA Y, 1980, J PHYS SOC JPN, V48, P472, DOI 10.1143/JPSJ.48.472; TOYOZAWA Y, 1961, PROG THEOR PHYS, V26, P29, DOI 10.1143/PTP.26.29; Toyozawa Y., 1980, Relaxation of Elementary Excitations. Proceedings of the Taniguchi International Symposium, P3; Ulstrup J., 1979, CHARGE TRANSFER PROC, DOI 10.1007/978-3-642-93116-1	33	206	210	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					202	205		10.1126/science.279.5348.202	http://dx.doi.org/10.1126/science.279.5348.202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422687				2022-12-28	WOS:000071408100034
J	Phelan, P; Stebbings, LA; Baines, RA; Bacon, JP; Davies, JA; Ford, C				Phelan, P; Stebbings, LA; Baines, RA; Bacon, JP; Davies, JA; Ford, C			Drosophila Shaking-B protein forms gap junctions in paired Xenopus oocytes	NATURE			English	Article							GIANT FIBER SYSTEM; SYNAPTIC CONNECTIVITY; MOLECULAR-BASIS; NERVOUS-SYSTEM; VOLTAGE; EXPRESSION; MELANOGASTER; CONNEXINS; MUTATIONS; LOCUS	In most multicellular organisms direct cell-cell communication is mediated by the intercellular channels of gap junctions. These channels allow the exchange of ions and molecules that are believed to be essential for cell signalling during development and in some differentiated tissues, Proteins called connexins, which are products of a multigene family, are the structural components of vertebrate gap junctions(1,2). Surprisingly, molecular homologues of the connexins have not been described in any invertebrate. A separate gene family, which includes the Drosophila genes shaking-B and l(1)ogre, and the Caenorhabditis elegans genes unc-7 and eat-5, encodes transmembrane proteins with a predicted structure similar to that of the connexins(3-9). shaking-B and eat-5 are required for the formation of functional gap junctions(8,10). To test directly whether Shaking-B is a channel protein, we expressed it in paired Xenopus oocytes. Here we show that Shaking-B localizes to the membrane, and that its presence induces the formation of functional intercellular channels. To our knowledge, this is the first structural component of an invertebrate gap junction to be characterized.	Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England; Univ Sussex, Sch Biol Sci, Dept Genet & Dev, Brighton BN1 9QG, E Sussex, England	University of Sussex; University of Sussex	Phelan, P (corresponding author), Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England.	bafb5@central.sussex.ac.uk		Phelan, Pauline/0000-0002-9348-837X; Baines, Richard/0000-0001-8571-4376				BARNES TM, 1994, TRENDS GENET, V10, P303, DOI 10.1016/0168-9525(94)90023-X; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BRUZZONE R, 1995, FEBS LETT, V358, P301, DOI 10.1016/0014-5793(94)01457-C; BRUZZONE R, 1994, J CELL SCI, V107, P955; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEVALIER S, 1995, J CELL SCI, V108, P1831; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CROMPTON D, 1995, DEV BIOL, V170, P142, DOI 10.1006/dbio.1995.1203; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; GHO M, 1994, J PHYSIOL-LONDON, V481, P371, DOI 10.1113/jphysiol.1994.sp020446; HANSEN P, 1981, STAIN TECHNOL, V56, P287; HENNEMANN H, 1992, J BIOL CHEM, V267, P17225; HOMYK T, 1980, MOL GEN GENET, V177, P553; KRISHNAN SN, 1993, CELL, V73, P967, DOI 10.1016/0092-8674(93)90274-T; KRISHNAN SN, 1995, P NATL ACAD SCI USA, V92, P2021, DOI 10.1073/pnas.92.6.2021; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Phelan P, 1996, J NEUROSCI, V16, P1101; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; STARICH TA, 1993, GENETICS, V133, P527; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; THOMAS JB, 1984, J NEUROSCI, V4, P530; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; WATANABE T, 1990, GENETICS, V126, P1033; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 1996, J BIOENERG BIOMEMBR, V28, P319, DOI 10.1007/BF02110108	26	132	139	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					181	184		10.1038/34426	http://dx.doi.org/10.1038/34426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428764				2022-12-28	WOS:000071380900052
J	Chaturvedi, N; Sjolie, AK; Stephenson, JM; Abrahamian, H; Keipes, M; Castellarin, A; Rogulja-Pepeonik, Z; Fuller, JH				Chaturvedi, N; Sjolie, AK; Stephenson, JM; Abrahamian, H; Keipes, M; Castellarin, A; Rogulja-Pepeonik, Z; Fuller, JH		EUCLID Study Grp	Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes	LANCET			English	Article							ANGIOTENSIN-CONVERTING ENZYME; BLOOD-RETINA BARRIER; BACKGROUND RETINOPATHY; INHIBITION; PERMEABILITY; NEPHROPATHY; PRESSURE; RISK; IDDM	Background Retinopathy commonly occurs in people with type 1 diabetes. Strict glycaemic control can decrease development and progression of retinopathy only partially. Blood pressure is also a risk factor for microvascular complications. Antihypertensive therapy, especially with inhibitors of angiotensin-converting enzyme (ACE), can slow progression of nephropathy, but the effects on retinopathy have not been established. We investigated the effect of lisinopril on retinopathy in type 1 diabetes. Methods As part of a 2-year randomised double-blind placebo-controlled trial, we took retinal photographs at baseline and follow-up (24 months) in patients aged 20-59 in 15 European centres. Patients were not hypertensive, and were normoalbuminuric (85%) or microalbuminuric. Retinopathy was classified from photographs on a five-fever scale (none to proliferative). Findings The proportion of patients with retinopathy at baseline was 65% (117) in the placebo group and 59% (103) in the lisinopril group (p=0.2). Patients on lisinopril had significantly lower HbA(1c) at baseline than those on placebo (6.9% vs 7.3 p=0.05). Retinopathy progressed by at least one level in 21 (13.2%) of 159 patients on lisinopril and 39 (23.4%) of 166 patients on placebo (odds ratio 0.50 [95% CI 0.28-0.89], p=0.02). This 50% reduction was the same when adjusted for centre and glycaemic control (0.55 [0.30-1.03], p=0.06). Lisinopril also decreased progression by two or move grades (0.27 [0.07-1.00], p=0.05), and progression to proliferative retinopathy (0.18 [0.04-0.82], p=0.03). Progression was not associated with albuminuric status at baseline. Treatment reduced retinopathy incidence (0.69 [0.30-1.59], p=0.4). Interpretation Lisinopril may decrease retinopathy progression in non-hypertensive patients who have type 1 diabetes with little or no nephropathy. These findings need to be confirmed before changes to clinical practice can be advocated.	UCL, Dept Epidemiol & Publ Hlth, EURODIAB, London WC1E 6BT, England; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Lainz Hosp, A-1130 Vienna, Austria; L Boltzmann Res Inst Metab Dis & Nutr, Vienna, Austria; Univ Verona, I-37100 Verona, Italy; Vuk Vrhovac Inst, Zagreb, Croatia	University of London; University College London; Aarhus University; University of Verona	Chaturvedi, N (corresponding author), UCL, Dept Epidemiol & Publ Hlth, EURODIAB, Mortimer St, London WC1E 6BT, England.	nish@public-health.ucl.ac.uk						ALDINGTON SJ, 1995, DIABETOLOGIA, V38, P437, DOI 10.1007/BF00410281; Boner G, 1996, DIABETOLOGIA, V39, P587; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; CHASE HP, 1993, ANN OPHTHALMOL, V25, P284; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DWYER MS, 1985, DIABETES CARE, V8, P316, DOI 10.2337/diacare.8.4.316; ENGLER CB, 1991, ACTA OPHTHALMOL, V69, P581; FEMAN SS, 1993, AM J MED SCI, V305, P280, DOI 10.1097/00000441-199305000-00002; HERMAN WH, 1994, DIABETES REV, V2, P384; JACKSON WE, 1992, ANN OPHTHALMOL, V24, P99; JANKA HU, 1989, DIABETES, V38, P460, DOI 10.2337/diabetes.38.4.460; JOHN WG, 1993, CLIN CHEM, V39, P663; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1989, ARCH INTERN MED, V149, P2427, DOI 10.1001/archinte.149.11.2427; LARSEN M, 1990, GRAEF ARCH CLIN EXP, V228, P505, DOI 10.1007/BF00918480; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MANTEL N, 1959, J NATL CANCER I, V22, P719; PARVING HH, 1989, DIABETOLOGIA, V32, P440, DOI 10.1007/BF00271264; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sjolie AK, 1997, OPHTHALMOLOGY, V104, P252, DOI 10.1016/S0161-6420(97)30327-3; STEPHENSON J, 1994, DIABETOLOGIA, V37, P278, DOI 10.1007/BF00398055; TEUSCHER A, 1988, DIABETES CARE, V11, P246, DOI 10.2337/diacare.11.3.246; Woolf B., 1995, ANN HUM GENET, V19, P251	27	543	580	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	1998	351	9095					28	31		10.1016/S0140-6736(97)06209-0	http://dx.doi.org/10.1016/S0140-6736(97)06209-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433426				2022-12-28	WOS:000071253100013
J	Oum, KW; Lakin, MJ; DeHaan, DO; Brauers, T; Finlayson-Pitts, BJ				Oum, KW; Lakin, MJ; DeHaan, DO; Brauers, T; Finlayson-Pitts, BJ			Formation of molecular chlorine from the photolysis of ozone and aqueous sea-salt particles	SCIENCE			English	Article							MARINE BOUNDARY-LAYER; AEROSOL; WATERS; GASES	Halogen atoms from the reactions of sea-salt particles may play a significant role in the marine boundary layer, Reactions of sodium chloride, the major component of sea-salt particles, with nitrogen oxides generate chlorine atom precursors, However, recent studies suggest there is an additional source of chlorine in the marine troposphere, This study shows that molecular chlorine is generated from the photolysis of ozone in the presence of sea-salt particles above their deliquescence point; this process may also occur in the ocean surface layer. Given the global distribution of ozone, this process may provide a global source of chlorine.	Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	DeHaan, DO (corresponding author), Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.	bjfinlay@uci.edu	Brauers, Theo/A-8444-2008	Brauers, Theo/0000-0001-6671-8566; Finlayson-Pitts, Barbara/0000-0003-4650-168X				ALBEICJURETIC A, 1992, BER BUNSEN PHYS CHEM, V96, P493; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Atkinson R, 1997, J PHYS CHEM REF DATA, V26, P215, DOI 10.1063/1.556012; Behnke W, 1995, ENVIRON CHEM, V1, P375; CAHILL TA, 1992, J GEOPHYS RES-ATMOS, V97, P14513, DOI 10.1029/92JD01373; DEHAAN DO, IN PRESS J PHYS CHEM; Finlayson-Pitts B.J., 1986, ATMOSPHERIC CHEM FUN; FinlaysonPitts BJ, 1997, SCIENCE, V276, P1045, DOI 10.1126/science.276.5315.1045; FINLAYSONPITTS BJ, 1993, RES CHEM INTERMEDIAT, V19, P235, DOI 10.1163/156856793X00091; Gong SL, 1997, J GEOPHYS RES-ATMOS, V102, P3819, DOI 10.1029/96JD03401; GRAEDEL TE, 1995, GLOBAL BIOGEOCHEM CY, V9, P47, DOI 10.1029/94GB03103; Gurol MD, 1996, AICHE J, V42, P3283, DOI 10.1002/aic.690421128; Impey GA, 1997, J GEOPHYS RES-ATMOS, V102, P16005, DOI 10.1029/97JD00851; Impey GA, 1997, J GEOPHYS RES-ATMOS, V102, P15999, DOI 10.1029/97JD00850; JAYSON GG, 1973, J CHEM SOC FARAD T 1, V69, P1597, DOI DOI 10.1039/F19736901597; KEENE WC, 1993, ENVIRON SCI TECHNOL, V27, P866, DOI 10.1021/es00042a008; KEENE WC, COMMUNICATION; KEENE WC, 1996, ATMOS ENVIRON, V30, P1; Keene WC, 1990, GLOBAL BIOGEOCHEM CY, V4, P407, DOI 10.1029/GB004i004p00407; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; ODowd CD, 1997, ATMOS ENVIRON, V31, P73, DOI 10.1016/S1352-2310(96)00106-9; ODOWD CD, 1993, J GEOPHYS RES-ATMOS, V98, P1137, DOI 10.1029/92JD02302; PEYTON GR, 1988, ENVIRON SCI TECHNOL, V22, P761, DOI 10.1021/es00172a003; PSZENNY AAP, 1993, GEOPHYS RES LETT, V20, P699, DOI 10.1029/93GL00047; RAMANATHAN V, 1988, SCIENCE, V240, P293, DOI 10.1126/science.240.4850.293; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; Ruggaber A, 1997, ATMOS ENVIRON, V31, P3137, DOI 10.1016/S1352-2310(97)00058-7; Sander R, 1996, J GEOPHYS RES-ATMOS, V101, P9121, DOI 10.1029/95JD03793; SINGH HB, 1988, J ATMOS CHEM, V7, P261, DOI 10.1007/BF00130933; SMITH RC, 1979, PHOTOCHEM PHOTOBIOL, V29, P311, DOI 10.1111/j.1751-1097.1979.tb07054.x; SPICER CW, UNPUB; TAUBE H, 1957, T FARADAY SOC, V53, P656, DOI 10.1039/tf9575300656; Vogt R, 1996, NATURE, V383, P327, DOI 10.1038/383327a0; VONGUNTEN U, 1994, ENVIRON SCI TECHNOL, V28, P1234, DOI 10.1021/es00056a009; WAGNER I, 1986, BER BUNSEN PHYS CHEM, V90, P864	35	275	279	4	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	1998	279	5347					74	77		10.1126/science.279.5347.74	http://dx.doi.org/10.1126/science.279.5347.74			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417027				2022-12-28	WOS:000071323900042
J	Sharp, PA; Burge, CB				Sharp, PA; Burge, CB			Classification of introns: U2-type or U12-type	CELL			English	Review							SPLICE SITES; AT-AC; NUCLEAR		MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sharp, PA (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.		Burge, Christopher B./AAH-2177-2020					AnsariLari MA, 1997, GENOME RES, V7, P268, DOI 10.1101/gr.7.3.268; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; DIETRICH RC, 1997, IN PRESS MOL CELL; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Kolossova I, 1997, RNA, V3, P227; Luukkonen BGM, 1997, EMBO J, V16, P779, DOI 10.1093/emboj/16.4.779; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Tarn WY, 1996, SCIENCE, V273, P1824, DOI 10.1126/science.273.5283.1824; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; TARN WY, 1996, CELL, V84, P1; Wu Q, 1996, SCIENCE, V274, P1005, DOI 10.1126/science.274.5289.1005; Wu Q, 1997, RNA, V3, P586	15	202	208	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					875	879		10.1016/S0092-8674(00)80479-1	http://dx.doi.org/10.1016/S0092-8674(00)80479-1			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428511	Bronze			2022-12-28	WOS:000071281400005
J	Black, JA				Black, JA			History - Two hundred Years since Malthus	BRITISH MEDICAL JOURNAL			English	Article									Victoria Mill House, Woodbridge IP13 9EG, Suffolk, England		Black, JA (corresponding author), Victoria Mill House, Woodbridge IP13 9EG, Suffolk, England.							DARWIN C, 1871, DESCENT MAN SELECTIO, P134; HAMMOND JL, 1995, VILLAGE LABOURER 176, P100; JOHNSON I, 1798, ESSAY PRINCIPLE POPU; Malthus Thomas, 1803, ESSAY PRINCIPLE POPU, P531; Meadows D., 1972, LIMITS GROWTH; WRIGLEY EA, 1981, POPULATION HIST ENGL, P403	6	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1686	1689		10.1136/bmj.315.7123.1686	http://dx.doi.org/10.1136/bmj.315.7123.1686			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448542	Green Published			2022-12-28	WOS:000071149400028
J	Wells, PS; Anderson, DR; Bormanis, J; Guy, F; Mitchell, M; Gray, L; Clement, C; Robinson, KS; Lewandowski, B				Wells, PS; Anderson, DR; Bormanis, J; Guy, F; Mitchell, M; Gray, L; Clement, C; Robinson, KS; Lewandowski, B			Value of assessment of pretest probability of deep-vein thrombosis in clinical management	LANCET			English	Article							IMPEDANCE PLETHYSMOGRAPHY; VENOUS THROMBOSIS; COMPRESSION ULTRASONOGRAPHY; OUTPATIENTS; DIAGNOSIS; ACCURACY; TRIAL	Background When ultrasonography is used to investigate deep-vein thrombosis, serial testing is recommended for those who test negative initially. Serial testing is inconvenient for patients and costly. We aimed to assess whether the calculation of pretest probability of deep-vein thrombosis, with a simple clinical model, could be used to improve the management of patients who present with suspected deep-vein thrombosis. Methods Consecutive outpatients with suspected deep-vein thrombosis had their pretest probability calculated with a clinical model. They then underwent compression ultrasound imaging of proximal veins of the legs. Patients at low pretest probability underwent a single ultrasound test. A negative ultrasound excluded the diagnosis of deep-vein thrombosis whereas a positive ultrasound was confirmed by venography. Patients at moderate pretest probability with a positive ultrasound were treated for deep-vein thrombosis patients with an initial negative ultrasound a single follow-up ultrasound 1 week later. at high pretest probability with a positive were treated whereas those with negative ultrasound underwent venography. All patients were followed up for 3 months for thromboembolic complications. Findings 95 (16.0%) of all 593 patients had deep-vein thrombosis; 3%, 17%, and 75% of the patients with low, moderate, and high pretest probability, respectively, had deep-vein thrombosis. Ten of 329 patients with low pretest probability had the diagnosis confirmed, nine at initial testing and one at follow-up. 32 of 193 patients with moderate pretest probability had deep-vein thrombosis, three diagnosed by the serial (1 week) test, and two during follow-up. 53 of 71 patients with high pretest probability had deep vein thrombosis (49 by the initial ultrasound and four by venography). Only three (0.6%) of all 501 (95% CI 0.1-1.8) patients diagnosed as not having deep-vein thrombosis had events during the 3-month follow-up. Overall only 33 (56%) of 593 patients required venography and serial testing was limited to 166 (28%) of 593 patients. Interpretation Management of patients with suspected deep vein thrombosis based on clinical probability and ultrasound of the proximal deep veins is safe and feasible. Our strategy reduced the need for serial ultrasound testing and reduced the rate of false-negative or false-positive ultrasound studies.	Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Dept Radiol, Ottawa, ON, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Dalhousie Univ, Dept Radiol, Halifax, NS, Canada	University of Ottawa; University of Ottawa; Dalhousie University; Dalhousie University	Wells, PS (corresponding author), Suite 467,737 Parkdale Ave, Ottawa, ON K1Y 1J8, Canada.			Anderson, David/0000-0003-0845-1722				COGO A, 1997, IN PRESS BMJ; COUSON F, 1993, THROMB HAEMOSTASIS, V70, P573; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, THROMB HAEMOSTASIS, V67, P510; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Rose S C, 1993, J Vasc Interv Radiol, V4, P111, DOI 10.1016/S1051-0443(93)71832-1; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1997, IN PRESS J INT MED	15	732	772	2	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1795	1798		10.1016/S0140-6736(97)08140-3	http://dx.doi.org/10.1016/S0140-6736(97)08140-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428249				2022-12-28	WOS:000071102500007
J	Egeland, GM; Middaugh, JP				Egeland, GM; Middaugh, JP			Balancing fish consumption benefits with mercury exposure	SCIENCE			English	Editorial Material							FETAL METHYLMERCURY; DIET				Egeland, GM (corresponding author), ALASKA DEPT HLTH & SOCIAL SERV,DIV PUBL HLTH,EPIDEMIOL SECT,ANCHORAGE,AK 99524, USA.							Anderson Paul D., 1995, P104; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Bauernfeind J., 1980, Vitamin E, P99; CRUMP K, 1995, RISK ANAL, V15, P523, DOI 10.1111/j.1539-6924.1995.tb00345.x; DAHL R, 1996, NEUROTOXICOL TERATOL, V18, P1; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; *EPA, 1996, EPA452R96001F; GRANDJEAN P, 1995, NEUROTOXICOLOGY, V16, P27; GRANDJEAN P, 1994, CLIN CHEM, V40, P1395; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; GRANDJEAN P, 1997, NEUROTOXICOL TERATOL, V20, P1; Hansen J.C., 1989, Meddelelser om Gronland Man & Society, V12, P161; HOLMAN RT, 1991, P NATL ACAD SCI USA, V88, P4835, DOI 10.1073/pnas.88.11.4835; IPCS, 1990, ENV HLTH CRIT 101 ME; Kinsella JE., 1987, SEAFOODS FISH OILS H; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P717; MARSH DO, 1987, ARCH NEUROL-CHICAGO, V44, P1017, DOI 10.1001/archneur.1987.00520220023010; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P629; *NIH, 1995, EFF FISH OILS POL OM; Shkilnyk A., 1985, POISON STRONGER THAN; SIU KWM, 1989, OCCURRENCE DISTRIBUT, P263; SKERFVING SB, 1976, B WORLD HEALTH ORGAN, V54, P101; TOLLEFSON L, 1986, ENVIRON HEALTH PERSP, V68, P203, DOI 10.2307/3430265; UAUYDAGACH R, 1995, CLIN PERINATOL, V22, P157; USHER PJ, 1995, COMMUNICATING CONTAM; WHEATLEY B, 1994, ARCT MED RES S2, V53, P386	27	117	124	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1904	1905		10.1126/science.278.5345.1904	http://dx.doi.org/10.1126/science.278.5345.1904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417640				2022-12-28	WOS:A1997YL00200023
J	Basso, O; Olsen, J; Johansen, AMT; Christensen, K				Basso, O; Olsen, J; Johansen, AMT; Christensen, K			Change in social status and risk of low birth weight in Denmark: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							FOR-GESTATIONAL-AGE; HEALTH; SMOKING	Objective: To estimate the risk of having a low birth-weight infant associated with changes in social, environmental, and genetic factors. Design: Population based, historical cohort study using the Danish medical birth registry and Statistic Denmark's fertility database. Subjects: All women who had a low birthweight infant (<2500 g) (index birth) and a subsequent liveborn infant (outcome birth) in Denmark between 1980 and 1992 (exposed cohort, n = 11 069) and a random sample of the population who gave birth to an infant weighing greater than or equal to 2500 g and to a subsequent liveborn infant (unexposed cohort, n = 10 211), Main outcome measures: Risk of having a low birthweight infant in the outcome birth as a function of changes in male partner, area of residence, type of job, and social status between the two births. Results: Women in the exposed cohort showed a high risk (18.5%) of having a subsequent low birthweight infant while women in the unexposed cohort had a risk of 2.8%. After adjustment for initial social status, a decline in social statics increased the absolute risk of having a low birthweight infant by about 5% in both cohorts, though this was significant only in the unexposed cohort, Change of male partner did not modify the risk of low birth weight in either cohort. Conclusion: Having had a low birthweight infant and a decline in social status are strong risk factors for having a low birthweight infant subsequently.	DANISH NATL BOARD HLTH,COPENHAGEN,DENMARK; ODENSE UNIV,CTR HLTH & SOCIAL POLICY,DK-5230 ODENSE M,DENMARK	University of Southern Denmark	Basso, O (corresponding author), AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL & SOCIAL MED,GULDBERGSGADE 10,DK-8000 AARHUS C,DENMARK.		Christensen, Kaare/C-2360-2009; Basso, Olga/E-5384-2010	Christensen, Kaare/0000-0002-5429-5292; Basso, Olga/0000-0001-9298-4921				BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; BAKKETEIG LS, 1986, EARLY HUM DEV, V14, P187, DOI 10.1016/0378-3782(86)90180-5; Bartley M, 1996, BRIT MED J, V313, P445; *DANM STAT, 1996, FERT DAT; *DANM STAT, 1986, DANM STAT ERHV 1 APR; KLINE J, 1989, CONCEPTION BIRTH EPI, P231; KNUDSEN LB, 1993, VITALSTATISTIK, V1, P33; LAHELMA E, 1989, UNEMPLOYMENT POVERTY, P135; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; MacGillivray I, 1988, TWINNING TWINS; MORRISON J, 1991, AUST NZ J OBSTET GYN, V31, P114, DOI 10.1111/j.1479-828X.1991.tb01795.x; MORTON NE, 1955, ANN HUM GENET, V20, P125; MUTALE T, 1991, BRIT J OBSTET GYNAEC, V98, P166, DOI 10.1111/j.1471-0528.1991.tb13363.x; Nordentoft M, 1996, AM J PUBLIC HEALTH, V86, P347, DOI 10.2105/AJPH.86.3.347; NORDSTROM ML, 1996, SCAND J SOC MED, V1, P55; OLSEN J, 1993, SCAND J SOC MED, V21, P90, DOI 10.1177/140349489302100206; Olsen J, 1997, EPIDEMIOLOGY, V8, P6, DOI 10.1097/00001648-199701000-00001; Power C, 1996, BRIT MED J, V313, P449; RAINE T, 1994, OBSTET GYNECOL, V84, P485; Read A W, 1993, Paediatr Perinat Epidemiol, V7, P177, DOI 10.1111/j.1365-3016.1993.tb00392.x; Read A W, 1991, Paediatr Perinat Epidemiol, V5, P138, DOI 10.1111/j.1365-3016.1991.tb00695.x; RUSH D, 1983, J EPIDEMIOL COMMUN H, V37, P249, DOI 10.1136/jech.37.4.249; *SUNDH, 1995, MED FODS 1993, P2; VLIETINCK R, 1989, BEHAV GENET, V19, P151, DOI 10.1007/BF01065890; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WILCOX MA, 1995, ACTA OBSTET GYN SCAN, V74, P15, DOI 10.3109/00016349509009936	26	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1498	1502		10.1136/bmj.315.7121.1498	http://dx.doi.org/10.1136/bmj.315.7121.1498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK986	9420490	Green Published			2022-12-28	WOS:A1997YK98600019
J	Parolini, O; Ressmann, G; Haas, OA; Pawlowsky, J; Gadner, H; Knapp, W; Holter, W				Parolini, O; Ressmann, G; Haas, OA; Pawlowsky, J; Gadner, H; Knapp, W; Holter, W			X-linked Wiskott-Aldrich syndrome in a girl	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOSOME-INACTIVATION; GENE; MUTATIONS; IDENTIFICATION; METHYLATION; FEMALE; CARRIERS; NONSENSE; REPEAT; FAMILY		Univ Vienna, NFI, Inst Immunol VIRCC, A-1235 Vienna, Austria; St Anna Childrens Hosp, A-1090 Vienna, Austria	Novartis; University of Vienna; Saint Anna Children's Hospital	Parolini, O (corresponding author), Univ Vienna, NFI, Inst Immunol VIRCC, Brunnerstr 59, A-1235 Vienna, Austria.		Haas, Oskar/AAM-5794-2020; PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020	PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430				ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Aral B, 1996, HUM MUTAT, V7, P52, DOI 10.1002/(SICI)1098-1004(1996)7:1<52::AID-HUMU7>3.3.CO;2-0; AZOFEIFA J, 1995, HUM GENET, V96, P167, DOI 10.1007/BF00207374; Belmont JW, 1996, AM J HUM GENET, V58, P1101; CLARKE JTR, 1991, AM J HUM GENET, V49, P289; CONLEY ME, 1992, BLOOD, V80, P1264; DERRY JM, 1994, CELL, V79, pA922; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; FEARON ER, 1988, BLOOD, V72, P1735; GREER WL, 1989, GENOMICS, V4, P60, DOI 10.1016/0888-7543(89)90315-7; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; KONDOH T, 1995, AM J MED GENET, V60, P364, DOI 10.1002/ajmg.1320600504; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; LYON MF, 1974, PROC R SOC SER B-BIO, V187, P243, DOI 10.1098/rspb.1974.0073; Naumova AK, 1996, AM J HUM GENET, V58, P1111; NISEN PD, 1989, J CLIN INVEST, V83, P1400, DOI 10.1172/JCI114028; Parolini O, 1997, BLOOD, V90, P70; Plenge R. M., 1995, American Journal of Human Genetics, V57, pA30; RemoldODonnell E, 1996, BLOOD, V87, P2621, DOI 10.1182/blood.V87.7.2621.bloodjournal8772621; RUSSELL SJ, 1995, BRIT J HAEMATOL, V90, P210; Schwarz K, 1996, IMMUNOL TODAY, V17, P496, DOI 10.1016/0167-5699(96)30061-3; Smith CIE, 1997, ADV GENET, V35, P57, DOI 10.1016/S0065-2660(08)60448-4; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; WENGLER G, 1995, BLOOD, V85, P2471, DOI 10.1182/blood.V85.9.2471.bloodjournal8592471; WENGLER GS, 1995, BLOOD, V86, P3648, DOI 10.1182/blood.V86.10.3648.bloodjournal86103648; Wengler GS, 1997, LIFE SCI, V61, P1405, DOI 10.1016/S0024-3205(97)00686-3	27	79	80	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					291	295		10.1056/NEJM199801293380504	http://dx.doi.org/10.1056/NEJM199801293380504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445409				2022-12-28	WOS:000071665200004
J	Hall, A				Hall, A			Rho GTPases and the actin cytoskeleton	SCIENCE			English	Article							GTP-BINDING PROTEIN; WISKOTT-ALDRICH SYNDROME; CELL-CYCLE PROGRESSION; MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; NEURITE RETRACTION; SIGNALING PATHWAY; STRESS FIBERS; CDC42 GTPASES; JUN KINASE	The actin cytoskeleton mediates a variety of essential biological functions in all eukaryotic cells. in addition to providing a structural framework around which cell shape and polarity are defined, its dynamic properties provide the driving force for cells to move and to divide. Understanding the biochemical mechanisms that control the organization of actin is thus a major goal of contemporary cell biology, with implications for health and disease. Members of the Rho family of small guanosine triphosphatases have emerged as key regulators of the actin cytoskeleton, and furthermore, through their interaction with multiple target proteins, they ensure coordinated control of other cellular activities such as gene transcription and adhesion.	Univ London Univ Coll, Canc Res Campaign, Oncogene & Signal Transduct Grp, MRC,Lab Mol Cell Biol, London WC1E 6BT, England	University of London; University College London	Hall, A (corresponding author), Univ London Univ Coll, Canc Res Campaign, Oncogene & Signal Transduct Grp, MRC,Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Allen WE, 1997, J CELL SCI, V110, P707; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DRECHSEL D, UNPUB; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOSHRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Leung T, 1996, MOL CELL BIOL, V16, P5313; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; NOBES CD, UNPUB; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; PRESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; SCHMIDT A, 1997, CELL, V88, P1; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Suidan HS, 1997, GLIA, V21, P244, DOI 10.1002/(SICI)1098-1136(199710)21:2<244::AID-GLIA7>3.0.CO;2-6; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tigyi G, 1996, J NEUROCHEM, V66, P549; VANELST L, 1997, GENE DEV, V11, P2295; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG S, 1996, CURR BIOL, V6, P598; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	76	5081	5236	14	527	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					509	514		10.1126/science.279.5350.509	http://dx.doi.org/10.1126/science.279.5350.509			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438836				2022-12-28	WOS:000071616000033
J	Hsia, CCW				Hsia, CCW			Mechanisms of disease - Respiratory function of hemoglobin	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PULMONARY GAS-EXCHANGE; OXYGEN-AFFINITY; HIGH-ALTITUDE; EXTREME ALTITUDE; MOUNT EVEREST; SEA-LEVEL; BLOOD; ADAPTATION; ORIGINS; HYPOXIA		Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsia, CCW (corresponding author), Univ Texas, SW Med Ctr, Dept Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Aste-Salazar H, 1944, AM J PHYSIOL, V142, P0733, DOI 10.1152/ajplegacy.1944.142.5.733; BAUER C, 1972, J PHYSIOL-LONDON, V227, P457, DOI 10.1113/jphysiol.1972.sp010042; BEALL CM, 1987, AM J PHYS ANTHROPOL, V73, P433, DOI 10.1002/ajpa.1330730404; Bohr C, 1904, SKAND ARCH PHYSIOL, V16, P402, DOI 10.1111/j.1748-1716.1904.tb01382.x; BUNN HF, 1970, NEW ENGL J MED, V282, P1414; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHIODI H, 1957, J APPL PHYSIOL, V10, P81, DOI 10.1152/jappl.1957.10.1.81; Christiansen J, 1914, J PHYSIOL-LONDON, V48, P244; DEMPSEY JA, 1975, J APPL PHYSIOL, V38, P1022, DOI 10.1152/jappl.1975.38.6.1022; DEMPSEY JA, 1984, J PHYSIOL-LONDON, V355, P161, DOI 10.1113/jphysiol.1984.sp015412; EATON JW, 1974, SCIENCE, V183, P743, DOI 10.1126/science.183.4126.743; EDSALL JT, 1986, PERSPECT BIOL MED, V29, pS107; EDSALL JT, 1980, FED PROC, V39, P226; FORSTER RE, 1992, KIDNEY PHYSL PATHOPH, V1, P171; FRISANCHO AR, 1988, RESP PHYSIOL, V72, P13, DOI 10.1016/0034-5687(88)90075-8; GILL SJ, 1979, J MOL BIOL, V130, P175, DOI 10.1016/0022-2836(79)90425-X; GROTE J, 1994, ADV EXP MED BIOL, V345, P145; Heath D., 1981, MAN HIGH ALTITUDE PA; HEBBEL RP, 1978, J CLIN INVEST, V62, P593, DOI 10.1172/JCI109165; Imai K., 1982, ALLOSTERIC EFFECTS H; JESSEN TH, 1991, P NATL ACAD SCI USA, V88, P6519, DOI 10.1073/pnas.88.15.6519; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOHNSON RL, 1977, CLIN CARDIOL, V1, P74; JOHNSON RL, 1992, KIDNEY PHYSL PATHOPH, V1, P193; Johnson RLJ, 1996, HDB PHYSIOL 12, P515; KELMAN GR, 1966, J APPL PHYSIOL, V21, P1484, DOI 10.1152/jappl.1966.21.5.1484; KELMAN GR, 1966, J APPL PHYSIOL, V21, P1375, DOI 10.1152/jappl.1966.21.4.1375; KILMARTIN JV, 1973, PHYSIOL REV, V53, P836, DOI 10.1152/physrev.1973.53.4.836; KLOCKE RA, 1973, J APPL PHYSIOL, V35, P673, DOI 10.1152/jappl.1973.35.5.673; Lehninger A., 1993, PRINCIPLES BIOCH; LENFANT C, 1969, RESP PHYSIOL, V7, P7, DOI 10.1016/0034-5687(69)90066-8; LENFANT C, 1968, J CLIN INVEST, V47, P2652, DOI 10.1172/JCI105948; Margaria R, 1933, J BIOL CHEM, V102, P611; MITCHELL JH, 1972, KIDNEY INT, V1, P375, DOI 10.1038/ki.1972.48; Monge C., 1990, HYPOXIA ADAPTATIONS, P53; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOORE LG, 1981, J LAB CLIN MED, V98, P145; Perkins J.F.J., 1964, HDB PHYSL 3, VI, P1; PETSCHOW D, 1977, J APPL PHYSIOL, V42, P139, DOI 10.1152/jappl.1977.42.2.139; PIIPER J, 1983, RESP PHYSIOL, V51, P287, DOI 10.1016/0034-5687(83)90023-3; PIIPER J, 1981, RESP PHYSIOL, V46, P193, DOI 10.1016/0034-5687(81)90121-3; Rahn, 1964, HANDBOOK PHYSIOLOG 3, P767; REYNAFARJE C, 1975, J APPL PHYSIOL, V38, P806, DOI 10.1152/jappl.1975.38.5.806; SAMAJA M, 1979, J APPL PHYSIOL, V47, P337, DOI 10.1152/jappl.1979.47.2.337; SEVERINGHAUS JW, 1958, J APPL PHYSIOL, V12, P485, DOI 10.1152/jappl.1958.12.3.485; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; TORRANCE J D, 1970, Respiration Physiology, V11, P1; UEDA Y, 1979, BLOOD, V53, P472; WAGNER PD, 1986, J APPL PHYSIOL, V61, P260, DOI 10.1152/jappl.1986.61.1.260; WEST JB, 1983, J APPL PHYSIOL, V55, P678, DOI 10.1152/jappl.1983.55.3.678; WINSLOW RM, 1985, RESP PHYSIOL, V61, P197, DOI 10.1016/0034-5687(85)90126-4; WINSLOW RM, 1984, J APPL PHYSIOL, V56, P109, DOI 10.1152/jappl.1984.56.1.109; WINSLOW RM, 1991, RESPONSE ADAPTATION, P143; Zhuang JG, 1996, RESP PHYSIOL, V103, P75, DOI 10.1016/0034-5687(95)00041-0	54	140	145	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					239	247		10.1056/NEJM199801223380407	http://dx.doi.org/10.1056/NEJM199801223380407			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435331				2022-12-28	WOS:000071594100007
J	Landon, BE; Tobias, C; Epstein, AM				Landon, BE; Tobias, C; Epstein, AM			Quality management by state Medicaid agencies converting to managed care - Plans and current practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Enrollment in Medicaid managed care plans has increased more than 5-fold in this decade, but how states monitor and encourage quality of care in these programs is not known. Objective.-To characterize the quality monitoring and assurance activities of state Medicaid agencies for Medicaid beneficiaries enrolled in comprehensive prepaid managed care programs. Design.-Structured telephone survey conducted between October 1996 and January 1997. Setting.-State Medicaid agencies. Participants.-Representatives from all state Medicaid agencies, including the District of Columbia, with beneficiaries enrolled in comprehensive prepaid managed care plans as of July 1, 1996. Main Outcome Measures.-Proportion of states with specific quality monitoring and assurance activities for Medicaid managed care. Results.-We surveyed all 34 states enrolling beneficiaries in comprehensive managed care programs. In 1996, all 34 states enrolled the population receiving assistance from the Aid to Families With Dependent Children (AFDC) program, while only 21 (62%) and 15 (44%) enrolled the disabled and elderly populations, respectively. In the period 1995 to 1996, 19 states (63%) collected data on satisfaction with care, and 25 states (83%) collected data on childhood immunizations, No more than half of the states collected data on other selected measures of access and quality, but a substantial number planned to collect such data in 1997, While at most 37% of states were providing comparative data to health plans, up to 80% were planning to provide such information in 1997. Similarly, while at most 10% of states provided beneficiaries with such information, up to 38% planned to do so in 1997. The breadth of contracting requirements designed to assure quality varied substantially across states. Conclusions.-State Medicaid agencies have already begun adapting to their new roles as purchasers of health care. Continued monitoring is essential to ensure that state agencies implement planned programs and that quality of care for Medicaid enrollees is preserved or improved.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Boston Univ, Sch Publ Hlth, Medicaid Working Grp, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University	Epstein, AM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.				BHP HRSA HHS [5T 32 PE11001-8] Funding Source: Medline	BHP HRSA HHS		Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; FeltLisk S, 1997, HEALTH AFFAIR, V16, P248, DOI 10.1377/hlthaff.16.3.248; FELTLISK S, 1996, QUALITY ASSURANCE RE, V1; Gold M, 1995, Health Care Financ Rev, V16, P85; Gold M, 1996, HEALTH AFFAIR, V15, P153, DOI 10.1377/hlthaff.15.3.153; HEGNER R, 1995, MEDICAID MANAGED CAR; *HJ KAIS FAM FDN, 1996, MATH POL RES EXP COL; *HLTH CAR FIN ADM, 1997, MED MAN CAR ENR REP; HURLEY RE, 1993, MANAGED CARE MEDICAI; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; *NAT COMM QUAL ASS, 1995, HEDIS 2 5; *NAT COMM QUAL ASS, 1993, HLTH PLANT EMPL DAT; *NAT COMM QUAL ASS, 1995, MED HEDIS; *NAT COMM QUAL ASS, 1997, HEDIS 3 0, V1; RILEY T, 1995, HEALTH CARE FINANC R, V16, P139; Rowland D, 1996, HEALTH AFFAIR, V15, P150, DOI 10.1377/hlthaff.15.3.150; SCHULTE F, 1994, FORT LAUDERDALE 1211; SHORT PF, 1996, INQUIRY, V25, P504; Sisk JE, 1996, JAMA-J AM MED ASSOC, V276, P50, DOI 10.1001/jama.276.1.50	20	43	43	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					211	216		10.1001/jama.279.3.211	http://dx.doi.org/10.1001/jama.279.3.211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR124	9438741				2022-12-28	WOS:000071460700031
J	De Guzman, RN; Wu, ZR; Stalling, CC; Pappalardo, L; Borer, PN; Summers, MF				De Guzman, RN; Wu, ZR; Stalling, CC; Pappalardo, L; Borer, PN; Summers, MF			Structure of the HIV-1 nucleocapsid protein bound to the SL3 Psi-RNA recognition element	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIPLE-RESONANCE NMR; ACID-BINDING-PROTEINS; MURINE LEUKEMIA-VIRUS; SIDE-CHAIN RESONANCES; GAG GENE-PRODUCTS; CYS-HIS BOX; PACKAGING SIGNAL; ZINC FINGERS; POSTTRANSLATIONAL MODIFICATIONS	The three-dimensional structure of the human immunodeficiency virus-type 1 (HIV-1) nucleocapsid protein (NC) bound to the SL3 stem-loop recognition element of the genomic Psi RNA packaging signal has been determined by heteronuclear magnetic resonance spectroscopy. Tight binding (dissociation constant, similar to 100 nM) is mediated by specific interactions between the amino-and carboxyl-terminal CCHC-type zinc knuckles of the NC protein and the G(7) and G(9) nucleotide bases, respectively, of the G(6)-G(7)-A(8)-G(9) RNA tetraloop. A(8) packs against the amino-terminal knuckle and forms a hydrogen bond with conserved Arg(32), and residues Lys(3) to Arg(10) of NC form a 3(10) helix that binds to the major groove of the RNA stem and also packs against the amino-terminal zinc knuckle. The structure provides insights into the mechanism of viral genome recognition, explains extensive amino acid conservation within NC, and serves as a basis for the development of inhibitors designed to interfere with genome encapsidation.	Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA; Univ Maryland Baltimore Cty, Howard Hughes Med Inst, Baltimore, MD 21250 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	Syracuse University; Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore County	Summers, MF (corresponding author), Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.		Pappalardo, Lucia/ABA-9311-2020	Pappalardo, Lucia/0000-0002-4491-2082; Pinnix, Chelsea/0000-0003-3982-3664; Borer, Philip N/0000-0003-1633-5393	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042561, R01GM032691, R29GM042561] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42561, GM32691] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Batey RT, 1995, METHOD ENZYMOL, V261, P300; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HAYASHI T, 1993, FEBS LETT, V327, P213, DOI 10.1016/0014-5793(93)80172-Q; HAYASHI T, 1992, VIROLOGY, V188, P590, DOI 10.1016/0042-6822(92)90513-O; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; McDonnell NB, 1997, J MED CHEM, V40, P1969, DOI 10.1021/jm970147+; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1988, J VIROL, V62, P3328; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MEYERS G, 1995, HUMAN RETROVIRUSES A; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; Nicholls A., GRASP GRAPHICAL REPR; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAPPALARDO L, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Ramos A, 1997, CURR OPIN STRUC BIOL, V7, P317, DOI 10.1016/S0959-440X(97)80046-2; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Schmitz U, 1996, RNA, V2, P1213; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; YOU JC, 1993, J BIOL CHEM, V268, P16519; YU XL, 1995, CHEM RES TOXICOL, V8, P586, DOI 10.1021/tx00046a013; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	89	589	600	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					384	388		10.1126/science.279.5349.384	http://dx.doi.org/10.1126/science.279.5349.384			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430589				2022-12-28	WOS:000071570800047
J	Medeiros-Ribeiro, G; Bratkovski, AM; Kamins, TI; Ohlberg, DAA; Williams, RS				Medeiros-Ribeiro, G; Bratkovski, AM; Kamins, TI; Ohlberg, DAA; Williams, RS			Shape transition of germanium nanocrystals on a silicon (001) surface from pyramids to domes	SCIENCE			English	Article							STRAINED ISLANDS; GROWTH; GE; SI(001)	Chemical vapor deposition of germanium onto the silicon (001) surface at atmospheric pressure and 600 degrees Celsius has previously been shown to produce distinct families of smaller (up to 6 nanometers high) and larger (all approximately 15 nanometers high) nanocrystals. Under ultrahigh-vacuum conditions, physical vapor deposition at approximately the same substrate temperature and growth rate produced a similar bimodal size distribution. In situ scanning tunneling microscopy revealed that the smaller square-based pyramids transform abruptly during growth to significantly larger multifaceted domes, and that few structures with intermediate size and shape remain. Both nanocrystal shapes have size-dependent energy minima that result from the interplay between strain relaxation at the facets and stress concentration at the edges. A thermodynamic model similar to a phase transition accounts for this abrupt morphology change.	Hewlett Packard Labs, Palo Alto, CA 94304 USA	Hewlett-Packard	Williams, RS (corresponding author), Hewlett Packard Labs, 3500 Deer Creek Rd,Mail Stop 26U, Palo Alto, CA 94304 USA.		ribeiro, gilberto medeiros/E-1835-2012; Williams, R. Stanley/A-8281-2009	ribeiro, gilberto medeiros/0000-0001-5309-2488; Williams, R. Stanley/0000-0003-0213-4259				Bauer E., 1958, Z KRISTALLOGR, V110, P372, DOI DOI 10.1524/ZKRI.1958.110.1-6.372; Chen CC, 1997, SCIENCE, V276, P398, DOI 10.1126/science.276.5311.398; Daruka I, 1997, PHYS REV LETT, V79, P3708, DOI 10.1103/PhysRevLett.79.3708; EAGLESHAM DJ, 1990, PHYS REV LETT, V64, P1943, DOI 10.1103/PhysRevLett.64.1943; Kamins TI, 1997, J APPL PHYS, V81, P211, DOI 10.1063/1.364084; MARCHENKO VI, 1981, SOV PHYS JETP, V54, P605; MO YW, 1990, PHYS REV LETT, V65, P1020, DOI 10.1142/S0217984990001732; SHCHUKIN VA, 1995, PHYS REV LETT, V75, P2968, DOI 10.1103/PhysRevLett.75.2968; TERSOFF J, 1994, PHYS REV LETT, V72, P3570, DOI 10.1103/PhysRevLett.72.3570; TERSOFF J, 1993, PHYS REV LETT, V70, P2782, DOI 10.1103/PhysRevLett.70.2782; TOLBERT SH, 1994, SCIENCE, V265, P373, DOI 10.1126/science.265.5170.373; TOMITORI M, 1994, APPL SURF SCI, V76, P322, DOI 10.1016/0169-4332(94)90362-X; ZINKEALLMANG M, 1992, SURF SCI REP, V16, P381	13	777	785	3	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					353	355		10.1126/science.279.5349.353	http://dx.doi.org/10.1126/science.279.5349.353			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430580				2022-12-28	WOS:000071570800038
J	Subbarao, K; Klimov, A; Katz, J; Regnery, H; Lim, W; Hall, H; Perdue, M; Swayne, D; Bender, C; Huang, J; Hemphill, M; Rowe, T; Shaw, M; Xu, XY; Fukuda, K; Cox, N				Subbarao, K; Klimov, A; Katz, J; Regnery, H; Lim, W; Hall, H; Perdue, M; Swayne, D; Bender, C; Huang, J; Hemphill, M; Rowe, T; Shaw, M; Xu, XY; Fukuda, K; Cox, N			Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness	SCIENCE			English	Article							A VIRUSES; HEMAGGLUTININ; CONJUNCTIVITIS; PATHOGENICITY; NEURAMINIDASE; CHICKENS; GENE	An avian H5N1 influenza A virus (A/Hong Kong/156/97) was isolated from a tracheal aspirate obtained from a 3-year-old child in Hong Kong with a fatal illness consistent with influenza. Serologic analysis indicated the presence of an H5 hemagglutinin. All eight RNA segments were derived from an avian influenza A virus. The hemagglutinin contained multiple basic amino acids adjacent to the cleavage site, a feature characteristic of highly pathogenic avian influenza A viruses. The virus caused 87.5 to 100 percent mortality in experimentally inoculated White Plymouth Rock and White Leghorn chickens. These results may have implications for global influenza surveillance and planning for pandemic influenza.	Ctr Dis Control & Prevent, Influenza Branch, Atlanta, GA 30333 USA; Queen Mary Hosp, Govt Virus Unit, Hong Kong, Hong Kong; ARS, SE Poultry Res Lab, USDA, Athens, GA 30605 USA	Centers for Disease Control & Prevention - USA; University of Hong Kong; United States Department of Agriculture (USDA)	Subbarao, K (corresponding author), Ctr Dis Control & Prevent, Influenza Branch, Atlanta, GA 30333 USA.		Rowe, Thomas/AAW-4899-2020; Swayne, David/AAP-7166-2020	Fukuda, Keiji/0000-0002-9598-9565; Subbarao, Kanta/0000-0003-1713-3056; Swayne, David/0000-0001-7472-1992				BEAN WJ, 1985, J VIROL, V54, P151, DOI 10.1128/JVI.54.1.151-160.1985; BLOK J, 1982, VIROLOGY, V118, P229, DOI 10.1016/0042-6822(82)90337-3; BROWN CC, 1992, J COMP PATHOL, V107, P341, DOI 10.1016/0021-9975(92)90009-J; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; ELS MC, 1985, VIROLOGY, V142, P241, DOI 10.1016/0042-6822(85)90332-0; Garcia M, 1996, J GEN VIROL, V77, P1493, DOI 10.1099/0022-1317-77-7-1493; KAWAOKA Y, 1984, VIROLOGY, V139, P303, DOI 10.1016/0042-6822(84)90376-3; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; KAWAOKA Y, 1988, MICROB PATHOGENESIS, V5, P311, DOI 10.1016/0882-4010(88)90032-0; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; Mo IP, 1997, AVIAN DIS, V41, P125, DOI 10.2307/1592452; Murphy B.R, 1996, FIELDS VIROLOGY, P1397; ROHM C, 1995, VIROLOGY, V209, P664, DOI 10.1006/viro.1995.1301; Senne DA, 1996, AVIAN DIS, V40, P425, DOI 10.2307/1592241; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SUBBARAO K, UNPUB; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; WEBSTER RG, 1987, CELL, V50, P665, DOI 10.1016/0092-8674(87)90321-7; WEBSTER RG, 1981, NEW ENGL J MED, V304, P911; WOOD GW, 1994, ARCH VIROL, V134, P185, DOI 10.1007/BF01379117; ZIEGLER T, 1995, J CLIN MICROBIOL, V33, P318, DOI 10.1128/JCM.33.2.318-321.1995	21	1087	1257	4	255	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					393	396		10.1126/science.279.5349.393	http://dx.doi.org/10.1126/science.279.5349.393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430591				2022-12-28	WOS:000071570800049
J	Morales, AM; Lieber, CM				Morales, AM; Lieber, CM			A laser ablation method for the synthesis of crystalline semiconductor nanowires	SCIENCE			English	Article							CARBON NANOTUBES; POROUS SILICON; QUANTUM WIRES; GROWTH; NANOCRYSTALS; 1ST-PRINCIPLES; NANORODS	A method combining laser ablation cluster formation and vapor-liquid-solid (VLS) growth was developed for the synthesis of semiconductor nanowires. in this process, laser ablation was used to prepare nanometer-diameter catalyst clusters that define the size of wires produced by VLS growth, This approach was used to prepare bulk quantities of uniform single-crystal silicon and germanium nanowires with diameters of 6 to 20 and 3 to 9 nanometers, respectively, and lengths ranging from 1 to 30 micrometers. Studies carried out with different conditions and catalyst materials confirmed the central details of the growth mechanism and suggest that well-established phase diagrams can De used to predict rationally catalyst materials and growth conditions for the preparation of nanowires.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.							Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0; BOOTSMA GA, 1971, J CRYST GROWTH, V10, P223, DOI 10.1016/0022-0248(71)90188-6; BRUS L, 1994, J PHYS CHEM-US, V98, P3575, DOI 10.1021/j100065a007; BRUS LE, 1995, J AM CHEM SOC, V117, P2915, DOI 10.1021/ja00115a025; BUDA F, 1992, PHYS REV LETT, V69, P1272, DOI 10.1103/PhysRevLett.69.1272; CHARLIER JC, 1997, SCIENCE, V275, P647; COLBERT DT, 1994, SCIENCE, V266, P1218, DOI 10.1126/science.266.5188.1218; DAI HJ, 1995, NATURE, V375, P769, DOI 10.1038/375769a0; DIETZ TG, 1980, J CHEM PHYS, V73, P4816, DOI 10.1063/1.440000; ELSHALL MS, 1996, NANOMATERIALS SYNTHE, P13; GIVARGIZOV EI, 1975, J CRYST GROWTH, V31, P20, DOI 10.1016/0022-0248(75)90105-0; GOLDSTEIN AN, 1992, SCIENCE, V256, P1425, DOI 10.1126/science.256.5062.1425; HEATH JR, 1993, CHEM PHYS LETT, V208, P263, DOI 10.1016/0009-2614(93)89073-Q; Hu J. L., UNPUB; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; LIEBER CM, 1996, RA WELCH 40 C CHEM R, P165; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Moffatt W.G., 1976, HDB BINARY PHASE DIA; READ AJ, 1992, PHYS REV LETT, V69, P1232, DOI 10.1103/PhysRevLett.69.1232; SAUNDERS GD, 1992, PHYS REV B, V45, P9202; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; TRENTLER TJ, 1995, SCIENCE, V270, P1791, DOI 10.1126/science.270.5243.1791; WAGNER RS, 1964, APPL PHYS LETT, V4, P89, DOI 10.1063/1.1753975; WAGNER RS, 1970, WHISKER TECHNOLOGY, P47; Westwater J, 1997, J VAC SCI TECHNOL B, V15, P554, DOI 10.1116/1.589291; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Wong EW, 1996, CHEM MATER, V8, P2041, DOI 10.1021/cm960083b; WU CG, 1994, SCIENCE, V266, P1013, DOI 10.1126/science.266.5187.1013; Yakobson BI, 1997, AM SCI, V85, P324; YAZAWA M, 1992, APPL PHYS LETT, V61, P2051, DOI 10.1063/1.108329	31	4115	4461	32	1495	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					208	211		10.1126/science.279.5348.208	http://dx.doi.org/10.1126/science.279.5348.208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422689				2022-12-28	WOS:000071408100036
J	Putney, JW				Putney, JW			Calcium signaling: Up, down, up, down ... What's the point?	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CALMODULIN; AUTOPHOSPHORYLATION; OSCILLATIONS		NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; SUH HH, 1992, J NEUROCHEM, V59, P993, DOI 10.1111/j.1471-4159.1992.tb08340.x; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSIEN RY, 1992, AM J PHYSIOL, V263, pC723, DOI 10.1152/ajpcell.1992.263.4.C723; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	11	81	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					191	192		10.1126/science.279.5348.191	http://dx.doi.org/10.1126/science.279.5348.191			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9446226				2022-12-28	WOS:000071408100030
J	Murray, N; Hansen, B; Holman, M; Tremaine, S				Murray, N; Hansen, B; Holman, M; Tremaine, S			Migrating planets	SCIENCE			English	Article							COMPANION	A planet orbiting in a disk of planetesimals can experience an instability in which it migrates to smaller orbital radii. Resonant interactions between the planet and plane-tesimals remove angular momentum from the planetesimals, increasing their eccentricities. Subsequently, the planetesimals either collide with or are ejected by the planet, reducing the semimajor axis of the planet. If the surface density of the planetesimals exceeds a critical value, corresponding to similar to 0.03 solar mass of gas inside the orbit of Jupiter, the planet will migrate inward a large distance. This instability may explain the presence of Jupiter-mass objects in small orbits around nearby stars.	Univ Toronto, Canadian Inst Theoret Astrophys, Toronto, ON M5S 3H8, Canada; Canadian Inst Adv Res, Program Cosmol & Grav, Toronto, ON M5T 1X4, Canada	University of Toronto; Canadian Institute for Advanced Research (CIFAR)	Murray, N (corresponding author), Univ Toronto, Canadian Inst Theoret Astrophys, 60 St George St, Toronto, ON M5S 3H8, Canada.		Tremaine, Scott D/M-4281-2015	Tremaine, Scott D/0000-0002-0278-7180; Murray, Norman/0000-0002-8659-3729				ALEXANDER JB, 1967, OBSERVATORY, V87, P238; Baliunas SL, 1997, ASTROPHYS J, V474, pL119, DOI 10.1086/310442; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; Binney J., 1987, GALACTIC DYNAMICS; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; Butler RP, 1997, ASTROPHYS J, V474, pL115, DOI 10.1086/310444; CHIRIKOV BV, 1983, CHAOTIC DYNAMICS HAM; Cochran WD, 1997, ASTROPHYS J, V483, P457, DOI 10.1086/304245; Dones L, 1996, ASTR SOC P, V107, P233; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; GRAY D, 1996, NATURE, V385, P795; Holman M, 1997, NATURE, V386, P254, DOI 10.1038/386254a0; Holman MJ, 1996, ASTRON J, V112, P1278, DOI 10.1086/118098; Innanen KA, 1997, ASTRON J, V113, P1915, DOI 10.1086/118405; KARNEY CFF, 1983, PHYSICA D, V8, P360, DOI 10.1016/0167-2789(83)90232-4; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; Liou JC, 1997, SCIENCE, V275, P375, DOI 10.1126/science.275.5298.375; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; Marcy GW, 1997, ASTROPHYS J, V481, P926, DOI 10.1086/304088; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; Mazeh T, 1997, ASTROPHYS J, V477, pL103, DOI 10.1086/310536; Murray N, 1997, ASTRON J, V114, P1246, DOI 10.1086/118558; MURRAY NW, 1991, PHYSICA D, V52, P220, DOI 10.1016/0167-2789(91)90124-R; Noyes RW, 1997, ASTROPHYS J, V487, pL195; Noyes RW, 1997, ASTROPHYS J, V483, pL111, DOI 10.1086/310754; Opik E.J., 1976, INTERPLANETARY ENCOU; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; Safronov V.S., 1960, ANAP, V23, P979; TOOMRE A, 1964, ASTROPHYS J, V139, P1217, DOI 10.1086/147861; Weidenschilling SJ, 1996, NATURE, V384, P619, DOI 10.1038/384619a0	36	178	179	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					69	72		10.1126/science.279.5347.69	http://dx.doi.org/10.1126/science.279.5347.69			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417025	Green Submitted			2022-12-28	WOS:000071323900040
J	Fried, I				Fried, I			Syndrome E	LANCET			English	Article							CEREBRAL BLOOD-FLOW	The transformation of groups of previously nonviolent individuals into repetitive killers of defenceless members of society has been a recurring phenomenon throughout history. This transformation is characterised by a set of symptoms and signs suggesting a common syndrome-Syndrome E. Affected individuals show obsessive ideation, compulsive repetition, rapid desensitisation to violence, diminished affective reactivity, hyperarousal, environmental dependency, group contagion, and failure to adapt to changing stimulus-reinforcement associations. Yet memory, language, planning, and problem-solving skills remain intact. The main risk factors are male sex and age between 15 and 50. A pathophysiological model-"cognitive fracture"-is hypothesised, where hyperaroused orbitofrontal and medial prefrontal cortices tonically inhibit the amygdala and are no longer regulated by visceral and somatic homoeostatic controls ordinarily supplied by subcortical systems. It is proposed that the syndrome is a product of neocortical development rather than the manifestation of a disinhibited primitive brain. Early recognition of symptoms and signs could lead to prevention through education and isolation of affected individuals.	Univ Calif Los Angeles, Sch Med, Brain Res Inst, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fried, I (corresponding author), Univ Calif Los Angeles, Sch Med, Brain Res Inst, Div Neurosurg, Los Angeles, CA 90095 USA.							Adorno Theodor W, 1950, AUTHORITARIAN PERSON; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Browning C., 1998, ORDINARY MEN RESERVE; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DAVIDSON RJ, 1995, CURR OPIN NEUROBIOL, V5, P217, DOI 10.1016/0959-4388(95)80029-8; FRIEDLANDER S, 1993, MEMORY HIST EXTERMIN, P104; Goldhagen DJ., 1996, HITLERS WILLING EXEC; GOODALL J, GREAT APES; Haney C. B., 1973, INT J CRIMINOLOGY PE, V1, P69, DOI DOI 10.1037/H0076835; LeDoux Joseph E., 1997, EMOTIONAL BRAIN MYST; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MILGRAM S, 1969, OBEIDIENCE AUTHORITY; Pich EM, 1997, SCIENCE, V275, P83; PRUNIER G, 1995, RWANDAN CRISIS, P237; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; SAADY JJ, 1994, EUR J DRUG METAB PH, V19, P41, DOI 10.1007/BF03188822; SERENY G, 1983, DARKNESS, P164; STEINER JM, 1980, SURVIVORS VICTIMS PE, P431	20	18	18	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1845	1847		10.1016/S0140-6736(97)09385-9	http://dx.doi.org/10.1016/S0140-6736(97)09385-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428268				2022-12-28	WOS:000071102500047
J	Brenner, H; Rothenbacher, D; Bode, G; Adler, G				Brenner, H; Rothenbacher, D; Bode, G; Adler, G			Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-PYLORI; LIVING-CONDITIONS; POPULATION; CHILDHOOD; GASTRITIS; SECRETION; ETHANOL; LIFE; RISK; AGE	Objective: To assess the relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection. Design: Cross sectional study of patients attending a general practitioner Active H pylori infection was measured by the C-13-urea breath test and detailed quantitative information on smoking and on alcohol and coffee consumption was obtained by a standardised self administered questionnaire. Setting: One general practice in Germany. Subjects: 447 patients aged 15-79 who had not had peptic ulcer disease or treatment for H pylori infection. Main outcome measures: Prevalence of H pylori infection according to smoking and alcohol and coffee consumption. Results: Overall prevalence of infection was 21% (94/447). There was no significant relation between smoking and active H pylori infection. Alcohol consumption showed a negative dose-response relation and coffee consumption a positive dose-response relation with active infection. After adjustment for potential confounders, the odds ratios for patients who drank less than or equal to 75 g and >75 g of ethanol a week compared with non-drinkers were 0.90 (95% confidence interval 0.55 to 1.59) and 0.33 (0.16 to 0.68), respectively (P value for trend 0.005, assuming that 1 litre of beer and 0.5 l of nine contain on average 50 g of ethanol in south Germany). Adjusted odds ratios for patients who drank <3 cups and greater than or equal to 3 cups of coffee per day compared with those who did not drink coffee were 1.49 (0.71 to 3.12) and 2.49 (1.23 to 5.03), respectively (P value for trend 0.007). Conclusion: These results suggest a protective effect of alcohol consumption against active infection with H pyolri and an opposite effect of coffee consumption.	UNIV ULM,DEPT INTERNAL MED 1,D-89069 ULM,GERMANY	Ulm University	Brenner, H (corresponding author), UNIV ULM,DEPT EPIDEMIOL,D-89069 ULM,GERMANY.		Brenner, Hermann/B-4627-2017; Brenner, Hermann/ABE-6383-2020	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Rothenbacher, Dietrich/0000-0002-3563-2791				[Anonymous], 1993, Gut, V34, P1672; BATESON MC, 1993, POSTGRAD MED J, V69, P41, DOI 10.1136/pgmj.69.807.41; BRENNER H, 1994, EPIDEMIOLOGY, V5, P510; CHODOS JE, 1988, AM J GASTROENTEROL, V83, P1226; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; ENDOH K, 1994, GASTROENTEROLOGY, V107, P864, DOI 10.1016/0016-5085(94)90138-4; FONTHAM ETH, 1995, AM J GASTROENTEROL, V90, P1094; GASBARRINI G, 1995, GUT, V36, P838, DOI 10.1136/gut.36.6.838; GILBOA S, 1995, INT J EPIDEMIOL, V24, P232, DOI 10.1093/ije/24.1.232; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; HOOKNIKANNE J, 1991, DIGESTION, V50, P92, DOI 10.1159/000200745; JIAN R, 1986, DIGEST DIS SCI, V31, P604, DOI 10.1007/BF01318691; MAXTON DG, 1990, POSTGRAD MED J, V66, P717, DOI 10.1136/pgmj.66.779.717; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MEYER B, 1991, GUT, V32, P347, DOI 10.1136/gut.32.4.347; *NIH CONS DEV PAN, 1994, JAMA-J AM MED ASSOC, V272, P65; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PAUNIO M, 1994, EUR J EPIDEMIOL, V10, P205, DOI 10.1007/BF01730371; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; ROKKAS T, 1987, AM J GASTROENTEROL, V82, P1149; *SAS I, 1990, SAS LANG REF; SINGER MV, 1987, GASTROENTEROLOGY, V93, P1247, DOI 10.1016/0016-5085(87)90252-6; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Weisse ME, 1995, BRIT MED J, V311, P1657, DOI 10.1136/bmj.311.7021.1657	25	118	121	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1489	1492		10.1136/bmj.315.7121.1489	http://dx.doi.org/10.1136/bmj.315.7121.1489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420488	Green Published			2022-12-28	WOS:A1997YK98600016
J	Rowe, PM				Rowe, PM			Signalling an end to transplant rejection?	LANCET			English	News Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1526	1526		10.1016/S0140-6736(05)63956-6	http://dx.doi.org/10.1016/S0140-6736(05)63956-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9417481				2022-12-28	WOS:A1997YH11500028
J	Vinetz, JM; Li, J; McCutchan, TF; Kaslow, DC				Vinetz, JM; Li, J; McCutchan, TF; Kaslow, DC			Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CALIFORNIA	Infect Dis Soc Amer			FALCIPARUM-MALARIA; IMMUNITY; VACCINE		NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Vinetz, JM (corresponding author), NIAID, Parasit Dis Lab, NIH, 9000 Rockville Pike,Bldg 4,Rm 126, Bethesda, MD 20892 USA.			Vinetz, Joseph/0000-0001-8344-2004				ADAMS F, 1986, HIPPOCRATES EPIDEMIC, P307; BELIOS G D, 1955, Riv Malariol, V34, P1; Bottius E, 1996, T ROY SOC TROP MED H, V90, P15, DOI 10.1016/S0035-9203(96)90463-0; CAVACINI LA, 1990, INFECT IMMUN, V58, P2946, DOI 10.1128/IAI.58.9.2946-2950.1990; COOK GC, 1996, MANSONS TROPICAL DIS, P23; FAKUNLE YM, 1981, CLIN HAEMATOL, V10, P963; FOX DA, 1989, THERAPY AUTOIMMUNE D, V7, P20; GREENBERG AE, 1991, NEW ENGL J MED, V325, P105, DOI 10.1056/NEJM199107113250206; GUERRERO IC, 1983, ANN INTERN MED, V99, P221, DOI 10.7326/0003-4819-99-2-221; HIRSCH VM, 1994, J INFECT DIS, V170, P51, DOI 10.1093/infdis/170.1.51; KROGSTAD DJ, 1995, MANDELL DOUGLAS BENN, V2, P2415; KUMAR S, 1989, J IMMUNOL, V143, P2017; LI J, 1995, EXP PARASITOL, V81, P182, DOI 10.1006/expr.1995.1107; LIVADAS G A, 1958, Riv Malariol, V37, P173; MULLER O, 1990, T ROY SOC TROP MED H, V84, P336, DOI 10.1016/0035-9203(90)90306-Y; SCHAEFER KU, 1995, TROP GEOGR MED, V47, P111; SIMOOYA OO, 1991, ANN TROP MED PARASIT, V85, P269, DOI 10.1080/00034983.1991.11812556; Sulzer A J, 1971, CRC Crit Rev Clin Lab Sci, V2, P601, DOI 10.3109/10408367109151318; SULZER AJ, 1969, AM J TROP MED HYG, V18, P199, DOI 10.4269/ajtmh.1969.18.199; TIKASINGH E, 1980, AM J TROP MED HYG, V29, P715, DOI 10.4269/ajtmh.1980.29.715; TSUCHIDA H, 1982, AM J TROP MED HYG, V31, P163, DOI 10.4269/ajtmh.1982.31.163; WALTER RD, 1991, PARASITOL RES, V77, P346, DOI 10.1007/BF00930913; WILSON M, 1970, AM J TROP MED HYG, V19, P401, DOI 10.4269/ajtmh.1970.19.401	23	90	94	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					367	371		10.1056/NEJM199802053380605	http://dx.doi.org/10.1056/NEJM199802053380605			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449730	Bronze			2022-12-28	WOS:000071822200005
J	Hetts, SW				Hetts, SW			To die or not to die - An overview of apoptosis and its role in disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGRAMMED CELL-DEATH; FAS GENE-MUTATIONS; LYMPHOPROLIFERATIVE SYNDROME; ICE/CED-3 PROTEASE; IMMUNE PRIVILEGE; TUMOR-CELLS; LIGAND; CD95; BCL-2; IDENTIFICATION	The death of cells in tissues of humans and other multicellular organisms is neither always abnormal nor always detrimental. Although necrosis ensues at the sites of massive cellular injury, most cells in the body die through a more subtle, noninflammatory, energy-dependent form of cell death called apoptosis. The number of cells in tissues is determined by the homeostatic balance between proliferation of new cells and death of senescent cells; the rates of proliferation and apoptosis vary widely from tissue to tissue. Recent reseal ch into the molecular mechanisms of apoptosis has revealed that apoptosis is a genetically programmed process that can become deranged when the components of the cellular apoptotic machinery are mutated or present in inappropriate quantities. Dysregulation of apoptosis is associated with the pathogenesis of a wide array of diseases: cancer, neurodegeneration, autoimmunity, heart disease, and other disorders. Products of genes involved in the regulation and execution of apoptosis are potentially excellent targets for diagnosis and therapeutic intervention in disease processes, and they offer renewed hope for cures and treatments for a wide array of maladies.	Harvard Univ, Sch Med, Oliver Wendell Homes Soc, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hetts, SW (corresponding author), Harvard Univ, Sch Med, Oliver Wendell Homes Soc, 260 Longwood Ave, Boston, MA 02115 USA.	shetts@student.med.harvard.edu		Hetts, Steven/0000-0001-5885-7259				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Benoist C, 1997, CELL, V89, P1, DOI 10.1016/S0092-8674(00)80174-9; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Colucci WS, 1996, NEW ENGL J MED, V335, P1224, DOI 10.1056/NEJM199610173351610; CORY S, 1995, ANNU REV IMMUNOL, V13, P543; COTRAN RS, 1994, PATHOLOGIC BASIS DIS, P1; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAJNO G, 1995, AM J PATHOL, V146, P3; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Paradis E, 1996, J NEUROSCI, V16, P7533; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; ROQUET N, 1996, CURR BIOL, V6, P1192; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tompkins MM, 1997, AM J PATHOL, V150, P119; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	78	413	442	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					300	307		10.1001/jama.279.4.300	http://dx.doi.org/10.1001/jama.279.4.300			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450715				2022-12-28	WOS:000071607000038
J	Rayner, MG; Zhang, YZ; Gorry, MC; Chen, YP; Post, JC; Ehrlich, GD				Rayner, MG; Zhang, YZ; Gorry, MC; Chen, YP; Post, JC; Ehrlich, GD			Evidence of bacterial metabolic activity in culture-negative otitis media with effusion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PCR; DNA	Context.-Otitis media with effusion (OME) can lead to significant hearing loss in children. Although previous studies have shown that bacterial DNA is present in a significant percentage of effusions sterile by culture, whether the DNA represents viable organisms or "fossilized remains" is unknown. Objective.-To determine if bacterial messenger RNA (mRNA), as detected by a reverse transcriptase-polymerase chain reaction (RT-PCR)-based assay, is present in chronic pediatric middle ear effusions that contain bacterial DNA but are sterile by standard cultural methods. Bacterial mRNAs have a half-life measured in seconds to minutes; therefore, detection of bacteria-specific mRNAs would be evidence that metabolically active organisms are present. Design.-Blinded comparative study. Patients.-A total of 93 effusions from pediatric outpatients seen for myringotomy and tube placement for chronic (>3 months) OME (median age of children, 17 months). Setting.-Tertiary care pediatric hospital. Main Outcome Measures.-Percentage of positive test results for RT-PCR-based assays compared with culture for Haemophilus influenzae and concordance between RT-PCR and PCR-based findings for bacterial nucleic acids. Results.-Eleven (11.8%) of the 93 specimens tested positive by culture, PCR, and RT-PCR for H influenzae, A total of 29 specimens (31.2%) were positive by PCR but negative by culture for H influenzae. All 29 specimens were positive by RT-PCR for H influenzae-specific mRNA. Conclusions.-The RT-PCR-based assay system can detect the presence of bacterial mRNA in a significant percentage of culturally sterile middle ear effusions, establishing the presence of viable, metabolically active, intact organisms in some culture-negative OME.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Ctr Genom Sci, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Dept Pediat Otolaryngol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ehrlich, GD (corresponding author), Allegheny Univ Hlth Sci, Ctr Genom Sci, 4 Allegheny Ctr,Suite 735, Pittsburgh, PA 15212 USA.			Ehrlich, Garth/0000-0003-1140-6594	NIDCD NIH HHS [DC02148, DC02398, DC02697] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC002697, R01DC002148, R29DC002398, R01DC002398] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BLUESTONE CD, 1992, OTOLARYNGOL HEAD NEC, V106, P204; Cantekin EI, 1996, JAMA-J AM MED ASSOC, V275, P186, DOI 10.1001/jama.1996.03530270026021; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DERETIC V, 1994, J BACTERIOL, V176, P2773, DOI 10.1128/JB.176.10.2773-2780.1994; EHRLICH G D, 1991, Clinical Microbiology Newsletter, V13, P149, DOI 10.1016/0196-4399(91)90060-9; GEESEY GG, 1978, LIMNOL OCEANOGR, V23, P1214, DOI 10.4319/lo.1978.23.6.1214; GIEBINK GS, 1989, PEDIATR INFECT DIS J, V8, pS18; HAGGARD MP, 1996, INT CLIN PRACTICE SE, P29; LEWIN BM, 1974, GENE EXPRESSION, V1, P285; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; POST JC, 1996, HAEMOPHILUS INFLUENZ, V1, P29; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHAPPERT SM, 1991, OFFICE VISITS OTITIS; SIRKO DA, 1993, PCR BASED DIAGNOSTIC, P19; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; UEYAMA T, 1995, J CLIN MICROBIOL, V33, P1835, DOI 10.1128/JCM.33.7.1835-1838.1995; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	19	200	220	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					296	299		10.1001/jama.279.4.296	http://dx.doi.org/10.1001/jama.279.4.296			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450714	Bronze			2022-12-28	WOS:000071607000037
J	Bulovic, V; Kozlov, VG; Khalfin, VB; Forrest, SR				Bulovic, V; Kozlov, VG; Khalfin, VB; Forrest, SR			Transform-limited, narrow-linewidth lasing action in organic semiconductor microcavities	SCIENCE			English	Article							LASERS	Lasing action in organic vertical-cavity surface-emitting laser (OVCSEL) structures is demonstrated. Optically pumped OVCSELs with an active layer composed of a thin-film organic semiconductor tris-(8-hydroxyquinoline) aluminum (Alq(3)) doped with DCM laser dye produced very narrow linewidth (0.2 +/- 0.1 angstrom), high-power (3 watts) emission that could be varied in different devices from orange to red. The efficient energy transfer from Alq(3) to DCM results in a threshold input energy of 300 microjoules per square centimeter. An operational lifetime >10(6) laser pulses was achieved for a device operated well above threshold in atmosphere. The linewidths above threshold are Fourier-transform-limited and could potentially be narrowed further.	Princeton Univ, Ctr Photon & Optoelect Mat, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University	Kozlov, VG (corresponding author), Princeton Univ, Ctr Photon & Optoelect Mat, Dept Elect Engn, Princeton, NJ 08544 USA.		Bulovic, Vladimir/U-5449-2019					Burrows PE, 1996, J APPL PHYS, V79, P7991, DOI 10.1063/1.362350; Coldren L.A., 1995, DIODE LASERS PHOTONI; Costela A, 1996, APPL PHYS LETT, V68, P593, DOI 10.1063/1.116478; Denton GJ, 1997, ADV MATER, V9, P547, DOI 10.1002/adma.19970090705; HENRY CH, 1986, J LIGHTWAVE TECHNOL, V4, P288, DOI 10.1109/JLT.1986.1074715; Kozlov VG, 1997, NATURE, V389, P362, DOI 10.1038/38693; Kozlov VG, 1997, APPL PHYS LETT, V71, P2575, DOI 10.1063/1.120186; Pope, 1982, ELECT PROCESSES ORGA; Schafer FP, 1977, DYE LASERS; WEISSBLUTH M, 1976, ATOMS MOL	10	216	228	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					553	555		10.1126/science.279.5350.553	http://dx.doi.org/10.1126/science.279.5350.553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438846				2022-12-28	WOS:000071616000043
J	Fuchs, E; Cleveland, DW				Fuchs, E; Cleveland, DW			A structural scaffolding of intermediate filaments in health and disease	SCIENCE			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; EPIDERMOLYSIS-BULLOSA SIMPLEX; MOTOR-NEURON DISEASE; WHITE SPONGE NEVUS; TRANSGENIC MICE; NEUROFILAMENT SUBUNIT; NF-L; PALMOPLANTAR KERATODERMA; MUSCULAR-DYSTROPHY; HUMAN KERATIN-14	The cytoplasm of animal cells is structured by a scaffolding composed of actin microfilaments, microtubules, and intermediate filaments. Intermediate filaments, so named because their 10-nanometer diameter is intermediate between that of microfilaments (6 nanometers) and microtubules (23 nanometers), assemble into an anastomosed network within the cytoplasm. In combination with a recently identified class of cross-linking proteins that mediate interactions between intermediate filaments and the other cytoskeletal networks, evidence is reviewed here that intermediate filaments provide a flexible intracellular scaffolding whose function is to structure cytoplasm and to resist stresses externally applied to the cell. Mutations that weaken this structural framework increase the risk of cell rupture and cause a variety of human disorders.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Cleveland, DW (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Fuchs, Elaine/G-1565-2016; Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; ANTONLAMPRECHT I, 1994, J INVEST DERMATOL, V103, pS6; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BOWDEN PE, 1995, NAT GENET, V10, P363, DOI 10.1038/ng0795-363; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CAMERON CHS, 1995, ACTA NEUROPATHOL, V89, P560, DOI 10.1007/BF00571512; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P25, DOI 10.1007/BF03028034; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOU CH, 1990, P NATL ACAD SCI USA, V86, P1885; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUNIA I, 1990, EUR J CELL BIOL, V53, P59; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; Fitzpatrick TB, 1987, DERMATOLOGY GEN MED, P1841; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fuchs E, 1997, MOL BIOL CELL, V8, P189, DOI 10.1091/mbc.8.2.189; Gache Y, 1996, J CLIN INVEST, V97, P2289, DOI 10.1172/JCI118671; Galou M, 1996, J CELL BIOL, V133, P853, DOI 10.1083/jcb.133.4.853; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GUMEY ME, 1994, SCIENCE, V264, P1772; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HENNIES HC, 1995, HUM MOL GENET, V4, P1015, DOI 10.1093/hmg/4.6.1015; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P471, DOI 10.1097/00005072-198409000-00002; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOROWITZ SH, 1994, MUSCLE NERVE, V17, P151, DOI 10.1002/mus.880170204; Irvine AD, 1997, NAT GENET, V16, P184, DOI 10.1038/ng0697-184; Jonkman MF, 1996, J INVEST DERMATOL, V107, P764, DOI 10.1111/1523-1747.ep12365805; KAWAMURA Y, 1981, J NEUROPATH EXP NEUR, V40, P667, DOI 10.1097/00005072-198111000-00008; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; Marszalek JR, 1996, J CELL BIOL, V135, P711, DOI 10.1083/jcb.135.3.711; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RICHARD G, 1995, NAT GENET, V11, P453, DOI 10.1038/ng1295-453; Rooke K, 1996, NEUROLOGY, V46, P789, DOI 10.1212/WNL.46.3.789; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; Rouleau GA, 1996, ANN NEUROL, V39, P128, DOI 10.1002/ana.410390119; RUGG EL, 1995, NAT GENET, V11, P450, DOI 10.1038/ng1295-450; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; SAKAGUCHI T, 1993, NEUROSCI LETT, V153, P65, DOI 10.1016/0304-3940(93)90078-Y; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; TORCHARD D, 1994, NAT GENET, V6, P106, DOI 10.1038/ng0194-106; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Vechio JD, 1996, ANN NEUROL, V40, P603, DOI 10.1002/ana.410400410; Vicart P, 1996, HUM GENET, V98, P422, DOI 10.1007/s004390050233; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121; WICHE G, 1989, CRIT REV BIOCHEM MOL, V24, P41, DOI 10.3109/10409238909082551; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Xu ZS, 1996, J CELL BIOL, V133, P1061, DOI 10.1083/jcb.133.5.1061; XU ZS, 1993, J CELL SCI, P101; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; ZHU Q, IN PRESS EXP NEUROL	103	779	802	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					514	519		10.1126/science.279.5350.514	http://dx.doi.org/10.1126/science.279.5350.514			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438837				2022-12-28	WOS:000071616000034
J	Davis, KD; Kiss, ZHT; Luo, L; Tasker, RR; Lozano, AM; Dostrovsky, JO				Davis, KD; Kiss, ZHT; Luo, L; Tasker, RR; Lozano, AM; Dostrovsky, JO			Phantom sensations generated by thalamic microstimulation	NATURE			English	Article							ADULT HUMAN BRAIN; CORTICAL REORGANIZATION; SOMATOSENSORY CORTEX; NERVOUS-SYSTEM; MONKEYS; DEAFFERENTATION; AMPUTATION; PLASTICITY; DIGIT; PAIN	Many amputees have a sense of their missing 'phantom' limb(1-3) Amputation can alter the representation of the body's surface in the cerebral cortex(4-14) and thalamus(15,16), but it is unclear how these changes relate to such phantom sensations, One possibility is that, in amputees who experience phantom sensations, the region of the thalamus that originally represented the missing limb remains functional and can give rise to phantom sensations even when some thalamic 'limb' neurons begin to respond to stimulation of other body regions, Here we use microelectrode recording and microstimulation during functional stereotactic mapping of the ventrocaudal thalamus in amputees to determine both the responses of the neurons to stimulation of the skin and the perceptual effects of electrical activation of these neurons. Thalamic mapping revealed an unusually large thalamic stump representation, consistent with the findings from animal experiments. We also found that thalamic stimulation in amputees with a phantom limb could evoke phantom sensations, including pain, even in regions containing neurons responsive to tactile stimulation of the stump, These findings support the hypothesis that the thalamic representation of the amputated limb remains functional. in amputees with phantoms.	Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto	Davis, KD (corresponding author), Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada.		Lozano, Andres M/A-5058-2012; Kiss, Zelma/D-2342-2016	Lozano, Andres M./0000-0001-8257-3694; Kiss, Zelma/0000-0002-8656-2690				AGLIOTI S, 1994, NEUROREPORT, V5, P473, DOI 10.1097/00001756-199401120-00026; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CARLEN PL, 1978, NEUROLOGY, V28, P211, DOI 10.1212/WNL.28.3.211; Clarke S, 1996, NEUROREPORT, V7, P2853, DOI 10.1097/00001756-199611250-00009; Davis KD, 1996, J NEUROPHYSIOL, V75, P1026, DOI 10.1152/jn.1996.75.3.1026; Doetsch GS, 1997, SOMATOSENS MOT RES, V14, P6, DOI 10.1080/08990229771178; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1995, J NEUROSCI, V15, P8083; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; Kew JJM, 1997, J NEUROPHYSIOL, V77, P2753, DOI 10.1152/jn.1997.77.5.2753; KISS ZHT, 1994, STEREOT FUNCT NEUROS, V62, P153, DOI 10.1159/000098612; Knecht S, 1995, NEUROSCI LETT, V201, P262, DOI 10.1016/0304-3940(95)12186-2; LENZ FA, 1988, J NEUROSURG, V68, P630, DOI 10.3171/jns.1988.68.4.0630; LENZ FA, 1988, J NEUROPHYSIOL, V59, P299, DOI 10.1152/jn.1988.59.2.299; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570, DOI 10.1152/jn.1994.72.4.1570; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10413, DOI 10.1073/pnas.90.22.10413; Rasmusson D, 1996, J COMP NEUROL, V364, P92; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; TASKER RR, 1995, NEUROSURG CLIN N AM, V6, P73; Tsoukatos J., 1996, Society for Neuroscience Abstracts, V22, P98; WALL JT, 1992, J NEUROSCI, V12, P3445; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	29	168	173	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					385	387		10.1038/34905	http://dx.doi.org/10.1038/34905			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450753				2022-12-28	WOS:000071604200053
J	Pappalardo, RT; Head, JW; Greeley, R; Sullivan, RJ; Pilcher, C; Schubert, G; Moore, WB; Carr, MH; Moore, JM; Belton, MJS; Goldsby, DL				Pappalardo, RT; Head, JW; Greeley, R; Sullivan, RJ; Pilcher, C; Schubert, G; Moore, WB; Carr, MH; Moore, JM; Belton, MJS; Goldsby, DL			Geological evidence for solid-state convection in Europa's ice shell	NATURE			English	Article							SATELLITES; WATER	The ice-rich surface of the jovian satellite Europa is sparsely cratered, suggesting that this moon might be geologically active today(1). Moreover, models of the satellite's interior indicate that tidal interactions with Jupiter might produce enough heat to maintain a subsurface liquid water layer(2-5). But the mechanisms of interior heat loss and resurfacing are currently unclear, as is the question of whether Europa has (or had at one time) a liquid water ocean(6,7). Here we report on the morphology and geological interpretation of distinct surface features-pits, domes and spots-discovered in high-resolution images of Europa obtained by the Galileo spacecraft. The features are interpreted as the surface manifestation of diapirs, relatively warm localized ice masses that have risen buoyantly through the subsurface. We find that the formation of the features can be explained by thermally induced solid-state convection within an ice shell, possibly overlying a liquid water layer. Our results are consistent with the possibility that Europa has a liquid water ocean beneath a surface layer of ice, but further tests and observations are needed to demonstrate this conclusively.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; NASA Headquarters, Washington, DC 20546 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; US Geol Survey, Menlo Park, CA 94025 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA	Brown University; Arizona State University; Arizona State University-Tempe; National Aeronautics & Space Administration (NASA); University of California System; University of California Los Angeles; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Optical Astronomy Observatory	Pappalardo, RT (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Pappalardo, Robert/AAP-8953-2021	Pappalardo, Robert/0000-0003-2571-4627; Goldsby, David/0000-0002-9004-0086				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CARR MH, 1995, J GEOPHYS RES-PLANET, V100, P18935, DOI 10.1029/95JE00971; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN PM, 1982, SATELLITES JUPITER, P93; DURHAM WB, 1992, J GEOPHYS RES-PLANET, V97, P20883, DOI 10.1029/92JE02326; GEISSLER P, 1997, P WORKSH REM SENS PL; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; Goldsby DL, 1997, SCRIPTA MATER, V37, P1399, DOI 10.1016/S1359-6462(97)00246-7; GOLDSBY DL, 1997, LUNAR PLANET SCI, V28, P429; GREELEY R, 1997, LUN PLAN SCI C ABSTR, V28, P455; GREENBERG R, 1997, LUN PLAN SCI C ABSTR, V28, P457; HOBBS PV, 1974, ICE PHYSICS; Jenyon M.K., 1986, SALT TECTONICS; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MCKINNON WB, 1997, B AM ASTRON SOC, V29, P984; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; OBRIEN GD, 1968, AAPG BULL, V8, P1; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; PAPPALARDO R, 1996, EOS, V78, pS203; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; SCHENK P, 1993, GEOLOGY, V21, P299, DOI 10.1130/0091-7613(1993)021<0299:DOTARO>2.3.CO;2; Schubert G., 1986, SATELLITES, P224; Squyres S. W., 1986, SATELLITES, P293; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STENGEL KC, 1982, J FLUID MECH, V120, P411, DOI 10.1017/S0022112082002821; WILLIAMS KK, 1997, EOS, V78, pF415	29	258	260	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					365	368		10.1038/34862	http://dx.doi.org/10.1038/34862			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450750				2022-12-28	WOS:000071604200046
J	Goldfeld, AE; Delgado, JC; Thim, S; Bozon, MV; Uglialoro, AM; Turbay, D; Cohen, C; Yunis, EJ				Goldfeld, AE; Delgado, JC; Thim, S; Bozon, MV; Uglialoro, AM; Turbay, D; Cohen, C; Yunis, EJ			Association of an HLA-DQ allele with clinical tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECROSIS-FACTOR-ALPHA; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DNA; AMPLIFICATION; POLYMORPHISM; INFECTION; RELEVANCE; HLA-DR1; VIRUS	Context.-Although tuberculosis (TB) is the leading worldwide cause of death due to an infectious disease, the extent to which progressive clinical disease is associated with genetic host factors remains undefined. Objective.-To determine the distribution of HLA antigens and the frequency of 2 alleles of the tumor necrosis factor alpha (TNF-alpha) gene in unrelated individuals with clinical TB (cases) compared with individuals with no history of clinical TB (controls) in a population with a high prevalence of TB exposure. Design.-A 2-stage, case-control molecular typing study conducted in 1995-1996. Setting.-Three district hospitals in Svay Rieng Province in rural Cambodia. Patients.-A total of 78 patients with clinical TB and 49 controls were included in the first stage and 48 patients with TB and 39 controls from the same area and socioeconomic status were included in the second stage. Main Outcome Measures.-Presence of HLA class I and class II alleles determined by sequence-specific oligonucleotide probe hybridization and presence of 2 TNF-alpha alleles determined by restriction fragment length polymorphism analysis. Results.-In the first stage, 7 DQB1*0503 alleles were detected among 156 alleles derived from patients with TB, whereas no DQB1*0503 alleles were found among the 98 alleles derived from controls (P=.04), There was no detectable difference in the distribution of the 2 TNF-alpha alleles in patients with TB compared with controls, In the second stage, we tested for the presence of a single variable, the DQB1*0503 allele, and found 9 DQB1*0503 alleles among 96 alleles derived from patients with TB and no DQB1*0503 alleles among 78 alleles in controls (P=.005), Conclusions.-The HLA-DQB1*0503 allele is significantly associated with susceptibility to TB in Cambodian patients and, to our knowledge, is the first identified gene associated with development of clinical TB.	Dana Farber Canc Inst, Div Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Immunogenet, Boston, MA 02115 USA; Dana Farber Canc Inst, Blood Bank, Boston, MA 02115 USA; Phnom Penh, Cambodian Hlth Comm, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Goldfeld, AE (corresponding author), Dana Farber Canc Inst, Div Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	anne_goldfeld@macmailgw.dfci.harvard.edu	Goldfeld, Anne/AAF-1818-2019		NHLBI NIH HHS [HL29583] Funding Source: Medline; NIMH NIH HHS [MH 40279] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040279, P30MH040279] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; BODMER JG, 1995, TISSUE ANTIGENS, V46, P1; BOTHAMLEY GH, 1989, J INFECT DIS, V159, P549, DOI 10.1093/infdis/159.3.549; Bozon MV, 1996, TISSUE ANTIGENS, V47, P512, DOI 10.1111/j.1399-0039.1996.tb02593.x; BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U; Brinkman BMN, 1996, J INFLAMM, V46, P32; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CEREB N, 1995, TISSUE ANTIGENS, V45, P1, DOI 10.1111/j.1399-0039.1995.tb02408.x; COHN DL, 1993, AIDS, V7, pS195, DOI 10.1097/00002030-199301001-00025; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; Farmer P, 1991, Semin Respir Infect, V6, P254; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GOLDFEL AE, 1994, COMMUNICATION   0210; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; KHOMENKO AG, 1990, TUBERCLE, V71, P187, DOI 10.1016/0041-3879(90)90074-I; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; Rajalingam R, 1996, J INFECT DIS, V173, P669, DOI 10.1093/infdis/173.3.669; RITH DN, 1996, P C ANT ACT CAMB PHN; Rom WN, 1996, TUBERCULOSIS, Vxxv; ROOK GAW, 1990, PATHOL BIOL, V38, P276; SALAZAR M, 1992, TISSUE ANTIGENS, V40, P116, DOI 10.1111/j.1399-0039.1992.tb02102.x; SKAMENE E, 1994, IMMUNOBIOLOGY, V191, P451, DOI 10.1016/S0171-2985(11)80451-1; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; *UN CHILDR FUND, 1990, CAMB SIT WOM CHILDR; *WHO, 1994, WHO REP TB EP; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; YUNIS JJ, 1993, TISSUE ANTIGENS, V41, P37, DOI 10.1111/j.1399-0039.1993.tb01975.x; YUNIS JJ, 1992, TISSUE ANTIGENS, V40, P41, DOI 10.1111/j.1399-0039.1992.tb01956.x	36	180	186	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					226	228		10.1001/jama.279.3.226	http://dx.doi.org/10.1001/jama.279.3.226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438744				2022-12-28	WOS:000071460700034
J	Faraone, SV; Biederman, J				Faraone, SV; Biederman, J			Depression: a family affair	LANCET			English	Editorial Material							CHILDHOOD		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Child Psychiat Serv,Paediat Psychopharmacol Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Faraone, SV (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Child Psychiat Serv,Paediat Psychopharmacol Unit, Boston, MA 02114 USA.		Faraone, Stephen V/O-7239-2018; Faraone, Stephen/AAE-7334-2019	Faraone, Stephen V/0000-0002-9217-3982; Faraone, Stephen/0000-0002-9217-3982				Beardslee WR, 1997, AM J PSYCHIAT, V154, P510; BIEDERMAN J, 1995, J AM ACAD CHILD PSY, V34, P579, DOI 10.1097/00004583-199505000-00010; BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120; Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1575, DOI 10.1097/00004583-199612000-00008; HARRINGTON R, 1990, ARCH GEN PSYCHIAT, V47, P463; LEFKOWITZ MM, 1978, PSYCHOL BULL, V85, P716, DOI 10.1037/0033-2909.85.4.716; Tsuang M, 1990, GENETICS MOOD DISORD; WEISSMAN MM, 1986, ARCH GEN PSYCHIAT, V43, P1104; Weissman MM, 1997, ARCH GEN PSYCHIAT, V54, P932	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					158	158		10.1016/S0140-6736(05)78214-3	http://dx.doi.org/10.1016/S0140-6736(05)78214-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449868				2022-12-28	WOS:000071616300007
J	Howard, G; Wagenknecht, LE; Burke, GL; Diez-Roux, A; Evans, GW; McGovern, P; Nieto, J; Tell, GS				Howard, G; Wagenknecht, LE; Burke, GL; Diez-Roux, A; Evans, GW; McGovern, P; Nieto, J; Tell, GS			Cigarette smoking and progression of atherosclerosis - The atherosclerosis risk in communities (ARIC) study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTIMA-MEDIA THICKNESS; POPULATION-BASED ULTRASONOGRAPHY; CORONARY HEART-DISEASE; CAROTID ATHEROSCLEROSIS; PASSIVE SMOKING; WALL THICKNESS; CARDIOVASCULAR HEALTH; ARTERY; DETERMINANTS; MORTALITY	Context.-Cigarette smoking is a powerful risk factor for incident heart disease and stroke, but the relationship of active and passive smoking with the progression of atherosclerosis has not been described. Objective.-To examine the impact of active smoking and exposure to environmental tobacco smoke (ETS) on the progression of atherosclerosis. Design.-A longitudinal assessment of the relationship between smoking exposure evaluated at the initial visit and the 3-year change in atherosclerosis. Setting.-A population-based cohort of middle-aged adults from 4 communities in the United States. Participants.-A total of 10914 participants from the Atherosclerosis Risk in Communities (ARIC) study enrolled between 1987 and 1989. Main Outcome Measure.-Change in atherosclerosis from baseline to the 5-year follow-up as indexed by intimal-medial thickness of the carotid artery assessed by ultrasound and adjusted for demographic characteristics, cardiovascular risk factors, and lifestyle variables. Results.-Exposure to cigarette smoke was associated with progression of atherosclerosis. Relative to never smokers and after adjustment for demographic characteristics, cardiovascular risk factors, and lifestyle variables, current cigarette smoking was associated with a 50% increase in the progression of atherosclerosis (mean progression rate over 3 years, 43.0 mu m for current and 28.7 mu m for never smokers, regardless of ETS exposure), and past smoking was associated with a 25% increase (mean progression rate over 3 years, 35.8 mu m for past smokers and 28.7 mu m for never smokers). Relative to those not exposed to ETS, exposure to ETS was associated with a 20% increase (35.2 mu m for those exposed to ETS vs 29.3 mu m for those not exposed). The impact of smoking on atherosclerosis progression was greater for subjects with diabetes and hypertension. Although more pack-years of exposure was independently associated with faster progression (P<.001), after controlling for the number of pack-years, the progression rates of current and past smokers did not differ (P=.11). Conclusions.-Both active smoking and ETS exposure are associated with the progression of an index of atherosclerosis. Smoking is of particular concern for patients with diabetes and hypertension. The fact that pack-years of smoking but not current vs past smoking was associated with progression of atherosclerosis suggests that some adverse effects of smoking may be cumulative and irreversible.	Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA; Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway	Wake Forest University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Bergen	Howard, G (corresponding author), Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA.		Tell, Grethe/G-5639-2015	Tell, Grethe/0000-0003-1386-1638; Howard, George/0000-0002-3068-5720	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055015, N01HC055016, N01HC055018] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, J Neuroimaging, V1, P68; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BELCARO G, 1995, VASA-J VASCULAR DIS, V24, P227; BOTS ML, 1993, ARTERIOSCLER THROMB, V13, P64, DOI 10.1161/01.ATV.13.1.64; BYINGTON RP, 1994, CIRCULATION, V90, P1; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CROUSE JR, 1992, CONTROL CLIN TRIALS, V13, P495, DOI 10.1016/0197-2456(92)90206-F; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DELCKER A, 1995, STROKE, V26, P2016, DOI 10.1161/01.STR.26.11.2016; DIEZROUX AV, 1995, PREV MED, V24, P48, DOI 10.1006/pmed.1995.1007; EVANS GW, 1996, CIRCULATION, V93, P624; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAY EC, 1992, DIABETES CARE, V15, P947, DOI 10.2337/diacare.15.8.947; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; KEYS A, 1957, LANCET, V2, P959; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; MARGITIC SE, 1992, CONTROL CLIN TRIALS, V13, P293; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; RILEY WA, 1991, J NEUROIMAGING, V1, P168; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V38, P113; SUAREZ L, 1984, AM J EPIDEMIOL, V120, P670, DOI 10.1093/oxfordjournals.aje.a113933; TELL GS, 1989, JAMA-J AM MED ASSOC, V261, P1178; TELL GS, 1994, CIRCULATION, V90, P2905, DOI 10.1161/01.CIR.90.6.2905; *US OFF SMOK HLTH, 1989, HLTH CONS SMOK CARD, P179; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; WILLARD JC, 1995, VITAL HTLH STAT, V263, P1; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; 1995, CONSUMER REPORTS, V20, P27	35	504	545	2	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					119	124		10.1001/jama.279.2.119	http://dx.doi.org/10.1001/jama.279.2.119			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440661	Bronze			2022-12-28	WOS:000071338900028
J	Lewis, G				Lewis, G			Continuum of self-destructiveness	LANCET			English	Editorial Material									Univ Wales Coll Med, Dept Psychol Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Lewis, G (corresponding author), Univ Wales Coll Med, Dept Psychol Med, Cardiff CF4 4XN, S Glam, Wales.		Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245				ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; James WPT, 1997, BMJ-BRIT MED J, V314, P1545, DOI 10.1136/bmj.314.7093.1545; Power C, 1997, LANCET, V350, P1584, DOI 10.1016/S0140-6736(97)07474-6; Rose G., 1992, STRATEGY PREVENTIVE; 1994, LANCET, V343, P1109	5	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					81	82		10.1016/S0140-6736(05)78154-X	http://dx.doi.org/10.1016/S0140-6736(05)78154-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439489				2022-12-28	WOS:000071591900006
J	Zhao, HQ; Ivic, L; Otaki, JM; Hashimoto, M; Mikoshiba, K; Firestein, S				Zhao, HQ; Ivic, L; Otaki, JM; Hashimoto, M; Mikoshiba, K; Firestein, S			Functional expression of a mammalian odorant receptor	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; RECOMBINANT ADENOVIRUS; OLFACTORY EPITHELIUM; CYSTIC-FIBROSIS; CELLS; NEURONS; MOUSE; RECOGNITION; FAMILY; VECTOR	Candidate mammalian odorant receptors were first cloned some 6 years ago. The physiological function of these receptors in initiating transduction in olfactory receptor neurons remains to be established. Here, a recombinant adenovirus was used to drive expression of a particular receptor gene in an increased number of sensory neurons in the rat olfactory epithelium. Electrophysiological recording showed that increased expression of a single gene led to greater sensitivity to a small subset of odorants.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Interdept Neurosci Program, New Haven, CT 06510 USA; RIKEN, Tsukuba Life Sci Ctr, Mol Neurobiol Lab, Tsukuba, Ibaraki 305, Japan	Columbia University; Yale University; RIKEN	Firestein, S (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Hashimoto, Mitsuhiro/G-1981-2010; Oka, Yoshitaka/C-9670-2010; Mikoshiba, Katsuhiko/N-7943-2015	Hashimoto, Mitsuhiro/0000-0002-8751-4068; Oka, Yoshitaka/0000-0002-3482-3051; 				BECKER TC, 1994, PROTEIN EXPRESSION A, P162; Breer Heinz, 1994, Seminars in Cell Biology, V5, P25, DOI 10.1006/scel.1994.1004; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hashimoto M, 1996, HUM GENE THER, V7, P149, DOI 10.1089/hum.1996.7.2-149; Holtmaat AJGD, 1996, MOL BRAIN RES, V41, P148, DOI 10.1016/0169-328X(96)00085-X; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LESALLE GL, 1993, SCIENCE, V259, P988; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; MACKAYSIM A, 1994, J NEUROPHYSIOL, V71, pC15; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; OTTOSON D, 1956, ACTA PHYSIOL SC S122, V35, P1; Ottoson D, 1971, HDB SENSORY PHYSIO 1, V4, P95; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RESTREPO D, 1995, EXPT CELL BIOL TASTE, P387; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1994, J NEUROPHYSIOL, V72, P2980, DOI 10.1152/jn.1994.72.6.2980; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SHIRLEY SG, 1987, BIOCHEM J, V245, P185, DOI 10.1042/bj2450185; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WELERDIECK C, 1997, CHEM SENSES, V22, P467; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1996, J NEUROBIOL, V30, P521, DOI 10.1002/(SICI)1097-4695(199608)30:4<521::AID-NEU7>3.0.CO;2-5	36	488	502	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					237	242		10.1126/science.279.5348.237	http://dx.doi.org/10.1126/science.279.5348.237			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422698				2022-12-28	WOS:000071408100045
J	Bevan, G				Bevan, G			Taking equity seriously: a dilemma for government from allocating resources to primary care groups	BRITISH MEDICAL JOURNAL			English	Article							FUNDHOLDING PRACTICES; RATES; NHS		Univ London London Sch Econ & Polit Sci, Dept Operat Res, London WC2A 2AE, England	University of London; London School Economics & Political Science	Bevan, G (corresponding author), Univ London London Sch Econ & Polit Sci, Dept Operat Res, Houghton St, London WC2A 2AE, England.							Andersen TF., 1990, CHALLENGES MED PRACT; *AUD COMM, 1996, WHAT DOCT ORD; Beecham L, 1997, BRIT MED J, V315, P209; BEVAN G, 1989, FISCAL STUDIES, V10, P53; Bevan G., 1997, RESOURCE ALLOCATION; BEVAN G, 1987, BRIT MED J, V308, P836; BEVAN G, 1996, RISK STRUCTURE COMPE; BEVAN G, 1980, HLTH CARE PRIORITIES; BEVAN G, 1984, FISCAL STUDIES, V5, P44; BEVAN G, 1987, BRIT MED J, V308, P1039; CAPER P, 1987, AM J PUBLIC HEALTH, V77, P669, DOI 10.2105/AJPH.77.6.669; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Crombie D L, 1988, Health Trends, V20, P53; *DEP HLTH OFF POP, 1995, PROBL HLTH CAR NAT H, P51; Department of Health and Social Security, 1976, SHAR RES HLTH ENGL R; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; Dowling B, 1997, BRIT MED J, V315, P290, DOI 10.1136/bmj.315.7103.290; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; Fleming D, 1991, Health Trends, V23, P100; Ham C, 1988, HLTH CARE VARIATIONS; Hillier F. S., 1995, INTRO OPERATIONS RES, P661; MAYS N, 1995, INT J EPIDEMIOL, V24, pS96, DOI 10.1093/ije/24.Supplement_1.S96; MAYS N, 1987, RESOURCE ALLOCATION; MILGROM P, 1992, EC ORG MANAGEMENT, P294; Mooney G, 1992, EC MED HLTH CARE, V2nd; National Audit Office, 1994, GEN PRACT FUNDH ENGL; *NHS EX, CHANG INT MARK; *NHS EX, 1996, GP FUNDH BUDG SETTL; PAULSHAHEEN P, 1987, J HEALTH POLIT POLIC, V12, P741, DOI 10.1215/03616878-12-4-741; SANDERS D, 1989, VARIATIONS HOSP ADMI; *SECR STAT HLTH, 1997, CM3807; *SECR STT HLTH WAL, 1989, CM555; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; Webster C., 1988, HLTH SERVICES WAR; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1985, MED CARE, V23, P512, DOI 10.1097/00005650-198505000-00012; WILKIN D, 1990, GEN PRACTITIONER REF	38	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					39	42		10.1136/bmj.316.7124.39	http://dx.doi.org/10.1136/bmj.316.7124.39			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451266	Green Published			2022-12-28	WOS:000071377900023
J	Geva, E; Amit, A; Lerner-Geva, L; Lessing, JB				Geva, E; Amit, A; Lerner-Geva, L; Lessing, JB			Prevention of early pregnancy loss in autoantibody seropositive women	LANCET			English	Article							ANTIBODIES		Lis Matern Hosp, Tel Aviv Sourasky Med Ctr, Sara Racine In Vitro Fertilizat Unit, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Lessing, JB (corresponding author), Lis Matern Hosp, Tel Aviv Sourasky Med Ctr, Sara Racine In Vitro Fertilizat Unit, IL-64239 Tel Aviv, Israel.							Geva E, 1997, FERTIL STERIL, V67, P599, DOI 10.1016/S0015-0282(97)81351-9; GEVA E, 1994, FERTIL STERIL, V62, P802; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; ROTE NS, 1992, AM J REPROD IMMUNOL, V28, P31, DOI 10.1111/j.1600-0897.1992.tb00753.x	4	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					34	35		10.1016/S0140-6736(05)78093-4	http://dx.doi.org/10.1016/S0140-6736(05)78093-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433430				2022-12-28	WOS:000071253100017
J	Chesebro, B				Chesebro, B			Prion diseases - BSE and prions: Uncertainties about the agent	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSGENIC MICE; NEURODEGENERATION; PROTEIN		NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chesebro, B (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA.							Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1997, COMMUNICATION; Chesebro B, 1997, NAT MED, V3, P491, DOI 10.1038/nm0597-491; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; CUGHEY B, 1997, TRENDS CELL BIOL, V7, P56; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	14	145	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					42	43		10.1126/science.279.5347.42	http://dx.doi.org/10.1126/science.279.5347.42			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9441410				2022-12-28	WOS:000071323900032
J	Schlessinger, J				Schlessinger, J			Direct binding and activation of receptor tyrosine kinases by collagen	CELL			English	Review							GROWTH-FACTOR; DISCOIDIN-I; SIGNAL-TRANSDUCTION; LIGANDS; FAMILY; OLIGOMERIZATION; ATTACHMENT; INTEGRINS		NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA	New York University	Schlessinger, J (corresponding author), NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA.							ALVES F, 1995, ONCOGENE, V10, P609; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156	20	73	73	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					869	872		10.1016/S0092-8674(00)80477-8	http://dx.doi.org/10.1016/S0092-8674(00)80477-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428509	hybrid			2022-12-28	WOS:000071281400003
J	Schwartz, LB				Schwartz, LB			Understanding human parturition	LANCET			English	Editorial Material							PROGESTERONE RECEPTORS; LABOR; ESTRADIOL; PREGNANCY; TERM		NYU, Med Ctr, Dept Obstet & Gynaecol, New York, NY 10016 USA	New York University	Schwartz, LB (corresponding author), NYU, Med Ctr, Dept Obstet & Gynaecol, New York, NY 10016 USA.							AMBRUS G, 1994, ENDOCRINOLOGY, V135, P2772, DOI 10.1210/en.135.6.2772; BECK P, 1978, OBSTET GYNECOL, V51, P686; CHWALISZ K, 1994, HUM REPROD, V9, P131, DOI 10.1093/humrep/9.suppl_1.131; Faber BM, 1996, OBSTET GYNECOL, V88, P174, DOI 10.1016/0029-7844(96)00136-6; FLINT APF, 1975, BIOCHEM SOC T, V3, P1189, DOI 10.1042/bst0031189; GIANNOPOULOS G, 1979, J CLIN ENDOCR METAB, V49, P100, DOI 10.1210/jcem-49-1-100; HOW H, 1995, OBSTET GYNECOL, V86, P936, DOI 10.1016/0029-7844(95)00306-C; JOHNSTON TA, 1993, BRIT J OBSTET GYNAEC, V100, P483, DOI 10.1111/j.1471-0528.1993.tb15277.x; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; KHANDAWOOD FS, 1984, AM J OBSTET GYNECOL, V150, P510; PADAYACHI T, 1990, J STEROID BIOCHEM, V37, P509, DOI 10.1016/0960-0760(90)90394-Z; PERROTAPPLANAT M, 1994, J CLIN ENDOCR METAB, V78, P216, DOI 10.1210/jc.78.1.216; Rezapour M, 1997, OBSTET GYNECOL, V89, P918, DOI 10.1016/S0029-7844(97)00116-6; Rezapour M, 1996, STEROIDS, V61, P338, DOI 10.1016/0039-128X(96)00035-9; WILSON L, 1996, REPROD ENDOCRINOLOGY, P452	15	14	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1792	1793		10.1016/S0140-6736(05)63632-X	http://dx.doi.org/10.1016/S0140-6736(05)63632-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428247	hybrid			2022-12-28	WOS:000071102500004
J	Widom, J				Widom, J			Transcription - Getting around the nucleosomes	SCIENCE			English	Editorial Material							HISTONE OCTAMER; MODEL; CHROMATIN		NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University	Widom, J (corresponding author), NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,2153 SHERIDAN RD,EVANSTON,IL 60208, USA.							JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LUGERK, 1997, NATURE, V389, P251; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Protacio RU, 1996, J MOL BIOL, V256, P458, DOI 10.1006/jmbi.1996.0101; PROTACIO RU, IN PRESS J MOL BIOL; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	13	10	10	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1899	1901		10.1126/science.278.5345.1899	http://dx.doi.org/10.1126/science.278.5345.1899			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417638				2022-12-28	WOS:A1997YL00200020
J	OBrien, E				OBrien, E			Walk in peace: banish landmines from our globe	BRITISH MEDICAL JOURNAL			English	Article											OBrien, E (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,ST STEPHENS GREEN,DUBLIN 2,IRELAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1456	1458		10.1136/bmj.315.7120.1456	http://dx.doi.org/10.1136/bmj.315.7120.1456			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418101	Green Published			2022-12-28	WOS:A1997YJ67200038
J	Cooper, RI; Neuhauser, T				Cooper, RI; Neuhauser, T			Borreliosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA	United States Department of Defense; United States Air Force	Cooper, RI (corresponding author), Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					231	231		10.1056/NEJM199801223380405	http://dx.doi.org/10.1056/NEJM199801223380405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435329				2022-12-28	WOS:000071594100005
J	Ravelli, ACJ; van der Meulen, JHP; Michels, RPJ; Osmond, C; Barker, DJP; Hales, CN; Bleker, OP				Ravelli, ACJ; van der Meulen, JHP; Michels, RPJ; Osmond, C; Barker, DJP; Hales, CN; Bleker, OP			Glucose tolerance in adults after prenatal exposure to famine	LANCET			English	Article							LOW-PROTEIN-DIET; DEPENDENT DIABETES-MELLITUS; CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE; FETAL GROWTH; BIRTH-WEIGHT; THRIFTY PHENOTYPE; INFANT GROWTH; YOUNG MEN; INSULIN	Background Reduced growth in utero is associated with type 2 (non-insulin-dependent) diabetes and impaired glucose tolerance in adult life. There is no direct evidence in human beings that maternal nutrition during gestation affects insulin-glucose metabolism. We investigated glucose tolerance in people born around the time of famine in the Netherlands during 1944-45. Methods We included 702 people born between Nov 1, 1943, and Feb 28, 1947, in Amsterdam, for whom we had detailed prenatal and birth records. We compared glucose and insulin responses to a standard oral glucose load in participants exposed to famine at any stage during gestation (exposed participants) with those who were born in the year before or conceived in the year after the famine (non-ex posed participants). Findings Glucose concentrations were increased 2 h after a standard glucose load among exposed participants (p=0.006), and were highest in men and women exposed during mid and late gestation. Mean 2 h glucose concentration among non-exposed participants was 5.8 mmol/L; concentrations were 0.5 mmol/L (95% Cl 0.1-0.9) higher among participants exposed during late gestation, 0.4 mmol/L (0-0.8) higher among those exposed during mid gestation, and 0.1 mmol/L (-0.4 to 0.6) among those exposed during early gestation. Participants born as thin babies to mothers with low bodyweights had the highest concentrations and concentrations were especially high among people exposed to famine who became obese as adults, Prenatal exposure to famine was related to increased fasting proinsulin (p=0.05) and 2 h insulin concentrations (p=0.04), which suggests an association with insulin resistance. Interpretation Prenatal exposure to famine, especially during late gestation, is linked to decreased glucose tolerance in adults. Poor nutrition in utero may lead to permanent changes in insulin-glucose metabolism, even if the effect on fetal growth is small. This effect of famine on glucose tolerance is especially important in people who become obese.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam Zuidoost, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1100 DE Amsterdam Zuidoost, Netherlands; Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton, Hants, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, NL-1100 DE Amsterdam Zuidoost, Netherlands	University of Amsterdam; University of Amsterdam; University of Southampton; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Amsterdam	van der Meulen, JHP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22700, NL-1100 DE Amsterdam Zuidoost, Netherlands.		Ravelli, Anita CJ/ABR-1494-2022	Ravelli, Anita CJ/0000-0002-3447-8286; van der Meulen, Jan/0000-0002-9451-2335; Osmond, Clive/0000-0002-9054-4655				Bakker B., 1997, SOCIALE WETENSCHAPPE, V40, P1; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Burger G., 1948, MALNUTRITION STARVAT; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forrester TE, 1996, BRIT MED J, V312, P156; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; HARDING JE, 1995, REPROD FERT DEVELOP, V7, P539, DOI 10.1071/RD9950539; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; Holemans K, 1996, J SOC GYNECOL INVEST, V3, P71, DOI 10.1016/1071-5576(95)00046-1; IglesiasBarreira V, 1996, ENDOCRINOLOGY, V137, P3797, DOI 10.1210/en.137.9.3797; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; Law CM, 1996, DIABETIC MED, V13, pS49; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Stein Z., 1975, FAMINE HUM DEV DUTCH; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Wareham N J, 1995, Diabet Med, V12, P931; Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	34	1095	1121	0	82	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					173	177		10.1016/S0140-6736(97)07244-9	http://dx.doi.org/10.1016/S0140-6736(97)07244-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449872				2022-12-28	WOS:000071616300011
J	Koritsanszky, T; Flaig, R; Zobel, D; Krane, HG; Morgenroth, W; Luger, P				Koritsanszky, T; Flaig, R; Zobel, D; Krane, HG; Morgenroth, W; Luger, P			Accurate experimental electronic properties of DL-proline monohydrate obtained within 1 day	SCIENCE			English	Article							CHARGE-DENSITY	A 1-day x-ray diffraction experiment on DL-proline monohydrate was performed at 100 kelvin with synchrotron radiation and a charge-coupled device area detection technique. The accuracy of the charge density distribution and of the related electronic properties extracted from these data is comparable or even superior to the accuracy obtained from a 6-week experiment on DL-aspartic acid with conventional x-ray diffraction methods. A data acquisition time of 1 day is comparable to the time needed for an ab initio calculation on the isolated molecules, This technique renders larger molecular systems of biological importance accessible to charge density experiments.	Free Univ Berlin, Inst Crystallog, D-14195 Berlin, Germany; Univ Bonn, Inst Mineral & Petrog, D-53115 Bonn, Germany; Univ Hamburg, Inst Mineral & Petrog, D-20146 Hamburg, Germany	Free University of Berlin; University of Bonn; University of Hamburg	Luger, P (corresponding author), Free Univ Berlin, Inst Crystallog, Takustr 6, D-14195 Berlin, Germany.	luger@chemie.fu-berlin.de	Morgenroth, Wolfgang HW/I-4541-2014; Morgenroth, Wolfgang/AAT-7606-2020	Morgenroth, Wolfgang HW/0000-0001-8921-0052; 				Bader R. F. W., 1990, ATOMS MOL QUANTUM TH; Bader R.F.W., 1994, ANGEW CHEM, V106, P647; BOLOTOVSKY R, 1995, J APPL CRYSTALLOGR, V28, P86, DOI 10.1107/S0021889894009696; Carducci M, 1996, ACTA CRYSTALLOGR A, V52, pC342, DOI 10.1107/S0108767396085844; Clementi E., 1974, Atomic Data and Nuclear Data Tables, V14, P177, DOI 10.1016/S0092-640X(74)80016-1; COPPENS P, 1967, SCIENCE, V158, P1577, DOI 10.1126/science.158.3808.1577; Coppens P., 1997, XRAY CHARGE DENSITIE; CRAVEN BM, 1981, ACTA CRYSTALLOGR B, V37, P1584, DOI 10.1107/S0567740881006626; Darovsky A, 1996, ACTA CRYSTALLOGR A, V52, pC547, DOI 10.1107/S0108767396077690; FLENSBURG C, 1995, J PHYS CHEM-US, V99, P10130, DOI 10.1021/j100025a013; Frisch M. J., 1992, GAUSSIAN 92; GATTI C, 1992, J MOL STRUC-THEOCHEM, V87, P409, DOI 10.1016/0166-1280(92)85022-D; HAIG F, IN PRESS J AM CHEM S; HANSEN NK, 1978, ACTA CRYSTALLOGR A, V34, P909, DOI 10.1107/S0567739478001886; KELLER E, 1988, SCHAKAL88 USER MANUA; KHANARIAN G, 1980, AUST J CHEM, V33, P1727, DOI 10.1071/CH9801727; Koritsanszky T, 1996, J PHYS CHEM-US, V100, P10547, DOI 10.1021/jp952466n; KORITSANSZKY T, 1995, XD COMPUTER PROGRAM; LECOMTE C, 1990, T AM CRYSTALLOGR A 5, V26, P55; Politzer P., 1981, CHEM APPL ATOMIC MOL; STEWART RF, 1969, J CHEM PHYS, V51, P4569, DOI 10.1063/1.1671828; SU ZW, 1992, ACTA CRYSTALLOGR A, V48, P188, DOI 10.1107/S0108767391009820	22	114	114	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					356	358		10.1126/science.279.5349.356	http://dx.doi.org/10.1126/science.279.5349.356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430581				2022-12-28	WOS:000071570800039
J	Kiefer, JR; Mao, C; Braman, JC; Beese, LS				Kiefer, JR; Mao, C; Braman, JC; Beese, LS			Visualizing DNA replication in a catalytically active Bacillus DNA polymerase crystal	NATURE			English	Article							ESCHERICHIA-COLI; KLENOW FRAGMENT; KINETIC MECHANISM; NUCLEIC-ACIDS; FIDELITY; BINDING	DNA polymerases copy DNA templates with remarkably high fidelity, checking for correct base-pair formation both at nucleotide insertion and at subsequent DNA extension steps(1-3). Despite extensive biochemical, genetic and structural studies(2,4), the mechanism by which nucleotides are correctly incorporated is not known, Here we present high-resolution crystal structures of a thermostable bacterial (Bacillus stearothermophiIus) DNA polymerase large fragment(5) with DNA primer templates bound productively at the polymerase active site. The active site retains catalytic activity, allowing direct observation of the products of several rounds of nucleotide incorporation, The polymerase also retains its ability to discriminate between correct and incorrectly paired nucleotides in the crystal, Comparison of the structures of successively translocated complexes allows the structural features for the sequence-independent molecular recognition of correctly formed base pairs to be deduced unambiguously. These include extensive interactions with the first four to five base pairs in the minor groove, location of the terminal base pair in a pocket of excellent steric complementarity favouring correct base-pair formation, and a conformational switch from B-form to underwound A-form DNA at the polymerase active site.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Stratagene, La Jolla, CA 92017 USA	Duke University	Beese, LS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.		beese, lorena/G-4993-2010	Kiefer, James/0000-0001-6317-0902				Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P607; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DICKERSON DE, 1997, OXFORD HDB NUCL ACID; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKINSON G, 1996, ACTA CRYSTALLOGR D, V52, P557; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Saenger W., 1984, PRINCIPLES NUCL ACID; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	482	494	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					304	307		10.1038/34693	http://dx.doi.org/10.1038/34693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440698				2022-12-28	WOS:000071484400057
J	Schillinger, D				Schillinger, D			The disability blues	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					15	15		10.1001/jama.279.1.15	http://dx.doi.org/10.1001/jama.279.1.15			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424031				2022-12-28	WOS:000071295100010
J	Sicherer, SH; Winkelstein, JA				Sicherer, SH; Winkelstein, JA			Primary immunodeficiency diseases in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMON VARIABLE IMMUNODEFICIENCY; ADENOSINE-DEAMINASE DEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; X-LINKED AGAMMAGLOBULINEMIA; SELECTIVE IGA DEFICIENCY; GENE-THERAPY; BONE-MARROW; HYPOGAMMAGLOBULINEMIA; REPLACEMENT; FAMILY		Johns Hopkins Hosp, Dept Pediat, Eudowood Div Immunol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Winkelstein, JA (corresponding author), Johns Hopkins Hosp, Dept Pediat, Eudowood Div Immunol, CMSC 1102, Baltimore, MD 21287 USA.							AMENT ME, 1973, MEDICINE, V52, P227, DOI 10.1097/00005792-197305000-00004; ASHMAN RF, 1992, J CLIN IMMUNOL, V12, P406, DOI 10.1007/BF00918852; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; CONLEY ME, 1986, J PEDIATR-US, V108, P915, DOI 10.1016/S0022-3476(86)80927-1; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; FINN A, 1990, ARCH DIS CHILD, V65, P942, DOI 10.1136/adc.65.9.942; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; FRENCH MAH, 1995, CLIN EXP IMMUNOL, V100, P47; Good RA, 1971, IMMUNOLOGIC INCOMPET, P149; HANSON LA, 1991, CLIN IMMUNOL IMMUNOP, V61, pS70, DOI 10.1016/S0090-1229(05)80040-6; HAUSSER C, 1983, AM J DIS CHILD, V137, P833, DOI 10.1001/archpedi.1983.02140350011004; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V2, P1725; HOLMES B, 1966, LANCET, V1, P1225; KORNFELD SJ, 1994, NEW ENGL J MED, V331, P949; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; OLERUP O, 1992, P NATL ACAD SCI USA, V89, P10653, DOI 10.1073/pnas.89.22.10653; Ozsahin H, 1997, BLOOD, V89, P2849, DOI 10.1182/blood.V89.8.2849; ROIFMAN CM, 1985, AM J MED, V79, P171, DOI 10.1016/0002-9343(85)90006-3; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; SCHAPIRO BL, 1991, NEW ENGL J MED, V325, P1786, DOI 10.1056/NEJM199112193252506; SHOVLIN CL, 1994, J IMMUNOL, V153, P2331; SNELLER MC, 1993, ANN INTERN MED, V118, P720, DOI 10.7326/0003-4819-118-9-199305010-00011; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; SWEINBERG SK, 1991, J ALLERGY CLIN IMMUN, V88, P96, DOI 10.1016/0091-6749(91)90306-9; VORECHOVSKY I, 1995, CLIN IMMUNOL IMMUNOP, V77, P185, DOI 10.1006/clin.1995.1142; WRIGHT JJ, 1990, BLOOD, V76, P2046	35	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					58	61		10.1001/jama.279.1.58	http://dx.doi.org/10.1001/jama.279.1.58			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424046				2022-12-28	WOS:000071295100037
J	Azuonye, IO				Azuonye, IO			A difficult case - Diagnosis made by hallucinatory voices	BRITISH MEDICAL JOURNAL			English	Article									Lambeth Healthcare NHS Trust, Adult Mental Hlth Unit, London SW9 9NT, England		Azuonye, IO (corresponding author), Lambeth Healthcare NHS Trust, Adult Mental Hlth Unit, London SW9 9NT, England.								0	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1685	1686		10.1136/bmj.315.7123.1685	http://dx.doi.org/10.1136/bmj.315.7123.1685			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448541	Green Published			2022-12-28	WOS:000071149400027
J	Boonen, A; van de Rest, J; Dequeker, J; van der Linden, S				Boonen, A; van de Rest, J; Dequeker, J; van der Linden, S			How Renoir coped with rheumatoid arthritis	BRITISH MEDICAL JOURNAL			English	Article									Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands; Reumafonds, NL-2508 GE The Hague, Netherlands; Univ Hosp Leuven, Dept Rheumatol, Louvain, Belgium	Maastricht University; Maastricht University Medical Centre (MUMC); KU Leuven; University Hospital Leuven	Boonen, A (corresponding author), Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands.							LOUIE JS, 1987, ART HIST ANTIQUITY R, P43; Renoir Jean, 1981, PA RENOIR MON PERE; Riviere Georges, 1921, RENOIR SES AMIS; Saudan Y, 1987, ART HIST ANTIQUITY R, P46; VANDUINKERKEN A, 1958, MENSEN HEBBEN HUN GE; WHITE BE, 1984, RENOIR HIS LIFE ART	6	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1704	1708		10.1136/bmj.315.7123.1704	http://dx.doi.org/10.1136/bmj.315.7123.1704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448547	Green Published			2022-12-28	WOS:000071149400039
J	McCune, JM				McCune, JM			Animal models of HIV-1 disease	SCIENCE			English	Article							SCID-HU MOUSE; IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN HEMATOLYMPHOID DIFFERENTIATION; TRANSGENIC MODELS; IN-VIVO; REPLICATION; CELLS		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV AIDS,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	McCune, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94110, USA.							AKKINA RK, 1994, BLOOD, V84, P1393; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bonyhadi ML, 1997, J VIROL, V71, P4707, DOI 10.1128/JVI.71.6.4707-4716.1997; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; Kitchen SG, 1997, J VIROL, V71, P6928, DOI 10.1128/JVI.71.9.6928-6934.1997; Klotman PE, 1996, CURR TOP MICROBIOL, V206, P197; Levy JA, 1996, J MED PRIMATOL, V25, P163, DOI 10.1111/j.1600-0684.1996.tb00013.x; LEWIS AD, 1995, TRENDS BIOTECHNOL, V13, P142, DOI 10.1016/S0167-7799(00)88925-8; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1992, BONE MARROW TRANSPL, V9, P74; MCCUNE JM, 1990, SEMIN VIROL, V1, P229; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; Rabin L, 1996, ANTIMICROB AGENTS CH, V40, P755, DOI 10.1128/AAC.40.3.755; RONCAROLO M, 1995, HUMAN HEMATOPOIESIS; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; Su LS, 1997, VIROLOGY, V227, P45, DOI 10.1006/viro.1996.8338; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Toggas SM, 1996, CURR TOP MICROBIOL, V206, P223	19	35	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2141	2142		10.1126/science.278.5346.2141	http://dx.doi.org/10.1126/science.278.5346.2141			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432722				2022-12-28	WOS:A1997YM23500058
J	Giannou, C				Giannou, C			Antipersonnel landmines: facts, fictions, and priorities	BRITISH MEDICAL JOURNAL			English	Article							LAND MINES; MOZAMBIQUE; INJURIES				Giannou, C (corresponding author), RED CROSS,INT COMM,DIV HLTH OPERAT,CAMPAIGN BAN ANTIPERSONNEL MINES,CH-1202 GENEVA,SWITZERLAND.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; COUPLAND R, 1997, ASSISTANCE VICTIMS A; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; *INT COMM RED CROS, 1996, ANT LANDM FRIEND FOE; *INT COMM RED CROS, 1995, WORLDW EP LANDM INJ; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; KAKAR F, 1996, PREHOSPITAL DISASTER, V11, P13; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P1245	9	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1453	1454		10.1136/bmj.315.7120.1453	http://dx.doi.org/10.1136/bmj.315.7120.1453			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418100	Green Published			2022-12-28	WOS:A1997YJ67200036
J	Meddings, DR				Meddings, DR			Weapons injuries during and after periods of conflict: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess the relative frequency of weapon injuries during conflict and after periods of conflict in the absence of disarmament. Design: Retrospective analysis of a database of war wounds. Setting: Region with a protracted conflict between rival combatant groups and a subsequent transition to the uncontested military authority of a single power. Subjects: 2332 people who received weapons injuries during the conflict or post-conflict periods and were admitted to hospital within 24 hours of injury. Main outcome measures: Percentage change in mean monthly admission rate by weapon type between conflict and post-conflict periods; annual incidence of injury by weapon type during conflict and post-conflict periods; percentage change in annual incidence by weapon type between conflict and post-conflict periods. Results: Mean monthly admission rates for-injuries from fragmentation munitions decreased by 8% between conflict and post-conflict periods and by 23% for injuries from mines and 32% for gunshot injuries. The decline in admissions for all injuries was 23%. After adjustment for population growth over the study period, declines in annual incidence were 22% for fragmentation munitions injuries, 34% for mine injuries, and 40% for gunshot injuries. The decline in incidence for all injuries was 33%. In-hospital mortality from weapons related injuries increased from 2.5% to 6.1% (P < 0.001) between conflict and post-conflict periods. Conclusions: In this setting, continued availability of weapons is associated with increased mortality and a level of injuries from weapons that is only somewhat reduced from that observed during a period of conflict.			Meddings, DR (corresponding author), INT COMM RED CROSS,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							COUPLAND RM, 1996, MED GLOBAL SURVIVAL, V3, pA1; COUPLAND RM, 1994, RECENT ADV SURG, P121; COX D, 1996, MANAGING ARMS PEACE, P83; EISEMAN B, 1979, J TRAUMA, V19, P848, DOI 10.1097/00005373-197911000-00011; GAMBA V, 1997, SOC SIEGE CRIME VIOL, P1; GAMBA V, 1996, MANAGING ARMS PEACE, pR13; Klare M. T., 1995, LETHAL COMMERCE GLOB; Smith C., 1995, LETHAL COMMERCE GLOB, P61; Williams P., 1997, SOC SIEGE CRIME VIOL; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	10	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1417	1420		10.1136/bmj.315.7120.1417	http://dx.doi.org/10.1136/bmj.315.7120.1417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418089	Green Published			2022-12-28	WOS:A1997YJ67200025
J	Shaywitz, SE				Shaywitz, SE			Current concepts - Dyslexia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW ACHIEVEMENT DEFINITIONS; READING-DISABILITY; PHONOLOGICAL AWARENESS; LEARNING-DISABILITIES; KINDERGARTEN-CHILDREN; ADULT DYSLEXICS; DISCREPANCY; PREVALENCE; DISORDER; PROFILE		Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA	Yale University	Shaywitz, SE (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06510 USA.				NICHD NIH HHS [P50 HD-25802, P01 HD-21888] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD025802, P01HD021888] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1982, ANN DYSLEXIA, DOI DOI 10.1007/BF02647960; [Anonymous], 1998, WOODCOCK READING MAS; Aram D. M., 1988, EXCEPTIONAL BRAIN NE, P70; BALL EW, 1991, READ RES QUART, V26, P49, DOI 10.1598/RRQ.26.1.3; BRADLEY L, 1983, NATURE, V301, P419, DOI 10.1038/301419a0; BROWN JI, 1993, NELSONDENNY READING; BRUCK M, 1992, DEV PSYCHOL, V28, P874, DOI 10.1037/0012-1649.28.5.874; CARDON LR, 1995, SCIENCE, V268, P1553, DOI 10.1126/science.7777847; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CATTS HW, IN PRESS LANGUAGE BA; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; Eden GF, 1996, NATURE, V382, P66, DOI 10.1038/382066a0; FELTON RH, 1990, BRAIN LANG, V39, P485, DOI 10.1016/0093-934X(90)90157-C; Finucci J.M., 1981, SEX DIFFERENCES DYSL, P1; FLETCHER JM, 1994, J EDUC PSYCHOL, V86, P6, DOI 10.1037//0022-0663.86.1.6; FLETCHER JM, IN PRESS NEURODEVELO; FLETCHER JM, 1996, USE IQ TESTS SPECIAL; FLYNN JM, 1994, PSYCHOL SCHOOLS, V31, P66, DOI 10.1002/1520-6807(199401)31:1<66::AID-PITS2310310109>3.0.CO;2-J; Foorman B.R., 1997, LEARN DISABIL-MULTI, V8, P63; Francis DJ, 1996, J EDUC PSYCHOL, V88, P3, DOI 10.1037/0022-0663.88.1.3; Friedman RF, 1993, CLIN NEUROPSYCHOLOGY, P37; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; Gilger J. W., 1996, DEV DYSLEXIA NEURAL, P63; Gough P.B., 1986, REM SPEC EDUC, V7, P6, DOI [10.1177/074193258600700104, DOI 10.1177/074193258600700104]; Grigorenko EL, 1997, AM J HUM GENET, V60, P27; *INT COMM LEARN DI, 1987, LEARN DIS; LEFLY DL, 1991, ANN DYSLEXIA, V41, P143, DOI 10.1007/BF02648083; LERNER JW, 1989, J AM ACAD CHILD PSY, V28, P326, DOI 10.1097/00004583-198905000-00004; Lyon G., 1997, LEARNING DISABILITIE, V8, P1; LYON GR, 1995, ANN DYSLEXIA, V45, P3, DOI 10.1007/BF02648210; Lyon GR, 1997, J LEARN DISABIL-US, V30, P578, DOI 10.1177/002221949703000601; LYON GR, 1996, NEUROIMAGING WINDOW; OLSON RK, 1994, VARIETIES ORTHOGRAPH, V1, P27; Pennington B.F., 1996, DEV DYSLEXIA NEURAL, P41; SCARBOROUGH HS, 1984, BRIT J PSYCHOL, V75, P329, DOI 10.1111/j.2044-8295.1984.tb01904.x; SCARBOROUGH HS, IN PRESS SPECIFIC RE; SHANKWEILER D, 1979, J EXP PSYCHOL-HUM L, V5, P531, DOI 10.1037/0278-7393.5.6.531; SHANWEILER D, 1995, PSYCHOL SCI, V6, P149, DOI 10.1111/j.1467-9280.1995.tb00324.x; Share DL., 1995, ISSUES ED CONTRIBUTI, V1, P1, DOI DOI 10.1111/J.1467-9817.1995.TB00075.X; SHAYWITZ BA, 1995, READ RES QUART, V30, P894, DOI 10.2307/748203; Shaywitz BA, 1995, CHILD NEUROPSYCHOL, V1, P170, DOI 10.1080/09297049508400223; SHAYWITZ BA, 1992, J LEARN DISABIL, V25, P639, DOI 10.1177/002221949202501003; Shaywitz S. E., 1996, LANGUAGE LEARNING BE, P199; SHAYWITZ SE, 1994, TOP LANG DISORD, V14, P1, DOI 10.1097/00011363-199408000-00003; SHAYWITZ SE, 1992, NEW ENGL J MED, V326, P145, DOI 10.1056/NEJM199201163260301; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; Shaywitz SE, 1996, SCI AM, V275, P98, DOI 10.1038/scientificamerican1196-98; SIEGEL LS, 1989, J LEARN DISABIL-US, V22, P514, DOI 10.1177/002221948902200814; SILVER LB, 1995, J CHILD NEUROL, V10, pS96, DOI 10.1177/08830738950100S119; STANOVICH KE, 1984, J EXP CHILD PSYCHOL, V38, P175, DOI 10.1016/0022-0965(84)90120-6; STANOVICH KE, 1994, J EDUC PSYCHOL, V86, P24, DOI 10.1037/0022-0663.86.1.24; Stein J, 1997, TRENDS NEUROSCI, V20, P147, DOI 10.1016/S0166-2236(96)01005-3; STEIN JF, 1993, VISUAL PROCESSES REA, P331; Thatcher RW, 1996, DEV NEUROIMAGING MAP, P91; TORGESEN J, 1995, WORKSH IQ TEST ED DE; TORGESEN JK, 1992, J EDUC PSYCHOL, V84, P364; TORGESEN JK, 1994, J LEARN DISABIL, V27, P276, DOI 10.1177/002221949402700503; WADSWORTH SJ, 1992, J CHILD PSYCHOL PSYC, V33, P1229, DOI 10.1111/j.1469-7610.1992.tb00941.x; WISE BW, 1995, ANN DYSLEXIA, V45, P99, DOI 10.1007/BF02648214	60	510	520	0	54	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					307	312		10.1056/NEJM199801293380507	http://dx.doi.org/10.1056/NEJM199801293380507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT963	9445412				2022-12-28	WOS:000071665200007
J	Nishibayashi, Y; Iwai, S; Hidai, M				Nishibayashi, Y; Iwai, S; Hidai, M			Bimetallic system for nitrogen fixation: Ruthenium-assisted protonation of coordinated N-2 on tungsten with H-2	SCIENCE			English	Article							DINITROGEN-MOLYBDENUM COMPLEXES; DIAZOALKANE COMPLEXES; MOLECULAR NITROGEN; ARYLATION	Treatment of the tungsten dinitrogen complex cis-[W(N-2)(2)(PMe2Ph)(4)] (Me = methyl, Ph = phenyl) with an equilibrium mixture of [RuCl(dppp)(2)]X and trans-[RuCl(eta(2)-H-2)(dppp)(2)]X [X = BF4, PF6, or OSO2CF3; dppp = 1,3-bis(diphenylphosphino)propane] under 1 atmosphere of dihydrogen at 55 degrees Celsius for 24 hours gave NH3 in moderate yield. The same reaction in the presence of acetone produced acetone azine in high yield. None of these reactions proceeded in the absence of dihydrogen.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Hidai, M (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Nishibayashi, Yoshiaki/E-9230-2010	Nishibayashi, Yoshiaki/0000-0001-9739-9588				BEVAN PC, 1978, J ORGANOMET CHEM, V160, P165, DOI 10.1016/S0022-328X(00)91210-5; CHATT J, 1977, J CHEM SOC DALTON, P1852, DOI 10.1039/dt9770001852; CHATT J, 1974, J CHEM SOC DALTON, P2074, DOI 10.1039/dt9740002074; Ertl G, 1991, CATALYTIC AMMONIA SY; Fryzuk MD, 1997, SCIENCE, V275, P1445, DOI 10.1126/science.275.5305.1445; GEORGE TA, 1988, INORG CHEM, V27, P2909, DOI 10.1021/ic00290a003; HIDAI M, 1995, CHEM REV, V95, P1115, DOI 10.1021/cr00036a008; HIDAI M, 1972, J AM CHEM SOC, V94, P110, DOI 10.1021/ja00756a021; HIDAI M, 1980, CHEM LETT, P645; HIDAI M, 1976, INORG CHEM, V15, P2694, DOI 10.1021/ic50165a025; HIDAI M, 1978, J AM CHEM SOC, V100, P5740, DOI 10.1021/ja00486a026; HIDAI M, 1991, CHEM LETT, P383; Hidai M., 1969, CHEM COMMUN, V1969, P1392; ISHII Y, 1992, J AM CHEM SOC, V114, P5429, DOI 10.1021/ja00039a067; ISHII Y, 1994, ORGANOMETALLICS, V13, P5062, DOI 10.1021/om00024a057; JIA G, 1991, INORG CHEM, V30, P594; MIZOBE Y, 1980, B CHEM SOC JPN, V53, P1781, DOI 10.1246/bcsj.53.1781; NISHIBAYASHI Y, UNPUB; NISHIHARA H, 1982, J AM CHEM SOC, V104, P4367, DOI 10.1021/ja00380a010; Rocchini E, 1997, INORG CHEM, V36, P711, DOI 10.1021/ic9605579; TAKAHASHI T, 1980, J AM CHEM SOC, V102, P7461, DOI 10.1021/ja00545a011; WATAKABE A, 1983, J ORGANOMET CHEM, V254, P75, DOI 10.1016/0022-328X(83)85119-5	22	145	148	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					540	542		10.1126/science.279.5350.540	http://dx.doi.org/10.1126/science.279.5350.540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438842				2022-12-28	WOS:000071616000039
J	Eiserich, JP; Hristova, M; Cross, CE; Jones, AD; Freeman, BA; Halliwell, B; van der Vliet, A				Eiserich, JP; Hristova, M; Cross, CE; Jones, AD; Freeman, BA; Halliwell, B; van der Vliet, A			Formation of nitric oxide derived inflammatory oxidants by myeloperoxidase in neutrophils	NATURE			English	Article							CONVERTING-ENZYME; OXIDATIVE DAMAGE; SYNOVIAL-FLUID; SYNTHASE; SERUM; PEROXYNITRITE; NITROTYROSINE; BIOACTIVITY; NITRATION; PEPTIDES	Nitric oxide ((NO)-N-.) plays a central role in the pathogenesis of diverse inflammatory and infectious disorders(1,2). The toxicity of (NO)-N-. is thought to be engendered, in part, by its reaction with superoxide (O-2(.-)), yielding the potent oxidant peroxynitrite (ONOO-)(3). However, evidence for a role of ONOO- in vivo is based largely upon detection of 3-nitrotyrosine in injured tissues(4-8). We have recently demonstrated that nitrite (NO2-), a major end-product of (NO)-N-. metabolism, readily promotes tyrosine nitration through formation of nitryl chloride (NO2Cl) and nitrogen dioxide ((NO2)-N-.) by reaction with the inflammatory mediators hypochlorous acid (HOCl) or myeloperoxidase(9,10). We now show that activated human polymorphonuclear neutrophils convert NO2- into NO2Cl and (NO2)-N-. through myeloperoxidase-dependent pathways. Polymorphonuclear neutrophil-mediated nitration and chlorination of tyrosine residues or 4-hydroxyphenylacetic acid is enhanced by addition of NO2- or by fluxes of (NO)-N-.. Addition of (NO2-)-N-15 led to N-15 enrichment of nitrated phenolic substrates, confirming its role in polymorphonuclear neutrophil-mediated nitration reactions. Polymorphonuclear neutrophil-mediated inactivation of endothelial cell angiotensin-converting enzyme was exacerbated by NO2-, illustrating the physiological significance of these reaction pathways to cellular dysfunction. Our data reveal that NO2- may regulate inflammatory processes through oxidative mechanisms, perhaps by contributing to the tyrosine nitration and chlorination observed in vivo.	Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; Univ Calif Davis, Facil Adv Instrumentat, Davis, CA 95616 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA; Univ London, Univ London Kings Coll, Neurodegenerat Dis Res Ctr, Pharmacol Grp, London SW3 6LX, England	University of California System; University of California Davis; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of London; King's College London	Eiserich, JP (corresponding author), Univ Alabama, Ctr Free Radical Biol, Dept Anesthesiol, 619 19th St S,946 THT, Birmingham, AL 35233 USA.		Freeman, Bruce A/H-9342-2012; Jones, Arthur D/C-2670-2013; Halliwell, Barry/C-8318-2009	Jones, A. Daniel/0000-0002-7408-6690				Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CHEN XL, 1993, AM J PHYSIOL, V265, pL243, DOI 10.1152/ajplung.1993.265.3.L243; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660	30	1291	1315	0	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					393	397		10.1038/34923	http://dx.doi.org/10.1038/34923			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450756				2022-12-28	WOS:000071604200056
J	Pablos-Mendez, A; Barr, RG; Shea, S				Pablos-Mendez, A; Barr, RG; Shea, S			Run-in periods in randomized trials - Implications for the application of results in clinical practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC HEART-FAILURE; TO-TREAT ANALYSIS; DESIGN; PATIENT; CONDUCT; WILL	Prerandomization run-in periods are being used to select or exclude patients in an increasing number of clinical trials, but the implications of run-in periods for interpreting the results of clinical trials and applying these results in clinical practice have not been systematically examined. We analyzed illustrative examples of reports of clinical trials in which run-in periods were used to exclude noncompliant subjects, placebo responders, or subjects who could not tolerate or did not respond to active drug. The Physicians' Health Study exemplifies the use of a prerandomization run-in period to exclude subjects who are nonadherent, while recent trials of tacrine for Alzheimer disease and carvedilol for congestive heart failure typify the use of run-in periods to exclude patients who do not tolerate or do not respond to the study drug. The reported results of these studies are valid. However, because the reported results apply to subgroups of patients who cannot be defined readily based on demographic or clinical characteristics, the applicability of the results in clinical practice is diluted. Compared with results that would have been observed without the run-in period, the reported results overestimate the benefits and underestimate the risks of treatment, underestimate the number needed to treat, and yield a smaller P value. The Cardiac Arrhythmia Suppression Trial exemplifies the use of an active-drug run-in period that enhances clinical applicability by selecting a group of study subjects who closely resembled patients undergoing active clinical management for this problem. Run-in periods can dilute or enhance the clinical applicability of the results of a clinical trial, depending on the patient group to whom the results will be applied. Reports of clinical trials using run-in periods should indicate how this aspect of their design affects the application of the results to clinical practice.	Columbia Univ, Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY USA	Columbia University; Columbia University	Pablos-Mendez, A (corresponding author), Columbia Univ, Coll Phys & Surg, Div Gen Med, PH 9 E Room 105,622 W 168th St, New York, NY 10032 USA.		Barr, Richard G./AEN-6134-2022	Barr, Richard G./0000-0001-8021-0072				[Anonymous], 1989, NEW ENGL J MED, V321, P406; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BLACKWELDER WC, 1990, CONTROL CLIN TRIALS, V11, P187, DOI 10.1016/0197-2456(90)90013-R; BRITTAIN E, 1990, CONTROL CLIN TRIALS, V11, P327, DOI 10.1016/0197-2456(90)90174-Z; Casella G., 2021, STAT INFERENCE; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; Fackler ML, 1996, ANN INTERN MED, V124, P741, DOI 10.7326/0003-4819-124-8-199604150-00007; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HENNEKENS CH, 1984, J NATL CANCER I, V73, P1473; KRUM H, 1995, CIRCULATION, V92, P212; LANG JM, 1990, STAT MED, V9, P87, DOI 10.1002/sim.4780090115; LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010; LIBERATI A, 1994, STAT MED, V13, P1485, DOI 10.1002/sim.4780131326; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; Meinert CL., 1986, CLIN TRIALS DESIGN C; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEDUZZI P, 1991, J THORAC CARDIOV SUR, V101, P481; Perez V, 1997, LANCET, V349, P1594, DOI 10.1016/S0140-6736(96)08007-5; Perry G, 1997, NEW ENGL J MED, V336, P525; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETO R, 1988, BMJ-BRIT MED J, V263, P313; POCOCK SJ, 1982, STATISTICIAN, V31, P1; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RUTTENVANMOLKEN MPMH, 1994, HEALTH ECON, V3, P333, DOI 10.1002/hec.4730030507; SACKETT DL, 1980, NEW ENGL J MED, V303, P1059, DOI 10.1056/NEJM198010303031812; SACKNERBERNSTEI.J, 1995, CIRCULATION S1, V92, P395; SCHECHTMAN KB, 1993, STAT MED, V12, P111, DOI 10.1002/sim.4780120204; SCHORK MA, 1967, J CHRON DIS, V20, P233, DOI 10.1016/0021-9681(67)90005-7; SENN SJ, 1990, J CLIN EPIDEMIOL, V43, P628, DOI 10.1016/0895-4356(90)90172-L; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; STIENEN U, 1992, J CARDIOVASC PHARM, V19, pS128, DOI 10.1097/00005344-199219001-00025; *US DEP HHS, 1997, GUID IND PROV CLIN E; 1996, DRUG THER B, V34, P38	37	125	125	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					222	225		10.1001/jama.279.3.222	http://dx.doi.org/10.1001/jama.279.3.222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438743				2022-12-28	WOS:000071460700033
J	Kawai, A; Woodruff, J; Healey, JH; Brennan, MF; Antonescu, CR; Ladanyi, M				Kawai, A; Woodruff, J; Healey, JH; Brennan, MF; Antonescu, CR; Ladanyi, M			SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KRUPPEL-ASSOCIATED BOX; TRANSLOCATION BREAKPOINTS; X-CHROMOSOME; CLASSIFICATION; IDENTIFICATION; DIAGNOSIS; SYT-SSX2; PROTEINS; FEATURES; SURVIVAL	Background Synovial sarcomas account for up to 10 percent of soft-tissue sarcomas and include two major histologic subtypes, biphasic and monophasic, defined respectively by the presence and absence of glandular epithelial differentiation in a background of spindle tumor cells, A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas, The translocation fuses the SYT gene from chromosome 18 to either of two highly homologous genes at Xp11, SSX1 or SSX2. SYT-SSX1 and SYT-SSX2 are thought to function as aberrant transcriptional regulators. We attempted to determine the influence of the two alternative forms of the SYT-SSX fusion gene on tumor morphology and clinical outcome in patients with this sarcoma. Methods We analyzed SYT-SSX fusion transcripts in 45 synovial sarcomas (33 monophasic and 12 biphasic) by the reverse-transcriptase polymerase chain reaction and compared the results with relevant clinical and pathological data. Results The SYT-SSX1 and SYT-SSX2 fusion transcripts were detected in 29 (64 percent) and 16 (36 percent) of the tumors, respectively. There was a significant relation (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had an SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0). There were no significant correlations between the type of SYT-SSX transcript and age, sex, tumor location and size, whether there were metastases at diagnosis, or whether patients underwent chemotherapy. Histologic subtype alone was not prognostically important. Conclusions The type of SYT-SSX fusion transcript correlates with both the histologic subtype and the clinical behavior of synovial sarcoma. SYT-SSX fusion transcripts are a defining diagnostic marker of synovial sarcomas and may also yield important independent prognostic information. (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.		Ladanyi, Marc/AAG-8585-2019	Healey, John/0000-0002-0802-1186				ARGANI P, IN PRESS MOD PATHOL; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; BRODSKY JT, 1992, CANCER-AM CANCER SOC, V70, P484, DOI 10.1002/1097-0142(19920715)70:2<484::AID-CNCR2820700217>3.0.CO;2-7; CAGLE LA, 1987, CANCER, V59, P1810, DOI 10.1002/1097-0142(19870515)59:10<1810::AID-CNCR2820591021>3.0.CO;2-R; Chand A, 1995, GENOMICS, V30, P545, DOI 10.1006/geno.1995.1275; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Connelly EF, 1996, SEMIN ONCOL, V23, P16; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DEALAVA E, IN PRESS J CLIN ONCO; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P757; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; KAMPE CE, 1993, CANCER-AM CANCER SOC, V72, P2161, DOI 10.1002/1097-0142(19931001)72:7<2161::AID-CNCR2820720716>3.0.CO;2-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; KRALL RA, 1981, AM J SURG PATHOL, V5, P137, DOI 10.1097/00000478-198103000-00005; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; ODA Y, 1993, AM J SURG PATHOL, V17, P35, DOI 10.1097/00000478-199301000-00004; PAPPO AS, 1994, J CLIN ONCOL, V12, P2360, DOI 10.1200/JCO.1994.12.11.2360; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; ROOSER B, 1989, CANCER, V63, P2182, DOI 10.1002/1097-0142(19890601)63:11<2182::AID-CNCR2820631120>3.0.CO;2-Y; ROSEN G, 1994, CANCER, V73, P2506, DOI 10.1002/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S; Shipley J, 1996, AM J PATHOL, V148, P559; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; Singer S, 1996, J CLIN ONCOL, V14, P1201, DOI 10.1200/JCO.1996.14.4.1201; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SREEKANTAIAH C, 1994, AM J PATHOL, V144, P1121; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	35	473	500	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					153	160		10.1056/NEJM199801153380303	http://dx.doi.org/10.1056/NEJM199801153380303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428816				2022-12-28	WOS:000071384500003
J	Vincenti, F; Kirkman, R; Light, S; Bumgardner, G; Pescovitz, M; Halloran, P; Neylan, J; Wilkinson, A; Ekberg, H; Gaston, R; Backman, L; Burdick, J				Vincenti, F; Kirkman, R; Light, S; Bumgardner, G; Pescovitz, M; Halloran, P; Neylan, J; Wilkinson, A; Ekberg, H; Gaston, R; Backman, L; Burdick, J		Daclizumab Triple Therapy Study Grp	Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMANIZED ANTI-TAC; RECEPTOR MONOCLONAL-ANTIBODY; RANDOMIZED CONTROLLED TRIAL; KIDNEY-TRANSPLANTATION; ALLOGRAFT SURVIVAL; IMMUNOSUPPRESSION; GLOBULIN; BINDS; OKT3	Background Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive T lymphocytes may cause selective immunosuppression. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the cu chain of the interleukin-2 receptor and may thus reduce the risk of rejection after renal transplantation. Methods We administered daclizumab (1.0 mg per kilogram of body weight) or placebo intravenously before transplantation and once every other week afterward, for a total of five doses, to 260 patients receiving first cadaveric kidney grafts and immunosuppressive therapy with cyclosporine, azathioprine, and prednisone. The patients were followed at regular intervals for 12 months. The primary end point was the incidence of biopsy-confirmed acute rejection within six months after transplantation. Results Of the 126 patients given daclizumab, 28 (22 percent) had biopsy-confirmed episodes of acute rejection, as compared with 47 of the 134 patients (35 percent) who received placebo (P=0.03). Graft survival at 12 months was 95 percent in the daclizumab-treated patients, as compared with 90 percent in the patients given placebo (P = 0.08). The patients given daclizumab did not have any adverse reactions to the drug, and at six months, there were no significant differences between the two groups with respect to infectious complications or cancers. The serum half-life of daclizumab was 20 days, and its administration resulted in prolonged saturation of interleukin-2 alpha receptors on circulating lymphocytes. Conclusions Daclizumab reduces the frequency of acute rejection in kidney-transplant recipients. (C) 1998, Massachusetts Medical Society.	Univ Calif San Francisco, Transplant Serv, San Francisco, CA 94143 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; Ohio State Univ, Columbus, OH 43210 USA; Indiana Univ, Indianapolis, IN 46204 USA; Univ Alberta, Edmonton, AB, Canada; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Malmo Univ Hosp, Malmo, Sweden; Univ Alabama Birmingham, Birmingham, AL USA; Gothenburg Univ, Sahlgrens Hosp, S-41345 Gothenburg, Sweden; Johns Hopkins Univ, Baltimore, MD USA	University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Roche Holding; University System of Ohio; Ohio State University; Indiana University System; Indiana University-Purdue University Indianapolis; University of Alberta; Emory University; University of California System; University of California Los Angeles; Lund University; Skane University Hospital; University of Alabama System; University of Alabama Birmingham; Sahlgrenska University Hospital; University of Gothenburg; Johns Hopkins University	Vincenti, F (corresponding author), Univ Calif San Francisco, Transplant Serv, 505 Parnassus Ave,Rm M884,Box 0116, San Francisco, CA 94143 USA.		Gaston, Robert/AAR-2932-2020; Halloran, Philip F/J-1390-2012	Halloran, Philip F/0000-0003-1371-1947; Bumgardner, Ginny/0000-0002-3256-0200				ANASETTI C, 1994, BLOOD, V84, P1320; BROWN PS, 1991, P NATL ACAD SCI USA, V88, P2663, DOI 10.1073/pnas.88.7.2663; FAYER BE, 1995, J IMMUNOL METHODS, V186, P47, DOI 10.1016/0022-1759(95)00131-S; FERGUSON R, 1994, CLIN TRANSPLANT, V8, P328; GRUBER SA, 1991, CLIN TRANSPLANT, V5, P219; HAKIMI J, 1991, J IMMUNOL, V147, P1352; Hakimi J., 1997, ANTIBODY THERAPEUTIC, P277; Kahan BD, 1997, TRANSPL P, V29, P48, DOI 10.1016/S0041-1345(96)00008-5; KIRKMAN RL, 1991, TRANSPLANTATION, V51, P107, DOI 10.1097/00007890-199101000-00016; KUPIECWEGLINSKI JW, 1986, P NATL ACAD SCI USA, V83, P2624, DOI 10.1073/pnas.83.8.2624; Morris RE, 1996, KIDNEY INT, V49, pS26; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; REDING R, 1993, TRANSPLANTATION, V55, P534, DOI 10.1097/00007890-199303000-00015; REED MH, 1989, TRANSPLANTATION, V47, P55, DOI 10.1097/00007890-198901000-00013; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VANGELDER T, 1995, TRANSPLANTATION, V60, P248; Vincenti F, 1997, TRANSPLANTATION, V63, P33, DOI 10.1097/00007890-199701150-00007; Vincenti F, 1996, TRANSPLANTATION, V61, P1576, DOI 10.1097/00007890-199606150-00005	20	665	712	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					161	165		10.1056/NEJM199801153380304	http://dx.doi.org/10.1056/NEJM199801153380304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428817	Bronze			2022-12-28	WOS:000071384500004
J	Vlahov, D; Graham, N; Hoover, D; Flynn, C; Bartlett, JG; Margolick, JB; Lyles, CM; Nelson, KE; Smith, D; Holmberg, S; Farzadegan, H				Vlahov, D; Graham, N; Hoover, D; Flynn, C; Bartlett, JG; Margolick, JB; Lyles, CM; Nelson, KE; Smith, D; Holmberg, S; Farzadegan, H			Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users - Plasma viral load and CD4(+) cell count	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PNEUMOCYSTIS-CARINII; PERIPHERAL-BLOOD; CUBIC MILLIMETER; RNA; QUANTITATION; PROGRESSION; ZIDOVUDINE; THERAPY; COHORT	Context.-Plasma human immunodeficiency virus type 1 (HIV-1) viral load and CD4(+) cell count are used to predict prognosis of persons infected with HIV. However, whether combining these markers improves prognostic accuracy and whether they predict prognosis for injection drug users (IDUs) and nonwhite persons infected with HIV has not been extensively investigated. Objective.-To evaluate plasma viral load and CD4(+) cell count as prognostic indicators for the acquired immunodeficiency syndrome (AIDS) and infectious disease deaths. Design.-Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9 years. Participants.-Injection drug users infected with HIV recruited from the community in Baltimore, Md. Main Outcome Measures.-Plasma HIV-1 RNA and CD4(+) cell count measured at baseline compared with time to first clinical AIDS diagnosis and death due to an infectious disease. Results.-Of 522 subjects, 96% were African American, 80% were male, 96% injected drugs within the past 6 months, and the median age was 33 years. A total of 146 cases of AIDS and 119 infectious disease deaths were seen during a median follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4(+) cell count were independent predictors of progression to AIDS and infectious disease deaths, but in proportional hazards models, viral load had better predictive value than CD4(+) cell count. Kaplan-Meier analysis of time to AIDS and to infectious disease deaths by Viral load (<500, 500-9999, 10 000-29 999, greater than or equal to 30 000 copies/mL) at 3 levels of CD4(+) cell count (<0.20, 0.20-0.49, and greater than or equal to 0.50X10(9)/L [<200, 200-499, and greater than or equal to 500/uL]) was reduced to a 5-stage classification scheme using a backward stepwise regression procedure. The 5-year cumulative probabilities for AIDS and infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral load, <500 copies/mL; CD4(+) cell count, 0.50X10(9)/L) to 81.2% and 76.1% respectively, for group V (viral load, greater than or equal to 10000 copies/mL; CD4(+) cell count, 0.20X10(9)/L). Conclusions.-In this study, plasma HIV-1 viral load independently and in combination with CD4(+) cell count measurements provided powerful prognostic information for progression to AIDS and death caused by infectious disease in a population of predominantly African American IDUs. Combining categories of both markers provided a simple method for prognostically staging HIV disease.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA	Vlahov, D (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Room E-6008,615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R37DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04334] Funding Source: Medline; PHS HHS [U54/CCU306802] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAIAFFA WT, 1994, AM J RESP CRIT CARE, V150, P1493, DOI 10.1164/ajrccm.150.6.7952605; *CDC, 1992, MMWR-MORBID MORTAL W, V41, pRR17; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CHAISSON RE, 1991, AIDS, V5, P177, DOI 10.1097/00002030-199102000-00007; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Cox D. R., 1984, ANAL SURVIVAL DATA; ESCAICH S, 1992, AIDS RES HUM RETROV, V8, P1833, DOI 10.1089/aid.1992.8.1833; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARZADEGAN H, 1996, 11 INT C AIDS JUL 7; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HARRISON K, 1995, J ACQ IMMUN DEF SYND, V10, P386; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HOLODNIY M, 1995, J CLIN MICROBIOL, V33, P1562, DOI 10.1128/JCM.33.6.1562-1566.1995; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HOOVER DR, 1995, DRUGS, V49, P20, DOI 10.2165/00003495-199549010-00003; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Manoff SB, 1996, EPIDEMIOLOGY, V7, P566, DOI 10.1097/00001648-199611000-00001; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SOLOMON L, 1995, J DRUG ISSUES, V25, P225, DOI 10.1177/002204269502500115; VLAHOV D, 1991, J DRUG ISSUES, V21, P767; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YERLY S, 1992, J INFECT DIS, V166, P269, DOI 10.1093/infdis/166.2.269	30	167	175	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					35	40		10.1001/jama.279.1.35	http://dx.doi.org/10.1001/jama.279.1.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424041				2022-12-28	WOS:000071295100032
J	Kerry, SM; Bland, JM				Kerry, SM; Bland, JM			Statistics notes - Analysis of a trial randomised in clusters	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Div Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London; St Georges University London	Kerry, SM (corresponding author), Univ London St Georges Hosp, Sch Med, Div Gen Practice & Primary Care, London SW17 0RE, England.							Altman DG, 1997, BRIT MED J, V314, P1874, DOI 10.1136/bmj.314.7098.1874; Bland JM, 1996, BMJ-BRIT MED J, V312, P1153; Bland JM, 1997, BRIT MED J, V315, P600; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; OAKESHOTT P, 1994, BRIT J GEN PRACT, V44, P197	5	109	110	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	1998	316	7124					54	54		10.1136/bmj.316.7124.54	http://dx.doi.org/10.1136/bmj.316.7124.54			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451271	Green Published, Bronze			2022-12-28	WOS:000071377900029
J	Burgin, AB				Burgin, AB			Can DNA topoisomerases be ribonucleases?	CELL			English	Review									San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University	Burgin, AB (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.							CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P11367; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Wang H, 1996, P NATL ACAD SCI USA, V93, P9477, DOI 10.1073/pnas.93.18.9477; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	6	7	7	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					873	874		10.1016/S0092-8674(00)80478-X	http://dx.doi.org/10.1016/S0092-8674(00)80478-X			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428510	Bronze			2022-12-28	WOS:000071281400004
J	Chen, ZL; Strickland, S				Chen, ZL; Strickland, S			Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin	CELL			English	Article							ADULT-RAT BRAIN; EXTRACELLULAR-MATRIX; NERVOUS-SYSTEM; GRANULE NEURONS; KAINIC ACID; ACTIVATOR; GENE; EXPRESSION; SURVIVAL; SEIZURE	Excess excitatory amino acids can provoke neuronal death in the hippocampus, and the extracellular proteases tissue plasminogen activator (tPA) and plasmin (ogen) have been implicated in this death. To investigate substrates for plasmin that might influence neuronal degeneration, extracellular matrix (ECM) protein expression was examined. Laminin is expressed in the hippocampus and disappears after excitotoxin injection. Laminin disappearance precedes neuronal death, is spatially coincident with regions that exhibit neuronal loss, and is blocked by either tPA-deficiency or infusion of a plasmin inhibitor, both of which also block neuronal degeneration. Preventing neuron-laminin interaction by infusion of anti-laminin antibodies into tPA-deficient mice restores excitotoxic sensitivity to their hippocampal neurons. These results indicate that disruption of neuron-ECM interaction via tPA/plasmin catalyzed degradation of laminin sensitizes hippocampal neurons to cell death.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Strickland, S (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.			Strickland, Sidney/0000-0002-3072-9244	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035704] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-35704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; Einheber S, 1996, J COMP NEUROL, V370, P105; EMSBERGER U, 1989, DEV BIOL, V135, P250; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gualandris A, 1996, J NEUROSCI, V16, P2220; HAGG T, 1989, NEURON, V3, P721, DOI 10.1016/0896-6273(89)90241-9; JUCKER M, 1992, BRAIN RES, V586, P166, DOI 10.1016/0006-8993(92)91390-Z; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; Liesi P, 1996, J CELL BIOL, V134, P477, DOI 10.1083/jcb.134.2.477; LIOTTA LA, 1981, CANCER RES, V41, P4629; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; Niquet J, 1996, DEV BRAIN RES, V95, P227, DOI 10.1016/S0165-3806(96)00089-2; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; PAULSSON M, 1988, EUR J BIOCHEM, V177, P477, DOI 10.1111/j.1432-1033.1988.tb14397.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Strickland S, 1996, COLD SPRING HARB SYM, V61, P739; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; YAMAMOTO T, 1988, J NEUROL SCI, V84, P1, DOI 10.1016/0022-510X(88)90169-4	46	527	544	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					917	925		10.1016/S0092-8674(00)80483-3	http://dx.doi.org/10.1016/S0092-8674(00)80483-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428515	Bronze			2022-12-28	WOS:000071281400009
J	Espinel, CH				Espinel, CH			A medical evaluation of Rembrandt. His self-portrait: ageing, disease, and the language of the skin	LANCET			English	Article									Georgetown Univ, Dept Med, Arlington, VA 22205 USA; Georgetown Univ, Ctr Clin Bioeth, Arlington, VA 22205 USA; Blood Pressure Ctr, Washington, DC USA	Georgetown University; Georgetown University	Espinel, CH (corresponding author), Georgetown Univ, Dept Med, 1715 N George Mason Dr, Arlington, VA 22205 USA.							BENESCH O, 1957, REMBRANDT; BIERMAN EL, 1994, PRINCIPLES GERIATRIC, P509; BOMFORD D, 1988, REMBRANDTS PAINTING, P21; Espinel CH, 1996, LANCET, V348, P1714, DOI 10.1016/S0140-6736(96)10054-4; Espinel CH, 1996, LANCET, V347, P1096, DOI 10.1016/S0140-6736(96)90285-8; GIFFORD M, 1992, TECHNICAL EXAMINATIO; Goldfarb MT, 1997, GERIATRIC MED, P667; HABIF T, 1996, ACNE ROBACEA RELATED, P148; HAZLEMAN BL, 1995, PRACTICAL RHEUMATOLO, P385; HOMER, 1979, ILIAD BOOK 24, P467; KENDAL ER, 1991, PRINCIPLES NEURAL SC, P400; KLIGMAN A, 1995, HDB BIOL AGING, P820; LAURIE AP, 1932, NIGHT WATCH JEWISH B, P23; LEBER W, 1982, INT J ADDICTION, V17; MARTIN GM, 1994, PRINCIPLES GERIATRIC, P19; MEE C, 1988, REMBRANDTS PORTRAIT; PESCE K, 1996, PREMATURE AGING SYND, P161; READ RC, 1984, AM J SURG, V148, P706, DOI 10.1016/0002-9610(84)90421-5; SPAETH G, 1990, OPHTHALMIC SURG PRIN, P528; Strauss Walter L., 1979, REMBRANDT DOCUMENTS; van Heel S.A.C. Dudok, 1991, REMBRANDT ZIJN WERKP, P50; WALKER J, 1984, NATL GALLERY ART WAS, P270; Wetering Ernst van de, 1991, REMBRANDT MASTER HIS, V1, P12; WHEELOCK A, 1995, DUTCH PAINTINGS 17 C, P261	24	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1835	1837		10.1016/S0140-6736(97)08504-8	http://dx.doi.org/10.1016/S0140-6736(97)08504-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428265	hybrid			2022-12-28	WOS:000071102500044
J	Letrilliart, L; Desenclos, JC; Flahault, A				Letrilliart, L; Desenclos, JC; Flahault, A			Risk factors for winter outbreak of acute diarrhoea in France: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTIC-ASSOCIATED DIARRHEA; GASTROENTERITIS	Objectives: To assess the potential role of consumption of shellfish (particularly raw oysters) and tap water in the winter epidemic of acute diarrhoea in France. Design: Population based, case-control study during the 1995-6 winter epidemic of acute diarrhoea in France. Setting: A national network comprising 1% of general practitioners in France. Subjects: 568 pairs of cases and controls consulting in general practice and interviewed by 209 doctors from 26 December 1995 to 31 January 1996. Cases and controls were matched for age, doctor, and time of consultation. Main outcome measures: Adjusted relative risk of diarrhoea estimated from conditional logistic regression. Results: The risk of acute diarrhoea was not increased in people who had recently eaten raw oysters (odds ratio 1.1; 95% confidence interval 0.9% to 1.4%) or other shellfish such as clams, cockles, and mussels, or in those people who usually consumed tap rather than bottled water (0.8; 0.6% to 1.1%). The risk was, however, increased in people who had had recent contact with a person with diarrhoea, either within the household (adjusted odds ratio 5.0) or in the workplace (3.1), and in people who lived with a child less than or equal to 2 years of age (1.6). Recent treatment with either oral penicillin or cephalosporin was also independently associated with acute diarrhoea in winter. Conclusions: The winter epidemic of acute diarrhoea in France is probably not caused by consumption of either shellfish or tap water. A viral aetiology, however, is suggested by the speed with which the acute diarrhoea is transmitted.	Inst Fed St Antoine Rech Sante, INSERM, U444, Paris, France; Reseau Natl Sante Publ, St Maurice, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Letrilliart, L (corresponding author), Inst Fed St Antoine Rech Sante, INSERM, U444, Paris, France.							BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; Carrat F, 1996, BEH, P143; DAURAT G, 1994, B EPIDEMIOL HEBD, V37, P170; DUFOUR A, 1995, OPINIONS FRANCAIS EN; FLAHAULT A, 1995, LANCET, V346, P162, DOI 10.1016/S0140-6736(95)91214-2; Fourquet F, 1997, LANCET, V349, P794; GARTHRIGHT WE, 1988, PUBLIC HEALTH REP, V103, P107; GEORGE WL, 1984, REV INFECT DIS, V6, pS208; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; HOSMER DW, 1989, APPL LOGISTIC REGRES; LAURSEN E, 1994, J EPIDEMIOL COMMUN H, V48, P453, DOI 10.1136/jech.48.5.453; LeBaron C W, 1990, MMWR Recomm Rep, V39, P1; *MET FRANC, 1996, B CLIM ANN 1995; MORSE DL, 1986, NEW ENGL J MED, V314, P678, DOI 10.1056/NEJM198603133141103; Ryan MJ, 1996, J INFECT DIS, V174, pS12, DOI 10.1093/infdis/174.Supplement_1.S12; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; THOMPSON SC, 1994, J PAEDIATR CHILD H, V30, P210, DOI 10.1111/j.1440-1754.1994.tb00621.x; WATSON AJM, 1992, BRIT MED J, V304, P1302, DOI 10.1136/bmj.304.6837.1302; World Health Organisation, 1993, MAN PREV DIARRH PRAC	19	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1645	1649		10.1136/bmj.315.7123.1645a	http://dx.doi.org/10.1136/bmj.315.7123.1645a			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448526	Green Published			2022-12-28	WOS:000071149400009
J	Whitfield, CR; Raafat, A; Urbaniak, SJ				Whitfield, CR; Raafat, A; Urbaniak, SJ			Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review	BRITISH MEDICAL JOURNAL			English	Article							PROPHYLAXIS		UNIV ABERDEEN,REG TRANSFUS CTR,DEPT MED & THERAPEUT,ACAD TRANSFUS MED UNIT,ABERDEEN AB9 2ZW,SCOTLAND	University of Aberdeen	Whitfield, CR (corresponding author), UNIV GLASGOW,QUEEN MOTHERS MATERN HOSP,DEPT OBSTET & GYNAECOL,GLASGOW G3 8SH,LANARK,SCOTLAND.							Bowman J M, 1988, Transfus Med Rev, V2, P129, DOI 10.1016/S0887-7963(88)70039-5; CLARKE C, 1994, J ROY COLL PHYS LOND, V28, P310; MURPHY KW, 1994, CONT REV OBSTETRICS, V6, P61; THORNTON JG, 1989, BMJ-BRIT MED J, V298, P1671, DOI 10.1136/bmj.298.6689.1671; Vick S, 1996, HEALTH ECON, V5, P319, DOI 10.1002/(SICI)1099-1050(199607)5:4<319::AID-HEC211>3.0.CO;2-6	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1504	1505		10.1136/bmj.315.7121.1504	http://dx.doi.org/10.1136/bmj.315.7121.1504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420492	Green Published			2022-12-28	WOS:A1997YK98600021
J	Ryan, CM; Schoenfeld, DA; Thorpe, WP; Sheridan, RL; Cassem, EH; Tompkins, RG				Ryan, CM; Schoenfeld, DA; Thorpe, WP; Sheridan, RL; Cassem, EH; Tompkins, RG			Objective estimates of the probability of death from burn injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROMPT ESCHAR EXCISION; INHALATION INJURY; MORTALITY	Background Over the past 20 years, there has been remarkable improvement in the chances of survival of patients treated in burn centers. A simple, accurate system for objectively estimating the probability of death would be useful in counseling patients and making medical decisions. Methods We conducted a retrospective review of all 1665 patients with acute burn injuries admitted from 1990 to 1994 to Massachusetts General Hospital and the Shriners Burns Institute in Boston. Using logistic-regression analysis, we developed probability estimates for the prediction of mortality based on a minimal set of well-defined variables. The resulting mortality formula was used to determine whether changes in mortality have occurred since 1984, and it was tested prospectively on all 530 patients with acute burn injuries admitted in 1995 or 1996. Results Of the 1665 patients (mean [+/-SD] age, 21+/-20 years; mean burn size, 14+/-20 percent of body-surface area), 1598 (96 percent) lived to discharge. The mean length of stay was 21+/-29 days. Three risk factors for death were identified: age greater than 60 years, more than 40 percent of body-surface area burned, and inhalation injury. The mortality formula we developed predicts 0.3 percent, 3 percent, 33 percent, or approximately 90 percent mortality, depending on whether zero, one, two, or three risk factors are present. The results of the prospective test of the formula were similar. A large increase in the proportion of patients who chose not to be resuscitated complicated comparisons of mortality over time. Conclusions The probability of death after burns is low and can be predicted soon after injury on the basis of simple, objective clinical criteria. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Shriners Burns Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Sumner Redstone Burn Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Psychiat Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Tompkins, RG (corresponding author), Massachusetts Gen Hosp, Trauma Serv, Bigelow 1302, Boston, MA 02114 USA.			Ryan, Colleen/0000-0002-6455-936X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, T32GM007035] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM P50-21700, GM T32-07035] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE JF, 1974, J TRAUMA, V14, P389, DOI 10.1097/00005373-197405000-00005; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; MANKTELOW A, 1989, J TRAUMA, V29, P203, DOI 10.1097/00005373-198902000-00009; Monafo WW, 1996, NEW ENGL J MED, V335, P1581, DOI 10.1056/NEJM199611213352108; PECK M D, 1991, Journal of Burn Care and Rehabilitation, V12, P282, DOI 10.1097/00004630-199105000-00017; PRUITT BA, 1964, ANN SURG, V159, P396; RYAN CM, 1995, ANN SURG, V222, P163, DOI 10.1097/00000658-199508000-00008; Ryan CM, 1997, J AM GERIATR SOC, V45, P1283, DOI 10.1111/j.1532-5415.1997.tb03792.x; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SCHOENFELD DA, 1982, STATISTICS MED RES, P432; SHERIDAN RL, 1997, SURG SCI PRINCIPLES, P422; SHIRANI KZ, 1987, ANN SURG, V205, P82, DOI 10.1097/00000658-198701000-00015; TOMPKINS RG, 1988, ANN SURG, V208, P577, DOI 10.1097/00000658-198811000-00006; TOMPKINS RG, 1986, ANN SURG, V204, P272, DOI 10.1097/00000658-198609000-00006; TREDGET EE, 1990, ANN SURG, V212, P720, DOI 10.1097/00000658-199012000-00011; ZAWACKI BE, 1979, ANN SURG, V189, P1, DOI 10.1097/00000658-197901000-00001	16	488	510	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					362	366		10.1056/NEJM199802053380604	http://dx.doi.org/10.1056/NEJM199802053380604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449729				2022-12-28	WOS:000071822200004
J	Weg, JG; Anzueto, A; Balk, RA; Wiedemann, HP; Pattishall, EN; Schork, A; Wagner, LA				Weg, JG; Anzueto, A; Balk, RA; Wiedemann, HP; Pattishall, EN; Schork, A; Wagner, LA			The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							END-EXPIRATORY PRESSURE; EXTRACORPOREAL CO2 REMOVAL; INVERSE RATIO VENTILATION; ACUTE LUNG INJURY; MECHANICAL VENTILATION; PULMONARY BAROTRAUMA; MICROVASCULAR INJURY; SYNDROME ARDS; TIDAL VOLUME; FAILURE	Background In patients with the acute respiratory distress syndrome, pneumothorax and other air leaks - any extrusion of air outside the tracheobronchial tree - have been attributed to high ventilatory pressures or volumes and linked to increased mortality. Methods We analyzed data from a prospective trial of aerosolized synthetic surfactant in 725 patients with the acute respiratory distress syndrome induced by sepsis. We compared the ventilatory pressures and volumes in the patients without any air leaks (the highest values during the five-day study) with the pressures and volumes in those with pneumothorax or with any air leaks (the highest values during the 16- and 24-hour periods before the complication developed). Results Fifty patients (6.9 percent) had pneumothorax, and 77 (10.6 percent) had pneumothorax or other air leaks. There were no significant differences between patients with air leaks and those without air leaks in any pressure or volume examined. Overall mortality at 30 days was 40.0 percent (95 percent confidence interval, 36.4 to 43.6); among the patients with pneumothorax, it was 46.0 percent (95 percent confidence interval, 32.2 to 59.8), and among those without pneumothorax, it was 39.3 percent (95 percent confidence interval, 35.6 to 43.0; P=0.35). The mortality rate was 45.5 percent (95 percent confidence interval, 34.4 to 56.6) in the group with any air leaks and 39.0 percent (95 percent confidence interval, 35.3 to 42.8) in the group without air leaks (P=0.28). Conclusions In patients with sepsis-induced acute respiratory distress syndrome who were receiving mechanical ventilation with conventional pressures and volumes, there were no significant correlations between high ventilatory pressures or volumes and the development of pneumothorax or other air leaks. Pneumothorax or other air leaks were not associated with a significantly increased mortality rate. (C) 1998, Massachusetts Medical Society.	Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Cleveland Clin, Cleveland, OH 44106 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Rush University; Cleveland Clinic Foundation; GlaxoSmithKline; University of Michigan System; University of Michigan	Weg, JG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care, B1H245,Box 0024,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			Wiedemann, Herbert/0000-0002-4587-4401				AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; CALDWELL EJ, 1970, AM REV RESPIR DIS, V102, P516; CLEVENGER FW, 1990, ARCH SURG-CHICAGO, V125, P1542; DIRUSSO SM, 1995, CRIT CARE MED, V23, P1485, DOI 10.1097/00003246-199509000-00008; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1995, AM J RESP CRIT CARE, V151, P1568, DOI 10.1164/ajrccm.151.5.7735616; GAMMON RB, 1995, AM J RESP CRIT CARE, V152, P1235, DOI 10.1164/ajrccm.152.4.7551376; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; GATTINONI L, 1995, AM J RESP CRIT CARE, V151, P1807, DOI 10.1164/ajrccm.151.6.7767524; GREENFIELD LJ, 1964, ANESTHESIOLOGY, V25, P312, DOI 10.1097/00000542-196405000-00009; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HOLLANDER M, 1973, NONPARAMETRI STAT ME; HOSMER DW, 1989, APPL LOGISTIC REGRES; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; Macklin CC, 1937, CAN MED ASSOC J, V36, P414; MATHIEUCOSTELLO OA, 1994, CHEST, V105, pS102, DOI 10.1378/chest.105.3_Supplement.102S; MAUNDER RJ, 1986, JAMA-J AM MED ASSOC, V255, P2463, DOI 10.1001/jama.255.18.2463; MEINERT CL, 1986, MONOGRAPHS EPIDEMIOL, V8; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; PEEVY KJ, 1990, CRIT CARE MED, V18, P634, DOI 10.1097/00003246-199006000-00012; PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; Pranikoff T, 1994, ASAIO J, V40, pM339, DOI 10.1097/00002480-199407000-00020; Remington RD, 1985, STAT APPL BIOL HLTH; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; SCHNAPP LM, 1995, CRIT CARE MED, V23, P272, DOI 10.1097/00003246-199502000-00012; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SLUTSKY AS, 1994, CHEST, V106, P656; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; TOMASHEFSKI JF, 1990, CLIN CHEST MED, V11, P593; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WRIGHT PE, 1994, CHEST, V106, P1517, DOI 10.1378/chest.106.5.1517; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	42	108	109	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					341	346		10.1056/NEJM199802053380601	http://dx.doi.org/10.1056/NEJM199802053380601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449726	Bronze			2022-12-28	WOS:000071822200001
J	Weidenschilling, SJ; Marzari, F; Hood, LL				Weidenschilling, SJ; Marzari, F; Hood, LL			The origin of chondrules at Jovian resonances	SCIENCE			English	Article							SOLAR NEBULA; ASTEROID BELT; PLANETESIMALS; ACCRETION; MOTION; AL-26; MODEL	Isotopic dating indicates that chondrules were produced a few million years after the solar nebula formed. This timing is incompatible with dynamical lifetimes of small particles in the nebula and short time scales for the formation of planetesimals. Temporal and dynamical constraints can be reconciled if chondrules were produced by heating of debris from disrupted first-generation planetesimals. Jovian resonances can excite planetesimal eccentricities enough to cause collisional disruption and melting of dust by bow shocks in the nebular gas. The ages of chondrules may indicate the limes of Jupiter's formation and dissipation of gas from the asteroidal region.	Planetary Sci Inst, Tucson, AZ 85705 USA; Univ Padua, Dipartimento Fis, I-35131 Padua, Italy; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Padua; University of Arizona	Weidenschilling, SJ (corresponding author), Planetary Sci Inst, Tucson, AZ 85705 USA.		Marzari, Francesco/X-2440-2019					ADACHI I, 1976, PROG THEOR PHYS, V56, P1756, DOI 10.1143/PTP.56.1756; Boss A. P., 1996, CHONDRULES PROTOPLAN, V27, P257; BOSS AP, 1993, ICARUS, V106, P168, DOI 10.1006/icar.1993.1164; Boynton W.V., 1985, PROTOSTARS PLANETS, VII, P772; BULIRSCH R, 1966, NUMER MATH, V8, P1, DOI 10.1007/BF02165234; CAMERON AGW, 1995, METEORITICS, V30, P133, DOI 10.1111/j.1945-5100.1995.tb01110.x; DERMOTT SF, 1983, NATURE, V301, P201, DOI 10.1038/301201a0; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; FERNANDEZ JA, 1981, ICARUS, V47, P470, DOI 10.1016/0019-1035(81)90195-0; GRADIE J, 1989, ASTEROIDS, V2, P316; Grossman J.N., 1988, METEORITES EARLY SOL, P680; Hewins R., 1996, CHONDRULES PROTOPLAN, P55; Holman MJ, 1996, ASTRON J, V112, P1278, DOI 10.1086/118098; HOOD L, IN PRESS METEORITICS; HOOD LL, 1991, ICARUS, V93, P259, DOI 10.1016/0019-1035(91)90211-B; HOOD LL, 1993, ICARUS, V106, P179, DOI 10.1006/icar.1993.1165; Hutchison R., 1996, CHONDRULES PROTOPLAN, P311; HUTCHISON R, 1983, SANDDRULES THEIR ORI, P162; Jones R.H., 1996, CHONDRULES PROTOPLAN, P163; LEVY EH, 1989, ICARUS, V81, P74, DOI 10.1016/0019-1035(89)90126-7; Liffman K., 1996, CHONDRULES PROTOPLAN, P285; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; Marzari F, 1997, PLANET SPACE SCI, V45, P337, DOI 10.1016/S0032-0633(96)00138-9; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; Rubin A. E., 1996, CHONDRULES PROTOPLAN, P173; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; RUSSELL SS, 1997, LUNAR PLANET SCI, V28, P1209; RUZMAIKINA TV, 1996, CHONDRULES PROTOPLAN, P277; Sanders IS, 1997, METEORIT PLANET SCI, V32, pA113; Scott E.R.D., 1996, CHONDRULES PROTOPLAN; Scott E.R.D., 1996, CHONDRULES PROTOPLAN, P265; Skinner W.R., 1990, LUNAR PLANET SCI, V21, P1168; Stoffler D., 1988, METEORITES EARLY SOL, P165; Symes SJK, 1997, METEORIT PLANET SCI, V32, pA127; Taylor G. J., 1983, CHONDRULES THEIR ORI, P262; Wasson J. T., 1996, CHONDRULES PROTOPLAN, P45; Weidenschilling S.J., 1993, PROTOSTARS PLANETS, P1031; Weidenschilling SJ, 1997, ICARUS, V127, P290, DOI 10.1006/icar.1997.5712; WEIDENSCHILLING SJ, 1980, ICARUS, V44, P172, DOI 10.1016/0019-1035(80)90064-0; WEIDENSCHILLING SJ, 1988, METEORITES EARLY SOL, P348; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E; WHIPPLE FL, 1971, NASA SPEC PUBL, P251; Wood JA, 1996, METORIT PLANET SCI, V31, P641, DOI 10.1111/j.1945-5100.1996.tb02037.x; WOOD JA, 1985, PROTOSTARS PLANETS, V2, P687; [No title captured]	47	90	90	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					681	684		10.1126/science.279.5351.681	http://dx.doi.org/10.1126/science.279.5351.681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445468	Green Published			2022-12-28	WOS:000071731500029
J	Strickler, HD; Rosenberg, PS; Devesa, SS; Hertel, J; Fraumeni, JF; Goedert, JJ				Strickler, HD; Rosenberg, PS; Devesa, SS; Hertel, J; Fraumeni, JF; Goedert, JJ			Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN BRAIN-TUMORS; CHOROID-PLEXUS; DNA-SEQUENCES; SV40	Context.-Poliovirus vaccine contaminated with live simian virus 40 (SV40), a polyomavirus that is tumorigenic in rodents, was used extensively in the United States between 1955 and 1963, Simian virus 40 DNA has recently been detected in several rare human tumors, including ependymomas, osteosarcomas. mesotheliomas. Objective.-To determine the risk of ependymoma, osteosarcoma, and mesothelioma among Americans who as children received SV40-contaminated poliovirus vaccine. Design.-Retrospective cohort study using data from the Surveillance, Epidemiology, and End Results program (1973-1993) and the Connecticut Tumor Registry (1950-1969), as well as national mortality statistics (1947-1973). Setting.-United States. Participants.-Birth cohorts that were likely to have received SV40-contaminated poliovirus vaccine as infants, born 1956 through 1962 (60 811 730 person-years of observation); as children, born 1947 through 1952 (46 430 953 person-years); or that were unexposed, born 1964 through 1969 (44 959 979 peron-years). Main Outcome Measures.-Relative risk (RR) of each cancer among exposed compared with unexposed birth cohorts. Results.-Age-specific cancer rates were generally low and were not significantly elevated in birth cohorts exposed to SV40-contaminated vaccine, Specifically, compared with the unexposed, the relative risk of ependymoma was not increased in the cohorts exposed as infants (RR, 1.06; 95% confidence interval [CI], 0.69-1.63), or as children (RR, 0.98; 95% CI, 0.57-1.69) nor did the exposed have an increased risk of all brain cancers. Osteosarcoma incidence also showed no relation to exposure as infants (RR, 0.87; 95% CI, 0.71-1.06) or children (RR, 0.85; 95% CI, 0.59-1.22). Last, mesotheliomas were not significantly associated with exposure, although the cohorts studied have not. yet reached the age at which these tumors tend to occur. Conclusions.-After more than 30 years of follow-up, exposure to SV40-contaminated poliovirus vaccine was not associated with significantly increased rates of ependymomas and other brain cancers, osteosarcomas, or mesotheliomas in the United States.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA; Informat Management Syst, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Strickler, HD (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 6130 Execut Blvd,EPN Room 434, Rockville, MD 20852 USA.			Rosenberg, Philip/0000-0001-6349-9126				BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; DIAMANDO.GT, 1973, JNCI-J NATL CANCER I, V50, P1347, DOI 10.1093/jnci/50.5.1347; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, FED PROC, V21, P930; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; GEISSLER E, 1990, PROG MED VIROL, V37, P211; HAENSZEL W, 1962, JNCI-J NATL CANCER I, V28, P947; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Martini F, 1996, CANCER RES, V56, P4820; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; POLEDNAK AP, 1995, CANCER, V75, P330, DOI 10.1002/1097-0142(19950101)75:1+<330::AID-CNCR2820751315>3.0.CO;2-5; SALONEN T, 1976, ANN CLIN RES, V8, P27; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; STEWART AM, 1965, LANCET, V2, P789; ZIPPIN C, 1995, CANCER, V76, P2343, DOI 10.1002/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#	21	130	133	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					292	295		10.1001/jama.279.4.292	http://dx.doi.org/10.1001/jama.279.4.292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450713	Bronze			2022-12-28	WOS:000071607000036
J	Shay, JW				Shay, JW			Accelerated telomere shortening in bone-marrow recipients	LANCET			English	Editorial Material							REPEATS; CELLS		Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.		Shay, Jerry W/F-7878-2011					ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Schulz VP, 1996, HUM GENET, V97, P750; Shay JW, 1996, LEUKEMIA, V10, P1255; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 1997, J CLIN PATHOL, V50, P799, DOI 10.1136/jcp.50.10.799; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZARI H, 1993, AM J HUM GENET, V53, P661; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x	14	38	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					153	154		10.1016/S0140-6736(05)78218-0	http://dx.doi.org/10.1016/S0140-6736(05)78218-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449864				2022-12-28	WOS:000071616300003
J	Hemesath, TJ; Price, ER; Takemoto, C; Badalian, T; Fisher, DE				Hemesath, TJ; Price, ER; Takemoto, C; Badalian, T; Fisher, DE			MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes	NATURE			English	Article							RECEPTOR TYROSINE KINASE; CULTURED MAST-CELLS; GENE-EXPRESSION; MI/MI GENOTYPE; MELANOMA-CELLS; IN-VIVO; MOUSE; ACTIVATION; MUTATIONS; PROTEIN	Germline mutations at loci encoding the transcription factor Microphthalmia (Mi), the cytokine receptor c-Kit, or its ligand Steel factor (Sl) result in strikingly similar defects in mast cell and melanocyte development(1-3). Here we describe a biochemical link between Kit signalling and the activity of Mi. Stimulation of melanoma cells with Sl results in activation of MAP kinase, which in turn phosphorylates Mi at a consensus target serine. This phosphorylation upregulates Mi transactivation of the tyrosinase pigmentation gene promoter. In addition to modulating pigment production, such signalling may regulate the expression of genes essential for melanocyte survival and development. The pathway represents a new application of the general MAP kinase machinery in transducing a signal between a tissue-specific receptor at the cell surface and a tissue-specific transcription factor in the nucleus.	Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Fisher, DE (corresponding author), Childrens Hosp, Div Pediat Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu	Takemoto, Clifford M/Y-7558-2018					Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EBI Y, 1992, BLOOD, V80, P1454; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; OKUDA K, 1992, BLOOD, V79, P2880; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	27	529	547	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	1998	391	6664					298	301		10.1038/34681	http://dx.doi.org/10.1038/34681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440696				2022-12-28	WOS:000071484400055
J	Hergott, LJ				Hergott, LJ			The time of the three dynasties: Reflections on imbalance in the practice of medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hergott, LJ (corresponding author), 2338 Leyden St, Denver, CO 80207 USA.							Chan, 1963, WAY LAO TZU TAO TE C; GRACIAN B, 1992, ART WORLDLY WISDOM; MERTON T, 1962, LORETTO GETHSEMANI; TZU C, 1965, WAY TZU C	4	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					149	151		10.7326/0003-4819-128-2-199801150-00013	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441577				2022-12-28	WOS:000071470800012
J	O'Leary, DH; Schaffer, PW; de la Monte, S				O'Leary, DH; Schaffer, PW; de la Monte, S			A 50-year-old woman with increasing headache and a left abducent-nerve palsy - Organizing subdural hygroma (consistent with the presence of spontaneous intracranial hypotension)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HYPERTROPHIC CRANIAL PACHYMENINGITIS; LYME-DISEASE; MENINGEAL ENHANCEMENT; DURAL ENHANCEMENT; MR; MENINGITIS; HYDROCEPHALUS; SARCOIDOSIS; BIOPSY; AIDS		New England Med Ctr, Dept Radiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Radiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	O'Leary, DH (corresponding author), New England Med Ctr, Dept Radiol, 750 Washington St, Boston, MA 02111 USA.		de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306				BARKHOF F, 1992, AM J NEURORADIOL, V13, P397; BLACK PM, 1981, J NEUROSURG, V55, P467, DOI 10.3171/jns.1981.55.3.0467; BRACCHI M, 1993, AM J NEURORADIOL, V14, P227; BRIGHTBILL TC, 1995, AM J NEURORADIOL, V16, P703; CHENG TM, 1994, NEUROSURGERY, V34, P590, DOI 10.1227/00006123-199404000-00004; Cushing H, 1910, BRAIN, V33, P204, DOI 10.1093/brain/33.3.204; DEMAEREL P, 1994, AM J NEURORADIOL, V15, P302; EUSTACE S, 1994, CAN ASSOC RADIOL J, V45, P463; FINKEL MJ, 1992, ARCH NEUROL-CHICAGO, V49, P102, DOI 10.1001/archneur.1992.00530250106024; FISHMAN RA, 1993, NEUROLOGY, V43, P609, DOI 10.1212/WNL.43.3_Part_1.609; Fukui MB, 1996, RADIOLOGY, V201, P605, DOI 10.1148/radiology.201.3.8939203; GOOD DC, 1993, NEUROLOGY, V43, P2698, DOI 10.1212/WNL.43.12.2698; GRIPSHOVER BM, 1995, MANDELL DOUGLAS BENN, V1, P865; GROSSMAN RI, 1994, NEURORADIOLOGY REQUI, P171; HOCHMAN MS, 1992, NEUROLOGY, V42, P1628, DOI 10.1212/WNL.42.8.1628; IOCONETTA G, 1994, ACTA NEUROL NAPOLI, V16, P214; JENSEN MC, 1993, AM J ROENTGENOL, V160, P153, DOI 10.2214/ajr.160.1.8416615; KEANE JR, 1976, ARCH NEUROL-CHICAGO, V33, P681, DOI 10.1001/archneur.1976.00500100015007; KIOUMEHR F, 1995, J COMPUT ASSIST TOMO, V19, P713, DOI 10.1097/00004728-199509000-00005; LEVY RM, 1993, INFECT DIS CENTRAL N, P47; MAMELAK AN, 1993, J NEUROSURG, V79, P270, DOI 10.3171/jns.1993.79.2.0270; MASTRIANNI JA, 1994, J NEURO-OPHTHALMOL, V14, P2; Meltzer CC, 1996, RADIOLOGY, V201, P297, DOI 10.1148/radiology.201.2.8888215; MILLER NR, 1995, WALSH HOYTS CLIN N 2, V5, P4394; MOKRI B, 1995, NEUROLOGY, V45, P1801, DOI 10.1212/WNL.45.10.1801; Mokri B, 1997, MAYO CLIN PROC, V72, P400, DOI 10.4065/72.5.400; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PANNULLO SC, 1993, NEUROLOGY, V43, P919, DOI 10.1212/WNL.43.5.919; RANOUX D, 1992, J NEUROL NEUROSUR PS, V55, P300, DOI 10.1136/jnnp.55.4.300; River Y, 1996, J NEUROSURG, V85, P777, DOI 10.3171/jns.1996.85.5.0777; SAVINO PJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1442, DOI 10.1001/archopht.1982.01030040420009; SELTZER S, 1991, AM J NEURORADIOL, V12, P1227; SZE G, 1987, SEMIN ROENTGENOL, V22, P42, DOI 10.1016/0037-198X(87)90021-6; Tanaka M, 1996, NEUROLOGY, V46, P554, DOI 10.1212/WNL.46.2.554; Tucker T, 1993, INFECT DIS CENTRAL N, P188	35	29	29	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					180	188		10.1056/NEJM199801153380308	http://dx.doi.org/10.1056/NEJM199801153380308			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9441223				2022-12-28	WOS:000071384500008
J	Hakim, AA; Petrovitch, H; Burchfiel, CM; Ross, GW; Rodriguez, BL; White, LR; Yano, K; Curb, JD; Abbott, RD				Hakim, AA; Petrovitch, H; Burchfiel, CM; Ross, GW; Rodriguez, BL; White, LR; Yano, K; Curb, JD; Abbott, RD			Effects of walking on mortality among nonsmoking retired men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; PHYSICAL-ACTIVITY; JAPANESE MEN; PROGRAM; RISK; DIETARY; STROKE; HAWAII; WEIGHT	Background The potential benefit of low-intensity activity in terms of longevity among older men has not been clearly documented. We examined the association between walking and mortality in a cohort of retired men who were nonsmokers and physically capable of participating in low-intensity activities on a daily basis. Methods We studied 707 nonsmoking retired men, 61 to 81 years of age, who were enrolled in the Honolulu Heart Program. The distance walked (miles per day) was recorded at a base-line examination, which took place between 1980 and 1982. Data on overall mortality (from any cause) were collected over a 12-year period of follow-up. Results During the follow-up period, there were 208 deaths. After adjustment for age, the mortality rate among the men who walked less than 1 mile (1.6 km) per day was nearly twice that among those who walked more than 2 miles (3.2 km) per day (40.5 percent vs. 23.8 percent, P=0.001). The cumulative incidence of death after 12 years for the most active walkers was reached in less than 7 years among the men who were least active. The distance walked remained inversely related to mortality after adjustment for overall measures of activity and other risk factors (P = 0.01). Conclusions Our findings in older physically capable men indicate that regular walking is associated with a lower overall mortality rate, Encouraging elderly people to walk may benefit their health. (C) 1998, Massachusetts Medical Society.	Univ Virginia, Sch Med, Div Biostat, Charlottesville, VA 22908 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA; Kuakini Med Ctr, Honolulu Heart Program, Honolulu, HI 96817 USA; NHLBI, Honolulu Epidemiol Res Sect, Epidemiol & Biometry Program, Honolulu, HI USA; Dept Vet Affairs, Honolulu, HI USA; NIA, Honolulu, HI USA	University of Virginia; University of Minnesota System; University of Minnesota Twin Cities; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Abbott, RD (corresponding author), Univ Virginia, Sch Med, Div Biostat, Box 600, Charlottesville, VA 22908 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC005102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011091] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR/AI 11091] Funding Source: Medline; NHLBI NIH HHS [N01-HC-05102] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; CASTELLI WP, 1977, J CHRON DIS, V30, P147, DOI 10.1016/0021-9681(77)90082-0; COX DR, 1972, J R STAT SOC B, V34, P187; DONAHUE RP, 1988, AM J PUBLIC HEALTH, V78, P683, DOI 10.2105/AJPH.78.6.683; GARCIAPALMIERI MR, 1982, AM J CARDIOL, V50, P749, DOI 10.1016/0002-9149(82)91229-2; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; Heilbrun L K, 1985, Hawaii Med J, V44, P294; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P818; LANE PW, 1982, BIOMETRICS, V38, P613, DOI 10.2307/2530043; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; SHERMAN SE, 1994, AM HEART J, V128, P965, DOI 10.1016/0002-8703(94)90596-7; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1986, ARTERIOSCLEROSIS, V6, P422, DOI 10.1161/01.ATV.6.4.422	21	381	387	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					94	99		10.1056/NEJM199801083380204	http://dx.doi.org/10.1056/NEJM199801083380204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ039	9420340				2022-12-28	WOS:000071341300004
J	Albert, CM; Hennekens, CH; O'Donnell, CJ; Ajani, UA; Carey, VJ; Willett, WC; Ruskin, JN; Manson, JE				Albert, CM; Hennekens, CH; O'Donnell, CJ; Ajani, UA; Carey, VJ; Willett, WC; Ruskin, JN; Manson, JE			Fish consumption and risk of sudden cardiac death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; POLYUNSATURATED FATTY-ACIDS; VENTRICULAR-FIBRILLATION; MYOCARDIAL-INFARCTION; MORTALITY; OMEGA-3-FATTY-ACIDS; REPRODUCIBILITY; POPULATION; PHYSICIANS	Context.-Dietary fish intake has been associated with a reduced risk of fatal cardiac end points, but not with nonfatal end points. Dietary fish intake may have a selective benefit on fatal arrhythmias and therefore sudden cardiac death. Objective.-To investigate prospectively the association between fish consumption and the risk of sudden cardiac death. Design.-Prospective cohort study. Setting.-The US Physicians' Health Study. Patients.-A total of 20 551 US male physicians 40 to 84 years of age and free of myocardial infarction, cerebrovascular disease, and cancer at baseline who completed an abbreviated, semiquantitative food frequency questionnaire on fish consumption and were then followed up to 11 years. Main Outcome Measure.-Incidence of sudden cardiac death (death within 1 hour of symptom onset) as ascertained by hospital records and reports of next of kin. Results.-There were 133 sudden deaths over the course of the study. After controlling for age, randomized aspirin and beta carotene assignment, and coronary risk factors, dietary fish intake was associated with a reduced risk of sudden death, with an apparent threshold effect at a consumption level of 1 fish meal per week (P for trend=.03). For men who consumed fish at least once per week, the multivariate relative risk of sudden death was 0.48 (95% confidence interval, 0.24-0.96; P=.04) compared with men who consumed fish less than monthly. Estimated dietary n-3 fatty acid intake from seafood also was associated with a reduced risk of sudden death but without a significant trend across increasing categories of intake. Neither dietary fish consumption nor n-3 fatty acid intake was associated with a reduced risk of total myocardial infarction, nonsudden cardiac death, or total cardiovascular mortality. However, fish consumption was associated with a significantly reduced risk of total mortality. Conclusion.-These prospective data suggest that consumption of fish at least once per week may reduce the risk of sudden cardiac death in men.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Cardiac Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Albert, CM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.			Albert, Christine/0000-0002-2081-1121	NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM HEART ASS, 1995, HEART STROK FACTS S; [Anonymous], 1988, NEW ENGL J MED, V318, P262; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; Broughton KS, 1997, AM J CLIN NUTR, V65, P1011, DOI 10.1093/ajcn/65.4.1011; BURR ML, 1989, LANCET, V2, P757; Christensen JH, 1997, AM J CARDIOL, V79, P1670, DOI 10.1016/S0002-9149(97)00220-8; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, NEW ENGL J MED, V313, P821; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOBSON AJ, 1983, AM J EPIDEMIOL, V117, P397, DOI 10.1093/oxfordjournals.aje.a113558; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GOLDSTEIN S, 1984, J AM COLL CARDIOL, V3, P1111, DOI 10.1016/S0735-1097(84)80167-9; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; Hartikainen JEK, 1996, J AM COLL CARDIOL, V28, P296, DOI 10.1016/0735-1097(96)00169-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KULLER L, 1967, MEDICINE, V46, P341, DOI 10.1097/00005792-196707000-00003; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MISHINA T, 1985, PROSTATE, V6, P423, DOI 10.1002/pros.2990060411; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; *USDA, 1963, AGR HDB SER, V8; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; *WHO, 1971, ISCH HEART DIS REG R; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	41	695	718	0	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					23	28		10.1001/jama.279.1.23	http://dx.doi.org/10.1001/jama.279.1.23			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424039				2022-12-28	WOS:000071295100030
J	Hawton, K				Hawton, K			Integration of treatments for male erectile dysfunction	LANCET			English	Editorial Material							THERAPY		Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	University of Oxford	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.							ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; BANCROFT J, 1989, HUMAN SEXUALITY ITS; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; HAWTON K, 1995, BRIT J PSYCHIAT, V167, P307, DOI 10.1192/bjp.167.3.307; Jeremy JY, 1997, BRIT J UROL, V79, P958, DOI 10.1046/j.1464-410X.1997.00206.x; PADMANATHAN H, 1997, NEW ENGL J MED, V336, P309; SPECKENS AEM, 1995, ARCH SEX BEHAV, V24, P157, DOI 10.1007/BF01541579; Stravynski A, 1997, BRIT J PSYCHIAT, V170, P338, DOI 10.1192/bjp.170.4.338	8	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					7	8		10.1016/S0140-6736(05)78097-1	http://dx.doi.org/10.1016/S0140-6736(05)78097-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433420				2022-12-28	WOS:000071253100006
J	Bannon, AW; Decker, MW; Holladay, MW; Curzon, P; Donnelly-Roberts, D; Puttfarcken, PS; Bitner, RS; Diaz, A; Dickenson, AH; Porsolt, RD; Williams, M; Arneric, SP				Bannon, AW; Decker, MW; Holladay, MW; Curzon, P; Donnelly-Roberts, D; Puttfarcken, PS; Bitner, RS; Diaz, A; Dickenson, AH; Porsolt, RD; Williams, M; Arneric, SP			Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors	SCIENCE			English	Article							BINDING-SITES; FORMALIN TEST; SPINAL-CORD; TAIL-FLICK; RAT; BRAIN; MORPHINE; ANTINOCICEPTION; EPIBATIDINE; STIMULATION	Development of analgesic agents for the treatment of severe pain requires the identification of compounds that are devoid of opioid receptor liabilities. A potent (inhibition constant = 37 picomolar) neuronal nicotinic acetylcholine receptor (nAChR) ligand called ABT-594 was developed that has antinociceptive properties equal in efficacy to those of morphine across a series of diverse animal models of acute thermal, persistent chemical, and neuropathic pain states. These effects were blocked by the nAChR antagonist mecamylamine. In contrast to morphine, repeated treatment with ABT-594 did not appear to elicit opioid-like withdrawal or physical dependence. Thus, ABT-594 may be an analgesic that lacks the problems associated with opioid analgesia.	Abbott Labs, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA; UCL, Neuropharmacol Pain Grp, London WC1E 6BT, England; ITEM LABO, F-94276 Le Kremlin Bicetre, France	Abbott Laboratories; University of London; University College London	Decker, MW (corresponding author), Abbott Labs, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA.	michael.w.decker@abbott.com		Diaz, Alvaro/0000-0002-8783-4555				ABBOTT FV, 1982, PHARMACOL BIOCHEM BE, V17, P1213, DOI 10.1016/0091-3057(82)90123-X; ARNERIC SP, COMMUNICATION; BADIO B, 1994, MOL PHARMACOL, V45, P563; BANNON AW, UNPUB; BENOWITZ NL, 1992, TRENDS CARDIOVAS MED, V1, P315; CAGGIULA AR, 1995, PSYCHOPHARMACOLOGY, V122, P310; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Cherny NI, 1996, DRUGS, V51, P713, DOI 10.2165/00003495-199651050-00002; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CRIDLAND RA, 1988, BRAIN RES, V462, P15, DOI 10.1016/0006-8993(88)90579-3; Davis L, 1932, SURG GYNECOL OBSTET, V55, P418; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; Decker MW, 1997, J PHARMACOL EXP THER, V283, P247; DECKER MW, 1994, J PHARMACOL EXP THER, V270, P319; Diaz A, 1997, PAIN, V69, P93, DOI 10.1016/S0304-3959(96)03271-X; DIRIG DM, 1995, PAIN, V62, P321, DOI 10.1016/0304-3959(95)00006-E; DONNELLYROBERTS DL, IN PRESS J PHARM EXP; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; GAMSE R, 1979, LIFE SCI, V25, P629, DOI 10.1016/0024-3205(79)90558-7; GOUDIE AJ, 1991, PSYCHOPHARMACOLOGY, V103, P529, DOI 10.1007/BF02244254; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HOLLADAY MW, IN PRESS J MED CHEM; IWAMOTO ET, 1991, J PHARMACOL EXP THER, V257, P120; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; LIPIELLO PM, 1996, J PHARMACOL EXP THER, V279, P1422; Lipman AG, 1996, CLIN GERIATR MED, V12, P501; LUKAS RJ, 1993, J PHARMACOL EXP THER, V265, P294; MARKS MJ, 1986, MOL PHARMACOL, V30, P427; Menzaghi F, 1997, J PHARMACOL EXP THER, V280, P393; Merskey H, 1997, ACTA ANAESTH SCAND, V41, P187, DOI 10.1111/j.1399-6576.1997.tb04636.x; MEYER EM, 1994, DRUG DEVELOP RES, V31, P127, DOI 10.1002/ddr.430310207; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; PORSOLT R, UNPUB; QIAN CG, 1993, EUR J PHARMACOL, V250, pR13; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; SULLIVAN JP, 1994, J PHARMACOL EXP THER, V271, P1; SULLIVAN JP, 1994, MED CHEM RES, V4, P502; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; TRIPATHI HL, 1982, J PHARMACOL EXP THER, V221, P91; WIENSENFELDHALL.Z, 1984, NEUROSCI LETT, V52, P199; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; YAKSH TL, 1994, PROG PAIN RES MANAG, V1, P151; YAKSH TL, 1994, TXB PAIN, P165	44	318	374	3	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					77	81		10.1126/science.279.5347.77	http://dx.doi.org/10.1126/science.279.5347.77			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417028				2022-12-28	WOS:000071323900043
J	McFadden, G				McFadden, G			Virology - Even viruses can learn to cope with stress	SCIENCE			English	Article									Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	McFadden, G (corresponding author), Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada.							BARINAGA M, 1992, SCIENCE, V258, P1730, DOI 10.1126/science.1334571; BARRY M, 1997, CYTOKINES HLTH DIS, P251; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; MCFADDEN G, 1995, VIROCEPTORS VIROKINE; MCFADDEN G, IN PRESS SEMIN VIROL; ODONNELLTORMEY J, 1985, J CLIN INVEST, V76, P80, DOI 10.1172/JCI111981; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Shisler JL, 1998, SCIENCE, V279, P102, DOI 10.1126/science.279.5347.102; SLATER AF, 1995, BIOCHIM BIOPHYS ACTA, V1121, P59; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; Taylor EW, 1997, BIOL TRACE ELEM RES, V56, P63, DOI 10.1007/BF02778984; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TURNER PC, IN PRESS SEMIN VIROL	17	22	23	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					40	41		10.1126/science.279.5347.40	http://dx.doi.org/10.1126/science.279.5347.40			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9441409				2022-12-28	WOS:000071323900030
J	Desplan, C				Desplan, C			Eye development: Governed by a dictator or a junta?	CELL			English	Review							EXPRESSION; DROSOPHILA; EVOLUTION; GENES		Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Desplan, C (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.			Desplan, Claude/0000-0002-6914-1413				Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Bonini NM, 1997, DEVELOPMENT, V124, P4819; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; HADORN E, 1968, SCI AM, V219, P110, DOI 10.1038/scientificamerican1168-110; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Johnston LA, 1996, DEVELOPMENT, V122, P3519; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; SALVINIPLAWEN LV, 1977, EVOLUTIONARY BIOL, V10, P207; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881	18	97	97	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					861	864		10.1016/S0092-8674(00)80475-4	http://dx.doi.org/10.1016/S0092-8674(00)80475-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428507	Bronze			2022-12-28	WOS:000071281400001
J	Shaw, LM; Rabinovitz, I; Wang, HHF; Toker, A; Mercurio, AM				Shaw, LM; Rabinovitz, I; Wang, HHF; Toker, A; Mercurio, AM			Activation of phosphoinositide 3-OH kinase by the alpha 6 beta 4 integrin promotes carcinoma invasion	CELL			English	Article							PROTEIN-KINASE; ACTIN POLYMERIZATION; CELL-ADHESION; E-CADHERIN; S6 KINASE; RAC; EXPRESSION; CDC42; HEMIDESMOSOMES; RHO	We demonstrate that the alpha 6 beta 4 integrin promotes carcinoma invasion through a preferential and localized targeting of phosphoinositide-3 OH kinase (PI3K) activity. Stable expression of alpha 6 beta 4 increased carcinoma invasion in a PI3K-dependent manner, and transient expression of a constitutively active PI3K increased invasion in the absence of alpha 6 beta 4. Ligation of alpha 6 beta 4 stimulated significantly more PI3K activity than ligation of beta 1 integrins, establishing specificity among integrins for PI3K activation. alpha 6 beta 4-regutated PI3K activity was required for the formation of lamellae, dynamic sites of motility, in carcinoma cells. The small G protein Rac is required downstream of PI3K for invasion. These studies define a mechanism by which the alpha 6 beta 4 integrin promotes carcinoma invasion and invoke a novel function for PI3K signaling.	Beth Israel Deaconess Med Ctr, Dept Med, GI Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston Biomedical Research Institute	Shaw, LM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, GI Div, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704] Funding Source: Medline; PHS HHS [A139264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBINI A, 1987, CANCER RES, V47, P3239; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; CANTLEY LC, 1994, J CELL SCI S, V18, P121; CAO C, 1996, CANCER RES, V56, P4811; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FALCIONI R, 1986, CANCER RES, V46, P5772; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Harden N, 1996, MOL CELL BIOL, V16, P1896; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; RABINOVITZ I, 1997, IN PRESS J CELL BIOL; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Serini G, 1996, J NATL CANCER I, V88, P442, DOI 10.1093/jnci/88.7.442; Shaw LM, 1996, CANCER RES, V56, P959; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tani T, 1996, AM J PATHOL, V149, P781; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VANWAES C, 1991, CANCER RES, V51, P2395; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324	62	531	542	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					949	960		10.1016/S0092-8674(00)80486-9	http://dx.doi.org/10.1016/S0092-8674(00)80486-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428518	Bronze			2022-12-28	WOS:000071281400012
J	Vento, S; Garofano, T; Renzini, C; Cainelli, F; Casali, F; Ghironzi, G; Ferraro, T; Concia, E				Vento, S; Garofano, T; Renzini, C; Cainelli, F; Casali, F; Ghironzi, G; Ferraro, T; Concia, E			Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; B VIRUS; A-HEPATITIS; LIVER-TRANSPLANTATION; VIRAL-HEPATITIS; INFECTION; RNA; ASSAY; DNA; ANTIBODIES	Background Hepatitis A virus (HAV) infection rarely causes fulminant hepatic failure in people with no underlying liver disease. There are limited data on the course of this infection in patients with chronic hepatitis B and chronic hepatitis C. Methods We prospectively followed, from June 1990 to July 1997, 595 adults with biochemical and histologic evidence of chronic hepatitis B (163 patients) or chronic hepatitis C (432 patients) who were seronegative for HAV antibodies. All were tested every four months for serum IgM and IgG antibodies to HAV. Results Twenty-seven patients acquired HAV superinfection, 10 of whom had chronic hepatitis B and 17 of whom had chronic hepatitis C. One of the patients with chronic hepatitis B, who also had cirrhosis, had marked cholestasis (peak serum bilirubin level, 28 mg per deciliter [479 mu mol per liter]); the other nine had uncomplicated courses of hepatitis A. Fulminant hepatic failure developed in seven of the patients with chronic hepatitis C, all but one of whom died. The other 10 patients with chronic hepatitis C had uncomplicated courses of hepatitis A. Conclusions Although most patients with chronic hepatitis B who acquired HAV infection had an uncomplicated course, patients with chronic hepatitis C had a substantial risk of fulminant hepatitis and death associated with HAV superinfection. Our data suggest that patients with chronic hepatitis C should be vaccinated against hepatitis A, (C) 1998, Massachusetts Medical Society.	Univ Verona, Dept Infect Dis, I-37124 Verona, Italy; A Pugliese Hosp, Infect Dis Unit, Catanzaro, Italy; San Marino State Hosp, Dept Internal Med, San Marino, San Marino; San Marino State Hosp, Cent Lab, San Marino, San Marino	University of Verona	Vento, S (corresponding author), Univ Verona, Dept Infect Dis, Via Locchi 12, I-37124 Verona, Italy.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062; Cainelli, Francesca/0000-0003-1838-3946				AJDUKIEW.AB, 1972, LANCET, V1, P803; Armitage P., 2001, STAT METHODS MED RES; BERNINGER M, 1982, J MED VIROL, V9, P57, DOI 10.1002/jmv.1890090109; *CDCP, 1994, 55 CDCP, P9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTEAS C, 1983, DIGEST DIS SCI, V28, P684, DOI 10.1007/BF01312556; CZAJA AJ, 1995, GASTROENTEROLOGY, V108, P157, DOI 10.1016/0016-5085(95)90020-9; DAVIS GL, 1984, J MED VIROL, V14, P141, DOI 10.1002/jmv.1890140208; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; FUSCONI M, 1990, J IMMUNOL METHODS, V130, P1, DOI 10.1016/0022-1759(90)90291-3; GANE E, 1995, J MED VIROL, V45, P35, DOI 10.1002/jmv.1890450107; GRETCH D, 1994, J INFECT DIS, V169, P1219, DOI 10.1093/infdis/169.6.1219; KEEFFE EB, 1995, AM J GASTROENTEROL, V90, P201; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LEMON SM, 1985, NEW ENGL J MED, V313, P1059, DOI 10.1056/NEJM198510243131706; MCFARLANE BM, 1985, J IMMUNOL METHODS, V77, P219, DOI 10.1016/0022-1759(85)90034-1; MCFARLANE BM, 1994, J MED VIROL, V42, P66, DOI 10.1002/jmv.1890420113; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TASSOPOULOS N, 1985, LIVER, V5, P348; Vento S, 1990, Prog Liver Dis, V9, P335; VENTO S, 1988, J CLIN LAB IMMUNOL, V25, P1; VIOLA LA, 1982, POSTGRAD MED J, V58, P80, DOI 10.1136/pgmj.58.676.80; YOTSUYANAGI H, 1993, J MED VIROL, V40, P35, DOI 10.1002/jmv.1890400108; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993; ZACHOVAL R, 1983, HEPATOLOGY, V3, P528; 1996, MMWR MORB MORTAL WKL, V45, P1	28	480	500	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					286	290		10.1056/NEJM199801293380503	http://dx.doi.org/10.1056/NEJM199801293380503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445408				2022-12-28	WOS:000071665200003
J	Doublie, S; Tabor, S; Long, AM; Richardson, CC; Ellenberger, T				Doublie, S; Tabor, S; Long, AM; Richardson, CC; Ellenberger, T			Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 angstrom resolution	NATURE			English	Article							ESCHERICHIA-COLI THIOREDOXIN; I KLENOW FRAGMENT; POLYMERASE-I; DEOXYNUCLEOSIDE TRIPHOSPHATE; DEOXYRIBONUCLEIC-ACID; EXONUCLEASE ACTIVITY; PROTEIN; MECHANISM; RESIDUES; MUTANT	DNA polymerases change their specificity for nucleotide substrates with each catalytic cycle, while achieving error frequencies in the range of 10(-5) to 10(-6). Here we present a 2.2 Angstrom crystal structure of the replicative DNA polymerase from bacteriophage T7 complexed with a primer-template and a nucleoside triphosphate in the polymerase active site. The structure illustrates how nucleotides are selected in a template-directed manner, and provides a structural basis for a metal-assisted mechanism of phosphoryl transfer by a large group of related polymerases.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	stabor@heckle.med.harvard.edu; tome@jeckle.med.harvard.edu		Doublie, Sylvie/0000-0002-6294-5304				ADLER S, 1983, J BIOL CHEM, V258, P6956; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUNGER AT, 1992, XPLOR VERSOIN 3 1 SY; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CARTER CW, 1992, CRYSTALLIZATION NUCL, P47; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; MODRICH P, 1975, J BIOL CHEM, V250, P5508; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rould MA, 1997, METHOD ENZYMOL, V276, P461, DOI 10.1016/S0076-6879(97)76072-5; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599	50	1075	1105	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	1998	391	6664					251	258		10.1038/34593	http://dx.doi.org/10.1038/34593			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440688				2022-12-28	WOS:000071484400040
J	Smith, RC; Lyles, JS; Mettler, J; Stoffelmayr, BE; Van Egeren, LF; Marshall, AA; Gardiner, JC; Maduschke, KM; Stanley, JM; Osborn, GG; Shebroe, V; Greenbaum, RB				Smith, RC; Lyles, JS; Mettler, J; Stoffelmayr, BE; Van Egeren, LF; Marshall, AA; Gardiner, JC; Maduschke, KM; Stanley, JM; Osborn, GG; Shebroe, V; Greenbaum, RB			The effectiveness of intensive training for residents in interviewing - A randomized, controlled study	ANNALS OF INTERNAL MEDICINE			English	Article							ADDITIONAL BASIC SCIENCE; PRIMARY CARE RESIDENTS; CLINICAL MEDICINE; PSYCHOSOCIAL MEDICINE; PATIENT COMMUNICATION; PHYSICAL-EXAMINATION; HISTORY-TAKING; SELF-EFFICACY; SKILLS; MODEL	Background: Interviewing and the physician-patient relationship are crucial elements of medical care, but residencies provide little formal instruction in these areas. Objective: To determine the effects of a training program in interviewing on 1) residents' attitudes toward and skills in interviewing and 2) patients' physical and psychosocial well-being and satisfaction with care. Design: Randomized, controlled study. Setting: Two university-based primary care residencies. Participants: 63 primary care residents in postgraduate year 1. Intervention: A 1-month, full-time rotation in interviewing and related psychosocial topics. Measurements: Residents and their patients were assessed before and after the 1-month rotation. Questionnaires were used to assess residents' commitment to interviewing and psychosocial medicine, estimate of the importance of such care, and confidence in their ability to provide such care. Knowledge of interviewing and psychosocial medicine was assessed with a multiple-choice test. Audiotaped interviews with real patients and videotaped interviews with simulated patients were rated for specific interviewing behaviors. Patients' anxiety, depression, and social dysfunction; role limitations; somatic symptom status; and levels of satisfaction with medical visits were assessed by questionnaires and telephone interviews. Results: Trained residents were superior to untrained residents in knowledge (difference in adjusted post-test mean scores, 15.7% [95% CI, 11% to 20%]); attitudes, such as confidence in psychological sensitivity (difference, 0.61 points on a 7-point scale [CI, 0.32 to 0.91 points]); somatization management (difference, 0.99 points [CI, 0.64 to 1.35 points]); interviewing of real patients (difference, 1.39 points on an 11-point scale [CI, 0.32 to 2.45 points]); and interviewing (data gathering) of simulated patients (difference, 2.67 points [CI, 1.77 to 3.56 points]). Mean differences between the study groups were consistently in the appropriate direction for patient satisfaction and patient well-being, but effect sizes were too small to be considered meaningful. Conclusion: An intensive 1-month training rotation in interviewing improved residents' knowledge about, attitudes toward, and skills in interviewing.	Michigan State Univ, Coll Human Med, Clin Ctr B312, E Lansing, MI 48824 USA; Michigan State Univ, Coll Human Med, Clin Ctr B338, E Lansing, MI 48824 USA	Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine	Smith, RC (corresponding author), Michigan State Univ, Coll Human Med, Clin Ctr B312, E Lansing, MI 48824 USA.		GARDINER, JOSEPH/AAN-9697-2021	GARDINER, JOSEPH/0000-0003-2605-6478; Smith, Robert/0000-0001-6996-9037				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASON NC, 1991, INTRO TXB PSYCHIAT; [Anonymous], 1967, PRAGMATICS HUMAN COM; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Breunlin DC, 1990, FAMILY SYSTEMS MED, V8, P48; BURNS BJ, 1983, GEN HOSP PSYCHIAT, V5, P157, DOI 10.1016/0163-8343(83)90051-8; DAVIDOFF F, 1996, WHO HAS SEEN BLOOD S, P76; Depression Guideline Panel, 1993, DEPR PRIM CAR, DOI [10.1002/depr.3050020202, DOI 10.1002/DEPR.3050020202]; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ENGEL GL, 1977, JOHNS HOPKINS MED J, V140, P222; ENGEL GL, 1987, AM J MED, V82, P107, DOI 10.1016/0002-9343(87)90384-6; FEINSTEIN AR, 1987, PERSPECT BIOL MED, V30, P215; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P705, DOI 10.7326/0003-4819-99-5-705; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P843, DOI 10.7326/0003-4819-99-6-843; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P393, DOI 10.7326/0003-4819-99-3-393; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOSS L, 1987, 2 MED REVOLUTION BIO; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HOUPT JL, 1977, INT J PSYCHIAT MED, V7, P295, DOI 10.2190/KX6X-41QU-8AXC-TG3C; INUI TS, 1985, MED CARE, V23, P521, DOI 10.1097/00005650-198505000-00013; Knowles M., 1980, MODERN PRACTICE ADUL; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; LAZARE A, 1975, ARCH GEN PSYCHIAT, V32, P553; Levenstein J.H., 1989, COMMUNICATING MED PA, P107; LEVENSTEIN JH, 1986, FAM PRACT, V3, P24, DOI 10.1093/fampra/3.1.24; Linfors E W, 1981, J R Coll Gen Pract, V31, P426; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; LIPKIN M, 1987, J GEN INTERN MED, V2, P363, DOI 10.1007/BF02596178; Lipkin MJ, 1995, MED INTERVIEW CLIN C; LIPP M, 1977, RESPECTFUL TREATMENT; LYLES J, 1996, THESIS MICHIGAN STAT; MARSHALL AA, 1995, AM J GASTROENTEROL, V90, P4; McKeachie W. J., 1990, TEACHING LEARNING CO, V3rd; McWhinney I., 1989, COMMUNICATING MEDICA, P25; McWhinney IR., 1981, INTRO FAMILY MED; MERKEL WT, 1990, J GEN INTERN MED, V5, P34, DOI 10.1007/BF02602307; MERKEL WT, 1983, SOC SCI MED, V17, P213, DOI 10.1016/0277-9536(83)90118-1; *NAT I MENT HLTH, 1989, DHHS PUBL; NOVACK DH, 1993, JAMA-J AM MED ASSOC, V269, P2101, DOI 10.1001/jama.269.16.2101; NOVACK DH, 1989, PSYCHOSOMATICS, V30, P213, DOI 10.1016/S0033-3182(89)72304-5; Nunnally JC., 1978, PSYCHOMETRIC THEORY, Vsecond edition., P245; PETERSON MC, 1992, WESTERN J MED, V156, P163; Prochaska J. O., 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; QUILL TE, 1991, ARCH INTERN MED, V151, P463; Rogers C.R., 1951, CLIENT CENT THER; ROTER DL, 1990, J GEN INTERN MED, V5, P347, DOI 10.1007/BF02600404; SAS Institute, 1989, SAS STAT US GUID; SCHMITT BP, 1986, J GEN INTERN MED, V1, P386, DOI 10.1007/BF02596424; SCHUBERT DSP, 1989, GEN HOSP PSYCHIAT, V11, P77, DOI 10.1016/0163-8343(89)90050-9; SCHUNK DH, 1985, PSYCHOL SCHOOLS, V22, P208, DOI 10.1002/1520-6807(198504)22:2<208::AID-PITS2310220215>3.0.CO;2-7; SIMPSON MA, 1985, MED TEACH, V7, P75, DOI 10.3109/01421598509036794; SMITH RC, 1995, J GEN INTERN MED, V10, P315, DOI 10.1007/BF02599950; SMITH RC, 1985, J FAM PRACTICE, V21, P294; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; SMITH RC, 1991, J GEN INTERN MED, V6, P535, DOI 10.1007/BF02598223; SMITH RC, 1995, ACAD MED, V70, P729, DOI 10.1097/00001888-199508000-00019; SMITH RC, 1994, J GEN INTERN MED, V9, P390, DOI 10.1007/BF02629520; SMITH RC, 1991, J GEN INTERN MED, V6, P168, DOI 10.1007/BF02598318; SMITH RC, 1996, TEACHING SUPPLEMENT; Smith RC, 1996, PATIENTS STORY INTEG; SMITH RC, 1995, MED INTERVIEW, P104; STOECKLE JD, 1987, J GEN INTERN MED, V2, P119, DOI 10.1007/BF02596310; STOFFELMAYR B, 1989, PRIMARY CARE, V16, P265; STRAIN JJ, 1986, J MED EDUC, V61, P958; STRAIN JJ, 1985, PSYCHOSOM MED, V47, P95, DOI 10.1097/00006842-198503000-00001; THOMPSON TL, 1982, INT J PSYCHIAT MED, V12, P153; *US DEP HHS, 1993, AHCPR PUBL; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WAITZKIN H, 1985, J HEALTH SOC BEHAV, V26, P81, DOI 10.2307/2136599; WILLIAMS GC, 1991, ANN INTERN MED, V115, P59, DOI 10.7326/0003-4819-115-1-59; WILLIAMSON PR, 1992, J GEN INTERN MED, V7, P235, DOI 10.1007/BF02598023; [No title captured]	76	178	182	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					118	126		10.7326/0003-4819-128-2-199801150-00008	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR200	9441572				2022-12-28	WOS:000071470800007
J	Cheskin, LJ; Miday, R; Zorich, N; Filloon, T				Cheskin, LJ; Miday, R; Zorich, N; Filloon, T			Gastrointestinal symptoms following consumption of olestra or regular triglyceride potato chips - A controlled comparison	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISORDERS	Context.-Olestra, a nonabsorbable, energy-free fat substitute used in snack foods, has been anecdotally reported to cause gastrointestinal (GI) adverse events, although such effects were not expected based on results from randomized trials, in which ii was consumed in typical snack patterns. Objective.-To determine whether ad libitum consumption of potato chips made with the fat substitute olestra results in a different level of GI symptoms than regular chips made with triglyceride (TG). Design-Randomized, double-blind, parallel, placebo-controlled trial. Setting.-A suburban Chicago, Ill, multiplex cinema. Subjects.-A total of 1123 volunteers aged 13 to 88 years. Intervention.-Subjects were given a beverage and an unlabeled, white 369-g (13-oz) bag of potato chips made with olestra or TG during a free movie screening. Main Outcome Measures.-Total and specific GI symptoms reported during a telephone interview conducted from 40 hours to 10 days after ingestion; level of potato chip consumption; and satiety level. Results.-Of 563 evaluable subjects in the olestra chip group, 89 (15.8%) reported 1 or more GI symptoms, while 93 (17.6%) of the 529 evaluable subjects in the regular TG chip group did so (difference in symptom frequency between olestra and TG, -1.8, 95% confidence interval, -6.2 to 27; P=.47). For specific GI symptoms leg, gas, diarrhea, abdominal cramping), there were no significant differences between olestra and TG chips. Fewer olestra chips were consumed than TG chips (60 vs 77 g [2.1 vs 2.7 oz]; P<00.1), with olestra chips receiving lower "taste scores (5.6 vs 6.4 on a 9-point scale; P<001). Consumption levels did not correlate with the rate of symptom reporting in either the olestra or TG group. There was no difference in satiety scores between olestra and TG chips (5.7 vs 5.9 on a 9-point scale; P=.07). Conclusions.-This study demonstrates that ad libitum consumption of olestra potato chips during 1 sitting is not associated with increased incidence or severity of GI symptoms, nor does the amount consumed predict who will report GI effects after short-term consumption of either olestra or TG potato chips.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Gastroenterol, Baltimore, MD 21224 USA; Procter & Gamble Co, Regulatory & Clin Dev Div, Cincinnati, OH USA	Johns Hopkins University; Johns Hopkins Medicine; Procter & Gamble	Cheskin, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Gastroenterol, 4940 Eastern Ave, Baltimore, MD 21224 USA.		Cheskin, Lawrence/AAM-1094-2021	Cheskin, Lawrence/0000-0003-0262-1030				BERGHOLZ CM, 1992, CRIT REV FOOD SCI, V32, P141, DOI 10.1080/10408399209527588; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; KANG JY, 1992, GUT, V33, P743, DOI 10.1136/gut.33.6.743; LEVINE A, 1997, US NEWS WORLD R 0505, P53; MATTSON FH, 1972, J NUTR, V102, P1171, DOI 10.1093/jn/102.9.1171; MATTSON FH, 1972, J LIPID RES, V13, P325; MILLER DL, 1995, FASEB J, V9, pA190; MYERS MG, 1987, CLIN PHARMACOL THER, V42, P250, DOI 10.1038/clpt.1987.142; Peters JC, 1997, J NUTR, V127, pS1719, DOI 10.1093/jn/127.8.1719S; Schlagheck TG, 1997, J NUTR, V127, pS1646, DOI 10.1093/jn/127.8.1646S; Schlagheck TG, 1997, J NUTR, V127, pS1666, DOI 10.1093/jn/127.8.1666S; *US FOOD DRUG ADM, 1995, COSTART COD SYMB THE; Zorich NL, 1997, REGUL TOXICOL PHARM, V26, P200, DOI 10.1006/rtph.1997.1164; 1996, FED REG, V61, P3118	14	33	35	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					150	152		10.1001/jama.279.2.150	http://dx.doi.org/10.1001/jama.279.2.150			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440666	Bronze			2022-12-28	WOS:000071338900033
J	L'Brown, J				L'Brown, J			Efficacy of combined interferon and ribavirin for treatment of hepatitis C	LANCET			English	Editorial Material							NON-B-HEPATITIS; NON-A; TRANSFUSION; VIRUS; ALFA		Gloucestershire Royal Hosp, Dept Gastroenterol, Gloucester GL1 3NN, England; Cranfield Univ, Inst Med Sci, Gloucestershire Royal Hosp, Gloucester GL1 3NN, England	Gloucestershire Royal Hospital; Cranfield University; Gloucestershire Royal Hospital	L'Brown, J (corresponding author), Gloucestershire Royal Hosp, Dept Gastroenterol, Gloucester GL1 3NN, England.			Brown, Jonathan/0000-0001-5540-297X				Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Chemello L, 1995, J HEPATOL, V23, P8; CROWE J, 1995, GASTROENTEROLOGY, V108, pA1054, DOI 10.1016/0016-5085(95)28518-0; DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; Kim WR, 1997, ANN INTERN MED, V127, P866, DOI 10.7326/0003-4819-127-10-199711150-00002; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; Lam NP, 1997, HEPATOLOGY, V26, P226; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; POWER JP, 1995, LANCET, V346, P372; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; REICHARD O, 1991, LANCET, V337, P1058, DOI 10.1016/0140-6736(91)91707-2; Schalm SW, 1997, J HEPATOL, V26, P961, DOI 10.1016/S0168-8278(97)80103-1; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	19	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	1998	351	9096					78	79		10.1016/S0140-6736(05)78157-5	http://dx.doi.org/10.1016/S0140-6736(05)78157-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439486				2022-12-28	WOS:000071591900003
J	Neeleman, J; Wessely, S; Wadsworth, M				Neeleman, J; Wessely, S; Wadsworth, M			Predictors of suicide, accidental death, and premature natural death in a general-population birth cohort	LANCET			English	Article							FOLLOW-UP; MORTALITY; DISORDERS; STOCKHOLM; CHILD	Background Whether putative suicide risk factors, such as conduct and emotional disorders, are specific to suicide or are general associations of a continuum between subintentional and intentional self-destruction is not clear. We undertook an investigation of this issue in a UK population-based birth cohort. Methods Using competing-risks analysis, we examined links between prospectively collected childhood and adolescent temperamental and behavioural variables and the risk of natural, accidental, and suicidal death, occurring between the ages of 16 and 50 years. Of the 5362 members of the cohort, full data were available for 3591. A panel of psychiatrists scored deaths on likely suicidal intention. These scores were used in a weighted logistic regression to examine independence of risk factors for (sub)intentional self-destruction. Findings There were 167 deaths among the risk-set between the 16th and 50th birthdays. 120 were due to natural causes; of the other 47, the panel of psychiatrists judged that 36 were accidental deaths and 11 were suicides (certainty rating greater than or equal to 51%). Adolescent emotional instability and conduct problems had different associations with the various causes of premature death, being lowest for natural death (odds ratio 1.0 [95% CI 0.8-1.2] and 1.2 [1.0-1.5]), intermediate for accidental death (1.1 [0.8-1.5] and 1.3 [1.0-1.7]), and highest for suicidal death (2.0 [1.2-3.6] and 1.8 [1.3-2.5]). Emotional instability (boys 1.3 [1.0-1.7], girls 1.4 [1.0-1.9]) increased risk for subintentional or intentional self-destruction, as did low anxiety in adolescence (1.7 [1.3-2.5]) and nocturnal enuresis at age 4 (1.4 [1.2-1.7]) in boys, and conduct problems in girls (1.4 [1.0-2.0]). Interpretation Suicide shares important risk factors with other causes of premature death. These findings suggest an aetiological continuum of self-destruction from subintentional to intentional. Research on premature mortality associated with psychological disorder should include all causes of death.	Univ Groningen, Dept Social Psychiat, NL-9700 RB Groningen, Netherlands; Kings Coll London, Sch Med, Dept Psychol Med, London SE5 9PJ, England; Inst Psychiat, London, England; UCL, Sch Med, London W1N 8AA, England	University of Groningen; University of London; King's College London; University of London; King's College London; University of London; University College London; UCL Medical School	Neeleman, J (corresponding author), Univ Groningen, Dept Social Psychiat, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.neeleman@med.rug.nl	Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1995, BRIT MED J, V311, P1203, DOI 10.1136/bmj.311.7014.1203; BRENT DA, 1993, J AM ACAD CHILD PSY, V32, P521, DOI 10.1097/00004583-199305000-00006; Caspi A, 1996, ARCH GEN PSYCHIAT, V53, P1033; CORNFIELD J, 1957, AM J PUBLIC HEALTH N, V47, P601, DOI 10.2105/AJPH.47.5.601; DECHATEAU P, 1990, ACTA PSYCHIAT SCAND, V81, P472, DOI 10.1111/j.1600-0447.1990.tb05484.x; ENGSTROM A, 1991, INT J ADDICT, V26, P91, DOI 10.3109/10826089109056241; Farberow N.L., 1980, MANY FACES SUICIDE I; FOX K, 1975, SOC PSYCHIATR, V10, P31, DOI 10.1007/BF00579862; Freud S., 1922, PLEASURE PRINCIPLE; FRIES JF, 1989, LANCET, V1, P481; GARRISON CZ, 1993, AM J PUBLIC HEALTH, V83, P179, DOI 10.2105/AJPH.83.2.179; Hansen V, 1997, BRIT J PSYCHIAT, V170, P186, DOI 10.1192/bjp.170.2.186; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; KAZDIN AE, 1995, EPIDEMIOLOGY CHILD A, P258; LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940; LUNSING RJ, 1991, DEV MED CHILD NEUROL, V33, P439; NORDENTOFT M, 1993, BRIT MED J, V306, P1637, DOI 10.1136/bmj.306.6893.1637; ODONNELL I, 1995, BRIT J PSYCHIAT, V166, P458, DOI 10.1192/bjp.166.4.458; Pintner R, 1937, ASPECTS PERSONALITY; *REG GEN, 1949, ABR LIF TABL 1946 19; Robins L. N., 1966, DEVIANT CHILDREN GRO; ROCKETT IRH, 1995, P INT EFF INJ STAT, V1; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; RORSMAN B, 1982, NEUROPSYCHOBIOLOGY, V8, P233, DOI 10.1159/000117904; RORSMAN B, 1982, NEUROPSYCHOBIOLOGY, V8, P188, DOI 10.1159/000117898; RUNESON B S, 1992, International Review of Psychiatry, V4, P197, DOI 10.3109/09540269209066317; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; SHAFFER D, 1988, J CLIN PSYCHIAT, V49, P36; VERHULST FC, 1991, PSYCHOL MED, V21, P965, DOI 10.1017/S0033291700029950; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300	30	91	93	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					93	97		10.1016/S0140-6736(97)06364-2	http://dx.doi.org/10.1016/S0140-6736(97)06364-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT341	9439493				2022-12-28	WOS:000071591900010
J	Reed, BA; Habicht, JP				Reed, BA; Habicht, JP			Sales of food aid as sign of distress, not excess	LANCET			English	Article								In 1996 the sale and export of food aid from refugee camps near Uvira, Zaire, prompted a reduction in donated rations. However, research has revealed that the sales did not reflect an excess of food in the camps. They were provoked by the absence of important components of the food basket, by cultural aversion to the staple (maize) and oil provided, by difficulties in food preparation, and by the refugees' limited ability to diversify their diet and cover pressing non-food needs. Food sales improved the micronutrient content of diets but at the expense of energy lost from an already energy-deficient diet. At most 23% of the refugee households were eating sufficient and adequate diets; the poorest one-fifth of households were twice as likely to sell or exchange food as were other households and their diets were the worst. These findings demonstrate the perils of the gap between policy and practice in food aid distribution.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Habicht, JP (corresponding author), Cornell Univ, Div Nutr Sci, Savage Hall, Ithaca, NY 14853 USA.							CHRISTENSEN H, 1982, 823 UN RES I SOC DEV, P1; Hansch S., 1992, Journal of Refugee Studies, V5, P300, DOI 10.1093/jrs/5.3-4.300; Harrell-Bond B., 1992, Journal of Refugee Studies, V5, P205, DOI 10.1093/jrs/5.3-4.205; Shoham J, 1996, DISASTERS, V20, P338, DOI 10.1111/j.1467-7717.1996.tb01048.x; Wilson K. B., 1992, Journal of Refugee Studies, V5, P226, DOI 10.1093/jrs/5.3-4.226; *WORLD FOOD PROGR, 1994, MEM UND JOINT WORK A	6	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					128	130		10.1016/S0140-6736(97)06329-0	http://dx.doi.org/10.1016/S0140-6736(97)06329-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439508	hybrid			2022-12-28	WOS:000071591900044
J	Nightingale, SL				Nightingale, SL			List of disqualified investigators available an Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-28	WOS:000071295100004
J	Dark, JH				Dark, JH			Priorities for lung transplantation	LANCET			English	Editorial Material									Freeman Rd Hosp, Cardiothorac Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK	Dark, JH (corresponding author), Freeman Rd Hosp, Cardiothorac Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.							BAVARIA J, 1997, J THORAC CARDIOVASC, V113, P5200; BENJAMIN M, 1994, NEW ENGL J MED, V330, P858, DOI 10.1056/NEJM199403243301211; BOUGE R, 1993, J HEART LUNG TRANSPL, V12, P549; Gaissert HA, 1996, J THORAC CARDIOV SUR, V111, P296, DOI 10.1016/S0022-5223(96)70438-5; Gutmann Thomas, 1997, Transplant Rev (Orlando), V11, P191, DOI 10.1016/S0955-470X(97)80038-9; HAYDEN AM, 1993, TRANSPLANTATION, V55, P1048, DOI 10.1097/00007890-199305000-00019; Hopkins WE, 1996, J HEART LUNG TRANSPL, V15, P100; SHARPLES LD, 1993, J HEART LUNG TRANSPL, V12, P699; STROM K, 1993, AM REV RESPIR DIS, V147, P585, DOI 10.1164/ajrccm/147.3.585; SUNDARESAN S, 1993, ANN THORAC SURG, V56, P1409, DOI 10.1016/0003-4975(93)90699-I	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					4	5		10.1016/S0140-6736(05)78099-5	http://dx.doi.org/10.1016/S0140-6736(05)78099-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433418				2022-12-28	WOS:000071253100004
J	Wilson, AC; Forsyth, JS; Greene, SA; Irvine, L; Hau, C; Howie, PW				Wilson, AC; Forsyth, JS; Greene, SA; Irvine, L; Hau, C; Howie, PW			Relation of infant diet to childhood health: seven year follow up of cohort of children in Dundee infant feeding study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; BRITISH CHILDREN; BLOOD-PRESSURE; SCHOOLCHILDREN; ASTHMA; GROWTH; LIFE	Objective: To investigate the relation of infant feeding practice to childhood respiratory illness, growth, body composition, and blood pressure. Design: Follow up study of a cohort of children (mean age 7.3 years) who had detailed infant feeding and demographic data collected prospectively during the first two years of life. Setting: Dundee. Subjects: 674 infants, of whom 545 (81%) were available for study. Data on respiratory illness were available for 545 children (mean age 7.3 (range 6.1-9.9) years); height for 410 children; weight and body mass index for 412 children; body composition for 405 children; blood pressure for 301 children (mean age 7.2 (range 6.9-10.0) years). Main outcome measures: Respiratory illness, weight, height, body mass index, percentage body fat, and blood pressure in relation to duration of breast feeding and timing of introduction of solids. Results: After adjustment for the significant confounding variables the estimated probability of ever having respiratory illness in children who received breast milk exclusively for at least 15 weeks was consistently lower (17.0% (95% confidence interval 15.9% to 18.1%) for exclusive breast feeding, 31.0% (26.8% to 35.2%) for partial breast feeding, and 32.2% (30.7% to 33.7%) for bottle feeding. Solid feeding before 15 weeks was associated with an inn eased probability of wheeze during childhood (21.0% (19.9% to 22.1%) v 9.7% (8.6% to 10.8%)). It was also associated with increased percentage body fat and weight in childhood (mean body fat 18.5% (18.2% to 18.8%) v 16.5% (16.0% to 17.0%); weight standard deviation score 0.02 (-0.02 to 0.06) v -0.09 (-0.16 to 0.02). Systolic blood pressure was raised significantly in children who were exclusively bottle fed compared with children who received breast milk (mean 94.2 (93.5 to 94.9) mm Hg v 90.7 (89.9 to 91.7) mm Hg). Conclusions: The probability of respiratory illness occurring at any time during childhood is significantly reduced in the child is fed exclusively breast milk for 15 weeks and no solid foods are introduced during this time. Breast feeding and the late introduction of solids may have a beneficial effect on childhood health and subsequent adult disease.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Forsyth, JS (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland.	stewart.f@dth.scot.nhs.uk		Irvine, Linda/0000-0002-8527-876X				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BROOK CGD, 1971, ARCH DIS CHILD, V46, P182, DOI 10.1136/adc.46.246.182; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DAVIES PSW, 1991, ARCH DIS CHILD, V66, P1467, DOI 10.1136/adc.66.12.1467-a; *DEP HLTH SOC SEC, 1994, WEAN WEAN DIET REP W; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; DHSS (Department of Health and Social Security), 1988, LANCET, V331, P975; ELLIOTT P, 1988, BRIT MED J, V297, P319; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; Forrester TE, 1996, BRIT MED J, V312, P156; FORSYTH JS, 1993, BMJ-BRIT MED J, V306, P1572, DOI 10.1136/bmj.306.6892.1572; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LUCAS A, 1991, BRIT MED J, V302, P350, DOI 10.1136/bmj.302.6772.350-b; LUCAS A, 1988, ARCH DIS CHILD, V63, P656, DOI 10.1136/adc.63.6.656; MARTIN J, 1988, INFANT FEEDING 1985; Office of Population Censuses and Surveys, 1980, CLASS OCC; TAITZ LS, 1971, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5744.315; Whincup PH, 1996, BMJ-BRIT MED J, V313, P79, DOI 10.1136/bmj.313.7049.79; WHITE EM, 1995, ARCH DIS CHILD, V72, P38, DOI 10.1136/adc.72.1.38	23	395	404	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	1998	316	7124					21	25		10.1136/bmj.316.7124.21	http://dx.doi.org/10.1136/bmj.316.7124.21			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451261	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000071377900018
J	Hurwitz, B; Richardson, R				Hurwitz, B; Richardson, R			Swearing to care: the resurgence in medical oaths	BRITISH MEDICAL JOURNAL			English	Article							HIPPOCRATIC OATH		Imperial Coll Sch Med, Dept Primary Care, London W2 1PG, England; UCL, Dept Anat, London WC1E 6BT, England	Imperial College London; University of London; University College London	Hurwitz, B (corresponding author), Imperial Coll Sch Med, Dept Primary Care, St Marys Campus, London W2 1PG, England.	b.hurwitz@ic.ac.uk						ADAM F, 1849, GENUINE WORKS HIPPOC; Baker R, 1997, JAMA-J AM MED ASSOC, V278, P163, DOI 10.1001/jama.278.2.163; BAKER R, 1993, COMPANION ENCY HIST, V2, P852; *BMA, 1992, MED BETR; *BMA, 1997, ANN REP COUNC 1996 7, P26; Boyd KM, 1997, NEW DICT MED ETHICS; *BRIT MED ASS GEN, 1994, COR VAL MED PROF 21; CRAWSHAW R, 1994, BRIT MED J, V309, P952, DOI 10.1136/bmj.309.6959.952; CRAWSHAW R, 1970, J CHRON DIS, V23, P145, DOI 10.1016/0021-9681(70)90091-3; DELAMOTHE T, 1994, BRIT MED J, V309, P953; DOWNIE RS, 1987, HLTH RESPECT, P247; FRANZBLAU SA, 1997, JAMA-J AM MED ASSOC, V237, P2293; *GEN MED COUNC, 1995, DUT DOCT GUID GEN ME; GILLON R, 1985, BRIT MED J, V290, P1194, DOI 10.1136/bmj.290.6476.1194; Goldsmith MF, 1997, JAMA-J AM MED ASSOC, V277, P1265, DOI 10.1001/jama.277.16.1265; LOEWY EH, 1996, TXB HLTH CARE ETHICS, P208; LOUDON I, 1994, BRIT MED J, V309, P414, DOI 10.1136/bmj.309.6951.414a; LOUDON I, 1994, BRIT MED J, V309, P952; Nutton V, 1995, J ROY COLL PHYS LOND, V29, P518; PENNINGTON TH, 1994, BRIT MED J, V309, P952; PLATT MPW, 1994, BRIT MED J, V309, P953, DOI 10.1136/bmj.309.6959.953; REISS H, 1994, BRIT MED J, V309, P952; ROBIN ED, 1994, BRIT MED J, V309, P96; WEIERMAN RJ, 1997, AM MED ASS C ETH AM; 1996, AM NEWS         0805	25	39	41	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1671	1674		10.1136/bmj.315.7123.1671	http://dx.doi.org/10.1136/bmj.315.7123.1671			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448537	Green Published			2022-12-28	WOS:000071149400022
J	Diau, EWG; Herek, JL; Kim, ZH; Zewail, AH				Diau, EWG; Herek, JL; Kim, ZH; Zewail, AH			Femtosecond activation of reactions and the concept of nonergodic molecules	SCIENCE			English	Article							VIBRATIONAL-ENERGY REDISTRIBUTION; LARGE POLYATOMIC-MOLECULES; CYCLIC-KETONES; REACTION-RATES; FORCE-FIELDS; DYNAMICS; STILBENE; ACETONE; SPECTRA; RRKM	The description of chemical reaction dynamics often assumes that vibrational modes are well coupled (ergodic) and redistribute energy rapidly with respect to the course of the reaction. To experimentally probe nonergodic, nonstatistical behavior, studies of a series of reactions induced by femtosecond activation for molecules of varying size but having the same reaction coordinates [CH2-(CH2)(n-2)-C = O dagger --> products, with n = 4, 5, 6, and 10] were performed. Comparison of the experimental results with theoretical electronic structure and rate calculations showed a two to four orders of magnitude difference, indicating that the basic assumption of statistical energy redistribution is invalid. These results suggest that chemical selectivity can be achieved with femtosecond activation even at very high energies.	CALTECH, Arthur Amos Noyes Lab Chem Phys, Pasadena, CA 91125 USA	California Institute of Technology	Diau, EWG (corresponding author), CALTECH, Arthur Amos Noyes Lab Chem Phys, Pasadena, CA 91125 USA.		Kim, Zee Hwan/A-9273-2010	gaber, sarah/0000-0002-5995-7291				BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Benson S.W, 1976, THERMOCHEMICAL KINET; BERNSHTEIN V, 1994, J PHYS CHEM-US, V98, P136, DOI 10.1021/j100052a024; BERSOHN R, UNPUB; Bolton K, 1996, CHEM PHYS, V207, P63, DOI 10.1016/0301-0104(96)00034-1; BUNKER DL, 1973, J CHEM PHYS, V59, P4621, DOI 10.1063/1.1680672; CORNISH TJ, 1987, J AM CHEM SOC, V109, P6915, DOI 10.1021/ja00257a001; Crim FF, 1996, J PHYS CHEM-US, V100, P12725, DOI 10.1021/jp9604812; Diau EWG, 1997, J CHEM PHYS, V106, P9236, DOI 10.1063/1.474025; DORER FH, 1973, J PHYS CHEM-US, V77, P954, DOI 10.1021/j100626a021; FELKER PM, 1985, J CHEM PHYS, V82, P3003, DOI 10.1063/1.448249; Frost W., 1973, THEORY UNIMOLECULAR; GENTILE AC, 1993, J CHEM PHYS, V98, P7898, DOI 10.1063/1.464545; Gilbert RG., 1990, THEORY UNIMOLECULAR; HARRIS HH, 1971, CHEM PHYS LETT, V11, P433, DOI 10.1016/0009-2614(71)80378-0; Hehre W. J., 1986, AB INITIO MOL ORBITA; HINSHELWOOD CN, 1927, P ROY SOC LOND A MAT, V113, P230; Kim SK, 1996, J PHYS CHEM-US, V100, P9202, DOI 10.1021/jp961066c; KIM SK, 1995, J CHEM PHYS, V103, P477, DOI 10.1063/1.469614; Langmuir I., 1922, T FARADAY SOC, V17, P598; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Leitner DM, 1997, CHEM PHYS LETT, V280, P411, DOI 10.1016/S0009-2614(97)01120-2; LETOHKOV VS, 1988, LASER CHEM IR MULTIP, V8; MANZ J, 1989, CHEM PHYS, V139, P1; MARCUS RA, 1952, J CHEM PHYS, V20, P359, DOI 10.1063/1.1700424; MARCUS RA, 1984, J PHYS CHEM-US, V88, P6717, DOI 10.1021/j150670a040; MARCUS RA, 1982, PICOSECOND PHENOMENA, P254; MEBEL AM, 1995, J CHEM PHYS, V103, P7414, DOI 10.1063/1.470313; Merchan M, 1996, J CHEM PHYS, V104, P1791, DOI 10.1063/1.470976; Nesbitt DJ, 1996, J PHYS CHEM-US, V100, P12735, DOI 10.1021/jp960698w; NORDHOLM S, 1974, J CHEM PHYS, V61, P768, DOI 10.1063/1.1682016; NORDHOLM S, 1975, J CHEM PHYS, V62, P157, DOI 10.1063/1.430248; NORDHOLM S, 1989, CHEM PHYS, V137, P109, DOI 10.1016/0301-0104(89)87097-1; NORTH SW, 1995, J CHEM PHYS, V102, P4447, DOI 10.1063/1.469493; OREF I, 1979, ACCOUNTS CHEM RES, V12, P166, DOI 10.1021/ar50137a002; OSTERHELD TH, 1993, J AM CHEM SOC, V115, P10311, DOI 10.1021/ja00075a054; OTOOLE L, 1991, J CHEM SOC FARADAY T, V87, P3343, DOI 10.1039/ft9918703343; PEDERSEN S, 1994, SCIENCE, V266, P1359, DOI 10.1126/science.266.5189.1359; QUACK M, 1990, ANNU REV PHYS CHEM, V41, P839, DOI 10.1146/annurev.pc.41.100190.004203; Rabinovitch B.S., 1964, ADV PHOTOCHEM, V3, P1; RABINOVITCH BS, 1964, Q REV CHEM SOC, V18, P122, DOI 10.1039/qr9641800122; RAUHUT G, 1995, J PHYS CHEM-US, V99, P3093, DOI 10.1021/j100010a019; ROBINSON PJ, 1972, UNIMIOLECULAR REACTI; SCALA AA, 1972, CAN J CHEM, V50, P3938, DOI 10.1139/v72-624; SEMMES DH, 1987, J AM CHEM SOC, V109, P4104, DOI 10.1021/ja00247a041; SEMMES DH, 1990, J CHEM PHYS, V92, P3359, DOI 10.1063/1.457847; SLATER NB, 1959, THEORY UNIMIOLECULAR; STEPHENS PJ, 1994, J PHYS CHEM-US, V98, P11623, DOI 10.1021/j100096a001; STUCHEBRUKHOV AA, 1993, J CHEM PHYS, V98, P6044, DOI 10.1063/1.464843; STURE K, 1974, J CHEM PHYS, V61, P203, DOI 10.1063/1.1681624; SYAGE JA, 1984, J CHEM PHYS, V81, P4706, DOI 10.1063/1.447520; TROE J, 1988, BER BUNSEN PHYS CHEM, V92, P242, DOI 10.1002/bbpc.198800058; TURECEK F, 1984, J AM CHEM SOC, V106, P2525, DOI 10.1021/ja00321a006; UZER T, 1991, PHYS REP, V199, P124; ZEWAIL AH, 1980, PHYS TODAY, V33, P27, DOI 10.1063/1.2913821; ZEWAIL AH, 1995, FEMTOCHEMISTRY ULTRA	56	137	139	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					847	851		10.1126/science.279.5352.847	http://dx.doi.org/10.1126/science.279.5352.847			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452381				2022-12-28	WOS:000071923500039
J	Amato, MBP; Barbas, CSV; Medeiros, DM; Magaldi, RB; Schettino, GDP; Lorenzi, G; Kairalla, RA; Deheinzelin, D; Munoz, C; Oliveira, R; Takagaki, TY; Carvalho, CRR				Amato, MBP; Barbas, CSV; Medeiros, DM; Magaldi, RB; Schettino, GDP; Lorenzi, G; Kairalla, RA; Deheinzelin, D; Munoz, C; Oliveira, R; Takagaki, TY; Carvalho, CRR			Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1996 American-Lung-Association/American-Thoracic-Society International Conference	MAY 10-15, 1996	NEW ORLEANS, LOUISIANA	Amer Lung Assoc, Amer Thorac Soc			END-EXPIRATORY PRESSURE; RANDOMIZED CLINICAL-TRIALS; HYALINE-MEMBRANE FORMATION; MECHANICAL VENTILATION; LUNG INJURY; PERMISSIVE HYPERCAPNIA; PULMONARY CAPILLARIES; LIMITED VENTILATION; AIRWAY PRESSURES; STRESS FAILURE	Background In patients with the acute respiratory distress syndrome, massive alveolar collapse and cyclic lung reopening and overdistention during mechanical ventilation may perpetuate alveolar injury. We determined whether a ventilatory strategy designed to minimize such lung injuries could reduce not only pulmonary complications but also mortality at 28 days in patients with the acute respiratory distress syndrome. Methods We randomly assigned 53 patients with early acute respiratory distress syndrome (including 28 described previously), all of whom were receiving identical hemodynamic and general support, to conventional or protective mechanical ventilation. Conventional ventilation was based on the strategy of maintaining the lowest positive end-expiratory pressure (PEEP) for acceptable oxygenation, with a tidal volume of 12 ml per kilogram of bodyweight and normal arterial carbon dioxide levels (35 to 38 mm Hg). Protective ventilation involved end-expiratory pressures above the lower inflection point on the static pressure-volume curve, a tidal volume of less than 6 ml per kilogram, driving pressures of less than 20 cm of water above the PEEP value, permissive hypercapnia, and preferential use of pressure-limited ventilatory modes. Results After 28 days, 11 of 29 patients (38 percent) in the protective-ventilation group had died, as compared with 17 of 24 (71 percent) in the conventional-ventilation group (P<0.001). The rates of weaning from mechanical ventilation were 66 percent in the protective-ventilation group and 29 per cent in the conventional-ventilation group (P=0.005); the rates of clinical barotrauma were 7 percent and 42 percent, respectively (P=0.02), despite the use of higher PEEP and mean airway pressures in the protective-ventilation group. The difference in survival to hospital discharge was not significant; 13 of 29 patients (45 percent) in the protective-ventilation group died in the hospital, as compared with 17 of 24 in the conventional-ventilation group (71 percent, P=0.37). Conclusions As compared with conventional ventilation, the protective strategy was associated with improved survival at 28 days, a higher rate of weaning from mechanical ventilation, and a lower rate of barotrauma in patients with the acute respiratory distress syndrome. Protective ventilation was not associated with a higher rate of survival to hospital discharge. (C) 1998, Massachusetts Medical Society.	Univ Sao Paulo, Hosp Clin, Div Pulm, Resp Intens Care Unit, BR-05508 Sao Paulo, Brazil; Santa Casa Misericordia, Gen Intens Care Unit, Porto Alegre, RS, Brazil	Universidade de Sao Paulo	Amato, MBP (corresponding author), 135 Rue Dr Joel Lagos, BR-05344000 Sao Paulo, Brazil.		Barbas, Carmen Silvia Valente/H-1048-2013; Kairalla, Ronaldo/D-5736-2014; Lorenzi-Filho, Geraldo GLF/E-1062-2012; Carvalho, Carlos Roberto R/N-9827-2018; Gomes, Susimeire/L-8738-2013; amato, Marcelo Britto Passo/L-5001-2016; Carvalho, Carlos RR/H-2161-2011	Barbas, Carmen Silvia Valente/0000-0002-3922-6256; Kairalla, Ronaldo/0000-0001-7194-0479; Lorenzi-Filho, Geraldo GLF/0000-0002-7011-7373; Carvalho, Carlos Roberto R/0000-0002-1618-8509; amato, Marcelo Britto Passo/0000-0003-3525-8282; Takagaki, Teresa/0000-0003-2277-2100				ALBERT RK, 1985, CHEST, V87, P2, DOI 10.1378/chest.87.1.2; AMATO MBP, 1992, CHEST, V102, P1225, DOI 10.1378/chest.102.4.1225; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; AMATO MBP, 1995, AM J RESP CRIT CARE, V151, pA550; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; BSHOUTY Z, 1988, J APPL PHYSIOL, V64, P1900, DOI 10.1152/jappl.1988.64.5.1900; CARLTON DP, 1990, J APPL PHYSIOL, V69, P577, DOI 10.1152/jappl.1990.69.2.577; Carvalho CRR, 1997, AM J RESP CRIT CARE, V156, P1458, DOI 10.1164/ajrccm.156.5.9604081; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; EDMONDS HL, 1981, CRIT CARE MED, V9, P524, DOI 10.1097/00003246-198107000-00005; FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Gattinoni L, 1991, MECHANICAL VENTILATI, P129; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; GREGORY GA, 1970, NEW ENGL J MED, V282, P1141, DOI 10.1056/NEJM197005142822007; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; JOHANSON WG, 1985, AM REV RESPIR DIS, V132, P358; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MARINI JJ, 1989, ANN INTERN MED, V110, P699, DOI 10.7326/0003-4819-110-9-699; MARINI JJ, 1994, ANESTHESIOLOGY, V80, P972, DOI 10.1097/00000542-199405000-00004; MATHIEUCOSTELLO O, 1995, J APPL PHYSIOL, V79, P908, DOI 10.1152/jappl.1995.79.3.908; MATHRU M, 1983, CRIT CARE MED, V11, P359, DOI 10.1097/00003246-198305000-00008; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; NAHUM A, 1996, AM J RESP CRIT CAR S, V153, pA531; PARKER JC, 1990, AM REV RESPIR DIS, V142, P321, DOI 10.1164/ajrccm/142.2.321; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETTY TL, 1988, AM REV RESPIR DIS, V138, P475, DOI 10.1164/ajrccm/138.2.475; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; SANDHAR BK, 1988, INTENS CARE MED, V14, P538, DOI 10.1007/BF00263527; SMITH PEM, 1986, INTENS CARE MED, V12, P86; SNYDER JV, 1987, OXYGEN TRANSPORT CRI, P358; SUGIURA M, 1994, J APPL PHYSIOL, V77, P1355, DOI 10.1152/jappl.1994.77.3.1355; TEBOUL JL, 1992, J CRIT CARE, V7, P22, DOI 10.1016/0883-9441(92)90005-R; TILSON MD, 1977, SURGERY, V82, P1833; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; WYSZOGRODSKI I, 1975, J APPL PHYSIOL, V38, P461, DOI 10.1152/jappl.1975.38.3.461; YEUNG HC, 1990, CRIT CARE MED, V18, P1347, DOI 10.1097/00003246-199012000-00007; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9	45	2287	2465	2	90	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					347	354		10.1056/NEJM199802053380602	http://dx.doi.org/10.1056/NEJM199802053380602			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449727				2022-12-28	WOS:000071822200002
J	Chen, FE; Huang, DB; Chen, YQ; Ghosh, G				Chen, FE; Huang, DB; Chen, YQ; Ghosh, G			Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA	NATURE			English	Article							IFN-BETA GENE; BINDING SUBUNIT; 65-KD SUBUNIT; P65 SUBUNIT; P50; SITE; REL; SPECIFICITY; RECOGNITION; PARAMETERS	The NF-kappa B p50/p65 heterodimer is the classical member of the Rel family of transcription factors which regulate diverse cellular functions such as immune response, cell growth, and development(1-3). Other mammalian Rel family members, including the proteins p52, proto-oncoprotein c-Rel, and RelB, all have amino-terminal Rel-homology regions (RHRs)(4-7). The RHR is responsible for the dimerization, DNA binding and cytosolic localization of these proteins by virtue of complex formation with inhibitor kappa B proteins(8), Signal-induced removal of kappa B inhibitors allows translocation of dimers to the cell nucleus and transcriptional regulation of kappa B DNA-containing genes(9), NF-kappa B specifically recognizes kappa B DNA elements(1,10,11) with a consensus sequence of 5'-GGGRNYYYCC-3' (R is an unspecified purine; Y is an unspecified pyrimidine; and N is any nucleotide), Here we report the crystal structure at 2.9 Angstrom resolution of the p50/p65 heterodimer bound to the kappa B DNA of the intronic enhancer of the immunoglobulin light-chain gene, Our structure reveals a 5-base-pair 5' subsite for p50, and a 4-base-pair 3' subsite for p65, This structure indicates why the p50/p65 heterodimer interface is stronger than that of either homodimer, A comparison of this structure with those of other Rel dimers reveals that both subunits adopt variable conformations in a DNA-sequence-dependent manner. Our results explain the different behaviour of the p50/p65 heterodimer with heterologous promoters.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gghosh@chem.ucsd.edu						BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHEN YQ, IN PRESS NATURE STRU; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Laskowski R.A., 1993, J APPL CRYSTALLOGR A, V42, P140; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZABEL U, 1991, J BIOL CHEM, V266, P252	31	480	511	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					410	413		10.1038/34956	http://dx.doi.org/10.1038/34956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450761				2022-12-28	WOS:000071604200061
J	Fix, AD; Strickland, GT; Grant, J				Fix, AD; Strickland, GT; Grant, J			Tick bites and Lyme disease in an endemic setting - Problematic use of serologic testing and prophylactic antibiotic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; ERYTHEMA MIGRANS; PREVENTION; AREA; MANIFESTATIONS; SERODIAGNOSIS; DIAGNOSIS; MARYLAND; CHILDREN	Context.-The use of serologic testing to diagnose Lyme disease (LD) is a source of controversy. Expert recommendations also discourage the routine use of antibiotic therapy for prophylaxis of LD following tick bites, but the extent to which physicians in endemic areas have adopted these recommendations is not known. Objective.-To assess the pattern of use of serologic testing and antibiotic therapy for tick bites and LD and associated charges for management in an endemic area. Design.-Active surveillance of patient-physician encounters for tick bites and LD. Setting.-Primary care practices on the Eastern Shore of Maryland. Patients.-Consecutive sample of 232 patients with tick bites, LD (defined by physician diagnosis in medical record), and suspected LD (physician notation of possible, but not definite LD) seen in 1995. Main Outcome Measures.-Serologic testing for LD, test results, antibiotic therapy, and direct costs of management. Results.-Surveillance identified 142 patients (61.2%) with diagnoses of tick bites, 40 patients (17.2%) with LD, and 50 patients (21.6%) with suspected LD. Of the 142 patients seen for tick bites, 95 (67%) underwent serologic testing for LD. Of these, 93 patients had initial negative or equivocal results; 24 (26%) of the 93 had convalescent testing, with 1 seroconversion. Seventy-eight patients (55%) with a diagnosis of tick bite received antibiotic therapy. No patients with tick bite developed clinical LD. Serologic testing for LD was performed for 36 patients (90%) with a diagnosis of LD and 46 patients (92%) with suspected LD. In most cases, antibiotics were prescribed before serologic test results became available. Convalescent testing was not performed for 37 (86%) of the 43 patients with suspected LD who had initial negative or equivocal results. Of these 37 patients, 25 (68%) did not receive antibiotic therapy. Direct charges for treatment of these 232 patients totaled $47 595, one third of which was attributable to serologic testing. A total of 32% of direct charges were for patients with tick bites, 48% were for patients with LD, and 20% were for patients with suspected LD. Conclusions.-In this setting, most patients consulting physicians for tick bites received prophylactic antibiotic therapy of unproven efficacy and underwent unnecessary, costly serologic testing. Despite almost universal use in this study, serologic testing for LD did not appear to influence treatment of patients diagnosed as having LD.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Kent Cty Hlth Dept, Chestertown, MD USA	University System of Maryland; University of Maryland Baltimore	Fix, AD (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 Redwood St, Baltimore, MD 21201 USA.				PHS HHS [R01MS07813-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRE F, 1993, AM J DIS CHILD, V147, P945, DOI 10.1001/archpedi.1993.02160330035013; AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BINGHAM PM, 1995, PEDIATRICS, V96, P1053; *CDC, 1991, CONN MED, V55, P691; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; Craven RB, 1996, EMERG INFECT DIS, V2, P136, DOI 10.3201/eid0202.960211; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; Dean A.G., 1994, EPI INFO VERSION 6 W; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EPPES SC, 1994, CLIN PEDIATR, V33, P130, DOI 10.1177/000992289403300301; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FALCO RC, 1988, AM J EPIDEMIOL, V128, P1146; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; Gerber M A, 1995, Conn Med, V59, P195; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; *MAR DEP HLTH MENT, 1996, MED MED J, V45, P715; Nachamkin I, 1996, CLIN DIAGN LAB IMMUN, V3, P287, DOI 10.1128/CDLI.3.3.287-289.1996; NADELMAN RD, 1993, LANCET, V342, P1052, DOI 10.1016/0140-6736(93)92907-B; Nocton J J, 1995, Adv Intern Med, V40, P69; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; Steinberg SH, 1996, ANN EPIDEMIOL, V6, P24, DOI 10.1016/1047-2797(95)00096-8; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; WORMSER GP, 1995, MT SINAI J MED, V62, P188; Ziska MH, 1996, INFECTION, V24, P182, DOI 10.1007/BF01713336; 1993, MMWR MORB MORTAL WKL, V42, P345	36	48	52	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					206	210		10.1001/jama.279.3.206	http://dx.doi.org/10.1001/jama.279.3.206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438740	Bronze			2022-12-28	WOS:000071460700030
J	Wynn, RF; Cross, MA; Hatton, C; Will, AM; Lashford, LS; Dexter, TM; Testa, NG				Wynn, RF; Cross, MA; Hatton, C; Will, AM; Lashford, LS; Dexter, TM; Testa, NG			Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants	LANCET			English	Article							DNA; AMPLIFICATION; LENGTH; AGE	Background The establishment of donor-derived haemopoiesis in the recipients of allogeneic bone-marrow transplants (BMT) involves extensive proliferation of haemopoietic stem cells. The biological consequences of this replicative stress are ill defined, but any "ageing" effect would carry the risk of an increased frequency of clonal disorders during later life. We compared blood-cell mean telomere lengths in donor/recipient pairs. Methods Mean telomere length was calculated by in-gel hybridisation to leucocyte DNA from 56 normal individuals aged 0-96 years, and from 14 consecutive BMT recipients (aged 2-14 years) plus their respective donors (aged 2-46 years). Engraftment was confirmed by variable numbers of tandem repeats (VNTR) or gender analysis. Findings On average, blood-cell telomeres of transplant recipients were 0.4 hb (95% CI -0.2 to -0.6) shorter than those of their respective donors. This degree of telomere loss is equivalent to a median of 15 years' (range 0-40) ageing in the healthy controls. Interpretation The kinetics of haemopoietic engraftment impose replicative stress on the haemopoietic stem cells, resulting in a pronounced ageing effect, which may be sufficient to accelerate the onset of clonal haemopoietic disorders usually associated with later life. Monitoring of haemopoietic status in BMT recipients as time since BMT increases will be important. Assessment of transplant protocols under development in terms of their effects on telomere shortening is also indicated.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Dept Expt Haematol, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, Dept Paediat Haematol & Oncol, Manchester M27 1HA, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Wynn, RF (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Dept Expt Haematol, Manchester M20 4BX, Lancs, England.			Wynn, robert/0000-0002-6046-8428; Cross, Michael/0000-0002-8815-7621				ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P2122; BROWN SA, 1995, EUR J HAEMATOL, V54, P98; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Engelhardt M, 1997, BLOOD, V90, P182; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KASAI K, 1990, J FORENSIC SCI, V35, P1196; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; OSCIER DG, 1987, CLIN HAEMATOL, V1, P389; PRIESTLEY L, 1990, HUM GENET, V85, P525; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203	17	191	197	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					178	181		10.1016/S0140-6736(97)08256-1	http://dx.doi.org/10.1016/S0140-6736(97)08256-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449873				2022-12-28	WOS:000071616300012
J	Sweeney, KG; MacAuley, D; Gray, DP				Sweeney, KG; MacAuley, D; Gray, DP			Personal significance: the third dimension	LANCET			English	Editorial Material									Univ Exeter, Postgrad Med Sch, Inst Gen Practice, Exeter EX2 5DW, Devon, England	University of Exeter	Sweeney, KG (corresponding author), Univ Exeter, Postgrad Med Sch, Inst Gen Practice, Barrack Rd, Exeter EX2 5DW, Devon, England.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				[Anonymous], 1995, LANCET, V346, P785; Balint M., 1957, DOCTOR; BECKER MH, 1974, HEALTH EDUC QUART, V2, P409, DOI 10.1177/109019817400200407; BURNAND B, 1990, J CLIN EPIDEMIOL, V43, P1273, DOI 10.1016/0895-4356(90)90093-5; CASSELL EJ, 1991, NATURE SUFFERING; CHARLTON BG, 1993, J ROY SOC MED, V86, P497; CHARLTON R, 1995, BRIT J GEN PRACT, V45, P639; Cromarty I, 1996, BRIT J GEN PRACT, V46, P525; FEINSTEIN AR, 1992, AM J MED, V92, P117, DOI 10.1016/0002-9343(92)90099-W; Fishbein M.A., 1975, PHILOS RHETORIC; Gill P, 1996, BRIT MED J, V312, P819; GREENHALGH T, 1996, BRIT MED J, V313, P9575; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Heath I., 1995, MYSTERY GEN PRACTICE; JOHNSTON M, 1974, PREVENTING CORONARY; KAPLAN SH, 1989, MED CARE S, V27, pS125; LANDAUE L, 1984, JAMA-J AM MED ASSOC, V252, P2458; Lilford RJ, 1996, BRIT MED J, V313, P603; McCormick J, 1996, LANCET, V348, P667, DOI 10.1016/S0140-6736(96)03512-X; MCWHINNEY IR, 1991, PRIMARY CARE RES TRA, P1; Neighbour R., 1987, INNER CONSULTATION; Pereira Gray D, 1995, HLTH HYGIENE, V16, P49; Rogers EM., 1983, DIFFUSION INNOVATION; RUDEBECK CE, 1992, SCAND J PRIMARY HL S, V1; Russell Bertrand, 1961, HIST W PHILOS, V2nd; Sackett D., 1985, CLIN EPIDEMIOLOGY; *SECR STAT HLTH, 1996, PROM CLIN EFF FRAM A; VANDERVLEUTEN CPM, 1995, LANCET, V345, P1032, DOI 10.1016/S0140-6736(95)90763-7	28	56	56	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					134	136		10.1016/S0140-6736(97)06316-2	http://dx.doi.org/10.1016/S0140-6736(97)06316-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439510				2022-12-28	WOS:000071591900046
J	Goulden, ML; Wofsy, SC; Harden, JW; Trumbore, SE; Crill, PM; Gower, ST; Fries, T; Daube, BC; Fan, SM; Sutton, DJ; Bazzaz, A; Munger, JW				Goulden, ML; Wofsy, SC; Harden, JW; Trumbore, SE; Crill, PM; Gower, ST; Fries, T; Daube, BC; Fan, SM; Sutton, DJ; Bazzaz, A; Munger, JW			Sensitivity of boreal forest carbon balance to soil thaw	SCIENCE			English	Article							TEMPERATURE-DEPENDENCE; ARCTIC TUNDRA; DIOXIDE; ECOSYSTEMS; VARIABILITY; RESPIRATION; VEGETATION; CLIMATE; FLUX; SINK	We used eddy covariance; gas-exchange chambers; radiocarbon analysis; wood, moss, and soil inventories; and laboratory incubations to measure the carbon balance of a 120-year-old black spruce forest in Manitoba, Canada. The site lost 0.3 +/- 0.5 metric ton of carbon per hectare per year (ton C ha(-1) year(-1)) from 1994 to 1997, with a gain of 0.6 +/- 0.2 ton C ha(-1) year(-1) in moss and wood offset by a loss of 0.8 +/- 0.5 ton C ha(-1) year(-1) from the soil. The soil remained frozen most of the year, and the decomposition of organic matter in the soil increased 10-fold upon thawing. The stability of the soil carbon pool (similar to 150 tons C ha(-1)) appears sensitive to the depth and duration of thaw, and climatic changes that promote thaw are likely to cause a net efflux of carbon dioxide from the site.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; US Geol Survey, Menlo Park, CA 94025 USA; Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; Univ New Hampshire, Complex Syst Res Ctr, Durham, NH 03824 USA; Univ Wisconsin, Dept Forest Ecol & Management, Madison, WI 53706 USA	Harvard University; United States Department of the Interior; United States Geological Survey; University of California System; University of California Irvine; University System Of New Hampshire; University of New Hampshire; University of Wisconsin System; University of Wisconsin Madison	Goulden, ML (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.		Fan, Song-Miao/A-8004-2008; Crill, Patrick/ABC-1357-2021; Trumbore, Susan/B-1948-2013; Goulden, Michael L/B-9934-2008; Munger, J William/H-4502-2013	Fan, Song-Miao/0000-0001-8352-8035; Munger, J William/0000-0002-1042-8452; Goulden, Michael/0000-0002-9379-3948; Harden, Jennifer W/0000-0002-6570-8259; Crill, Patrick/0000-0003-1110-3059				[Anonymous], 1975, COMMUNITIES ECOSYSTE; BILLINGS WD, 1982, OECOLOGIA, V53, P7, DOI 10.1007/BF00377129; Billings WD, 1992, GLOBAL WARMING BIOL, P233; BROWN R J E, 1969, P11; BUBLER J, UNPUB; CHAPMAN WL, 1993, B AM METEOROL SOC, V74, P33, DOI 10.1175/1520-0477(1993)074<0033:RVOSIA>2.0.CO;2; CLAS P, 1995, SCIENCE, V269, P1098; CLEIN JS, 1995, SOIL BIOL BIOCHEM, V27, P1231, DOI 10.1016/0038-0717(95)00044-F; CUENCA RH, 1996, EOS             1112; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; Frolking S, 1996, GLOBAL CHANGE BIOL, V2, P343, DOI 10.1111/j.1365-2486.1996.tb00086.x; Gates D.M., 1993, CLIMATE CHANGE ITS B; GORHAM E, 1991, ECOL APPL, V1, P182, DOI 10.2307/1941811; Gorham E., 1995, BIOTIC FEEDBACKS GLO, P169; Goulden ML, 1997, TREE PHYSIOL, V17, P537; Goulden ML, 1996, GLOBAL CHANGE BIOL, V2, P169, DOI 10.1111/j.1365-2486.1996.tb00070.x; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; GOULDEN ML, IN PRESS J GEOPHYS R; GOWER ST, IN PRESS J GEOPHYS R; Grelle A, 1997, THESIS SWEDISH U AGR; HARDEN JW, IN PRESS J GEOPHYS R; Keeling CD, 1996, NATURE, V382, P146, DOI 10.1038/382146a0; KIRSCHBAUM MUF, 1995, SOIL BIOL BIOCHEM, V27, P753, DOI 10.1016/0038-0717(94)00242-S; LARSON JA, 1980, BOREAL ECOSYSTEM; LLOYD J, 1994, FUNCT ECOL, V8, P315, DOI 10.2307/2389824; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Oechel W. C, 1992, ARCTIC ECOSYSTEMS CH, P139; OECHEL WC, 1993, NATURE, V361, P520, DOI 10.1038/361520a0; Overpeck J, 1997, SCIENCE, V278, P1251, DOI 10.1126/science.278.5341.1251; RAICH JW, 1992, TELLUS B, V44, P81, DOI 10.1034/j.1600-0889.1992.t01-1-00001.x; SCHLESINGER WH, 1977, ANNU REV ECOL SYST, V8, P51, DOI 10.1146/annurev.es.08.110177.000411; SELLERS P, 1995, B AM METEOROL SOC, V76, P1549, DOI 10.1175/1520-0477(1995)076<1549:TBESAO>2.0.CO;2; Trumbore S. E., 1996, Mass spectrometry of soils., P311; TRUMBORE SE, IN PRESS J GEOPHYS R; VANCLEVE K, 1990, CAN J FOREST RES, V20, P1530, DOI 10.1139/x90-203; WINSTON GC, IN PRESS J GEOPHYS R; 1995, CLIMATE CHANGE 1995	37	606	670	4	273	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					214	217		10.1126/science.279.5348.214	http://dx.doi.org/10.1126/science.279.5348.214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422691	Green Submitted			2022-12-28	WOS:000071408100038
J	Wu, GY; Cline, HT				Wu, GY; Cline, HT			Stabilization of dendritic arbor structure in vivo by CaMKII	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; GROWTH CONE MOTILITY; NEURITE OUTGROWTH; SYNAPTIC TRANSMISSION; FUNCTIONAL COMPONENTS; ELECTRICAL-ACTIVITY; GENETIC DISSECTION; EXPRESSION	Calcium-calmodulin-dependent protein kinase II (CaMKII) promotes the maturation of retinotectal glutamatergic synapses in Xenopus. Whether CaMKII activity also controls morphological maturation of optic tectal neurons was tested using in vivo time-lapse imaging of single neurons over periods of up to 5 days. Dendritic arbor elaboration slows with maturation, in correlation with the onset of CaMKII expression. Elevating CaMKII activity in young neurons by viral expression of constitutively active CaMKII slowed dendritic growth to a rate comparable to that of mature neurons. CaMKII overexpression stabilized dendritic structure in more mature neurons, whereas CaMKII inhibition increased their dendritic growth. Thus, endogenous CaMKII activity limits dendritic growth and stabilizes dendrites, and it may act as an activity-dependent mediator of neuronal maturation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Cline, HT (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	cline@cshl.org						ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FIELDS RD, 1990, J NEUROSCI, V10, P2950; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; HAYDON PG, 1994, J NEUROBIOL, V25, P694, DOI 10.1002/neu.480250609; ISAAC JTR, 1997, NEURON, V18, P1; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LAZAR G, 1973, J ANAT, V116, P347; Liao DZ, 1996, LEARN MEMORY, V3, P138, DOI 10.1101/lm.3.2-3.138; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Masse T, 1997, J NEUROSCI, V17, P924; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MURRAY KD, 1994, NEUROSCIENCE, V60, P37, DOI 10.1016/0306-4522(94)90202-X; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Otmakhov N, 1997, J NEUROSCI, V17, P5357; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; REGEHR WG, 1992, J NEUROSCI, V12, P4202; Scheetz AJ, 1996, EUR J NEUROSCI, V8, P1322, DOI 10.1111/j.1460-9568.1996.tb01594.x; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Stewart BA, 1996, J NEUROSCI, V16, P3877; Tashima K, 1996, J NEUROCHEM, V66, P57; TSUJIMOTO T, 1990, J NEUROSCI, V10, P2059; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; Witte S, 1996, J NEUROBIOL, V31, P219, DOI 10.1002/(SICI)1097-4695(199610)31:2<219::AID-NEU7>3.0.CO;2-E; Wu G., UNPUB; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; ZHONG Y, 1995, J NEUROSCI, V15, P6679; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	50	306	314	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					222	226		10.1126/science.279.5348.222	http://dx.doi.org/10.1126/science.279.5348.222			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422694				2022-12-28	WOS:000071408100041
J	Nern, A; Arkowitz, RA				Nern, A; Arkowitz, RA			A GTP-exchange factor required for cell orientation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MATING FACTOR; GENE-PRODUCT; YEAST-CELLS; POLARIZATION; PROTEIN; CDC42; CDC24; GRADIENTS; PATHWAY	The Rho-family of GTPases and their regulators are essential for cytoskeletal reorganization and transcriptional activation in response to extracellular signals(1,2). Little is known about what Links these molecules to membrane receptors. In the budding yeast Saccharomyces cerevisiae, haploid cells respond to mating pheromone through a G-protein-coupled receptor and the beta gamma subunit of the G protein(3), resulting in arrest of the cell cycle, transcriptional activation, and polarized growth towards a mating partner(4,5). The Rho-family GTPase Cdc42 and its exchange factor Cdc24 have been implicated in the mating process(6,7), but their specific role is unknown. Here we report the identification of cdc24 alleles that do not affect vegetative growth but drastically reduce the ability of yeast cells to mate, When exposed to mating pheromone, these mutants arrest growth, activate transcription, and undergo characteristic morphological and actin-cytoskeleton polarization, However, the mutants are unable to orient towards a pheromone gradient, and instead position their mating projection adjacent to their previous bud site. The mutants are specifically defective in the binding of Cdc24 to the G-protein beta gamma subunit, Our results demonstrate that the association of an exchange factor and the beta gamma subunit of a hetero-trimeric G protein links receptor-mediated activation to oriented cell growth.	MRC, Mol Biol Lab, Div Cell Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Arkowitz, RA (corresponding author), MRC, Mol Biol Lab, Div Cell Biol, Hills Rd, Cambridge CB2 2QH, England.	ra2@mrc-lmb.cam.ac.uk	arkowitz, robert/ABC-1860-2021	arkowitz, robert/0000-0002-5216-5013				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHENEVERT J, 1994, GENETICS, V136, P1287; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Hirschman JE, 1997, J BIOL CHEM, V272, P240; James P, 1996, GENETICS, V144, P1425; LANGLEROUAULT F, 1995, NUCLEIC ACIDS RES, V23, P3079, DOI 10.1093/nar/23.15.3079; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Rose M. D., 1991, METHODS YEAST GENETI; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	30	116	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					195	198		10.1038/34458	http://dx.doi.org/10.1038/34458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428768				2022-12-28	WOS:000071380900056
J	Nightingale, SL				Nightingale, SL			Rezulin labeling updated to recommend more frequent patient monitoring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							1997, JAMA, V278, P1728	1	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-28	WOS:000071295100003
J	Lewis, JE; Kristan, WB				Lewis, JE; Kristan, WB			A neuronal network for computing population vectors in the leech	NATURE			English	Article							LOCAL BENDING REFLEX; SENSORY INFORMATION; NEURAL NETWORKS; INTERNEURONS	The correlation of neuronal activity with sensory input and behavioural output has revealed that information is often encoded in the activity of many neurons across a population, that is, a neural population code is used(1,2). The possible algorithms that downstream networks use to read out this population code have been studied by manipulating the activity of a few neurons in a population(3,4). We have used this approach to study population coding in a small network underlying the leech local bend, a body bend directed away from a touch stimulus(5), Because of the small size of this network we are able to monitor and manipulate the complete set of sensory inputs to the network. We show here that the population vector(6) formed by the spike counts of the active mechanosensory neurons is well correlated with bend direction, A model based on the known connectivity of the identified neurons in the local bend network can account for our experimental results, and is suitable for reading out the neural population vector, Thus, for the first time to our knowledge, it is possible to link a proposed algorithm for neural population coding with synaptic and network mechanisms in an experimental system.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kristan, WB (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.							ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; Batschelet E., 1981, CIRCULAR STAT BIOL; CARLTON T, 1995, J COMP PHYSIOL A, V177, P781, DOI 10.1007/BF00187637; GEOGOPOULOS A, 1994, NEURON, V13, P257; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Groh JM, 1997, J NEUROSCI, V17, P4312; Gur M, 1997, J NEUROSCI, V17, P2914; KRISTAN WB, 1982, J EXP BIOL, V96, P143; KRISTAN WB, 1982, J EXP BIOL, V96, P161; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; LEWIS JE, 1997, THESIS U CALIFORNIA; LOCKERY SR, 1990, J NEUROSCI, V10, P1816; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; LOCKERY SR, 1989, NATURE, V340, P468, DOI 10.1038/340468a0; LOCKERY SR, 1992, J NEUROSCI, V12, P3877; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; MULLER KJ, 1981, NEUROBIOLOGY LEECH; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; SALINAS E, 1995, J NEUROSCI, V15, P6461; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; Shaw BK, 1997, J NEUROSCI, V17, P786; SPARKS DL, 1997, NEURONS NETWORKS MOT, P21	22	95	95	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					76	79		10.1038/34172	http://dx.doi.org/10.1038/34172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422507				2022-12-28	WOS:000071326100051
J	Nichol, G; Dennis, DT; Steere, AC; Lightfoot, R; Wells, G; Shea, B; Tugwell, P				Nichol, G; Dennis, DT; Steere, AC; Lightfoot, R; Wells, G; Shea, B; Tugwell, P			Test-treatment strategies for patients suspected of having Lyme disease: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI; DECISION-MAKING; HEART-BLOCK; MYOSITIS; DERMATOMYOSITIS; MANIFESTATIONS; FIBROMYALGIA; POPULATION; ARTHRITIS; DIAGNOSIS	Purpose: To examine the cost-effectiveness of test-treatment strategies for patients suspected of having Lyme disease. Data Sources: The medical literature was searched for information on outcomes and costs. Expert opinion was sought for information on utilities. Study Selection: Articles that described patient population, diagnostic criteria, dose and duration of therapy, and criteria for assessment of outcomes. Data Extraction: The decision analysis evaluated the following strategies: 1) no testing-no treatment; 2) testing with enzyme-linked immunosorbent assay (ELISA) followed by antibiotic treatment of patients with positive results; 3) two-step testing with ELISA followed by Western blot and antibiotic treatment for patients with positive results on either test; and 4) empirical antibiotic therapy. Three patient scenarios were considered: myalgic symptoms, rash resembling erythema migrans, and recurrent oligoarticular inflammatory arthritis. Results were calculated as costs per quality-adjusted life-year and were subjected to sensitivity analysis. Adjustment was made for the diagnostic value of common clinical features of Lyme disease. Data Synthesis: For myalgic symptoms without other features suggestive of Lyme disease, the no testing-no treatment strategy was most economically attractive (that is, had the most favorable cost-effectiveness ratio). For rash, empirical antibiotic therapy was less costly and more effective than other strategies. For oligoarticular arthritis with a history of rash and tick bite, two-step testing was associated with the lowest cost-effectiveness ratio. Testing with ELISA and empirical antibiotic therapy cost an additional $880 000 and $34 000 per quality-adjusted life-year, respectively. For oligoarticular arthritis with one or no other features suggestive of Lyme disease, two-step testing was most economically attractive. Conclusions: Neither testing nor antibiotic treatment is cost-effective if the pretest probability of Lyme disease is low. Empirical antibiotic therapy is recommended if the pretest probability is high, and two-step testing is recommended if the pretest probability is intermediate.	Ottawa Gen Hosp, Dept Med, Ottawa, ON K1H 8L6, Canada; Ottawa Civic Hosp, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Ft Collins, CO 80521 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Kentucky, Kentucky Clin J511, Div Rheumatol, Lexington, KY 40536 USA; Tufts Univ, Med Ctr, Boston, MA 02111 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Centers for Disease Control & Prevention - USA; Tufts Medical Center; University of Kentucky; Tufts University	Tugwell, P (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Steere, Allen/0000-0002-5268-9853				*AM MED ASS CTR HL, 1993, PHYS MARK STAT PROF; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; ATLAS E, 1988, ANN INTERN MED, V109, P245, DOI 10.7326/0003-4819-109-3-245; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BLAAUW I, 1992, J CLIN EPIDEMIOL, V45, P1229, DOI 10.1016/0895-4356(92)90163-H; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; COCKBURN J, 1987, BRIT MED J, V295, P814, DOI 10.1136/bmj.295.6602.814; DATTWYLER RJ, 1988, LANCET, V1, P1191; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EPPES SC, 1994, CLIN PEDIATR, V33, P130, DOI 10.1177/000992289403300301; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FRASER DD, 1992, CLIN EXP RHEUMATOL, V10, P387; GEISLER WO, 1977, PARAPLEGIA, V14, P262, DOI 10.1038/sc.1976.44; Gold MR, 1996, COST EFFECTIVENESS H; GUSTAFSON R, 1992, EUR J CLIN MICROBIOL, V11, P894, DOI 10.1007/BF01962369; HOFFMANN JC, 1995, ARTHRITIS RHEUM-US, V38, P1157, DOI 10.1002/art.1780380820; HOROWITZ HW, 1994, CLIN INFECT DIS, V18, P166, DOI 10.1093/clinids/18.2.166; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; JACOBS P, 1995, PHARMACOECONOMICS, V8, P182, DOI 10.2165/00019053-199508030-00002; Jung P I, 1994, Md Med J, V43, P447; KARLSSON M, 1994, NEUROLOGY, V44, P1203, DOI 10.1212/WNL.44.7.1203; KARMA A, 1995, AM J OPHTHALMOL, V119, P127, DOI 10.1016/S0002-9394(14)73864-4; KENGEN RAM, 1989, CLIN NUCL MED, V14, P728, DOI 10.1097/00003072-198910000-00002; Lew EA, 1990, MED RISKS TRENDS MOR; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; LUI NY, 1989, ARTHRITIS RHEUM, V32, pS46; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MALANE MS, 1991, ANN INTERN MED, V114, P490, DOI 10.7326/0003-4819-114-6-490; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; *MED EC, 1993, DRUG TOP RED BOOK; MELSKI JW, 1993, ARCH DERMATOL, V129, P709, DOI 10.1001/archderm.129.6.709; *NAT CTR HLTH STAT, 1994, ANN SUMM BIRTHS MARR; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; REIMERS CD, 1993, J NEUROL, V240, P278, DOI 10.1007/BF00838161; RUBIN DA, 1992, PACE, V15, P252, DOI 10.1111/j.1540-8159.1992.tb06492.x; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHMUTZHARD E, 1986, KLIN WOCHENSCHR, V64, P1204, DOI 10.1007/BF01728463; SCHOEN RT, 1991, ARTHRITIS RHEUM, V34, P1056, DOI 10.1002/art.1780340817; SCHOENEN J, 1989, J NEUROL NEUROSUR PS, V52, P1002, DOI 10.1136/jnnp.52.8.1002; SEIDENBERG KB, 1990, AM J OPHTHALMOL, V109, P13, DOI 10.1016/S0002-9394(14)75571-0; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SMITH JL, 1991, J CLIN NEURO-OPHTHAL, V11, P7; Sox HC, 1988, MED DECISION MAKING; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; Wharton M, 1990, MMWR Recomm Rep, V39, P1; 1993, MMWR MORB MORTAL WKL, V42, P39; 1995, MMWR MORB MORTAL WKL, V44, P459; 1996, MMWR MORB MORTAL WKL, V45, P481; 1994, MMWR MORB MORTAL WKL, V43, P564	66	45	46	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					37	48		10.7326/0003-4819-128-1-199801010-00007	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424980				2022-12-28	WOS:000071158000007
J	Fabre, J				Fabre, J			Medicine as a profession - Hip, hip, Hippocrates: extracts from the Hippocratic Doctor	BRITISH MEDICAL JOURNAL			English	Article																		Jones W. H. S., 1923, HIPPOCRATES, V1; Jones W. H. S., 1923, HIPPOCRATES, VII; Jones W. H. S., 1931, HIPPOCRATES, V4; Potter Paul, 1995, HIPPOCRATES, VVIII; Smith Wesley D., 1994, HIPPOCRATES, V7, P4; Withington ET, 1928, HIPPOCRATES, V149	6	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1669	1670		10.1136/bmj.315.7123.1669	http://dx.doi.org/10.1136/bmj.315.7123.1669			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448536	Green Published			2022-12-28	WOS:000071149400021
J	Fisher, DA; Koerner, RM; Bourgeois, JC; Zielinski, G; Wake, C; Hammer, CU; Clausen, HB; Gundestrup, N; Johnsen, S; Goto-Azuma, K; Hondoh, T; Blake, E; Gerasimoff, M				Fisher, DA; Koerner, RM; Bourgeois, JC; Zielinski, G; Wake, C; Hammer, CU; Clausen, HB; Gundestrup, N; Johnsen, S; Goto-Azuma, K; Hondoh, T; Blake, E; Gerasimoff, M			Penny ice cap cores, Baffin Island, Canada, and the Wisconsinan Foxe Dome connection: Two states of Hudson Bay ice cover	SCIENCE			English	Article							BORE-HOLE; RECORD; VOLCANISM; CLIMATE; TEMPERATURE; 7000-BC; NWT	Ice cores from Penny Ice Cap, Baffin Island, Canada, provide continuous Holocene records of oxygen isotopic composition (delta(18)O, proxy for temperature) and atmospheric impurities. A time scale was established with the use of altered seasonal variations, some volcanic horizons, and the age for the end of the Wisconsin ice age determined from the GRIP and GISP2 ice cores. There is pre-Holocene ice near the bed. The change in delta(18)O since the last glacial maximum (LGM) is at least 12.5 per mil, compared with an expected value of 7 per mil, suggesting that LGM ice originated at the much higher elevations of the then existing Fore Dome and Fore Ridge of the Laurentide Ice Sheet. The LGM delta(18)O values suggest thick ice frozen to the bed of Hudson Bay.	Geol Survey Canada, Terrain Sci Div, Ottawa, ON K1A 0E8, Canada; Univ New Hampshire, Glacier Res Grp, Durham, NH 03824 USA; Univ Copenhagen, Niels Bohr Inst, Dept Geophys, DK-2100 Copenhagen, Denmark; Nagaoka Inst Snow & Ice Studies, Nagaoka, Niigata 940, Japan; Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 060, Japan; Icefield Instruments, Whitehorse, YT Y1A 5H4, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University System Of New Hampshire; University of New Hampshire; University of Copenhagen; Niels Bohr Institute; Hokkaido University	Fisher, DA (corresponding author), Geol Survey Canada, Terrain Sci Div, 601 Booth St, Ottawa, ON K1A 0E8, Canada.		Clausen, Helene/AAU-8786-2020; Wake, Cameron/G-8114-2014; HONDOH, TAKEO/E-7551-2011	HONDOH, TAKEO/0000-0003-4129-022X; Wake, Cameron/0000-0002-5961-5902				ALLEY RB, 1995, NATURE, V373, P393, DOI 10.1038/373393b0; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; [Anonymous], 1959, J GLACIOL, DOI DOI 10.3189/S002214300001724X; Clausen HB, 1995, NATO ASI SER SER I, V30, P175; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; DANSGAARD W, 1973, MEDDELELSER GRONLAND, V197, P53; DYKE AS, 1979, ARCTIC ALPINE RES, V11, P179, DOI 10.2307/1550644; Fisher D. A, 1985, ANN GLACIOL, V7, P117, DOI DOI 10.3189/S0260305500006017; Fisher D. A., 1985, ANN GLACIOL, V7, P76, DOI DOI 10.1017/S0260305500005942; Fisher D.A., 1987, INT ASS HYDROL SCI, V170, P45; Fisher D.A., 1985, GEROGR PHYS QUATERN, V39, P229, DOI [DOI 10.7202/032605AR, 10.7202/032605ar]; FISHER DA, 1995, HOLOCENE, V5, P19, DOI 10.1177/095968369500500103; FISHER DA, 1986, J GLACIOL, V32, P501, DOI 10.3189/S0022143000012211; FISHER DA, 1992, COLD REG SCI TECHNOL, V21, P61, DOI 10.1016/0165-232X(92)90006-G; FISHER DA, 1992, NATO ASI SER, V12, P267; FISHER DA, 1977, THESIS U COPENHAGEN; Hammer CU, 1978, J GLACIOL, V20, P3; HANSSON ME, 1994, TELLUS B, V46, P390, DOI 10.1034/j.1600-0889.1994.t01-4-00005.x; HOLDSWORTH G, 1984, J GLACIOL, V30, P3, DOI 10.3189/S002214300000842X; HOOKE RL, 1982, GEOL SOC AM BULL, V93, P784, DOI 10.1130/0016-7606(1982)93<784:WAHOVB>2.0.CO;2; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; JOHNSEN SJ, IN PRESS J GEOPHYS R; JOHNSEN SJ, 1977, IAHS-AISH PUBL, V118, P388; JONSSON S, 1990, GEOGR ANN A, V72, P41, DOI 10.2307/521236; KOERNER RM, 1990, NATURE, V343, P630, DOI 10.1038/343630a0; NEFTEL A, 1985, GEOPHYS MONOGR SER, V33, P32; OBRIEN SR, 1995, SCIENCE, V270, P1962, DOI 10.1126/science.270.5244.1962; PATERSON WSB, 1977, NATURE, V266, P508, DOI 10.1038/266508a0; Robin G.deQ., 1955, J GLACIOL, V2, P523, DOI [10.3189/002214355793702028, DOI 10.3189/002214355793702028]; TERS M, 1987, CLIMATE HIST P0ERIOD, P205; WAKE C, UNPUB; ZHENG J, IN PRESS HOLOCENE; ZIELINSKI GA, 1994, SCIENCE, V264, P948, DOI 10.1126/science.264.5161.948; ZIELINSKI GA, 1995, SCIENCE, V267, P257, DOI 10.1126/science.267.5195.257	35	87	88	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					692	695		10.1126/science.279.5351.692	http://dx.doi.org/10.1126/science.279.5351.692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445472				2022-12-28	WOS:000071731500033
J	Echard, A; Jollivet, F; Martinez, O; Lacapere, JJ; Rousselet, A; Janoueix-Lerosey, I; Goud, B				Echard, A; Jollivet, F; Martinez, O; Lacapere, JJ; Rousselet, A; Janoueix-Lerosey, I; Goud, B			Interaction of a Golgi-associated kinesin-like protein with Rab6	SCIENCE			English	Article							HEAVY-CHAIN; BINDING; TRANSPORT; MOTOR; MICROTUBULES; EFFECTOR; DOMAINS; BRAIN; NCD	Rab guanosine triphosphatases regulate vesicular transport and membrane traffic within eukaryotic cells. Here, a kinesin-like protein that interacts with guanosine triphosphate (GTP)-bound forms of Rab6 was identified. This protein, termed Rabkinesin-6, was localized to the Golgi apparatus and shown to play a role in the dynamics of this organelle. The carboxyl-terminal domain of Rabkinesin-6, which contains the Rab6-interacting domain, inhibited the effects of Rab6-GTP on intracellular transport, Thus, a molecular motor is a potential effector of a Rab protein, and coordinated action between members of these two families of proteins could control membrane dynamics and directional vesicular traffic.	Inst Curie, CNRS, Unite Mixte Rech 144 & 168, F-75248 Paris 05, France; Inst Curie, INSERM, U248, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Goud, B (corresponding author), Inst Curie, CNRS, Unite Mixte Rech 144 & 168, 26 Rue Ulm, F-75248 Paris 05, France.	bgoud@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Goud, Bruno/GWC-4807-2022	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Echard, Arnaud/0000-0001-7402-1398				ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DERETIC D, 1995, J CELL SCI, V108, P215; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; ECHARD A, UNPUB; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; Johannes L, 1996, J CELL SCI, V109, P2875; JOHANNES L, UNPUB; KURIYAMA R, 1994, J CELL SCI, V107, P3485; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MARTINEZ O, 1997, THESIS U PARIS; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; ROA M, 1993, J CELL SCI, V106, P789; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	37	406	418	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					580	585		10.1126/science.279.5350.580	http://dx.doi.org/10.1126/science.279.5350.580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438855				2022-12-28	WOS:000071616000052
J	Weiskopf, RB; Viele, MK; Feiner, J; Kelley, S; Lieberman, J; Noorani, M; Leung, JM; Fisher, DM; Murray, WR; Toy, P; Moore, MA				Weiskopf, RB; Viele, MK; Feiner, J; Kelley, S; Lieberman, J; Noorani, M; Leung, JM; Fisher, DM; Murray, WR; Toy, P; Moore, MA			Human cardiovascular and metabolic response to acute, severe isovolemic anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 17-25, 1996	NEW ORLEANS, LA	Amer Soc Anesthesiologists			OXYGEN DELIVERY; HEMODYNAMICS; HEMODILUTION; TRANSFUSION	Context.-Although concern over the risks of red blood cell transfusion has resulted in several practice guidelines for transfusion, lack of data regarding the physiological effects of anemia in humans has caused uncertainty regarding the blood hemoglobin (Hb) concentration requiring treatment. Objective.-To test the hypothesis that acute isovolemic reduction of blood Hb concentration to 50 g/L in healthy resting humans would produce inadequate cardiovascular compensation and result in tissue hypoxia secondary to inadequate oxygen transport. Design.-Before and after interventional study. Setting.-Academic tertiary care medical center. Participants.-Conscious healthy patients (n=11) prior to anesthesia and surgery and volunteers not undergoing surgery (n=21). Interventions.-Aliquots of blood (450-900 mL) were removed to reduce blood Hb concentration from 131 (2) g/L to 50 (1) g/L [mean (SE)]. Isovolemia was maintained with 5% human albumin and/or autologous plasma. Cardiovascular parameters, arterial and mixed venous oxygen content, oxyhemoglobin saturation, and arterial blood lactate were measured before and after removal of each aliquot of blood, Electrocardiogram and, in a subset, Holter monitor were monitored continuously. Main Outcome Measures.-"Critical" oxygen delivery (TO2) as assessed by oxygen consumption ((V)over dot O-2), plasma lactate concentration, and ST changes on electrocardiogram. Results.-Acute, isovolemic reduction of Hb concentration decreased systemic vascular resistance and TO2 and increased heart rate, stroke volume, and cardiac index (each P<.001). We did not find evidence of inadequate oxygenation: (V)over dot O-2 increased slightly from a mean (SD) of 3.07 (0.44) mL of oxygen per kilogram per minute (mL O-2.kg(-1).min(-1)) to 3.42 (0.54) mL O-2.kg(-1).min(-1) (P<.001) and plasma lactate concentration did not change (0.81 [0.11] mmol/L to 0.62 [0.19] mmol/L; P=.09). Two subjects developed significant ST changes on Holter monitor: one apparently related to body position or activity, the other to an increase in heart rate (at an Hb concentration of 46-53 g/L); both occurred in young women and resolved without sequelae. Conclusions.-Acute isovolemic reduction of blood Hb concentration to 50 g/L in conscious healthy resting humans does not produce evidence of inadequate systemic TO2, as assessed by lack of change of (V)over dot O-2 and plasma lactate concentration. Analysis of Hotter readings suggests that at this Hb concentration in this resting healthy population, myocardial ischemia would occur infrequently.	Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weiskopf, RB (corresponding author), Univ Calif San Francisco, Dept Anesthesia, 521 Parnassus Ave,C450, San Francisco, CA 94143 USA.	weiskopf@jemo.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054476] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 P50HL54476] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RP, 1982, J APPL PHYSIOL, V53, P660, DOI 10.1152/jappl.1982.53.3.660; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Beal B., 1992, NONMEM USERS GUIDE; BEAL SL, 1985, DRUG FATE METABOLISM; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; CAIN SM, 1977, J APPL PHYSIOL, V42, P228, DOI 10.1152/jappl.1977.42.2.228; CAIN SM, 1965, AM J PHYSIOL, V209, P604, DOI 10.1152/ajplegacy.1965.209.3.604; CHAITMAN BR, 1981, AM J CARDIOL, V47, P1335, DOI 10.1016/0002-9149(81)90267-8; CHAMORRO G, 1973, CIRC RES, V33, P530; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; JAN KM, 1977, AM J PHYSIOL, V233, pH106, DOI 10.1152/ajpheart.1977.233.1.H106; LEVINE E, 1990, TRANSFUSION, V30, P11, DOI 10.1046/j.1537-2995.1990.30190117621.x; LOWENSTEIN E, 1987, CARDIAC ANESTHESIA; MICHENFELDERJD, 1988, ANESTHESIA BRAIN; MURRAY JF, 1969, AM J PHYSIOL, V216, P638, DOI 10.1152/ajplegacy.1969.216.3.638; NOLDGE GFE, 1992, ANESTH ANALG, V75, P660; RESTORFF WV, 1975, PFLUG ARCH EUR J PHY, V357, P25, DOI 10.1007/BF00584542; RESTORFF WV, 1975, PFLUG ARCH EUR J PHY, V357, P15, DOI 10.1007/BF00584541; Royal College of Physicians of Edinburgh, 1994, TRANSFUSION MED, V4, P177; VANWOERKENS ECSM, 1992, ANESTH ANALG, V75, P818; VIELE MK, 1994, TRANSFUSION, V34, P396, DOI 10.1046/j.1537-2995.1994.34594249050.x; WOHLGELERNTER D, 1986, J AM COLL CARDIOL, V7, P1245, DOI 10.1016/S0735-1097(86)80143-7	24	430	451	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					217	221		10.1001/jama.279.3.217	http://dx.doi.org/10.1001/jama.279.3.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YR124	9438742	Bronze			2022-12-28	WOS:000071460700032
J	Gray, RH; Wawer, MJ; Serwadda, D; Sewankambo, N; Li, CJ; Wabwire-Mangen, F; Paxton, L; Kiwanuka, N; Kigozi, G; Konde-Lule, J; Quinn, TC; Gaydos, CA; McNairn, D				Gray, RH; Wawer, MJ; Serwadda, D; Sewankambo, N; Li, CJ; Wabwire-Mangen, F; Paxton, L; Kiwanuka, N; Kigozi, G; Konde-Lule, J; Quinn, TC; Gaydos, CA; McNairn, D			Population-based study of fertility in women with HIV-1 infection in Uganda	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LIGASE CHAIN-REACTION; PREGNANCY; MORTALITY; DISTRICT; DISEASE; COHORT; IMPACT; RATES; URINE	Background To assess the effects of HIV-1 and other sexually transmitted infections on pregnancy, we undertook cross-sectional and prospective-studies of a rural population in Rakai district, Uganda. Methods 4813 sexually active women aged 15-49 years were surveyed to find out the prevalence of pregnancy by interview and selective urinary human chorionic gonadotropin tests. The incidence of recognised conception and frequency of pregnancy loss were assessed by follow-up. Samples were taken to test for HIV-1 infection, syphilis, and other sexually transmitted diseases. Findings At time of survey, 757 (21.4%) of 3544 women without HIV-1 infection or syphilis were pregnant, compared with 46 (14.6%) of 316 HIV-1-negative women with active syphilis, 117 (14.2%) of 823 HIV-1-positive women with no concurrent syphilis, and 11 (8.5%) of 130 women with both syphilis and HIV-1 infection. The multivariate adjusted odds ratio of pregnancy in HIV-1-infected women was 0.45 (95% CI 0.35-0.57); the odds of pregnancy were low both in HIV-1-infected women without symptoms (0.49 [0.39-0.62]) and in women with symptoms of HIV-1-associated disease (0.23 [0.11-0.48]). In women with concurrent HIV-1 infection and syphilis the odds ratio was 0.28 (0.14-0.55). The incidence rate of recognised pregnancy during the prospective followup study was lower in HIV-1-positive than in HIV-1-negative women (23.5 vs 30.1 per 100 woman-years; adjusted risk ratio 0.73 [0.57-0.93]). Rates of pregnancy loss were higher among HIV-1-infected than uninfected women (18.5 vs 12.2%; odds ratio 1.50 [1.01-2.27]). The prevalence of HIV-1 infection was significantly lower in pregnant than in non-pregnant women (13.9 vs 21.3%). Interpretation Pregnancy prevalence is greatly reduced in HIV-1-infected women, owing to lower rates of conception and increased rates of pregnancy loss. HIV-1 surveillance confined to pregnant women underestimates the magnitude of the HIV-1 epidemic in the general population.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY USA; Makerere Univ, Inst Publ Hlth, Kampala, Uganda; Makerere Univ, Dept Med, Kampala, Uganda; Rakai Project, Entebbe, Uganda; NIAID, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Columbia University; Makerere University; Makerere University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gray, RH (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Room 4030,615 N Wolfe St, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Sewankambo, Nelson/0000-0001-9362-053X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34826-03] Funding Source: Medline; NICHD NIH HHS [5P30HD06268] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; ASSIMWEOKIROR G, 1995, 9 INT C AIDS STDS AF, P14; BACKE E, 1993, AIDS, V7, P896, DOI 10.1097/00002030-199306000-00025; Bongaarts J, 1996, POPUL DEV REV, V22, P21, DOI 10.2307/2137685; BRETTLE RP, 1995, AIDS, V9, P1177, DOI 10.1097/00002030-199510000-00010; Carpenter LM, 1997, HLTH TRANSITION R S2, V7, P113; CHENG CY, 1997, J INFECT DIS, V174, P1390; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; HOCKE C, 1995, OBSTET GYNECOL, V86, P886, DOI 10.1016/0029-7844(95)00257-R; HOSMER DW, 1989, APPL LOGISTIC REGRES; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KIGADYE RM, 1993, AIDS, V7, P849, DOI 10.1097/00002030-199306000-00014; KORN A, 1994, J ACQ IMMUN DEF SYND, V9, P361; KRIEGER JN, 1991, J INFECT DIS, V164, P464, DOI 10.1093/infdis/164.3.464; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; PAPE JW, 1989, PAHO B, V23, P50; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; Schulz K, 1990, HOMES SEXUALLY TRANS, P821; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; SMITH KR, 1995, J CLIN MICROBIOL, V33, P455, DOI 10.1128/JCM.33.2.455-457.1995; Steinberg Shari, 1995, pS16; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; TEMMERMAN M, 1994, INT J GYNECOL OBSTET, V44, P107, DOI 10.1016/0020-7292(94)90062-0; TEMMERMAN M, 1995, AIDS, V9, P1057, DOI 10.1097/00002030-199509000-00011; TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002; *US BUR CENS, 1995, 9 INT C AIDS STDS AF, P1; WASSERHEIT JN, 1992, REPROD BIOL, P7; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; WOODS JW, 1994, BIOL BIOMETRY DEMOGR, P305	33	223	225	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					98	103		10.1016/S0140-6736(97)09381-1	http://dx.doi.org/10.1016/S0140-6736(97)09381-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439494	hybrid			2022-12-28	WOS:000071591900011
J	Friend, SH; Oliff, A				Friend, SH; Oliff, A			Emerging uses for genomic information in drug discovery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN HOMOLOG; GENE		Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Merck Res Labs, W Point, PA 19486 USA	Fred Hutchinson Cancer Center; Merck & Company	Friend, SH (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.							DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DOYE V, 1995, TRENDS GENET, V11, P293; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SEKELSKY JJ, 1995, GENETICS, V139, P1347	9	24	24	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					125	126		10.1056/NEJM199801083380211	http://dx.doi.org/10.1056/NEJM199801083380211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420347				2022-12-28	WOS:000071341300011
J	Lowe, J; Amos, LA				Lowe, J; Amos, LA			Crystal structure of the bacterial cell-division protein FtsZ	NATURE			English	Article							NUCLEOTIDE-BINDING-PROTEIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; TUBULIN; MECHANISM; GTPASE	Bacterial cell division ends with septation, the constriction of the cell wall and cell membranes that leads to the formation of two daughter cells(1,2). During septation, FtsZ, a protein of relative molecular mass 40,000 which is ubiquitous in eubacteria and is also found in archaea and chloroplasts(3), localizes early at the division site to form a ring-shaped septum. This septum is required for the mechanochemical process of membrane constriction(4). FtsZ is a GTPase(5,6) with weak sequence homology to tubulins(7). The nature of FtsZ polymers in vivo is unknown, but FtsZ can form tubules, sheets and minirings in vitro(8,9). Here we report the crystal structure at 2.8 Angstrom resolution of recombinant FtsZ from the hyperthermophilic methanogen Methanococcus jannaschii. FtsZ has two domains, one of which is a GTPase domain with a fold related to one found in the proteins p21(ras) and elongation factor EF-Tu. The carboxy-terminal domain, whose function is unknown, is a four-stranded beta-sheet tilted by 90 degrees against the beta-sheet of the GTPase domain. The two domains are arranged around a central helix GDP binding is different from that typically found in GTPases and involves four phosphate-binding loops and a sugar-binding loop in the first domain, with guanine being recognized by residues in the central connecting helix The three-dimensional structure of FtsZ is similar to the structure of alpha- and beta-tubulin(10).	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Lowe, J (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019	Lowe, Jan/0000-0002-5218-6615; Amos, Linda/0000-0001-8305-5346				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BULT CJ, 1996, NATURE, V269, P496; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14203, DOI 10.1021/bi961357b; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LINSE K, 1988, J BIOL CHEM, V263, P15205; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Park J. T., 1992, NATURE, V359, P251; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sackett D L, 1995, Subcell Biochem, V24, P255; Sage CR, 1995, BIOCHEMISTRY-US, V34, P16870; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S	30	699	731	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					203	206		10.1038/34472	http://dx.doi.org/10.1038/34472			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428770				2022-12-28	WOS:000071380900058
J	Feig, AL; Scott, WG; Uhlenbeck, OC				Feig, AL; Scott, WG; Uhlenbeck, OC			Inhibition of the hammerhead ribozyme cleavage reaction by site-specific binding of Tb(III)	SCIENCE			English	Article							SELF-CLEAVAGE; TRANSFER-RNA; CRYSTAL-STRUCTURE; METAL-BINDING; OLIGORIBONUCLEOTIDES; MECHANISM; PHOSPHOROTHIOATE; REQUIREMENTS; EUROPIUM; DOMAIN	Terbium(III) [Tb(III)] was shown to inhibit the hammerhead ribozyme by competing with a single magnesium(II) ion, X-ray crystallography revealed that the Tb(III) ion binds to a site adjacent to an essential guanosine in the catalytic core of the ribozyme, approximately 10 angstroms from the cleavage site. Synthetic modifications near this binding site yielded an RNA substrate that was resistant to Tb(III) binding and capable of being cleaved, even in the presence of up to 20 micromolar Tb(III). it is suggested that the magnesium(II) ion thought to bind at this site may act as a switch, affecting the conformational changes required to achieve the transition state.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	University of Colorado System; University of Colorado Boulder; Indiana University System; Indiana University Bloomington	Uhlenbeck, OC (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Feig, Andrew/B-7414-2011	Feig, Andrew/0000-0002-5783-1097; Scott, William/0000-0002-9273-3564	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036944, R01GM036944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36944, R01 GM087721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bassi GS, 1996, RNA, V2, P756; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BRUNGER AT, 1987, XPLOR VERSION 3 1; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; ClouetDOrval B, 1996, RNA, V2, P483; DRAPER DE, 1985, BIOPHYS CHEM, V21, P91, DOI 10.1016/0301-4622(85)85011-0; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FEIG AL, UNPUB; FORSTER AC, 1987, COLD SPRING HARB SYM, V52, P249, DOI 10.1101/SQB.1987.052.01.030; HENDRIX C, 1995, BIOCHEM BIOPH RES CO, V210, P67, DOI 10.1006/bbrc.1995.1628; HENDRIX C, 1995, NUCLEIC ACIDS RES, V23, P51, DOI 10.1093/nar/23.1.51; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Holbrook SR, 1997, BIOPOLYMERS, V44, P3; HORROCKS WDW, 1993, METHOD ENZYMOL, V226, P495, DOI 10.1016/0076-6879(93)26023-3; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JONES TA, 1992, O MANUAL MANUAL O VE; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; KUIMELIS RG, 1995, J AM CHEM SOC, V117, P11019, DOI 10.1021/ja00149a030; Maniatis T., 1982, MOL CLONING LAB MANU; McKay DB, 1996, RNA, V2, P395; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORET E, 1991, J LESS-COMMON MET, V171, P273, DOI 10.1016/0022-5088(91)90151-S; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RINGER DP, 1980, ANAL BIOCHEM, V103, P337, DOI 10.1016/0003-2697(80)90620-X; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Segel I.H, 1993, ENZYME KINETICS; SHELDON CC, 1990, NUCLEIC ACIDS MOL BI, V4, P227; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; WOLFSON JM, 1975, BIOCHEMISTRY-US, V14, P1436, DOI 10.1021/bi00678a014	41	115	116	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					81	84		10.1126/science.279.5347.81	http://dx.doi.org/10.1126/science.279.5347.81			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417029				2022-12-28	WOS:000071323900044
J	Jaworek, T; Neher, D; Wegner, G; Wieringa, RH; Schouten, AJ				Jaworek, T; Neher, D; Wegner, G; Wieringa, RH; Schouten, AJ			Electromechanical properties of an ultrathin layer of directionally aligned helical polypeptides	SCIENCE			English	Article							BENZYL-L-GLUTAMATE; SILICON CRYSTAL-SURFACE; LANGMUIR-BLODGETT-FILM; CHEMICAL-REACTION; 2ND-HARMONIC GENERATION; THIN-FILMS; CRA FILM; POLYMERS; PIEZOELECTRICITY; MONOLAYERS	The electromechanical properties of a monomolecular film of poly-gamma-benzyl-L-glutamate (PBLG) 15 nanometers thick grafted at the carboxyl-terminal end to a flat aluminum surface were measured. The field-induced change in film thickness, dominated by a large inverse-piezoelectric effect, demonstrates that the "grafting-from" technique forces the chains into a parallel arrangement. The mechanical plate modulus of the film as determined by electrostriction agrees with the theoretical prediction for a single PBLG molecule along the chain axis. The experiments show that ultrathin polypeptide layers with large persistent polarization can be fabricated by the grafting approach.	Max Planck Inst Polymerforsch, D-55128 Mainz, Germany; Univ Groningen, Dept Polymer Chem, NL-9747 AG Groningen, Netherlands	Max Planck Society; University of Groningen	Wegner, G (corresponding author), Max Planck Inst Polymerforsch, Ackermannweg 10, D-55128 Mainz, Germany.		Colella, Stefano/A-7040-2008; Neher, Dieter/A-9334-2015	Colella, Stefano/0000-0003-3139-6055; 				Advincula R, 1996, POLYM ADVAN TECHNOL, V7, P571; Beyer D, 1995, THIN SOLID FILMS, V271, P73, DOI 10.1016/0040-6090(96)80085-X; Block H., 1983, POLY GAMMA BENZYL L; BLOCK H, 1992, POLYMER, V33, P2489; Blum G, 1995, ADV MATER, V7, P1017, DOI 10.1002/adma.19950071210; BURLAND DM, 1994, CHEM REV, V94, P31, DOI 10.1021/cr00025a002; CRESSWELL JP, 1992, THIN SOLID FILMS, V210, P216, DOI 10.1016/0040-6090(92)90215-W; DUDA G, 1988, THIN SOLID FILMS, V159, P221, DOI 10.1016/0040-6090(88)90633-5; Eckert T, 1996, MACROMOL RAPID COMM, V17, P767, DOI 10.1002/marc.1996.030171103; FUKADA E, 1968, ULTRASONICS      OCT, P229; FURUKAWA T, 1984, JPN J APPL PHYS 2, V23, pL677, DOI 10.1143/JJAP.23.L677; HALLER I, 1978, J AM CHEM SOC, V100, P8050, DOI 10.1021/ja00494a003; Heise A, 1997, LANGMUIR, V13, P723, DOI 10.1021/la960467g; HELFRICH J, 1994, MACROMOLECULES, V27, P472, DOI 10.1021/ma00080a022; JACKSON CL, 1991, POLYMER, V32, P221, DOI 10.1016/0032-3861(91)90005-4; KURTH DG, 1995, LANGMUIR, V11, P3061, DOI 10.1021/la00008a035; LEVINE BF, 1976, J CHEM PHYS, V65, P1989, DOI 10.1063/1.433297; Lin WB, 1996, J AM CHEM SOC, V118, P8034, DOI 10.1021/ja960395f; Luo Y, 1997, CHEM PHYS LETT, V275, P145, DOI 10.1016/S0009-2614(97)00731-8; LUPO D, 1988, J OPT SOC AM B, V5, P300, DOI 10.1364/JOSAB.5.000300; MACHIDA S, 1992, J CHEM SOC CHEM COMM, P1628, DOI 10.1039/c39920001628; MACHIDA S, 1992, J CHEM SOC CHEM COMM, P1626, DOI 10.1039/c39920001626; Machida S, 1995, LANGMUIR, V11, P4838, DOI 10.1021/la00012a041; MARTIN PG, 1987, POLYMER, V28, P897, DOI 10.1016/0032-3861(87)90160-1; MCGRUM NG, 1967, ANELASTIC DIELECTRIC; MOPSIK FI, 1975, J APPL PHYS, V46, P4204, DOI 10.1063/1.321433; NACIRI J, 1995, MACROMOLECULES, V28, P5274, DOI 10.1021/ma00119a016; NIZZOLI F, 1989, PHYS REV B, V40, P3323, DOI 10.1103/PhysRevB.40.3323; OOSTERLING MLCM, 1995, POLYMER, V36, P4463, DOI 10.1016/0032-3861(95)96854-2; PALACIOS P, 1991, ANGEW MAKROMOL CHEM, V193, P77, DOI 10.1002/apmc.1991.051930108; SANO K, 1992, CHEM LETT, P1477, DOI 10.1246/cl.1992.1477; SESSLER GM, 1987, TOP APPL PHYS, P7; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; TOKARSKI Z, 1994, CHEM MATER, V6, P2063, DOI 10.1021/cm00047a028; URANO TI, 1994, J CHEM SOC CHEM COMM, P231, DOI 10.1039/c39940000231; WADA A, 1962, POLYAMINO ACIDS POLY, P131; WHITESELL JK, 1994, MOL CRYST LIQ CRYS A, V240, P251, DOI 10.1080/10587259408029736; WHITESELL JK, 1993, SCIENCE, V261, P73, DOI 10.1126/science.261.5117.73; WHITESELL JK, 1994, ANGEW CHEM, V106, P921; WIENNGA RH, UNPUB; Wieringa RH, 1996, MACROMOLECULES, V29, P3032, DOI 10.1021/ma9508358; Winkelhahn HJ, 1996, MACROMOLECULES, V29, P6865, DOI 10.1021/ma960080k; WINKELHAHN HJ, 1994, APPL PHYS LETT, V64, P1347, DOI 10.1063/1.111930	44	128	129	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					57	60		10.1126/science.279.5347.57	http://dx.doi.org/10.1126/science.279.5347.57			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417021	Green Submitted			2022-12-28	WOS:000071323900036
J	Goldfarb, S; Henrich, WL				Goldfarb, S; Henrich, WL			Update in nephrology	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; DIETARY-PROTEIN RESTRICTION; RENAL-DISEASE; PROGRESSION; METAANALYSIS; MICROALBUMINURIA; NEPHROPATHY		Univ Penn Hlth Syst, Dept Med, Philadelphia, PA 19104 USA; Med Coll Ohio, Dept Internal Med, Toledo, OH 43614 USA; Madrona Med Grp, Bellingham, WA 98226 USA	University of Pennsylvania	Goldfarb, S (corresponding author), Univ Penn Hlth Syst, Dept Med, 100 Centrex,3400 Spruce St, Philadelphia, PA 19104 USA.							Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Barza M, 1996, BRIT MED J, V312, P338; CHAZAN JA, 1995, NEPHRON, V69, P228, DOI 10.1159/000188461; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; Grossman E, 1996, JAMA-J AM MED ASSOC, V276, P1328, DOI 10.1001/jama.276.16.1328; Gutthann SP, 1996, ARCH INTERN MED, V156, P2433, DOI 10.1001/archinte.1996.00440200041005; Hatala R, 1996, ANN INTERN MED, V124, P717, DOI 10.7326/0003-4819-124-8-199604150-00003; HIRTH RA, 1993, JAMA-J AM MED ASSOC, V276, P1303; Ihle BU, 1996, AM J KIDNEY DIS, V27, P489, DOI 10.1016/S0272-6386(96)90158-4; Jones DC, 1996, NEW ENGL J MED, V335, P226, DOI 10.1056/NEJM199607253350402; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; KLEIN R, 1988, ARCH INTERN MED, V148, P181, DOI 10.1001/archinte.148.1.181; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; MOSCONI L, 1996, KIDNEY INT, V49, P591; Nelson RG, 1996, NEW ENGL J MED, V335, P1636, DOI 10.1056/NEJM199611283352203; OSTERBY R, 1984, Applied Pathology, V2, P205; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; *US REN DAT SYST, 1995, USRDS 1995 ANN DAT R; VIBERTI GC, 1982, LANCET, V1, P1430	20	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					49	55		10.7326/0003-4819-128-1-199801010-00008	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424981				2022-12-28	WOS:000071158000008
J	Sakahira, H; Enari, M; Nagata, S				Sakahira, H; Enari, M; Nagata, S			Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis	NATURE			English	Article							CELL-DEATH; PROTEASES; FAS; EXPRESSION; SURVIVAL; GENOME; BCL-2	Various molecules such as cytokines and anticancer drugs, as well as factor deprivation, rapidly induce apoptosis (programmed cell death)(1,2), which is morphologically characterized by cell shrinkage and the blebbing of plasma membranes and by nuclear condensation(3,4). Caspases, particularly caspase 3, are proteases that are activated during apoptosis and which cleave substrates such as poly(ADP-ribose) polymerase, actin, fodrin, and lamin(5,6). Apoptosis is also accompanied by the internucleosomal degradation of chromosomal DNA(7-9). In the accompanying Article(10), we have identified and molecularly cloned a caspase-activated deoxyribonuclease (CAD) and its inhibitor (ICAD). Here we show that caspase 3 cleaves ICAD and inactivates its CAD-inhibitory effect, We identified two caspase-3 cleavage sites in ICAD by site-directed mutagenesis. When human Jurkat cells were transformed with ICAD-expressing plasmid, occupation of the receptor Fas, which normally triggers apoptosis, did not result in DNA degradation, The ICAD transformants were also resistant to staurosporine-induced DNA degradation, although staurosporine still killed the cells by activating caspase. Our results indicate that activation of CAD downstream of the caspase cascade is responsible for internucleosomal DNA degradation during apoptosis, and that ICAD works as an inhibitor of this process.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Enari, Masato/E-5507-2014; Nagata, Shigekazu/AAG-3203-2019	Enari, Masato/0000-0003-4293-3848; Nagata, Shigekazu/0000-0001-9758-8426; Duriez, Patrick/0000-0003-1814-2552				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66	28	1360	1403	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					96	99		10.1038/34214	http://dx.doi.org/10.1038/34214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422513				2022-12-28	WOS:000071326100057
J	Gill, PS; Dowell, A; Harris, CM				Gill, PS; Dowell, A; Harris, CM			Effect of doctors' ethnicity and country of qualification on prescribing patterns in single handed general practices: linkage of information collected by questionnaire and from routine data	BRITISH MEDICAL JOURNAL			English	Article							ALLOCATING CENSUS-DATA; PRACTICE POPULATIONS; PRACTITIONERS; AGE; SEX	Objectives: To test whether Asian general practitioners who qualified in the Indian subcontinent prescribe items more often, more expensive items, and fewer generic drugs than their British trained Asian and non-Asian counterparts. Design: Linkage study using data collected by questionnaire and from routine sources. Setting: General practices in England. Subjects: 155 single handed general practitioners: 42 Asian doctors qualified in United Kingdom (group 1). 58 white doctors qualified in United Kingdom (group 2), and 55 Asian doctors qualified in Indian subcontinent (group 3). Main outcome measures: Prescribing cost (cost per ASTRO-PU), prescribing frequency (number of items per ASTRO-PU), and generic prescribing (percentage of drugs prescribed that are generic). Results: Doctors in group 1 were significantly younger than those in the other groups and had a higher proportion of patients who were from deprived wards. There was no difference between the groups in the proportion of female doctors and total list size. After adjustment for confounding factors, there were no significant differences between the three groups for prescribing cost (16.58 (95% confidence interval 6.39 to 26.77) for group 1, 17.31 (6.92 to 27.69) for group 2, 17.80 (7.22 to 28.38) for group 3, P = 0.55); prescribing frequency (6.58 (4.60 to 8.40), 6.45 (4.70 to 8.30), 7.89 (6.16 to 9.64), P = 0.34); and generic prescribing (44.44 (38.95 to 49.93), 47.41 (42.12 to 52.70), 44.04 (38.75 to 49.33), P = 0.37). Conclusions: Asian doctors qualified from the Indian subcontinent did not differ from British trained doctors in their prescribing practice. This study refutes the common belief that Asian doctors are high volume and high cost prescribers.	Univ Leeds, Ctr Res Primary Care, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Acad Unit Gen Practice, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Gill, PS (corresponding author), Univ Birmingham, Dept Gen Practice, Birmingham B15 2TT, W Midlands, England.							[Anonymous], 1993, SPSS WINDOWS BASE SY; Armitage P., 1987, STAT METHODS MED RES; Armstrong D, 1996, BRIT MED J, V312, P949; AVEYARD P, 1995, BRIT MED J, V311, P875, DOI 10.1136/bmj.311.7009.875b; *BMA ROYAL PHARM S, 1993, BRIT NAT FORM    SEP; BOWLING A, 1989, BRIT MED J, V298, P545, DOI 10.1136/bmj.298.6673.545; CARTWRIGHT A, 1978, BRIT MED J, V2, P1419, DOI 10.1136/bmj.2.6149.1419; CHATURVEDI N, 1994, J EPIDEMIOL COMMUNIT, V64, P1036; DORLING D, 1993, RADICAL STATISTICS, V55, P14; Eaton G, 1976, J R Coll Gen Pract, V26 Suppl 1, P31; *GEN MED COUNC, 1993, MED REG; GREEN JM, 1993, BRIT MED J, V307, P607, DOI 10.1136/bmj.307.6904.607; GREENHALGH P, 1997, BRIT MED J, V315, P1482; HARRIS CM, 1990, ANAL PRESCRIBING GEN; INMAN W, 1993, LANCET, V342, P658, DOI 10.1016/0140-6736(93)91763-C; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; PRINGLE M, 1995, 68 ROYAL COLL GEN PR; REES P, 1992, ESRC DATA ARCH B, V51, P12; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; *SASPAC, 1992, SASPAC US MAN 2; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Townsend PP., 1988, HLTH DEPRIVATION INE; Tuckett D., 1976, INTRO MED SOCIOLOGY; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; Wilkin David, 1987, ANATOMY URBAN GEN PR; [No title captured]	26	16	17	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1590	1594		10.1136/bmj.315.7122.1590	http://dx.doi.org/10.1136/bmj.315.7122.1590			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437279	Green Published			2022-12-28	WOS:000071021900026
J	Barrie, AR; Ward, AM				Barrie, AR; Ward, AM			Questioning behaviour in general practice: a pragmatic study	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION NEEDS; CLINICAL QUESTIONS; FAMILY PHYSICIANS; SEEKING; CARE	Objective: To study the extent to which general practitioners' questioning behaviour in routine practice is likely to encourage the adoption of evidence based medicine. Design: Self recording of questions by doctors during consultations immediately followed by semistructured interview. Setting: Urban Australian general practice. Subjects: Random sample of 27 general practitioners followed over a half day of consultations. Main outcome measures: Rate of recording of clinical questions about patients' care which doctors would like answered; frequency with which doctors found answers to their questions. Results: Doctors asked a total of 85 clinical questions, at a rate of 2.4 for every 10 patients seen. They found satisfactory answers to 67 (79%) of these questions. Doctors who worked in small practices (of one or two doctors) had a significantly lower rate of questioning than did those in larger practices (1.6 questions per 10 patients v 8.0 patients, P = 0.049). No other factors were significantly related to rate of questioning. Conclusions: These results do not support the vie iv that doctors routinely generate a large number of unanswered clinical questions. It may be necessary to promote questioning behaviour in routine practice if evidence based medicine and other forms of self directed learning are to be successfully introduced.	UNIV WESTERN AUSTRALIA,DEPT GEN PRACTICE,PERTH,WA 6009,AUSTRALIA	University of Western Australia	Barrie, AR (corresponding author), PONTILEN,RUTHIN LL15 1UL,DENBIGH,WALES.							CONNELLY DP, 1990, J FAM PRACTICE, V30, P353; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; CURLEY SP, 1990, MED DECIS MAKING, V10, P231, DOI 10.1177/0272989X9001000401; DEE C, 1993, B MED LIBR ASSOC, V81, P259; ELY JW, 1992, J FAM PRACTICE, V35, P265; FORSYTHE DE, 1992, COMPUT BIOMED RES, V25, P181, DOI 10.1016/0010-4809(92)90020-B; GORMAN PN, 1995, J AM SOC INFORM SCI, V46, P729, DOI 10.1002/(SICI)1097-4571(199512)46:10<729::AID-ASI3>3.0.CO;2-2; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; Gruppen L D, 1987, Mobius, V7, P18, DOI 10.1002/chp.4760070306; GRUPPEN LD, 1990, B MED LIBR ASSOC, V78, P165; Sackett DL, 1995, J ROY SOC MED, V88, P620; Smith R, 1996, BRIT MED J, V313, P1062; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; TIMPKA T, 1990, METHOD INFORM MED, V29, P23	14	53	53	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1512	1515		10.1136/bmj.315.7121.1512	http://dx.doi.org/10.1136/bmj.315.7121.1512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK986	9420495	Green Published			2022-12-28	WOS:A1997YK98600026
J	Falk, S; Fallon, M				Falk, S; Fallon, M			ABC of palliative care - Emergencies	BRITISH MEDICAL JOURNAL			English	Review									UNIV GLASGOW,WESTERN INFIRM,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND	Beatson Oncology Centre; University of Glasgow	Falk, S (corresponding author), BRISTOL ONCOL CTR,BRISTOL,ENGLAND.			Fallon, Marie/0000-0001-9214-0091					0	15	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1525	1528		10.1136/bmj.315.7121.1525	http://dx.doi.org/10.1136/bmj.315.7121.1525			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420498	Green Published, Green Submitted			2022-12-28	WOS:A1997YK98600030
J	Logie, DE; Benatar, SR				Logie, DE; Benatar, SR			Africa in the 21st century: Can despair be turned to hope?	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAPE TOWN,ZA-7925 CAPE TOWN,SOUTH AFRICA	University of Cape Town	Logie, DE (corresponding author), MED ACT GLOBAL SECUR,LONDON N19 4DJ,ENGLAND.							Benatar S.R., 1997, MED CONFLICT SURVIVA, V13, P229, DOI DOI 10.1080/13623699708409343; Bergstrom S, 1996, BRIT MED J, V313, P316, DOI 10.1136/bmj.313.7053.316; BRITTAIN V, 1997, GUARDIAN        0612, P12; CORNIA GA, 1992, AFRICAS RECOVERY 199, P19; FLANDERS S, 1997, FINANCIAL TIMES 0414, P13; GERVASI S, W STATE TERRORISM, P212; Harrison KA, 1997, LANCET, V349, P644, DOI 10.1016/S0140-6736(97)02192-2; *JUB 2000, 1996, DEBT CUTT HDB; LAFOND A, 1996, SUSTAINING PRIMARY H; NOVICKI M, 1996, AFRICA RECOVERY  MAY, P12; *OXF, 1996, DEBT REL POV RED NEW; *OXF, 1996, OXF POV REP; *OXF, 1997, POOR COUNTR DEBT REL; PETTIFOR A, 1996, WORLD BANK IMF PROP; *UN, 1996, UN SYST WID SPEC IN; *UN, 1996, IMPL STRAT HLTH SECT; *UN DEV PROGR, 1997, HUM DEV REP, P9; WOODWARD D, 1997, US CHARG HLTH SERV D; *WORLD BANK, 1996, LANCET, V347, P411; *WORLD BANK, 1994, BETT HLTH AFR EXP LE, P24; 1997, S AFRICAN EC    0415, P7	21	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1444	1446		10.1136/bmj.315.7120.1444	http://dx.doi.org/10.1136/bmj.315.7120.1444			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418097	Green Published			2022-12-28	WOS:A1997YJ67200033
J	Ernst, HJ; Charra, F; Douillard, L				Ernst, HJ; Charra, F; Douillard, L			Interband electronic excitation-assisted atomic-scale restructuring of metal surfaces by nanosecond pulsed laser light	SCIENCE			English	Article								Interaction of high-power laser light with materials often causes irreversible damage of the near-surface region. It is shown that copper single-crystal surfaces can be patterned by laser light, Irradiation with green light produced adatoms and vacancies, which self-organized into nanoscale pyramids. This restructuring can be removed by annealing. In contrast to green light, infrared laser irradiation at equivalent absorbed energy density did not produce any structural change. This, for metallic systems, unforeseen spectral difference in laser light action points to a concerted process as the source for structural modification, which involves long-lived primary excitation of localized d-electrons through interband transition together with phonon excitation.	SRSIM, Dept Rech Etat Condense, Direct Sci Mat, Commissariat Energie Atom Saclay, F-91191 Gif Sur Yvette, France	CEA	Ernst, HJ (corresponding author), SRSIM, Dept Rech Etat Condense, Direct Sci Mat, Commissariat Energie Atom Saclay, F-91191 Gif Sur Yvette, France.		Douillard, Ludovic/S-9245-2017; Charra, Fabrice/F-6621-2010	Douillard, Ludovic/0000-0001-6370-6586; Charra, Fabrice/0000-0003-1228-0583				ASCHROFT NW, 1976, SOLID STATE PHYSICS; CAO J, 1997, PHYS REV B, V56, P10997; EHRLICH G, 1966, J CHEM PHYS, V44, P1039, DOI 10.1063/1.1726787; ERNST HJ, 1994, PHYS REV LETT, V72, P112, DOI 10.1103/PhysRevLett.72.112; Ernst HJ, 1997, SURF SCI, V383, pL755, DOI 10.1016/S0039-6028(97)00242-2; FANN WS, 1992, PHYS REV LETT, V68, P2834, DOI 10.1103/PhysRevLett.68.2834; FOLLSTAEDT DM, 1981, APPL PHYS LETT, V39, P327, DOI 10.1063/1.92709; FROHN J, 1994, SURF SCI, V320, P93, DOI 10.1016/0039-6028(94)00511-7; HICKS JM, 1995, ADV SERIES PHYSICAL, V5, P589; HOOGERS G, 1994, SURF SCI, V310, P147, DOI 10.1016/0039-6028(94)91380-3; Luce TA, 1997, Z PHYS B CON MAT, V102, P223, DOI 10.1007/s002570050283; MARRS CD, 1992, APPL OPTICS, V21, P4063; MURATA Y, 1995, ADV SERIES PHYSICAL, V5, P729; MUSAL HM, 1980, NBS SPEC PUBL, V568, P159; Poelsema B., 1989, SPRINGER TRACTS MODE, V115; PROKHOROV AM, 1990, A HILGER SERIES OPTI; SCHWOEBEL RL, 1969, J APPL PHYS, V40, P614, DOI 10.1063/1.1657442; WEAVER JC, COMMUNICATION; Zhang ZY, 1997, SCIENCE, V276, P377, DOI 10.1126/science.276.5311.377; Zuo JK, 1997, PHYS REV LETT, V78, P2791, DOI 10.1103/PhysRevLett.78.2791	20	35	37	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					679	681		10.1126/science.279.5351.679	http://dx.doi.org/10.1126/science.279.5351.679			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445467				2022-12-28	WOS:000071731500028
J	Itano, WM; Bollinger, JJ; Tan, JN; Jelenkovic, B; Huang, XP; Wineland, DJ				Itano, WM; Bollinger, JJ; Tan, JN; Jelenkovic, B; Huang, XP; Wineland, DJ			Bragg diffraction from crystallized ion plasmas	SCIENCE			English	Article							ONE-COMPONENT PLASMA; MONTE-CARLO CALCULATIONS; N-DEPENDENCE; STORAGE RING; EQUATION; ENERGY; STATE	Single crystals of a one-component plasma were observed by optical Bragg diffraction, The plasmas contained 10(5) to 10(6) single-positive beryllium-9 ions ((9)Be(+)) at particle densities of 10(8) to 10(9) per cubic centimeter. In approximately spherical plasmas, single body-centered cubic (bcc) crystals or, in some cases, two or more bce crystals having fixed orientations with respect to each other were observed. In some oblate plasmas, a mixture of bce and face-centered cubic ordering was seen. Knowledge of the properties of one-component plasma crystals is required for models of white dwarfs and neutron stars, which are believed to contain matter in that form.	Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80303 USA	National Institute of Standards & Technology (NIST) - USA	Itano, WM (corresponding author), Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80303 USA.	witano@nist.gov	Jelenkovic, Brana/AAE-8831-2020; Itano, Wayne/AAV-8781-2020					ASHCROFT NW, 1976, SOLID STATE PHYS, pCH5; BIRKL G, 1992, NATURE, V357, P310, DOI 10.1038/357310a0; BOLLINGER JJ, 1984, PHYS REV LETT, V53, P348, DOI 10.1103/PhysRevLett.53.348; BOLLINGER JJ, 1994, PHYS PLASMAS, V1, P1403, DOI 10.1063/1.870690; BREWER LR, 1988, PHYS REV A, V38, P859, DOI 10.1103/PhysRevA.38.859; DAVIDSON RC, 1990, PHYSICS NONNEUTRAL P; DREWSEN M, UNPUB; DUBIN DHE, 1988, PHYS REV LETT, V60, P511, DOI 10.1103/PhysRevLett.60.511; DUBIN DHE, 1990, PHYS REV A, V42, P4972, DOI 10.1103/PhysRevA.42.4972; DUBIN DHE, 1989, PHYS REV A, V40, P1140, DOI 10.1103/PhysRevA.40.1140; DUBIN DHE, 1990, N-HOLLAND D, P189; GILBERT SL, 1988, PHYS REV LETT, V60, P2022, DOI 10.1103/PhysRevLett.60.2022; HASSE RW, 1991, PHYS REV A, V44, P4506, DOI 10.1103/PhysRevA.44.4506; Huang XP, 1998, PHYS REV LETT, V80, P73, DOI 10.1103/PhysRevLett.80.73; Huang XP, 1997, PHYS REV LETT, V78, P875, DOI 10.1103/PhysRevLett.78.875; ICHLMARU S, 1982, REV MOD PHYS, V54, P1017; MALMBERG JH, 1977, PHYS REV LETT, V39, P1333, DOI 10.1103/PhysRevLett.39.1333; OGATA S, 1987, PHYS REV A, V36, P5451, DOI 10.1103/PhysRevA.36.5451; POLLOCK EL, 1973, PHYS REV A, V8, P3110, DOI 10.1103/PhysRevA.8.3110; RAHMAN A, 1986, PHYS REV LETT, V57, P1133, DOI 10.1103/PhysRevLett.57.1133; SCHIFFER JP, 1988, PHYS REV LETT, V61, P1843, DOI 10.1103/PhysRevLett.61.1843; SCHIFFER JP, 1995, AIP C P, V331, P191; SLATTERY WL, 1982, PHYS REV A, V26, P2255, DOI 10.1103/PhysRevA.26.2255; SLATTERY WL, 1980, PHYS REV A, V21, P2087, DOI 10.1103/PhysRevA.21.2087; STRINGFELLOW GS, 1990, PHYS REV A, V41, P1105, DOI 10.1103/PhysRevA.41.1105; TAN JN, 1995, PHYS REV LETT, V75, P4198, DOI 10.1103/PhysRevLett.75.4198; TAN JN, 1996, PHYSICS STRONGLY COU, P387; TOTSUJI H, 1987, STRONGLY COUPLED PLA, P19; VANHORN HM, 1991, SCIENCE, V252, P384, DOI 10.1126/science.252.5004.384	29	180	181	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					686	689		10.1126/science.279.5351.686	http://dx.doi.org/10.1126/science.279.5351.686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445470				2022-12-28	WOS:000071731500031
J	Mukhopadhyay, CK; Attieh, ZK; Fox, PL				Mukhopadhyay, CK; Attieh, ZK; Fox, PL			Role of ceruloplasmin in cellular iron uptake	SCIENCE			English	Article							K562 CELLS; SERUM IRON; FET3 GENE; TRANSFERRIN; METABOLISM; YEAST; HEMOCHROMATOSIS; FERROXIDASE; DEFICIENCY; TRANSPORT	Individuals with hereditary ceruloplasmin (Cp) deficiency have profound iron accumulation in most tissues, which suggests that Cp is important for normal release of cellular iron. Here, in contrast to expectations, Cp was shown to increase iron uptake by HepG2 cells, increasing the apparent affinity for the substrate by three times. Consistent with its role in iron uptake, Cp synthesis was regulated by iron supply and was increased four- to fivefold after iron depletion. Unlike other iron controllers that are posttranscriptionally regulated, Cp synthesis was transcriptionally regulated. Thus, iron-deficient cells could increase Cp synthesis to maintain intracellular iron homeostasis, so that defects would lead to global accumulation of iron in tissues.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, PL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@cesmtp.ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052692, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582, HL52692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BACON BR, 1988, ANN NY ACAD SCI, V526, P155, DOI 10.1111/j.1749-6632.1988.tb55502.x; BATEY RG, 1980, DIGEST DIS SCI, V25, P340, DOI 10.1007/BF01308057; BOUMA ME, 1989, IN VITRO CELL DEV B, V25, P267; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; BRITTON RS, 1994, IRON METABOLISM HLTH, P311; BROCK JH, 1994, IRON METABOLISM HLTH, P353; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hart EB, 1928, J BIOL CHEM, V77, P796; HERSHKO C, 1978, BRIT J HAEMATOL, V40, P255, DOI 10.1111/j.1365-2141.1978.tb03662.x; Kaplan J, 1996, J CLIN INVEST, V98, P3, DOI 10.1172/JCI118772; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LOGAN JI, 1994, Q J MED, V87, P663; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; MUKHOPADHYAY C, UNPUB; OSAKI S, 1969, J BIOL CHEM, V244, P5757; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PARKES JG, 1995, BBA-GEN SUBJECTS, V1243, P373, DOI 10.1016/0304-4165(94)00162-Q; RAGAN HA, 1969, AM J PHYSIOL, V217, P1320, DOI 10.1152/ajplegacy.1969.217.5.1320; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STEIN BS, 1986, J BIOL CHEM, V261, P319; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	30	170	176	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					714	717		10.1126/science.279.5351.714	http://dx.doi.org/10.1126/science.279.5351.714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445478				2022-12-28	WOS:000071731500039
J	Roose, SP; Laghrissi-Thode, F; Kennedy, JS; Nelson, JC; Bigger, JT; Pollock, BG; Gaffney, A; Narayan, M; Finkel, MS; McCafferty, J; Gergel, I				Roose, SP; Laghrissi-Thode, F; Kennedy, JS; Nelson, JC; Bigger, JT; Pollock, BG; Gaffney, A; Narayan, M; Finkel, MS; McCafferty, J; Gergel, I			Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARRHYTHMIA SUPPRESSION TRIAL; MYOCARDIAL-INFARCTION; RATE-VARIABILITY; TRICYCLIC ANTIDEPRESSANTS; INCREASED MORTALITY; CARDIAC PATIENTS; IMIPRAMINE; ASSOCIATION; DESIPRAMINE; FLUOXETINE	Context.-Depression and ischemic heart disease often are comorbid conditions and, in patients who have had a myocardial infarction, the presence of depression is associated with increased mortality. Patients with heart disease need a safe and effective treatment for depression. Objective.-To compare the efficacy, cardiovascular effects, and safety of a specific serotonin reuptake inhibitor, paroxetine, with a tricyclic antidepressant, nortriptyline hydrochloride, in depressed patients with ischemic heart disease. Design.-Two-week placebo lead-in followed by a double-blind randomized 6-week medication trial. Setting.-Research clinics in 4 university centers. Patients.-Eighty-one outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depressive disorder and with documented ischemic heart disease. Interventions.-Treatment with either paroxetine, 20 to 30 mg/d, or nortriptyline targeted to a therapeutic plasma level, 190 to 570 nmol/L (50-150 ng/mL), for 6 weeks. Main Outcome Measures.-For effectiveness of treatment, a decline in the score of the Hamilton Rating Scale for Depression by 50% and final score of 8 or less; for cardiovascular safety, heart rate and rhythm, supine and standing systolic and diastolic blood pressures, electrocardiogram conduction intervals, indexes of heart rate variability, and rate of adverse events. Results.-By intent-to-treat analysis, 25 (61%) of 41 patients improved during treatment with paroxetine and 22 (55%) of 40 improved with nortriptyline. Neither drug significantly affected blood pressure or conduction intervals. Paroxetine had no sustained effects on heart rate or rhythm or indexes of heart rate variability, whereas patients treated with nortriptyline had a sustained 11% increase in heart rate from a mean of 75 to 83 beats per minute (P<.001) and a reduction in heart rate variability, as measured by the SD of all normal R-R intervals over a 24-hour period, from 112 to 96 (P<.01). Adverse cardiac events occurred in 1 (2%) of 41 patients treated with paroxetine and 7 (18%) of 40 patients treated with nortriptyline (P<.03). Conclusions.-Paroxetine and nortriptyline are effective treatments for depressed patients with ischemic heart disease. Nortriptyline treatment was associated with a significantly higher rate of serious adverse cardiac events compared with paroxetine.	Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Clin Cardiol, Nashville, TN 37212 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; W Virginia Univ, Sch Med, Dept Med, Cardiol Sect, Morgantown, WV 26506 USA; SmithKline Beecham Pharmaceut, Dept Clin Res & Dev, Philadelphia, PA 19103 USA	Columbia University; Columbia University; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University; Vanderbilt University; Vanderbilt University; Yale University; West Virginia University; GlaxoSmithKline	Roose, SP (corresponding author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 722 W 168th St,Unit 98, New York, NY 10032 USA.	spr2@columbia.edu						[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1990, AM J CARDIOL, V65, pD3; CARNEY RM, 1995, AM J CARDIOL, V76, P562, DOI 10.1016/S0002-9149(99)80155-6; COOPER GL, 1988, BRIT J PSYCHIAT, V153, P77, DOI 10.1192/S000712500029733X; DYER AR, 1980, AM J EPIDEMIOL, V112, P736, DOI 10.1093/oxfordjournals.aje.a113046; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FISCH C, 1985, J CLIN PSYCHIAT, V46, P42; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FREYSCHUSS U, 1970, Pharmacologia Clinica, V2, P68, DOI 10.1007/BF00420708; GIARDINA EGV, 1983, INT J CARDIOL, V2, P375, DOI 10.1016/0167-5273(83)90009-8; GIARDINA EGV, 1986, J AM COLL CARDIOL, V7, P1363, DOI 10.1016/S0735-1097(86)80158-9; GILLUM RF, 1991, AM HEART J, V121, P172, DOI 10.1016/0002-8703(91)90970-S; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; GREENBERG HM, 1995, BRIT HEART J, V74, P631; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; KANTOR SJ, 1978, AM J PSYCHIAT, V135, P534; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KUHS H, 1990, PSYCHOPHARMACOLOGY, V102, P379, DOI 10.1007/BF02244107; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROOSE SP, 1987, ARCH GEN PSYCHIAT, V44, P273; ROOSE SP, 1989, J CLIN PSYCHIAT, V50, P12; ROOSE SP, 1991, J CLIN PSYCHIAT, V52, P34; ROOSE SP, IN PRESS AM J PSYCHI; SCHROEDER JS, 1989, J AM ACAD CHILD PSY, V28, P376, DOI 10.1097/00004583-198905000-00012; The Cardiac Arrhythmia Pilot Study. The CAPS investigators, 1986, AM J CARDIOL, V57, P91; UPWARD JW, 1988, BRIT J CLIN PHARMACO, V26, P399, DOI 10.1111/j.1365-2125.1988.tb03397.x; VOHRA J, 1975, AUST NZ J MED, V5, P7, DOI 10.1111/j.1445-5994.1975.tb03247.x; WALSH BT, 1994, J AM ACAD CHILD PSY, V33, P191, DOI 10.1097/00004583-199402000-00006; WERNICKE JF, 1985, J CLIN PSYCHIAT, V46, P59; YERAGANI VK, 1992, NEUROPSYCHOBIOLOGY, V26, P27, DOI 10.1159/000118892; ZIEGLER VE, 1977, AM J PSYCHIAT, V134, P441	32	330	333	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					287	291		10.1001/jama.279.4.287	http://dx.doi.org/10.1001/jama.279.4.287			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT472	9450712	Bronze			2022-12-28	WOS:000071607000035
J	Cohen, AN; Carlton, JT				Cohen, AN; Carlton, JT			Accelerating invasion rate in a highly invaded estuary	SCIENCE			English	Article							SAN-FRANCISCO BAY; BIOLOGICAL INVASIONS; CALIFORNIA; COMPETITION; PATTERNS; INTRODUCTIONS; COMMUNITY; BENTHOS; SUCCESS; FISHES	Biological invasions are a major global environmental and economic problem. Analysis of the San Francisco Bay and Delta ecosystem revealed a large number of exotic species that dominate many habitats in terms of number of species, number of individuals and biomass, and a high and accelerating rate of invasion. These factors suggest that this may be the most invaded estuary in the world. Possible causes include a large number and variety of transport vectors, a depauperate native biota, and extensive natural and anthropogenic disturbance.	San Francisco Estuary Inst, Richmond, CA 94804 USA; Williams Coll Myst Seaport, Maritime Studies Program, Mystic, CT 06355 USA	Williams College	Cohen, AN (corresponding author), San Francisco Estuary Inst, 1325 S 46 St, Richmond, CA 94804 USA.		Ross, Donald J/F-7607-2012	Ross, Donald J/0000-0002-8659-3833				Aldrich F. A., 1961, P ACAD NAT SCI PHILA, V113, P21; [Anonymous], 1976, TIME SERIES ANAL; Arthington A.H., 1986, P34; ARTHINGTON AH, 1991, CAN J FISH AQUAT SCI, V48, P33, DOI 10.1139/f91-302; Boudouresque Charles F., 1994, P8; BROOKE RK, 1995, OECOLOGIA, V103, P337, DOI 10.1007/BF00328622; Bruton M.N., 1986, P47; Carlton James T., 1997, P187; Carlton JT, 1996, ECOLOGY, V77, P1653, DOI 10.2307/2265767; CARLTON JT, 1989, CONSERV BIOL, V3, P265, DOI 10.1111/j.1523-1739.1989.tb00086.x; CARLTON JT, 1979, HIST BIOGEOGRAPHY EC; CASE TJ, 1990, P NATL ACAD SCI USA, V87, P9610, DOI 10.1073/pnas.87.24.9610; COHEN AN, 1996, THESIS U CALIFORNIA; Cohen Andrew N., 1995, NONINDIGENOUS AQUATI; Conomos T. J., 1979, SAN FRANCISCO BAY UR, P47; Courtenay W.R. Jr, 1986, P675; Duncan RP, 1997, AM NAT, V149, P903, DOI 10.1086/286029; Elton C. S., 1958, ECOLOGY INVASIONS; Eno NC, 1996, AQUAT CONSERV, V6, P215, DOI 10.1002/(SICI)1099-0755(199612)6:4<215::AID-AQC191>3.0.CO;2-Q; FILICE FP, 1959, WASMANN J BIOL, V16, P159; FURLANI DM, 1996, 5 COMM SCI IN RES OR; GRAHAM HW, 1945, ECOLOGY, V26, P375, DOI 10.2307/1931659; Hall R.W., 1979, Bulletin of the Entomological Society of America, V25, P280; HEDGPETH JW, 1968, PACIRFIC TIDES, P231; HERBOLD B, 1989, 85722 US FISH WILDL; Hess L, UNPUB; HUTCHINGS PA, 1987, OCCASIONAL REPORTS A, V3, P1; HYMANSON Z, 1994, 38 CAL DEP WAT RES I; JANSSON K, 1994, 4357 SWED ENV PROT A; Jones L. L., 1940, Proceedings 6th Pacific Science Congress, V3, P485; LEIDY RA, 1985, BIOL CONSERV, V33, P247, DOI 10.1016/0006-3207(85)90016-3; LEPPAKOSKI E, 1993, NONINDIGENOUS ESTUAR, P37; LODGE DM, 1993, TRENDS ECOL EVOL, V8, P133, DOI 10.1016/0169-5347(93)90025-K; Loope LL, 1989, BIOL INVASIONS GLOBA, P257; *MADR ASS, 1977, NAT RES NAP MARSH; MARKMANN C, 1986, 12 CAL DEP WAT RES I; Mayr E., 1965, GENETICS COLONIZING; McCann J.A., 1996, NONINDIGENOUS AQUATI; MENG L, 1994, T AM FISH SOC, V123, P498, DOI 10.1577/1548-8659(1994)123<0498:CIAADO>2.3.CO;2; Mills EL, 1996, ESTUARIES, V19, P814, DOI 10.2307/1352299; MILLS EL, 1993, J GREAT LAKES RES, V19, P1, DOI 10.1016/S0380-1330(93)71197-1; MOULTON MP, 1993, AM NAT, V141, P105, DOI 10.1086/285463; Moyle P.B., 1986, Ecological Studies, P27; MOYLE P B, 1976, Biological Conservation, V9, P101, DOI 10.1016/0006-3207(76)90043-4; Moyle PB, 1996, ECOLOGY, V77, P1666, DOI 10.2307/2265770; Nalepa T, 1993, ZEBRA MUSSELS BIOL I; NICHOLS FH, 1985, HYDROBIOLOGIA, V129, P121, DOI 10.1007/BF00048691; NICHOLS FH, 1990, MAR ECOL PROG SER, V66, P95, DOI 10.3354/meps066095; NICHOLS FH, 1985, MAR ECOL PROG SER, V24, P83, DOI 10.3354/meps024083; Nichols FH, 1977, ECOLOGY MARINE BENTH, P339; Pimm SL, 1989, BIOL INVASIONS GLOBA, P351; Pollard D.A., 1990, Asian Fisheries Science, V3, P205; Pollard D.A., 1990, Asian Fisheries Science, V3, P223; Ribera M.A., 1995, PROGR PHYCOLOGICAL R, V11, P187; SIEGFRIED CA, 1980, ESTUARIES, V3, P296, DOI 10.2307/1352085; SIMBERLOFF D, 1991, AM NAT, V138, P300, DOI 10.1086/285219; Simberloff D., 1986, Ecological Studies, P3; Simberloff Daniel, 1995, Pacific Science, V49, P87; TRAVIS J, 1993, SCIENCE, V262, P1366, DOI 10.1126/science.262.5138.1366; U.S. Congress O.T.A., 1993, HARMF NON SPEC US; VASSALLO M T, 1969, Veliger, V11, P223; WALDICHUK M, 1996, BIODIVERSITY BRIT CO, P220; WALFORD L, 1973, 121 FAO; WELCOMME RL, 1981, 213 FAO; Zaitsev Y.P., 1997, MARINE BIOL DIVERSIT; Zibrowius Helmut, 1991, Mesogee, V51, P83	66	827	886	5	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					555	558		10.1126/science.279.5350.555	http://dx.doi.org/10.1126/science.279.5350.555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438847				2022-12-28	WOS:000071616000044
J	Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Tunio, GM; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y				Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Tunio, GM; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y			Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; LIGAND-INDEPENDENT ACTIVATION; HUMAN SMALL-INTESTINE; INTERSTITIAL-CELLS; BONE-MARROW; MAST-CELLS; W-LOCUS; CONSTITUTIVE ACTIVATION; POSSIBLE INVOLVEMENT; SUBMUCOSAL BORDER	Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their molecular etiology and cellular origin are unknown. Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains. All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF). Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development. GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Div Pathol, Osaka, Japan; Osaka Rosai Hosp, Div Pathol, Sakai, Osaka, Japan; Toyonaka Municipal Hosp, Div Pathol, Toyonaka, Osaka, Japan; Osaka Natl Hosp, Div Pathol, Osaka, Japan; Osaka Univ, Sch Med, Dept Hematol Oncol, Suita, Osaka 565, Japan	Osaka University; Osaka University; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Rosai Hospital; Osaka National Hospital; Osaka University	Kitamura, Y (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Yamada Oka 2-2, Suita, Osaka 565, Japan.	kitamura@patho.med.osaka-u.ac.jp						ASHMAN LK, 1991, BLOOD, V78, P30; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CATLETT JP, 1991, BLOOD, V78, P3186; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FAUSSONEPELLEGRINI MS, 1990, CAN J PHYSIOL PHARM, V68, P1437, DOI 10.1139/y90-218; FAUSSONEPELLEGRINI MS, 1989, J SUBMICR CYTOL PATH, V21, P439; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HIROTA S, 1995, LAB INVEST, V72, P64; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; ISOZAKI K, 1995, GASTROENTEROLOGY, V109, P456, DOI 10.1016/0016-5085(95)90333-X; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MAEDA H, 1992, DEVELOPMENT, V116, P369; MATSUDA R, 1993, AM J PATHOL, V142, P339; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; MONIHAN JM, 1994, HISTOPATHOLOGY, V25, P469, DOI 10.1111/j.1365-2559.1994.tb00009.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; RUMESSEN JJ, 1993, GASTROENTEROLOGY, V104, P343, DOI 10.1016/0016-5085(93)90400-7; RUMESSEN JJ, 1993, LAB INVEST, V68, P481; RUMESSEN JJ, 1992, GASTROENTEROLOGY, V102, P56, DOI 10.1016/0016-5085(92)91784-2; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; Tsujimura T, 1996, BLOOD, V87, P273; VANDERIJN M, 1994, HUM PATHOL, V25, P776; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P279, DOI 10.1053/gast.1996.v111.pm8690192; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	3250	3549	3	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					577	580		10.1126/science.279.5350.577	http://dx.doi.org/10.1126/science.279.5350.577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438854				2022-12-28	WOS:000071616000051
J	Evans, RS; Pestotnik, SL; Classen, DC; Clemmer, TP; Weaver, LK; Orme, JF; Lloyd, JF; Burke, JP				Evans, RS; Pestotnik, SL; Classen, DC; Clemmer, TP; Weaver, LK; Orme, JF; Lloyd, JF; Burke, JP			A computer-assisted management program for antibiotics and other antiinfective agents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; QUALITY; SURVEILLANCE; SEVERITY; ILLNESS; SYSTEM; COSTS	Background and Methods Optimal decisions about the use of antibiotics and other antiinfective agents in critically ill patients require access to a large amount of complex information. We have developed a computerized decision-support program linked to computer-based patient records that can assist physicians in the use of antiinfective agents and improve the quality of care. This program presents epidemiologic information, along with detailed recommendations and warnings. The program recommends antiinfective regimens and courses of therapy for particular patients and provides immediate feedback. We prospectively studied the use of the computerized antiinfectives-management program for one year in a 12-bed intensive care unit. Results During the intervention period, all 545 patients admitted were cared for with the aid of the antiinfectives-management program. Measures of processes and outcomes were compared with those for the 1136 patients admitted to the same unit during the two years before the intervention period. The use of the program led to significant reductions in orders for drugs to which the patients had reported allergies (35, vs. 146 during the preintervention period; P<0.01), excess drug dosages (87 vs. 405, P<0.01), and antibiotic-susceptibility mismatches (12 vs. 206, P<0.01). There were also marked reductions in the mean number of days of excessive drug dosage (2.7 vs. 5.9, P<0.002) and in adverse events caused by antiinfective agents (4 vs. 28, P<0.02). In analyses of patients who received antiinfective agents, those treated during the intervention period who always received the regimens recommended by the computer program (n=203) had significant reductions, as compared with those who did not always receive the recommended regimens (n=195) and those in the preintervention cohort (n=766), in the cost of an tiinfective agents (adjusted mean, $102 vs. $427 and $340, respectively; P<0.001), in total hospital costs (adjusted mean, $26,315 vs. $44,865 and $35,283; P<0.001), and in the length of the hospital stay (adjusted mean, 10.0 vs. 16.7 and 12.9 days; P<0.001). Conclusions A computerized antiinfectives-management program can improve the quality of patient care and reduce costs. (C) 1998, Massachusetts Medical Society.	Latter Day St Hosp, Dept Clin Epidemiol, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Crit Care, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Med Informat, Salt Lake City, UT 84143 USA		Evans, RS (corresponding author), Latter Day St Hosp, Dept Clin Epidemiol, 8th Ave & C St, Salt Lake City, UT 84143 USA.							Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Burke JP, 1996, CURR OPIN INFECT DIS, V9, P253, DOI 10.1097/00001432-199608000-00008; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CLASSEN DC, 1992, JAMA-J AM MED ASSOC, V267, P1922; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans R S, 1995, Proc Annu Symp Comput Appl Med Care, P651; EVANS RS, 1993, M D COMPUT, V10, P17; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; EVANS RS, 1992, 15 ANN S COMP APPL M, P23; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; HULSE RK, 1976, AM J HOSP PHARM, V33, P1061, DOI 10.1093/ajhp/33.10.1061; Iezzoni LI, 1997, ANN INTERN MED, V126, P588, DOI 10.7326/0003-4819-126-5-199703010-00009; Iezzoni LI, 1997, ANN INTERN MED, V126, P391, DOI 10.7326/0003-4819-126-5-199703010-00009; Logan RL, 1996, LANCET, V347, P595, DOI 10.1016/S0140-6736(96)91284-2; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MAXWELL M, 1993, BRIT MED J, V307, P1470; McDonald CJ, 1996, ANN INTERN MED, V124, P170, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00018; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; STOLLEY PD, 1969, J CHRON DIS, V22, P395, DOI 10.1016/0021-9681(69)90003-4; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39	28	792	812	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					232	238		10.1056/NEJM199801223380406	http://dx.doi.org/10.1056/NEJM199801223380406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435330				2022-12-28	WOS:000071594100006
J	Geissler, PE; Greenberg, R; Hoppa, G; Helfenstein, P; McEwen, A; Pappalardo, R; Tufts, R; Ockert-Bell, M; Sullivan, R; Greeley, R; Belton, MJS; Denk, T; Clark, B; Burns, J; Veverka, J				Geissler, PE; Greenberg, R; Hoppa, G; Helfenstein, P; McEwen, A; Pappalardo, R; Tufts, R; Ockert-Bell, M; Sullivan, R; Greeley, R; Belton, MJS; Denk, T; Clark, B; Burns, J; Veverka, J		Galileo Imaging Team	Evidence for non-synchronous rotation of Europa	NATURE			English	Article							ICE SHELL; GALILEAN SATELLITES; POLAR WANDER	Non-synchronous rotation of Europa was predicted on theoretical grounds(1), by considering the orbitally averaged torque exerted by Jupiter on the satellite's tidal bulges, If Europa's orbit were circular, or the satellite were comprised of a frictionless fluid without tidal dissipation, this torque would average to zero. However, Europa has a small forced eccentricity e approximate to 0.01 (ref. 2), generated by its dynamical interaction with Io and Ganymede, which should cause the equilibrium spin rate of the satellite to be slightly faster than synchronous, Recent gravity data(3) suggest that there may be a permanent asymmetry in Europa's interior mass distribution which is large enough to offset the tidal torque; hence, if non-synchronous rotation is observed, the surface is probably decoupled from the interior by a subsurface layer of liquid(4) or ductile ice(1), Non-synchronous rotation was invoked to explain Europa's global system of lineaments and an equatorial region of rifting seen in Voyager images(5,6). Here we report an analysis of the orientation and distribution of these surface features, based on initial observations made by the Galileo spacecraft. We find evidence that Europa spins faster than the synchronous rate (or did so in the past), consistent with the possibility of a global subsurface ocean.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85712 USA; Cornell Univ, Lab Planetary Sci, Ithaca, NY 14853 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; DLR, Inst Planetary Explorat, D-12489 Berlin, Germany	University of Arizona; Cornell University; Brown University; National Optical Astronomy Observatory; Arizona State University; Arizona State University-Tempe; Helmholtz Association; German Aerospace Centre (DLR)	Geissler, PE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85712 USA.	geissler@pirl.lpl.arizona.edu	Sullivan, Robert/AAR-8193-2020; Pappalardo, Robert/AAP-8953-2021	Pappalardo, Robert/0000-0003-2571-4627				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BURNS JA, 1986, SATELLITES, pCH1; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; GREENBERG R, 1984, ICARUS, V58, P186, DOI 10.1016/0019-1035(84)90038-1; GREENBERG R, 1997, LUN PLAN SCI C ABSTR, V28, P457; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; HOPPA GV, 1997, LUNAR PLANET SCI, V28, P597; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; LUCCHITTA BK, 1982, SATELLITES JUPITER, pCH14; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PIERI DC, 1981, NATURE, V289, P17, DOI 10.1038/289017a0; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SULLIVAN R, 1997, LUNAR PLANET SCI, V28, P1395	17	89	93	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					368	370		10.1038/34869	http://dx.doi.org/10.1038/34869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450751				2022-12-28	WOS:000071604200047
J	Jull, AJT; Courtney, C; Jeffrey, DA; Beck, JW				Jull, AJT; Courtney, C; Jeffrey, DA; Beck, JW			Isotopic evidence for a terrestrial source of organic compounds found in martian meteorites Allan Hills 84001 and Elephant Moraine 79001	SCIENCE			English	Article							ACCELERATOR MASS-SPECTROMETRY; SNC METEORITES; WEATHERING PRODUCTS; ALH 84001; CARBON; EETA-79001; MARS; ALH84001; NITROGEN; OXYGEN	Stepped-heating experiments on martian meteorites Allan Hills 84001 (ALH84001) and Elephant Moraine 79001 (EETA79001) revealed low-temperature (200 to 430 degrees Celsius) fractions with a carbon isotopic composition delta(13)C between -22 and -33 per mil and a carbon-14 content that is 40 to 60 percent of that of modern terrestrial carbon, consistent with a terrestrial origin for most of the organic material. Intermediate-temperature (400 to 600 degrees Celsius) carbonate-rich fractions of ALH84001 have delta(13)C of +32 to 140 per mil with a low carbon-14 content, consistent with an extraterrestrial origin, whereas some of the carbonate fraction of EETA79001 is terrestrial, In addition, ALH84001 contains a small preterrestrial carbon component of unknown origin that combusts at intermediate temperatures. This component is likely a residual acid-insoluble carbonate or a more refractory organic phase.	Univ Arizona, Natl Sci Fdn, Arizona Accelerator Mass Spect Facil, Tucson, AZ 85721 USA	National Science Foundation (NSF); University of Arizona	Jull, AJT (corresponding author), Univ Arizona, Natl Sci Fdn, Arizona Accelerator Mass Spect Facil, Tucson, AZ 85721 USA.							Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; Bada JL, 1998, SCIENCE, V279, P362, DOI 10.1126/science.279.5349.362; Becker L, 1997, GEOCHIM COSMOCHIM AC, V61, P475, DOI 10.1016/S0016-7037(96)00400-0; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; DONAHUE DJ, 1990, RADIOCARBON, V32, P135, DOI 10.1017/S0033822200040121; DONAHUE DJ, 1995, INT J MASS SPECTROM, V143, P235, DOI 10.1016/0168-1176(94)04132-Q; Friedman I., 1977, DATA GEOCHEMISTRY; Garrison DH, 1997, METEORIT PLANET SCI, V32, pA45; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; GRADY MM, 1994, METEORITICS, V29, P469; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HUTCHINS KS, 1997, THESIS U COLORADO; JAGOUTZ E, 1994, METEORITICS, V29, P478; JULL AJT, 1989, GEOCHIM COSMOCHIM AC, V53, P2095, DOI 10.1016/0016-7037(89)90327-X; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; JULL AJT, 1988, GEOCHIM COSMOCHIM AC, V52, P1309, DOI 10.1016/0016-7037(88)90285-2; LEVIN I, 1985, RADIOCARBON, V27, P1, DOI 10.1017/S0033822200006895; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; Neupert U, 1997, METEORIT PLANET SCI, V32, pA98; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SLOTA PJ, 1987, RADIOCARBON, V29, P303; SPERGEL MS, 1986, J GEOPHYS RES-SOLID, V91, pD483, DOI 10.1029/JB091iB04p0D483; Taylor RE, 1987, RADIOCARBON DATING A; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; WRIGHT IP, 1988, GEOCHIM COSMOCHIM AC, V52, P917, DOI 10.1016/0016-7037(88)90362-6; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W; WRIGHT IP, 1997, LUNAR PLANET SCI, V28, P1591; [No title captured]	35	119	125	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					366	369		10.1126/science.279.5349.366	http://dx.doi.org/10.1126/science.279.5349.366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430584				2022-12-28	WOS:000071570800042
J	Cnattingius, S; Bergstrom, R; Lipworth, L; Kramer, MS				Cnattingius, S; Bergstrom, R; Lipworth, L; Kramer, MS			Prepregnancy weight and the risk of adverse pregnancy outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; PRETERM BIRTH; WOMEN; PREECLAMPSIA; GAIN; STILLBIRTH; PREVALENCE; NUTRITION; INFANTS	Background Obesity before pregnancy is associated with an increased risk of several adverse outcomes of pregnancy. The risk profiles among lean, normal, or mildly overweight women are not, however, well established. Methods We studied the associations between prepregnancy body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and the frequency of late fetal death, early neonatal death, preterm delivery, and delivery of a small-for-gestational-age infant in a population-based cohort of 167,750 women in Sweden in 1992 and 1993. The women were categorized as follows, according to body-mass index: lean, less than 20.0; normal, 20.0 through 24.9; overweight, 25.0 through 29.9; and obese, 30.0 or more. The estimates were adjusted for maternal age, parity, smoking, educa tion, whether the mother was living with the father, and maternal height. Results Among nulliparous women, the odds ratios for late fetal death were increased among women with higher body-mass indexes as compared with lean women, as follows: normal women, 2.2 (95 percent confidence interval, 1.2 to 4.1); overweight women, 3.2 (95 percent confidence interval, 1.6 to 6.2); and obese women, 4.3 (95 percent confidence interval, 2.0 to 9.3). Among parous women, only obese women had a significant increase in the risk of late fetal death (odds ratio, 2.0; 95 percent confidence interval, 1.2 to 3.3). Among nulliparous women, the risk of very preterm delivery (at less than or equal to 32 weeks' gestation) was significantly increased among obese as compared with lean women (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3), whereas among parous women, the risk was highest among those who were lean. The risk of delivering a small-for-gestational-age infant decreased more with increasing body-mass index among parous than among nulliparous women. Conclusions Higher maternal weight before pregnancy increases the risk of late fetal death, although it protects against the delivery of a small-for-gestational-age infant. (C) 1998, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Uppsala Univ, Dept Stat, S-75105 Uppsala, Sweden; Mt Sinai Sch Med, Dept Community Med, New York, NY USA; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; McGill Univ, Fac Med, Dept Biostat & Epidemiol, Montreal, PQ, Canada	Karolinska Institutet; Uppsala University; Icahn School of Medicine at Mount Sinai; McGill University; McGill University	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; ESKENAZI, 1995, AM J OBSTET GYNECOL, V173, P950; ESKENAZI B, 1993, AM J OBSTET GYNECOL, V169, P1112, DOI 10.1016/0002-9378(93)90265-K; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; GLEICHER N, 1986, AM J OBSTET GYNECOL, V154, P1044, DOI 10.1016/0002-9378(86)90747-7; *I MED, 1992, NUTR PREGN LACT IMPL; Institute of Medicine (Subcommittees on Nutritional Status and Weight Gain During Pregnancy and Dietary Intake and Nutrient Supplements During Pregnancy Committee on Nutritional Status During Pregnancy and Lactation Food and Nutrition Board), 1990, NUTR PREGN 1; KAMINSKI M, 1973, INT J EPIDEMIOL, V2, P195, DOI 10.1093/ije/2.2.195; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRASOVEC K, 1991, B WORLD HEALTH ORGAN, V69, P523; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P195, DOI 10.1136/jech.47.3.195; *LIB ALLM FORL, 1986, SWED VERS INT CLASS; LITTLE RE, 1993, AM J EPIDEMIOL, V137, P1177, DOI 10.1093/oxfordjournals.aje.a116620; LUCAS A, 1988, BRIT MED J, V296, P1495, DOI 10.1136/bmj.296.6635.1495; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; MITCHELL MC, 1989, J AM DIET ASSOC, V89, P634; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; NAEYE RL, 1979, AM J OBSTET GYNECOL, V135, P3; RANTAKALLIO P, 1995, J CLIN EPIDEMIOL, V48, P199, DOI 10.1016/0895-4356(94)00130-I; RYDHSTROM H, 1994, ACTA OBSTET GYN SCAN, V73, P779, DOI 10.3109/00016349409072504; SKODOVA Z, 1991, Cor et Vasa, V33, P114; STEIN ZA, 1984, SEMIN PERINATOL, V8, P5; STONE JL, 1994, OBSTET GYNECOL, V83, P357; WOLFE HM, 1991, AM J OBSTET GYNECOL, V164, P1306, DOI 10.1016/0002-9378(91)90705-V; WYNN A H A, 1991, Nutrition and Health (Bicester), V7, P69	31	748	767	0	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					147	152		10.1056/NEJM199801153380302	http://dx.doi.org/10.1056/NEJM199801153380302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428815	Bronze			2022-12-28	WOS:000071384500002
J	Goldin-Meadow, S; Mylander, C				Goldin-Meadow, S; Mylander, C			Spontaneous sign systems created by deaf children in two cultures	NATURE			English	Article							GESTURAL COMMUNICATION; LANGUAGE-DEVELOPMENT; PARENTAL INPUT	Deaf children whose access to usable conventional linguistic input, signed or spoken, is severely limited nevertheless use gesture to communicate(1-3). These gestures resemble natural language in that they are structured at the level both of sentence(4) and of word(5). Although the inclination Ito use gesture maybe traceable to the fact that the deaf children's]tearing parents, like all speakers, gesture as they talk(6), the children themselves are responsible for introducing language-like structure into their gestures(7). We have explored the robustness of this phenomenon by observing deaf children of hearing parents in two cultures, an American and a Chinese culture, that differ in their child-rearing practices(8-12) and in the way gesture is used in relation to speech(13). The spontaneous sign systems developed in these cultures shared a number of structural similarities: patterned production and deletion of semantic elements ii the surface structure of a sentence; patterned ordering of those elements within the sentence; and concatenation of propositions within a sentence. These striking similarities offer critical empirical input towards resolving the ongoing debate about the 'innateness' of language in human infants(14-16).	Univ Chicago, Dept Psychol, Chicago, IL 60637 USA	University of Chicago	Goldin-Meadow, S (corresponding author), Univ Chicago, Dept Psychol, 5730 S Woodlawn Ave, Chicago, IL 60637 USA.		Galantucci, Bruno/E-5770-2010					CHEN CS, 1988, HUM DEV, V31, P351, DOI 10.1159/000276334; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; Dixon R. M. W., 1994, ERGATIVITY; Dixon R. M. W., 1976, GRAMMATICAL CATEGORI, P112; Fant L. J., 1972, AMESLAN; FEYEREISEN P, 1991, GESTURE SPEECH; GLEITMAN L, 1995, LANGUAGE INVITATION, V1, P1; Goldin-Meadow S., 1996, INT J PRIMATOL, V17, P145; GOLDINMEADOW S, 1994, COGNITIVE PSYCHOL, V27, P259, DOI 10.1006/cogp.1994.1018; GOLDINMEADOW S, 1995, COGNITION, V56, P195, DOI 10.1016/0010-0277(95)00662-I; GOLDINMEADOW S, 1983, SCIENCE, V221, P372, DOI 10.1126/science.6867713; GOLDINMEADOW S, 1984, MONOGR SOC RES CHILD, V49, P1, DOI 10.2307/1165838; GOLDINMEADOW S, 1977, SCIENCE, V197, P401, DOI 10.1126/science.877567; McNeill D., 1992, HAND MIND WHAT HANDS; MCNEILL D, UNPUB LANGUAGE GESTU; Miller PJ, 1997, CHILD DEV, V68, P557, DOI 10.2307/1131678; MOORES DF, 1974, LANGUAGE PERSPECTIVE, P377; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; Pinker S, 1995, LANGUAGE INSTINCT; SIEGEL S., 1956, NONPARAMETRIC STAT B; Stevenson H W, 1990, Monogr Soc Res Child Dev, V55, P1; TERVOORT BT, 1961, AM ANN DEAF, V106, P436; Wang X.-L., 1996, RES FAMILY RESOURCES, P363; Wimsatt W.C., 1986, INTEGRATING SCI DISC, P185, DOI 10.1007/978-94-010-9435-1_11; YOUNG NF, 1972, AMERASIA J, V1, P31; Zar JH., 1999, BIOSTAT ANAL	26	175	176	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					279	281		10.1038/34646	http://dx.doi.org/10.1038/34646			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YR328	9440690				2022-12-28	WOS:000071484400049
J	Grady, TA; Chiu, AC; Snader, CE; Marwick, TH; Thomas, JD; Pashkow, FJ; Lauer, MS				Grady, TA; Chiu, AC; Snader, CE; Marwick, TH; Thomas, JD; Pashkow, FJ; Lauer, MS			Prognostic significance of exercise-induced left bundle-branch block	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; CLINICAL-SIGNIFICANCE; HEART-DISEASE	Context.-Approximately 0.5% of all patients who undergo exercise testing develop a transient left bundle-branch block (LBBB) during exercise, but its prognostic significance is unclear. Objective.-To determine whether exercise-induced LBBB is an independent predictor of mortality and cardiac morbidity. Design.-Matched control cohort study. Between September 1990 and February 10, 1994, 17 277 exercise stress tests were performed on patients. Setting.-Tertiary care, academic medical center. Patients.-From the cohort, 70 cases of exercise-induced LBBB were identified. The controls comprised 70 individuals without LBBB at rest or during exercise that matched the 70 cases based on age, test date, sex, prior history of coronary artery disease, hypertension, diabetes, smoking, and beta-blocker use. Main Outcome Measures.-All-cause mortality, percutaneous coronary intervention, open heart surgery, nonfatal myocardial infarction, documented symptomatic or sustained ventricular tachydysrhythmia, or implantation of a permanent pacemaker or an implantable cardiac defibrillator. Results.-A total of 37 events (28 events from the exercise-induced LBBB cases and 9 from the control cohort) occurred in 25 patients (17 exercise-induced LBBB patients and 8 control patients) during a mean follow-up period of 3.7 (0.9 years) (median, 3.8 years [range, 0.9-5.2 years]). There were 7 deaths, of which 5 occurred among patients with exercise-induced LBBB. Four-year Kaplan-Meier event rates were 19% among exercise-induced LBBB patients and 10% among controls (log-rank chi(2), 5.2; P=.02). After further adjusting for small differences in age, exercise-induced LBBB remained associated with a higher risk of primary events (adjusted relative risk, 2.78; 95% confidence interval, 1.16-6.65; P=.02). Conclusion.-Exercise-induced LBBB independently predicts a higher risk of death and major cardiac events.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, George M & Linda H Kaufman Ctr Heart Failure, Desk F-25, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013; Marwick, Thomas H/C-7261-2013	Lauer, Michael S/0000-0002-9217-8177; Marwick, Thomas H/0000-0001-9065-0899				[Anonymous], STRESS TESTING PRINC; BOUNHOURE J, 1991, ARCH MAL COEUR VAISS, V842, P167; BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; CHAPMAN JH, 1977, CHEST, V71, P776, DOI 10.1378/chest.71.6.776; CHOU T, 1995, ELECTROCARDIOGRAPHY, P939; COX DR, 1972, J R STAT SOC B, V34, P187; *CRIT COMM NEW YOR, 1994, NOM CRIT DIAGN DIS H, P210; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GIBBONS R, 1997, AM J CARDIOL, V30, P260; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAND M, 1988, AM HEART J, V118, P23; HEINSIMER JA, 1987, AM J CARDIOL, V60, P1065, DOI 10.1016/0002-9149(87)90353-5; HERTZEANU H, 1992, EUR HEART J, V13, P1447, DOI 10.1093/oxfordjournals.eurheartj.a060084; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; KAFKA H, 1984, AM J CARDIOL, V54, P676, DOI 10.1016/0002-9149(84)90276-5; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MORAN JF, 1992, J ELECTROCARDIOL, V3, P229; *SAS INC, 1996, SAS STAT SOFTW CHANG, P835; SCHNEIDER JF, 1979, ANN INTERN MED, V90, P303, DOI 10.7326/0003-4819-90-3-303; VASEY C, 1985, AM J CARDIOL, V56, P892, DOI 10.1016/0002-9149(85)90777-5; VIEWEG WVR, 1976, CHEST, V69, P123, DOI 10.1378/chest.69.1.123; VIRTANEN KS, 1982, CHEST, V81, P326, DOI 10.1378/chest.81.3.326; WAYNE V, 1993, AM J CARDIOLF, V52, P283; WILLIAMS MA, 1988, AM J CARDIOL, V61, P346, DOI 10.1016/0002-9149(88)90942-3	24	58	72	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					153	156		10.1001/jama.279.2.153	http://dx.doi.org/10.1001/jama.279.2.153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440667	Bronze			2022-12-28	WOS:000071338900034
J	Relman, AS; Lundberg, GD				Relman, AS; Lundberg, GD			Business and professionalism in medicine at the American Medical Association	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		LUNDBERG GD, 1997, JAMA-J AM MED ASSOC, V278, P1703	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					169	170		10.1001/jama.279.2.169	http://dx.doi.org/10.1001/jama.279.2.169			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440671				2022-12-28	WOS:000071338900038
J	Robinson, JC				Robinson, JC			Consolidation of medical groups into physician practice management organizations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; ARRANGEMENTS; CAPITATION; CALIFORNIA; GROWTH	Context.-Medical groups are growing and merging to improve efficiency and bargaining leverage in the competitive managed care environment. An increasing number are affiliating with physician practice management (PPM) firms that offer capital financing, expertise in utilization management, and global capitation contracts with health insurance entities. These physician organizations provide an alternative to affiliation with a hospital system and to individual physician contracting with health plans. Objective.-To describe the growth, structure, and strategy of PPM organizations that coordinate medical groups in multiple markets and contract with health maintenance organizations (HMOs). Design.-Case studies, including interviews with administrative and clinical leaders, review of company documents, and analysis of documents from investment bankers, the Securities and Exchange Commission, and industry observers. Setting.-Medical groups and independent practice associations (IPAs) in California and New Jersey affiliated with MedPartners, FPA Medical Management, and UniMed. Outcome Measures.-Growth in number of primary care and specialty care physicians employed by and contracting with affiliated medical groups; growth in patient enrollment from commercial, Medicare, and Medicaid HMOs; growth in capitation and noncapitation revenues; structure and governance of affiliated management service organizations and professional corporations; and contracting strategies with HMOs. Results.-Between 1994 and 1996, medical groups and IPAs affiliated with 3 PPMs grew from 3787 to 25 763 physicians; 65% of employed physicians provide primary care, while the majority of contracting physicians provide specialty care. Patient enrollment in HMOs grew from 285 503 to 3 028 881. Annual capitation revenues grew from $190 million to $2.1 billion, Medical groups affiliated with PPMs are capitated for most professional, hospital, and ancillary clinical services and are increasingly delegated responsibility by HMOs for utilization management and quality assurance. Comment.-Physician practice management organizations and their affiliated medical groups face the challenge of continuing rapid growth, sustaining stock values, and improving practice efficiencies while maintaining the loyalty of physicians and patients.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Robinson, JC (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.	jamie@uclink4.berkeley.edu						Burns L R, 1993, Health Care Manage Rev, V18, P7; CAIN JE, 1996, BEST BREEDS COMP ALT; *FPA MED MAN, 1995, PROSP COMM STOCK; *FPA MED MAN, 1996, VAL HLTH 1995 ANN RE; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; HEWITT CL, 1996, PHYSICIAN PRACTICE M; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; JENSEN MC, 1989, HARVARD BUS REV, V67, P61, DOI 10.2139/ssrn.146149; KERMS EH, 1996, PHYSICIAN PRACTICE M; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; KROLL EE, 1996, FPA MED MANAGEMENT; LAUDAN KR, 1996, PHYSICIAN PRACTICE M; MARSCH LC, 1995, PHYSICIAN MED MANAGE; *MED, 1997, NAT IN SURV HOSP SPO; *MEDP, 1996, PROSP COMM STOCK; *MEDP MULL, 1996, 1995 ANN REP; Morrisey MA, 1996, HEALTH AFFAIR, V15, P62, DOI 10.1377/hlthaff.15.4.62; ONEIL BG, 1996, MEDPARTNERS; ONEIL BG, 1995, PHYSICIAN PRATICE MA; Robinson JC, 1997, MED CARE RES REV, V54, P3, DOI 10.1177/107755879705400101; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; Robinson JC, 1996, HEALTH AFFAIR, V15, P155, DOI 10.1377/hlthaff.15.2.155; ROSENBLUTH J, 1993, GROUP PRACTICE MANAG; RUNDLE RL, 1997, WALL STREET J   0703, pB6; SCHENKIN B, 1995, JAMA-J AM MED ASSOC, V273, P1937; SHORTELL SM, 1995, MILBANK Q, V73, P131, DOI 10.2307/3350254; SHORTELL SM, 1994, HEALTH AFFAIR, V13, P46, DOI 10.1377/hlthaff.13.5.46; *UN, 1996, REP COMM 1995; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WIBERG E, 1996, FPA MED MANAGEMENT I; WILSON GL, 1996, FPA MED MANAGEMENT I	33	41	41	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					144	149		10.1001/jama.279.2.144	http://dx.doi.org/10.1001/jama.279.2.144			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ015	9440665	Green Published			2022-12-28	WOS:000071338900032
J	Middeldorp, S; Henkens, CMA; Koopman, MMW; van Pampus, ECM; Hamulyak, K; van der Meer, J; Prins, MH; Buller, HR				Middeldorp, S; Henkens, CMA; Koopman, MMW; van Pampus, ECM; Hamulyak, K; van der Meer, J; Prins, MH; Buller, HR			The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; thromboembolism; heterozygote; mutation; factor	ACTIVATED PROTEIN-C; DEEP-VEIN THROMBOSIS; COAGULATION-FACTOR-V; RESISTANCE; OUTPATIENTS; POPULATION; DEFICIENCY; PREGNANCY; THERAPY; WOMEN	Background: The factor V Leiden mutation is a genetic defect associated with an increased incidence of Venous thromboembolism. When the incidence of venous thromboembolism in relatives of patients known to have the mutation outweighs the disadvantages of prophylactic strategies, family screening may be necessary. Objective: To determine the incidence of venous thromboembolism in first-degree relatives of symptomatic carriers of the factor V Leiden mutation. Design: Retrospective blinded study. Setting: University hospitals. Participants: 437 first-degree relatives of 112 heterozygous propositi and 30 relatives of 6 homozygous propositi. Measurements: Before DNA testing, information on previous venous thromboembolism and concomitant risk factors was obtained. Relatives with and without the FV: Q(506) mutation were compared. Results: The annual incidence of thromboembolism in relatives of heterozygous propositi was 0.45% (95% CI, 0.28% to 0.61%) in those with the mutation and 0.10% (CI, 0.02% to 0.19%) in those without the mutation (relative risk, 4.2 [CI, 1.8 to 9.9]). Among carriers, the incidence increased from 0.25% (CI, 0.12% to 0.49%) in the 15- to 30-year-old age group to 1.1% (CI, 0.24% to 3.33%) in persons older than 60 years of age. Half of the episodes of Venous thromboembolism occurred spontaneously, 20% were related to surgery, and 30% were associated with pregnancy or use of oral contraceptives. Conclusions: The observed low annual risk for venous thromboembolism in persons carrying the factor V Leiden mutation does not seem to outweigh the risks for bleeding associated with coumarin prophylaxis or justify discouragement of the use of oral contraceptives. A general policy of screening the families of all patients with the factor V Leiden mutation does not seem to be indicated. The observations in this moderate-size, retrospective study need to be confirmed by prospective follow-up studies.	Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, NL-1105 AZ Amsterdam, Netherlands; Ziekenhuis Rivienland, Dept Intern Med, NL-4002 WP Tiel, Netherlands; Univ Hosp Maastricht, Dept Haematol, NL-6229 HX Maastricht, Netherlands; Univ Groningen Hosp, Dept Haematol, Div Haematostasis Thrombosis & Rheol, NL-9713 EZ Groningen, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam	Middeldorp, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, F-4,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Middeldorp, Saskia/ABI-8197-2020	Middeldorp, Saskia/0000-0002-1006-6420				ALLAART CF, 1995, BRIT MED J, V311, P910; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIDEY F, 1995, THROMB HAEMOSTASIS, V74, P1382; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; Friederich PW, 1996, ANN INTERN MED, V125, P955, DOI 10.7326/0003-4819-125-12-199612150-00003; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1989, AM J MED, V87, P144; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	21	183	185	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					15	+		10.7326/0003-4819-128-1-199801010-00003	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424976	Green Submitted			2022-12-28	WOS:000071158000003
J	Crayford, T; Hooper, R; Evans, S				Crayford, T; Hooper, R; Evans, S			Death rates of characters in soap operas on British television: is a government health warning required?	BRITISH MEDICAL JOURNAL			English	Article								Objective: To measure mortality among characters in British soap operas on television. Design: Cohort analysis of deaths in EastEnders and Coronation Street, supplemented by an analysis of deaths in Brookside and Emmerdale. Main outcome measures: Standardised mortality ratios and the proportional mortality ratio for deaths attributable to external causes (E code of ICD-9 (international classification of diseases, ninth revision). Results: Staying alive in a television soap opera is not easy, Standardised mortality ratios for characters were among the highest for any occupation yet described (771 (95% confidence interval 415 to 1127) for characters in EastEnders), and this was not just because all causes of death were overrepresented. Deaths in soap operas were almost three times more likely to be from violent causes than would be expected from a character's age and sex. A character in EastEnders was twice as likely as a similar character in Coronation Street to die during an episode. Conclusions: The most dangerous job in the United Kingdom is not, as expected, bomb disposal expert, steeplejack, or Formula One racing driver but having a role in one of the United Kingdom's most well known soap operas. This is the first quantitative estimate of the size of the pinch of salt which should be taken when watching soap operas.	Univ London Kings Coll Hosp, Dept Epidemiol & Publ Hlth, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Crayford, T (corresponding author), Univ London Kings Coll Hosp, Dept Epidemiol & Publ Hlth, Denmark Hill, London SE5 9RS, England.			Hooper, Richard/0000-0002-1063-0917				Breslow NE., 1987, STAT METHODS CANC RE, P81; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; GERBNER G, 1985, JOURNALISM QUART, V62, P449; GERBNER G, 1985, JOURNALISM QUART, V62, P384; *OFF NAT STAT, 1996, 20 CENT MORT CD ROM; Office of Population Censuses and Surveys, 1980, CLASS OCC 1980	6	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1649	1652		10.1136/bmj.315.7123.1649	http://dx.doi.org/10.1136/bmj.315.7123.1649			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448527	Green Published			2022-12-28	WOS:000071149400010
J	Smith, GD; Frankel, S; Yarnell, J				Smith, GD; Frankel, S; Yarnell, J			Sex and death: are they related? Findings from the Caerphilly cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; LAY EPIDEMIOLOGY; HEALTH-EDUCATION; MORTALITY; PREVENTION; WOMEN; RISK; MEN	Objective: To examine the relation between frequency of orgasm and mortality, Study design: Cohort study with a 10 year follow up. Setting: The town of Caerphilly, South Wales, and five adjacent villages. Subjects: 918 men aged 45-59 at time of recruitment between 1979 and 1983. Main outcome measures: All deaths and deaths from coronary heart disease. Result: Mortality risk was 50% lower in the group with high orgasmic frequency than in the group with low orgasmic frequency, with evidence of a dose-response relation across the groups. Age adjusted odds ratio for all cause mortality was 2.0 for the group with low frequency of orgasm (95% confidence interval 1.1 to 3.5, test for trend P = 0.02). With adjustment for risk factors this became 1.9 (1.0 to 3.4, test for trend P = 0.04). Death from coronary heart disease and from other causes showed similar associations with frequency of orgasm, although the gradient was most marked for deaths from coronary heart disease. Analysed in terms of actual frequency of orgasm, the odds ratio for total mortality associated with an increase in 100 orgasms per year was 0.64 (0.44 to 0.95). Conclusion: Sexual activity seems to have a protective effect on men's health.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland	University of Bristol; Queens University Belfast	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; s, hema/0000-0002-3440-9475				ABRAMOV LA, 1976, PSYCHOSOM MED, V38, P418, DOI 10.1097/00006842-197611000-00006; Acker Kathy, 1984, BLOOD GUTS HIGH SCH; Alter JS, 1997, MED ANTHROPOL Q, V11, P275, DOI 10.1525/maq.1997.11.3.275; Butler SM, 1996, J GERONTOL B-PSYCHOL, V51, pS201, DOI 10.1093/geronb/51B.4.S201; COHEN KN, 1984, PALEOPATHOLOGY ORIGI; Cohen L., 1963, FAVOURITE GAME; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; DEMING W, 1995, PAUL MARRIAGE CELIBA; DRORY Y, 1995, AM J CARDIOL, V75, P835, DOI 10.1016/S0002-9149(99)80425-1; EASTON EB, 1988, AM PSYCHO; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Frankel Stephen, 1986, HULI RESPONSE ILLNES; FRASER I, 1984, BRIT MED J, V288, P242, DOI 10.1136/bmj.288.6412.242-b; GREER G, 1968, FEMALE EUNUCH; HAIRE N, 1924, REJUVENATION; Joyce James, 1916, PORTRAIT ARTIST YOUN; KAPLAN SD, 1988, PREV MED, V17, P335, DOI 10.1016/0091-7435(88)90008-4; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LOCK S, 1983, BRIT MED J, V287, P1964, DOI 10.1136/bmj.287.6409.1964; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; NYYSSONEN K, 1997, BMJ-BRIT MED J, V314, P6348; PALMORE EB, 1982, GERONTOLOGIST, V22, P513, DOI 10.1093/geront/22.6.513; PERSSON G, 1981, ACTA PSYCHIAT SCAND, V64, P244, DOI 10.1111/j.1600-0447.1981.tb00780.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PURDY J, 1961, COLOR DARKNESS; SCHUTTE H, 1975, INVEST UROL, V12, P330; *SCUM AUX, 1983, OBSC IND CLASS; SHARP I, 1997, LEAST 5 DAY STRATEGI; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; Solanas Valerie, 1971, SCUM MANIFESTO; Whiteman MC, 1997, LANCET, V350, P541, DOI 10.1016/S0140-6736(96)03141-8; YARNELL JWG, 1993, ARTERIOSCLER THROMB, V13, P517, DOI 10.1161/01.ATV.13.4.517; YARNELL JWG, 1994, BRIT HEART J, V71, P293	37	112	116	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 20	1997	315	7123					1641	1644		10.1136/bmj.315.7123.1641	http://dx.doi.org/10.1136/bmj.315.7123.1641			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448525	Green Published			2022-12-28	WOS:000071149400007
J	Caro, J; Klittich, W; McGuire, A; Ford, J; Norrie, J; Pettitt, D; McMurray, J; Shepherd, J				Caro, J; Klittich, W; McGuire, A; Ford, J; Norrie, J; Pettitt, D; McMurray, J; Shepherd, J		W Scotland Coronary Prevention Study Group	The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; COST-EFFECTIVENESS	Objective: To estimate the economic efficiency of using pravastatin to prevent the transition from health to cardiovascular disease in men with hypercholesterolaemia. Design: Economic benefit analysis based on data from the West of Scotland coronary prevention study. Treatment specific hazards of developing cardiovascular disease according to various definitions were estimated. Scottish record linkage data provided disease specific survival. Cost estimates were based on extracontractual tariffs and event specific average lengths of stay calculated from the West of Scotland coronary prevention study. Subjects: Men with hypercholesterolaemia similar to the subjects in the West of Scotland coronary prevention study. Main outcome: Cost consequences, the number of transitions from health to cardiovascular disease prevented, the number needed to start treatment, and cost per life year gained. Results: If 10 000 of these men started taking pravastatin, 318 of them would not make the transition from health to cardiovascular disease (number needed to treat, 31.4), at a net discounted cost of pound 20m over 5 years. These benefits imply an undiscounted gain of 2460 years of life, and thus pound 8121 per life year gained, or pound 20 375 per life year gained if benefits are discounted, Restriction to the 40% of men at highest risk reduces the number needed to treat to 22.5 (pound 5601 per life year gained (undiscounted) and pound 13 995 per life year gained (discounted)). Conclusions: In subjects without evidence of prior myocardial infarction but who have hypercholesterolaemia, the use of pravastatin yields substantial health benefits at a cost that is not prohibitive overall and can be quite efficient in selected high risk subgroups.	Caro Res, Concord, MA 01742 USA; City Univ London, Dept Econ, London EC1V 0HB, England; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; Bristol Myers Squibb Outcomes Res, Princeton, NJ 08543 USA; Univ Glasgow, CRI Heart Failure, Glasgow G12 8QQ, Lanark, Scotland; Glasgow Royal Infirm, Dept Pathol Biochem, Glasgow G4 0SF, Lanark, Scotland	City University London; University of Glasgow; Bristol-Myers Squibb; University of Glasgow; University of Glasgow	Caro, J (corresponding author), Caro Res, 336 Baker Ave, Concord, MA 01742 USA.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975; Caro, Jaime/0000-0001-5470-3754				COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; *DEP HLTH CHIEF ME, 1995, STAT PUBL HLTH ANN R; *DEP HLTH CHIEF ME, 1995, HLTH SCOTL REP CHIEF; Jonsson B, 1996, EUR HEART J, V17, P1001; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; LORD I, 1992, J CLIN EPIDEMIOL, V45, P849, DOI 10.1016/0895-4356(92)90068-X; OBRIEN JA, 1996, CLIN THER, V149, P21; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; PYORALA K, 1994, EUR HEART J, V15, P1300; *REG GEN SCOTL, 1995, ANN REP 1994; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stinett AA, 1996, COST EFFECTIVENESS H, P349; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210	15	136	137	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1577	1582		10.1136/bmj.315.7122.1577	http://dx.doi.org/10.1136/bmj.315.7122.1577			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437275	Green Published			2022-12-28	WOS:000071021900022
J	Majeed, A; Evans, N; Head, P				Majeed, A; Evans, N; Head, P			What can PACT tell us about prescribing in general practice?	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE INDICATORS; ENGLAND; WEIGHTINGS; ADMISSIONS; ASTHMA; COSTS; AGE; SEX; PUS		WILSON HOSP,MERTON SUTTON & WANDSWORTH HLTH AUTHOR,LONDON CR4 4TP,ENGLAND; KINGSTON & RICHMOND HLTH AUTHOR,SURBITON KT5 9AL,ENGLAND		Majeed, A (corresponding author), ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Majeed, Azeem/0000-0002-2357-9858				*AUD COMM, 1994, PRESCR IMPR MOR RAT; AVEYARD P, 1997, BR J GEN PRACT, V420, P423; Baker SJ, 1996, BRIT MED J, V312, P58, DOI 10.1136/bmj.312.7022.58b; Bateman DN, 1996, BRIT J GEN PRACT, V46, P20; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; FREEMANTLE N, 1995, BRIT MED J, V310, P955, DOI 10.1136/bmj.310.6985.955; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; GRIFFITHS C, 1997, BRIT MED J, V314, P1482; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; LLOYD DCEF, 1995, BRIT MED J, V311, P991; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; REEVES CL, 1996, EL96107 NHS EX; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; Shelley M, 1996, BRIT MED J, V313, P1124, DOI 10.1136/bmj.313.7065.1124; Wilson RPH, 1996, BRIT MED J, V313, P595	17	70	72	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1515	1519		10.1136/bmj.315.7121.1515	http://dx.doi.org/10.1136/bmj.315.7121.1515			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420496	Green Published			2022-12-28	WOS:A1997YK98600027
J	Hosking, D; Chilvers, CED; Christiansen, C; Ravn, P; Wasnich, R; Ross, P; McClung, M; Balske, A; Thompson, D; Daley, M; Yates, AJ				Hosking, D; Chilvers, CED; Christiansen, C; Ravn, P; Wasnich, R; Ross, P; McClung, M; Balske, A; Thompson, D; Daley, M; Yates, AJ		Early Postmenopausal Intervention Cohort Study	Prevention of bone loss with alendronate in postmenopausal women under 60 years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; BREAST-CANCER; ORAL ALENDRONATE; MINERAL DENSITY; OSTEOPOROSIS; ESTROGEN; RISK; MASS; PROGESTIN; FRACTURES	Background Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies carl prevent osteoporosis in t:hese women is also not clear. Methods We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo on bone mineral density in 1174 postmenopausal women under 60 years of age. An additional 435 women who were prepared to receive a combination of estrogen and progestin were randomly assigned to one cf the above treatments or open-label estrogen-progestin. The main outcome measure was the change in bone mineral density of the lumbar spine, hip, distal forearm, and total body measured annually for two years by dual-energy x-ray absorptiometry. Results The women who received placebo lost bone mineral density at all measured sites, whereas the women treated with 5 mg of alendronate daily had a mean (+/-SE) increase in bone mineral density of 3.5+/-0.2 percent at the lumbar spine, 1.9+/-0.1 percent at the hip, and 0.7+/-0.1 percent for the total body (all P<0.001). Women treated with 2.5 mg of alendronate daily had smaller increases in bone mineral density. Alendronate: did not increase bone mineral density of the forearm, but it slowed the loss. The responses to estrogen-progestin were 1 to 2 percentage points greater than those to the 5-mg dose of alendronate. Alendronate was well tolerated, with a safety profile similar to that of placebo or estrogen-progestin. Conclusions Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen-progestin. (C) 1998, Massachusetts Medical Society.	City Hosp, DIv Mineral Metab, Nottingham NG5 1PB, England; Univ Nottingham, Sch Med, Sch Community Hlth Sci, Nottingham, England; Ctr Clin & Basic Res, Ballerup, Denmark; Hawaii Osteoporosis Ctr, Honolulu, HI USA; Providence Hlth Syst, Oregon Osteoporosis Ctr, Portland, OR USA; Merck Res Labs, Rahway, NJ USA	University of Nottingham; University of Nottingham; Center Clinical & Basic Research; Oregon Osteoporosis Center; Merck & Company	Hosking, D (corresponding author), City Hosp, DIv Mineral Metab, Hucknall Rd, Nottingham NG5 1PB, England.		Ravn, Pernillle/AAT-9761-2020; McClung, Michael/ABA-4100-2021	Ravn, Pernillle/0000-0001-8752-1121; McClung, Michael/0000-0002-7827-0778; Christiansen, Cindy/0000-0001-9951-480X				ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872; BLACK DM, 1992, J BONE MINER RES, V7, P639; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CHRISTIANSEN C, 1981, LANCET, V1, P459; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DALY E, 1992, BRIT MED BULL, V48, P368, DOI 10.1093/oxfordjournals.bmb.a072552; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; DEMPSTER DW, 1986, J BONE MINER RES, V1, P15; Devogelaer JP, 1996, BONE, V18, P141, DOI 10.1016/8756-3282(95)00436-X; ETTINGER B, 1994, OBSTET GYNECOL, V83, P693; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LINDSAY R, 1976, LANCET, V1, P1038; Lindsay R, 1996, OBSTET GYNECOL, V87, pS16, DOI 10.1016/0029-7844(95)00430-0; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; RIGGS BL, 1993, NEW ENGL J MED, V328, P65; RODAN GA, 1993, OSTEOPOROS INT S3, V3, pSM; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; STUMPF PG, 1994, OBSTET GYN CLIN N AM, V21, P219; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; Wild RA, 1996, OBSTET GYNECOL, V87, pS27, DOI 10.1016/0029-7844(95)00434-3	29	398	418	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					485	492		10.1056/NEJM199802193380801	http://dx.doi.org/10.1056/NEJM199802193380801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9443925				2022-12-28	WOS:000072061400001
J	Beitel, A				Beitel, A			A moment of clarity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					256	256		10.1001/jama.279.4.256	http://dx.doi.org/10.1001/jama.279.4.256			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450692				2022-12-28	WOS:000071607000001
J	Jones, SM; Howell, KE; Henley, JR; Cao, H; McNiven, MA				Jones, SM; Howell, KE; Henley, JR; Cao, H; McNiven, MA			Role of dynamin in the formation of transport vesicles from the trans-Golgi network	SCIENCE			English	Article							TEMPERATURE-SENSITIVE MUTANT; GTP-BINDING PROTEINS; DROSOPHILA-MELANOGASTER; REVERSIBLE BLOCKAGE; MEMBRANE RETRIEVAL; ENDOCYTOSIS; SHIBIRE; MUTATIONS; FAMILY; FORMS	Dynamin guanosine triphosphatases support the scission of clathrin-coated vesicles from the plasmalemma during endocytosis. By fluorescence microscopy of cultured rat hepatocytes, a green fluorescent protein-dynamin II fusion protein localized with clathrin-coated vesicles at the Golgi complex. A cell-free assay was utilized to demonstrate the role of dynamin in vesicle formation at the trans-Golgi. Addition of peptide-specific anti-dynamin antibodies to the assay mixture inhibited both constitutive exocytic and clathrin-coated vesicle formation. Immunodepletion of dynamin proteins also inhibited vesicle formation, and budding efficiency was restored upon readdition of purified dynamin. These data suggest that dynamin participates in the formation of distinct transport vesicles from the trans-Golgi network.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Univ Colorado, Sch Med, Dept Cellular & Struct Biol, Denver, CO 80262 USA	Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McNiven, MA (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.		Henley, John/D-7171-2011		NCI NIH HHS [P30 CA-46934] Funding Source: Medline; NIDDK NIH HHS [P30 DK-34914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO H, UNPUB; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Cook T, 1996, J NEUROCHEM, V67, P927; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HENLEY JR, IN PRESS J CELL BIOL; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JONES M, 1997, J CELL BIOL, V139, P339; JONES SM, 1997, CELL BIOL LAB HDB, V2, P12; JONES SM, UNPUB; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1990, DEV BIOL, V138, P464, DOI 10.1016/0012-1606(90)90212-2; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	31	264	266	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					573	577		10.1126/science.279.5350.573	http://dx.doi.org/10.1126/science.279.5350.573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438853				2022-12-28	WOS:000071616000050
J	Carr, MH; Belton, MJS; Chapman, CR; Davies, AS; Geissler, P; Greenberg, R; McEwen, AS; Tufts, BR; Greeley, R; Sullivan, R; Head, JW; Pappalardo, RT; Klaasen, KP; Johnson, TV; Kaufman, J; Senske, D; Moore, J; Neukum, G; Schubert, G; Burns, JA; Thomas, P; Veverka, J				Carr, MH; Belton, MJS; Chapman, CR; Davies, AS; Geissler, P; Greenberg, R; McEwen, AS; Tufts, BR; Greeley, R; Sullivan, R; Head, JW; Pappalardo, RT; Klaasen, KP; Johnson, TV; Kaufman, J; Senske, D; Moore, J; Neukum, G; Schubert, G; Burns, JA; Thomas, P; Veverka, J			Evidence for a subsurface ocean on Europa	NATURE			English	Article							GALILEAN SATELLITES; ICE SHELL	Ground-based spectroscopy of Jupiter's moon Europa, combined with gravity data, suggests that the satellite has an icy crust roughly 150 km thick and a rocky interior(1-4). In addition, images obtained by the voyager spacecraft revealed that Europa's surface is crossed by numerous intersecting ridges and dark bands (called lineae) and is sparsely cratered, indicating that the terrain is probably significantly younger than that of Ganymede and Callisto(5). It has been suggested that Europa's thin outer ice shell might be separated from the moon's silicate interior by a liquid water layer, delayed or prevented from freezing by tidal heating(6-10); in this model, the lineae could be explained by repetitive tidal deformation of the outer ice shell(11-13). However, observational confirmation of a subsurface ocean was largely frustrated by the low resolution (>2 km per pixel) of the Voyager images(14). Here we present high-resolution (54 m per pixel) Galileo spacecraft images of Europa, in which we find evidence for mobile 'icebergs'. The detailed morphology of the terrain strongly supports the presence of liquid water at shallow depths below the surface, either today or at some time in the past. Moreover, lower-resolution observations of much larger regions suggest that the phenomena reported here are widespread.	US Geol Survey, Menlo Pk, CA 94025 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; SW Res Inst, Boulder, CO 80302 USA; Rand Corp, Santa Monica, CA 90406 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Cornell Univ, Ithaca, NY 14853 USA; Brown Univ, Dept Geol, Providence, RI 02912 USA; Jet Prop Lab, Pasadena, CA 91909 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; DLR, Inst Planetenerkundung, D-12489 Berlin, Germany; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	United States Department of the Interior; United States Geological Survey; National Optical Astronomy Observatory; RAND Corporation; University of Arizona; Arizona State University; Arizona State University-Tempe; Cornell University; Brown University; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Helmholtz Association; German Aerospace Centre (DLR); University of California System; University of California Los Angeles	Carr, MH (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	carr@astmnl.wr.usgs.gov	Pappalardo, Robert/AAP-8953-2021; Sullivan, Robert/AAR-8193-2020	Pappalardo, Robert/0000-0003-2571-4627; 				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CHAPMAN C, 1997, LUNAR PLANET SCI C, V28, P217; GREELEY R, UNPUB; GREENBERG R, 1984, ICARUS, V58, P186, DOI 10.1016/0019-1035(84)90038-1; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; KUIPER GP, 1961, PLANETS SATELLITES; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; MOROZ VI, OSV ASTRON A J, V9, P999; MORRISON D, 1974, SPACE SCI REV, V15, P641, DOI 10.1007/BF00175241; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Pappalardo R. T, 1996, P EUR OC C, P59; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PAPPALARDO RT, 1996, LUNAR PLANET SCI C, V27, P997; ROSS M, 1986, NATURE, V325, P13; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SHOEMAKER EM, 1996, P EUR OC C, P65; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; SULLIVAN R, 1997, LUNAR PLANET SCI, V28, P1395; TUFTS RB, 1997, LUNAR PLANET SCI C, V28, P1455	24	378	386	1	162	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					363	365		10.1038/34857	http://dx.doi.org/10.1038/34857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450749				2022-12-28	WOS:000071604200045
J	Collins, KL; Chen, BK; Kalams, SA; Walker, BD; Baltimore, D				Collins, KL; Chen, BK; Kalams, SA; Walker, BD; Baltimore, D			HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FINE SPECIFICITY; DOWN-MODULATION; ANTIGENS; RNA	Cytotoxic T lymphocytes (CTLs) lyse virally infected cells that display viral peptide epitopes in association with major histocompatibility complex (MHC) class I molecules on the cell surface. However, despite a strong CTL response directed against viral epitopes, untreated people infected with the human immunodeficiency virus (HIV-1) develop AIDS. To resolve this enigma, we have examined the ability of CTLs to recognize and kill infected primary T lymphocytes, We found that CTLs inefficiently lysed primary cells infected with HIV-1 if the viral nef gene product was expressed. Resistance of infected cells to CTL killing correlated with nef-mediated downregulation of MHC class I (ref. 1) and could be overcome by adding an excess of the relevant HIV-1 epitope as soluble peptide. Thus, Nef protected infected cells by reducing the epitope density on their surface. This effect of nef may allow evasion of CTL lysis by HN-1-infected cells.	MIT, Dept Biol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Combined Infect Dis Training Program, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA; Rockefeller Univ, New York, NY 10021 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Rockefeller University	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	baltimo@caltech.edu		Chen, Benjamin K/0000-0002-5404-1997				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; HILL AB, 1995, J EXP MED, V181, P2221, DOI 10.1084/jem.181.6.2221; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; OBRIEN MC, 1995, CYTOMETRY, V19, P243, DOI 10.1002/cyto.990190308; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; Walter JB, 1997, INT IMMUNOL, V9, P451, DOI 10.1093/intimm/9.3.451; XU X, 1997, J EXP MED, V186, P1; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996	27	830	849	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					397	401		10.1038/34929	http://dx.doi.org/10.1038/34929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450757				2022-12-28	WOS:000071604200057
J	Campbell, SS; Murphy, PJ				Campbell, SS; Murphy, PJ			Extraocular circadian phototransduction in humans	SCIENCE			English	Article							SLEEP PHASE SYNDROME; FREE-RUNNING HUMAN; BRIGHT LIGHT; COUESIUS-PLUMBEUS; VISUAL-SYSTEM; WAKE SCHEDULE; NITRIC-OXIDE; SHIFT WORK; LAKE CHUB; JET LAG	Physiological and behavioral rhythms are governed by an endogenous circadian clock. The response of the human circadian clock to extraocular light exposure was monitored by measurement of body temperature and melatonin concentrations throughout the circadian cycle before and after light pulses presented to the popliteal region (behind the knee). A systematic relation was found between the timing of the light pulse and the magnitude and direction of phase shifts, resulting in the generation of a phase response curve. These findings challenge the belief that mammals are incapable of extraretinal circadian phototransduction and have implications for the development of more effective treatments for sleep and circadian rhythm disorders.	Cornell Univ, Coll Med, Dept Psychiat, Lab Human Chronobiol, White Plains, NY 10605 USA	Cornell University	Campbell, SS (corresponding author), Cornell Univ, Coll Med, Dept Psychiat, Lab Human Chronobiol, 21 Bloomingdale Rd, White Plains, NY 10605 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054617, R01MH045067, K02MH001099] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH45067, K02 MH01099, R01 MH54617] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLER K, 1976, PHOTOCHEM PHOTOBIOL, V23, P275, DOI 10.1111/j.1751-1097.1976.tb07250.x; BEISWANGER CM, 1981, J EXP ZOOL, V216, P13, DOI 10.1002/jez.1402160104; BLOCK GD, 1974, J COMP PHYSIOL, V89, P237, DOI 10.1007/BF00696189; CADUSSEAU J, 1980, EXP BRAIN RES, V40, P339; CAMPBELL SS, 1993, J AM GERIATR SOC, V41, P829, DOI 10.1111/j.1532-5415.1993.tb06179.x; Campbell SS, 1995, J BIOL RHYTHM, V10, P105, DOI 10.1177/074873049501000203; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; DAAN S, 1984, PSYCHOPHARMACOL BULL, V20, P566; DEMIAN JJ, 1977, J HERPETOL, V11, P131, DOI 10.2307/1563133; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; EASTMAN CI, 1990, WORK STRESS, V4, P245, DOI 10.1080/02678379008256987; EASTMAN CI, 1994, SLEEP, V17, P535, DOI 10.1093/sleep/17.6.535; ELLIOTT AL, 1972, J PHYSIOL-LONDON, V221, P227, DOI 10.1113/jphysiol.1972.sp009750; ESKIN A, 1971, Z VERGL PHYSIOL, V74, P353, DOI 10.1007/BF00341401; Foster R.G, 1993, LIGHT BIOL RHYTHMS M, P73; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; FOSTER RG, 1994, NEUROSCI BIOBEHAV R, V18, P541, DOI 10.1016/0149-7634(94)90009-4; FOSTER RG, 1989, J COMP PHYSIOL A, V165, P565, DOI 10.1007/BF00611242; FOSTER RG, 1993, CURRENT DIRECTIONS P, V2, P34; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GIBSON QH, 1957, NATURE, V180, P1416, DOI 10.1038/1801416b0; GROOS GA, 1981, EXPERIENTIA, V37, P71, DOI 10.1007/BF01965576; HOBAN TM, 1989, CHRONOBIOL INT, V6, P347, DOI 10.3109/07420528909056941; HONMA K, 1991, JPN J PSYCHIAT NEUR, V45, P153; HONMA K, 1987, EXPERIENTIA, V43, P1205, DOI 10.1007/BF01945525; KAVALIERS M, 1980, BEHAV NEURAL BIOL, V30, P56, DOI 10.1016/S0163-1047(80)90884-5; KAVALIERS M, 1979, J EXP ZOOL, V209, P33, DOI 10.1002/jez.1402090104; KLEIN T, 1993, SLEEP, V16, P333, DOI 10.1093/sleep/16.4.333; Lack L., 1993, SLEEP RES, V22, P225; Lack LC, 1996, J SLEEP RES, V5, P211, DOI 10.1111/j.1365-2869.1996.00211.x; MCMILLAN JP, 1975, J COMP PHYSIOL, V102, P251, DOI 10.1007/BF01464359; MENAKER M, 1968, P NATL ACAD SCI USA, V59, P414, DOI 10.1073/pnas.59.2.414; MENAKER M, 1976, PHOTOCHEM PHOTOBIOL, V23, P299, DOI 10.1111/j.1751-1097.1976.tb07251.x; MENAKER M, 1971, BIOL REPROD, V4, P295, DOI 10.1093/biolreprod/4.3.295; MINORS DS, 1989, CHRONOBIOL INT, V6, P29, DOI 10.3109/07420528909059140; MINORS DS, 1991, NEUROSCI LETT, V133, P36, DOI 10.1016/0304-3940(91)90051-T; MORIN LP, 1994, BRAIN RES REV, V19, P102, DOI 10.1016/0165-0173(94)90005-1; NELSON RJ, 1981, COMP BIOCHEM PHYS A, V69, P145, DOI 10.1016/0300-9629(81)90651-4; Oren DA, 1996, NEUROSCIENTIST, V2, P207, DOI 10.1177/107385849600200408; REGESTEIN QR, 1995, AM J PSYCHIAT, V152, P602; Richter C.P, 1965, BIOL CLOCKS MED PSYC; ROSENTHAL NE, 1990, SLEEP, V13, P354; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; TAYLOR DH, 1970, SCIENCE, V168, P390, DOI 10.1126/science.168.3929.390; UNDERWOOD H, 1982, EXPERIENTIA, V38, P1013, DOI 10.1007/BF01955345; UNDERWOOD H, 1973, J COMP PHYSIOL, V83, P187, DOI 10.1007/BF00696895; VANVEEN T, 1976, J COMP PHYSIOL, V111, P209, DOI 10.1007/BF00605532; VAUGHAN GM, 1993, J PINEAL RES, V15, P88, DOI 10.1111/j.1600-079X.1993.tb00514.x; VENTURINI CM, 1993, J PHARMACOL EXP THER, V266, P1497; WEBER JM, 1997, SLEEP RES, V26, P757; WEHR TA, 1987, AM J PSYCHIAT, V144, P753; WEVER RA, 1985, ANN NY ACAD SCI, V453, P282, DOI 10.1111/j.1749-6632.1985.tb11818.x; YOKOYAMA K, 1978, SCIENCE, V201, P76, DOI 10.1126/science.566467; 1982, EXPERIENTIA, V39, P989	54	176	185	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					396	399		10.1126/science.279.5349.396	http://dx.doi.org/10.1126/science.279.5349.396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430592				2022-12-28	WOS:000071570800050
J	Barker, RA; Knowles, GK; Sheppard, MN				Barker, RA; Knowles, GK; Sheppard, MN			Breathlessness and profuse haemoptysis	LANCET			English	Article							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; PATHOLOGICAL SPECTRUM; DISEASE		Kingston Hosp, Surrey KT2 7QB, England; Royal Brompton Hosp, London SW3 6LY, England	Royal Brompton Hospital	Barker, RA (corresponding author), Addenbrookes Hosp, Dept Neurol, Hills Rd, Cambridge CB2 2QQ, England.		Sheppard, Mary N/AAB-3364-2019	Sheppard, Mary N/0000-0003-2724-3881				GAL AA, 1994, ARCH PATHOL LAB MED, V118, P1209; GAUDIN PB, 1995, AM J CLIN PATHOL, V104, P7, DOI 10.1093/ajcp/104.1.7; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; LEAKER B, 1992, THORAX, V47, P988, DOI 10.1136/thx.47.11.988; Unsworth DJ, 1996, LANCET, V347, P115, DOI 10.1016/S0140-6736(96)90240-8	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					108	108		10.1016/S0140-6736(97)08174-9	http://dx.doi.org/10.1016/S0140-6736(97)08174-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439496				2022-12-28	WOS:000071591900013
J	Rabusin, M; Lepore, L; Costantinides, F; Bussani, R				Rabusin, M; Lepore, L; Costantinides, F; Bussani, R			A child with severe asthma	LANCET			English	Article							CHURG-STRAUSS-SYNDROME; POLYARTERITIS-NODOSA		Maternal & Child Hlth Inst Burlo Garofolo, Dept Pediat, I-34100 Trieste, Italy; Univ Trieste, Inst Legal Med, Trieste, Italy; Univ Trieste, Inst Histol & Pathol, Trieste, Italy	IRCCS Burlo Garofolo; University of Trieste; University of Trieste	Rabusin, M (corresponding author), Maternal & Child Hlth Inst Burlo Garofolo, Dept Pediat, Via Istria 65-1, I-34100 Trieste, Italy.			Bussani, Rossana/0000-0001-8241-9726				CHURG J, 1951, AM J PATHOL, V27, P277; GRAVANIS MB, 1991, J HEART LUNG TRANSPL, V10, P688; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; LHOTE F, 1995, RHEUM DIS CLIN N AM, V21, P911; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806	5	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					32	32		10.1016/S0140-6736(97)09499-3	http://dx.doi.org/10.1016/S0140-6736(97)09499-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433427				2022-12-28	WOS:000071253100014
J	Doll, R				Doll, R			One for the heart	BRITISH MEDICAL JOURNAL			English	Review							MODERATE ALCOHOL-CONSUMPTION; MYOCARDIAL-INFARCTION; DEVELOPED-COUNTRIES; DISEASE; MORTALITY; RISK; DRINKERS; WINE		Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Doll, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.							ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; COCHRANE AL, 1978, J EPIDEMIOL COMMUN H, V32, P200, DOI 10.1136/jech.32.3.200; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, EUR HEART J SUPPL, V8, P73; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; Doll R, 1997, EUR HEART J, V18, P23, DOI 10.1093/oxfordjournals.eurheartj.a015112; Doll R, 1997, NONRANDOM REFLECTION; Edwards G., 1994, ALCOHOL POLICY PUBLI; English D.R., 1995, QUANTIFICATION DRUG; HALL EM, 1953, AM J PATHOL, V29, P993; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; KEYS A, 1957, LANCET, V2, P959; Kiechl S, 1996, BRIT MED J, V313, P1040; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; McElduff P, 1997, BRIT MED J, V314, P1159, DOI 10.1136/bmj.314.7088.1159; MEADE TW, 1987, LANCET, V2, P986; MONTAIGNE M, 1995, ESSAYS MONTAIGNE; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Pearl R., 1926, ALCOHOL LONGEVITY; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V488, P445; POLICH JM, 1981, AM J PUBLIC HEALTH, V71, P1125, DOI 10.2105/AJPH.71.10.1125; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; RIMM EB, 1995, BRIT MED J, V310, P55; Shaper AG, 1995, EUR HEART J, V16, P1760, DOI 10.1093/oxfordjournals.eurheartj.a060824; SHAPER AG, 1988, LANCET, V2, P1268; SIMPURA J, 1987, FINNISH DRINKING HAB; STASON WB, 1976, AM J EPIDEMIOL, V104, P603, DOI 10.1093/oxfordjournals.aje.a112338; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; THORNTON J, 1983, LANCET, V2, P819; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401	39	56	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1664	1668		10.1136/bmj.315.7123.1664	http://dx.doi.org/10.1136/bmj.315.7123.1664			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448535	Green Published			2022-12-28	WOS:000071149400019
J	Thurston, J				Thurston, J			How to do it - How to acquire a coat of arms	BRITISH MEDICAL JOURNAL			English	Article									Fac Accid & Emergency Med, London WC2A 3PN, England		Thurston, J (corresponding author), Fac Accid & Emergency Med, London WC2A 3PN, England.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1682	1684		10.1136/bmj.315.7123.1682	http://dx.doi.org/10.1136/bmj.315.7123.1682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448540	Green Published			2022-12-28	WOS:000071149400026
J	Hawkes, CH; Macdonald, AM; Schapira, AHV				Hawkes, CH; Macdonald, AM; Schapira, AHV			Use of general practitioner computerised records to create a population based twin sample: pilot study based on Parkinson's disease	BRITISH MEDICAL JOURNAL			English	Article									IPSWICH HOSP,DEPT CLIN NEUROL,IPSWICH IP4 5PD,SUFFOLK,ENGLAND; INST PSYCHIAT,DEPT PSYCHOL MED,SECT GENET EPIDEMIOL & STAT,LONDON SE5 8AF,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT CLIN NEUROSCI,LONDON NW3 2PF,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				BenShlomo Y, 1996, J NEUROL NEUROSUR PS, V61, P4, DOI 10.1136/jnnp.61.1.4; BUNDEY S, 1991, J NEUROL, V238, P360, DOI 10.1007/BF00319852; MUTCH WJ, 1986, BRIT MED J, V292, P534, DOI 10.1136/bmj.292.6519.534; *ROYAL COLL GEN PR, 1995, 7 RCGP; WEINBERG W, 1901, PFLUGERS ARCH, V88, P34	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1510	1511		10.1136/bmj.315.7121.1510	http://dx.doi.org/10.1136/bmj.315.7121.1510			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420494	Green Published			2022-12-28	WOS:A1997YK98600024
J	Kanamori, H; Anderson, DL; Heaton, TH				Kanamori, H; Anderson, DL; Heaton, TH			Frictional melting during the rupture of the 1994 Bolivian earthquake	SCIENCE			English	Article							DEEP-FOCUS EARTHQUAKES; JUNE 9; MECHANISM; FAULT; LITHOSPHERE; SEQUENCE	The source parameters of the 1994 Bolivian earthquake (magnitude M-w?, = 8.3) suggest that the maximum seismic efficiency eta was 0.036 and the minimum frictional stress was 550 bars. Thus, the source process was dissipative, which is consistent with the observed slow rupture speed, only 20% of the local S-wave velocity, The amount of nonradiated energy produced during the Bolivian rupture was comparable to, or larger than, the thermal energy of the 1980 Mount St, Helens eruption and was sufficient to have melted a layer as thick as 31 centimeters, Once rupture was initiated, melting could occur, which reduces friction and promotes fault slip.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Kanamori, H (corresponding author), CALTECH, Seismol Lab, Pasadena, CA 91125 USA.							Antolik M, 1996, GEOPHYS RES LETT, V23, P1589, DOI 10.1029/96GL00968; BECK SL, 1995, HDB PHYSICAL CONSTAN, P2257; Bowden FP, 1939, PROC R SOC LON SER-A, V172, P0280, DOI 10.1098/rspa.1939.0104; CHEN WP, 1995, GEOPHYS RES LETT, V22, P2261, DOI 10.1029/95GL01805; CLAUSER C, 1995, HDB PHYSICAL CONSTAN, P105; ESHELBY JD, 1969, J MECH PHYS SOLIDS, V17, P177, DOI 10.1016/0022-5096(69)90032-5; ESTABROOK CHH, 1995, HDB PHYSICAL CONSTAN, P2277; Friedman J. D., 1981, The 1980 eruptions of Mount St. Helens, Washington, P557; FURUMOTO M, 1977, PHYS EARTH PLANET IN, V15, P1, DOI 10.1016/0031-9201(77)90005-X; GOES S, 1995, HDB PHYSICAL CONSTAN, P2249; GREEN HW, 1989, NATURE, V341, P733, DOI 10.1038/341733a0; HARA T, 1995, GEOPHYS RES LETT, V22, P2265, DOI 10.1029/95GL01602; HEATON TH, 1990, PHYS EARTH PLANET IN, V64, P1, DOI 10.1016/0031-9201(90)90002-F; HOUSTON H, 1991, NATURE, V352, P520, DOI 10.1038/352520a0; HOUSTON H, 1996, EOS, V77, P491; IHMLE PF, 1995, HDB PHYSICAL CONSTAN, P2253; Jeffreys H., 1942, GEOL MAG, V79, P291, DOI DOI 10.1017/S0016756800076019; KIKUCHI M, 1994, GEOPHYS RES LETT, V21, P2341, DOI 10.1029/94GL02483; KIRBY SH, 1991, SCIENCE, V252, P216, DOI 10.1126/science.252.5003.216; Kirby SH, 1996, REV GEOPHYS, V34, P261, DOI 10.1029/96RG01050; KOSTROV BV, 1966, PMM-J APPL MATH MEC+, V30, P1241; LUNDGREN P, 1995, HDB PHYSICAL CONSTAN, P2241; MCKENZIE D, 1972, GEOPHYS J ROY ASTR S, V29, P65, DOI 10.1111/j.1365-246X.1972.tb06152.x; Mott NF, 1948, MEC ENG, V165, P16; MYERS SC, 1995, GEOPHYS RES LETT, V22, P2269, DOI 10.1029/95GL01600; Navrotsky A, 1995, HDB PHYS CONSTANTS, P18; Orowan E., 1960, GEOL SOC AM MEM, V79, P323, DOI DOI 10.1130/MEM79-P323; RICHARDS PG, 1976, B SEISMOL SOC AM, V66, P1; ROSAKIS AJ, 1985, INT J FRACTURE, V27, P169, DOI 10.1007/BF00017966; SIBSON RH, 1973, NATURE-PHYS SCI, V243, P66, DOI 10.1038/physci243066a0; SILVER PG, 1995, SCIENCE, V268, P69, DOI 10.1126/science.268.5207.69; *US GEOL SURV, 1994, 694 EDR US GEOL SURV, P145; WIENS DA, 1995, GEOPHYS RES LETT, V22, P2245, DOI 10.1029/95GL01598; WINSLOW N, UNPUB; WU J, 1995, GEOPHYS RES LETT, V22, P2237, DOI 10.1029/95GL02232	35	202	208	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					839	842		10.1126/science.279.5352.839	http://dx.doi.org/10.1126/science.279.5352.839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452378				2022-12-28	WOS:000071923500036
J	Ray, WA; Gigante, J; Mitchel, EF; Hickson, GB				Ray, WA; Gigante, J; Mitchel, EF; Hickson, GB			Perinatal outcomes following implementation of TennCare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; MEDICAID; TENNESSEE; ELIGIBILITY	Context.-The abrupt initiation of capitated Medicaid care in Tennessee (TennCare) in 1994 prompted many questions about changes in quality of care. Objective.-To evaluate the effect on perinatal outcomes of the transition to TennCare in 1994. Design.-Before and after retrospective cohort analysis. Setting and Population.-Births to women residing in Tennessee between 1990 and 1995 with complete demographic information on birth certificates, with a focus on women enrolled in Medicaid giving birth in 1993 (before TennCare) and 1995 (after TennCare). Outcome Measures.-Late prenatal care (after the fourth month of pregnancy) or inadequate prenatal visits, low and very low birth weight, and death in the first 60 days of life. Results.-Tennessee residents had 72 014 study births in 1993 and 72 278 in 1995, of which 37 543 (52.1%) and 35 707 (49.4%) were to women enrolled in Medicaid at delivery. For these Medicaid births, there were no changes after TennCare In the proportions with late prenatal care (16.2% in 1993 vs 15.8% in 1995), inadequate prenatal visits (5.9% vs 5.6%), low birth weight (9.4% vs 9.0%), very low birth weight (1.6% vs 1.5%), and death in the first 60 days (0.6% both years). These findings were unchanged in multivariate analysis, in analysis of high-risk subgroups, and in analysis of women with demographics characteristic of Medicaid women. Conclusion.-Study perinatal outcomes did not change among Medicaid births following the transition to TennCare.	Vanderbilt Univ, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Ray, WA (corresponding author), Vanderbilt Univ, Dept Prevent Med, A-1124 MCN, Nashville, TN 37232 USA.				PHS HHS [18-C-90029] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; PIPER JM, 1991, AM J PUBLIC HEALTH, V81, P1046, DOI 10.2105/AJPH.81.8.1046; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; PIPER JM, 1994, AM J PUBLIC HEALTH, V84, P1626, DOI 10.2105/AJPH.84.10.1626; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; Ray WA, 1997, AM J PREV MED, V13, P292, DOI 10.1016/S0749-3797(18)30178-8; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMITH T, 1996, TENNESSEAN      0921, pB6; *US BUR CENS, 1993, 1992 TECHN DOC PREP; *US BUR CENS, 1992, CENS POP HOUS 1990 S; *US BUR CENS, 1993, 1992 PREP BUR CENS; US Bureau of the Census, 1992, CENS POP HOUS SUMM S	18	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					314	316		10.1001/jama.279.4.314	http://dx.doi.org/10.1001/jama.279.4.314			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450717				2022-12-28	WOS:000071607000040
J	Crair, MC; Gillespie, DC; Stryker, MP				Crair, MC; Gillespie, DC; Stryker, MP			The role of visual experience in the development of columns in cat visual cortex	SCIENCE			English	Article							BINOCULAR IMPULSE BLOCKADE; OCULAR DOMINANCE COLUMNS; ORIENTATION SELECTIVITY; MONOCULAR DEPRIVATION; POSTNATAL-DEVELOPMENT; SENSITIVE PERIOD; CORTICAL-CELLS; KITTENS; FERRET; CONNECTIONS	The role of experience in the development of the cerebral cortex has long been controversial. Patterned visual experience in the cat begins when the eyes open about a week after birth. Cortical maps for orientation and ocular dominance in the primary visual cortex of cats were found to be present by 2 weeks. Early pattern vision appeared unimportant because these cortical maps developed identically until nearly 3 weeks of age, whether or not the eyes were open. The naive maps were powerfully dominated by the contralateral eye, and experience was needed for responses to the other eye to become strong, a process unlikely to be strictly Hebbian, With continued visual deprivation, responses to both eyes deteriorated, with a time course parallel to the well-known critical period of cortical plasticity. The basic structure of cortical maps is therefore innate, but experience is essential for specific features of these maps, as well as for maintaining the responsiveness and selectivity of cortical neurons.	Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Stryker, MP (corresponding author), Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, Box 0444, San Francisco, CA 94143 USA.			Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY002874, R37 EY002874-20, EY09760, EY02874] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; ANTONINI A, 1993, J NEUROSCI, V13, P3549; Antonini A, 1996, J COMP NEUROL, V369, P64; BARLOW HB, 1971, J PHYSIOL-LONDON, V218, P98; BLAKEMORE C, 1973, NATURE, V241, P467, DOI 10.1038/241467a0; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BONHOEFFER T, 1996, BRAIN MAPPING METHOD, P75; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1997, J NEUROPHYSIOL, V77, P3381, DOI 10.1152/jn.1997.77.6.3381; CRAIR MC, UNPUB; FREGNAC Y, 1978, J PHYSIOL-LONDON, V278, P27, DOI 10.1113/jphysiol.1978.sp012290; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IMBERT M, 1975, EXP BRAIN RES, V22, P25; Kohonen T., 1989, SELF ORG ASS MEMORY; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Movshon J.A., 1990, P155; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PETTIGREW JD, 1974, J PHYSIOL-LONDON, V237, P49, DOI 10.1113/jphysiol.1974.sp010469; PRESTON KL, 1993, EARLY VISUAL DEV NOR, P80; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHERK H, 1976, J NEUROPHYSIOL, V39, P63, DOI 10.1152/jn.1976.39.1.63; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TORREALBA F, 1982, J COMP NEUROL, V211, P377, DOI 10.1002/cne.902110405; von der Malsburg C, 1979, Biol Cybern, V32, P49, DOI 10.1007/BF00337452; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	40	436	447	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					566	570		10.1126/science.279.5350.566	http://dx.doi.org/10.1126/science.279.5350.566			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438851	Green Accepted			2022-12-28	WOS:000071616000048
J	Bucher, HC; Griffith, LE; Guyatt, GH				Bucher, HC; Griffith, LE; Guyatt, GH			Effect of HMGcoA reductase inhibitors on stroke - A meta-analysis of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med		HMGcoA inhibitors; cerebrovascular; meta-analysis; randomized; hypercholesterolemia	CORONARY HEART-DISEASE; CHOLESTEROL-LOWERING TRIALS; PRIMARY-PREVENTION TRIAL; MIDDLE-AGED MEN; SERUM-CHOLESTEROL; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ARTERY DISEASE; MORTALITY; RISK	Background: Stroke is a leading cause of death in the industrialized world, and hypercholesterolemia may be a risk factor for stroke. Objective: To determine whether reducing cholesterol levels with HMGcoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors or other antilipidemic interventions reduces risk for nonfatal and fatal stroke. Data Sources: A systematic search in the MEDLINE and EMBASE databases of the English-language and non-English-language literature published from 1966 through October 1996. Study Selection: All randomized, controlled trials of any cholesterol-lowering intervention that reported data on nonfatal and fatal strokes, on death from coronary heart disease, and on overall mortality were included. Whether treatment effects differed according to the type of cholesterol-lowering intervention used was investigated. Data Extraction: Trials were reviewed for methods, inclusion and exclusion criteria, and outcomes. Data Synthesis: 28 trials (for a total of 49 477 study participants in the intervention group and 56 636 participants in the control group) were included. The risk ratio for nonfatal and fatal stroke with HMGcoA reductase inhibitors was 0.76 (95% CI, 0.62 to 0.92; test of heterogeneity, P > 0.2). The risk ratios for nonfatal and fatal stroke with fibrates, resins, and dietary interventions were all close to 1.0, and the difference between the HMGcoA reductase inhibitor effect and the pooled estimate for all other interventions would, under the null hypothesis, be unlikely to occur by chance (P = 0.01). Trials with HMGcoA reductase inhibitors also showed reductions in rates of death from coronary heart disease and overall mortality. Conclusion: This meta-analysis of randomized, controlled trials suggests that in hyperlipidemic patients who have not previously had stroke, HMGcoA reductase inhibitors reduce the incidence of stroke.	Univ Basel, Kantonsspital, Med Poliklin, CH-4031 Basel, Switzerland; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	Kantonsspital Aarau AG (KSA); University of Basel; McMaster University	Bucher, HC (corresponding author), Univ Basel, Kantonsspital, Med Poliklin, CH-4031 Basel, Switzerland.							ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1970, JAMA, V214, P1303; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1993, Am J Cardiol, V72, P1031; [Anonymous], 1973, Stroke, V4, P684; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; Begg T B, 1971, Minerva Med, V62, P3469; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1994, AM J CARDIOL, V73, P1133, DOI 10.1016/0002-9149(94)90297-6; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HJERMANN I, 1981, LANCET, V2, P1303; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Leren P, 1966, Acta Med Scand Suppl, V466, P1; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PEDERSEN TR, 1994, LANCET, V344, P1383; Qizilbash N, 1995, LANCET, V346, P1647; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SACKS FM, 1995, J AM COLL CARDIOL, V25, P1492, DOI 10.1016/0735-1097(95)00095-L; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; *SCOTT SOC PHYS, 1971, BMJ-BRIT MED J, V790, P775; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; The Coronary Drug Project, 1972, JAMA-J AM MED ASSOC, V220, P996, DOI [10.1001/jama.1972.03200070084015, DOI 10.1001/JAMA.1972.03200070084015]; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009; *VET ADM COOP STUD, 1966, CIRCULATION S, V33, P113; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065	52	176	178	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					89	+		10.7326/0003-4819-128-2-199801150-00002	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YR200	9441587				2022-12-28	WOS:000071470800002
J	Strain, L; Dean, JCS; Hamilton, MPR; Bonthron, DT				Strain, L; Dean, JCS; Hamilton, MPR; Bonthron, DT			A true hermaphrodite chimera resulting from embryo amalgamation after in vitro fertilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCIES; MAP		Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Aberdeen Royal Infirm, Dept Med Genet, Aberdeen, Scotland; Univ Aberdeen, Aberdeen Matern Hosp, Dept Obstet & Gynaecol, Assisted Reprod Unit, Aberdeen, Scotland	University of Edinburgh; University of Aberdeen; University of Aberdeen	Bonthron, DT (corresponding author), Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.			Bonthron, David/0000-0001-8132-8179				Bernasko J, 1997, OBSTET GYNECOL, V89, P368, DOI 10.1016/S0029-7844(96)00527-3; BIEBER FR, 1981, SCIENCE, V213, P775, DOI 10.1126/science.7196086; BROMILOW IM, 1989, VOX SANG, V57, P147, DOI 10.1111/j.1423-0410.1989.tb01153.x; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FARAG TI, 1987, J MED GENET, V24, P784, DOI 10.1136/jmg.24.12.784; FITZGERALD PH, 1979, CLIN GENET, V15, P89; FORD CE, 1969, BRIT MED BULL, V25, P104, DOI 10.1093/oxfordjournals.bmb.a070658; FRIEDLER S, 1992, HUM REPROD, V7, P1159, DOI 10.1093/oxfordjournals.humrep.a137813; GREEN AJ, 1994, J MED GENET, V31, P816, DOI 10.1136/jmg.31.10.816; Olivennes F, 1996, FERTIL STERIL, V66, P105, DOI 10.1016/S0015-0282(16)58395-2; Poissonnier M, 1987, J Genet Hum, V35, P119; Roest J, 1997, FERTIL STERIL, V67, P290, DOI 10.1016/S0015-0282(97)81913-9; Saunders K, 1996, PEDIATRICS, V97, P688; SAWAI T, 1994, AM J MED GENET, V49, P428, DOI 10.1002/ajmg.1320490415; SCHOENLE E, 1983, HUM GENET, V64, P86, DOI 10.1007/BF00289485; STAESSEN C, 1993, HUM REPROD, V8, P1650, DOI 10.1093/oxfordjournals.humrep.a137907; STRAIN L, 1995, NAT GENET, V11, P164, DOI 10.1038/ng1095-164; VERP MS, 1992, FERTIL STERIL, V57, P346; WATKINS WM, 1981, J IMMUNOGENET, V8, P113	20	79	80	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					166	169		10.1056/NEJM199801153380305	http://dx.doi.org/10.1056/NEJM199801153380305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428825				2022-12-28	WOS:000071384500005
J	Freedberg, KA; Scharfstein, JA; Seage, GR; Losina, E; Weinstein, MC; Craven, DE; Paltiel, AD				Freedberg, KA; Scharfstein, JA; Seage, GR; Losina, E; Weinstein, MC; Craven, DE; Paltiel, AD			The cost-effectiveness of preventing AIDS-related opportunistic infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SECONDARY PROPHYLAXIS; RANDOMIZED TRIAL; CUBIC MILLIMETER; VIRUS INFECTION; RIFABUTIN; THERAPY; DISEASE	Context-Multiple options are now available for prophylaxis of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS). However, because of differences in incidence rates as well as drug efficacy, toxicity, and costs, the role of different types of prophylaxis remains uncertain. Objective.-To determine the clinical impact, cost, and cost-effectiveness of strategies for preventing opportunistic infections in patients with advanced human immunodeficiency virus (HIV) disease. Design.-We developed a Markov simulation model to compare different strategies for prophylaxis of Pneumocystis carinii pneumonia (PCP), toxoplasmosis, Mycobacterium avium complex (MAC) infection, fungal infections, and cytomegalovirus (CMV) disease in HIV-infected patients. Data for the model were derived from the Multicenter AIDS Cohort Study, randomized controlled trials, and the national AIDS Cost and Services Utilization Survey. Main Outcome Measures.-Projected life expectancy, quality-adjusted life expectancy, total lifetime direct medical costs, and cost-effectiveness in dollars per quality-adjusted life-year (QALY) saved. Results.-For patients with CD4 cell counts of 0.200 to 0.300x10(9)/L (200-300/mu L) who receive no prophylaxis, we projected a quality-adjusted life expectancy of 39.08 months and average total lifetime costs of $40 288. Prophylaxis for PCP and toxoplasmosis with trimethoprim-sulfamethoxazole for patients with CD4 cell counts of 0.200x10(9)/L (200/mu L) or less increased quality-adjusted life expectancy to 42.56 months, implying an incremental cost of $16 000 per QALY saved. Prophylaxis for MAC for patients with CD4 cell counts of 0.050x10(9)/L (50/mu L) or less produced smaller gains in quality-adjusted life expectancy; incremental cost-effectiveness ratios were $35 000 per QALY saved for azithromycin and $74 000 per QALY saved for rifabutin. Oral ganciclovir for the prevention of CMV infection was the least cost-effective prophylaxis ($314 000 per QALY saved). Results were most sensitive to the risk of developing an opportunistic infection, the impact of opportunistic infection history on long-term survival, and the cost of prophylaxis. Conclusions.-The cost-effectiveness of prophylaxis against HIV-related opportunistic infections varies widely, but prophylaxis against PCP or toxoplasmosis and against MAC delivers the greatest comparative value. In an era of limited resources, these results can be used to set priorities and explore new alternatives for improving HIV patient care.	Boston Univ, Med Ctr, Dept Med, Clin Econ Res Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Clin AIDS Program, Boston, MA 02118 USA; Boston Univ, Med Ctr, Evans Med Fdn, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Yale University	Freedberg, KA (corresponding author), Boston Univ, Med Ctr, Dept Med, Clin Econ Res Unit, 91E Concord St,Suite 200, Boston, MA 02118 USA.			Losina, ELENA/0000-0002-3424-0892; Paltiel, A. David/0000-0002-4861-3290	AHRQ HHS [1-RO1-HS07317-01A1] Funding Source: Medline; NIAMS NIH HHS [K24 AR057827] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR057827] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERK M, 1993, AHCPR PUBLICATION; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; BROSGART C, 1996, 11 INT C AIDS JUL 7; *BUR CENS, 1995, STAT ABSTR US; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; *CDCP, 1993, HIV AIDS SURVEIL FEB, P7; DOYLE A, 1997, STATE AIDS DRUG ASSI; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Finkelstein DM, 1996, J ACQ IMMUN DEF SYND, V12, P38, DOI 10.1097/00042560-199605010-00006; Freedberg KA, 1996, MED DECIS MAKING, V16, P29, DOI 10.1177/0272989X9601600110; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; Freedberg KA, 1997, J ACQ IMMUN DEF SYND, V15, P275, DOI 10.1097/00042560-199708010-00005; GOLD MR, 1996, GOST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; JACOBSON MA, 1997, 4 C RETR OPP INF JAN; KAPLAN JE, 1995, CLIN INFECT DIS    S, V21, P512; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KASPAR R, 1997, 4 C RETR OPP INF JAN; *MED EC, 1996, DRUG TOP RED BOOK; MIETTINEN OS, 1983, AM J EPIDEMIOL, V38, P963; MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; *NAT PUBL HLTH HOS, 1991, HOSP AIDS HIV SURV; *NAT TECHN INF SER, 1994, AIDS COST SERV UT SU; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PALTIEL AD, IN PRESS INTERFACES; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; ROBBINS GK, 1997, 4 C RETR OPP INF JAN; Rose DN, 1997, AIDS, V11, P883, DOI 10.1097/00002030-199707000-00007; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; Scharfstein JA, 1997, MED DECIS MAKING, V17, P373, DOI 10.1177/0272989X9701700402; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7; WALMSLEY S, 1997, 4 C RETR OPP INF JAN	48	167	169	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					130	136		10.1001/jama.279.2.130	http://dx.doi.org/10.1001/jama.279.2.130			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440663	Bronze			2022-12-28	WOS:000071338900030
J	Hemminki, A; Markie, D; Tomlinson, I; Avizienyte, E; Roth, S; Loukola, A; Bignell, G; Warren, W; Aminoff, M; Hoglund, P; Jarvinen, H; Kristo, P; Pelin, K; Ridanpaa, M; Salovaara, R; Toro, T; Bodmer, W; Olschwang, S; Olsen, AS; Stratton, MR; de la Chapelle, A; Aaltonen, LA				Hemminki, A; Markie, D; Tomlinson, I; Avizienyte, E; Roth, S; Loukola, A; Bignell, G; Warren, W; Aminoff, M; Hoglund, P; Jarvinen, H; Kristo, P; Pelin, K; Ridanpaa, M; Salovaara, R; Toro, T; Bodmer, W; Olschwang, S; Olsen, AS; Stratton, MR; de la Chapelle, A; Aaltonen, LA			A serine/threonine kinase gene defective in Peutz-Jegheus syndrome	NATURE			English	Article							MUTATIONS; CANCER	Studies of hereditary cancer syndromes have contributed greatly to our understanding of molecular events involved in tumorigenesis. Here we investigate the molecular background of the Peutz-Jeghers syndrome(1,2) (PJS), a rare hereditary disease in which there is predisposition to benign and malignant tumours of many organ systems. A locus for this condition was recently assigned to chromosome 19p (ref. 3). We have identified truncating germline mutations in a gene residing on chromosome 19p in multiple individuals affected by PJS. This previously identified but unmapped gene, LKB1 (ref. 4), has strong homology to a cytoplasmic Xenopus serine/threonine protein kinase XEEK1 (ref. 5), and weaker similarity to many other protein kinases. Peutz-Jeghers syndrome is therefore the first cancer-susceptibility syndrome to be identified that is due to inactivating mutations in a protein kinase.	Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00290 Helsinki, Finland; Folkhalsan Inst Genet, Helsinki 00280, Finland; John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Canc & Immunogenet Lab, Oxford OX3 9DS, England; Fdn Jean Dausset CEPH, INSERM, U434, F-75010 Paris, France; Univ Calif Lawrence Livermore Natl Lab, Ctr Human Genome, Livermore, CA 94550 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; University of Helsinki; University of Otago; University of London; Institute of Cancer Research - UK; University of Oxford; University of Helsinki; Helsinki University Central Hospital; University of Oxford; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Aaltonen, LA (corresponding author), Univ Helsinki, Haartman Inst, Dept Med Genet, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Lauri.Aaltonen@Helsinki.Fi	Markie, David/I-7893-2019; Aaltonen, Lauri/A-5375-2010; Olschwang, Sylviane/G-2716-2013	Aaltonen, Lauri/0000-0001-6839-4286; Olschwang, Sylviane/0000-0001-7078-3029; Bodmer, Walter/0000-0001-6244-9792; Pelin, Katarina/0000-0002-7040-7266; Loukola, Anu-Maria/0000-0003-0542-5967; Markie, David/0000-0001-5452-9194				ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; JEGHERS H, 1949, NEW ENGL J MED, V241, P992; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KO MSH, SYSTEMATIC ANAL MOUS; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEZU J, UNPUB MOL CLONING NO; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; PHILLIPS RK, 1994, FAMILIAL ADENOMATOUS; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	15	1165	1243	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					184	187		10.1038/34432	http://dx.doi.org/10.1038/34432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428765				2022-12-28	WOS:000071380900053
J	Cogo, A; Lensing, AWA; Koopman, MMW; Piovella, F; Siragusa, S; Wells, PS; Villalta, S; Buller, HR; Turpie, AGG; Prandoni, P				Cogo, A; Lensing, AWA; Koopman, MMW; Piovella, F; Siragusa, S; Wells, PS; Villalta, S; Buller, HR; Turpie, AGG; Prandoni, P			Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							SERIAL IMPEDANCE PLETHYSMOGRAPHY; VENOUS THROMBOSIS; OUTPATIENTS; ULTRASOUND	Objective: To evaluate the safety of withholding anticoagulant treatment from patients with clinically suspected deep vein thrombosis but normal findings on compression ultrasonography. Design: Compression ultrasonography was done with a simplified diagnostic procedure limited to the common femoral vein in the groin and the popliteal vein extending down to the trifurcation of the calf veins. Patients with normal ultrasonography findings at presentation were retested 1 week later. Main outcome measure: The incidence of venous thromboembolic complications during follow up for 6 months in patients in whom anticoagulant treatment was withheld on the basis of normal results on two ultrasonography tests 1 week apart. Setting: University research centres in four hospitals. Results: A total of 1702 patients were included in the study. Abnormal results on compression ultrasonography at presentation or at 1 week were found in 400 and 12 patients, respectively, for a prevalence of deep vein thrombosis of 24%. None of the patients were lost to follow up. Venous thromboembolic complications during the week of serial testing occurred in a single patient and in eight patients during 6 months' follow up, resulting in a cumulative rate of venous thromboembolic complications of 0.7% (95% confidence interval 0.3% to 1.2%). The mean number of extra hospital visits and additional tests required per initially referred patient was 0.8. Conclusion: It is safe to withhold anticoagulant treatment from patients with clinically suspected deep vein thrombosis who have a normal result on compression ultrasonography at the time of presentation and at 1 week.	Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Hamilton Gen Hosp, HGH McMaster Clin, Hamilton, ON L8L 2X2, Canada; Policlin San Matteo, Med Clin 2, I-27100 Pavia, Italy; Univ Padua, Ist Semeiot Med, I-35128 Padua, Italy	University of Amsterdam; Academic Medical Center Amsterdam; McMaster University; IRCCS Fondazione San Matteo; University of Padua	Lensing, AWA (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, H-2, NL-1105 AZ Amsterdam, Netherlands.	a.w.lensing@amc.uva.nl	Piovella, Franco/AAM-8305-2020					APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184	15	298	307	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					17	20		10.1136/bmj.316.7124.17	http://dx.doi.org/10.1136/bmj.316.7124.17			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451260	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071377900016
J	Dickstein, K				Dickstein, K			Natriuretic peptides in detection of heart failure	LANCET			English	Editorial Material									Cent Hosp Rogaland, Div Cardiol, N-4011 Stavanger, Norway		Dickstein, K (corresponding author), Cent Hosp Rogaland, Div Cardiol, N-4011 Stavanger, Norway.							COWIE MR, 1997, LANCET, V350, P1347; HALL C, 1995, CIRCULATION, V91, P911; Muders F, 1997, AM HEART J, V134, P442, DOI 10.1016/S0002-8703(97)70079-6; MURDOCH D, 1997, HEART, V398, P594	4	27	30	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					4	4		10.1016/S0140-6736(05)78100-9	http://dx.doi.org/10.1016/S0140-6736(05)78100-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433417				2022-12-28	WOS:000071253100003
J	Pogue, J; Yusuf, S				Pogue, J; Yusuf, S			Overcoming the limitations of current meta-analysis of randomised controlled trials	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; INTRAVENOUS-MAGNESIUM; SYSTEMATIC REVIEWS; HEALTH-CARE; METAANALYSIS; INTERVENTION; OVERVIEWS; MORTALITY; SURGERY	For a meta-analysis to give definitive information, it should meet at least the minimum standards that would be expected of a well-designed, adequately powered, and carefully conducted randomised controlled trial. These minimum standards include both qualitative characteristics-a prospective protocol, comparable definitions of key outcomes, quality control of data, and inclusion of all patients from all trials in the final analysis-and quantitative standards-an assessment of whether the total sample is large enough to provide reliable results and the use of appropriate statistical monitoring guidelines to indicate when the results of the accumulating data of a meta-analysis are conclusive. We believe that rigorous meta-analyses undertaken according to these principles will lead to more reliable evidence about the efficacy and safety of interventions than either retrospective meta-analysis or individual trials.	McMaster Univ, Div Cardiol, Hamilton, ON, Canada; Hamilton Civ Hosp, Prevent Cardiol & Therapeut Program, Res Ctr, Hamilton, ON, Canada	McMaster University; McMaster University	Yusuf, S (corresponding author), Hamilton Gen Hosp, McMaster Clin, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.csu.mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				Alderman EL, 1996, NEW ENGL J MED, V335, P217; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANELLO C, 1995, J CLIN EPIDEMIOL, V48, P109, DOI 10.1016/0895-4356(94)00084-4; [Anonymous], 1996, Lancet, V348, P283; [Anonymous], 1993, Lancet, V342, P767; [Anonymous], 1986, Lancet, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BEROYZ G, 1994, LANCET, V343, P619; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P768; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; Clarke M. J., 1995, SYSTEMATIC REV, P37; COLLINS R, 1995, LANCET, V345, P669; Connolly SJ, 1996, CIRCULATION, V94, P578, DOI 10.1161/01.CIR.94.3.578; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Dickersin K, 1995, SYSTEMATIC REV, P17; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; FURBERG CD, 1987, STAT MED, V6, P295, DOI 10.1002/sim.4780060316; HALPERIN M, 1982, CONTROL CLIN TRIALS, V3, P311, DOI 10.1016/0197-2456(82)90022-8; LABIANCA R, 1995, LANCET, V345, P939; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; *N AM SYMPT CAR EN, 1997, NEUROLOGY, V48, P911; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; PATER JL, 1994, STAT MED, V13, P1337, DOI 10.1002/sim.4780131307; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; POGUE J, IN PRESS CONTROLLED; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Sandercock P, 1997, LANCET, V349, P1569; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SOMMER A, 1986, LANCET, V1, P1169; TEO KK, 1993, DRUGS, V46, P347, DOI 10.2165/00003495-199346030-00002; Valsecchi MG, 1996, ANN ONCOL, V7, P1005; VICTOR N, 1995, J CLIN EPIDEMIOL, V48, P5, DOI 10.1016/0895-4356(94)00107-2; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1987, STAT MED, V6, P281, DOI 10.1002/sim.4780060314; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; YUSUF S, 1993, CIRCULATION, V87, P2043, DOI 10.1161/01.CIR.87.6.2043	48	299	317	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	1998	351	9095					47	52		10.1016/S0140-6736(97)08461-4	http://dx.doi.org/10.1016/S0140-6736(97)08461-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433436				2022-12-28	WOS:000071253100044
J	Best, PJ; Daoud, MS; Pittelkow, MR; Petitt, RM				Best, PJ; Daoud, MS; Pittelkow, MR; Petitt, RM			Hydroxyurea-induced leg ulceration in 14 patients	ANNALS OF INTERNAL MEDICINE			English	Article							THERAPY	Background: Hydroxyurea is an antineoplastic agent commonly used to treat myeloproliferative disorders and other nonneoplastic conditions. Objective: To further define the typical features of hydroxyurea-related cutaneous ulcers of the leg. Design: Retrospective, descriptive study of the medical records of patients who developed leg ulcers while receiving hydroxyurea therapy. Setting: A tertiary care medical center. Patients: Patients with myeloproliferative disorders who were treated with hydroxyurea. Results: 14 patients with extremely painful leg ulcers were identified. The most common ulcer site was the malleoli. Multiple ulcers were seen in 64% of patients. Patients had received hydroxyurea for an average of 6 years before ulcers developed. All ulcers healed after discontinuation of hydroxyurea treatment, and 2 patients developed ulcers after treatment was restarted. Conclusion: Hydroxyurea induces painful leg ulcers that are usually difficult to treat and require cessation of hydroxyurea therapy.	Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pittelkow, MR (corresponding author), Mayo Clin & Mayo Fdn, Dept Dermatol, 200 1st St SW, Rochester, MN 55905 USA.							BOYD AS, 1991, J AM ACAD DERMATOL, V25, P518, DOI 10.1016/0190-9622(91)70233-R; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Daoud MS, 1997, J AM ACAD DERMATOL, V36, P178, DOI 10.1016/S0190-9622(97)70276-7; DONEHOWER RC, 1992, SEMIN ONCOL, V19, P11; FITZPATRICK JE, 1993, J CUTAN PATHOL, V20, P1, DOI 10.1111/j.1600-0560.1993.tb01242.x; KINSELLA TJ, 1992, SEMIN ONCOL, V19, P41; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; MONTEFUSCO E, 1986, TUMORI, V72, P317, DOI 10.1177/030089168607200314; NGUYEN TV, 1993, CUTIS, V52, P217; RODGERS GP, 1993, NEW ENGL J MED, V328, P73, DOI 10.1056/NEJM199301143280201; STOCK CC, 1960, CANCER RES, V20, P193; YARBRO JW, 1992, SEMIN ONCOL, V19, P1	12	111	113	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					29	32		10.7326/0003-4819-128-1-199801010-00005	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424978				2022-12-28	WOS:000071158000005
J	Meulenberg, F				Meulenberg, F			The hidden delight of psoriasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Dutch Coll Gen Practitioners, NL-3511 AN Utrecht, Netherlands		Meulenberg, F (corresponding author), Dutch Coll Gen Practitioners, Oudegracht 16, NL-3511 AN Utrecht, Netherlands.							BENNETT P, 1991, PRACTITIONER, V235, P241; Boyd Brian, 1991, V NABOKOV AM YEARS; Boyd Brian, 1990, V NABOKOV RUSSIAN YE; FARBER EM, 1991, INT J DERMATOL, V30, P295, DOI 10.1111/j.1365-4362.1991.tb04644.x; Fuller Graham Fuller, 1993, POTTER POTTER; Gupta M A, 1990, Adv Dermatol, V5, P21; INGRAM JT, 1954, BMJ-BRIT MED J, V2, P823, DOI 10.1136/bmj.2.4892.823; Ishiguro Kazuo, 1995, UNCONSOLED; JOWETT S, 1985, SOC SCI MED, V20, P425, DOI 10.1016/0277-9536(85)90021-8; LANIGAN SW, 1991, BRIT J DERMATOL, V125, P340, DOI 10.1111/j.1365-2133.1991.tb14168.x; NABOKOV V, 1990, SELECTED LETT 1940 1, P25; Nabokov Vladimir, 1971, ADA ARDOR FAMILY CHR; Nabokov Vladimir, 1974, STRONG OPINIONS; PALMEN C, 1992, LAWS; Potter Dennis, 1986, SINGING DETECTIVE; POUER D, 1994, SEEING BLOSSOM 2 INT; RAMSAY B, 1988, BRIT J DERMATOL, V118, P195, DOI 10.1111/j.1365-2133.1988.tb01774.x; UPDIKE J, 1980, PROBLEMS OTHER STORI, P181; UPDIKE J, 1991, ODD JOBS ESSAYS CRIT, P865; UPDIKE J, 1963, CENTAUR; Updike John, 1989, SELF CONSCIOUSNESS M; WITTKOWER E, 1946, LANCET, V250, P566	22	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 20	1997	315	7123					1709	1711		10.1136/bmj.315.7123.1709	http://dx.doi.org/10.1136/bmj.315.7123.1709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448549	Green Published			2022-12-28	WOS:000071149400041
J	van Loon, AJ; Mantingh, A; Serlier, EK; Kroon, G; Mooyaart, EL; Huisjes, HJ				van Loon, AJ; Mantingh, A; Serlier, EK; Kroon, G; Mooyaart, EL; Huisjes, HJ			Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term	LANCET			English	Article							MANAGEMENT; DELIVERY	Background Pelvimetry is widely used in women with breech presentation at term to select those for whom planned vaginal delivery is appropriate. However, its clinical value has never been established, We evaluated pelvimetry in a randomised controlled trial. The main outcome measures were the elective and emergency caesarean-section rates and the early condition of the neonate. Methods Magnetic-resonance (MR) pelvimetry was done on 235 women. The women were then randomly assigned to two groups-for the study group (n=118), the pelvimetry results were reported to the responsible obstetricians, who used them as the basis for decisions on whether to schedule elective caesarean or trial of labour; for the control group (n=117), the pelvimetry results were not disclosed until 8 weeks post partum, and decisions about obstetric management were made on the basis of clinical factors only. Findings 35 women (15 [13%] study group, 20 [17%] control group) had abnormalities on pelvimetry. The overall caesarean-section rates did not differ significantly between the study and control groups (50 [42%] vs 59 [50%], p=0.24) but the emergency caesarean-section rate was significantly lower in the study group than in the control group (22 [19%] vs 41 [35%], p=0.0052). The mean 1 min Apgar scores in the study and control groups were 8 1 and 8.0 (p=0.93) and the mean 3 min scores 9.5 and 9.4, respectively (p=0.28). There were no significant differences in the early neonatal outcome for infants born vaginally, by emergency caesarean section, or by elective caesarean section in the two groups, except for a significantly lower Apgar score in the six infants born vaginally to control-group women who had pelvic abnormalities. Interpretation The use of MR pelvimetry in breech presentation at term did not significantly reduce the overall caesarean-section rate. However, it allowed better selection of the delivery route, with a significantly lower emergency caesarean-section rate. Neonatal outcome was not compromised by use of the pelvimetry data.	Univ Groningen Hosp, Dept Obstet & Gynaecol, Groningen, Netherlands; Univ Groningen Hosp, Dept Radiol, Groningen, Netherlands	University of Groningen; University of Groningen	van Loon, AJ (corresponding author), Martini Hosp Groningen, Dept Obstet & Gynaecol, POB 30033, NL-9700 RM Groningen, Netherlands.							BAKER PN, 1994, AM J OBSTET GYNECOL, V170, P32; BAUER M, 1992, GEBURTSH FRAUENHEILK, V52, P322, DOI 10.1055/s-2007-1023759; BEERS GJ, 1989, MAGN RESON IMAGING, V7, P309, DOI 10.1016/0730-725X(89)90556-0; BERKOWITZ RL, 1983, CLIN DIAGNOSTIC PR A, P191; CALLY E, 1993, BRIT J OBSTET GYNAEC, V100, P531; CHENG M, 1993, OBSTET GYNECOL, V82, P605; COLLEA JV, 1980, AM J OBSTET GYNECOL, V137, P235, DOI 10.1016/0002-9378(80)90780-2; Confino E, 1985, Obstet Gynecol Surv, V40, P330, DOI 10.1097/00006254-198506000-00002; DIEHL J, 1968, ACTA OBSTET GYNEC S7, V47, P1; FELTMAN GB, 1985, NEW ENGL J MED, V312, P1264; GIMOVSKY ML, 1983, AM J OBSTET GYNECOL, V146, P34, DOI 10.1016/0002-9378(83)90923-7; HARRIS JM, 1959, JAMA-J AM MED ASSOC, V169, P570, DOI 10.1001/jama.1959.03000230026006; JOYCE DN, 1975, BMJ-BRIT MED J, V4, P505, DOI 10.1136/bmj.4.5995.505; Kauppila O, 1975, Acta Obstet Gynecol Scand Suppl, V39, P1; KWAST BE, 1994, LANCET, V343, P1399; MYERS SA, 1987, AM J OBSTET GYNECOL, V156, P6, DOI 10.1016/0002-9378(87)90193-1; NOTZON FC, 1987, NEW ENGL J MED, V316, P386, DOI 10.1056/NEJM198702123160706; OLEARY JA, 1979, OBSTET GYNECOL, V53, P341; ROVINSKY JJ, 1973, AM J OBSTET GYNECOL, V115, P497, DOI 10.1016/0002-9378(73)90398-0; SCHIFRIN BS, 1974, CONT OB GYN, V4, P77; STARK DD, 1985, AM J ROENTGENOL, V144, P947, DOI 10.2214/ajr.144.5.947; TODD WD, 1963, OBSTET GYNECOL, V22, P583; VANLOON AJ, 1990, AM J OBSTET GYNECOL, V163, P1256, DOI 10.1016/0002-9378(90)90702-9	23	63	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1799	1804		10.1016/S0140-6736(97)05431-7	http://dx.doi.org/10.1016/S0140-6736(97)05431-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428250				2022-12-28	WOS:000071102500008
J	Edwards, D; Johnson, NW; Cooper, D; Warnakulasuriya, KAAS				Edwards, D; Johnson, NW; Cooper, D; Warnakulasuriya, KAAS			Management of cancers of the head and neck in the United Kingdom: questionnaire survey of consultants	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Surg England, Dept Dent Sci, London SE5 9RW, England; Univ London Kings Coll, Sch Med & Dent, Sch Dent, Dept Oral Med & Pathol, London SE5 9RW, England; Univ London Kings Coll, Sch Med & Dent, Comp Informat Ctr, Western Educ Ctr, London SE5 9DJ, England	Royal College of Surgeons of England; University of London; King's College London; University of London; King's College London	Edwards, D (corresponding author), Bedfordshire Hlth Author, Charter House, Luton LU1 2PL, Beds, England.		Johnson, Newell W/D-8152-2019; , WARNAKULASURIYA/ABB-3793-2020	Johnson, Newell W/0000-0001-5866-262X; Warnakulasuriya, Saman/0000-0003-2103-0746				Birchall M, 1995, HEAD NECK CANC SERVI; EDWARDS D, 1997, FACE FACE HEAD NECK; *EXP ADV GROUP CAN, 1995, REP EXP ADV GROUP CA; LORE JM, 1987, ARCH OTOLARYNGOL, V113, P1165; RAPIDIS AD, 1980, ANN ROY COLL SURG, V62, P116	5	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1589	1589		10.1136/bmj.315.7122.1589	http://dx.doi.org/10.1136/bmj.315.7122.1589			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437278	Green Published			2022-12-28	WOS:000071021900025
J	Rothwell, PM; Slattery, J; Warlow, CP				Rothwell, PM; Slattery, J; Warlow, CP			Clinical and angiographic predictors of stroke and death from carotid endarterectomy: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSIENT ISCHEMIC ATTACKS; NEUROLOGIC COMPLICATIONS; RISK-FACTORS; STENOSIS; ARTERY; SURGERY; AGE; INFARCTION; ANESTHESIA; OPERATIONS	Objective: To identify risk factors for operative stroke and death from carotid endarterectomy. Design: Systematic review of all studies published since 1980 which related risk of stroke and death to various preoperative clinical and angiographic characteristics, including unpublished data on 1729 patients from the European carotid surgery trial Main outcome measure: Operative risk of stroke and death. Results: Thirty sh published studies fulfilled our criteria. The effect of 14 potential risk factors was examined. The odds of stroke and death were decreased in patients with ocular ischaemia alone (amaurosis fugax or retinal artery occlusion) compared with those with cerebral transient ischaemic attack or stroke (seven studies; odds ratio 0.49; 95% confidence interval 0.37 to 0.66; P < 0.00001). The odds were increased in women (seven studies; 1.41; 1.14 to 1.83; P < 0.005), subjects aged greater than or equal to 75 years (10 studies; 1.36; 1.09 to 1.71; P < 0.01), and with systolic blood pressure > 180 mm Hg (four studies; 1.82; 1.37 to 2.41; P < 0.0001), peripheral vascular disease (one study; 2.19; 1.40 to 3.60; P < 0.0005), occlusion of the contralateral internal carotid artery (14 studies; 1.91; 1.35 to 2.69; P < 0.0001), stenosis of the ipsilateral internal carotid siphon (five studies; 1.56; 1.03 to 2.36; P = 0.02), and stenosis of the ipsilateral external carotid artery (one study; 1.61; 1.05 to 2.47; P = 0.03). Operative risk was not significantly related to presentation with cerebral transient ischaemic attack versus stroke, diabetes, angina, recent myocardial infarction, current cigarette smoking, or plaque surface irregularity at angiography. Multiple regression analysis of data from the European carotid surgery trial identified cerebral versus ocular events at presentation, female sex, systolic hypertension, and peripheral vascular disease as independent risk factors. Conclusions: The risk of stroke and death from carotid endarterectomy is related to several clinical and angiographic characteristics. These observations may help clinicians to estimate operative risks for individual patients and will also facilitate more meaningful comparison of the operative risks of different surgeons or at different institutions by allowing some adjustment for differences in case mix.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Woodstock Rd, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLCUTT D A, 1991, British Journal of Neurosurgery, V5, P257, DOI 10.3109/02688699109005185; [Anonymous], 1995, Lancet, V345, P209; BASS A, 1987, J VASC SURG, V5, P893; BEEBE HG, 1989, STROKE, V20, P314; BERNSTEIN EF, 1987, J VASC SURG, V6, P333, DOI 10.1067/mva.1987.avs0060333; CAFFERATA HT, 1986, J CARDIOVASC SURG, V27, P557; DUTCH TIA, 1993, STROKE, V24, P527; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; FISHER ES, 1989, AM J PUBLIC HEALTH, V79, P1617, DOI 10.2105/AJPH.79.12.1617; FODE NC, 1986, STROKE, V17, P370, DOI 10.1161/01.STR.17.3.370; FRIEDMANN P, 1988, STROKE, V19, P1323, DOI 10.1161/01.STR.19.11.1323; GOLDSTEIN LB, 1994, STROKE, V25, P1116, DOI 10.1161/01.STR.25.6.1116; HAFNER CD, 1988, J VASC SURG, V7, P232, DOI 10.1067/mva.1988.avs0070232; HAFNER CD, 1984, J VASC SURG, V1, P392, DOI 10.1067/mva.1984.avs0010392; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HERTZER NR, 1982, SURGERY, V92, P1049; HERTZER NR, 1986, ANN SURG, V204, P163, DOI 10.1097/00000658-198608000-00010; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; JANSEN C, 1993, STROKE, V24, P665, DOI 10.1161/01.STR.24.5.665; KIRSHNER DL, 1989, J VASC SURG, V10, P178, DOI 10.1067/mva.1989.vs0100178; LEES CD, 1981, ARCH SURG-CHICAGO, V116, P1561; MACKEY WC, 1989, J VASC SURG, V10, P432; MACKEY WC, 1990, J VASC SURG, V11, P778, DOI 10.1067/mva.1990.20249; Magnan P E, 1993, Ann Vasc Surg, V7, P521, DOI 10.1007/BF02000146; MATTOS MA, 1992, J CARDIOVASC SURG, V33, P387; MAXWELL JG, 1990, AM J SURG, V160, P598, DOI 10.1016/S0002-9610(05)80753-6; MCCRORY DC, 1993, STROKE, V24, P1285, DOI 10.1161/01.STR.24.9.1285; MEYER FB, 1991, MAYO CLIN PROC, V66, P464, DOI 10.1016/S0025-6196(12)62385-4; MOORE DJ, 1984, J VASC SURG, V1, P409, DOI 10.1067/mva.1984.avs0010409; MOORE WS, 1995, STROKE, V26, P188, DOI 10.1161/01.STR.26.1.188; MORROW CE, 1988, SURGERY, V103, P242; NUNN DB, 1988, J VASC SURG, V8, P447; OURIEL K, 1986, SURG GYNECOL OBSTET, V162, P334; PEITZMAN AB, 1982, ANN SURG, V196, P59, DOI 10.1097/00000658-198207000-00013; PERLER BA, 1992, J VASC SURG, V16, P347, DOI 10.1016/0741-5214(92)90367-H; PINKERTON JA, 1990, J VASC SURG, V11, P650, DOI 10.1067/mva.1990.19227; PLECHA FR, 1985, J VASC SURG, V2, P769, DOI 10.1067/mva.1985.avs0020769; RILES TS, 1994, J VASC SURG, V19, P206, DOI 10.1016/S0741-5214(94)70096-6; ROTHWELL P, 1995, LANCET, V346, P1623, DOI 10.1016/S0140-6736(95)91953-8; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; Rothwell PM, 1996, CEREBROVASC DIS, V6, P54, DOI 10.1159/000107997; Rothwell PM, 1996, STROKE, V27, P266, DOI 10.1161/01.STR.27.2.266; ROTHWELL PM, 1994, CEREBROVASC DIS, V1, P260; SACHS SM, 1984, SURGERY, V96, P839; SANDMANN W, 1993, STROKE, V24, P1098, DOI 10.1161/01.STR.24.7.1098; SCHULER JJ, 1982, SURGERY, V92, P1058; SCHULTZ RD, 1988, SURG GYNECOL OBSTET, V166, P245; SISE MJ, 1989, STROKE, V20, P329, DOI 10.1161/01.STR.20.3.329; Slattery J, 1996, LANCET, V347, P1591; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; TAKOLANDER RJ, 1983, BRIT J SURG, V70, P13, DOI 10.1002/bjs.1800700105; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WEINTRAUB WS, 1993, CIRCULATION, V88, P79; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1995, COCHRANE DATABASE SY	57	274	280	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 13	1997	315	7122					1571	1577		10.1136/bmj.315.7122.1571	http://dx.doi.org/10.1136/bmj.315.7122.1571			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437274	Green Published			2022-12-28	WOS:000071021900021
J	Tracey, JM; Arroll, B; Richmond, DE; Barham, PM				Tracey, JM; Arroll, B; Richmond, DE; Barham, PM			The validity of general practitioner's self assessment of knowledge: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CONTINUING MEDICAL-EDUCATION; PERFORMANCE	Objective: To determine whether general practitioners can make accurate self assessments of their knowledge in specific areas. Design: 67 general practitioners completed a self assessment of their level of knowledge over a variety of topics using a nine point semantic differential scale, An objective assessment of their knowledge was then made by administering true-false tests an two of the topics: thyroid disorders and non-insulin dependent diabetes. The study was repeated with another group of 60 general practitioners, using sexually transmitted diseases as the topic. Setting: General practices in New Zealand, Subjects: Random sample of 67 general practitioners in Auckland. Main outcome measure: Test scores fur self assessment and for actual knowledge. Results: Correlations between self assessments and test scores were poor for all three topics studied (r = 0.19 for thyroid disorders, 0.21 for non-insulin dependent diabetes, 0.19 for sexually transmitted diseases). Conclusions: As general practitioners cannot accurately assess their own level of knowledge on a given topic, professional development programmes that rely on the doctors' self perceptions to assess their-needs are likely to be seriously flawed.	UNIV AUCKLAND,FAC MED & HLTH SCI,DEPT GEN PRACTICE,AUCKLAND 1,NEW ZEALAND	University of Auckland	Tracey, JM (corresponding author), UNIV AUCKLAND,FAC MED & HLTH SCI,GOODFELLOW UNIT,PRIVATE BAG 92019,AUCKLAND 1,NEW ZEALAND.							DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; GABB R, 1994, CERTIFICATION RECERT, P47; JANSEN JJM, 1995, MED EDUC, V29, P247, DOI 10.1111/j.1365-2923.1995.tb02839.x; Knowles M., 1984, ANDRAGOGY ACTION APP; Knowles MS., 1978, ADULT LEARNER NEGLEC, V2nd ed; NORCINI JJ, 1994, ACAD MED, V69, pS90, DOI 10.1097/00001888-199410000-00053; Rogers C.R., 1969, FREEDOM LEARN; *SAS, 1994, SAS COMMUNICATIONS, V20, P1; STEIN LS, 1981, J MED EDUC, V56, P103; WARD J, 1988, MED J AUSTRALIA, V148, P77, DOI 10.5694/j.1326-5377.1988.tb104512.x; WOOLLISCROFT JO, 1993, ACAD MED, V68, P285, DOI 10.1097/00001888-199304000-00016	11	105	107	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1426	1428		10.1136/bmj.315.7120.1426	http://dx.doi.org/10.1136/bmj.315.7120.1426			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418092	Green Published			2022-12-28	WOS:A1997YJ67200028
J	Weder, C; Sarwa, C; Montali, A; Bastiaansen, G; Smith, P				Weder, C; Sarwa, C; Montali, A; Bastiaansen, G; Smith, P			Incorporation of photoluminescent polarizers into liquid crystal displays	SCIENCE			English	Article							CONJUGATED POLYMERS; ELECTROLUMINESCENCE; POLYETHYLENE	Liquid crystal displays, the dominant flat panel display technology, are limited in brightness and energy efficiency because of the use of absorbing polarizers and color filters. Liquid crystal-based photoluminescent display devices have been fabricated that use thin, polarized photoluminescent layers that have highly anisotropic absorption or emission. These layers both polarize light and generate bright color. This approach can simplify device design and substantially increase device brightness, contrast, efficiency, and (in specific configurations) viewing angle.	ETH Zurich, Inst Polymers, Dept Mat, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Weder, C (corresponding author), ETH Zurich, Inst Polymers, Dept Mat, UNO C14, CH-8092 Zurich, Switzerland.		Weder, Christoph/K-7453-2012	Weder, Christoph/0000-0001-7183-1790				BAUR G, 1977, APPL PHYS LETT, V31, P4, DOI 10.1063/1.89476; BECHTLER M, 1977, ELECTRONICS, V50, P113; Bradley D, 1996, CURR OPIN SOLID ST M, V1, P789, DOI 10.1016/S1359-0286(96)80103-3; Chan L. K. M., 1994, ENCY ADV MAT, V2, P1294; Cimrova V, 1996, ADV MATER, V8, P146, DOI 10.1002/adma.19960080209; COLES HJ, 1993, LIQ CRYST, V14, P1039, DOI 10.1080/02678299308027811; CROSSLAND WA, 1997, P SID S, V27, P837; DYREKLEV P, 1995, ADV MATER, V7, P43, DOI 10.1002/adma.19950070108; FUNADA F, 1982, Patent No. 4336980; Giesa R, 1996, J MACROMOL SCI R M C, VC36, P631; HAGLER TW, 1991, PHYS REV B, V44, P8652, DOI 10.1103/PhysRevB.44.8652; HAGLER TW, 1991, POLYM COMMUN, V32, P339; KOBAYASHI H, 1993, P SOC PHOTO-OPT INS, V1910, P15, DOI 10.1117/12.151162; Lommel E., 1879, ANN PHYS CHEM, V8, P634; Lussem G, 1996, LIQ CRYST, V21, P903, DOI 10.1080/02678299608032908; Montali AT, 1997, P SOC PHOTO-OPT INS, V3148, P298, DOI 10.1117/12.279328; Steiger D, 1997, MACROMOL RAPID COMM, V18, P643, DOI 10.1002/marc.1997.030180804; Weder C, 1997, ADV MATER, V9, P1035, DOI 10.1002/adma.19970091308; Weder C, 1996, MACROMOLECULES, V29, P5157, DOI 10.1021/ma950902y; WEDER C, Patent No. 971112297; WEDER C, 1997, POLYM PREPR, V38, P404; WUDL F, 1993, Patent No. 5189136	22	280	294	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					835	837		10.1126/science.279.5352.835	http://dx.doi.org/10.1126/science.279.5352.835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452376				2022-12-28	WOS:000071923500034
J	Arioli, T; Peng, LC; Betzner, AS; Burn, J; Wittke, W; Herth, W; Camilleri, C; Hofte, H; Plazinski, J; Birch, R; Cork, A; Glover, J; Redmond, J; Williamson, RE				Arioli, T; Peng, LC; Betzner, AS; Burn, J; Wittke, W; Herth, W; Camilleri, C; Hofte, H; Plazinski, J; Birch, R; Cork, A; Glover, J; Redmond, J; Williamson, RE			Molecular analysis of cellulose biosynthesis in Arabidopsis	SCIENCE			English	Article							PLASMA-MEMBRANE ROSETTES; PLANT TRANSFORMATION; ACETOBACTER-XYLINUM; CATALYTIC SUBUNIT; THALIANA; SEQUENCE; SYNTHASE; GENE; GENOME; MAP	Cellulose, an abundant, crystalline polysaccharide, is central to plant morphogenesis and to many industries. Chemical and ultrastructural analyses together with map-based cloning indicate that the RSW1 locus of Arabidopsis encodes the catalytic subunit of cellulose synthase. The cloned gene complements the rsw1 mutant whose temperature-sensitive allele is changed in one amino acid. The mutant allele causes a specific reduction in cellulose synthesis, accumulation of noncrystalline beta-1,4-glucan, disassembly of cellulose synthase, and widespread morphological abnormalities. Microfibril crystallization may require proper assembly of the RSW1 gene product into synthase complexes whereas glucan biosynthesis per se does not.	Australian Natl Univ, Res Sch Biol Sci, Plant Cell Biol Grp, Glycobiol Unit, Canberra, ACT 2601, Australia; Australian Natl Univ, Cooperat Res Ctr Plant Sci, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Grp Limagrain Pacific, Canberra, ACT 2601, Australia; Zellenlehre, D-69120 Heidelberg, Germany; INRA, Biol Cellulaire Lab, F-78026 Versailles, France	Australian National University; Australian National University; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Williamson, RE (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Plant Cell Biol Grp, Glycobiol Unit, POB 475, Canberra, ACT 2601, Australia.	richard@rsbs.anu.edu.au						BASKIN TI, 1992, AUST J PLANT PHYSIOL, V19, P427, DOI 10.1071/PP9920427; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CARPITA NC, 1989, ANAL CARBOHYDRATES G, P157; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; Cutler S, 1997, CURR BIOL, V7, pR108, DOI 10.1016/S0960-9822(06)00050-9; DELMER DP, 1995, PLANT CELL, V7, P987, DOI 10.1105/tpc.7.7.987; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HELM DR, 1991, PESTIC BIOCH PHYSL, V39, P93; HERTH W, 1985, PLANTA, V164, P12, DOI 10.1007/BF00391020; HERTH W, 1985, BOTANICAL MICROSCOPY, P285; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; Kawagoe Yasushi, 1997, Plant Physiology (Rockville), V114, P85; KONCZ C, 1992, METHODS ARABIDOPSISR; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kutish GF, 1996, VIROLOGY, V223, P303, DOI 10.1006/viro.1996.0482; MATTHYSSE AG, 1995, J BACTERIOL, V177, P1069, DOI 10.1128/jb.177.4.1069-1075.1995; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NEEDS PW, 1993, PHYTOCHEM ANALYSIS, V4, P210, DOI 10.1002/pca.2800040504; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; Saxena IM, 1997, CELLULOSE, V4, P33, DOI 10.1023/A:1018411101036; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHNEIDER B, 1986, PROTOPLASMA, V131, P142, DOI 10.1007/BF01285036; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; UPDEGRAFF DM, 1969, ANAL BIOCHEM, V32, P420, DOI 10.1016/S0003-2697(69)80009-6; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130	32	624	689	15	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					717	720		10.1126/science.279.5351.717	http://dx.doi.org/10.1126/science.279.5351.717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445479				2022-12-28	WOS:000071731500040
J	Nimnual, AS; Yatsula, BA; Bar-Sagi, D				Nimnual, AS; Yatsula, BA; Bar-Sagi, D			Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos	SCIENCE			English	Article							TRANSFORMATION; ACTIVATION; PROTEIN; PATHWAY; KINASE; DBL; PLECKSTRIN; EFFECTORS; SEVENLESS; DISTINCT	The Son of Sevenless (Sos) proteins control receptor-mediated activation of Ras by catalyzing the exchange of guanosine diphosphate for guanosine triphosphate on Ras. The NH2-terminal region of Sos contains a Dbl homology (DH) domain in tandem with a pleckstrin homology (PH) domain. In COS-1 cells, the DH domain of Sos stimulated guanine nucleotide exchange on Rac but not Cdc42 in vitro and in vivo. The tandem DH-PH domain of Sos (DH-PH-Sos) was defective in Rac activation but regained Rac stimulating activity when it was coexpressed with activated Ras, Ras-mediated activation of DH-PH-Sos did not require activation of mitogen-activated protein kinase but it was dependent on activation of phosphoinositide 3-kinase. These results reveal a potential mechanism for coupling of Ras and Rac signaling pathways.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NCI NIH HHS [CA55360, CA09176, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, P01CA028146, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BROEK D, COMMUNICATION; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NIMNUAL A, UNPUB; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAMEH LE, 1997, J BIOL CHEM, V272, P21999; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YATSULA B, UNPUB; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	30	382	386	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					560	563		10.1126/science.279.5350.560	http://dx.doi.org/10.1126/science.279.5350.560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438849				2022-12-28	WOS:000071616000046
J	Sullivan, R; Greeley, R; Homan, K; Klemaszewski, J; Belton, MJS; Carr, MH; Chapman, CR; Tufts, R; Head, JW; Pappalardo, R; Moore, J; Thomas, P				Sullivan, R; Greeley, R; Homan, K; Klemaszewski, J; Belton, MJS; Carr, MH; Chapman, CR; Tufts, R; Head, JW; Pappalardo, R; Moore, J; Thomas, P		Galileo Imaging Team	Episodic plate separation and fracture infill on the surface of Europa	NATURE			English	Article								Images obtained by the Voyager spacecraft revealed dark, wedge-shaped bands on Europa that were interpreted as evidence that surface plates, 50-100 km across, moved and rotated relative to each other(1). This implied that they may be mechanically decoupled from the interior by a layer of warm ice or Liquid water(2,3). Here we report similar features seen in higher resolution images (420 metres per pixel) obtained by the Galileo spacecraft that reveal new details of wedge-band formation. In particular, the interior of one dark band shows bilateral symmetry of parallel lineaments and pit complexes which indicates that plate separation occurred in discrete episodes from a central axis. The images also show that this style of tectonic activity involved plates < 10 km across. Although this tectonic style superficially resembles aspects of similar activity on Earth, such as sea-floor spreading and the formation of ice leads in polar seas, there are significant differences in the underlying physical mechanisms: the wedge-shaped bands on Europa most probably formed when lower material (ice or water) rose to fill the fractures that widened in response to regional surface stresses.	Cornell Univ, Ithaca, NY 14853 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; US Geol Survey, Menlo Pk, CA 94025 USA; SW Res Inst, Boulder, CO 80302 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA	Cornell University; National Optical Astronomy Observatory; United States Department of the Interior; United States Geological Survey; University of Arizona; Brown University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Arizona State University; Arizona State University-Tempe	Sullivan, R (corresponding author), Cornell Univ, 308 Space Sci, Ithaca, NY 14853 USA.		Pappalardo, Robert/AAP-8953-2021; Sullivan, Robert/AAR-8193-2020	Pappalardo, Robert/0000-0003-2571-4627; 				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; FANALE FP, 1977, PLANETARY SATELLITES, P379; GOLOMBEK MP, 1990, ICARUS, V83, P441, DOI 10.1016/0019-1035(90)90078-N; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SCHENK PM, 1980, EOS T AM GEOPHYS UN, V61, P286; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; TUFTS BR, 1996, LUNAR PLANET SCI, V27, P1343; TUFTS BR, 1993, LUN PLANET SCI C, V24, P1445; TUFTS BR, 1997, LUNAR PLANET SCI C, V28, P1455	13	88	89	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					371	373		10.1038/34874	http://dx.doi.org/10.1038/34874			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450752				2022-12-28	WOS:000071604200048
J	Carapeti, EA; Kamm, MA; McDonald, PJ; Phillips, RKS				Carapeti, EA; Kamm, MA; McDonald, PJ; Phillips, RKS			Double-blind randomised controlled trial of effect of metronidazole on pain after day-case haemorrhoidectomy	LANCET			English	Article							INTERNAL SPHINCTEROTOMY; HEMORRHOIDECTOMY; LIGATION; FISSURE	Background Haemorrhoidectomy is commonly an inpatient procedure because patients and doctors worry about postoperative pain. Day-case haemorrhoidectomy (DCH) is possible if patient anxiety is addressed and postoperative pain and bower function are managed. Pain sometimes increases a few days after haemorrhoidectomy, possibly because of secondary infection. We studied the effect of metronidazole on pain after DCH, Methods We randomly assigned 40 consecutive patients admitted for DCH metronidazole 400 mg (n=20) or placebo (n=20) three times daily, both for 7 days. All patients received lactulose from 2 days before surgery for 2 weeks. Diathermy DCH was performed without pedicle ligature or anal-canal dressing, and a diclofenac suppository was administered at the end of the procedure. Patients were discharged on the same day with diclofenac, 0.2% glyceryl-trinitrate ointment, lactulose, a telephone number to call for queries in emergencies, and an outpatient appointment. Patients took paracetamol or Co-dydramol (dihydrocodeine and paracetamol) as required; they completed linear analogue charts every day and completed questionnaires on satisfaction at 1 and 6 weeks. Findings 34 patients had all three major piles excised, of whom seven had additional division and reconstruction of the posterior skin bridge. Overall, both groups of patients experienced less pain than expected, except on days 3 and 4. Patients in the metronidazole group had significantly less pain than those in the placebo group on days 5, 6, and 7 (p=0.004, p=0.02, and p=0.006). Median time to return to work or normal activity was 15 days (range 12-28) in the metronidazole group and 18 days (7-34) in the placebo group (p=0.009). The patient satisfaction score was higher in the metronidazole group than in the placebo group at 1 week (p=0.005). Interpretation Prophylactic metronidazole in diathermy DCH suppressed secondary pain around days 5-7 and increased patient satisfaction and earlier return to work.	St Marks Hosp, Dept Surg, Harrow HA1 3UJ, Middx, England; St Marks Hosp, Dept Physiol, Harrow HA1 3UJ, Middx, England	Imperial College London; Imperial College London	Phillips, RKS (corresponding author), St Marks Hosp, Dept Surg, Harrow HA1 3UJ, Middx, England.							ADAMI B, 1981, DIS COLON RECTUM, V24, P373, DOI 10.1007/BF02603422; ANDREWS BT, 1993, DIS COLON RECTUM, V36, P580, DOI 10.1007/BF02049865; ASFAR SK, 1988, DIS COLON RECTUM, V31, P181, DOI 10.1007/BF02552543; Bullock N, 1997, BRIT MED J, V314, P419, DOI 10.1136/bmj.314.7078.419; CHENG FCY, 1981, AUST NZ J SURG, V51, P458, DOI 10.1111/j.1445-2197.1981.tb05985.x; CHESTER JF, 1990, DIS COLON RECTUM, V33, P487, DOI 10.1007/BF02052143; DEPAULA PR, 1991, DIS COLON RECTUM, V34, P664, DOI 10.1007/BF02050347; GOLDSTEIN ET, 1993, DIS COLON RECTUM, V36, P439, DOI 10.1007/BF02050008; HODGSON WJB, 1995, DIS COLON RECTUM, V38, P1265; JUSTINS DM, 1992, ANN ROY COLL SURG, V74, P78; KHUBCHANDANI IT, 1989, BRIT J SURG, V76, P431, DOI 10.1002/bjs.1800760504; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; Loder PB, 1993, CURR PRACT SURG, V5, P29; LONDON NJM, 1987, BRIT MED J, V295, P363, DOI 10.1136/bmj.295.6594.363; ODONOVAN S, 1994, DIS COLON RECTUM, V37, P793, DOI 10.1007/BF02050144; Pfenninger JL, 1997, BMJ-BRIT MED J, V314, P1211, DOI 10.1136/bmj.314.7089.1211; PRYN SJ, 1989, ANAESTHESIA, V44, P964, DOI 10.1111/j.1365-2044.1989.tb09196.x; RUDD WWH, 1989, INT SURG, V74, P148; SANTOS G, 1993, DIS COLON RECTUM, V36, P958, DOI 10.1007/BF02050633; SCARPA FJ, 1988, SURGERY, V103, P383; SEOWCHOEN F, 1992, DIS COLON RECTUM, V35, P1165, DOI 10.1007/BF02251970; WALKER WA, 1985, DIS COLON RECTUM, V28, P832, DOI 10.1007/BF02555487; WATTS JMK, 1965, SURG GYNECOL OBSTETR, V120, P1037	23	138	149	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					169	172		10.1016/S0140-6736(97)09003-X	http://dx.doi.org/10.1016/S0140-6736(97)09003-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449871				2022-12-28	WOS:000071616300010
J	Arap, W; Pasqualini, R; Ruoslahti, E				Arap, W; Pasqualini, R; Ruoslahti, E			Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model	SCIENCE			English	Article							PHAGE DISPLAY LIBRARY; INTEGRIN ALPHA(V)BETA(3); SOLID TUMORS; ANGIOGENESIS; PEPTIDE; THERAPY; ANTIBODIES; RECEPTOR; BINDING; LIGAND	In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels. When coupled to the anticancer drug doxorubicin, two of these peptides-one containing an alpha(v) integrin-binding Arg-Gly-Asp motif and the other an Asn-Gly-Arg motif-enhanced the efficacy of the drug against human breast cancer xenografts in nude mice and also reduced its toxicity. These results indicate that it may be possible to develop targeted chemotherapy strategies that are based on selective expression of receptors in tumor vasculature.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruoslahti@burnham-inst.org			NCI NIH HHS [CA30199, CA74238-01, CA62042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074238, R01CA062042, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, UNPUB; Bauminger S, 1980, Methods Enzymol, V70, P151; Berger DP, 1991, NUDE MOUSE ONCOLOGY, P165; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman Judah, 1997, P3075; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GETTER MR, 1973, NATURE, V246, P221; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HART SL, 1994, J BIOL CHEM, V269, P12468; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; JAIN RK, 1996, CANCER METAST REV, V9, P253; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Max R, 1997, INT J CANCER, V72, P706, DOI 10.1002/(SICI)1097-0215(19970807)72:4<706::AID-IJC25>3.0.CO;2-7; Nagy A, 1996, P NATL ACAD SCI USA, V93, P7269, DOI 10.1073/pnas.93.14.7269; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; RAJOTTE D, UNPUB; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAKAMOTO M, UNPUB; SHOCKLEY TR, 1991, ANN NY ACAD SCI, V618, P367, DOI 10.1111/j.1749-6632.1991.tb27257.x; Steiner R, 1992, EXS, V61, P449	37	1732	1987	5	422	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					377	380		10.1126/science.279.5349.377	http://dx.doi.org/10.1126/science.279.5349.377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430587				2022-12-28	WOS:000071570800045
J	Bada, JL; Glavin, DP; McDonald, GD; Becker, L				Bada, JL; Glavin, DP; McDonald, GD; Becker, L			A search for endogenous amino acids in martian meteorite ALH84001	SCIENCE			English	Article							MURCHISON METEORITE; GENERATION; HYDROLYSIS; MARS	Trace amounts of glycine, serine, and alanine were detected in the carbonate component of the martian meteorite ALH84001 by high-performance liquid chromatography. The detected amino acids were not uniformly distributed in the carbonate component and ranged in concentration from 0.1 to 7 parts per million. Although the detected alanine consists primarily of the L enantiomer, low concentrations (<0.1 parts per million) of endogenous D-alanine may be present in the ALH84001 carbonates. The amino acids present in this sample of ALH84001 appear to be terrestrial in origin and similar to those in Allan Hills ice, although the possibility cannot be ruled out that minute amounts of some amino acids such as D-alanine are preserved in the meteorite.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System	Bada, JL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	jbada@ucsd.edu	Glavin, Daniel P/D-6194-2012	Glavin, Daniel P/0000-0001-7779-7765				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; BADA JL, 1995, NATURE, V374, P594, DOI 10.1038/374594a0; Bada JL, 1996, ANAL CHEM, V68, pA668, DOI 10.1021/ac9621231; BADA JL, 1983, NATURE, V301, P494, DOI 10.1038/301494a0; Bada JL, 1997, SCIENCE, V275, P942, DOI 10.1126/science.275.5302.942; Becker L, 1997, GEOCHIM COSMOCHIM AC, V61, P475, DOI 10.1016/S0016-7037(96)00400-0; Brinton KLF, 1996, GEOCHIM COSMOCHIM AC, V60, P349, DOI 10.1016/0016-7037(95)00404-1; BRINTON KLF, IN PRESS ORIGINS LIF; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; D'Hendecourt L., 1997, Astronomical Society of the Pacific Conference Series, V122, P129; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; EVANS JCE, 1996, NATURE, V381, P644; GIBSON EK, 1980, P LUNAR PLANET SCI C, V12, P1223; GRADY MM, 1994, METEORITICS, V29, P469; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; Jull AJT, 1998, SCIENCE, V279, P366, DOI 10.1126/science.279.5349.366; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; KEIL RG, 1991, MAR CHEM, V33, P243, DOI 10.1016/0304-4203(91)90070-D; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; MACKENZIE AS, 1982, SCIENCE, V217, P491, DOI 10.1126/science.217.4559.491; MCDONALD GD, 1995, GEOCHIM COSMOCHIM AC, V59, P1179, DOI 10.1016/0016-7037(95)00033-V; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1991, GEOCHIM COSMOCHIM AC, V55, P77, DOI 10.1016/0016-7037(91)90401-P; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; POLLOCK GE, 1975, GEOCHIM COSMOCHIM AC, V39, P1571, DOI 10.1016/0016-7037(75)90159-3; RAMDAHL T, 1983, NATURE, V306, P580, DOI 10.1038/306580a0; Scott ERD, 1997, NATURE, V387, P377, DOI 10.1038/387377a0; SIMONEIT BRT, 1990, APPL GEOCHEM, V5, P3, DOI 10.1016/0883-2927(90)90031-Y; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; ZHAO MX, 1995, J CHROMATOGR A, V690, P55, DOI 10.1016/0021-9673(94)00927-2; ZHAO MX, 1989, NATURE, V339, P463, DOI 10.1038/339463a0	38	137	140	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					362	365		10.1126/science.279.5349.362	http://dx.doi.org/10.1126/science.279.5349.362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430583				2022-12-28	WOS:000071570800041
J	Lledo, PM; Zhang, XY; Sudhof, TC; Malenka, RC; Nicoll, RA				Lledo, PM; Zhang, XY; Sudhof, TC; Malenka, RC; Nicoll, RA			Postsynaptic membrane fusion and long-term potentiation	SCIENCE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC TRANSMISSION; NEUROMUSCULAR SYNAPSES; SILENT SYNAPSES; LTP; EXPRESSION; MECHANISM; ENDOSOMES; GLUTAMATE	The possibility that membrane fusion events in the postsynaptic cell may be required for the change in synaptic strength resulting from long-term potentiation (LTP) was examined. Introducing substances into the postsynaptic cell that block membrane fusion at a number of different steps reduced LTP. Introducing SNAP, a protein that promotes membrane fusion, into cells enhanced synaptic transmission, and this enhancement was significantly less when generated in synapses that expressed LTP. Thus, postsynaptic fusion events, which could be involved either in retrograde signaling or in regulating postsynaptic receptor function or both, contribute to LTP.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Calakos N, 1996, PHYSIOL REV, V76, P1; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FRANKI N, 1995, AM J PHYSIOL-CELL PH, V269, pC797, DOI 10.1152/ajpcell.1995.269.3.C797; GIROD R, 1995, J NEUROSCI, V15, P2826; Glitsch M, 1996, J PHYSIOL-LONDON, V497, P531, DOI 10.1113/jphysiol.1996.sp021786; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; HENLEY JW, COMMUNICATION; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Maletic-Savatic M. M., 1995, Society for Neuroscience Abstracts, V21, P1743; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MCWILLIAMS JR, 1981, BRAIN RES, V211, P158; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; TARRANT SB, 1977, TISSUE CELL, V9, P461, DOI 10.1016/0040-8166(77)90006-4; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WESTRUM LE, 1962, J COMP NEUROL, V119, P281, DOI 10.1002/cne.901190303; ZIFF EB, COMMUNICATION	38	310	322	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					399	403		10.1126/science.279.5349.399	http://dx.doi.org/10.1126/science.279.5349.399			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430593				2022-12-28	WOS:000071570800051
J	Devesa, R; Torrents, M				Devesa, R; Torrents, M			Fetal micturition	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Inst Univ Dexeus, E-08017 Barcelona, Spain		Devesa, R (corresponding author), Inst Univ Dexeus, E-08017 Barcelona, Spain.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					170	170		10.1056/NEJM199801153380306	http://dx.doi.org/10.1056/NEJM199801153380306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428818				2022-12-28	WOS:000071384500006
J	Preston, SL; Drusano, GL; Berman, AL; Fowler, CL; Chow, AT; Dornseif, B; Reichl, V; Natarajan, J; Corrado, M				Preston, SL; Drusano, GL; Berman, AL; Fowler, CL; Chow, AT; Dornseif, B; Reichl, V; Natarajan, J; Corrado, M			Pharmacodynamics of levofloxacin - A new paradigm for early clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPTIMAL SAMPLING THEORY; PHARMACOKINETICS; CIPROFLOXACIN; MODEL	Context.-One purpose of early clinical trials is to establish the appropriate dose of an antibiotic for phase 3 trials. Development of a relationship between the ratio of drug exposure to organism minimum inhibitory concentration (MIC) and therapeutic response early in the development process would allow an optimal choice of dose to maximize response. Objective.-To prospectively quantitate the relationship between plasma levels of levofloxacin and successful clinical and/or microbiological outcomes and occurrence of adverse events in infected patients. Design.-Multicenter open-label trial. Setting.-Twenty-two enrolling university-affiliate medical centers. Patients.-A total of 313 patients with clinical signs and symptoms of bacterial infections of the respiratory tract, skin, or urinary tract. Main Outcome Measures.-Clinical response and microbiological eradication of pathogenic organisms. Results.-Of 313 patients, 272 had plasma concentration-time data obtained. Of these, 134 patients had a pathogen recovered from the primary infection site and had an MIC of the pathogen to levofloxacin determined. These patients constituted the primary analysis group for clinical outcome. Groups of 116 and 272 patients, respectively, were analyzed for microbiological outcome and incidence of adverse events. In a logistic regression analysis, the clinical outcome was predicted by the ratio of peak plasma concentration to MIC (Peak/MIC) and site of infection (P<.001). Microbiological eradication was predicted by the Peak/MIC ratio (P<.001). Both clinical and microbiological outcomes were most likely to be favorable if the Peak/MIC ratio was at least 12.2. Conclusions.-Levofloxacin generated clinical and microbiological response rates of 95% and 96%, respectively. These response rates included fluoroquinolone "problem pathogens," such as Streptococcus pneumoniae and Staphylococcus aureus. Exposure to levofloxacin was significantly associated with successful clinical and microbiological outcomes. The principles used in these analyses can be applied to other classes of drugs to develop similar relationships between exposure and outcome. This pharmacokinetic modeling could be used to determine optimal treatment dose in clinical trials in a shorter time frame with fewer patients. This modeling also should be evaluated for its potential to improve outcomes (maximizing therapeutic response, preventing emergence of resistance, and minimizing adverse events) of patients treated with this drug.	Albany Med Coll, Dept Med, Div Clin Pharmacol, Albany, NY 12208 USA; Albany Med Coll, Dept Pharmacol, Albany, NY 12208 USA; Albany Med Coll, Dept Pharm Practice, Albany, NY 12208 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Albany Medical College; Albany Medical College; Albany Medical College; Johnson & Johnson; Johnson & Johnson USA	Drusano, GL (corresponding author), Albany Med Coll, Dept Med, Div Clin Pharmacol, 47 New Scotland Ave, Albany, NY 12208 USA.							BLASER J, 1987, ANTIMICROB AGENTS CH, V31, P1054, DOI 10.1128/AAC.31.7.1054; Breiman L., 1984, CLASSIFICATION REGRE; CHILD J, 1995, ANTIMICROB AGENTS CH, V39, P2749, DOI 10.1128/AAC.39.12.2749; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DARGENIO DZ, 1992, ADAPT 2 PROGRAM SIMU; DRUSANO GL, 1988, CLIN PHARMACOL THER, V44, P232, DOI 10.1038/clpt.1988.142; DRUSANO GL, 1989, CLIN PHARMACOL THER, V45, P635, DOI 10.1038/clpt.1989.84; DRUSANO GL, 1993, ANTIMICROB AGENTS CH, V37, P483, DOI 10.1128/AAC.37.3.483; FORREST A, 1993, ANTIMICROB AGENTS CH, V37, P1073, DOI 10.1128/AAC.37.5.1073; GITTERMAN SR, 1990, CLIN PHARMACOL THER, V48, P161, DOI 10.1038/clpt.1990.131; GOODWIN SD, 1994, ANTIMICROB AGENTS CH, V38, P799, DOI 10.1128/AAC.38.4.799; Preston SL, 1996, J CLIN PHARMACOL, V36, P301, DOI 10.1002/j.1552-4604.1996.tb04205.x; SCHUMITZKY A, 1991, APPL MATH COMPUT, V45, P143, DOI 10.1016/0096-3003(91)90077-Z; SHEINER LB, 1977, J PHARMACOKINET BIOP, V5, P445, DOI 10.1007/BF01061728; Wong FA, 1997, J PHARMACEUT BIOMED, V15, P765, DOI 10.1016/S0731-7085(96)01890-0; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; YUEN GJ, 1989, CLIN PHARMACOL THER, V46, P451, DOI 10.1038/clpt.1989.164	17	497	528	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					125	129		10.1001/jama.279.2.125	http://dx.doi.org/10.1001/jama.279.2.125			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440662	Bronze			2022-12-28	WOS:000071338900029
J	Horton, R				Horton, R			The realpolitik of a new National Health Service for the UK	LANCET			English	Editorial Material																		ALBERTI KGM, 1997, TIMES           1226, P17; Chalkley M., 1997, THEORY EVIDENCE COST; Dean M, 1997, LANCET, V350, P1829, DOI 10.1016/S0140-6736(05)63652-5; Hart JT, 1997, J EPIDEMIOL COMMUN H, V51, P623, DOI 10.1136/jech.51.6.623; HORTON RC, 1993, FABIAN REV, V105, P11; HUNT PA, 1997, TIMES           1230, P15; Kendall MJ, 1996, LANCET, V348, P528, DOI 10.1016/S0140-6736(96)03483-6; NHS, 1997, NHS MOD DEP, P86; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; 1997, GUARDIAN        1210, P18; 1997, TIMES           1210, P19	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					76	77		10.1016/S0140-6736(98)22002-2	http://dx.doi.org/10.1016/S0140-6736(98)22002-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439485				2022-12-28	WOS:000071591900002
J	Ridker, PM; Hennekens, CH; Roitman-Johnson, B; Stampfer, MJ; Allen, J				Ridker, PM; Hennekens, CH; Roitman-Johnson, B; Stampfer, MJ; Allen, J			Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men	LANCET			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; E-SELECTIN; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; ICAM-1; EXPRESSION; INTERFERON; DISEASE; VCAM-1	Background The intercellular adhesion molecule ICAM-1 mediates adhesion and transmigration of leucocytes to the vascular endothelial wall, a step proposed to be critical in the initiation and progression of atherosclerosis. Whether concentrations of soluble ICAM-1 (sICAM-1) are raised in apparently healthy individuals who later suffer acute myocardial infarction is unknown. Methods We obtained baseline plasma samples from a prospective cohort of 14 916 healthy men enrolled in the Physicians' Health Study. With a nested case-control design, we measured sICAM-1 concentrations for 474 participants who developed a first myocardial infarction, and 474 controls (participants who remained healthy throughout the 9-year, follow-up). Cases were matched to controls according to age and smoking status at the time of myocardial infarction. Findings We found a significant association between increasing concentration of sICAM-1 and risk of future myocardial infarction (p=0.003), especially among participants with baseline sICAM-1 concentrations in the highest quartile (>260 ng/mL; relative risk 1.6 [95% CI 1.1-2.4], p=0.02). This association was present overall as well as among non-smokers, and persisted after control for lipid and non-lipid risk factors. In multivariate analyses, the risk of future myocardial infarction was 80% higher for participants with baseline sICAM-1 concentrations in the highest quartile (relative risk 1.8 [1.1-2.8], p=0.02). Similar risk estimates were seen among non-smokers. We found slight but significant correlations between sICAM-1 and fibrinogen, high-density-lipoprotein cholesterol, homocysteine, triglycerides, tissue-type plasminogen-activator antigen, and C-reactive protein, but adjustment for these altered the risk little. The risk of myocardial infarction associated with raised concentrations of sICAM-1 seemed to increase with length of follow-up. Interpretation Our data support the hypothesis that cellular mediators of inflammation have a role in atherogenesis and provide a clinical basis to consider antiadhesion therapies as a novel means of cardiovascular disease prevention.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; R&D Syst Inc, Minneapolis, MN USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Ridker, PM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Dis, 900 Commonwealth Ave E, Boston, MA 02115 USA.	pmridker@bics.bwh.harvard.edu						ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; Blann AD, 1997, THROMB RES, V85, P433, DOI 10.1016/S0049-3848(97)00031-5; BLANN AD, 1994, THROMB HAEMOSTASIS, V72, P151; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; Duperray A, 1997, J BIOL CHEM, V272, P435; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Hackman A, 1996, CIRCULATION, V93, P1334, DOI 10.1161/01.CIR.93.7.1334; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEEWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Peter K, 1997, ARTERIOSCL THROM VAS, V17, P505, DOI 10.1161/01.ATV.17.3.505; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; Plow EF, 1997, CIRCULATION, V95, P1355; POBER JS, 1986, J IMMUNOL, V137, P1893; POSTON RN, 1992, AM J PATHOL, V140, P665; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; Ridker PM, 1997, CIRCULATION, V95, P1777; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANDERWAL AC, 1992, AM J PATHOL, V141, P1427; Yasukawa H, 1997, CIRCULATION, V95, P1515; ZOUKI C, 1997, J CLIN INVEST, V100, P5221	33	1005	1056	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					88	92		10.1016/S0140-6736(97)09032-6	http://dx.doi.org/10.1016/S0140-6736(97)09032-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439492				2022-12-28	WOS:000071591900009
J	Nogales, E; Wolf, SG; Downing, KH				Nogales, E; Wolf, SG; Downing, KH			Structure of the alpha beta tubulin dimer by electron crystallography	NATURE			English	Article							TAXOL-BINDING-SITE; COLCHICINE-BINDING; EXCHANGEABLE GTP; GUANOSINE TRIPHOSPHATE; BRAIN BETA-1-TUBULIN; AMINO-ACIDS; MICROTUBULE; HYDROLYSIS; LOCALIZATION; PHOTOLABELS	The alpha beta tubulin heterodimer is the structural subunit of microtubules, which are cytoskeletal elements that are essential for intracellular transport and cell division in all eukaryotes. Each tubulin monomer binds a guanine nucleotide, which is non-exchangeable when it is bound in the alpha subunit, or N site, and exchangeable when bound in the beta subunit, or E site. The alpha- and beta-tubulins share 40% amino-acid sequence identity, both exist in several isotype forms, and both undergo a variety of posttranslational modifications'. Limited sequence homology has been found with the proteins FtsZ(2) and Misato(3), which are involved in cell division in bacteria and Drosophila, respectively. Here we present an atomic model of the alpha beta tubulin dimer fitted to a 3.7-Angstrom density map obtained by electron crystallography of zinc-induced tubulin sheets. The structures of alpha- and beta-tubulin are basically identical: each monomer is formed by a core of two beta-sheets surrounded by alpha-helices. The monomer structure is very compact, but can be divided into three functional domains: the amino-terminal domain containing the nucleotide-binding region, an intermediate domain containing the Taxol-binding site, and the carboxy-terminal domain, which probably constitutes the binding surface for motor proteins.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BURNS RG, 1993, MICROTUBULES, P3; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; GUERITTEVOEGELEIN F, 1990, ACTA CRYSTALLOGR C, V46, P781, DOI 10.1107/S0108270189009376; HESSE J, 1987, J BIOL CHEM, V262, P15472; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LITTLE M, 1985, EMBO J, V4, P51, DOI 10.1002/j.1460-2075.1985.tb02316.x; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Ludvena R. F., 1998, INT REV CYTOL, V178, P207; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Miklos GLG, 1997, P NATL ACAD SCI USA, V94, P5189, DOI 10.1073/pnas.94.10.5189; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Nogales E, 1997, J STRUCT BIOL, V118, P119, DOI 10.1006/jsbi.1997.3841; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; NOGALES E, 1995, J STRUCT BIOL, V115, P199, DOI 10.1006/jsbi.1995.1044; Ponstingl H, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P191; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P894, DOI 10.1021/bi00170a007; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VALE RD, 1994, J BIOL CHEM, V269, P23769; Wolf SG, 1996, J MOL BIOL, V262, P485, DOI 10.1006/jmbi.1996.0530	30	1725	1791	5	229	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					199	203		10.1038/34465	http://dx.doi.org/10.1038/34465			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428769				2022-12-28	WOS:000071380900057
J	Wood, D; Halfon, N; Donald-Sherbourne, C; Mazel, RM; Schuster, M; Hamlin, JS; Pereyra, M; Camp, P; Grabowsky, M; Duan, NH				Wood, D; Halfon, N; Donald-Sherbourne, C; Mazel, RM; Schuster, M; Hamlin, JS; Pereyra, M; Camp, P; Grabowsky, M; Duan, NH			Increasing immunization rates among inner-city, African American children - A randomized trial of case management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; DELAYED IMMUNIZATION; COVERAGE	Context.-Immunization rates in the inner city remain lower than in the general US population, but efforts to raise immunization levels in inner-city areas have been largely untested. Objective.-To assess the effectiveness of case management in raising immunization levels among infants of inner-city, African American families. Design.-Randomized controlled trial with follow-up through 1 year of life. Setting.-Low-income areas of inner-city Los Angeles, Calif. Patients.-A representative sample of 419 African American infants and their families. Interventions.-In-depth assessment by case managers before infants were 6 weeks of age, with home visits 2 weeks prior to when immunizations were scheduled and additional follow-up visits as needed. Main Outcome Measures.-Percentage of children with up-to-date immunizations at age 1 year, characteristics associated with improved immunization rates, and cost-effectiveness of case management intervention. Results.-A total of 365 newborns were followed up to age 1 year. Overall, the immunization completion for the case management group was 13.2 percentage points higher than the control group (63.8% vs 50.6%; P=.01). In a logistic model, the case management effect was limited to the 25% of the sample who reported 3 or fewer well-child visits (odds ratio, 3.43; 95% confidence interval, 1.26-9.35); for them, immunization levels increased by 28 percentage points. Although for the case management group intervention was not cost-effective ($12 022 per additional child immunized), it was better ($4546) for the 25% of the sample identified retrospectively to have inadequate utilization of preventive health visits. Conclusions.-A case management intervention in the first year of life was effective but not cost-effective at raising immunization levels in inner-city, African American infants. The intervention was demonstrated to be particularly effective for subpopulations that do not access well-child care; however, currently there are no means to identify these groups prospectively. For case management to be a useful tool to raise immunizations levels among high-risk populations, better methods of tracking and targeting, such as immunization registries, need to be developed.	Shriners Hosp, Dept Pediat, Tampa, FL 33631 USA; Rand Corp, Santa Monica, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; NIH, Vaccine & Prevent Res Branch, Div Aids, Bethesda, MD USA	RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA	Wood, D (corresponding author), Shriners Hosp, Dept Pediat, POB 31356, Tampa, FL 33631 USA.			Duan, Naihua/0000-0001-9411-2924	PHS HHS [200-91-0942] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Baker BJ, 1997, AM J PREV MED, V13, P42, DOI 10.1016/S0749-3797(18)30112-0; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BOBO JK, 1993, PEDIATRICS, V91, P308; *CAL DEP HLTH SERV, 1996, IMM UPD; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P613; *CDCP, 1989, MMWR-MORBID MORTAL W, V38, P49; Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P705; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P619; COLOMBO TJ, 1979, AM J PUBLIC HEALTH, V69, P465, DOI 10.2105/AJPH.69.5.465; *COMP RES CTR, 1992, STATA TECHN MAN VERS; CORDERO F, 1997, AM J PREV MED S, V13, P122; FIELDING JE, 1994, JAMA-J AM MED ASSOC, V271, P525, DOI 10.1001/jama.271.7.525; Gubernick RS, 1997, AM J PREV MED, V13, P86, DOI 10.1016/S0749-3797(18)30121-1; LIEU TA, 1994, AM J PUBLIC HEALTH, V84, P1621, DOI 10.2105/AJPH.84.10.1621; MARKS JS, 1979, PEDIATRICS, V64, P304; Olds DL., 1998, FUTURE CHILD, V3, P53, DOI [DOI 10.2307/1602543, 10.2307/1602543]; PEARSON RW, 1992, QUESTIONS QUESTIONS; Schulte JM, 1996, SOUTHERN MED J, V89, P793, DOI 10.1097/00007611-199608000-00007; SELBYHARRINGTON M, 1995, AM J PUBLIC HEALTH, V85, P1412, DOI 10.2105/AJPH.85.10.1412; SILAGYI PG, 1994, ARCH PEDIAT ADOLESC, V148, P158; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; *US GEN ACC OFF, 1994, GAONSIAD954, P7; *US GEN ACC OFF, 1996, GAOPEMD9616; Watson WC, 1997, AM J PREV MED, V13, P3, DOI 10.1016/S0749-3797(18)30104-1; WILLIAMS IT, 1995, PEDIATRICS, V96, P439; WOOD D, 1995, PEDIATRICS, V96, P295; WOOD D, 1993, INCREASING IMMUNIZAT; WOOD DL, 1997, AMBUL CHILD HLTH, V4, P319; WOOD DL, 1996, RANDOMIZED TRIAL CAS; WOOD DL, 1997, 31 CDCP IMM C MAY 6; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833	32	86	86	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					29	34		10.1001/jama.279.1.29	http://dx.doi.org/10.1001/jama.279.1.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424040	Bronze			2022-12-28	WOS:000071295100031
J	Egger, M; Smith, GD				Egger, M; Smith, GD			Meta-analysis - Bias in location and selection of studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MOLECULAR-WEIGHT HEPARIN; CORONARY HEART-DISEASE; PUBLICATION BIAS; CLINICAL-TRIALS; LOWERING CHOLESTEROL; SYSTEMATIC REVIEWS; METAANALYSIS; GEMFIBROZIL; PREVENTION; MORTALITY		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Egger, M (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	m.egger@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BODEN WE, 1992, AM J CARDIOL, V69, P681, DOI 10.1016/0002-9149(92)90164-T; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Chalmers I, 1989, EFFECTIVE CARE PREGN; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; *COCHR CONTR TRIAL, 1997, COCHR LIB; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Egger M, 1996, LANCET, V347, P1047, DOI 10.1016/S0140-6736(96)90188-9; EYSENCK HJ, 1978, AM PSYCHOL, V33, P517, DOI 10.1037/0003-066X.33.5.517.a; FELSON DT, 1992, J CLIN EPIDEMIOL, V45, P885, DOI 10.1016/0895-4356(92)90072-U; FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LEVY G, 1992, CLIN PHARMACOL THER, V52, P115, DOI 10.1038/clpt.1992.119; Light R.J., 1984, SUMMING SCI REV RES; MACMAHON S, 1992, AUST NZ J MED, V22, P580, DOI 10.1111/j.1445-5994.1992.tb00481.x; MANN C, 1990, SCIENCE, V249, P476, DOI 10.1126/science.2382129; MANN C, 1990, SCIENCE, V249, P479; MANNINEN V, 1983, AM J CARDIOL, V52, pB35, DOI 10.1016/0002-9149(83)90656-2; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PEARN J, 1995, BRIT MED J, V310, P1313, DOI 10.1136/bmj.310.6990.1313; PETO R, 1985, CIRCULATION, V72, P451; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; SINGH R, 1994, LANCET, V344, P546, DOI 10.1016/S0140-6736(94)91938-0; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, IN PRESS BMJ; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; TANG JL, IN PRESS BMJ; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; ZIELINSKI C, 1995, BRIT MED J, P1780; 1984, DIABETOLOGIA, V25, pA4	53	938	959	2	49	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	1998	316	7124					61	66		10.1136/bmj.316.7124.61	http://dx.doi.org/10.1136/bmj.316.7124.61			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451274	Green Published			2022-12-28	WOS:000071377900035
J	Miki, H; Sasaki, T; Takai, Y; Takenawa, T				Miki, H; Sasaki, T; Takai, Y; Takenawa, T			Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP	NATURE			English	Article							CDC42; KINASE; RAC; POLYMERIZATION; GTPASES; COFILIN; BRAIN	Cdc42 is a small GTPase of the Rho family which regulates the formation of actin filaments to generate filopodia(1,2). Although there are several proteins such as PAK(3), ACK(4) and WASP (Wiskott-Aldrich syndrome protein)(5) that bind Cdc42 directly, none of these can account for the filopodium formation induced by Cdc42. Here we demonstrate that before it can induce filopodium formation, Cdc42 must bind a WASP-related protein, N-WASP, that is richest in neural tissues(6) but is expressed ubiquitously. N-WASP induces extremely long actin microspikes only when coexpressed with active Cdc42, whereas WASP, which is expressed in haematopoietic cells, does not, despite the structural similarities between WASP and N-WASP. In a cell-free system, addition of active Cdc42 significantly stimulates the actin-depolymerizing activity of N-WASP, creating free barbed ends from which actin polymerization can then take place. This activation seems to be caused by exposure of N-WASP's actin-depolymerizing region induced by Cdc42 binding.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 565, Japan	University of Tokyo; Osaka University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Shirokanedai 4-6-1, Tokyo 108, Japan.							AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; ASPENSTROM P, 1996, CURR BIOL, V15, P5725; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; FUKUOKAM, 1997, GENE, V196, P43; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8	15	553	560	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					93	96		10.1038/34208	http://dx.doi.org/10.1038/34208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422512				2022-12-28	WOS:000071326100056
J	Albrecht, U; Sun, ZS; Eichele, G; Lee, CC				Albrecht, U; Sun, ZS; Eichele, G; Lee, CC			A differential response of two putative mammalian circadian regulators, mper1 and mper2, to light	CELL			English	Article							SUPRACHIASMATIC NUCLEUS; DROSOPHILA PERIOD; BEHAVIORAL RHYTHMS; MESSENGER-RNA; CLOCK; PROTEIN; GENE; RAT; TIMELESS; DOMAIN	A mouse gene, mper1, having all the properties expected of a circadian clock gene, was reported recently. This gene is expressed in a circadian pattern in the suprachiasmatic nucleus (SCN). mper1 maintains this pattern of circadian expression in constant darkness and can be entrained to a new light/dark cycle. Here we report the isolation of a second mammalian gene, mper2, which also has these properties and greater homology to Drosophila period. Expression of mper1 and mper2 is overlapping but asynchronous by 4 hr. mper1, unlike period and mper2, is expressed rapidly after exposure to light at CT22. It appears that mper1 is the pacemaker component which responds to light and thus mediates photic entrainment.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Sun, Zhongsheng/AAS-4883-2020; Jansen, Heiko T./A-5770-2008; Albrecht, Urs/A-9831-2011	Sun, Zhongsheng/0000-0002-7640-5026; Jansen, Heiko T./0000-0003-0178-396X; Albrecht, Urs/0000-0002-0663-8676				Albrecht U, 1997, MOL CELLULAR METHODS, P23; Albrecht U., 1998, HUMAN GENOME METHODS, P93; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ASCHOFF J, 1969, AEROSPACE MED, V40, P844; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; CARD JP, 1991, SUPRACHIASMATIC NUCL, P51; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; HALL JC, 1993, P NATL ACAD SCI USA, V90, P5382, DOI 10.1073/pnas.90.12.5382; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HASTINGS MH, 1995, CIBA F SYMP, V183, P175; HENDRICKSON AE, 1972, Z ZELLFORSCH MIK ANA, V135, P1, DOI 10.1007/BF00307084; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1995, CIBA F SYMP, V183, P88; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Sambrook J., 2002, MOL CLONING LAB MANU; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SCHWARTZ WJ, 1995, SEMIN NEUROSCI, V7, P53, DOI 10.1016/1044-5765(95)90017-9; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1992, J NEUROGENET, V8, P33, DOI 10.3109/01677069209167270; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	44	710	725	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1055	1064		10.1016/S0092-8674(00)80495-X	http://dx.doi.org/10.1016/S0092-8674(00)80495-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428527	Bronze			2022-12-28	WOS:000071281400021
J	Lambert, PH; Siegrist, CA				Lambert, PH; Siegrist, CA			Science, medicine, and the future - Vaccines and vaccination	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VECTORS		WHO, Vaccine Res & Dev Global Programme Vaccines & Imm, CH-1211 Geneva 27, Switzerland; Univ Geneva, WHO, Ctr Neonatal Vaccinol, Dept Pediat, CH-1211 Geneva 4, Switzerland; Univ Geneva, WHO, Ctr Neonatal Vaccinol, Dept Pathol, CH-1211 Geneva 4, Switzerland	World Health Organization; University of Geneva; World Health Organization; University of Geneva; World Health Organization	Lambert, PH (corresponding author), WHO, Vaccine Res & Dev Global Programme Vaccines & Imm, CH-1211 Geneva 27, Switzerland.	lambert@who.ch						Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; KAUFMANN SHE, 1995, IMMUN INFEKT, V23, P119; Levine MM, 1996, J BIOTECHNOL, V44, P193, DOI 10.1016/0168-1656(95)00094-1; Liu MA, 1997, VACCINE, V15, P909, DOI 10.1016/S0264-410X(96)00280-0; Paoletti E, 1996, P NATL ACAD SCI USA, V93, P11349, DOI 10.1073/pnas.93.21.11349; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; *WHO, 1996, 1995 WORLD HLTH STAT; Young DB, 1997, MOL MED TODAY, V3, P6, DOI 10.1016/S1357-4310(96)20035-8	8	9	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 13	1997	315	7122					1595	1598		10.1136/bmj.315.7122.1595	http://dx.doi.org/10.1136/bmj.315.7122.1595			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437280	Green Published			2022-12-28	WOS:000071021900028
J	Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA				Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA			Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme	BRITISH MEDICAL JOURNAL			English	Article									Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England	University of Nottingham	Mayne, S (corresponding author), Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England.							[Anonymous], 1991, PRESCRIBERS J, V1, P137; HUCHET J, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P101; LETSKY EA, 1994, BRIT MED J, V309, P213, DOI 10.1136/bmj.309.6949.213; RAAFAT A, 1996, TRANSFUSION MED S2, V6, P26; TOVEY LAD, 1983, LANCET, V2, P244	5	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1588	1588		10.1136/bmj.315.7122.1588	http://dx.doi.org/10.1136/bmj.315.7122.1588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437277	Green Published			2022-12-28	WOS:000071021900024
J	Veeken, H				Veeken, H			Sudan: eating dust and returning to dust	BRITISH MEDICAL JOURNAL			English	Article											Veeken, H (corresponding author), MED SANS FRONTIERES,POB 10014,NL-1001 EA AMSTERDAM,NETHERLANDS.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1458	1460		10.1136/bmj.315.7120.1458	http://dx.doi.org/10.1136/bmj.315.7120.1458			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418102	Green Published			2022-12-28	WOS:A1997YJ67200039
J	Meier, R; Owen, TC; Matthews, HE; Jewitt, DC; Bockelee-Morvan, D; Biver, N; Crovisier, J; Gautier, D				Meier, R; Owen, TC; Matthews, HE; Jewitt, DC; Bockelee-Morvan, D; Biver, N; Crovisier, J; Gautier, D			A determination of the HDO/H2O ratio in comet C/1995 O1 (Hale-Bopp)	SCIENCE			English	Article							WATER; D/H; RATES	Deuterated water (HDO) was detected in comet C/1995 O1 (Hale-Bopp) with the use of the James Clerk Maxwell Telescope on Mauna Kea, Hawaii. The inferred D/H ratio in Hale-Bopp's water is (3.3 +/- 0.8) x 10(-4). This result is consistent with in situ measurements of comet P/Halley and the value found in C/1996 B2 (Hyakutake). This D/H ratio, higher than that in terrestrial water and more than 10 times the value for protosolar H-2,, implies that comets cannot be the only source for the oceans on Earth.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V8X 4M6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA; Observ Paris, F-92195 Meudon, France	University of Hawaii System; National Research Council Canada; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Meier, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.							Bailey ME, 1996, MON NOT R ASTRON SOC, V281, P916, DOI 10.1093/mnras/281.3.916; BALSIGER H, 1995, J GEOPHYS RES-SPACE, V100, P5827, DOI 10.1029/94JA02936; BIVER N, 1997, B AM ASTRON SOC, V29, P1047; BIVER N, 1997, THESIS U PARIS 7; BOCKELEEMORVAN D, UNPUB; BROWN PD, 1989, MON NOT R ASTRON SOC, V237, P661, DOI 10.1093/mnras/237.3.661; CROVISIER J, 1994, J GEOPHYS RES-PLANET, V99, P3777, DOI 10.1029/93JE02088; De Wit JC., 1980, GEOSTANDARD NEWSLETT, V4, P33, DOI [DOI 10.1111/J.1751-908X.1980.TB00270.X, 10.1111/j.1751-908X.1980.tb00270.x]; DELLORUSSO N, 1997, B AM ASTRON SOC, V29, P1050; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Gensheimer PD, 1996, ASTRON ASTROPHYS, V314, P281; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Haser L., 1957, B ACAD ROY SCI BELGI, V43, P740; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; LUNINE JI, 1991, ICARUS, V94, P333, DOI 10.1016/0019-1035(91)90232-I; MEHRINGER D, 1997, 6614 IAU; MEIER R, 1997, 6615 IAU; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Oort J. H., 1950, B ASTRON I NETH, V11, P91; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Owen T. C., 1997, Astronomical Society of the Pacific Conference Series, V122, P435; SCHLEICHER DG, 1997, B AM ASTRON SOC, V29, P1033; WEISSMAN PR, 1991, COMETS POST HALLEY E, V1, P463	25	203	205	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					842	844		10.1126/science.279.5352.842	http://dx.doi.org/10.1126/science.279.5352.842			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452379				2022-12-28	WOS:000071923500037
J	Schotland, H				Schotland, H			Barotrauma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hosp Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Schotland, H (corresponding author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					372	372		10.1056/NEJM199802053380606	http://dx.doi.org/10.1056/NEJM199802053380606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449731				2022-12-28	WOS:000071822200006
J	Pullen, N; Dennis, PB; Andjelkovic, M; Dufner, A; Kozma, SC; Hemmings, BA; Thomas, G				Pullen, N; Dennis, PB; Andjelkovic, M; Dufner, A; Kozma, SC; Hemmings, BA; Thomas, G			Phosphorylation and activation of p70(s6k) by PDK1	SCIENCE			English	Article							S6 KINASE; DOMAIN; SITE	Activation of the protein p70(s6k) by mitogens leads to increased translation of a family of messenger RNAs that encode essential components of the protein synthetic apparatus. Activation of the kinase requires hierarchical phosphorylation at multiple sites, culminating in the phosphorylation of the threonine in position 229 (Thr(229)), in the catalytic domain. The homologous site in protein kinase B (PKB), Thr(308), has been shown to be phosphorylated by the phosphoinositide-dependent protein kinase PDK1.A regulatory link between p70(s6k) and PKB was demonstrated, as PDK1 was found to selectively phosphorylate p70(s6k) at Thr(229). More importantly, PDK1 activated p70(s6k) in vitro and in vivo, whereas the catalytically inactive PDK1 blocked insulin-induced activation of p70(s6k).	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149; Pullen, Nicholas/0000-0002-4014-9278				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dennis P.B., UNPUB; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; HANKS SK, 1995, PROTEIN KINASE FACTS; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Meyuhas Oded, 1996, V30, P363; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	17	718	732	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					707	710		10.1126/science.279.5351.707	http://dx.doi.org/10.1126/science.279.5351.707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445476				2022-12-28	WOS:000071731500037
J	Brown, DE; Moffatt, DJ; Wolkow, RA				Brown, DE; Moffatt, DJ; Wolkow, RA			Isolation of an intrinsic precursor to molecular chemisorption	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; THERMAL-DESORPTION; LATERAL INTERACTIONS; ADSORBED STATE; ADSORPTION; BENZENE; KINETICS; SURFACE; ENERGY; NITROGEN	Over the past 70 years, numerous gas-surface adsorption studies have indicated the existence of a weakly bound, mobile intermediate that is a precursor to chemical bond formation, The direct observation and characterization of such a species are presented. Precursor and chemisorbed benzene on a silicon surface were clearly distinguished with the use of a tunable-temperature scanning tunneling microscope. Precursor decay to chemisorption was observed, allowing the salient features of the potential energy surface to be determined.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Wolkow, RA (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.							ALNOT P, 1983, SURF SCI, V126, P359, DOI 10.1016/0039-6028(83)90729-X; ARUMAINAYAGAM CR, 1991, PROGR SURFACE SCI, V38; Avouris P, 1996, SURF SCI, V363, P368, DOI 10.1016/0039-6028(96)00163-X; BECKER JA, 1953, J PHYS CHEM-US, V57, P153, DOI 10.1021/j150503a006; BECKER R, 1993, METHODS EXPT PHYSICS, V27, P149; BECKERLE JD, 1988, SURF SCI, V195, P77, DOI 10.1016/0039-6028(88)90781-9; CASSUTO A, 1981, SURF SCI, V102, P388, DOI 10.1016/0039-6028(81)90036-4; DEVELYN MP, 1987, SURF SCI, V180, P47, DOI 10.1016/0039-6028(87)90036-7; DOREN DJ, 1988, LANGMUIR, V4, P256, DOI 10.1021/la00080a004; DOREN DJ, 1991, J CHEM PHYS, V94, P8428, DOI 10.1063/1.460076; EHRLICH G, 1956, J PHYS CHEM-US, V60, P1388, DOI 10.1021/j150544a014; EIGLER DM, 1991, PHYS REV LETT, V66, P1189, DOI 10.1103/PhysRevLett.66.1189; Filipe JAN, 1995, PHYS REV E, V52, P6044, DOI 10.1103/PhysRevE.52.6044; FISCHER TE, 1977, SURF SCI, V64, P157, DOI 10.1016/0039-6028(77)90264-3; GADZUK JW, 1970, J APPL PHYS, V41, P286, DOI 10.1063/1.1658335; GRUNZE MJ, 1984, SURF SCI, V139, P109, DOI 10.1016/0039-6028(84)90012-8; HOOD ES, 1985, PHYS REV LETT, V55, P2437, DOI 10.1103/PhysRevLett.55.2437; JAKOB P, 1988, SURF SCI, V201, P503, DOI 10.1016/0039-6028(88)90500-6; Kelly M. K., 1985, Proceedings of the 17th International Conference on the Physics of Semiconductors, P109; KING DA, 1977, SURF SCI, V64, P43, DOI 10.1016/0039-6028(77)90256-4; KING DA, 1978, CRC CR REV SOL STATE, V7, P167, DOI 10.1080/10408437808243438; KING DA, 1974, PROC R SOC LON SER-A, V339, P245, DOI 10.1098/rspa.1974.0120; KISLIUK P, 1957, J PHYS CHEM SOLIDS, V3, P95, DOI 10.1016/0022-3697(57)90054-9; Kreuzer HJ, 1996, J CHEM PHYS, V104, P9593, DOI 10.1063/1.471701; Langmuir I, 1929, CHEM REV, V6, P451; Lennard-Jones JE, 1932, T FARADAY SOC, V28, P0333, DOI 10.1039/tf9322800333; LIN RF, 1983, SURF SCI, V134, P161, DOI 10.1016/0039-6028(83)90318-7; MACPHERSON CD, 1991, SOLID STATE COMMUN, V80, P217, DOI 10.1016/0038-1098(91)90184-W; Morrison JL, 1939, PROC R SOC LON SER-A, V173, P0001, DOI 10.1098/rspa.1939.0123; NORDMEYER T, 1992, J CHEM PHYS, V97, P9345, DOI 10.1063/1.463311; PLANCASTELLI MN, 1994, J ELECTRON SPECTROSC, V68, P383; RETTNER CT, 1988, J CHEM PHYS, V89, P3337, DOI 10.1063/1.454942; STRANICK SJ, 1994, SCIENCE, V266, P99, DOI 10.1126/science.266.5182.99; Stroscio J. A., 1992, Nanotechnology, V3, P133, DOI 10.1088/0957-4484/3/3/006; STROSCIO JA, 1991, SCIENCE, V254, P1319, DOI 10.1126/science.254.5036.1319; TAGUCHI Y, 1991, J CHEM PHYS, V95, P6870, DOI 10.1063/1.461498; TAGUCHI Y, 1991, CHEM PHYS LETT, V178, P363, DOI 10.1016/0009-2614(91)90266-C; TANG SL, 1986, J CHEM PHYS, V84, P6488, DOI 10.1063/1.450746; TATARENKO, 1982, J CHIM PHYS PCB, V79, P409, DOI 10.1051/jcp/1982790409; Taylor JB, 1933, PHYS REV, V44, P0423, DOI 10.1103/PhysRev.44.423; WADDILL GD, 1985, PHYS REV B, V31, P4940, DOI 10.1103/PhysRevB.31.4940; WHITMAN LJ, 1991, SCIENCE, V251, P1206, DOI 10.1126/science.251.4998.1206; WOLKOW R, 1988, PHYS REV LETT, V60, P1049, DOI 10.1103/PhysRevLett.60.1049; WOLKOW RA, 1992, REV SCI INSTRUM, V63, P4049, DOI 10.1063/1.1143264; Wolkow RA, 1995, J CHEM PHYS, V103, P10696, DOI 10.1063/1.469856	45	116	116	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					542	544		10.1126/science.279.5350.542	http://dx.doi.org/10.1126/science.279.5350.542			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438843				2022-12-28	WOS:000071616000040
J	Krentz, AJ; Evans, AJ				Krentz, AJ; Evans, AJ			Selective imidazoline receptor agonists for metabolic syndrome	LANCET			English	Editorial Material							INSULIN-RESISTANCE; HYPERTENSION; ABNORMALITIES; DISEASE; SYSTEM		Southampton Gen Hosp, Dept Endocrinol & Diabet, Southampton SO16 6YD, Hants, England	University of Southampton	Krentz, AJ (corresponding author), Southampton Gen Hosp, Dept Endocrinol & Diabet, Southampton SO16 6YD, Hants, England.		Krentz, Andrew/AAD-2493-2019					CHRISP P, 1992, DRUGS, V44, P993, DOI 10.2165/00003495-199244060-00008; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Ernsberger P, 1996, CARDIOVASC DRUG THER, V10, P275, DOI 10.1007/BF00120497; JULIUS S, 1991, J HYPERTENS, V9, P983, DOI 10.1097/00004872-199111000-00001; KAAN EC, 1995, CARDIOVASC RISK F S1, V5, P19; Landsberg Lewis, 1996, Blood Pressure, V5, P25; LITHELL H, 1997, EUR CARD SOC STOCKH; OGHIHARA T, 1995, AM J HYPERTENS, V8, P316; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; Rosen P, 1997, J HYPERTENS, V15, pS31	11	18	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					152	153		10.1016/S0140-6736(98)22003-4	http://dx.doi.org/10.1016/S0140-6736(98)22003-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449863				2022-12-28	WOS:000071616300002
J	Dexter, PR; Wolinsky, FD; Gramelspacher, GP; Zhou, XH; Eckert, GJ; Waisburd, M; Tierney, WM				Dexter, PR; Wolinsky, FD; Gramelspacher, GP; Zhou, XH; Eckert, GJ; Waisburd, M; Tierney, WM			Effectiveness of computer-generated reminders for increasing discussions about advance directives and completion of advance directive forms - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						reminder systems; advance directives; computer systems; communication; physician's role	SELF-DETERMINATION ACT; LIFE-SUSTAINING TREATMENTS; PREVENTIVE CARE; LIVING WILLS; HEALTH-CARE; PATIENT; PHYSICIANS; ATTITUDES; PREFERENCES; IMPLEMENTATION	Background: Physicians can increase the rate of completion of advance directive forms by discussing directives with their patients, but the means by which physicians can be induced to initiate these discussions are unclear. Computer-generated reminders have been shown to increase physician compliance with practice guidelines. Objective: To determine the effects of computer-generated reminders to physicians on the frequency of advance directive discussions between patients and their primary caregivers and the frequency of consequent establishment of advance directives. Design: Randomized, controlled trial with a 2 x 2 factorial design. Setting: An outpatient general medicine practice associated with an urban public hospital. Participants: Participants were 1) 1009 patients who were at least 75 years of age or were at least 50 years of age with serious underlying disease and 2) 147 primary care physicians (108 housestaff and 39 faculty). Intervention: Computer-generated reminders that recommended discussion of one or both of two types of advance directives compared with no reminders. Measurements: Discussions about advance directives, determined by patient interviews after all scheduled patient-physician outpatient encounters, and completed advance directive forms. The study period was approximately 1 year. Results: Physicians who did not receive reminders (controls) discussed advance directives with 4% of the study patients compared with 24% for physicians who received both types of reminders (adjusted odds ratio, 7.7 [95% CI, 3.4 to 18]; P < 0.001). Physicians who did not receive reminders completed advance directive forms with only 4% of their study patients compared with 15% for physicians who received both types of reminders (adjusted odds ratio, 7.0 [CI, 2.9 to 17]; P < 0.001). Overall, 45% of patients with whom advance directives were discussed completed at least one type of advance directive. Conclusions: Simple computer-generated reminders aimed at primary caregivers can increase the rates of discussion of advance directives and completion of advance directive forms among elderly outpatients with serious illnesses.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Wishard Mem Hosp, Program Med Eth, Indianapolis, IN 46262 USA; Div Biostat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis	Tierney, WM (corresponding author), Regenstrief Inst Hlth Care, 1001 W 10th St, Indianapolis, IN 46202 USA.		Wolinsky, Fredric D/F-9231-2011	Wolinsky, Fredric/0000-0002-0916-4955; Zhou, Xiaohua/0000-0001-7935-1222	AHRQ HHS [R01-HS07632] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Boyd K, 1996, ARCH INTERN MED, V156, P1821, DOI 10.1001/archinte.156.16.1821; BROADWELL AW, 1993, SOUTH MED J, V86, P165, DOI 10.1097/00007611-199302000-00003; CHAMBERS CV, 1994, ARCH INTERN MED, V154, P541, DOI 10.1001/archinte.154.5.541; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DICK AS, 1991, COMPUTER BASED PATIE; Duffield P, 1996, J FAM PRACTICE, V42, P378; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GILLICK M, 1994, ARCH INTERN MED, V154, P2134; Gramelspacher GP, 1997, J GEN INTERN MED, V12, P346, DOI 10.1007/s11606-006-5082-9; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HIGH DM, 1993, GERONTOLOGIST, V33, P342, DOI 10.1093/geront/33.3.342; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; HUGHES DL, 1992, CAN MED ASSOC J, V146, P1937; JACOBSON JA, 1994, WESTERN J MED, V160, P232; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; LURIE N, 1992, J AM GERIATR SOC, V40, P1205, DOI 10.1111/j.1532-5415.1992.tb03642.x; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MCDONALD CJ, 1988, JAMA-J AM MED ASSOC, V259, P3433, DOI 10.1001/jama.259.23.3433; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MCINTYRE KM, 1992, ARCH INTERN MED, V152, P925, DOI 10.1001/archinte.152.5.925; MCINTYRE KM, 1992, ARCH INTERN MED, V152, P259, DOI 10.1001/archinte.152.2.259; Meier DE, 1996, J AM GERIATR SOC, V44, P37, DOI 10.1111/j.1532-5415.1996.tb05635.x; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; METZGER JB, 1995, PATIENT CARE INFORMA, P1; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V265, P1868; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; *PC STUD ETH PROBL, 1983, PUBL PRES COMM STUD; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PIJNENBORG L, 1995, ARCH INTERN MED, V155, P286, DOI 10.1001/archinte.155.3.286; REILLY BM, 1995, ARCH INTERN MED, V155, P2317, DOI 10.1001/archinte.155.21.2317; ROBINSON MK, 1993, J FAM PRACTICE, V37, P363; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; Sulmasy DP, 1996, J GEN INTERN MED, V11, P657, DOI 10.1007/BF02600156; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1991, MED CARE, V29, pJS57; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; *US DEP HHS, 1980, INT CLASS DIS; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WENGER NS, 1994, J GEN INTERN MED, V9, P539, DOI 10.1007/BF02599276; 1996, MD COMPUT, V13, P485	54	143	143	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					102	+		10.7326/0003-4819-128-2-199801150-00005	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR200	9441569				2022-12-28	WOS:000071470800004
J	Quemeneur, E; Moutiez, M; Charbonnier, JB; Menez, A				Quemeneur, E; Moutiez, M; Charbonnier, JB; Menez, A			Engineering cyclophilin into a proline-specific endopeptidase	NATURE			English	Article							CIS-TRANS-ISOMERASE; ESCHERICHIA-COLI; ENZYME; ISOMERIZATION; HYDROLYSIS; MECHANISM; PROGRAM	Designing an enzyme requires, among a number of parameters, the appropriate positioning of catalytic machinery within a substrate-binding cleft. Using the structures of cyclophilin-peptide complexes(1-4), we have engineered a new catalytic activity into an Escherichia coli cyclophilin by mutating three amino acids, close to the peptide binding deft, to form a catalytic triad similar to that found in serine proteases. In conjunction with cyclophilin's specificity for proline-bearing peptides, this creates a unique endopeptidase, cyproase 1, which cleaves peptides on the amino-side of proline residues. When acting on an Ala-Pro dipeptide, cyproase 1 has an efficiency (k(cat)/K-m) of 0.7 x 10(4) M-1 s(-1) and enhances the rate of reaction (k(cat)/k(uncat)) 8 x 10(8)-fold. This activity depends upon a deprotonated histidine and is inhibited by nucleophile-specific reagents, as occurs in natural serine proteases. Cyproase 1 can hydrolyse a protein substrate with a proline-specific endoprotease activity.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Quemeneur, E (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Moutiez, Mireille/T-7788-2019; Charbonnier, Jean-Baptiste/A-3868-2009	Moutiez, Mireille/0000-0002-0064-8291; Charbonnier, Jean-Baptiste/0000-0002-5219-1983				BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P69; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; Konno M, 1996, J MOL BIOL, V256, P897, DOI 10.1006/jmbi.1996.0136; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MAILLERE B, 1995, TOXICON, V33, P475, DOI 10.1016/0041-0101(94)00186-C; MATTHEWS BW, 1994, P NATL ACAD SCI USA, V91, P4103, DOI 10.1073/pnas.91.10.4103; MENEZ A, 1980, BIOCHEMISTRY-US, V19, P5202, DOI 10.1021/bi00564a008; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Segel IH., 1993, ENZYME KINETICS BEHA; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	25	55	60	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					301	304		10.1038/34687	http://dx.doi.org/10.1038/34687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440697				2022-12-28	WOS:000071484400056
J	Marsden, AFA; Wilkinson, B; Cortes, J; Dunster, NJ; Staunton, J; Leadlay, PF				Marsden, AFA; Wilkinson, B; Cortes, J; Dunster, NJ; Staunton, J; Leadlay, PF			Engineering broader specificity into an antibiotic-producing polyketide synthase	SCIENCE			English	Article							BIOSYNTHETIC GENE-CLUSTER; SACCHAROPOLYSPORA-ERYTHRAEA; STREPTOMYCES-HYGROSCOPICUS; ORGANIZATION; AVERMECTINS; RAPAMYCIN; DOMAIN; ACID; BACTERIA; SEQUENCE	The wide-specificity loading module for the avermectin-producing polyketide synthase was grafted onto the first multienzyme component (DEBS1) of the erythromycin-producing polyketide synthase in place of the normal loading module. Expression of this hybrid enzyme in the erythromycin producer Saccharopolyspora erythraea produced several novel antibiotic erythromycins derived from endogenous branched-chain acid starter units typical of natural avermectins. Because the avermectin polyketide synthase is known to accept more than 40 alternative carboxylic acids as starter units, this approach opens the way to facile production of novel analogs of antibiotic macrolides.	Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1QW, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England; Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1EW, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Leadlay, PF (corresponding author), Univ Cambridge, Cambridge Ctr Mol Recognit, Tennis Court Rd, Cambridge CB2 1QW, England.			Cortes, Jesus/0000-0002-2475-6983; Leadlay, Peter/0000-0002-3247-509X				Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BROWN MJB, 1995, J CHEM SOC CHEM COMM, P1517, DOI 10.1039/c39950001517; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1983, J AM CHEM SOC, V105, P4110, DOI 10.1021/ja00350a070; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; CUTTER A, UNPUB; Davies J, 1996, NATURE, V383, P219, DOI 10.1038/383219a0; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; Hopwood D.A., 1985, GENETIC MANIPULATION; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Jack DB, 1996, MOL MED TODAY, V2, P499, DOI 10.1016/S1357-4310(97)81453-0; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kim CG, 1996, J AM CHEM SOC, V118, P7486, DOI 10.1021/ja9601292; Kuhstoss S, 1996, GENE, V183, P231, DOI 10.1016/S0378-1119(96)00565-3; LAMBALOT RH, 1995, BIOCHEMISTRY-US, V34, P1858, DOI 10.1021/bi00006a006; Leadlay PF, 1997, CURR OPIN CHEM BIOL, V1, P162, DOI 10.1016/S1367-5931(97)80005-1; Lowden PAS, 1996, ANGEW CHEM INT EDIT, V35, P2249, DOI 10.1002/anie.199622491; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MACNEIL DJ, 1994, ANN NY ACAD SCI, V721, P123, DOI 10.1111/j.1749-6632.1994.tb47384.x; MCARTHUR HAI, IN PRESS DEV IND MIC; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; PAIVA NL, 1993, J IND MICROBIOL, V12, P423, DOI 10.1007/BF01569676; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; TRAEDER W, 1994, TIERARZTL UMSCHAU, V49, P465; Wallace KK, 1997, J BACTERIOL, V179, P3884, DOI 10.1128/jb.179.12.3884-3891.1997; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; Williams DH, 1996, CHEMTECH, V26, P17	42	191	224	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					199	202		10.1126/science.279.5348.199	http://dx.doi.org/10.1126/science.279.5348.199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422686				2022-12-28	WOS:000071408100033
J	Dickson, N; Paul, C; Herbison, P; Silva, P				Dickson, N; Paul, C; Herbison, P; Silva, P			First sexual intercourse: age, coercion, and later regrets reported by a birth cohort	BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR; ADOLESCENTS; SAMPLE	Objectives: To investigate how age at first sexual intercourse is related to the reported circumstances and to determine how these corresponded to views in early adulthood about its timing, Design: Cross sectional study within a birth cohort using a questionnaire presented by computer. Setting: Dunedin, New Zealand in 1993-4. Subjects: 477 men and 458 women enrolled in the Dunedin Multidisciplinary Health and Development Study, comprising 92% of survivors of the cohort. Results: The median age at first intercourse was 17 years for men and 16 years for women. Only one man (0.2%) but 30 (7%) women reported being forced to have intercourse on the first occasion. For women, there were increasing races of coercion with younger age at first intercourse. More men than women reported that they and their partner were equally willing (77% (316/413) v 53% (222/419)). Mutual willingness of both partners was greater for those who reported that it was also the first time for their partner, Timing of first intercourse was consider ed about right by 49% (200/411) of men and 38% (148/388) of women, Many women (54% (211/388) reported that they should have waited longer; and this rose to 70% (90/129) for women reporting intercourse before age 16. Conclusions: Most women regretted having sexual intercourse before age 16, First intercourse at younger ages is associated with risks that are shared unequally between men and women. This information is important to young people themselves.	Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Sch Med, Dunedin Multidisciplinary Hlth & Dev Unit, Dunedin, New Zealand	University of Otago; University of Otago	Dickson, N (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.	ndickson@gandalf.otago.ac.nz		Herbison, Graham Peter/0000-0002-5684-024X				Craib Ian, 1992, TRANSFORMATION INTIM; CURTIS HA, 1988, ARCH DIS CHILD, V63, P373, DOI 10.1136/adc.63.4.373; Dean A.G., 1994, EPI INFO VERSION 6 W; DICKSON N, 1993, GENITOURIN MED, V69, P133; Dickson N, 1996, NEW ZEAL MED J, V109, P308; *FAC PUBL HLTH MED, 1995, GUID HLTH PROM, V42; HAYES CD, 1987, RISKING FUTURE; JOHNSON AM, 1989, AIDS, V3, P135, DOI 10.1097/00002030-198903000-00003; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KRAFT P, 1991, SOC SCI MED, V33, P207, DOI 10.1016/0277-9536(91)90182-C; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; LEWIN B, 1982, ARCH SEX BEHAV, V11, P417, DOI 10.1007/BF01541574; MILLSTEIN SG, 1983, J PEDIATR-US, V103, P815, DOI 10.1016/S0022-3476(83)80493-4; PAUL C, 1995, AUST J PUBLIC HEALTH, V19, P13; Silva P., 1996, CHILD ADULT DUNEDIN; StuartSmith S, 1996, BRIT MED J, V312, P390; THOMPSON S, 1989, PLEASURE DANGER EXPL, P350; USA Centers of Disease Control, 1991, Morbidity and Mortality Weekly Report, V40, P885; WADSWORTH J, 1991, J ROY STAT SOC A STA, V154, P367; Wellings K, 1994, SEXUAL BEHAV BRITAIN	20	133	136	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					29	33		10.1136/bmj.316.7124.29	http://dx.doi.org/10.1136/bmj.316.7124.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ353	9451263	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071377900020
J	Harris, AJ; Regan, P; Burge, S				Harris, AJ; Regan, P; Burge, S			Lesson of the week - Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT PYODERMA; HEAD; NECK		Stoke Mandeville NHS Trust, Dept Dermatol, Aylesbury HP21 8AL, Bucks, England; Stoke Mandeville NHS Trust, Dept Plast Surg, Aylesbury HP21 8AL, Bucks, England		Harris, AJ (corresponding author), Guys Hosp, Dept Dermatol, London SE1 9RT, England.							Chow RKP, 1996, J AM ACAD DERMATOL, V34, P1047, DOI 10.1016/S0190-9622(96)90285-6; FOWLER JF, 1983, DERMATOL CLIN, V1, P615, DOI 10.1016/S0733-8635(18)31015-5; HICKMAN JG, 1980, BRIT J DERMATOL, V102, P235, DOI 10.1111/j.1365-2133.1980.tb05699.x; MALKINSON FD, 1987, ARCH DERMATOL, V123, P333, DOI 10.1001/archderm.123.3.333; MICALI G, 1994, INT J DERMATOL, V33, P477, DOI 10.1111/j.1365-4362.1994.tb02858.x; PRYSTOWSKY JH, 1989, ARCH DERMATOL, V125, P57, DOI 10.1001/archderm.125.1.57; SNYDER RA, 1986, ARCH DERMATOL, V122, P295, DOI 10.1001/archderm.122.3.295; SU WPD, 1986, J CUTAN PATHOL, V13, P323, DOI 10.1111/j.1600-0560.1986.tb00466.x; WERNIKOFF S, 1987, ARCH DERMATOL, V123, P371, DOI 10.1001/archderm.123.3.371	9	29	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					52	53		10.1136/bmj.316.7124.52	http://dx.doi.org/10.1136/bmj.316.7124.52			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451270	Green Published			2022-12-28	WOS:000071377900028
J	Gans, PB; Bohrson, WA				Gans, PB; Bohrson, WA			Suppression of volcanism during rapid extension in the Basin and Range province, United States	SCIENCE			English	Article							GREAT-BASIN; MAGMATISM; NEVADA; ZONE	Continental extension and volcanism are generally thought to be complementary. Stratigraphic and structural data from some highly extended parts of the Basin and Range province reveal instead that rapid extension appears to have suppressed volcanism, This relation may reflect enhanced crystallization of midcrustal magmas during extension resulting from exsolution of magmatic volatiles, increased interaction of magmas with meteoric water, and dispersal of magma into smaller bodies, Some rift environments may thus be characterized by voluminous synextensional plutonism with little or no concomitant volcanism.	Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Crustal Studies, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Gans, PB (corresponding author), Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA.							ANDERSON RE, 1971, GEOL SOC AM BULL, V82, P43, DOI 10.1130/0016-7606(1971)82[43:TSDITR]2.0.CO;2; BEST MG, 1991, J GEOPHYS RES-SOLID, V96, P13509, DOI 10.1029/91JB00244; BIBBY HM, 1995, J VOLCANOL GEOTH RES, V68, P29, DOI 10.1016/0377-0273(95)00007-H; BIRD P, 1979, J GEOPHYS RES, V84, P7561, DOI 10.1029/JB084iB13p07561; BRADSHAW TK, 1993, EARTH PLANET SC LETT, V116, P45, DOI 10.1016/0012-821X(93)90044-A; CHRISTIANSEN RL, 1992, DECADE N AM GEOLOGY; DALEY EE, 1992, GEOLOGY, V20, P104, DOI 10.1130/0091-7613(1992)020<0104:IEFLTD>2.3.CO;2; DARVALL P., 1994, GEOL SOC AM ABSTR, V26, P53; DILLES JH, 1995, GEOL SOC AM BULL, V107, P474, DOI 10.1130/0016-7606(1995)107<0474:TCOCVA>2.3.CO;2; GANS P, UNPUB; GANS PB, 1992, GEOL SOC AM ABSTR, V25, P108; GANS PB, 1989, GEOL SOC AM SPEC PAP, V233, P1, DOI DOI 10.1130/SPE233; GLAZNER AF, 1984, TECTONICS, V3, P385, DOI 10.1029/TC003i003p00385; HOWARD K, 1994, 940246 US GEOL SURV; HOWARD KA, 1987, SPEC PUBL GEOL SOC, V28, P299, DOI DOI 10.1144/GSL.SP.1987.028.01.19.; MCKENZIE D, 1988, J PETROL, V29, P625, DOI 10.1093/petrology/29.3.625; MEYER J, 1991, GEOL SOC AM BULL, V103, P993, DOI 10.1130/0016-7606(1991)103<0993:MTIDER>2.3.CO;2; OXBURGH ER, 1986, NATURE, V324, P632, DOI 10.1038/324632a0; PLATT JP, 1993, AM J SCI, V293, P307; SAWYER DA, 1994, GEOL SOC AM BULL, V106, P1304, DOI 10.1130/0016-7606(1994)106<1304:ECVITM>2.3.CO;2; SENGOR AMC, 1978, GEOPHYS RES LETT, V5, P419, DOI 10.1029/GL005i006p00419; SPENCER JE, 1995, J GEOPHYS RES-SOL EA, V100, P10321, DOI 10.1029/94JB02817; TAYLOR HP, 1987, GEOCHEM SOC SPEC PUB, V1, P337; WILSON CJN, 1995, J VOLCANOL GEOTH RES, V68, P1, DOI 10.1016/0377-0273(95)00006-G	24	91	94	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					66	68		10.1126/science.279.5347.66	http://dx.doi.org/10.1126/science.279.5347.66			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417024				2022-12-28	WOS:000071323900039
J	Gilder, S; Glen, J				Gilder, S; Glen, J			Magnetic properties of hexagonal closed-packed iron deduced from direct observations in a diamond anvil cell	SCIENCE			English	Article							INNER-CORE ANISOTROPY; PHASE-DIAGRAM; GEOMAGNETIC-FIELD; EARTH CORE; HCP-IRON; PRESSURE; TEMPERATURE; ELASTICITY; ALLOYS	The attraction of hexagonal closed packed (hcp) iron to a magnet at 16.9 gigapascals and 261 degrees centigrade suggests that hcp iron is either paramagnetic or ferromagnetic with susceptibilities from 0.15 to 0.001 and magnetizations from 1800 to 15 amperes per meter, If dominant in Earth's inner core, paramagnetic hcp iron could stabilize the geodynamo.	Inst Phys Globe, Lab Paleomagnetisme, F-75252 Paris 05, France; Berkeley Gerontol Ctr, Berkeley, CA 94709 USA; Univ Calif Santa Cruz, Inst Tecton, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Gilder, S (corresponding author), Inst Phys Globe, Lab Paleomagnetisme, 4 Pl Jussieu, F-75252 Paris 05, France.		Gilder, Stuart A/B-1871-2016	Gilder, Stuart A/0000-0001-8724-7812				ADAMS DM, 1976, J PHYS E SCI INSTRUM, V9, P1140, DOI 10.1088/0022-3735/9/12/034; AKIMOTO S, 1987, HIGH PRESSURE RES MI, V39, P149; ANDERSON OL, 1986, GEOPHYS J INT, V84, P561, DOI 10.1111/j.1365-246X.1986.tb04371.x; BASSETT WA, 1990, J GEOPHYS RES-SOLID, V95, P21709, DOI 10.1029/JB095iB13p21709; Boehier R., 1990, HIGH PRESSURE RES, V6, P133, DOI DOI 10.1080/08957959008203204; BOEHLER R, 1986, GEOPHYS RES LETT, V13, P1153, DOI 10.1029/GL013i011p01153; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; CLEMENT BM, 1995, EARTH PLANET SC LETT, V130, P75, DOI 10.1016/0012-821X(94)00264-Y; COLLINGS EW, 1970, PHYS REV B, V2, P235, DOI 10.1103/PhysRevB.2.235; Collinson D.W., 1983, METHODS ROCK MAGNETI; CORT G, 1982, J APPL PHYS, V53, P2064, DOI 10.1063/1.330745; DERANGO P, 1991, NATURE, V349, P770, DOI 10.1038/349770a0; FARRELL DE, 1987, PHYS REV B, V36, P4025, DOI 10.1103/PhysRevB.36.4025; FLETCHER GC, 1974, J PHYS F MET PHYS, V4, P1951, DOI 10.1088/0305-4608/4/11/020; GLATZMAIER GA, 1995, NATURE, V377, P203, DOI 10.1038/377203a0; HAPPEL J, 1986, LOW REYNOLDS NUMBER; HOLLERBACH R, 1993, NATURE, V365, P541, DOI 10.1038/365541a0; HUANG E, 1987, GEOPHYS MONOGR SER, V39, P165; JEANLOZ R, 1988, GEOPHYS RES LETT, V15, P72, DOI 10.1029/GL015i001p00072; JEPHCOAT AP, 1986, J GEOPHYS RES-SOLID, V91, P4677, DOI 10.1029/JB091iB05p04677; KARATO S, 1993, SCIENCE, V262, P1708, DOI 10.1126/science.262.5140.1708; MANGHNANI MH, 1987, GEOPHYS MONOGR SER, V39, P155; Mao H., 1987, GEOPHYS MONOGR SER, V39, P135; MERRILL RT, 1979, PHYS EARTH PLANET IN, V20, P75, DOI 10.1016/0031-9201(79)90029-3; MORELLI A, 1986, GEOPHYS RES LETT, V13, P1545, DOI 10.1029/GL013i013p01545; OHNO H, 1971, J PHYS SOC JPN, V31, P92, DOI 10.1143/JPSJ.31.92; OHNO H, 1971, J PHYS SOC JPN, V31, P102, DOI 10.1143/JPSJ.31.102; PEARSON DIC, 1979, J PHYS F MET PHYS, V9, P1797, DOI 10.1088/0305-4608/9/9/010; QUIDELLEUR X, 1994, GEOPHYS RES LETT, V21, P1639, DOI 10.1029/94GL01105; ROSS M, 1990, J GEOPHYS RES-SOLID, V95, P21713, DOI 10.1029/JB095iB13p21713; ROUAULT M, 1965, ELECTRICITE; SHEARER PM, 1988, NATURE, V333, P228, DOI 10.1038/333228a0; SONG XD, 1993, GEOPHYS RES LETT, V20, P2591, DOI 10.1029/93GL02812; Stephan K., 1979, VISCOSITY DENSE FLUI; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; TAYLOR RD, 1991, J APPL PHYS, V69, P6126, DOI 10.1063/1.348779; TAYLOR RD, 1982, J APPL PHYS, V53, P8199, DOI 10.1063/1.330289; VOLKENSHTEIN E, 1969, SOV PHYS JETP, V29, P79; WASILEWSKI P, 1977, ADV EARTH PLANET SCI, V1, P123; WENK HR, 1988, GEOPHYS RES LETT, V15, P76, DOI 10.1029/GL015i001p00076; WILLIAMS Q, 1987, SCIENCE, V236, P181, DOI 10.1126/science.236.4798.181; YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473	42	22	23	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					72	74		10.1126/science.279.5347.72	http://dx.doi.org/10.1126/science.279.5347.72			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417026				2022-12-28	WOS:000071323900041
J	Ekwall, K; Olsson, T; Turner, BM; Cranston, G; Allshire, RC				Ekwall, K; Olsson, T; Turner, BM; Cranston, G; Allshire, RC			Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres	CELL			English	Article							POSITION-EFFECT VARIEGATION; INACTIVE X-CHROMOSOME; MATING-TYPE LOCI; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; CPG ISLANDS; ACETYLATION; HETEROCHROMATIN; MUTATIONS; GENE	Histone acetylation may act to mark and maintain transcriptionally active or inactive chromosomal domains through the cell cycle and in different lineages. A novel role for histone acetylation in centromere regulation has been identified. Exposure of fission yeast cells to TSA, a specific inhibitor of histone deacetylase, interferes with repression of marker genes in centromeric heterochromatin, causes chromosome loss, and disrupts the localization of Swi6p, a component of centromeric heterochromatin. Transient TSA treatment induces a heritable hyperacetylated state in centromeric chromatin that is propagated in lineages in the absence of drug. This state is linked in cis to the treated centromere locus and correlates with inheritance of functionally defective centromeres and persistent chromosome segregation problems. Thus, assembly of fully functional centromeres is partly imprinted in the underacetylated or transcriptionally silent state of centromeric chromatin.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Gothenburg Univ, Dept Mol Biol, Lundberg Lab, S-41390 Gothenburg, Sweden; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of Edinburgh; University of Gothenburg; University of Birmingham	Allshire, RC (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.			Allshire, Robin/0000-0002-8005-3625; Ekwall, Karl/0000-0002-3029-4041	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ALLSHIRE RC, 1996, EPIGENETIC MECH GENE; Belyaev ND, 1996, HUM GENET, V97, P573; BICKMORE WA, 1995, J CELL SCI, V108, P2801; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DORN R, 1986, CHROMOSOMA, V93, P398, DOI 10.1007/BF00285820; duSart D, 1997, NAT GENET, V16, P144; EKWALL K, 1994, GENETICS, V136, P53; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Grewal SIS, 1997, GENETICS, V146, P1221; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HOFFMAN CS, 1991, GENE DEV, V5, P561, DOI 10.1101/gad.5.4.561; Javerzat JP, 1996, NUCLEIC ACIDS RES, V24, P4676, DOI 10.1093/nar/24.23.4676; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KARPEN G, 1998, IN PRESS TRENDS GENE; KELLUM R, 1995, J CELL SCI, V108, P1419; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; THON G, 1992, GENETICS, V131, P287; Thon G, 1997, GENETICS, V145, P685; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; WOLFFE AP, 1997, J BIOL CHEM, V387, P16	41	317	325	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					1021	1032		10.1016/S0092-8674(00)80492-4	http://dx.doi.org/10.1016/S0092-8674(00)80492-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428524	Bronze			2022-12-28	WOS:000071281400018
J	Baron, JH				Baron, JH			Illnesses and creativity - Byron's appetites, James Joyce's gut, and Melba's meals and mesalliances	BRITISH MEDICAL JOURNAL			English	Article									CUNY Mt Sinai Sch Med, Div Gastroenterol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Baron, JH (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Div Surg, London W12 0NN, England.							BLESSINGTON, 1834, CONSERVATIONS BYRON; BROWNE D, 1960, P ROY SOC MED, V53, P440, DOI 10.1177/003591576005300615; COLE D, 1977, MY IMPOSSIBLE HLTH C; COLSON P, 1932, MELBA UNCONVENTIONAL; DINKEL J, 1986, ROYAL PAVILION BRIGH, P28; ELWIN M, 1962, BYRONS WIFE, P326; Grosskurth Phylliss, 1997, BYRON FLAWED ANGEL; HETHERINGTON J, 1967, MELBA BIOGRAPHY; HOBHOUSE JC, 1910, RECOLLECTIONS LONG L, V4, P5; HUNT JHL, 1828, BYRON SOME HIS CONT, V1, P15; JACKSON S, 1989, SAVOY CENTURY TASTE; Lyons Jack B., 1973, J JOYCE MED; MARCHAND L, 1973, BYRONS LETT J; Marchand Leslie, 1957, BYRON BIOGRAPHY; MAYNE EC, 1929, LIFE LETT A ISABELLA, P184; Medwin Thomas, 1824, CONVERSATIONS BYRON; MELBA N, 1980, MELODIES MEMORIES; Moore Doris Langley, 1974, BYRON ACCOUNTS RENDE; MOORE T, 1833, LETT J BYRON NOTICES; MORGAN S, 1862, MEMORIES AUTOBIOGRAP, V2, P200; ORIGO I, 1949, LAST ATTACHMENT, P378; PATERSON W, 1982, WORLD MED       0515, P35; PATERSON W, 1990, BYRONS RELISH REGENC; PATON A, 1975, BRIT MED J, V2, P636; RAYMOND J, 1964, REMINISCENCES RECOLL, P121; RICHARDSON J, 1988, BYRON SOME HIS CONT; ROGERS S, 1887, RECOLLECTIONS TABLE, P231; TRELAWNY EJ, 1933, LIFE PB SHELLEY, V2, P184; WADD W, 1829, COMMENTS CORPULENCY, P80; WADD W, 1810, CURSORY REMARKS CORP	30	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1697	1703		10.1136/bmj.315.7123.1697	http://dx.doi.org/10.1136/bmj.315.7123.1697			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448545	Green Published			2022-12-28	WOS:000071149400037
J	McFadzean, J; Monson, JP; Watson, JD; Coakley, JH				McFadzean, J; Monson, JP; Watson, JD; Coakley, JH			Ethical debate - The dilemma of the incapacitated patient who has previously refused consent for surgery	BRITISH MEDICAL JOURNAL			English	Article								What should doctors do if a patient is critically ill and unable to give consent to a procedure that he or she has previously refused to consent to? Such a case is described below and discussed by a medicolegal specialist and by an ethicist.	ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London									0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1530	1531		10.1136/bmj.315.7121.1530	http://dx.doi.org/10.1136/bmj.315.7121.1530			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420500	Green Published			2022-12-28	WOS:A1997YK98600032
J	Veeken, H				Veeken, H			Tajikistan: no pay, no care	BRITISH MEDICAL JOURNAL			English	Article											Veeken, H (corresponding author), MED SANS FRONTIERES,POB 10014,NL-1001 EA AMSTERDAM,NETHERLANDS.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1460	1461		10.1136/bmj.315.7120.1460	http://dx.doi.org/10.1136/bmj.315.7120.1460			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418103	Green Published			2022-12-28	WOS:A1997YJ67200040
J	Wood, CGA; Whittet, S; Bradbeer, CS				Wood, CGA; Whittet, S; Bradbeer, CS			ABC of palliative care - HIV infection and AIDS	BRITISH MEDICAL JOURNAL			English	Review									GUYS & ST THOMASS HOSP TRUST,LONDON,ENGLAND		Wood, CGA (corresponding author), N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND.								0	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1433	1436		10.1136/bmj.315.7120.1433	http://dx.doi.org/10.1136/bmj.315.7120.1433			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418094	Green Published			2022-12-28	WOS:A1997YJ67200030
J	Freudenreich, CH; Kantrow, SM; Zakian, VA				Freudenreich, CH; Kantrow, SM; Zakian, VA			Expansion and length-dependent fragility of CTG repeats in yeast	SCIENCE			English	Article							NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; MYOTONIC-DYSTROPHY; HUMAN-CHROMOSOMES; HUMAN-DISEASE; DNA-SYNTHESIS; GENE; DELETION; SITES; INSTABILITY	Expansion of DNA trinucleotide repeats (TNRs) is the causative mutation in a growing number of human genetic diseases. Large expansions of a CTG tract were obtained and shown by genetic and physical assays to be length-dependent sites of chromosome breakage in Saccharomyces cerevisiae. Deletion of RAD27, which encodes a nuclease involved in Okazaki fragment processing, caused length-dependent destabilization of CTG tracts and a substantial increase in expansion frequency. The genetic assay described here can be used to evaluate other factors that induce TNR expansion or chromosome fragility in humans.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	vzakian@molecular.princeton.edu		Freudenreich, Catherine/0000-0002-1652-2917	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM043265, R01GM026938] Funding Source: NIH RePORTER; NIA NIH HHS [AG05740-02, F32 AG005740] Funding Source: Medline; NIGMS NIH HHS [GM26938, GM43265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; JALAL SM, 1993, AM J MED GENET, V46, P441, DOI 10.1002/ajmg.1320460419; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Korneluk RG, 1997, NAT GENET, V15, P119, DOI 10.1038/ng0297-119; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SUGAWARA N, 1995, BIOESSAYS, V17, P609; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; TISHKOFF DX, 1997, CELL, V88, P263; Wenger SL, 1996, AM J MED GENET, V66, P60, DOI 10.1002/(SICI)1096-8628(19961202)66:1<60::AID-AJMG13>3.0.CO;2-O	33	340	342	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					853	856		10.1126/science.279.5352.853	http://dx.doi.org/10.1126/science.279.5352.853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452383				2022-12-28	WOS:000071923500041
J	Stewart, TE; Meade, MO; Cook, DJ; Granton, JT; Hodder, RV; Lapinsky, SE; Mazer, CD; McLean, RF; Rogovein, TS; Schouten, BD; Todd, TRJ; Slutsky, AS; MacDonald, R; Hooper, B; Cheeatowa, A; Guslits, B; Loewen, M; Sharma, K; Oddi, M; Aubin, M; Mcrae, D; Mawhinney, G; Villar, J; Kavanaugh, B; Cruchly, P; Cooper, R; Hanly, P; Wong, D				Stewart, TE; Meade, MO; Cook, DJ; Granton, JT; Hodder, RV; Lapinsky, SE; Mazer, CD; McLean, RF; Rogovein, TS; Schouten, BD; Todd, TRJ; Slutsky, AS; MacDonald, R; Hooper, B; Cheeatowa, A; Guslits, B; Loewen, M; Sharma, K; Oddi, M; Aubin, M; Mcrae, D; Mawhinney, G; Villar, J; Kavanaugh, B; Cruchly, P; Cooper, R; Hanly, P; Wong, D		Pressure Volume-Limit Ventil Strat	Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTRACORPOREAL MEMBRANE-OXYGENATION; POSITIVE-PRESSURE VENTILATION; MECHANICAL VENTILATION; PERMISSIVE HYPERCAPNIA; PULMONARY BAROTRAUMA; AIRWAY PRESSURE; TIDAL VOLUME; CO2 REMOVAL; EDEMA; SURVIVAL	Background A strategy of mechanical ventilation that limits airway pressure and tidal volume while permitting hypercapnia has been recommended for patients with the acute respiratory distress syndrome. The goal is to reduce lung injury due to overdistention. However, the efficacy of this approach has not been established. Methods Within 24 hours of intubation, patients at high risk for the acute respiratory distress syndrome were randomly assigned to either pressure-and volume-limited ventilation (limited-ventilation group), with the peak inspiratory pressure maintained at 30 cm of water or less and the tidal volume at 8 ml per kilogram of body weight or less, or to conventional ventilation (control group), with the peak inspiratory pressure allowed to rise as high as 50 cm of water and the tidal volume at 10 to 15 ml per kilogram. All other ventilatory variables were similar in the two groups. Results A total of 120 patients with similar clinical features underwent randomization (60 in each group). The patients in the limited-ventilation and control groups were exposed to different mean (+/-SD) tidal volumes (7.2+/-0.8 vs. 10.8+/-1.0 ml per kilogram, respectively; P<0.001) and peak inspiratory pressures (23.6+/-5.8 vs. 34.0+/-11.0 cm of water, P<0.001). Mortality was 50 percent in the limited-ventilation group and 47 percent in the control group (relative risk, 1.07; 95 percent confidence interval, 0.72 to 1.57; P=0.72). In the limited-ventilation group, permissive hypercapnia (arterial carbon dioxide tension, >50 mm Hg) was more common (52 percent vs. 28 percent, P=0.009), more marked (54.4+/-18.8 vs. 45.7+/-9.8 mm Hg, P=0.002), and more prolonged (146+/-265 vs. 25+/-22 hours, P=0.017) than in the control group. The incidence of barotrauma, the highest multiple-organ-dysfunction score, and the number of episodes of organ failure were similar in the two groups; however, the numbers of patients who required paralytic agents (23 vs. 13, P=0.05) and dialysis for renal failure (13 vs. 5, P=0.04) were greater in the limited-ventilation group than in the control group. Conclusions In patients at high risk for the acute respiratory distress syndrome, a strategy of mechanical ventilation that limits peak inspiratory pressure and tidal volume does not appear to reduce mortality and may increase morbidity. (C) 1998, Massachusetts Medical Society.	Wellesley Cent Hosp, Rm 245,Jones Bldg,160 Wellesley St E, Toronto, ON M4Y 1J3, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Univ Toronto, Crit Care Med Programme, Toronto, ON, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; St Josephs Hlth Ctr, Toronto, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Crit Care Med Programme, Hamilton, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Henry Ford Hosp, Detroit, MI USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario); McMaster University; McMaster University; University of Ottawa; Henry Ford Health System; Henry Ford Hospital	Stewart, TE (corresponding author), Wellesley Cent Hosp, Rm 245,Jones Bldg,160 Wellesley St E, Toronto, ON M4Y 1J3, Canada.		Slutsky, Arthur S/A-6013-2008; Villar, Jesús/R-4526-2019; Lapinsky, Stephen/C-4624-2015; Slutsky, Arthur/M-3325-2019	Slutsky, Arthur S/0000-0002-6063-3876; Villar, Jesús/0000-0001-5687-3562; Lapinsky, Stephen/0000-0002-6930-0306; Mazer, Cyril David/0000-0003-2566-4308				Amato M. B. P., 1996, AM J RESP CRIT CARE, V153, pA531; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; BERSENTES TJ, 1965, AM J PHYSIOL, V212, P633; CILLEY RE, 1993, J PEDIATR SURG, V28, P488, DOI 10.1016/0022-3468(93)90253-H; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Gattinoni L, 1986, J Thorac Imaging, V1, P25, DOI 10.1097/00005382-198607000-00005; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HICKLING KG, 1990, INTENS CARE MED, V16, P219, DOI 10.1007/BF01705155; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; LIND T, 1981, ARCH INTERN MED, V141, P1749, DOI 10.1001/archinte.141.13.1749; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; ORTIZ RM, 1987, PEDIATR CLIN N AM, V34, P39; PARKER JC, 1990, AM REV RESPIR DIS, V142, P321, DOI 10.1164/ajrccm/142.2.321; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; SANDHAR BK, 1988, INTENS CARE MED, V14, P538, DOI 10.1007/BF00263527; SLUTSKY AS, 1994, INTENS CARE MED, V20, P64, DOI 10.1007/BF02425061; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SLUTSKY AS, 1994, INTENS CARE MED, V20, P378; SLUTSKY AS, 1994, CHEST, V106, P656; STEWART TE, 1996, CAN RESP J, V3, P403; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; TUXEN DV, 1994, AM J RESP CRIT CARE, V150, P870, DOI 10.1164/ajrccm.150.3.8087364; VANSAENE HKF, 1995, CRIT CARE MED, V23, P601, DOI 10.1097/00003246-199503000-00033; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	36	585	609	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					355	361		10.1056/NEJM199802053380603	http://dx.doi.org/10.1056/NEJM199802053380603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449728	Bronze			2022-12-28	WOS:000071822200003
J	Kemp, M				Kemp, M			Durer's diagnoses	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	1	1	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					341	341		10.1038/34806	http://dx.doi.org/10.1038/34806			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450744	Bronze			2022-12-28	WOS:000071604200032
J	Cooper, RS; Osotimehin, B; Kaufman, JS; Forrester, T				Cooper, RS; Osotimehin, B; Kaufman, JS; Forrester, T			Disease burden in sub-Saharan Africa: what should we conclude in the absence of data?	LANCET			English	Editorial Material									Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Coll Ibadan Hosp, Ibadan, Nigeria; Trop Metab Res Unit, Mona, Jamaica	Loyola University Chicago	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.		Swaibu, Ramadhani A/H-3164-2011	Kaufman, Jay/0000-0003-1606-401X				Akinkugbe OO, 1997, FINAL REPORT NATL SU; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Asuzu M C, 1996, World Health Forum, V17, P373; Barker DJP, 1992, FETAL INFANT ORIGINS; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 1996, TROP CARDIOL, V22, P69; Gwatkin DR, 1997, LANCET, V350, P141, DOI 10.1016/S0140-6736(97)26028-9; Jamison D.T., 1993, DIS CONTROL PRIORITI; Kaufman JS, 1996, J HUM HYPERTENS, V10, P461; MANTON K G, 1988, World Health Statistics Quarterly, V41, P255; MULLER AS, 1991, DIS MORTALITY SUBSAH, P267; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray CJL, 1992, HLTH ADULTS DEV WORL, P113; *NAT CTR HLTH STAT, 1995, HLTH US 1994; OWOAJE E, 1997, E AFR MED J, V74, P29; Patterson Orlando, 1982, SLAVERY SOCIAL DEATH; Tanner M., 1991, DIS MORTALITY SUBSAH	17	95	95	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					208	210		10.1016/S0140-6736(97)06512-4	http://dx.doi.org/10.1016/S0140-6736(97)06512-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449884				2022-12-28	WOS:000071616300043
J	Kuivenhoven, JA; Jukema, JW; Zwinderman, AH; de Knijff, P; McPherson, R; Bruschke, VG; Lie, KI; Kastelein, JJP				Kuivenhoven, JA; Jukema, JW; Zwinderman, AH; de Knijff, P; McPherson, R; Bruschke, VG; Lie, KI; Kastelein, JJP		Regress Growth Evaluat Statin Study Grp	The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; TRANSGENIC MICE; ARTERY DISEASE; PLASMA-LIPOPROTEINS; REDUCTASE INHIBITOR; HDL CHOLESTEROL; HEART-DISEASE; CETP GENE; PRAVASTATIN; MUTATION	Background The high-density lipoprotein (HDL) cholesterol concentration is inversely related to the risk of coronary artery disease, The cholesteryl ester transfer protein (CETP) has a central role in the metabolism of this lipoprotein and may therefore alter the susceptibility to atherosclerosis. Methods The DNA of 807 men with angiographically documented coronary atherosclerosis was analyzed for the presence of a polymorphism in the gene coding for CETP. The presence of this DNA variation was referred to as B1, and its absence as B2. All patients participated in a cholesterol-lowering trial designed to induce the regression of coronary atherosclerosis and were randomly assigned to treatment with either pravastatin or placebo for two years. Results The B1 variant of the CETP gene was associated with both higher plasma CETP concentrations (mean [+/-SD], 2.29+/-0.62 mu g per milliliter for the B1B1 genotype vs. 1.76+/-0.51 mu g per milliliter for the B2B2 genotype) and lower HDL cholesterol concentrations (34+/-8 vs. 39+/-10 mg per deciliter). In addition, we observed a significant dose-dependent association between this marker and the progression of coronary atherosclerosis in the placebo group (decrease in mean luminal diameter: 0.14+/-0.21 mm for the B1B1 genotype, 0.10+/-0.20 mm for the B1B2 genotype, and 0.05+/-0.22 mm for the B2B2 genotype). This association was abolished by pravastatin. Pravastatin therapy slowed the progression of coronary atherosclerosis in B1B1 carriers but not in B2B2 carriers (representing 16 percent of the patients taking pravastatin). Conclusions There is a significant relation between variation at the CETP gene locus and the progression of coronary atherosclerosis that is independent of plasma HDL cholesterol levels and the activities of lipolytic plasma enzymes, This common DNA variant appears to predict whether men with coronary artery disease will benefit from treatment with pravastatin to delay the progression of coronary atherosclerosis. (C) 1998, Massachusetts Medical Society.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Dept Cardiol, Leiden, Netherlands; Leiden Univ, Dept Biostat, Leiden, Netherlands; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Ottawa Heart Inst, Lipoprot & Atherosclerosis Grp, Ottawa, ON, Canada; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Ottawa; University of Ottawa Heart Institute; Interuniversity Cardiology Institute of the Netherlands; Utrecht University	Kastelein, JJP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Rm G1-123,Meibergdreef 9,POB 22-700, NL-1105 AZ Amsterdam, Netherlands.		Jukema, J. Wouter/ABD-6503-2021; de Knijff, Peter/Y-2519-2018; Kastelein, John/AAF-7950-2020	Jukema, J. Wouter/0000-0002-3246-8359; de Knijff, Peter/0000-0002-0899-771X; 				AGELLON LB, 1991, J BIOL CHEM, V266, P10796; AHNADI CE, 1993, ATHEROSCLEROSIS, V99, P219, DOI 10.1016/0021-9150(93)90024-O; Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; BAGDADE JD, 1990, J LIPID RES, V31, P1263; BHATNAGAR D, 1993, ATHEROSCLEROSIS, V98, P25, DOI 10.1016/0021-9150(93)90220-O; BHATNAGAR D, 1995, DIABETES, V44, P460, DOI 10.2337/diabetes.44.4.460; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BU XD, 1994, HUM GENET, V93, P639, DOI 10.1007/BF00201563; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; CHEUNG MC, 1993, ATHEROSCLEROSIS, V102, P107, DOI 10.1016/0021-9150(93)90089-D; DRAYNA D, 1987, NUCLEIC ACIDS RES, V15, P4698, DOI 10.1093/nar/15.11.4698; Fielding CJ, 1996, J CLIN INVEST, V97, P2687, DOI 10.1172/JCI118719; FOGER B, 1995, J MOL MED, V73, P369; FREEMAN DJ, 1994, ARTERIOSCLER THROMB, V14, P336, DOI 10.1161/01.ATV.14.3.336; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Groenemeijer BE, 1997, CIRCULATION, V95, P2628, DOI 10.1161/01.CIR.95.12.2628; GUERIN M, 1995, ARTERIOSCL THROM VAS, V15, P1359, DOI 10.1161/01.ATV.15.9.1359; HANNUKSELA ML, 1994, ATHEROSCLEROSIS, V110, P35, DOI 10.1016/0021-9150(94)90065-5; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Kreisberg RA, 1996, AM J MED, V101, P455, DOI 10.1016/S0002-9343(96)00311-7; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; *STAT EP RES CORP, 1991, EGRET STAT ART EP CO; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Tamminen M, 1996, ATHEROSCLEROSIS, V124, P237, DOI 10.1016/0021-9150(96)05833-9; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; ZAMBON A, 1996, CIRCULATION S1, V94, P539; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	39	502	546	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					86	93		10.1056/NEJM199801083380203	http://dx.doi.org/10.1056/NEJM199801083380203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420339				2022-12-28	WOS:000071341300003
J	Morrison, J; Anderson, JL				Morrison, J; Anderson, JL			Footwall refrigeration along a detachment fault: Implications for the thermal evolution of core complexes	SCIENCE			English	Article							ANGLE NORMAL FAULTS; TECTONIC IMPLICATIONS; METAMORPHIC ROCKS; ARIZONA; CALIFORNIA; MINERALIZATION; MOUNTAINS; HISTORIES; PRESSURE; SYSTEMS	Oxygen isotope compositions of epidote and quartz from chloritic breccias that underlie the detachment fault in the metamorphic core complex of the Whipple Mountains yielded quartz-epidote fractionations that range from 4.1 to 6.4 per mil and increase systematically toward the fault. These fractionations give mean temperatures that decrease from similar to 432 degrees C at 50 meters below the fault to similar to 350 degrees C at 12 meters below the fault. This extreme thermal gradient of 82 degrees C over 38 meters (2160 degrees C per kilometer) is best explained by advective heat extraction by means of circulating surface-derived fluids. Models of lithospheric extension consider only conductive cooling resulting from tectonic denudation and thus require revision to include fluid-induced fault-zone refrigeration.	Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA	University of Southern California	Morrison, J (corresponding author), Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA.							Anderson E.M., 1942, DYNAMICS FAULTING; ANDERSON JL, 1988, GEOLOGY, V16, P366, DOI 10.1130/0091-7613(1988)016<0366:MCCROC>2.3.CO;2; ANDERSON JL, 1988, METAMORPHISM CRUSTAL, P503; ARMSTRONG RL, 1982, ANNU REV EARTH PL SC, V10, P129, DOI 10.1146/annurev.ea.10.050182.001021; AXEN GJ, 1992, J GEOPHYS RES-SOL EA, V97, P8979, DOI 10.1029/92JB00517; BICKLE MJ, 1987, CONTRIB MINERAL PETR, V95, P384, DOI 10.1007/BF00371852; BUCK WR, 1988, TECTONICS, V7, P959, DOI 10.1029/TC007i005p00959; BUCK WR, 1988, TECTONICS, V7, P213, DOI 10.1029/TC007i002p00213; Crittenden Jr M. D., 1980, GEOL SOC AM MEM, V153; DAVIS G A, 1980, GEOLOGICAL SOC AM ME, V153, P79, DOI DOI 10.1130/MEM153-P79; DAVIS GA, 1988, SPEC PAP GEOL SOC AM, V218, P133; DEWITT E, 1986, GEOL SOC AM ABSTR, V118, P584; DOKKA RK, 1993, GEOLOGY, V21, P711, DOI 10.1130/0091-7613(1993)021<0711:ODASMO>2.3.CO;2; DOKKA RK, 1979, CENOZOIC PALEOGEOGRA, P141; FOSTER DA, 1990, J GEOPHYS RES-SOLID, V95, P20005, DOI 10.1029/JB095iB12p20005; FURLONG KP, 1991, REV MINERAL, V26, P437; GREGORY RT, 1986, REV MINERAL, V16, P91; Halfkenny R. D., 1989, ARIZONA GEOLOGICAL S, V198, P190; HOLM DK, 1993, EARTH PLANET SC LETT, V116, P63, DOI 10.1016/0012-821X(93)90045-B; JACKSON JA, 1987, CONTINENTAL EXTENSIO, V28, P3; KERRICH R, 1987, GEOLOGY, V15, P58, DOI 10.1130/0091-7613(1987)15<58:FMAWTM>2.0.CO;2; Losh S, 1997, GEOL SOC AM BULL, V109, P300, DOI 10.1130/0016-7606(1997)109<0300:SIAMSO>2.3.CO;2; MATTHEWS A, 1994, J METAMORPH GEOL, V12, P211, DOI 10.1111/j.1525-1314.1994.tb00017.x; MORRISON J, 1994, J METAMORPH GEOL, V12, P827, DOI 10.1111/j.1525-1314.1994.tb00062.x; REYNOLDS SJ, 1987, GEOLOGY, V15, P3622; RODDY MS, 1988, GEOL SOC AM BULL, V100, P1627, DOI 10.1130/0016-7606(1988)100<1627:KMADRM>2.3.CO;2; RUPPEL C, 1988, TECTONICS, V7, P947, DOI 10.1029/TC007i005p00947; SCOTT RJ, IN PRESS GEOL SOC AM; SHARP ZD, 1990, GEOCHIM COSMOCHIM AC, V54, P1353, DOI 10.1016/0016-7037(90)90160-M; SMITH BM, 1991, GEOL SOC AM BULL, V103, P559, DOI 10.1130/0016-7606(1991)103<0559:DSFIID>2.3.CO;2; SPENCER JE, 1986, GEOLOGY, V14, P195, DOI 10.1130/0091-7613(1986)14<195:PCOBAP>2.0.CO;2; Valley JW, 1995, GEOCHIM COSMOCHIM AC, V59, P5223, DOI 10.1016/0016-7037(95)00386-X; WERNICKE B, 1988, GEOLOGY, V16, P848, DOI 10.1130/0091-7613(1988)016<0848:OTROII>2.3.CO;2; WERNICKE B, 1981, NATURE, V291, P645, DOI 10.1038/291645a0; WERNICKE B, 1995, J GEOPHYS RES-SOL EA, V100, P20159, DOI 10.1029/95JB01911; WERNICKE B, 1985, CAN J EARTH SCI, V22, P108, DOI 10.1139/e85-009; WILKINS J, 1986, ARIZ GEOL SOC DIG, V16, P108; YIN A, 1989, TECTONICS, V8, P469, DOI 10.1029/TC008i003p00469	38	86	86	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					63	66		10.1126/science.279.5347.63	http://dx.doi.org/10.1126/science.279.5347.63			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417023				2022-12-28	WOS:000071323900038
J	Birdwell, BG; Raskob, GE; Whitsett, TL; Durica, SS; Comp, PC; George, JN; Tytle, TL; McKee, PA				Birdwell, BG; Raskob, GE; Whitsett, TL; Durica, SS; Comp, PC; George, JN; Tytle, TL; McKee, PA			The clinical validity of normal compression ultrasonography in outpatients suspected of raving deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						ultrasonography; thrombophlebitis; thromboembolism; thrombolytic therapy; pulmonary embolism	PROXIMAL-VEIN-THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; INITIAL TREATMENT; LOWER-EXTREMITY; DIAGNOSIS; LEG; MANAGEMENT; VENOGRAPHY; HEPARIN	Background: Ultrasonography using Vein compression accurately detects proximal deep Venous thrombosis in symptomatic outpatients. Repeated testing is required for patients with normal results at presentation, but the optimal management of such patients is uncertain. Objective: To test the safety of withholding anticoagulation in outpatients suspected of having first-episode deep venous thrombosis who have normal results on simplified compression ultrasonography at presentation and on a single repeated test done 5 to 7 days later. Design: Prospective cohort study. Setting: Noninvasive vascular laboratories at a university teaching hospital and a Veterans Administration medical center. Patients: 405 consecutive outpatients suspected of having first-episode deep Venous thrombosis. Intervention: Ultrasonography was performed at presentation. The common femoral and popliteal veins were assessed for compressibility. If the result was normal, anticoagulation was withheld and testing was repeated 5 to 7 days later. Anticoagulation was withheld from all patients whose results remained normal according to compression ultrasonography, regard less of their symptoms. The safety of this approach was tested by follow-up lasting 3 months. Measurements: Objective testing was done during follow-up in all patients with symptoms or signs of venous thromboembolism. The outcome measure was symptomatic Venous thrombosis or pulmonary embolism during follow-up, confirmed by objective testing. Results: Ultrasonography had normal results in 335 patients (83%) and abnormal results in 70 (17%). None of the patients with normal results died of pulmonary embolism. Venous thromboembolism occurred during follow-up in 2 patients with normal ultrasonographic results (0.6% [95% CI, 0.07% to 2.14%]) and in 4 patients with abnormal results (5.7% [CI, 1.58% to 13.99%]) (P = 0.009). Conclusions: It is safe to withhold anticoagulation in outpatients suspected of having first-episode deep venous thrombosis if results of simplified compression ultrasonography are normal at presentation and on a single repeated test done 5 to 7 days later.	Vet Adm Med Ctr, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Warren Med Res Inst, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Birdwell, BG (corresponding author), Vet Adm Med Ctr, 151,921 NE 13th St, Oklahoma City, OK 73104 USA.				NHLBI NIH HHS [HL 08756, HL 08883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008756, F32HL008883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; CRANLEY JJ, 1976, ARCH SURG-CHICAGO, V111, P34; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; DARKE SG, 1991, VENOUS DISORDERS, P227; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HILLNER BE, 1992, ARCH INTERN MED, V152, P165, DOI 10.1001/archinte.152.1.165; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1978, CIRCULATION, V58, P898, DOI 10.1161/01.CIR.58.5.898; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KEARON C, 1994, THROMB HAEMOSTASIS, V72, P652; KOBAK M, 1954, AMA ARCH SURG, V68, P350, DOI 10.1001/archsurg.1954.01260050352011; Lensing Anthonie W. A., 1996, P115; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; Pezzullo JA, 1996, RADIOLOGY, V198, P67, DOI 10.1148/radiology.198.1.8539408; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; STRANDNESS DE, 1972, ARCH SURG-CHICAGO, V104, P180; SUMNER D, 1990, J VASC SURG, V11, P60; Sumner DS, 1993, VASCULAR DIAGNOSIS, P785; VOGEL P, 1987, RADIOLOGY, V163, P747, DOI 10.1148/radiology.163.3.3554344; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER HB, 1982, ARCH SURG-CHICAGO, V117, P1206; WILLIAMS SG, 1953, VENOUS DISORDERS, V97, P769	38	205	210	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					1	+		10.7326/0003-4819-128-1-199801010-00001	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424975				2022-12-28	WOS:000071158000001
J	Xie, JW; Murone, M; Luoh, SM; Ryan, A; Gu, QM; Zhang, CH; Bonifas, JM; Lam, CW; Hynes, M; Goddard, A; Rosenthal, A; Epstein, EH; de Sauvage, FJ				Xie, JW; Murone, M; Luoh, SM; Ryan, A; Gu, QM; Zhang, CH; Bonifas, JM; Lam, CW; Hynes, M; Goddard, A; Rosenthal, A; Epstein, EH; de Sauvage, FJ			Activating Smoothened mutations in sporadic basal-cell carcinoma	NATURE			English	Article							HUMAN HOMOLOG; GENE; RECEPTOR; HEDGEHOG	Basal-cell carcinomas (BCCs) are the commonest human cancer(1). Insight into their genesis came from identification of mutations in the PATCHED gene (PTCH) in patients with the basal-cell nevus syndrome, a hereditary disease characterized by multiple BCCs and by developmental abnormalities(2-7). The binding of Sonic hedgehog (SHH) to its receptor, PTCH, is thought to prevent normal inhibition by PTCH of Smoothened (SMO), a seven-span transmembrane protein(8,9). According to this model, the inhibition of SMO signalling is relieved following mutational inactivation of PTCH in basal-cell nevus syndrome, We report here the identification of activating somatic missense mutations in the SMO gene itself in sporadic BCCs from three patients. Mutant SMO, unlike wild type, can cooperate with adenovirus E1A to transform rat embryonic fibroblast cells in culture, Furthermore, skin abnormalities similar to BCCs developed in transgenic murine skin overexpressing mutant SMO. These findings support the role of SMO as a signalling component of the SHH-receptor complex and provide direct evidence that mutated SMO can function as an oncogene in BCCs.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA; Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Chinese University of Hong Kong; Prince of Wales Hospital	de Sauvage, FJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, 1001 Potrero St,Rm 269,Bldg 100, San Francisco, CA 94110 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Hynes, Mary/0000-0001-6623-6727; Zhang, Chengfei/0000-0002-6016-9436				BYME C, 1993, MOL CELL BIOL, V13, P3176; Chidambaram A, 1996, CANCER RES, V56, P4599; Fan H., 1997, Journal of Investigative Dermatology, V108, P544; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; Unden Anne Birgitte, 1997, Journal of Investigative Dermatology, V108, P596; Wicking C, 1997, AM J HUM GENET, V60, P21; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Xie JW, 1997, CANCER RES, V57, P2369; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	21	1029	1091	1	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					90	92		10.1038/34201	http://dx.doi.org/10.1038/34201			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422511				2022-12-28	WOS:000071326100055
J	Powers, T; Walter, P				Powers, T; Walter, P			Protein synthesis - A ribosome at the end of the tunnel	SCIENCE			English	Editorial Material							ENDOPLASMIC-RETICULUM MEMBRANE; CONDUCTING CHANNEL; SECRETORY PROTEINS; ER MEMBRANE; TRANSLOCATION; ENVIRONMENT; COMPLEX; SEC61P		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Powers, T (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.							Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RAPOPORT TA, 1997, POP MECH, V4, P26; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8	16	7	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2072	2073		10.1126/science.278.5346.2072	http://dx.doi.org/10.1126/science.278.5346.2072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432719				2022-12-28	WOS:A1997YM23500039
J	Floyd, K; Wilkinson, D; Gilks, C				Floyd, K; Wilkinson, D; Gilks, C			Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY TUBERCULOSIS; KINSHASA; PROGRAM; ZAIRE	Objective: To conduct an economic evaluation of directly observed treatment (DOT) and conventionally delivered treatment for the management of new cases of tuberculosis in adults. Design: Community based directly observed treatment, which has been implemented in the Hlabisa district of South Africa since 1991, was compared with a conventional approach to tuberculosis treatment widely used in Africa. Each was assessed in terms of cost, cost effectiveness, and feasibility of implementation within existing resource constraints. Setting: Hlabisa Health District, South Africa, Subjects: Adult patients with new cases of tuberculosis on smear testing; the number of cases increased from 20 per month to over 100 from 1991 to 1996. Main outcome measures: Cost of case management in 1996, cost effectiveness in terms of the cost per case cured, and bed requirements in comparison with bed availability for the 1990, 1993, and 1996 caseload. Costs are expressed in US dollars at values for 1996. Results: Directly observed treatment was 2.8 times cheaper overall than conventional treatment ($740.90 compared with $2047.70) to deliver. Directly observed treatment worked out 2.4-4.2 times more cost effective, costing $890.50 per patient cured compared with either $2095.60 (best case) or $3700.40 (worst case) for conventional treatment The 1996 caseload of tuberculosis required 47 beds to be dedicated to tuberculosis to implement directly observed treatment whereas conventionally delivered treatment would have required 160 beds; the current number of beds for tuberculosis treatment in Hlabisa is fixed at 56. Conclusions: Because of the reduced stay in hospital, directly observed treatment is cheaper, more cost effective, and more feasible than conventional treatment in managing tuberculosis in Hlabisa, given the existing hospital bed capacity and the escalating caseload due to the HIV/AIDS epidemic Such results may hold elsewhere, and wherever conventional tuberculosis management is practised a switch to directly observed treatment will increase hospital capacity to cope with a growing caseload.	UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,DIV TROP MED,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND; MRC,CTR EPIDEMIOL RES,ZA-3935 MTUBATUBA,SOUTH AFRICA	Liverpool School of Tropical Medicine; University of Liverpool			Wilkinson, David/A-6207-2008; Gilks, Charles/B-4184-2012	Wilkinson, David/0000-0002-7265-9846; Gilks, Charles/0000-0002-8953-3123				Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; FLOYD K, 1997, COMMUNITY BASED DIRE; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Graf Petra, 1994, P325; Harries A. D., 1994, P241; Harries AD, 1996, LANCET, V347, P807, DOI 10.1016/S0140-6736(96)90874-0; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1; *S AFR DEP HLTH, 1996, S AFR TUB CONTR PROG; Sawert H., 1996, COST ANAL COST CONTA; *TUB CHEM CTR, 1959, B WORLD HEALTH ORGAN, V21, P51; Whiteside A., 1995, IMPACT HIV AIDS PLAN; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094; Wilkinson D, 1997, S AFR MED J, V87, P451; Wilkinson D, 1997, TROP MED INT HEALTH, V2, P700, DOI 10.1046/j.1365-3156.1997.d01-358.x; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P87, DOI 10.1016/S0035-9203(97)90407-7; Wilkinson D, 1996, S AFR MED J, V86, P64; *WORLD BANK, 1993, WORLD DEV REP; World Health Organization, 1993, TREATM TUB GUID NAT	23	82	84	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1407	1411		10.1136/bmj.315.7120.1407	http://dx.doi.org/10.1136/bmj.315.7120.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418087	Green Published			2022-12-28	WOS:A1997YJ67200023
J	Mermall, V; Post, PL; Mooseker, MS				Mermall, V; Post, PL; Mooseker, MS			Unconventional myosins in cell movement, membrane traffic, and signal transduction	SCIENCE			English	Review							HEAVY-CHAIN KINASE; CLASS-V MYOSIN; HAIR-CELLS; MECHANOELECTRICAL TRANSDUCTION; ACTIN-FILAMENTS; PURKINJE-CELLS; PROTEIN-KINASE; MOTOR-ACTIVITY; GENE ENCODES; I ISOFORMS	In the past few years genetic, biochemical, and cytolocalization data have implicated members of the myosin superfamily of actin-based molecular motors in a variety of cellular functions including membrane trafficking, cell movements, and signal transduction. The importance of myosins is illustrated by the identification of myosin genes as targets for disease-causing mutations. The task at hand is to decipher how the multitude of myosins function at both the molecular and cellular level-a task facilitated by our understanding of myosin structure and function in muscle.	Yale Univ, Dept Biol, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Mooseker, MS (corresponding author), Yale Univ, Dept Biol, POB 6666, New Haven, CT 06520 USA.	mark.mooseker@yale.edu			NIDDK NIH HHS [DK38979, DK25387] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025387, R37DK025387, P01DK038979] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; ASSAD JA, 1992, J NEUROSCI, V12, P3291; Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; DeOca GM, 1997, ARCH MED RES, V28, P321; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; EMONS AMC, 1991, BIOTECHNOLOGY CURREN, P311; Espindola F. S., 1996, Molecular Biology of the Cell, V7, p372A; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Evans LL, 1997, J CELL SCI, V110, P439; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fukui Y, 1997, CELL MOTIL CYTOSKEL, V36, P339; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; Gillespie PG, 1996, COLD SPRING HARB SYM, V61, P309; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; HAARER BK, 1994, J CELL SCI, V107, P1055; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasson T, 1997, CELL MOTIL CYTOSKEL, V37, P127, DOI 10.1002/(SICI)1097-0169(1997)37:2<127::AID-CM5>3.0.CO;2-5; Hasson T, 1997, AM J HUM GENET, V61, P801, DOI 10.1086/514890; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Heintzelman MB, 1997, J MOL BIOL, V271, P139, DOI 10.1006/jmbi.1997.1167; Hicks JL, 1996, CELL MOTIL CYTOSKEL, V35, P367, DOI 10.1002/(SICI)1097-0169(1996)35:4<367::AID-CM8>3.0.CO;2-3; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; HOWARD J, 1987, P NATL ACAD SCI USA, V84, P3064, DOI 10.1073/pnas.84.9.3064; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Hudspeth AJ, 1997, CURR OPIN NEUROBIOL, V7, P480, DOI 10.1016/S0959-4388(97)80026-8; HURVITZ H, 1993, EUR J PEDIATR, V152, P402, DOI 10.1007/BF01955897; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MARKERT CL, 1956, GENETICS, V41, P429; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; MERMALL V, 1995, J CELL BIOL, V129, P1575, DOI 10.1083/jcb.129.6.1575; MILLER DD, 1995, J CELL SCI, V108, P2549; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nascimento AAC, 1997, MOL BIOL CELL, V8, P1971, DOI 10.1091/mbc.8.10.1971; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Ng KP, 1996, BIOCHEMISTRY-US, V35, P9392, DOI 10.1021/bi960181a; Novak KD, 1997, J CELL BIOL, V136, P633, DOI 10.1083/jcb.136.3.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; NOVAK KD, IN PRESS MOL BIOL CE; Ostap EM, 1996, J CELL BIOL, V133, P221, DOI 10.1083/jcb.133.2.221; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; POST PL, IN PRESS J CELL SCI; PoucellHatton S, 1997, GASTROENTEROLOGY, V113, P649, DOI 10.1053/gast.1997.v113.pm9247487; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Spudich JA, 1995, COLD SPRING HARB SYM, V60, P783, DOI 10.1101/SQB.1995.060.01.084; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Temesvari LA, 1996, J CELL SCI, V109, P663; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Walker RG, 1996, P NATL ACAD SCI USA, V93, P2203, DOI 10.1073/pnas.93.5.2203; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wessels D, 1996, CELL MOTIL CYTOSKEL, V33, P64, DOI 10.1002/(SICI)1097-0169(1996)33:1<64::AID-CM7>3.0.CO;2-I; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; WILLIAMS DS, 1991, BIOESSAYS, V13, P171, DOI 10.1002/bies.950130405; Wirth JA, 1996, J CELL SCI, V109, P653; Wu XF, 1997, J CELL SCI, V110, P847; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; YAMAMOTO K, 1995, J MOL BIOL, V254, P109, DOI 10.1006/jmbi.1995.0603; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	104	505	520	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					527	533		10.1126/science.279.5350.527	http://dx.doi.org/10.1126/science.279.5350.527			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438839				2022-12-28	WOS:000071616000036
J	Neven, P; Vergote, I				Neven, P; Vergote, I			Should tamoxifen users be screened for endometrial lesions?	LANCET			English	Editorial Material							BREAST-CANCER PATIENTS		Algemene Klin St Jan, Dept Obstet & Gynaecol, Brussels, Belgium; UZ Gasthuisberg, Dept Gynaecol Oncol, B-3000 Louvain, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; University Hospital Leuven	Neven, P (corresponding author), Algemene Klin St Jan, Dept Obstet & Gynaecol, Brussels, Belgium.							ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; Carmichael PL, 1996, CANCER RES, V56, P1475; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; Hemminki K, 1996, CANCER RES, V56, P4374; *INT AG RES CANC, 1996, IARC MON EV CARC RIS, V66; KAUFMANN M, 1995, BREAST, V4, P245; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; Neven P, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78091-0; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; TIMMERMAN D, IN PRESS AM J OBSTET	12	41	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					155	157		10.1016/S0140-6736(05)78216-7	http://dx.doi.org/10.1016/S0140-6736(05)78216-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449866				2022-12-28	WOS:000071616300005
J	Huang, ZP; Willett, WC; Manson, JE; Rosner, B; Stampfer, MJ; Speizer, FE; Colditz, GA				Huang, ZP; Willett, WC; Manson, JE; Rosner, B; Stampfer, MJ; Speizer, FE; Colditz, GA			Body weight, weight change, and risk for hypertension in women	ANNALS OF INTERNAL MEDICINE			English	Article						body; weight; weight gain; hypertension; body index	HIGH BLOOD-PRESSURE; UNITED-STATES; NUTRITIONAL FACTORS; MILD HYPERTENSION; OBESITY; REDUCTION; INTERVENTION; OVERWEIGHT; DISEASE; PROGRAM	Background: Obesity increases the risk for hypertension, but the effects of modest long-term weight changes have not been precisely quantified. Objective: To investigate body mass index (BMI) and weight change in relation to risk for hypertension. Design: Cohort study. Setting: General community. Participants: Cohort of 82 473 U.S. female nurses 30 to 55 years of age followed every 2 years since 1976. The follow-up rate was 95%. Measurements: Primary risk factors examined were 1) BMI at age 18 years and midlife and 2) long-term and medium-term weight changes. The outcome was incident cases of hypertension. Results: By 1992, 16 395 incident cases of hypertension had been diagnosed. After adjustment for multiple covariates, BMI at 18 years of age and midlife were positively associated with occurrence of hypertension (P for trend < 0.001). Long-term weight loss after 18 years of age was related to a significantly lower risk for hypertension, and weight gain dramatically increased the risk for hypertension (compared with weight change less than or equal to 2 kg, multivariate relative risks were 0.85 for a loss of 5.0 to 9.9 kg, 0.74 for a loss greater than or equal to 10 kg, 1.74 for a gain of 5.0 to 9.9 kg, and 5.21 for a gain greater than or equal to 25.0 kg). Among women in the top tertile of baseline BMI at age 18 years, weight loss had a greater apparent benefit. The association between weight change and risk for hypertension was stronger in younger (<45 years of age) than older women (greater than or equal to 55 years of age). Medium-term weight changes after 1976 showed similar relations to risk for hypertension. Conclusions: Excess weight and even modest adult weight gain substantially increase risk for hypertension. Weight loss reduces the risk for hypertension.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huang, ZP (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Cassano Patricia A., 1990, Annals of Epidemiology, V1, P33; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; EPSTEIN FH, 1965, AM J EPIDEMIOL, V81, P307, DOI 10.1093/oxfordjournals.aje.a120517; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAVLIK RJ, 1983, ANN INTERN MED, V98, P855, DOI 10.7326/0003-4819-98-5-855; Hebert Patricia R., 1995, Annals of Epidemiology, V5, P130, DOI 10.1016/1047-2797(94)00057-Z; HIGGINS MW, 1980, HYPERTENSION, V2, pI117, DOI 10.1161/01.HYP.2.4_Pt_2.I117; HSUEH WA, 1994, ENDOCRIN METAB CLIN, V23, P405, DOI 10.1016/S0889-8529(18)30105-1; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; Ikeda T, 1996, HYPERTENSION, V27, P1180, DOI 10.1161/01.HYP.27.5.1180; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KULLER LH, 1980, HYPERTENSION, V2, pI109, DOI 10.1161/01.HYP.2.4_Pt_2.I109; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MAKELA M, 1978, J CHRON DIS, V31, P587, DOI 10.1016/0021-9681(78)90019-X; MICOZZI MS, 1990, AM J PHYS ANTHROPOL, V81, P375, DOI 10.1002/ajpa.1330810307; REED D, 1982, HYPERTENSION, V4, P406, DOI 10.1161/01.HYP.4.3.406; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SEVER PS, 1980, LANCET, V2, P60; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS VJ, 1993, ARCH INTERN MED, V153, P849, DOI 10.1001/archinte.153.7.849; TROY LM, 1995, INT J OBESITY, V19, P570; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602; *USDA, 1995, DIET GUID AM, P15; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WEINSTEIN MC, 1976, HYPERTENSION POLICY; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; Willett W., 2012, NUTR EPIDEMIOLOGY; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; YONG LC, 1993, AM J EPIDEMIOL, V138, P973, DOI 10.1093/oxfordjournals.aje.a116817	39	455	470	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					81	+		10.7326/0003-4819-128-2-199801150-00001	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441586				2022-12-28	WOS:000071470800001
J	Sinclair, DA; Guarente, L				Sinclair, DA; Guarente, L			Extrachromosomal rDNA circles - A cause of aging in yeast	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; PODOSPORA-ANSERINA; MITOCHONDRIAL-DNA; SYNDROME GENE; LONGEVITY; TRANSCRIPTION; REPLICATION; SENESCENCE	Although many cellular and organismal changes have been described in aging individuals, a precise, molecular cause of aging has yet to be found. A prior study of aging yeast mother cells showed a progressive enlargement and fragmentation of the nucleolus. Here we show that these nucleolar changes are likely due to the accumulation of extrachromosomal rDNA circles (ERCs) in old cells and that, in fact, ERCs cause aging. Mutants for sgs1, the yeast homolog of the Werner's syndrome gene, accumulate ERCs more rapidly, leading to premature aging and a shorter life span. We speculate on the generality of this molecular cause of aging in higher species, including mammals.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sinclair, David/0000-0002-9936-436X	NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHEN JB, 1990, MOL MICROBIOL, V4, P2081, DOI 10.1111/j.1365-2958.1990.tb00568.x; Childress AM, 1996, MICROBIOL-UK, V142, P2289, DOI 10.1099/13500872-142-8-2289; CLARKWALKER GD, 1980, NUCLEIC ACIDS RES, V8, P1009; CUMMINGS DJ, 1985, J MOL BIOL, V185, P659, DOI 10.1016/0022-2836(85)90052-X; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; DORMAN JB, 1995, GENETICS, V141, P1399; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EMILGEZ NK, 1989, J BACTERIOL, V171, P37; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORDON CN, 1977, J CELL SCI, V24, P81; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLM C, 1982, CELL, V29, P585, DOI 10.1016/0092-8674(82)90174-X; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; JAMETVIERNY C, 1980, CELL, V21, P189, DOI 10.1016/0092-8674(80)90126-9; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARIONOV V, 1984, GENE, V28, P229, DOI 10.1016/0378-1119(84)90260-9; LARIONOV VL, 1980, GENE, V12, P41, DOI 10.1016/0378-1119(80)90014-1; LARSEN PL, 1995, GENETICS, V139, P1567; LISKENS M, 1988, MOL CELL BIOL, V8, P4927; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; Nierras CR, 1997, CHROMOSOMA, V105, P444; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; RINE J, 1987, GENETICS, V116, P9; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sherman F, 1979, METHODS YEAST GENETI; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; SWEENEY R, 1989, GENETICS, V122, P749; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TTSUKAMOTO Y, 1997, NATURE, V388, P900; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	69	1113	1142	3	61	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1033	1042		10.1016/S0092-8674(00)80493-6	http://dx.doi.org/10.1016/S0092-8674(00)80493-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428525	Bronze			2022-12-28	WOS:000071281400019
J	Cooke, F; Morse, R				Cooke, F; Morse, R			Do you know your chocolates? Recognition survey among medical staff of various grades	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Integrat Med, Cardiff CF4 4XW, S Glam, Wales; Royal Brompton Hosp, London SW3 6NP, England	Cardiff University; Royal Brompton Hospital	Morse, R (corresponding author), Univ Wales Hosp, Dept Integrat Med, Heath Pk, Cardiff CF4 4XW, S Glam, Wales.							SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P305	1	0	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1655	1656		10.1136/bmj.315.7123.1655	http://dx.doi.org/10.1136/bmj.315.7123.1655			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448530	Green Published			2022-12-28	WOS:000071149400013
J	Bourne, HR				Bourne, HR			Signal transduction - Pieces of the true Grail: A G protein finds its target	SCIENCE			English	Editorial Material							ADENYLYL CYCLASES; CRYSTAL-STRUCTURE				Bourne, HR (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,SAN FRANCISCO,CA 94143, USA.							Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	17	10	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1898	1899		10.1126/science.278.5345.1898	http://dx.doi.org/10.1126/science.278.5345.1898			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417637				2022-12-28	WOS:A1997YL00200019
J	Black, N; Griffiths, J; Pope, C; Bowling, A; Abel, P				Black, N; Griffiths, J; Pope, C; Bowling, A; Abel, P			Impact of surgery for stress incontinence on morbidity: cohort study	BRITISH MEDICAL JOURNAL			English	Article							WOMEN	Objectives: To describe the impact of surgery for stress incontinence on the severity of symptoms, other mental and physical symptoms, and overall health. To describe the incidence of postoperative complications. Design: Prospective cohort study; questionnaires completed by patients before and 3, 6, and 12 months after surgery Questionnaires completed by surgeons both before and after surgery. Setting: 18 hospitals in the North Thames region. Subjects: 442 women treated surgically for stress incontinence between January 1993 and June 1994. 367 women returned the 3 month questionnaire; 364 returned the 6 month questionnaire; and 359 returned the 12 month questionnaire. 49 surgeons provided perioperative information on 285 of the 442 women and postoperative information on 278. Main outcome measures: Stress incontinence symptom severity index, other urinary symptoms, bowel function, mental health, complications, global measures. Results: Most women (288; 87%) reported an improvement in the severity of their stress incontinence, though only 92 (28%) were cured (continent). These improvements persisted for at least 12 months. The likelihood of improvement was similar regardless of whether urodynamic pressure studies had been conducted before surgery. Following surgery, women were less likely to suffer from urinary frequency, nocturia, postvoid fullness, dysuria, and urgency. While mental health improved for 194 (71%), a quarter of women reported deterioration. Only 37 (10%) were satisfied with postoperative pain control. A third experienced one or more complications while in hospital, most commonly difficulty urinating. This problem affected 1 in 11 women after discharge. A year after surgery two thirds of women reported feeling better (251; 72%), that the outcome met or exceeded their expectations (230; 66%), and that they would recommend the operation to a friend in a similar situation (239; 68%). Surgeons tended to be more optimistic about the effects of surgery; they were satisfied with the outcome in 176 (85%) cases and would again treat 245 (94%) of the women as they had done previously. Conclusions: Although surgery reduces the severity of stress incontinence it is not as effective as current textbooks suggest. Women considering surgery should be provided with more accurate information on the likelihood of an improvement in symptoms and the occurrence of complications, including postoperative pain. Urgency and urge incontinence should not be considered contraindications to surgery The need for urodynamic assessment before surgery should be reappraised.	ROYAL POSTGRAD MED SCH,DEPT SURG,LONDON W12 0NN,ENGLAND	Imperial College London	Black, N (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Pope, Catherine/0000-0002-8935-6702				BERGMAN A, 1994, MANAGEMENT COMMON PR, P489; Black N, 1996, NEUROUROL URODYNAM, V15, P630, DOI 10.1002/(SICI)1520-6777(1996)15:6<630::AID-NAU4>3.3.CO;2-B; Black NA, 1996, BRIT J UROL, V78, P497, DOI 10.1046/j.1464-410X.1996.01422.x; Black NA, 1996, BRIT J UROL, V78, P847, DOI 10.1046/j.1464-410X.1996.02607.x; CARDOZO L, 1995, DEWHURSTS TXB OBSTET, P653; CLARKE A, 1995, BRIT J OBSTET GYNAEC, V102, P611, DOI 10.1111/j.1471-0528.1995.tb11398.x; DECHERNEY AH, 1994, CURRENT OBSTET GYNEC, P836; DEVINE EC, 1992, PATIENT EDUC COUNS, V19, P129, DOI 10.1016/0738-3991(92)90193-M; DOLL HA, 1992, J UROLOGY, V147, P1566, DOI 10.1016/S0022-5347(17)37628-0; FANTL JA, 1996, AHCPR PUB; *HLTH OUTC I, 1994, PAT SCREEN FORM 8 0; SAS Institute, 1989, SAS STAT US GUID; STANTON SL, 1991, CLIN GYNAECOLOGY, P302	13	110	110	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1493	1498		10.1136/bmj.315.7121.1493	http://dx.doi.org/10.1136/bmj.315.7121.1493			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420489	Green Published			2022-12-28	WOS:A1997YK98600018
J	Reyes, H; Coninx, R				Reyes, H; Coninx, R			Pitfalls of tuberculosis programmes in prisons	BRITISH MEDICAL JOURNAL			English	Article											Reyes, H (corresponding author), RED CROSS,INT COMM,GENEVA,SWITZERLAND.							CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; MARTIN V, 1994, TUBERCLE LUNG DIS, V74, P49; MORRIS N, 1995, OXFORD HIST PRISON, P151; *WHO, 1995, REP TUB EP STOP TB S, P183	5	67	76	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1447	1450		10.1136/bmj.315.7120.1447	http://dx.doi.org/10.1136/bmj.315.7120.1447			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418098	Green Published			2022-12-28	WOS:A1997YJ67200034
J	Jennings, DE; Sada, PV				Jennings, DE; Sada, PV			Water in Betelgeuse and Antares	SCIENCE			English	Article							ALPHA-ORIONIS; STELLAR SPECTRA; SCORPII; STARS; COOL; DUST; DIAMETERS; EMISSION; SUN; IAB	Absorption lines of hot water have been identified in the infrared spectra of Betelgeuse (alpha Orionis) and Antares (alpha Scorpii) near 12.3 micrometers (811 to 819 wavenumbers). The water lines originate in the atmospheres of the stars, not in their circumstellar material. The spectra are similar in structure to umbral sunspot spectra. Pure rotation water lines of this type will occur throughout the spectra of cool stars at wavelengths greater than 10 micrometers. From the water spectra, the upper limit for the temperature in the line formation region in both stars is 2800 kelvin, The water column density in both stars is (3 +/- 2) x 10(18) molecules per square centimeter, yielding an abundance relative to atomic hydrogen of n(H-2,O)/n(H) approximate to 10(-7).	NASA, Planetary Syst Branch, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Consultoria Astron Monterrey, Garza Garcia 66250, NL, Mexico	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Jennings, DE (corresponding author), NASA, Planetary Syst Branch, Goddard Space Flight Ctr, Code 693, Greenbelt, MD 20771 USA.		Jennings, Donald/D-7978-2012					ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; ALLER LH, 1960, STELLAR ATMOSPHERES, P252; BASRI GS, 1981, ASTROPHYS J, V251, P162, DOI 10.1086/159451; BEER R, 1972, ASTROPHYS J, V172, P89, DOI 10.1086/151330; BERNAT AP, 1979, ASTROPHYS J, V233, pL135, DOI 10.1086/183092; Bester M, 1996, ASTROPHYS J, V463, P336, DOI 10.1086/177246; BLOEMHOF EE, 1995, ASTROPHYS J, V440, pL93, DOI 10.1086/187769; CARPENTER KG, 1994, ASTROPHYS J, V428, P329, DOI 10.1086/174244; COBB ML, 1987, ASTROPHYS J, V315, P325, DOI 10.1086/165137; DEKOTER A, 1988, ASTRON ASTROPHYS, V200, P146; DIBENEDETTO GP, 1993, ASTRON ASTROPHYS, V270, P315; *DOW CHEM, 1965, JANAF THERM TABL; GEZARI DY, 1984, NASA RES PUBL, V1119; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; HOFFLEIT D, 1982, BRIGHT STAR CATALOG, P422; JENNINGS DE, 1986, ASTROPHYS J, V310, pL39, DOI 10.1086/184778; JENNINGS DE, 1992, INFRARED SOLAR PHYSI, P151; KLUCKERS MG, 1997, MON NOT R ASTRON SOC, V284, P711; Lewis G.N., 1961, THERMODYNAMICS, P419; MAURON N, 1990, ASTRON ASTROPHYS, V227, P141; Polyansky OL, 1997, SCIENCE, V277, P346, DOI 10.1126/science.277.5324.346; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; RIDGWAY ST, 1984, ASTROPHYS J SUPPL S, V54, P177, DOI 10.1086/190925; ROTHMAN LS, 1987, APPL OPTICS, V26, P4058, DOI 10.1364/AO.26.004058; SLOAN GC, 1993, ASTROPHYS J, V404, P328, DOI 10.1086/172282; SNOW TP, 1987, ASTROPHYS J, V321, P921, DOI 10.1086/165685; SPINRAD H, 1965, ASTROPHYS J, V141, P965, DOI 10.1086/148190; Treffers R., 1974, Astrophysical Journal, V188, P545, DOI 10.1086/152746; Tsuji T, 1997, ASTRON ASTROPHYS, V320, pL1; Tsuji T., 1964, ANN TOKYO ASTRON OBS, V9, P1; TSUJI T, 1995, ELEMENTARY PROCESSES, P193; VANDERHUCHT KA, 1980, ASTRON ASTROPHYS, V82, P14; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; Wallace L, 1996, ASTROPHYS J SUPPL S, V107, P312, DOI 10.1086/192367; WALLACE L, 1994, 199401 NAT SOL OBS	35	35	35	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					844	847		10.1126/science.279.5352.844	http://dx.doi.org/10.1126/science.279.5352.844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452380	Green Submitted			2022-12-28	WOS:000071923500038
J	Mound, JE; Mitrovica, JX				Mound, JE; Mitrovica, JX			True polar wander as a mechanism for second-order sea-level variations	SCIENCE			English	Article							EARTHS ROTATION; MANTLE RHEOLOGY; SUBDUCTION; CONTINENTS; PLATE; FLUCTUATIONS; PLEISTOCENE; TOPOGRAPHY; VISCOSITY; INVERSION	Long-term wander of the rotation pole can be a significant contributor to second-order (time scales of similar to 100 million years) sea-level variations. Numerical predictions based on realistic viscoelastic Earth models and paleomagnetically constrained polar motion yield global-scale, differential sea-level trends that can be as large as similar to 200 meters. From the results presented here, it is argued that the well-documented, second-order, Cretaceous-Tertiary sea-level cycle should be reinterpreted as some combination of a eustatic and a regionally varying rotational signal.	Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada	University of Toronto	Mound, JE (corresponding author), Univ Toronto, Dept Phys, 60 St George St, Toronto, ON M5S 1A7, Canada.			Mound, Jon/0000-0002-1243-6915				ANDREWS JA, 1985, J GEOPHYS RES-SOLID, V90, P7737, DOI 10.1029/JB090iB09p07737; BESSE J, 1991, J GEOPHYS RES-SOLID, V96, P4029, DOI 10.1029/90JB01916; Bills BG, 1996, GEOPHYS RES LETT, V23, P3023, DOI 10.1029/96GL02886; COFFIN MF, 1992, U TEXAS I GEOPHYS TE, V122, P49; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EARDLEY AJ, 1964, AM SCI, V52, P488; FLATTE SM, 1965, J GEOPHYS RES, V70, P5189, DOI 10.1029/JZ070i020p05189; Forte AM, 1996, GEOPHYS RES LETT, V23, P1147, DOI 10.1029/96GL00964; FORTE AM, 1995, SCIENCE, V268, P386, DOI 10.1126/science.268.5209.386; GRAND SP, 1987, J GEOPHYS RES-SOLID, V92, P14065, DOI 10.1029/JB092iB13p14065; GURNIS M, 1993, GEOLOGY, V21, P29, DOI 10.1130/0091-7613(1993)021<0029:DCHBOT>2.3.CO;2; GURNIS M, 1993, NATURE, V364, P589, DOI 10.1038/364589a0; GURNIS M, 1990, SCIENCE, V250, P970, DOI 10.1126/science.250.4983.970; HAGER BH, 1984, J GEOPHYS RES, V89, P6003, DOI 10.1029/JB089iB07p06003; HALLAM A, 1978, PALAEOGEOGR PALAEOCL, V23, P1, DOI 10.1016/0031-0182(78)90079-2; HAN DZ, 1989, GEOPH MONOG SERIES, V49, P1; HAQ BU, 1987, SCIENCE, V235, P1156, DOI 10.1126/science.235.4793.1156; Harrison C. G. A., 1990, SEA LEVEL CHANGE, P141; HAYS JD, 1973, NATURE, V246, P18, DOI 10.1038/246018a0; IRVING E, 1983, GEOPHYS SURV, V5, P299, DOI 10.1007/BF01453985; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; Miall A.D., 1990, PRINCIPLES SEDIMENTA, DOI [10.1007/978-1-4757-4235-0, DOI 10.1007/978-1-4757-4235-0]; Milne GA, 1996, GEOPHYS J INT, V126, pF13, DOI 10.1111/j.1365-246X.1996.tb04691.x; MITROVICA JX, 1989, TECTONICS, V8, P1079, DOI 10.1029/TC008i005p01079; Mitrovica JX, 1996, J GEOPHYS RES-SOL EA, V101, P555, DOI 10.1029/95JB03208; Mitrovica JX, 1996, J GEODYN, V22, P79, DOI 10.1016/0264-3707(96)00008-7; Morner N. A, 1980, CRETACEOUS RES, V1, P329; MORNER NA, 1981, GEOLOGY, V9, P344, DOI 10.1130/0091-7613(1981)9<344:RICSA>2.0.CO;2; NAKADA M, 1989, GEOPHYS J INT, V96, P497, DOI 10.1111/j.1365-246X.1989.tb06010.x; Pay- ton C.E., 1977, AAPG BULL, V26, P83, DOI DOI 10.1306/M26490C6; RICARD Y, 1991, GEOPHYS J INT, V105, P561, DOI 10.1111/j.1365-246X.1991.tb00796.x; RICHARDS MA, 1984, J GEOPHYS RES, V89, P5987, DOI 10.1029/JB089iB07p05987; SABADINI R, 1990, NATURE, V345, P708, DOI 10.1038/345708a0; Steinberger B, 1997, NATURE, V387, P169, DOI 10.1038/387169a0; Turcotte D., 2014, GEODYNAMICS, V3rd edn.; WATTS AB, 1979, M EWING SERIES, V3, P218, DOI DOI 10.1029/ME003P0218; Williams GE, 1997, GEOPHYS RES LETT, V24, P421, DOI 10.1029/97GL00234; WILLIAMS GE, 1990, J PHYS EARTH, V38, P475, DOI 10.4294/jpe1952.38.475; WU P, 1984, GEOPHYS J ROY ASTR S, V76, P753, DOI 10.1111/j.1365-246X.1984.tb01920.x	39	43	43	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					534	537		10.1126/science.279.5350.534	http://dx.doi.org/10.1126/science.279.5350.534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438840				2022-12-28	WOS:000071616000037
J	Roeper, J; Sewing, S; Zhang, Y; Sommer, T; Wanner, SG; Pongs, O				Roeper, J; Sewing, S; Zhang, Y; Sommer, T; Wanner, SG; Pongs, O			NIP domain prevents N-type inactivation in voltage-gated potassium channels	NATURE			English	Article							K+ CHANNELS; RAT-BRAIN; ALPHA-SUBUNITS; BETA-SUBUNITS; MECHANISMS; PROTEINS	Shaker-related voltage-gated K+ (K-v) channels(1,2) are assembled from ion-conducting K-v alpha subunits, which are integral membrane proteins, and auxiliary K-v beta subunits. This leads to the formation of highly diverse heteromultimeric K-v channels that mediate outward currents with a wide range of time courses for inactivation, Two principal inactivation mechanisms have been recognized(1): C-type inactivation correlated with carboxy-terminal K-v alpha-subunit structures(3), and N-type inactivation conferred by 'ball' domains in the amino termini of certain K-v alpha(4,5) and K-v beta(6) subunits, Assembly of heteromultimers with one or more K-v alpha(4,7)- and/or K-v beta(6) ball domains appears to be an essential principle of the generation of A-type K-v channel diversity, Here we show that, unexpectedly, the presence of K-v alpha- or K-v beta-ball domains does not dominate the gating phenotype in heteromultimers containing K(v)1.6 alpha subunits. These heteromultimers mediate non-inactivating currents because of the dominant-negative activity of a new type of N-type inactivation-prevention (NIP) domain present in the K(v)1.6 amino terminus. Mutations in the NIP domain lead to loss of function, and its transfer to another K-v alpha subunit leads to gain of function. Our discovery of the NIP domain, which neutralizes the activity of K-v alpha- and K-v beta-inactivation gates, establishes a new determinant for the gating behaviour of heteromultimeric K-v channels.	Zentrum Mol Neurobiol Hamburg, Inst Neurale Signalverarbeitung, D-20246 Hamburg, Germany; Univ Innsbruck, Fak Med, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Innsbruck	Pongs, O (corresponding author), Zentrum Mol Neurobiol Hamburg, Inst Neurale Signalverarbeitung, Martinistr 52, D-20246 Hamburg, Germany.	pointuri@uke.uni-hamburg.de		Roeper, Jochen/0000-0003-2145-8742; Sommer, Tobias/0000-0002-3504-7357				Chandy K. G., 1994, HDB RECEPTORS CHANNE, P1; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN YN, 1997, ANN REVNEUROSCI, V20, P91; Knaus HG, 1996, J NEUROSCI, V16, P955; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; VEH RW, 1995, EUR J NEUROSCI, V7, P21089; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	1998	391	6665					390	393		10.1038/34916	http://dx.doi.org/10.1038/34916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450755				2022-12-28	WOS:000071604200055
J	Shinohara, A; Ogawa, T				Shinohara, A; Ogawa, T			Stimulation by Rad52 of yeast Rad51-mediated recombination	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; STRAND-EXCHANGE; PROTEIN; RECA; MUTATIONS; FILAMENT; REPAIR; GENE	In Saccharomyces cerevisiae, the RAD51 and RAD52 genes are involved in recombination and in repair of damaged DNA(1-3). The RAD51 gene is a structural and functional homologue of the recA gene(4,5) and the gene product participates in strand exchange and single-stranded-DNA-dependent ATP hydrolysis by means of nucleoprotein filament formation(6-11). The RAD52 gene(12) is important in RAD51-mediated recombination(1-3). Binding of this protein to Rad51 (refs 4, 13) suggests that they cooperate In recombination. Homologues of both Rad51 and Rad52 are conserved from yeast to humans(14-16), suggesting that the mechanisms used for pairing homologous DNA molecules during recombination may be universal in eukaryotes. Here we show that Rad52 protein stimulates Rad51 reactions and that binding to Rad51 is necessary for this stimulatory effect. We conclude that this binding is crucial in recombination and that it facilitates the formation of Rad51 nucleoprotein filaments.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Natl Inst Genet, Shizuoka 4110801, Japan	Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shinohara, A (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	ashino@bio.sci.osaka-u.ac.jp; tomogawa@lab.nig.jp						ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURRIS DFR, 1994, MUTAT RESDNA REPAIR, V315, P295; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OGAWA T, 1995, ADV BIOPHYS, V31, P93, DOI 10.1016/0065-227X(95)99385-3; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK M A, 1987, P157; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, UNPUB GENES CELLS; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P587; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	373	384	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	1998	391	6665					404	407		10.1038/34943	http://dx.doi.org/10.1038/34943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450759				2022-12-28	WOS:000071604200059
J	Spiro, HM; Mandell, HN				Spiro, HM; Mandell, HN			When doctors get sick	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Spiro, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,Box 208019, New Haven, CT 06520 USA.							Mandell H, 1987, DOCTORS GET SICK; Scarry E., 1985, BODY PAIN	2	18	19	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					152	154		10.7326/0003-4819-128-2-199801150-00014	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441578				2022-12-28	WOS:000071470800013
J	Li, YG; Vidale, JE; Aki, K; Xu, F; Burdette, T				Li, YG; Vidale, JE; Aki, K; Xu, F; Burdette, T			Evidence of shallow fault zone strengthening after the 1992 M7.5 Landers, California, earthquake	SCIENCE			English	Article							RUPTURE PROCESS; ROCK FRICTION; SLIP; DEFORMATION; SEQUENCE	Repeated seismic surveys of the Landers, California, fault zone that ruptured in the magnitude (M) 7.5 earthquake of 1992 reveal an increase in seismic velocity with time, P, S, and fault zone trapped waves were excited by near-surface explosions in two locations in 1994 and 1996, and were recorded on two linear, three-component seismic arrays deployed across the Johnson Valley fault trace, The travel times of P and S waves for identical shot-receiver pairs decreased by 0.5 to 1.5 percent from 1994 to 1996, with the larger changes at stations located within the fault zone. These observations indicate that the shallow Johnson Valley fault is strengthening after the main shock, most likely because of closure of cracks that were opened by the 1992 earthquake, The increase in velocity is consistent with the prevalence of dry over wet cracks and with a reduction in the apparent crack density near the fault zone by approximately 1.0 percent from 1994 to 1996.	Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; US Geol Survey, Menlo Park, CA 94025 USA	University of Southern California; University of California System; University of California Los Angeles; United States Department of the Interior; United States Geological Survey	Li, YG (corresponding author), Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA.	ygli@terra.usc.edu	Vidale, John/H-4965-2011	Vidale, John/0000-0002-3658-818X				AKI K, 1972, TECTONOPHYSICS, V13, P423, DOI 10.1016/0040-1951(72)90032-7; Bock Y, 1997, J GEOPHYS RES-SOL EA, V102, P18013, DOI 10.1029/97JB01379; Burgmann R, 1997, J GEOPHYS RES-SOL EA, V102, P4933, DOI 10.1029/96JB03171; COHEE BP, 1994, B SEISMOL SOC AM, V84, P692; DIETERICH JH, 1979, J GEOPHYS RES, V84, P2161, DOI 10.1029/JB084iB05p02161; DIETERICH JH, 1979, J GEOPHYS RES, V84, P2169, DOI 10.1029/JB084iB05p02169; DIETERICH JH, 1972, J GEOPHYS RES, V77, P3690, DOI 10.1029/JB077i020p03690; Dodge DA, 1997, J GEOPHYS RES-SOL EA, V102, P24437, DOI 10.1029/97JB02024; GARBIN HD, 1973, Q APPL MATH, V30, P453, DOI 10.1090/qam/99719; GARBIN HD, 1975, Q APPL MATH, V33, P301, DOI 10.1090/qam/99661; GARBIN HD, 1975, Q APPL MATH, V33, P296, DOI 10.1090/qam/99662; HERZBERG M, 1993, EOS, V74, P612; HOUSTON H, 1990, GEOPHYS RES LETT, V17, P1021, DOI 10.1029/GL017i007p01021; Kanamori H, 1986, GEOPHYS MONOGR SER, V37, P227, DOI DOI 10.1029/GM037P0227; Karageorgi E, 1997, B SEISMOL SOC AM, V87, P39; KRANZ RL, 1977, J GEOPHYS RES, V82, P4893, DOI 10.1029/JB082i030p04893; LI YG, 1994, SCIENCE, V265, P367, DOI 10.1126/science.265.5170.367; LI YG, 1994, J GEOPHYS RES-SOL EA, V99, P11705, DOI 10.1029/94JB00464; MAGISTRALE H, 1992, J GEOPHYS RES-SOL EA, V97, P14115, DOI 10.1029/92JB00494; MARONE C, 1995, GEOPHYS RES LETT, V22, P3095, DOI 10.1029/95GL03076; MARONE C, UNPUB; MOONEY WD, 1986, PURE APPL GEOPHYS, V124, P141, DOI 10.1007/BF00875723; Mori J, 1996, B SEISMOL SOC AM, V86, P1845; NUR A, 1972, B SEISMOL SOC AM, V62, P1217; Peltzer G, 1996, SCIENCE, V273, P1202, DOI 10.1126/science.273.5279.1202; REVENAUGH J, 1995, SCIENCE, V270, P1344, DOI 10.1126/science.270.5240.1344; RICE JR, 1993, J GEOPHYS RES-SOL EA, V98, P9885, DOI 10.1029/93JB00191; Rubin CM, 1997, J GEOPHYS RES-SOL EA, V102, P15319, DOI 10.1029/97JB00265; SAVAGE JC, 1994, J GEOPHYS RES-SOL EA, V99, P13757, DOI 10.1029/94JB00507; Scholz C. H., 1990, MECH EARTHQUAKES FAU; SCHOLZ CH, 1978, SCIENCE, V201, P441, DOI 10.1126/science.201.4354.441; SCHOLZ CH, 1986, B SEISMOL SOC AM, V76, P65; SCHOLZ CH, 1993, J GEOPHYS RES-SOL EA, V98, P21951, DOI 10.1029/93JB01008; Shen ZK, 1996, J GEOPHYS RES-SOL EA, V101, P27957, DOI 10.1029/96JB02544; SIEH K, 1993, SCIENCE, V260, P171, DOI 10.1126/science.260.5105.171; VIDALE JE, 1994, NATURE, V368, P624, DOI 10.1038/368624a0; WALD DJ, 1994, B SEISMOL SOC AM, V84, P668	37	157	166	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					217	219		10.1126/science.279.5348.217	http://dx.doi.org/10.1126/science.279.5348.217			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422692				2022-12-28	WOS:000071408100039
J	Enari, M; Sakahira, H; Yokoyama, H; Okawa, K; Iwamatsu, A; Nagata, S				Enari, M; Sakahira, H; Yokoyama, H; Okawa, K; Iwamatsu, A; Nagata, S			A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD	NATURE			English	Article							FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CELL-DEATH; ICE-LIKE; PROTEASE; PROTEINS; FAMILY; FRAGMENTATION; IDENTIFICATION; INVOLVEMENT	The homeostasis of animals is regulated not only by the growth and differentiation of cells, but also by cell death through a process known as apoptosis. Apoptosis is mediated by members of the caspase family of proteases, and eventually causes the degradation of chromosomal DNA. A caspase-activated deoxyribonuclease (CAD) and its inhibitor (ICAD) have now been identified in the cytoplasmic fraction of mouse lymphoma cells. CAD is a protein of 343 amino acids which carries a nuclear-localization signal; ICAD exists in a long and a short form. Recombinant ICAD specifically inhibits CAD-induced degradation of nuclear DMA and its DNase activity. When CAD is expressed with ICAD In COS cells or in a cell-free system, CAD is produced as a complex with ICAD: treatment with caspase 3 releases the DNase activity which causes DNA fragmentation in nuclei. ICAD therefore seems to function as a chaperone for CAD during its synthesis, remaining complexed with CAD to inhibit its DNase activity; caspases activated by apoptotic stimuli then cleave ICAD, allowing CAD to enter the nucleus and degrade chromosomal DNA.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Kirin Brewery Co Ltd, Cent Lab Key Technol, Kanagawa 236, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University; Kirin Brewery Company Limited	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETISCH MC, 1993, EMBO J, V12, P371; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shiokawa D, 1997, ARCH BIOCHEM BIOPHYS, V346, P15, DOI 10.1006/abbi.1997.0275; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0	44	2641	2809	2	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					43	50		10.1038/34112	http://dx.doi.org/10.1038/34112			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422506				2022-12-28	WOS:000071326100042
J	Campbell, D				Campbell, D			Medicine needs its MI5	BRITISH MEDICAL JOURNAL			English	Article									IPTV, Edinburgh EH2 1EP, Midlothian, Scotland		Campbell, D (corresponding author), IPTV, 45 Frederick St, Edinburgh EH2 1EP, Midlothian, Scotland.							GoldbeckWood S, 1997, BRIT MED J, V315, P1252; Smith R, 1996, BRIT MED J, V312, P789	2	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1677	1680		10.1136/bmj.315.7123.1677	http://dx.doi.org/10.1136/bmj.315.7123.1677			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448539	Green Published			2022-12-28	WOS:000071149400024
J	Subbarayappa, BV				Subbarayappa, BV			Siddha medicine: an overview	LANCET			English	Article									Indian Inst World Culture, Ctr Hist & Philosophy Sci, Bangalore 56004, Karnataka, India		Subbarayappa, BV (corresponding author), Indian Inst World Culture, Ctr Hist & Philosophy Sci, Bangalore 56004, Karnataka, India.							Bagchi, 1931, INDIAN HIST Q, V7, P1; BALARAMAIAH V, 1980, VADAVAIDYATTUKKI A 1, P6; BALARAMAIAH V, 1980, VADAVAIDYATTUKKI A 1, P22; BHATTACHARYA C, 1933, MATRKABHEDATANTRAM; CHAKRAVARTHY C, 1963, TANTRAS STUDIES THEI; GANAPATHI AG, 1995, SIDDA SEYAL; IYER KCV, 1932, ACHARYA PCR COMMEMOR, P466; IYER KCV, 1932, STUDY ALCHEMY TAMILA, P460; JOSEPH JT, 1984, HERITAGE TAMILS SIDD, P89; *MIN HLTH FAM WELF, 1993, IND SYST MED HOM IND, P66; MUDALIYAR K, 1987, SIDDBA MARUTTUVUM, P40; NEEDHAM J, 1974, SCI CIVILISATION CHI, V5, P128; NEEDHAM J, 1974, SCI CIVILIZATION CHI, V5, P109; NEEDHAM J, 1974, SCI CIVILIZATION CHI, V5, P13; RAJAN MC, 1989, MACCHAMUNI NAYANAR, P72; Roy M, 1976, RASARNAVAKALPA; ROYAN CSU, 1978, SIDDHA PHARMACOPOEIA; Royan CU, 1957, SIDDHA HOSP PHARMACO, P45; SAHIB PMA, 1975, AGASTYAR PALLU 200; SUBBARAYAPPA BV, 1971, CONCISE HIST SCI IND, P335; SUBRAMANIAN SV, 1984, HERITAGE TAMILS SIDD, P238; SUBRAMANIAN SV, 1984, HERITAGE TAMILS SIDD, P562; THEVAR VG, 1975, BHOGAR YELAIRAM YIRA; THYAGARAJAN R, 1974, THERAIER VENBA, P136; VAIDYACINTAMANI Y, 1980, VADAVAIDYATTUKKI A 1, P13; VELAN AS, 1963, SIDDHARS SCI LONGEVI, P202; VELAN AS, 1963, SIDDHARS SCI LONGEVI, V4, P67; VELAN AS, 1963, SIDDHARS SCI LONGEVI, P95; VLAENTINE DE, 1984, FLUID SIGNS, P173; 1989, FORMULARY SIDDHA MED, P1; 1953, PATANJALI YOGA SUTRA; 1975, AGASTYAR KANDAM, P4; 1980, YUGIMUNIVAR VAIDYA 1, P4; 1976, YUGIMUNIVAR VAIDYA 1, P47; 1976, THERAIER YEMAKA VE 1, P13; 1953, PANTAJALI YOGA SUTRA, V4, P1; 1976, THERAIER YEMAKA VE 1, P63	37	41	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1841	1844		10.1016/S0140-6736(97)04223-2	http://dx.doi.org/10.1016/S0140-6736(97)04223-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428267				2022-12-28	WOS:000071102500046
J	Britten, N; Ukoumunne, O				Britten, N; Ukoumunne, O			The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE	Objectives: To measure patients' expectations of receiving prescriptions and general practitioners' perceptions of these expectations and to determine the factors most closely associated with the decision to prescribe. Design: Questionnaires were completed by patients waiting to see their general practitioners, and by their doctors immediately after the consultations. Setting: Four non-fundholding group practices in southeast London. Subjects: 544 unselected patients consulting 15 general practitioners. Main outcome measures: Doctors' perceptions of patients' expectations; doctors' decisions to prescribe. Results: 67% (354/526) of patients hoped for a prescription; doctors perceived that 56% (305/542) of patients wanted prescriptions; and doctors wrote prescriptions in 59% (321/543) of consultations. Despite the close-agreement between patients' hopes and doctors' perceptions, 25% (89/353) of patients hoped for a prescription but did not receive one. In 22% (68/313) of consultations in which prescriptions were written, they were not strictly indicated on purely medical grounds, and in only 66% (202/306) of consultations in which prescriptions were written were they both indicated and hoped for. Doctors' perceptions of patients' expectations were the strongest predictor of the decision to prescribe, but the final regression model also included patients' hopes and ethnic group, and the doctor's feeling of being pressurised. Conclusions:In an area oflow prescribing and high expectations the decision to prescribe was closely related to actual and perceived expectations, but the latter was the more significant influence.			Britten, N (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND.							*AUD COMM, 1994, PRESCR IMPR MOR RAT; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BRADLEY CP, 1990, THESIS TRINITY COLL; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; BRITTEN N, 1996, MODERN MED LAY PERSP; CARTWRIGHT A, 1983, DOCTOR PATIENT COMMU; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; *DEP HLTH, 1995, STAT B 1995 15 STAT; Fitton F., 1979, DOCTOR PATIENT RELAT; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; JEFFERYS M, 1983, RETHINKING GENERAL P; Lamberts H., 1987, ICPC INT CLASSIFICAT; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Rice N, 1996, J Health Serv Res Policy, V1, P154; Stimson G. V., 1975, GOING SEE DOCTOR CON; Taylor D.G., 1990, MED NHS EUROPE BALAN; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WEBB S, 1994, BRIT J GEN PRACT, V44, P165; WOODHOUSE G, 1996, MULTILEVEL MODELLING	21	232	235	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1506	1510		10.1136/bmj.315.7121.1506	http://dx.doi.org/10.1136/bmj.315.7121.1506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420493	Green Published			2022-12-28	WOS:A1997YK98600023
J	Coupland, RM				Coupland, RM			Abhorrent weapons and ''superfluous injury or unnecessary suffering'': from field surgery to law	BRITISH MEDICAL JOURNAL			English	Article											Coupland, RM (corresponding author), RED CROSS,INT COMM,HLTH OPERAT DIV,CH-1202 GENEVA,SWITZERLAND.							*INT COMM RED CROS, 1997, SIRUS PROJ DET WHICH	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1450	1452		10.1136/bmj.315.7120.1450	http://dx.doi.org/10.1136/bmj.315.7120.1450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418099	Green Published			2022-12-28	WOS:A1997YJ67200035
J	Walker, R				Walker, R			General management of end stage renal disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DIALYSIS; FAILURE; SURVIVAL; HYPERPARATHYROIDISM; ERYTHROPOIETIN; CONSEQUENCES; THERAPY; RHUEPO				Walker, R (corresponding author), OTAGO CLIN SCH MED, DEPT MED, DUNEDIN, NEW ZEALAND.		Walker, Robert J/B-1498-2010	Walker, Robert J/0000-0003-3366-0956				ATTMAN PO, 1993, AM J KIDNEY DIS, V21, P573, DOI 10.1016/S0272-6386(12)80030-8; BERGSTROM J, 1993, KIDNEY INT, V43, pS39; BERGSTROM J, 1995, J AM SOC NEPHROL, V6, P1329; Brancaccio D, 1996, NEPHROL DIAL TRANSPL, V11, P420; Charra B, 1996, AM J NEPHROL, V16, P35, DOI 10.1159/000168968; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; DRUEKE TB, 1995, NEPHROL DIAL TRANSPL, V10, P62, DOI 10.1093/ndt/10.supp2.62; Eadington DW, 1996, NEPHROL DIAL TRANSPL, V11, P2124, DOI 10.1093/oxfordjournals.ndt.a027123; FELLNER SK, 1993, KIDNEY INT, V44, P1309, DOI 10.1038/ki.1993.383; FOLEY RN, 1995, J AM SOC NEPHROL, V5, P2024; HAKIM RM, 1995, J AM SOC NEPHROL, V6, P1319; IKRIZLER TA, 1996, KIDNEY INT, V50, P343; JUNGERS P, 1993, NEPHROL DIAL TRANSPL, V8, P1089; KAYSEN GA, 1994, BLOOD PURIFICAT, V12, P60, DOI 10.1159/000170146; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; MACDOUGALL IC, 1995, NEPHROL DIAL TRANSPL, V10, P85, DOI 10.1093/ndt/10.supp2.85; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; MASSRY SG, 1994, SEMIN NEPHROL, V14, P219; Massy Z A, 1996, Curr Opin Nephrol Hypertens, V5, P141, DOI 10.1097/00041552-199603000-00007; MASSY ZA, 1995, KIDNEY INT, V48, P188, DOI 10.1038/ki.1995.284; Parfrey P S, 1995, Curr Opin Nephrol Hypertens, V4, P105, DOI 10.1097/00041552-199503000-00001; PASCUAL J, 1991, CLIN NEPHROL, V35, P280; POLLOCK CA, 1994, KIDNEY INT, V45, P897, DOI 10.1038/ki.1994.118; QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223; RAINE AEG, 1991, NEPHROL DIAL TRANSPL, V6, P902; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; Slatopolsky E, 1996, NEPHROL DIAL TRANSPL, V11, P130; *US REN DAT SYST, 1995, AM J KIDNEY DIS S, V26, pS69	28	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	1997	315	7120					1429	1432		10.1136/bmj.315.7120.1429	http://dx.doi.org/10.1136/bmj.315.7120.1429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418093	Green Published			2022-12-28	WOS:A1997YJ67200029
J	Stephens, L; Anderson, K; Stokoe, D; Erdjument-Bromage, H; Painter, GF; Holmes, AB; Gaffney, PRJ; Reese, CB; McCormick, F; Tempst, P; Coadwell, J; Hawkins, PT				Stephens, L; Anderson, K; Stokoe, D; Erdjument-Bromage, H; Painter, GF; Holmes, AB; Gaffney, PRJ; Reese, CB; McCormick, F; Tempst, P; Coadwell, J; Hawkins, PT			Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B	SCIENCE			English	Article							3-KINASE; AKT; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; EGF	Protein kinase B (PKB) is activated in response to phosphoinositide 3-kinases and their lipid products phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P-3] and PtdIns(3,4)P-2 in the signaling pathways used by a wide variety of growth factors, antigens, and inflammatory stimuli. PKB is a direct target of these lipids, but this regulation is complex. The lipids can bind to the pleckstrin homologqus domain of PKB, causing its translocation to the membrane, and also enable upstream, Thr(308)-directed kinases to phosphorylate and activate PKB. Four isoforms of these PKB kinases were purified from sheep brain. They bound PtdIns(3,4,5)P-3 and associated with lipid vesicles containing ii. These kinases contain an NH2-terminal catalytic domain and a COOH-terminal pleckstrin homologous domain, and their heterologous expression augments receptor activation of PKB, which suggests they are the primary signal transducers that enable PtdIns(3,4,5)P-3 or PtdIns(3,4)P-2 to activate PKB and hence to control signaling pathways regulating cell survival, glucose uptake, and glycogen metabolism.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ London Kings Coll, Dept Chem, London WC2R 2LS, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of Cambridge; University of London; King's College London	Stephens, L (corresponding author), Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England.	len.stephens@bbsrc.ac.uk		Hawkins, Phillip/0000-0002-6979-0464; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Anderson, Karen/0000-0002-7394-6660; stephens, len/0000-0002-2771-3487	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSON K, UNPUB; BALLACOSA A, 1993, ONCOGENE, V8, P745; BUNN TC, 1996, GENOME RES, V6, P525; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STEPHENS LR, UNPUB; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358	25	899	941	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					710	714		10.1126/science.279.5351.710	http://dx.doi.org/10.1126/science.279.5351.710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445477				2022-12-28	WOS:000071731500038
J	Misrahi, M; Teglas, JP; N'Go, N; Burgard, M; Mayaux, MJ; Rouzioux, C; Delfraissy, JF; Blanche, S				Misrahi, M; Teglas, JP; N'Go, N; Burgard, M; Mayaux, MJ; Rouzioux, C; Delfraissy, JF; Blanche, S		French Pediatric HIV Infect Study Grp	CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION; INDIVIDUALS; RESISTANCE; ALLELES; INFANTS; GENE; RNA	Context.-Studies suggest that adults with the CCR5 Delta 32 deletion are less likely to become infected with the human immunodeficiency virus (HIV) and to develop HIV-related disease progression, but the effect of the mutation in children is not known. Objective.-To study the effect of the CCR5 chemokine receptor mutant allele on mother-to-child transmission of HIV type 1 (HIV-1) and subsequent disease progression in infected children. Design.-Multicenter, prospective study of infants born to mothers seropositive for HIV-1. Setting.-A total of 52 medical centers participating in the French Pediatric HIV Cohort studies. Participants.-The CCR5 Delta 32 deletion was studied in 512 non-African children, born between 1983 and 1996 to HIV-1-infected mothers. Among them, 276 children were infected and 236 were not. Main Outcome Measures.-HIV-1 infection status and, in infected children followed up since birth, incidence of category B and C disease events and severe immunosuppression as defined in the new pediatric Centers for Disease Control and Prevention (CDC) classification, according to CCR5 genotype. Results.-The 32-base pair deleted allele was detected at a frequency of 0.05, Only 1 infant, not infected by HIV-1, was homozygous for the Delta 32 deletion. The 49 heterozygous children (9.6% of the total; 95% confidence interval [CI], 7.1-12.2) were equally distributed into the infected (9.8%) and uninfected (9.3%) groups. The incidence of stage C symptoms in heterozygous infected children was 9% at 36 months vs 28% in children homozygous for the normal allele (P<.004). The proportion of children at 8 years old with no stage B or C symptoms was 49% for heterozygous children and 11% for children homozygous for the normal allele (P<.003). The progression of severe immune deficiency (CD4 <15%, CDC stage 3) was also significantly different between the 2 groups (P<.001). Conclusions.-Heterozygosity for the CCR5 Delta 32 deletion does not protect children from infection by the maternal virus but substantially reduces the progression of the disease in HIV-1-infected children.	Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, F-75743 Paris 15, France; Hop Bicetre, Lab Hormonal & Mol Biol, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, U292, Unite Publ Hlth Epidemiol & Human Reprod, Le Kremlin Bicetre, France; Hop Bicetre, Dept Internal Med, Le Kremlin Bicetre, France; Hop Necker Enfants Malad, Virol Lab, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Blanche, S (corresponding author), Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, 149 Rue Sevres, F-75743 Paris 15, France.	stephane.blanche@nck.ap-hop.paris.fr	Ngo-Giang-Huong, Nicole/G-2860-2017	Ngo-Giang-Huong, Nicole/0000-0001-8950-3234				[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; Balotta C, 1997, AIDS, V11, pF67, DOI 10.1097/00002030-199710000-00001; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Hill AVS, 1996, NAT MED, V2, P395, DOI 10.1038/nm0496-395; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004; JUST JJ, 1995, J PEDIATR-US, V127, P544, DOI 10.1016/S0022-3476(95)70110-9; Kourtis AP, 1996, NEW ENGL J MED, V335, P1431, DOI 10.1056/NEJM199611073351904; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; MEYER L, 1997, AIDS, V11, P5908; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, LANCET, V350, P741, DOI 10.1016/S0140-6736(05)63551-9; Strachan T., 2004, HUM MOL GENET, V3; Theodorou I, 1997, LANCET, V349, P1219; Winchester R, 1995, P NATL ACAD SCI USA, V92, P12374, DOI 10.1073/pnas.92.26.12374; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	34	94	96	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					277	280		10.1001/jama.279.4.277	http://dx.doi.org/10.1001/jama.279.4.277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450710	Bronze			2022-12-28	WOS:000071607000033
J	Weiss, RA				Weiss, RA			Transgenic pigs and virus adaptation	NATURE			English	Editorial Material							ACCELERATING FACTOR CD55; HUMAN-SERUM; CELLS; PROTEINS; RECEPTOR; CD46		Inst Canc Res, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weiss, RA (corresponding author), Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.							BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; Darrieussecq Marie, 1997, PIG TALES; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorling A, 1997, LANCET, V349, P867, DOI 10.1016/S0140-6736(96)09404-4; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; McMorrow IM, 1997, TRANSPLANTATION, V64, P501, DOI 10.1097/00007890-199708150-00021; Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Murphy FA, 1996, SCIENCE, V273, P746, DOI 10.1126/science.273.5276.746; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; Takeuchi Y, 1997, J VIROL, V71, P6174, DOI 10.1128/JVI.71.8.6174-6178.1997; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; VAUGHAN HA, 1994, TRANSPLANTATION, V58, P879, DOI 10.1097/00007890-199410270-00003; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; White D, 1996, TRENDS BIOTECHNOL, V14, P3, DOI 10.1016/0167-7799(96)80906-1	20	139	142	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					327	328		10.1038/34772	http://dx.doi.org/10.1038/34772			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450739	Bronze			2022-12-28	WOS:000071604200022
J	Lau, J; Ioannidis, JPA; Schmid, CH				Lau, J; Ioannidis, JPA; Schmid, CH			Summing up evidence: one answer is not always enough	LANCET			English	Article							RANDOMIZED CONTROLLED TRIALS; ACUTE MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; INTRAVENOUS-MAGNESIUM; METAANALYSIS; RISK; HETEROGENEITY; QUALITY; EXAMPLE; BENEFIT	Are meta-analyses the brave new world, or are the critics of such combined analyses right to say that the biases inherent in clinical trials make them uncombinable? Negative trials are often unreported, and hence can be missed by meta-analysts. And how much heterogeneity between trials is acceptable? A recent major criticism is that large randomised trials do not always agree with a prior meta-analysis. Neither individual trials nor meta-analyses, reporting as they do on population effects, tell how to treat the individual patient. Here we take a more rounded approach to meta-analyses, arguing that their strengths outweigh their weaknesses, although the latter must not be brushed aside.	Tufts Univ, New England Med Ctr Hosp, Sch Med, Div Clin Care Res, Boston, MA 02111 USA; NIAID, NIH, Bethesda, MD 20892 USA	Tufts Medical Center; Tufts University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lau, J (corresponding author), Tufts Univ, New England Med Ctr Hosp, Sch Med, Div Clin Care Res, Box 63,750 Washington St, Boston, MA 02111 USA.	joseph.lau@es.nemc.org	Ioannidis, John P. A./G-9836-2011; Schmid, Christopher H./J-2398-2014	Schmid, Christopher H./0000-0002-0855-5313				ABE O, 1995, NEW ENGL J MED, V333, P1444; ANELLO C, 1995, J CLIN EPIDEMIOL, V48, P109, DOI 10.1016/0895-4356(94)00084-4; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERLIN JA, 1995, AM J EPIDEMIOL, V142, P383, DOI 10.1093/oxfordjournals.aje.a117645; BERLIN JA, 1994, ONLINE J CURR CLIN T; BEROYZ G, 1994, LANCET, V343, P619; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; BUCHER HC, 1996, JAMA-J AM MED ASSOC, V275, P113; Cappelleri J., 1995, ONLINE J CURR CLIN T; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; Chalmers TC, 1996, STAT MED, V15, P1263, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1263::AID-SIM305>3.3.CO;2-B; COLLINS R, 1995, LANCET, V345, P669; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVITA C, 1994, LANCET, V343, P1115; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; Hedges L.V., 1994, HDB RES SYNTHESIS; IOANNIDIS JP, 1997, ONLINE J CURR C 0515; IOANNIDIS JP, IN PRESS N ENGL J ME; Ioannidis JPA, 1996, LANCET, V348, P756, DOI 10.1016/S0140-6736(05)65647-4; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2; Ioannidis JPA, 1996, AM J EPIDEMIOL, V144, P1074, DOI 10.1093/oxfordjournals.aje.a008881; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; NAYLOR CD, 1996, J EVAL CLIN PRACT, V1, P127; Raudenbush S. W., 1994, HDB RES SYNTHESIS, P301, DOI DOI 10.1111/ACPS.12078; RUBIN DB, 1992, J EDUC STAT, V17, P363, DOI 10.2307/1165129; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; SCHMID CH, IN PRESS STAT MED; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SENN S, 1994, STAT MED, V13, P293, DOI 10.1002/sim.4780130310; Sharp SJ, 1996, BRIT MED J, V313, P735; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TOPOL EJ, 1992, BRIT HEART J, V68, P348; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WOODS KL, 1995, LANCET, V346, P611, DOI 10.1016/S0140-6736(95)91440-4; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	49	522	535	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	1998	351	9096					123	127		10.1016/S0140-6736(97)08468-7	http://dx.doi.org/10.1016/S0140-6736(97)08468-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439507				2022-12-28	WOS:000071591900043
J	Bais, C; Santomasso, B; Coso, O; Arvanitakis, L; Raaka, EG; Gutkind, JS; Asch, AS; Cesarman, E; Gerhengorn, MC; Mesri, EA				Bais, C; Santomasso, B; Coso, O; Arvanitakis, L; Raaka, EG; Gutkind, JS; Asch, AS; Cesarman, E; Gerhengorn, MC; Mesri, EA			G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DNA-SEQUENCES; CELLS; EXPRESSION; VIRUS	The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is a gamma-2 herpesvirus(1-5) that is implicated in the pathogenesis of Kaposi's sarcoma(1,5) and of primary effusion B-cell lymphomas (PELs)(6). KSHV infects malignant and progenitor cells of Kaposi's sarcoma(7) and PEL2,6,8, it encodes putative oncogenes(4,5,9) and genes that may cause Kaposi's sarcoma pathogenesis by stimulating angiogenesis(4,5,9,10). The G-protein-coupled receptor encoded by an open reading frame (ORF 74) of KSHV9 is expressed in Kaposi's sarcoma lesions and in PEL9,11 and stimulates signalling pathways linked to cell proliferation(12) in a constitutive (agonist-independent) way(12). Here we show that signalling by this KSHV G-protein-coupled receptor leads to cell transformation and tumorigenicity, and induces a switch to an angiogenic phenotype(13) mediated by vascular endothelial growth factor(14), an angiogenesis(13,14) and Kaposi's-spindle-cell growth factor(15-17). We find that this receptor can activate two protein kinases, JNK/SAPK and p38MAPK, by triggering signalling cascades like those induced by inflammatory cytokines(18) that are angiogenesis activators(19) and mitogens for Kaposi's sarcoma cells(10) and B cells. We conclude that the KSHV G-protein-coupled receptor is a viral oncogene that can exploit cell signalling pathways to induce transformation and angiogenesis in KSHV-mediated oncogenesis.	Cornell Univ, Coll Med, Lab Viral Oncogenesis, New York, NY 10021 USA; Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Mol Med, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; NIDR, Mol Signaling Unit, Cellular Dev & Oncol Lab, NIH, Bethesda, MD 20892 USA	Cornell University; Cornell University; Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Mesri, EA (corresponding author), Cornell Univ, Coll Med, Lab Viral Oncogenesis, New York, NY 10021 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Santomasso, Bianca/0000-0001-9423-4059				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; ARVANITAKIS L, 1996, BLOOD, V86, P2708; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1997, CURR OPIN INFECT DIS, V10, P26, DOI 10.1097/00001432-199702000-00007; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cornali E, 1996, AM J PATHOL, V149, P1851; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; GOTO F, 1993, LAB INVEST, V69, P508; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANAHAN D, 1996, CELL, V86, P356; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; MESRI EA, 1995, CIRC RES, V76, P161, DOI 10.1161/01.RES.76.2.161; MONTESANO R, 1993, J CELL SCI, V105, P1013; Nakamura S, 1997, J IMMUNOL, V158, P4992; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAAKA EG, UNPUB J EXP MED; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; RUSSO JJ, 1997, P NATL ACAD SCI USA, V93, P14862; SAMANIEGO F, 1995, J IMMUNOL, V154, P3582; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577	30	685	710	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					86	89		10.1038/34193	http://dx.doi.org/10.1038/34193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422510				2022-12-28	WOS:000071326100054
J	Ricote, M; Li, AC; Willson, TM; Kelly, CJ; Glass, CK				Ricote, M; Li, AC; Willson, TM; Kelly, CJ; Glass, CK			The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation	NATURE			English	Article							INTERFERON-GAMMA; EXPRESSION; GENE; CELLS; METALLOPROTEINASES; LIPOPOLYSACCHARIDE; COLLAGENASE; LIGAND; J(2); AP-1	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors that is predominantly expressed in adipose tissue, adrenal gland and spleen(1-3). PPAR-gamma has been demonstrated to regulate adipocyte differentiation and glucose homeostasis in response to several structurally distinct compounds, including thiazolidinediones and fibrates(3-6). Naturally occurring compounds such as fatty acids and the prostaglandin D-2 metabolite 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)) bind to PPAR-gamma and stimulate transcription of target genes(7-10). Prostaglandin D-2 metabolites have not yet been identified in adipose tissue, but are major products of arachidonic-acid metabolism in macrophages(11), raising the possibility that they might serve as endogenous PPAR-gamma ligands in this cell type, Here we show that PPAR-gamma is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ(2) and synthetic PPAR-gamma ligands, PPAR-gamma inhibits gene expression in part by antagonizing the activities of the transcription factors AP-1, STAT and NF-kappa B, These observations suggest that PPAR-gamma and locally produced prostaglandin D-2 metabolites are involved in the regulation of inflammatory responses, and raise the possibility that synthetic PPAR-gamma ligands may be of therapeutic value in human diseases such as atherosclerosis and rheumatoid arthritis in which activated macrophages exert pathogenic effects.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; San Diego Vet Affairs Med Ctr, Div Cellular & Mol Med, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Endocrinol & Metab, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Cardiol, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Nephrol, La Jolla, CA 92161 USA	University of California System; University of California San Diego; GlaxoSmithKline	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021; feinstein, doug/M-9414-2019; Ricote, Mercedes/L-4615-2014	Glass, Christopher/0000-0003-4344-3592; Ricote, Mercedes/0000-0002-8090-8902				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Greene M. E., 1995, Gene Expression, V4, P281; Hawke RL, 1997, J LIPID RES, V38, P1189; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P8730; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SATO H, 1993, ONCOGENE, V8, P395; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; URADE Y, 1989, J IMMUNOL, V143, P2982; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zhu Y, 1996, MOL CELL BIOL, V16, P4808	27	3082	3243	5	173	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					79	82		10.1038/34178	http://dx.doi.org/10.1038/34178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422508				2022-12-28	WOS:000071326100052
J	Cameron, H; Robertson, A				Cameron, H; Robertson, A			The colon in medicine: nothing to do with the intestinal tract	BRITISH MEDICAL JOURNAL			English	Article									Zeneca Pharmaceut, Med Affairs Dept, Macclesfield SK10 4TG, Cheshire, England		Cameron, H (corresponding author), Zeneca Pharmaceut, Med Affairs Dept, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1657	1658		10.1136/bmj.315.7123.1657	http://dx.doi.org/10.1136/bmj.315.7123.1657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448532	Green Published			2022-12-28	WOS:000071149400015
J	Gjonca, A; Bobak, M				Gjonca, A; Bobak, M			Albanian paradox, another example of protective effect of Mediterranean lifestyle?	LANCET			English	Article							CORONARY HEART-DISEASE; FRENCH PARADOX; MORTALITY; ALCOHOL; DIET	Background Low mortality in Mediterranean populations has stimulated much interest, a possible explanation being diet. We have analysed data from Albania, the poorest country in Europe, to see if they corroborate findings from elsewhere in the region. Methods Data on mortality routinely collected in Albania, corrected for incompleteness, were analysed. Demographic and food consumption data from United Nations agency sources were used to identify potential explanations for the mortality pattern. Findings Consistent with its economic situation, Albania has one of the highest infant mortality rates in Europe (45.4 per 1000 live births for males and 38.0 for females in 1990). By contrast, adult mortality, including mortality from cardiovascular diseases, is similar to that in other Mediterranean countries, For example, age-standardised mortality for coronary heart disease in males aged 0-64 was 41 per 100 000 in Albania in 1990, less than half the rate in the UK but similar to that in Italy. Analysis of the geographical distribution of mortality within Albania (1978) showed that mortality was lowest in the southwest where most of the olive oil, fruits, and vegetables are produced and consumed. Interpretation This parardox of high adult life expectancy in very-low-income country can be most plausibly explained by diet-namely, low consumption of total energy, meat, and milk products but high consumption of fruit, vegetables, and carbohydrates. If this hypothesis is confirmed by future research, Albanian experience can contribute to formulation of preventive policy in high mortality countries.	Univ London London Sch Econ & Polit Sci, Dept Social Policy & Adm, London WC2A 2AE, England; UCL, Int Ctr Hlth & Soc, Dept Epidemiol & Publ Hlth, London, England	University of London; London School Economics & Political Science; University of London; University College London	Gjonca, A (corresponding author), Univ London London Sch Econ & Polit Sci, Dept Social Policy & Adm, Houghton St, London WC2A 2AE, England.	a.gjonca@lse.ac.uk		Bobak, Martin/0000-0002-2633-6851	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT NG, 1984, DEMOGRAPHY, V21, P217, DOI 10.2307/2061041; Bobak M, 1996, BRIT MED J, V312, P421; BOLLANO P, 1984, ALBANIAN LIFE, V21, P29; BRASS W, 1983, MANUAL 10 INDIRECT D; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *FAO, 1992, FOOD BAL SHEETS; Gjonca A, 1997, POPUL DEV REV, V23, P585, DOI 10.2307/2137576; HELSING E, 1995, AM J CLIN NUTR, V61, p1329S, DOI 10.1093/ajcn/61.6.1329S; *I STAT ALB, 1993, LIV STAND SURV; *I STAT ALB, 1991, STAT YB ALB; Keys A., 1980, 7 COUNTRIES STUDY MU; KUSHI LH, 1995, AM J CLIN NUTR, V61, p1416S, DOI 10.1093/ajcn/61.6.1407S; KUSHI LH, 1995, AM J CLIN NUTR, V61, p1407S, DOI 10.1093/ajcn/61.6.1407S; MEKSI E, 1994, POPULATION, V49, P607, DOI 10.2307/1533960; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; *SCI TECHN OPT ASS, 1994, NUTR EUR; *UN CHILDR FUND, 1997, 4 UNICEF; World Bank, 1996, WORLD DEV REP 1996 P	19	81	81	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	1997	350	9094					1815	1817		10.1016/S0140-6736(97)08347-5	http://dx.doi.org/10.1016/S0140-6736(97)08347-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YM803	9428253				2022-12-28	WOS:000071102500011
J	Hornblum, AM				Hornblum, AM			They were cheap and available: prisoners as research subjects in twentieth century America	BRITISH MEDICAL JOURNAL			English	Article									TEMPLE UNIV,DEPT URBAN STUDIES,PHILADELPHIA,PA 19122	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; Butterfield WJH, 1951, COMMUNICATION; CHERIN E, 1989, REV INFECT DIS, V111, P996; COHN V, 1975, WASHINGTON POST 0220; COPELAND RW, 1951, COMMUNICATION   1030; Etheridge Elizabeth W., 1972, BUTTERFLY CASTE, P7; George J., 1946, ATLANTIAN, V6, P14; HORNBLUM AM, IN PRESS ACRES SKIN; KAPLAN M, 1947, NY TIMES        1011; Laurence William L., 1945, NEW YORK TIMES 0926, P1; LEE G, 1994, WASHINGTON POST 1128, P33; LEPOLD N, 1958, LIFE PLUS 99 YEARS; LOGAN RR, 1935, STARRY CROSS, P19; *MED RES PRIS, 1975, CLEARINGHOUSE EN JUN, P2; MITFORD J, 1974, KIND VISUAL PUNISHME, P172; OHARA JL, 1948, READERS DIG, V52, P32; PAPPWORTH MH, 1967, HUMAN GUINEA PIGS, P61; ROTHMAN DJ, 1987, NEW ENGL J MED, V317, P1195, DOI 10.1056/NEJM198711053171906; ROTHMAN DJ, 1991, STRANGERS BEDSIDE, P53; Rugaber W., 1969, NY TIMES        0729, P20; SCHMECK HM, 1966, NY TIMES        0414, P72; SMYTH WF, 1951, COMMUNICATION   1030; Stanley LL, 1922, ENDOCRINOLOGY, V6, P787, DOI 10.1210/endo-6-6-787; STRONG RP, 1906, PHILIPP J SCI, V181, P186; SULLIVAN W, 1961, NY TIMES        0629; TABER S, 1907, J ZOOPHILY, V16, P94; TYLER HR, 1975, 3603 HR; *US DEP JUST, 1944, FED PRIS YEAR END RE, P22; *US DEP JUST, 1951, FED PRIS YEAR END RE, P28; WEIDMAN F, 1952, J INVEST DERMATOL, V18, P246; WHARTON D, 1954, AM MERCURY, V79, P53; 1956, NEWSWEEK        0604, P67; 1934, NY TIMES        1211; 1949, NY TIMES        1223, P1; 1934, NY TIMES        0326; 1953, NY TIMES        0720; 1946, JAMA-J AM MED ASSOC, V132, P714; 1961, NY TIMES        0505; 1954, NY TIMES        1209; 1976, NY TIMES        0302; 1949, ABRIDGED TRANSCRIPTS, V1, P27; 1966, NY TIMES        0316; 1934, NY TIMES        0416; 1934, NY TIMES        0320; 1949, NY TIMES        0604, P1; 1948, JAMA-J AM MED ASSOC, V136, P457; 1950, NY TIMES        0904	47	77	80	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1437	1441		10.1136/bmj.315.7120.1437	http://dx.doi.org/10.1136/bmj.315.7120.1437			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418095	Green Published			2022-12-28	WOS:A1997YJ67200031
J	Lambert, ML; Francois, I; Salort, C; Slypen, V; Bertrand, F; Tonglet, R				Lambert, ML; Francois, I; Salort, C; Slypen, V; Bertrand, F; Tonglet, R			Household survey of locomotor disability caused by poliomyelitis and landmines in Afghanistan	BRITISH MEDICAL JOURNAL			English	Article									HANDICAP INT BELGIUM,B-1040 BRUSSELS,BELGIUM; HANDICAP INT AFGHANISTAN,QUETTA,PAKISTAN		Lambert, ML (corresponding author), UNIV CATHOLIQUE LOUVAIN,SCH PUBL HLTH,EPIDEMIOL UNIT,CLOS CHAPELLE AUX CHAMPS 30,UCL 30-34,B-1200 BRUSSELS,BELGIUM.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; BERNIER R, 1984, EPIGEN843 WHO; KALSBEEK W, 1995, EPI INFO VERSON 6 WO; *MIN CLEAR PLANN A, 1993, REP NAT SURV MIN SIT; *WHO, 1992, EXP PROGR IMM EPI CO	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1424	1425		10.1136/bmj.315.7120.1424	http://dx.doi.org/10.1136/bmj.315.7120.1424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418091	Green Published			2022-12-28	WOS:A1997YJ67200027
J	Armstrong, E				Armstrong, E			Not all self help groups discourage sick doctors from being members	BRITISH MEDICAL JOURNAL			English	Letter																		ARMSTRONG E, 1997, BRIT MED J, V314, P2; Stafford NJ, 1997, BRIT MED J, V315, P191, DOI 10.1136/bmj.315.7101.191a	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1235	1235		10.1136/bmj.315.7117.1235	http://dx.doi.org/10.1136/bmj.315.7117.1235			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9417292	Green Published			2022-12-28	WOS:A1997YF25200047
J	Danielson, E; Devenney, M; Giaquinta, DM; Golden, JH; Haushalter, RC; McFarland, EW; Poojary, DM; Reaves, CM; Weinberg, WH; Wu, XD				Danielson, E; Devenney, M; Giaquinta, DM; Golden, JH; Haushalter, RC; McFarland, EW; Poojary, DM; Reaves, CM; Weinberg, WH; Wu, XD			A rare-earth phosphor containing one-dimensional chains identified through combinatorial methods	SCIENCE			English	Article								An unusual luminescent inorganic oxide, Sr,2CeO4,, was identified by parallel screening techniques from within a combinatorial library of more than 25,000 members prepared by automated thin-film synthesis. A bulk sample of single-phase Sr,2CeO4, was prepared, and its structure, determined from powder x-ray diffraction data, reveals one-dimensional chains of edge-sharing CeO6, octahedra, with two terminal oxygen atoms per cerium center, that are isolated from one another by Sr2+ cations. The emission maximum at 485 nanometers appears blue-white and has a quantum yield of 0.48 +/- 0.02. The excited-state lifetime, electron spin resonance, magnetic susceptibility, and structural data all suggest that luminescence originates from a ligand-to-metal Ce4+ charge transfer.	Symyx Technol, Santa Clara, CA 95051 USA		Weinberg, WH (corresponding author), Symyx Technol, 3100 Cent Expressway, Santa Clara, CA 95051 USA.	hweinberg@symyx.com	McFarland, Eric/G-1763-2014					Altomare A, 1995, J APPL CRYSTALLOGR, V28, P842, DOI 10.1107/S0021889895005619; ALTOMARE A, 1991, ACTA CRYSTALLOGR A, V47, P744, DOI 10.1107/S0108767391006566; Blasse G., 1994, LUMINESCENT MAT, DOI [DOI 10.1007/978-3-642-79017-1_1, 10.1007/978-3-642-79017-1_1]; BRICENO G, 1995, SCIENCE, V270, P273, DOI 10.1126/science.270.5234.273; Danielson E, 1997, NATURE, V389, P944, DOI 10.1038/40099; HOEFDRAAD HE, 1975, J INORG NUCL CHEM, V37, P1917, DOI 10.1016/0022-1902(75)80915-8; MASTROMONACO MD, 1969, ANN CHIM-ROME, V59, P465; OUWELTJES JL, 1965, MOD MATER, V5, P161; XIANG XD, 1995, SCIENCE, V268, P1738, DOI 10.1126/science.268.5218.1738	9	410	436	6	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					837	839		10.1126/science.279.5352.837	http://dx.doi.org/10.1126/science.279.5352.837			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452377				2022-12-28	WOS:000071923500035
J	Schlumberger, MJ				Schlumberger, MJ			Medical progress - Papillary and follicular thyroid carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOXORUBICIN PLUS CISPLATIN; PROGNOSTIC SCORING SYSTEM; FOLLOW-UP; SERUM THYROGLOBULIN; CANCER PATIENTS; DISTANT METASTASES; BONE METASTASES; TRIIODOTHYRONINE WITHDRAWAL; RETROSPECTIVE ANALYSIS; EXTERNAL RADIOTHERAPY		Univ Paris 11, Inst Gustave Roussy, F-94805 Villejuif, France	UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Schlumberger, MJ (corresponding author), Univ Paris 11, Inst Gustave Roussy, Rue Camille Desmoulins, F-94805 Villejuif, France.							American Association of Clinical Endocrinologists Clinical practice guidelines for the management of thyroid carcinoma, 1997, ENDOCR PRACT, V3, P60; ASHCRAFT MW, 1981, AM J MED, V71, P806, DOI 10.1016/0002-9343(81)90368-5; BARTALENA L, 1987, J CLIN ENDOCR METAB, V64, P849, DOI 10.1210/jcem-64-4-849; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Brierley JD, 1997, CANCER, V79, P2414; BYAR DP, 1979, EUR J CANCER, V15, P1033, DOI 10.1016/0014-2964(79)90291-3; CADY B, 1988, SURGERY, V104, P947; CASARA D, 1993, J NUCL MED, V34, P1626; CHALLETON C, 1995, ONCOGENE, V11, P601; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DEMEURE MJ, 1990, ENDOCRIN METAB CLIN, V19, P663, DOI 10.1016/S0889-8529(18)30316-5; deVathaire F, 1997, BRIT J CANCER, V75, P734, DOI 10.1038/bjc.1997.130; DINNEEN SF, 1995, J CLIN ENDOCR METAB, V80, P2041, DOI 10.1210/jc.80.7.2041; DOBYNS BM, 1992, WORLD J SURG, V16, P126, DOI 10.1007/BF02067128; DOTTORINI ME, 1995, J NUCL MED, V36, P21; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FAGIN JA, 1996, WERNER INGBARS THYRO, P909; Feine U, 1996, J NUCL MED, V37, P1468; FRANCESCHI S, 1993, CRIT REV ONCOGENESIS, V4, P25; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; GOLDMAN JM, 1980, J CLIN ENDOCR METAB, V50, P734, DOI 10.1210/jcem-50-4-734; Grebe S K, 1996, Surg Oncol Clin N Am, V5, P43; Guimaraes V, 1996, THYROID, V6, P69, DOI 10.1089/thy.1996.6.69; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HAY ID, 1993, SURGERY, V114, P1050; HAY ID, 1992, SURGERY, V112, P1139; HAY ID, 1987, SURGERY, V102, P1088; Hedinger CE., 1988, HISTOLOGICAL TYPING; Hermanek P., 1992, TNM CLASSIFICATION M, P35; HOEFNAGEL CA, 1986, J NUCL MED, V27, P1854; HOIE J, 1988, CANCER, V61, P1, DOI 10.1002/1097-0142(19880101)61:1<1::AID-CNCR2820610102>3.0.CO;2-R; ITO T, 1992, CANCER RES, V52, P1369; KATOH R, 1992, CANCER-AM CANCER SOC, V70, P1585, DOI 10.1002/1097-0142(19920915)70:6<1585::AID-CNCR2820700623>3.0.CO;2-Z; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; Ladenson PW, 1997, NEW ENGL J MED, V337, P888, DOI 10.1056/NEJM199709253371304; Lind P, 1997, J NUCL MED, V38, P348; MARCOCCI C, 1989, SURGERY, V106, P960; MARCOCCI C, 1994, J CLIN ENDOCR METAB, V78, P818, DOI 10.1210/jc.78.4.818; MARIOTTI S, 1995, J CLIN ENDOCR METAB, V80, P468, DOI 10.1210/jc.80.2.468; MAXON HR, 1992, J NUCL MED, V33, P1132; MAXON HR, 1983, NEW ENGL J MED, V309, P937, DOI 10.1056/NEJM198310203091601; MAXON HR, 1990, ENDOCRIN METAB CLIN, V19, P685, DOI 10.1016/S0889-8529(18)30317-7; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; MAZZAFERRI EL, 1995, J CLIN ENDOCR METAB, V80, P1485, DOI 10.1210/jc.80.5.1485; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MAZZAFERRI EL, 1995, AM J MED, V98, P215; NIEDERLE B, 1986, SURGERY, V100, P1088; Nikiforov YE, 1997, CANCER RES, V57, P1690; OZATA M, 1994, J CLIN ENDOCR METAB, V79, P98, DOI 10.1210/jc.79.1.98; PACINI F, 1992, J CLIN ENDOCR METAB, V74, P1401, DOI 10.1210/jc.74.6.1401; PACINI F, 1994, J NUCL MED, V35, P1418; PACINI F, 1985, CLIN ENDOCRINOL, V23, P405, DOI 10.1111/j.1365-2265.1985.tb01098.x; PACINI F, 1987, J NUCL MED, V28, P1888; PARK HM, 1994, THYROID, V4, P49, DOI 10.1089/thy.1994.4.49; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PINEDA JD, 1995, J CLIN ENDOCR METAB, V80, P1488, DOI 10.1210/jc.80.5.1488; RALL JE, 1957, J CLIN ENDOCR METAB, V17, P263; RAYMOND JP, 1989, J CLIN ENDOCR METAB, V69, P186, DOI 10.1210/jcem-69-1-186; REGALBUTO C, 1994, LANCET, V344, P1501, DOI 10.1016/S0140-6736(94)90316-6; RICARD M, 1993, EUR J NUCL MED, V20, P426; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Rosai J, 1992, ATLAS TUMOR PATHOL, P297; RUSSELL WO, 1963, CANCER, V16, P1425, DOI 10.1002/1097-0142(196311)16:11<1425::AID-CNCR2820161106>3.0.CO;2-E; RUSSO D, 1995, ONCOGENE, V11, P1907; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; SAMAAN NA, 1992, J CLIN ENDOCR METAB, V75, P714, DOI 10.1210/jc.75.3.714; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHLUMBERGER M, 1980, J CLIN ENDOCR METAB, V51, P513, DOI 10.1210/jcem-51-3-513; Schlumberger M, 1996, J NUCL MED, V37, P598; Schlumberger M, 1996, J NUCL MED, V37, P606; SCHLUMBERGER M, 1988, J NUCL MED, V29, P1790; SCHLUMBERGER M, 1987, J CLIN ENDOCR METAB, V65, P1088, DOI 10.1210/jcem-65-6-1088; SCHLUMBERGER M, 1981, ACTA ENDOCRINOL-COP, V98, P215, DOI 10.1530/acta.0.0980215; SCHLUMBERGER M, 1993, HEAD NECK CANC, V3, P903; SCHNEIDER AB, 1981, J CLIN ENDOCR METAB, V53, P1199, DOI 10.1210/jcem-53-6-1199; Schneider Arthur B., 1996, P902; SHERMAN SI, 1994, J CLIN ENDOCR METAB, V78, P629, DOI 10.1210/jc.78.3.629; SHIMAOKA K, 1985, CANCER, V56, P2155, DOI 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SIMPSON WJ, 1988, INT J RADIAT ONCOL, V14, P1063, DOI 10.1016/0360-3016(88)90381-1; Singer PA, 1996, ARCH INTERN MED, V156, P2165, DOI 10.1001/archinte.156.19.2165; Solomon BL, 1996, J CLIN ENDOCR METAB, V81, P333, DOI 10.1210/jc.81.1.333; Tenenbaum F, 1996, EUR J CANCER, V32A, P1262, DOI 10.1016/0959-8049(96)00020-2; TENENBAUM F, 1993, EUR J NUCL MED, V20, P1168; TUBIANA M, 1985, CANCER, V55, P2062, DOI 10.1002/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO;2-O; TUBIANA M, 1985, CANCER-AM CANCER SOC, V55, P794, DOI 10.1002/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z; VANHERLE AJ, 1973, J CLIN INVEST, V52, P1320, DOI 10.1172/JCI107303; VASSILOPOULOUSELLIN R, 1993, CANCER, V71, P1348, DOI 10.1002/1097-0142(19930215)71:4<1348::AID-CNCR2820710429>3.0.CO;2-3; WILLIAMS SD, 1986, CANCER TREAT REP, V70, P405; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	94	1202	1266	1	52	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					297	306		10.1056/NEJM199801293380506	http://dx.doi.org/10.1056/NEJM199801293380506			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445411				2022-12-28	WOS:000071665200006
J	Cho, YW; Terasaki, PI; Cecka, JM; Gjertson, DW				Cho, YW; Terasaki, PI; Cecka, JM; Gjertson, DW			Transplantation of kidneys from donors whose hearts have stopped beating	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CADAVER DONORS; PROCUREMENT; EXPERIENCE; ALLOGRAFTS	Background Attempts have recently been made to expand the number of cadaveric kidneys available for transplantation by using kidneys from donors without heartbeats in addition to those from brain-dead donors with beating hearts. We studied the efficacy of transplanting kidneys from donors without heartbeats on the basis of aggregate results from the Kidney Transplant Registry of the United Network for Organ Sharing. Methods We compared the early function and survival rates of 229 kidney grafts from donors without heartbeats with those of 8718 grafts from cadaveric donors with heartbeats. All transplantations were performed at 64 U.S. transplantation centers. Cox proportional-hazards analysis was used to evaluate 10 major risk factors for graft failure. Results The survival rate at one year was 83 percent for kidney grafts from donors without heartbeats, as compared with 86 percent for grafts from donors with heartbeats (P=0.26). Among the kidneys from donors without heartbeats, the survival rate at one year was 89 percent for grafts from donors who had died of trauma, as compared with 78 percent for grafts from donors who had died of other causes (P=0.04). The survival rates were high for grafts from donors without heartbeats despite the poorer early function of these grafts; 48 percent of the recipients required dialysis within the first week after transplantation, as compared with 22 percent of the recipients of grafts from donors with heartbeats. The primary-failure rate for kidneys from donors without heartbeats was 4 percent, as compared with 1 percent for kidneys from donors with heartbeats. Conclusions Transplantation of kidneys from donors whose hearts have stopped beating, especially those who have died of trauma, is often successful, and the use of kidneys from such donors could increase the overall supply of cadaveric kidney transplants. (C) 1998, Massachusetts Medical Society.	Univ Calif Los Angeles, Sch Med, Dept Surg, Tissue Typing Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cho, YW (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Surg, Tissue Typing Lab, 950 Vet Ave, Los Angeles, CA 90095 USA.							Alonso A, 1997, TRANSPL P, V29, P1378, DOI 10.1016/S0041-1345(96)00714-2; ANAISE D, 1990, TRANSPLANTATION, V49, P290, DOI 10.1097/00007890-199002000-00013; CASAVILLA A, 1995, TRANSPLANTATION, V59, P197, DOI 10.1097/00007890-199501270-00008; CASTELAO AM, 1993, TRANSPLANT P, V25, P1513; DALESSANDRO AM, 1995, TRANSPLANT P, V27, P707; DALESSANDRO AM, 1995, TRANSPLANT REV, V9, P168; GUILLARD G, 1993, TRANSPLANT P, V25, P1505; Hauet T, 1996, TRANSPLANT P, V28, P2896; HOSHINAGA K, 1995, TRANSPLANT P, V27, P703; HUME DM, 1963, ANN SURG, V158, P608, DOI 10.1097/00000658-196310000-00010; Kievit JK, 1997, TRANSPL P, V29, P1381, DOI 10.1016/S0041-1345(96)00603-3; Kootstra G, 1997, TRANSPLANTATION, V63, P917, DOI 10.1097/00007890-199704150-00001; KOOTSTRA G, 1991, TRANSPLANT P, V23, P910; KOZAKI M, 1991, TRANSPLANT P, V23, P2575; MATSUNO N, 1993, TRANSPLANT P, V25, P1516; Nicholson ML, 1997, TRANSPL P, V29, P1386, DOI 10.1016/S0041-1345(96)00605-7; ORLOFF MS, 1994, ANN SURG, V220, P578; RIGOTTI P, 1991, TRANSPLANT P, V23, P2579; Schlumpf R, 1996, TRANSPLANT P, V28, P107; Shiroki R, 1997, TRANSPL P, V29, P1388, DOI 10.1016/S0041-1345(96)00606-9; STARZL TE, 1964, JAMA-J AM MED ASSOC, V187, P734; TERASAKL PAUL I., 1967, TRANSPLANTATION, V5, P76, DOI 10.1097/00007890-196701000-00009; *UN NETW ORG SHAR, 1997, 1997 ANN REP US SCI; WIJNEN RMH, 1995, LANCET, V345, P1067, DOI 10.1016/S0140-6736(95)90815-3; WYNEN RMH, 1993, TRANSPLANT P, V25, P1522; YIN L, 1988, CLIN TRANSPLANT, V2, P295	26	217	221	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					221	225		10.1056/NEJM199801223380403	http://dx.doi.org/10.1056/NEJM199801223380403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT358	9435327				2022-12-28	WOS:000071594100003
J	Rao, PM; Rhea, JT; Novelline, RA; Mostafavi, AA; McCabe, CJ				Rao, PM; Rhea, JT; Novelline, RA; Mostafavi, AA; McCabe, CJ			Effect of computed tomography of the appendix on treatment of patients and use of hospital resources	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAGNOSIS; EMERGENCY; CT; APPENDECTOMY; ACCURACY	Background In patients with clinically suspected appendicitis, computed tomography (CT) is diagnostically accurate. However, the effect of routine CT of the appendix on the treatment of such patients and the use of hospital resources is unknown. Method's We performed appendiceal CT on 100 consecutive patients in the emergency department who, on the basis of history, physical examination, and laboratory results, were to be hospitalized for observation for suspected appendicitis or for urgent appendectomy. Outcomes were determined at surgery and by pathological examination in 59 patients, and by clinical follow-up two months later in 41 patients. Treatment plans made before CT were compared with the patients' actual treatment, We also determined the costs of surgery that revealed no appendicitis (from data on 61 patients), one day of observation in the hospital (from data on 350 patient-days in patients with suspected appendicitis), and appendiceal CT (from data on all pelvic CT examinations in 1996). Results Fifty-three patients had appendicitis, and 47 did not. The interpretations of the appendiceal CT scans were 98 percent accurate. The results of CT led to changes in the treatment of 59 patients. These changes resulted in the prevention of unnecessary appendectomy in 13 patients, admission to the hospital for observation in 18 patients, admission to the hospital for observation before necessary appendectomy in 21 patients, and admission to the hospital for observation before the diagnosis of other conditions by CT in 11 patients. The effects of performing appendiceal CT on the use of hospital resources included the prevention of unnecessary appendectomy in 13 patients (for a savings of $47,281) and the prevention of unnecessary hospital admission for 50 patient-days (for a savings of $20,250). After the cost of 100 appendiceal CT studies ($22,800) was subtracted, the overall savings was $447 per patient. Conclusions Routine appendiceal CT performed in patients who present with suspected appendicitis improves patient care and reduces the use of hospital resources. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Rao, PM (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.							ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; BALTHAZAR EJ, 1994, RADIOLOGY, V190, P31, DOI 10.1148/radiology.190.1.8259423; BALTHAZAR EJ, 1991, RADIOLOGY, V180, P21, DOI 10.1148/radiology.180.1.2052696; CALDER JDF, 1995, BRIT J HOSP MED, V54, P129; Cohen M M, 1993, J Laparoendosc Surg, V3, P93, DOI 10.1089/lps.1993.3.93; IZBICKI JR, 1992, EUR J SURG, V158, P227; JESS P, 1981, AM J SURG, V141, P232, DOI 10.1016/0002-9610(81)90164-1; Lane MJ, 1997, AM J ROENTGENOL, V168, P405, DOI 10.2214/ajr.168.2.9016216; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; MALONE AJ, 1993, AM J ROENTGENOL, V160, P763, DOI 10.2214/ajr.160.4.8456661; MCCALLION J, 1987, AGE AGEING, V16, P256, DOI 10.1093/ageing/16.4.256; OHMANN C, 1995, EUR J SURG, V161, P273; Rao PM, 1997, RADIOLOGY, V202, P139, DOI 10.1148/radiology.202.1.8988203; Rao PM, 1997, AM J ROENTGENOL, V169, P1275, DOI 10.2214/ajr.169.5.9353441; Rao PM, 1997, J COMPUT ASSIST TOMO, V21, P686, DOI 10.1097/00004728-199709000-00002; REYNOLDS SL, 1993, PEDIATR EMERG CARE, V9, P1, DOI 10.1097/00006565-199302000-00002; Rhea JT, 1997, AM J ROENTGENOL, V169, P113, DOI 10.2214/ajr.169.1.9207509; ROTHROCK SG, 1991, ANN EMERG MED, V20, P45, DOI 10.1016/S0196-0644(05)81117-5; Rothrock Steven G., 1995, Journal of Emergency Medicine, V13, P1, DOI 10.1016/0736-4679(94)00104-9; SHUST N, 1993, PEDIATR RADIOL, V23, P289, DOI 10.1007/BF02010917; SIMMEN HP, 1991, HEPATO-GASTROENTEROL, V38, P279; TRAUTLEIN JJ, 1984, ANN EMERG MED, V13, P709, DOI 10.1016/S0196-0644(84)80733-7; VELANOVICH V, 1992, AM SURGEON, V58, P264; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039	24	498	511	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					141	146		10.1056/NEJM199801153380301	http://dx.doi.org/10.1056/NEJM199801153380301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428814				2022-12-28	WOS:000071384500001
J	Lebwohl, M; Tan, MH				Lebwohl, M; Tan, MH			Psoriasis and stress	LANCET			English	Editorial Material									Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Lebwohl, M (corresponding author), Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA.							FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; Fortune DG, 1997, BRIT J DERMATOL, V137, P755; Fortune DG, 1997, J PSYCHOSOM RES, V42, P467, DOI 10.1016/S0022-3999(97)00036-6; GINSBURG IH, 1993, INT J DERMATOL, V32, P587, DOI 10.1111/j.1365-4362.1993.tb05031.x; Savin J A, 1970, Trans St Johns Hosp Dermatol Soc, V56, P139; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	6	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					82	82		10.1016/S0140-6736(05)78153-8	http://dx.doi.org/10.1016/S0140-6736(05)78153-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT341	9439490				2022-12-28	WOS:000071591900007
J	Zipf, EC; Prasad, SS				Zipf, EC; Prasad, SS			Evidence for new sources of NOx in the lower atmosphere	SCIENCE			English	Article							SCHUMANN-RUNGE BANDS; OSCILLATOR-STRENGTHS; ABSORPTION; OXYGEN; PHOTODISSOCIATION; IONIZATION; O-16(2)	Laboratory studies show that the reaction of short-lived O-2(B-3 Sigma(u)) molecules (lifetime similar to 10 picoseconds) with N-2 and the photodissociation of the N-2:O-2 dimer produce NOx in the stratosphere at a rate comparable to the oxidation of N2O by O(D-1). this finding implies the existence of unidentified NOX sinks in the stratosphere. The NO2 observed in this experiment is isotopically heavy with a large N-15/N-14 enhancement. However; photodissociation of this NO2 unexpectedly produced NO molecules with a low N-15/N-14 ratio. The diurnal odd-nitrogen cycle in the stratosphere will be marked by a complex isotope signature that will be imprinted on the halogen and HOX catalytic cycles.	Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA; Creat Res Enterprises, Pleasanton, CA 94566 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zipf, EC (corresponding author), Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA.							ANDERSON JA, 1997, RES SUMMARIES 1994 1, P100; BATES DR, 1989, PLANET SPACE SCI, V37, P881, DOI 10.1016/0032-0633(89)90139-6; HUESTIS DL, 1994, CAN J PHYS, V72, P1109, DOI 10.1139/p94-145; LEWIS BR, 1986, J QUANT SPECTROSC RA, V36, P209, DOI 10.1016/0022-4073(86)90069-5; LEWIS BR, 1986, J QUANT SPECTROSC RA, V36, P187, DOI 10.1016/0022-4073(86)90068-3; Mallard W., 1994, NIST CHEM KINETICS D; MARIC D, 1992, J PHOTOCH PHOTOBIO A, V66, P291, DOI 10.1016/1010-6030(92)80002-D; Nevison CD, 1997, GEOPHYS RES LETT, V24, P803, DOI 10.1029/97GL00549; NICOLET M, 1980, PLANET SPACE SCI, V28, P85, DOI 10.1016/0032-0633(80)90106-3; PRINSLOW DA, 1989, J PHYS CHEM-US, V93, P1836, DOI 10.1021/j100342a029; RUDICH Y, 1993, J CHEM PHYS, V99, P4500, DOI 10.1063/1.466049; SAPERS SP, 1988, J CHEM PHYS, V88, P3638, DOI 10.1063/1.453863; SHARDANAND, 1977, J QUANT SPECTROSC RA, V18, P525, DOI 10.1016/0022-4073(77)90051-6; UHLIK F, 1993, THERMOCHIM ACTA, V225, P1, DOI 10.1016/0040-6031(93)85076-L; YOSHINO K, 1983, PLANET SPACE SCI, V31, P339, DOI 10.1016/0032-0633(83)90085-5; ZIPF EC, 1985, PLANET SPACE SCI, V33, P1303, DOI 10.1016/0032-0633(85)90008-X	16	27	28	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					211	213		10.1126/science.279.5348.211	http://dx.doi.org/10.1126/science.279.5348.211			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422690				2022-12-28	WOS:000071408100037
J	Youngner, JS				Youngner, JS			The scientific misconduct process - A scientist's view from the inside	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Youngner, JS (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.							Parrish DM, 1997, JAMA-J AM MED ASSOC, V277, P1315; FED REG, V59, P29809	2	3	3	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					62	64		10.1001/jama.279.1.62	http://dx.doi.org/10.1001/jama.279.1.62			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424047				2022-12-28	WOS:000071295100038
J	Kisker, C; Schindelin, H; Pacheco, A; Wehbi, WA; Garrett, RM; Rajagopalan, KV; Enemark, JH; Rees, DC				Kisker, C; Schindelin, H; Pacheco, A; Wehbi, WA; Garrett, RM; Rajagopalan, KV; Enemark, JH; Rees, DC			Molecular basis of sulfite oxidase deficiency from the structure of sulfite oxidase	CELL			English	Article							CRYSTAL-STRUCTURE; PROTEIN CRYSTALLOGRAPHY; NITRATE REDUCTASE; CHICKEN LIVER; MOLYBDENUM; DOMAINS; OXIDOREDUCTASE; CYSTEINE-207; PURIFICATION; RESOLUTION	The molybdenum-containing enzyme sulfite oxidase catalyzes the conversion of sulfite to sulfate, the terminal step in the oxidative degradation of cysteine and methionine. Deficiency of this enzyme in humans usually leads to major neurological abnormalities and early death. The crystal structure of chicken liver sulfite oxidase at 1.9 Angstrom resolution reveals that each monomer of the dimeric enzyme consists of three domains. At the active site, the Mo is penta-coordinated by three sulfur ligands, one oxo group, and one water/hydroxo. A sulfate molecule adjacent to the Mo identifies the substrate binding pocket. Four variants associated with sulfite oxidase deficiency have been identified: two mutations are near the sulfate binding site, while the other mutations occur within the domain mediating dimerization.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of Arizona; Duke University	Kisker, C (corresponding author), CALTECH, Howard Hughes Med Inst, 147-75CH, Pasadena, CA 91125 USA.		Enemark, John/AAQ-4395-2020; Schindelin, Hermann/Q-2697-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037773, R01GM050775] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37773, GM50775, GM00091] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1909, BIOCHEMISTRY-US, V28, P5075; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; Johnson JL, 1989, METABOLIC BASIS INHE, P1463; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KESSLER DL, 1972, J BIOL CHEM, V247, P6566; KIPKE CA, 1989, ARCH BIOCHEM BIOPHYS, V270, P383, DOI 10.1016/0003-9861(89)90041-6; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KLEYWEGT GJ, 1994, CCP4 P, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVE C, 1995, RADIAT PHYS CHEM, V45, P483, DOI 10.1016/0969-806X(95)92800-E; Naylor CE, 1996, BLOOD, V87, P2974, DOI 10.1182/blood.V87.7.2974.bloodjournal8772974; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1996, METHOD ENZYMOL, P307; RAPPE AK, 1982, J AM CHEM SOC, V104, P448, DOI 10.1021/ja00366a013; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SOUTHERLAND WM, 1978, J BIOL CHEM, V253, P8747; SULLIVAN EP, 1993, BIOCHEMISTRY-US, V32, P12465, DOI 10.1021/bi00097a026; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	50	440	445	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					973	983		10.1016/S0092-8674(00)80488-2	http://dx.doi.org/10.1016/S0092-8674(00)80488-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428520	Bronze			2022-12-28	WOS:000071281400014
J	Kozielski, F; Sack, S; Marx, A; Thormahlen, M; Schonbrunn, E; Biou, V; Thompson, A; Mandelkow, EM; Mandelkow, E				Kozielski, F; Sack, S; Marx, A; Thormahlen, M; Schonbrunn, E; Biou, V; Thompson, A; Mandelkow, EM; Mandelkow, E			Phe crystal structure of dimeric kinesin and implications for microtubule-dependent motility	CELL			English	Article							3-DIMENSIONAL STRUCTURE; MOTOR DOMAIN; BETA-TUBULIN; PROTEIN; COMPLEX; ACTIN; MYOSIN; HEAD; NCD; IDENTIFICATION	The dimeric form of the kinesin motor and neck domain from rat brain with bound ADP has been solved by X-ray crystallography. The two heads of the dimer are connected via a coiled-coil alpha-helical interaction of their necks. They are broadly similar to one another; differences are most apparent in the head-neck junction and in a moderate reorientation of the neck helices in order to adopt to the coiled-coil conformation. The heads show a rotational symmetry (similar to 120 degrees) about an axis close to that of the coiled-coil. This arrangement is unexpected since it is not compatible with the microtubule lattice. In this arrangement, the two heads of a kinesin dimer could not have equivalent interactions with microtubules.	DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; European Synchrotron Radiat Facil, F-38042 Grenoble, France	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; European Synchrotron Radiation Facility (ESRF)	Kozielski, F (corresponding author), Inst Biol Struct, 41 Av Martyrs, F-38027 Grenoble, France.			Schonbrunn, Ernst/0000-0002-3589-3510				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; CROSS RA, 1995, J MUSCLE RES CELL M, V16, P91, DOI 10.1007/BF00122526; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; Hilgenfeld R, 1995, CURR OPIN STRUC BIOL, V5, P810, DOI 10.1016/0959-440X(95)80015-8; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kozielski F, 1997, J STRUCT BIOL, V119, P28, DOI 10.1006/jsbi.1997.3872; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RAMENT I, 1996, STRUCTURE, V4, P501; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; Tripet B, 1997, J BIOL CHEM, V272, P8946; TTHORMAHLEN M, 1998, IN PRESS J MOL BIOL; TTUCKER C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	48	341	350	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					985	994		10.1016/S0092-8674(00)80489-4	http://dx.doi.org/10.1016/S0092-8674(00)80489-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428521	Bronze			2022-12-28	WOS:000071281400015
J	Sun, XP; Wahlstrom, J; Karpen, G				Sun, XP; Wahlstrom, J; Karpen, G			Molecular structure of a functional Drosophila centromere	CELL			English	Article							HUMAN Y-CHROMOSOME; ALPHA-SATELLITE DNA; TRANSPOSABLE ELEMENTS; MELANOGASTER HETEROCHROMATIN; SCHIZOSACCHAROMYCES-POMBE; INSITU HYBRIDIZATION; MARKER CHROMOSOME; FISSION YEAST; CENP-C; SEQUENCES	Centromeres play a critical role in chromosome inheritance but are among the most difficult genomic components to analyze in multicellular eukaryotes. Here, we present a highly detailed molecular structure of a functional centromere in a multicellular organism. The centromere of the Drosophila minichromosome Dp1187 is contained within a 420 kb region of centric heterochromatin. We have used a new approach to characterize the detailed structure of this centromere and found that it is primarily composed of satellites and single, complete transposable elements. In the rest of the Drosophila genome, these satellites and transposable elements are neither unique to the centromeres nor present at all centromeres. We discuss the impact of these results on our understanding of heterochromatin structure and on the determinants of centromere identity and function.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Karpen, G (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054549] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ALFENITO MR, 1993, GENETICS, V135, P589; AULT JG, 1988, CHROMOSOMA, V97, P71, DOI 10.1007/BF00331796; BONACCORSI S, 1990, CHROMOSOMA, V99, P260, DOI 10.1007/BF01731701; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; CARMENA M, 1995, CHROMOSOMA, V103, P676; CHARLESWORTH B, 1994, GENET RES, V64, P183, DOI 10.1017/S0016672300032845; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHOO KH, 1991, NUCLEIC ACIDS RES, V19, P1179, DOI 10.1093/nar/19.6.1179; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.ge.19.120185.000333; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Cook KR, 1997, GENETICS, V145, P737; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; Davis PS, 1995, DROSOPH INF SERV, V76, P134; Dernburg AF, 1996, GENETICS, V143, P1629; DEVLIN RH, 1990, GENETICS, V125, P129; DINOCERA PP, 1988, NUCLEIC ACIDS RES, V16, P4041; DINOCERA PP, 1983, J MOL BIOL, V168, P715; DINOCERA PP, 1987, P NATL ACAD SCI USA, V84, P5843; DUSART D, 1997, DNA CELL BIOL, V16, P144; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FINNEGAN DJ, 1985, INT REV CYTOL, V93, P281, DOI 10.1016/S0074-7696(08)61376-5; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GATTI M, 1994, METHOD CELL BIOL, V44, P371, DOI 10.1016/S0091-679X(08)60924-3; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; HOCHSTENBACH R, 1993, CHROMOSOMA, V102, P526, DOI 10.1007/BF00368346; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1990, CELL, V63, P97; Kurek R, 1996, CHROMOSOME RES, V4, P87, DOI 10.1007/BF02259701; KURENOVA EV, 1990, GENETIKA+, V26, P1701; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; LE MH, 1995, GENETICS, V141, P283; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; LOHE AR, 1993, GENETICS, V134, P1149; MITCHELL AR, 1985, CHROMOSOMA, V92, P369, DOI 10.1007/BF00327469; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; OHASHI H, 1994, AM J HUM GENET, V55, P1202; PAGE SL, 1995, HUM MOL GENET, V4, P289, DOI 10.1093/hmg/4.2.289; PARDUE ML, 1986, IN SITU HYBRIDIZATIO; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RATTNER JB, 1991, BIOESSAYS, V13, P51, DOI 10.1002/bies.950130202; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RUSSO VEA, 1996, COLD SPRING HARBOR M, V32; Sacchi N, 1996, CYTOGENET CELL GENET, V73, P123, DOI 10.1159/000134322; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHULMAN I, 1991, ANNU REV CELL BIOL, V7, P311, DOI 10.1146/annurev.cellbio.7.1.311; SHEVELYOV YY, 1993, MOL GEN GENET, V239, P205, DOI 10.1007/BF00281619; SNYDER MP, 1982, P NATL ACAD SCI-BIOL, V79, P7430, DOI 10.1073/pnas.79.23.7430; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SUNKEL CE, 1995, CURR OPIN GENET DEV, V5, P756, DOI 10.1016/0959-437X(95)80008-S; TOWER J, 1993, GENETICS, V133, P347; TTALOR SS, 1996, CHROMOSOMA, V105, P70; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; VIG BK, 1994, MUTAT RES-FUND MOL M, V309, P1, DOI 10.1016/0027-5107(94)90036-1; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; WILLIAMS B, 1998, IN PRESS NAT GENET; YUKI S, 1986, EUR J BIOCHEM, V158, P403, DOI 10.1111/j.1432-1033.1986.tb09767.x; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	75	209	223	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1007	1019		10.1016/S0092-8674(00)80491-2	http://dx.doi.org/10.1016/S0092-8674(00)80491-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428523	Bronze, Green Accepted			2022-12-28	WOS:000071281400017
J	Walkinshaw, SA				Walkinshaw, SA			Pelvimetry and breech delivery at term	LANCET			English	Editorial Material									Liverpool Womens Hosp, Fetal Ctr, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Walkinshaw, SA (corresponding author), Liverpool Womens Hosp, Fetal Ctr, Liverpool L8 7SS, Merseyside, England.							CHENG M, 1993, OBSTET GYNECOL, V82, P605; Danielian PJ, 1996, BRIT MED J, V312, P1451, DOI 10.1136/bmj.312.7044.1451; GIFFORD DS, 1995, OBSTET GYNECOL, V85, P1047, DOI 10.1016/0029-7844(95)00053-T; KREBS L, 1995, ACTA OBSTET GYN SCAN, V74, P702, DOI 10.3109/00016349509021178; Lindqvist A, 1997, BRIT J OBSTET GYNAEC, V104, P1288, DOI 10.1111/j.1471-0528.1997.tb10976.x; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P18, DOI 10.1016/S0002-9378(96)70244-2; THORPEBEESTON JG, 1992, BRIT MED J, V305, P746, DOI 10.1136/bmj.305.6856.746	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1791	1792		10.1016/S0140-6736(05)63631-8	http://dx.doi.org/10.1016/S0140-6736(05)63631-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428246				2022-12-28	WOS:000071102500003
J	Lidor, C; Goichman, E				Lidor, C; Goichman, E			Postinfectious brachial neuritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Kupat Holim Meuchedet, IL-46782 Herzeliya, Israel		Lidor, C (corresponding author), Kupat Holim Meuchedet, IL-46782 Herzeliya, Israel.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					296	296		10.1056/NEJM199801293380505	http://dx.doi.org/10.1056/NEJM199801293380505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9446027				2022-12-28	WOS:000071665200005
J	Schmidt, PJ; Nieman, LK; Danaceau, MA; Adams, LF; Rubinow, DR				Schmidt, PJ; Nieman, LK; Danaceau, MA; Adams, LF; Rubinow, DR			Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TENSION SYNDROME; DIAGNOSTIC-CRITERIA; DEPOT LEUPROLIDE; HORMONE AGONIST; PROGESTERONE; MANAGEMENT; BUSERELIN; SYMPTOMS; ESTROGEN; SCALES	Background The symptoms of women with premenstrual syndrome improve in response to suppression of ovarian function, although these women have no evidence of ovarian dysfunction. We undertook a study to determine the role of estrogen and progesterone in this syndrome. Methods We first studied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasing hormone, or placebo on symptoms in 20 women with premenstrual syndrome. Ten women whose symptoms improved during leuprolide treatment were given estradiol and progesterone in a double-blind, crossover design, each for four weeks, during continued leuprolide administration. Women without premenstrual syndrome (normal women) participated in a similar protocol. Outcomes were assessed on the basis of daily self-reports by the patients and biweekly rater-administered symptom-rating scales. Results The 10 women with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as compared with base-line values and with values for the 10 women who were given placebo. The 10 women with premenstrual syndrome who were given leuprolide plus estradiol or progesterone had a significant recurrence of symptoms, but no changes in mood occurred in 15 normal women who received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone during continued leuprolide administration. Conclusions In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes. (C) 1998, Massachusetts Medical Society.	NIMH, Behav Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIH, Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Schmidt, PJ (corresponding author), NIMH, Behav Endocrinol Branch, NIH, Bldg 10,Rm 3N238,10 Ctr Dr,MSC 1276, Bethesda, MD 20892 USA.							ABRAHAM GE, 1971, J CLIN ENDOCR METAB, V32, P619, DOI 10.1210/jcem-32-5-619; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BANCROFT J, 1987, CLIN ENDOCRINOL, V27, P171, DOI 10.1111/j.1365-2265.1987.tb01142.x; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BROWN CS, 1994, OBSTET GYNECOL, V84, P779; CASPER RF, 1986, AM J OBSTET GYNECOL, V155, P862, DOI 10.1016/S0002-9378(86)80040-0; Endicott J, 1982, PSYCHOPHARMACOL BULL, V18, P109; FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; HALBREICH U, 1985, CAN J PSYCHIAT, V30, P489, DOI 10.1177/070674378503000706; HALBREICH U, 1986, ACTA PSYCHIAT SCAND, V74, P576, DOI 10.1111/j.1600-0447.1986.tb06287.x; HAMMARBACK S, 1988, ACTA OBSTET GYN SCAN, V67, P159, DOI 10.3109/00016348809004191; HASKETT RF, 1983, PSYCHIAT RES, V9, P125, DOI 10.1016/0165-1781(83)90034-3; HURT SW, 1992, AM J PSYCHIAT, V149, P525; HUSSAIN SY, 1992, GYNECOL ENDOCRINOL, V6, P57, DOI 10.3109/09513599209081007; JIANG NS, 1969, MAYO CLIN PROC, V44, P461; MEZROW G, 1994, FERTIL STERIL, V62, P932; MORTOLA JF, 1991, J CLIN ENDOCR METAB, V72, pA252; MUSE KN, 1984, NEW ENGL J MED, V311, P1345, DOI 10.1056/NEJM198411223112104; REDEI E, 1995, PSYCHONEUROENDOCRINO, V20, P259, DOI 10.1016/0306-4530(94)00057-H; RUBINOW DR, 1984, AM J PSYCHIAT, V141, P684; SARNO AP, 1987, OBSTET GYNECOL, V70, P33; SCHMIDT PJ, 1991, NEW ENGL J MED, V324, P1174, DOI 10.1056/NEJM199104253241705; SCHNURR PP, 1988, AM J PSYCHIAT, V145, P491; Schnurr PP, 1989, PSYCHOL ASSESSMENT, V1, P277; Spielberger C. D., 1983, MIND GARDEN; Spitzer RL, 1990, STRUCTURED CLIN INTE; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; Wang MD, 1996, J CLIN ENDOCR METAB, V81, P1076, DOI 10.1210/jc.81.3.1076; WEST CP, 1994, HUM REPROD, V9, P1058, DOI 10.1093/oxfordjournals.humrep.a138633	29	483	496	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 22	1998	338	4					209	216		10.1056/NEJM199801223380401	http://dx.doi.org/10.1056/NEJM199801223380401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT358	9435325				2022-12-28	WOS:000071594100001
J	Boyers, SP; Gilbert, WM				Boyers, SP; Gilbert, WM			Elective repeat caesarean section versus trial of labour: the neonatologist's view	LANCET			English	Editorial Material							VAGINAL BIRTH		Univ Calif Davis, Sch Med, Dept Obstet & Gynecol, Sacramento, CA 95816 USA	University of California System; University of California Davis	Boyers, SP (corresponding author), Univ Calif Davis, Sch Med, Dept Obstet & Gynecol, Sacramento, CA 95816 USA.							American College of Obstetricians and Gynecologists Committee on Ethics, 1991, ACOG COMM OP; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P285; *DEP HLTH HUM SERV, 1991, USDHHS PUBL, P378; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; Hook B, 1997, PEDIATRICS, V100, P348, DOI 10.1542/peds.100.3.348; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; ROSEN MG, 1991, OBSTET GYNECOL, V77, P465; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					155	155		10.1016/S0140-6736(05)78217-9	http://dx.doi.org/10.1016/S0140-6736(05)78217-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449865				2022-12-28	WOS:000071616300004
J	Ilver, D; Arnqvist, A; Ogren, J; Frick, IM; Kersulyte, D; Incecik, ET; Berg, DE; Covacci, A; Engstrand, L; Boren, T				Ilver, D; Arnqvist, A; Ogren, J; Frick, IM; Kersulyte, D; Incecik, ET; Berg, DE; Covacci, A; Engstrand, L; Boren, T			Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging	SCIENCE			English	Article							HUMAN GASTRIC EPITHELIUM; NEISSERIA-GONORRHOEAE; VIRULENCE FACTORS; HUMAN STOMACH; EXPRESSION; INFECTION; CYTOTOXIN; DISEASE; STRAINS; CLONING	The bacterium Helicobacter pylori is the causative agent for peptic ulcer disease. Bacterial adherence to the human gastric epithelial lining is mediated by the fucosylated Lewis b (Le(b)) histo-blood group antigen. The Le(b)-binding adhesin, BabA, was purified by receptor activity-directed affinity tagging. The bacterial Le(b)-binding phenotype was associated with the presence of the cag pathogenicity island among clinical isolates of H. pylori. A vaccine strategy based on the BabA adhesin might serve as a means to target the virulent type I strains of H. pylori.	Umea Univ, Dept Oral Biol, SE-90187 Umea, Sweden; Umea Univ, Dept Microbiol, SE-90187 Umea, Sweden; Univ Lund, Dept Cell & Mol Biol, SE-22100 Lund, Sweden; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Immunobiol Res Inst Siena, I-53100 Siena, Italy; Univ Hosp, Dept Clin Microbiol & Canc Epidemiol, SE-75185 Uppsala, Sweden	Umea University; Umea University; Lund University; Washington University (WUSTL); Uppsala University; Uppsala University Hospital	Boren, T (corresponding author), Umea Univ, Dept Oral Biol, SE-90187 Umea, Sweden.	thomas.boren@micro.umu.se		Ilver, Dag/0000-0002-3618-9496				Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; Blaser MJ, 1997, LANCET, V349, P1020, DOI 10.1016/S0140-6736(96)09133-7; BLASER MJ, 1996, SCI AM, V274, P92; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BOREN T, UNPUB; BOREN T, 1994, SCI MED, V1, P28; Brunner J, 1996, TRENDS CELL BIOL, V6, P154, DOI 10.1016/0962-8924(96)40001-0; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; DUBOIS A, 1995, EMERG INFECT DIS, V1, P79, DOI 10.3201/eid0103.950302; FALK P, 1994, METHOD ENZYMOL, V236, P353; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALK P, 1994, METHOD CELL BIOL, V45, P161; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; KIRSCHNER DE, 1995, J THEOR BIOL, V176, P281, DOI 10.1006/jtbi.1995.0198; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL B, 1983, LANCET, V1, P1273; Mol O, 1996, FEMS MICROBIOL REV, V19, P25, DOI 10.1016/0168-6445(96)00022-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; WANG Y, 1990, GENE, V94, P23, DOI 10.1016/0378-1119(90)90463-2; WARREN JR, 1983, LANCET, V1, P1273; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	32	907	963	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					373	377		10.1126/science.279.5349.373	http://dx.doi.org/10.1126/science.279.5349.373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430586				2022-12-28	WOS:000071570800044
J	Garkavtsev, I; Grigorian, IA; Ossovskaya, VS; Chernov, MV; Chumakov, PM; Gudkov, AV				Garkavtsev, I; Grigorian, IA; Ossovskaya, VS; Chernov, MV; Chumakov, PM; Gudkov, AV			The candidate tumour suppressor p33(ING1) cooperates with p53 in cell growth control	NATURE			English	Article							FIBROBLASTS	The candidate tumour-suppressor gene ING1 has been identified by using the genetic suppressor element (GSE) methodology(1). ING1 encodes a nuclear protein, p33(ING1), overexpression of which inhibits growth of different cell lines. The properties of p33(ING1) suggest its involvement in the negative regulation of cell proliferation and in the control of cellular ageing, anchorage dependence and apoptosis(1-3). These cellular functions depend largely on the activity of p53, a tumour-suppressor gene that determines the cellular response to various types of stress(4). Here we report that the biological effects of ING1 and p53 are interrelated and require the activity of both genes: neither of the two genes can, on its own, cause growth inhibition when the other one is suppressed. Furthermore, activation of transcription from the P21/WAF1 promoter, a key mechanism of p53-mediated growth control, depends on the expression of ING1. A physical association between p33(ING1) and p53 proteins has been detected by immunoprecipitation. These results indicate that p33(ING1) is a component of the p53 signalling pathway that cooperates with p53 in the negative regulation of cell proliferation by modulating p53-dependent transcriptional activation.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada; VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Cleveland Clin Fdn, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Calgary; University of Calgary; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Chumakov, Peter/0000-0002-8078-2908				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Helbing CC, 1997, CANCER RES, V57, P1255; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kondratov R. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P613; KOPNIN BP, 1995, ONCOL RES, V7, P299; Maestro R, 1996, CANCER RES, V56, P1146; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ZEREMSKI M, 1997, CELL MOL GENET, V23, P233	18	270	326	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					295	298		10.1038/34675	http://dx.doi.org/10.1038/34675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440695				2022-12-28	WOS:000071484400054
J	Snow, TP; Le Page, V; Keheyan, Y; Bierbaum, VM				Snow, TP; Le Page, V; Keheyan, Y; Bierbaum, VM			The interstellar chemistry of PAH cations	NATURE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; BANDS; MOLECULES; IONS; HYDROGEN; C10H8+; DUST	Diffuse interstellar bands (DIBs) are mysterious absorption lines in the optical spectra of stars, and have been known for 75 years(1). Although it is widely believes(2-4) that they arise from gas-phase organic molecules (rather than from dust grains) in the interstellar medium, no consensus has been reached regarding their precise cause. The realization that many emission features in astronomical infrared spectra probably arise from polycyclic aromatic hydrocarbons(5-8) (PAHs), which may themselves be very abundant in the interstellar medium, has led to the suggestion that ionized PAHs might be the source of the DIBs(9-12). Laboratory investigations have revealed that small, positively charged PAHs in matrices have absorption features that bear some resemblance to DIBs(13-15), but no clear identification of any DIB with any specific PAH cation has yet been made. Here we report a laboratory study of the chemical reactivity of PAH cations (C6H6+, C10H8+ and C16H10+) in the gas phase. We find that these PAH cations are very reactive, and are therefore unlikely to survive in high abundances in the interstellar medium. Rather, such molecules will react rapidly with hydrogen, and we therefore suggest that the resulting protonated PAH cations (and species derived from them) should become the focus of future searches for a correspondence between molecular absorption features and the DIBs.	Univ Colorado, Ctr Astrophys & Space Astron, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; CNR, Ist Chim Nucl, I-00016 Rome, Italy	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Consiglio Nazionale delle Ricerche (CNR)	Snow, TP (corresponding author), Univ Colorado, Ctr Astrophys & Space Astron, Campus Box 389, Boulder, CO 80309 USA.							ABOUELAZIZ H, 1993, J CHEM PHYS, V99, P237, DOI 10.1063/1.465801; ADAMSON AJ, 1991, MON NOT R ASTRON SOC, V252, P234, DOI 10.1093/mnras/252.2.234; Allain T, 1996, ASTRON ASTROPHYS, V305, P602; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; CRAWFORD MK, 1985, ASTROPHYS J, V293, pL45, DOI 10.1086/184488; DEPETRIS G, 1994, INT J MASS SPECTROM, V136, P155, DOI 10.1016/0168-1176(94)04022-2; GILES K, 1989, INT J MASS SPECTROM, V89, P303, DOI 10.1016/0168-1176(89)83066-6; Heger M. L, 1922, LICK OBSERVATORY B, V10, P146; HERBIG GH, 1995, ANNU REV ASTRON ASTR, V33, P19, DOI 10.1146/annurev.aa.33.090195.000315; HOWORKA F, 1978, J CHEM PHYS, V68, P804, DOI 10.1063/1.435866; LEGER A, 1985, ASTRON ASTROPHYS, V146, P81; LEGER A, 1995, ASTRON ASTROPHYS, V293, pL53; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; LePage V, 1997, J AM CHEM SOC, V119, P8373, DOI 10.1021/ja971330v; LEPAGE V, UNPUB J AM CHEM SOC; OMONT A, 1986, ASTRON ASTROPHYS, V164, P159; PETRIE S, 1992, J AM CHEM SOC, V114, P9205, DOI 10.1021/ja00049a072; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; SALAMA F, 1992, ASTROPHYS J, V395, P301, DOI 10.1086/171652; Salama F, 1996, ASTROPHYS J, V458, P621, DOI 10.1086/176844; SALAMA F, 1992, NATURE, V358, P42, DOI 10.1038/358042a0; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Scott GBI, 1997, J PHYS CHEM A, V101, P4973, DOI 10.1021/jp9706947; SETSER DW, 1979, REACTIVE INTERMEDIAT; SNOW TP, 1995, ASTRON ASTROPHYS, V296, pL37; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SNOW TP, 1997, STARDUST PLANETESIMA, P147; Tielens A. G. G. M., 1995, DIFFUSE INTERSTELLAR; TOSI P, 1984, J CHEM PHYS, V80, P1905, DOI 10.1063/1.446951; VANDERZWET GP, 1985, ASTRON ASTROPHYS, V146, P76; VANDOREN JM, 1987, INT J MASS SPECTROM, V81, P85, DOI 10.1016/0168-1176(87)80007-1	32	196	196	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					259	260		10.1038/34602	http://dx.doi.org/10.1038/34602			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440689				2022-12-28	WOS:000071484400041
J	Chiodini, PL				Chiodini, PL			Non-microscopic methods for diagnosis of malaria	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM		Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Chiodini, PL (corresponding author), Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England.							Banchongaksorn T, 1996, B WORLD HEALTH ORGAN, V74, P47; BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; CHIODINI PL, 1996, MDA9633; Craig MH, 1997, T ROY SOC TROP MED H, V91, P279, DOI 10.1016/S0035-9203(97)90074-2; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P1; Humar A, 1997, AM J TROP MED HYG, V56, P44, DOI 10.4269/ajtmh.1997.56.44; Laferi H, 1997, NEW ENGL J MED, V337, P1635, DOI 10.1056/NEJM199711273372219; MAKLER MT, 1993, AM J TROP MED HYG, V48, P205, DOI 10.4269/ajtmh.1993.48.205; Reilly JT, 1997, CLIN LAB HAEMATOL, V19, P165, DOI 10.1111/j.1365-2257.1997.tb00001.x; Singh N, 1997, T ROY SOC TROP MED H, V91, P396, DOI 10.1016/S0035-9203(97)90254-6	10	29	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					80	81		10.1016/S0140-6736(05)78155-1	http://dx.doi.org/10.1016/S0140-6736(05)78155-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439488				2022-12-28	WOS:000071591900005
J	Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER				Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER			Over-the-counter analgesics and risk of ovarian cancer	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLORECTAL-CANCER; COLON-CANCER; ASPIRIN USE	Background Evidence that aspirin and other non-steroidal anti-inflammatory drugs reduce risk for colorectal cancer has prompted interest in their ability to prevent other cancers. We aimed to find out what effect over-the-counter analgesics have on risk of ovarian cancer. Methods In a case-control study we compared use of over-the-counter analgesics by 563 women from eastern Massachusetts and New Hampshire, USA, who had epithelial ovarian cancer with 523 women from the general population. We calculated exposure odds ratios to estimate the effect of over-the-counter analgesics on ovarian cancer risk. Use of over-the-counter analgesics was assessed through interviews and defined as use al least once a week continuously for at least 6 months. Findings The odds ratio for risk of ovarian cancer for aspirin use was 0.75 (95% CI 0.52-1.10), that for ibuprofen was 1.03 (0.64-1.64), and that for paracetamol was 0.52 (0.31-0.86), after adjusting for age, study centre, education, religion, parity, oral contraceptive use, and menstrual, arthritic, or headache pain. Relative to no use, the lower risk of ovarian cancer associated with paracetamol was more apparent for use on a daily basis, 0.39 (0.21-0.74), for more than 10 years of use, 0.40 (0.19-0.88), or for more than 20 tablet years defined as (tablets per dayXyears of use), 0.45 (0.20-0.99). Interpretation In our data, there was a statistically significant inverse association between paracetamol use and ovarian cancer risk. There was a modest but nonsignificant inverse association with aspirin use and ovarian cancer and no association with ibuprofen use. Experimental studies in rodents demonstrating uterine and ovarian atrophy at high doses of paracetamol and decreased ovarian-cyst formation at lower doses suggest a biological basis for our observations.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Dartmouth College; Norris Cotton Cancer Center	Cramer, DW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA 02115 USA.			Harlow, Bernard/0000-0002-6735-8862	NCI NIH HHS [R01 CA 54419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berkel HJ, 1996, EPIDEMIOL REV, V18, P205, DOI 10.1093/oxfordjournals.epirev.a017926; GOODWIN JS, 1981, MED CLIN N AM, V65, P829, DOI 10.1016/S0025-7125(16)31500-0; GREENBERG ER, 1996, IARC SCI PUBL, V139, P91; *INT AG RES CANC W, 1990, IARC MONOGRAPHS; ISENHOWER WD, 1986, BIOL RES PREG PERIN, V7, P6; LOGAN RF, 1993, BRIT MED J, V309, P285; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; *NAT TOX PROGR, 1993, NIH PUBL; PASHA KV, 1989, BRAIN RES BULL, V22, P617, DOI 10.1016/0361-9230(89)90079-8; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; SANTACOLOMA TA, 1991, BIOCHEM BIOPH RES CO, V176, P1256, DOI 10.1016/0006-291X(91)90421-3; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301	15	190	192	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					104	107		10.1016/S0140-6736(97)08064-1	http://dx.doi.org/10.1016/S0140-6736(97)08064-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439495				2022-12-28	WOS:000071591900012
J	Silver, PG; Russo, RM; Lithgow-Bertelloni, C				Silver, PG; Russo, RM; Lithgow-Bertelloni, C			Coupling of South American and African Plate motion and Plate deformation	SCIENCE			English	Article							MID-ATLANTIC RIDGE; GEODYNAMIC MODELS; DRIVING FORCES; MANTLE PLUMES; EVOLUTION; BENEATH; ANISOTROPY; VOLCANISM; TECTONICS; SEAMOUNTS	Although the African Plate's northeastward absolute motion slowed abruptly 30 million years ago, the South Atlantic's spreading velocity has remained roughly constant over the past 80 million years, thus requiring a simultaneous westward acceleration of the South American Plate, This plate velocity correlation occurs because the two plates are coupled to general mantle circulation. The deceleration of the African Plate, due to its collision with the Eurasian Plate, diverts mantle flow westward, increasing the net basal driving torque and westward velocity of the South American Plate. One result of South America's higher plate velocity is the increased cordilleran activity along its western edge, beginning at about 30 million years ago.	Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	Northwestern University; Carnegie Institution for Science	Silver, PG (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.		Lithgow-Bertelloni, Carolina/C-4827-2011; Lithgow-Bertelloni, Carolina/P-3952-2019	Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; Lithgow-Bertelloni, Carolina/0000-0003-0924-6587				ALLMENDINGER RW, 1990, TECTONICS, V9, P789, DOI 10.1029/TC009i004p00789; ALLMENDINGER RW, 1983, TECTONICS, V2, P1, DOI 10.1029/TC002i001p00001; BABY P, 1992, TECTONICS, V11, P523, DOI 10.1029/91TC03090; Burke K, 1996, S AFR J GEOL, V99, P341; Dercourt J, 1993, ATLAS TETHYS PALEOEN; Dixon TH, 1997, GEOPHYS RES LETT, V24, P535, DOI 10.1029/97GL00284; DOUGLASS J, 1995, GEOPHYS RES LETT, V22, P2893, DOI 10.1029/95GL02665; DUNCAN RA, 1984, J GEOPHYS RES, V89, P9980, DOI 10.1029/JB089iB12p09980; GRIPP AE, 1990, GEOPHYS RES LETT, V17, P1109, DOI 10.1029/GL017i008p01109; HARTNADY CJH, 1985, EARTH PLANET SCI LET, V75; Hsu KJ, 1989, GEOL SOC LOND SPEC P, V45, P421, DOI DOI 10.1144/GSL.SP.1989.045.01.23; James DE, 1996, GEOPHYS J INT, V126, P1, DOI 10.1111/j.1365-246X.1996.tb05263.x; Leffler L, 1997, GEOPHYS RES LETT, V24, P1031, DOI 10.1029/97GL00770; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; LITHGOWBERTELLONI C, 1995, GEOPHYS RES LETT, V22, P1317, DOI 10.1029/95GL01325; MADEIRA J, 1990, TECTONOPHYSICS, V184, P405, DOI 10.1016/0040-1951(90)90452-E; MAMMERICKX J, 1986, J GEOPHYS RES-SOLID, V91, P1975, DOI 10.1029/JB091iB02p01975; MEGARD F, 1984, J GEOL SOC LONDON, V141, P893, DOI 10.1144/gsjgs.141.5.0893; MORGAN WJ, 1972, AM ASSOC PETR GEOL B, V56, P203; NORABUENA E, IN PRESS SCIENCE; OCONNOR JM, 1992, EARTH PLANET SC LETT, V113, P343, DOI 10.1016/0012-821X(92)90138-L; OCONNOR JM, 1990, J GEOPHYS RES-SOLID, V95, P17475, DOI 10.1029/JB095iB11p17475; OSAKARSSON N, 1985, J GEOPHYS RES, V90, P10011; Richards MA, 1996, EARTH PLANET SC LETT, V137, P19, DOI 10.1016/0012-821X(95)00209-U; RICHARDS MA, 1994, EOS T AM GEOPHYS UN, V75, P63; Russo RM, 1996, GEOLOGY, V24, P511, DOI 10.1130/0091-7613(1996)024<0511:CFMDAT>2.3.CO;2; RUSSO RM, 1994, SCIENCE, V263, P1105, DOI 10.1126/science.263.5150.1105; SANDWELL DT, IN PRESS J GEOPHYS R; SCHILLING JG, 1994, J GEOPHYS RES-SOL EA, V99, P12005, DOI 10.1029/94JB00337; SCHILLING JG, 1991, NATURE, V352, P397, DOI 10.1038/352397a0; SEMPERE T, 1990, GEOLOGY, V18, P946, DOI 10.1130/0091-7613(1990)018<0946:LOEMMT>2.3.CO;2; SHAW PR, 1990, J GEOPHYS RES-SOLID, V95, P2625, DOI 10.1029/JB095iB03p02625; SHEFFELS BM, 1990, GEOLOGY, V18, P812, DOI 10.1130/0091-7613(1990)018<0812:LBOTAO>2.3.CO;2; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; STEIN S, 1977, EARTH PLANET SC LETT, V36, P51, DOI 10.1016/0012-821X(77)90187-X; Stoddard PR, 1996, J GEOPHYS RES-SOL EA, V101, P5425, DOI 10.1029/95JB03540; TUCHOLKE BE, 1990, J GEOPHYS RES-SOLID, V95, P17555, DOI 10.1029/JB095iB11p17555; UYEDA S, 1979, J GEOPHYS RES, V84, P1049, DOI 10.1029/JB084iB03p01049; VANDECAR JC, 1995, NATURE, V378, P25, DOI 10.1038/378025a0; WIDOM E, UNPUB CHEM GEOL; Zhong SJ, 1996, NATURE, V383, P245, DOI 10.1038/383245a0	41	186	191	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					60	63		10.1126/science.279.5347.60	http://dx.doi.org/10.1126/science.279.5347.60			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417022				2022-12-28	WOS:000071323900037
J	Schacker, T; Hu, HL; Koelle, DM; Zeh, J; Saltzman, R; Boon, R; Shaughnessy, M; Barnum, G; Corey, L				Schacker, T; Hu, HL; Koelle, DM; Zeh, J; Saltzman, R; Boon, R; Shaughnessy, M; Barnum, G; Corey, L			Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons - A double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	3rd National Conference on Human Retroviruses	JAN 31, 1996	WASHINGTON, D.C.			famciclovir; herpes simplex; human immunodeficiency; virus infections; virus latency; virus activation	GENITAL HERPES; ACYCLOVIR-RESISTANT; ORAL ACYCLOVIR; TYPE-2; AIDS; IMMUNODEFICIENCY; PENCICLOVIR; PREVALENCE; IMMUNOBLOT; ANTIBODIES	Background: Herpes simplex virus (HSV) infection is one of the most common opportunistic infections in HIV-infected persons. However, most documentation of the effectiveness of antiviral therapy in reducing HSV reactivation is anecdotal. Objective: To evaluate the quantitative effect of antiviral therapy on the frequency of HSV reactivation in HIV-infected persons. Design: Double-blind, placebo-controlled, crossover trial. Setting: Research clinic at a university hospital. Patients: 48 persons (45 men and 3 women) who were HIV positive and HSV seropositive. Intervention: Patients were randomly assigned to receive famciclovir, 500 mg orally twice dairy, or placebo for 8 weeks. They then crossed over to receive the other regimen after a 1-week washout period. Measurements: Patients obtained daily cultures of their perirectal, urethral, oral, and genital areas and kept diary records of signs and symptoms of genital and oral-labial herpes. Results: The median CD4 cell count at study entry was 384 cells/mm(3). In the intention-to-treat analysis of the first study period, HSV was isolated on 122 of 1114 (11%) placebo days compared with 9 of 1071 (1%) famciclovir days (relative risk, 0.15; P < 0.001). For patients who completed the crossover, the median difference in days with symptoms between placebo and famciclovir was 13.8% of days and the median difference in days on which HSV was isolated was 5.4% of days (P < 0.001 for both). Percentage of days with HSV-2 shedding was reduced from 9.7% to 1.3%. Breakthrough reactivations that occurred while patients were receiving famciclovir were infrequent, short, and often asymptomatic; HSV-2 isolates from these reactivations were susceptible to penciclovir in vitro. Conclusions: Antiviral chemotherapy with famciclovir results in clinically and statistically significant reductions in the symptoms associated with HSV infection and the symptomatic and asymptomatic shedding of HSV among HIV-positive persons.	Univ Washington, Dept Stat, Seattle, WA 98195 USA; SmithKline Beecham, Collegeville, PA 19426 USA	University of Washington; University of Washington Seattle; GlaxoSmithKline	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St,M115, Seattle, WA 98104 USA.		Corey, Lawrence/AAE-1796-2020; Koelle, David/Q-6529-2016	Corey, Lawrence/0000-0002-2179-2436; Koelle, David/0000-0003-1255-9023	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01228] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; AUGENBRAUN M, 1995, ANN INTERN MED, V123, P845, DOI 10.7326/0003-4819-123-11-199512010-00006; BAGDADES EK, 1992, AIDS, V6, P1317, DOI 10.1097/00002030-199211000-00012; BOYD MR, 1993, ANTIVIR CHEM CHEMOTH, V4, P3, DOI 10.1177/095632029300401S01; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; ENZENSBERGER R, 1991, INFECTION, V19, P140, DOI 10.1007/BF01643233; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; HODGE RAV, 1993, ANTIVIR CHEM CHEMOTH, V4, P67, DOI 10.1177/095632029300400201; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P223, DOI 10.1128/AAC.33.2.223; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; MANN SL, 1984, J INFECT DIS, V149, P1026, DOI 10.1093/infdis/149.6.1026; MERTZ GJ, 1990, MED CLIN N AM, V74, P1433, DOI 10.1016/S0025-7125(16)30489-8; MOLE L, IN PRESS J INFECT DI; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; PERRY CM, 1995, DRUGS, V50, P396, DOI 10.2165/00003495-199550020-00011; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; SAFRIN S, 1993, ANTIMICROB AGENTS CH, V37, P2241, DOI 10.1128/AAC.37.10.2241; SAFRIN S, 1991, AIDS, V5, P1107, DOI 10.1097/00002030-199109000-00008; SAFRIN S, 1992, J CLIN MICROBIOL, V30, P1312, DOI 10.1128/JCM.30.5.1312-1314.1992; Schmidt NJ, 1989, DIAGNOSTIC PROCEDURE; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; SWIERKOSZ EM, 1987, ANTIMICROB AGENTS CH, V31, P1465, DOI 10.1128/AAC.31.10.1465; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WENTWORTH BB, 1971, AM J EPIDEMIOL, V94, P496, DOI 10.1093/oxfordjournals.aje.a121347	30	117	123	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					21	+		10.7326/0003-4819-128-1-199801010-00004	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YN342	9424977				2022-12-28	WOS:000071158000004
J	Shigeyoshi, Y; Taguchi, K; Yamamoto, S; Takekida, S; Yan, L; Tei, H; Moriya, T; Shibata, S; Loros, JJ; Dunlap, JC; Okamura, H				Shigeyoshi, Y; Taguchi, K; Yamamoto, S; Takekida, S; Yan, L; Tei, H; Moriya, T; Shibata, S; Loros, JJ; Dunlap, JC; Okamura, H			Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript	CELL			English	Article							RAT SUPRACHIASMATIC NUCLEUS; VASOACTIVE INTESTINAL POLYPEPTIDE; MESSENGER-RNA; CEREBROSPINAL-FLUID; VASOPRESSIN RHYTHM; PHOTIC REGULATION; GENE-EXPRESSION; FEEDBACK LOOP; TIMELESS; NEURONS	To understand how light might entrain a mammalian circadian clock, we examined the effects of light on mPer1, a sequence homolog of Drosophila per, that exhibits robust rhythmic expression in the SCN.mPer1 is rapidly induced by short duration exposure to light at levels sufficient to reset the clock, and dose-response curves reveal that mPer1 induction shows both reciprocity and a strong correlation with phase shifting of the overt rhythm. Thus, in both the phasing of dark expression and the response to light mPer1 is most similar to the Neurospora clock gene fro. Within the SCN there appears to be localization of the induction phenomenon, consistent with the localization of both light-sensitive and light-insensitive oscillators in this circadian center.	Kobe Univ, Sch Med, Dept Anat & Brain Sci, Chuo Ku, Kobe, Hyogo 650, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan; Waseda Univ, Sch Human Sci, Dept Pharmacol & Brain Sci, Tokorozawa, Saitama 359, Japan; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Kobe University; University of Tokyo; Waseda University; Dartmouth College	Okamura, H (corresponding author), Kobe Univ, Sch Med, Dept Anat & Brain Sci, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.		Dunlap, Jay/L-6232-2013; Jansen, Heiko T./A-5770-2008; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; Jansen, Heiko T./0000-0003-0178-396X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034985, R01GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONIN N, 1991, SUPRACHIASMATIC NUCL, P445; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aschoff J., 1981, BIOL RHYTHMS HDB BEH; Ban Y, 1997, J NEUROSCI, V17, P3920; BEST J, 1996, HOW QUICKLY DOES LIG, P105; COLWELL CS, 1992, J COMP NEUROL, V324, P135, DOI 10.1002/cne.903240202; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Davisson M T, 1995, Trends Genet, P35; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; ELLIOT J, 1996, TIME COURSE HAMSTER, P105; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gillette MU, 1996, PROG BRAIN RES, V111, P121, DOI 10.1016/S0079-6123(08)60404-5; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; Hall JC, 1997, CELL, V90, P9, DOI 10.1016/S0092-8674(00)80308-6; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; Hastings MH, 1997, TRENDS NEUROSCI, V20, P459, DOI 10.1016/S0166-2236(97)01087-4; Hastings MH, 1996, PROG BRAIN RES, V111, P147, DOI 10.1016/S0079-6123(08)60406-9; HENDRICKSON AE, 1972, Z ZELLFORSCH MIK ANA, V135, P1, DOI 10.1007/BF00307084; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Millar AJ, 1997, CURR BIOL, V7, pR474, DOI 10.1016/S0960-9822(06)00240-5; MOORE RY, 1973, BRAIN RES, V49, P403, DOI 10.1016/0006-8993(73)90431-9; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; OKAMURA H, 1987, BIOMED RES-TOKYO, V8, P253, DOI 10.2220/biomedres.8.253; OKAMURA H, 1995, MOL BRAIN RES, V29, P358, DOI 10.1016/0169-328X(94)00278-M; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PITTENDRIGH CS, 1996, ANN REV PHYSL, V16, P4182; Qiu J, 1996, MOL CELL BIOL, V16, P4182; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SCHWARTZ WJ, 1983, BRAIN RES, V263, P105, DOI 10.1016/0006-8993(83)91205-2; SCHWARTZ WJ, 1985, J NEUROSCI, V5, P2771; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SHINOHARA K, 1994, NEUROSCI LETT, V170, P183, DOI 10.1016/0304-3940(94)90269-0; SHINOHARA K, 1993, J NEUROSCI, V13, P793; SUN S, 1997, CELL, V90, P1003; SWANSON LW, 1974, J COMP NEUROL, V156, P143, DOI 10.1002/cne.901560203; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WINFREE A, 1976, MOL BASIS CIRCADIAN, P109; WINFREE AT, 1967, J THEOR BIOL, V16, P15, DOI 10.1016/0022-5193(67)90051-3; WINFREE AT, 1971, BIOCHRONOMETRY, P81; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	57	707	722	1	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1043	1053		10.1016/S0092-8674(00)80494-8	http://dx.doi.org/10.1016/S0092-8674(00)80494-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428526	hybrid			2022-12-28	WOS:000071281400020
J	Cruess, SR; Cruess, RL				Cruess, SR; Cruess, RL			Professionalism must be taught	BRITISH MEDICAL JOURNAL			English	Article									McGill Univ, Ctr Med Educ, Montreal, PQ H3A 1A3, Canada	McGill University	Cruess, SR (corresponding author), McGill Univ, Ctr Med Educ, 1110 Pine Ave W, Montreal, PQ H3A 1A3, Canada.							Abelson J, 1997, BRIT MED J, V315, P382, DOI 10.1136/bmj.315.7105.382; [Anonymous], 1989, OXFORD ENGLISH DICT; Cruess RL, 1997, ACAD MED, V72, P941, DOI 10.1097/00001888-199711000-00009; Elliot P, 1972, SOCIOLOGY PROFESSION; Freidson E., 1994, PROFESSIONALISM REBO; Freidson E., 1970, PROFESSIONAL DOMINAN; Freidson E., 1988, PROFESSION MED STUDY; GOODE WJ, 1960, AM SOCIOL REV, V25, P902; Haug Marie R., 1972, SOCIOL REV MONOGR, V20, P195, DOI 10.1111/j.1467-954X.1972.tb03217.x; HUGHES EC, 1960, CAN J ECON POLIT SCI, V26, P54, DOI 10.2307/138818; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; Johnson Terrence, 1972, PROFESSIONS POWER; KLEIN R, 1993, CHANGING MED PROFESS, P202; Kultgen John H., 1988, ETHICS PROFESSIONALI; Larson MS, 1977, RISE PROFESSIONALISM; MCKINLAY JB, 1985, INT J HEALTH SERV, V15, P161, DOI 10.2190/JBMN-C0W6-9WFQ-Q5A6; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; MECHANIC D, 1985, NEW ENGL J MED, V312, P181, DOI 10.1056/NEJM198501173120312; Parsons T, 1939, SOC FORCES, V17, P457, DOI 10.2307/2570695; SAUNDERS ANC, 1928, PROFESSIONS THEIR OR; Sohl P, 1980, SOC SCI MED, V22, P1175; Starr Paul., 1984, SOCIAL TRANSFORMATIO; 1992, TIMES           0316; 1992, TIMES           0302; 1992, TIMES           0310; 1992, TIMES           0308; 1992, TIMES           0623; 1992, TIMES           0224; 1992, TIMES           0203; 1992, TIMES           0217	31	164	171	2	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1674	1677		10.1136/bmj.315.7123.1674	http://dx.doi.org/10.1136/bmj.315.7123.1674			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448538	Green Published			2022-12-28	WOS:000071149400023
J	Prendergast, BD				Prendergast, BD			La salle de garde: bastion of the French lunch hour for junior doctors	BRITISH MEDICAL JOURNAL			English	Article									Hop Lariboisiere, INSERM, Unite Rech Biol & Pathophysiol Syst Cardiovasc, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Prendergast, BD (corresponding author), Hop Lariboisiere, INSERM, Unite Rech Biol & Pathophysiol Syst Cardiovasc, 2 Rue Ambroise Pare, F-75010 Paris, France.							BALLOUL P, 1994, SALLE GARDE PLAISIR, V2, P78	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1708	1709		10.1136/bmj.315.7123.1708	http://dx.doi.org/10.1136/bmj.315.7123.1708			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448548	Green Published			2022-12-28	WOS:000071149400040
J	Croft, A; Garner, P				Croft, A; Garner, P			Mefloquine to prevent malaria: a systematic review of trials	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; PRACTICE GUIDELINES; CONSORT STATEMENT; PROPHYLAXIS; CHEMOPROPHYLAXIS; TOLERABILITY; TRAVELERS; REGIMENS; AUTHORS	Objective: To evaluate the research evidence on the efficacy and tolerability of mefloquine chemoprophylaxis. Search strategy: Any potentially relevant trial from the Cochrane Infectious Disease Group's register of controlled trials; systematic searches of Medline, Embase, Lilacs and Science Citation Index; scanning citations; and consulting drug companies and key investigators. We considered studies in all languages. Inclusion criteria: Trials carried out in non-immune adult travellers, and in non-travelling volunteers, where an attempt had been made to conduct a randomised comparison of mefloquine against placebo or against alternative standard prophylaxis. Results: 37 potentially eligible trials of mefloquine prophylaxis were identified, and 10 met the inclusion criteria These 10 trials comprised a total of 2750 non-immune adult participants randomised to mefloquine or to a control. One placebo controlled trial examined malaria incidence directly and showed mefloquine to be highly effective in preventing malaria in an area of drug resistance. However, four placebo controlled trials showed that mefloquine was not well tolerated, and withdrawals were consistently higher in mefloquine treatment arms than in placebo arms (odds ratio 3.49 (95% confidence interval 1.42 to 8.56)). Five field trials compared mefloquine with other chemoprophylaxis. Mefloquine was no worse tolerated than other chemoprophylaxis, although there was possibly a trend towards higher withdrawals in mefloquine arms (odds ratio 1.33 (0.75 to 2.36)). Conclusion: One trial showed mefloquine to be effective in preventing malaria, but withdrawal rates, presumably from side effects, were high across most studies. This is likely to impair mefloquine's effectiveness in general travellers, and it may therefore not be useful for routine prophylaxis. Mefloquine may be useful in specific situations such as for groups travelling to regions with a high risk of chloroquine resistant malaria and only limited access to effective medical care.	UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,INT HLTH DIV,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND	Liverpool School of Tropical Medicine; University of Liverpool	Croft, A (corresponding author), MINIST DEF,HEADQUARTERS DEF SECONDARY CARE AGCY,ST GILES COURT,LONDON WC2H 8LD,ENGLAND.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941				Altman DG, 1996, BRIT MED J, V313, P570; ARTHUR JD, 1990, LANCET, V335, P972, DOI 10.1016/0140-6736(90)91035-9; ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BEM JL, 1992, J TROP MED HYG, V95, P167; BOUDREAU E, 1993, TROP MED PARASITOL, V44, P257; Bradley D J, 1997, Commun Dis Rep CDR Rev, V7, pR137; *CDC, 1994, HLTH INF INT TRAV; *COCHR COLL, 1997, COCHR COLL HDB; *COMM DEP HUM SERV, 1995, HLTH INF INT TRAV; COOK GC, 1995, BRIT MED J, V311, P190, DOI 10.1136/bmj.311.6998.190b; Corbett EL, 1996, BRIT MED J, V313, P1552, DOI 10.1136/bmj.313.7071.1552b; Corominas N, 1997, MED CLIN-BARCELONA, V108, P772; CROFT A, 1995, BRIT MED J, V311, P191, DOI 10.1136/bmj.311.6998.191b; Croft AMJ, 1996, LANCET, V347, P326, DOI 10.1016/S0140-6736(96)90500-0; Croft AMJ, 1997, T ROY SOC TROP MED H, V91, P199, DOI 10.1016/S0035-9203(97)90223-6; CROFT AMJ, 1997, COCHRANE LIB; CROFT AMJ, UNPUB MEFLOQUINE PRO; Davis TME, 1996, BRIT J CLIN PHARMACO, V42, P415, DOI 10.1111/j.1365-2125.1996.tb00003.x; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Evans MR, 1996, BRIT MED J, V313, P1554, DOI 10.1136/bmj.313.7071.1554b; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P480, DOI 10.1136/bmj.315.7106.480; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; HANDSCHIN J, 1995, LANCET, V346, P1294, DOI 10.1016/S0140-6736(95)91892-2; HELD TK, 1994, Q J MED, V87, P17; HOLLYOAK V, 1995, BRIT MED J, V310, P1329, DOI 10.1136/bmj.310.6990.1329; Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x; INGRAM RJH, 1996, HLTH ADVICE OVERSEAS; *INSP GEZ, 1996, MAL; Jacobson LD, 1997, BRIT J GEN PRACT, V47, P449; Kollaritsch H, 1997, J INFECT DIS, V175, P871, DOI 10.1086/513984; Liberati A, 1997, BRIT MED J, V315, P499, DOI 10.1136/bmj.315.7107.499; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; MacLean M, 1997, NAT MED, V3, P14, DOI 10.1038/nm0197-14; MACPHERSON D, 1997, 5 INT C TRAV MED GEN; Meszaros K, 1996, CAN J PSYCHIAT, V41, P196; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; PERRY IC, 1995, BRIT MED J, V310, P1673, DOI 10.1136/bmj.310.6995.1673a; Phillips, 1996, J Travel Med, V3, P40, DOI 10.1111/j.1708-8305.1996.tb00695.x; *ROYAL COLL GEN PR, 1995, 26 RCGP WORK GROUP; Schlagenhauf P, 1996, TROP MED INT HEALTH, V1, P485, DOI 10.1046/j.1365-3156.1996.d01-85.x; Schlagenhauf P, 1997, AM J TROP MED HYG, V56, P235, DOI 10.4269/ajtmh.1997.56.235; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9; SCOTT M, 1990, MED AUDIT GEN PRACTI, P180; SMITH PG, 1996, FIELD TRIALS HLTH IN, P44; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; TERKUILE FO, 1992, J INFECT DIS, V166, P1393, DOI 10.1093/infdis/166.6.1393; vanRiemsdijk MM, 1997, EUR J CLIN PHARMACOL, V52, P1, DOI 10.1007/s002280050240; Vuurman EFPM, 1996, EUR J CLIN PHARMACOL, V50, P475, DOI 10.1007/s002280050144; West E, 1997, BRIT MED J, V315, P324; *WHO, 1995, INT TRAV HLTH VACC R; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; Woolf SH, 1996, ANNU REV PUBL HEALTH, V17, P511, DOI 10.1146/annurev.pu.17.050196.002455	54	63	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1412	1416		10.1136/bmj.315.7120.1412	http://dx.doi.org/10.1136/bmj.315.7120.1412			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418088	Green Published			2022-12-28	WOS:A1997YJ67200024
J	Krug, EG; Kresnow, MJ; Peddicord, JP; Dahlberg, LL; Powell, KE; Crosby, AE; Annest, JL				Krug, EG; Kresnow, MJ; Peddicord, JP; Dahlberg, LL; Powell, KE; Crosby, AE; Annest, JL			Suicide after natural disasters	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; STRESS; COMMUNITIES; MORTALITY; RECOVERY; DISTRESS; VICTIMS; TERM; WAR	Background Among the victims of floods, earthquakes, and hurricanes, there is an increased prevalence of post-traumatic stress disorder and depression, which are risk factors for suicidal thinking. We conducted this study to determine whether natural disasters affect suicide rates. Methods From a list of all the events declared by the U.S. government to be federal disasters between 1982 and 1989, we selected the 377 counties that had each been affected by a single natural disaster during that period, We collected data on suicides during the 36 months before and the 48 months after the disaster and aligned the data around the month of the disaster. Pooled rates were calculated according to the type of disaster. Comparisons were made between the suicide rates before and those after disasters in the affected counties and in the entire United States. Results Suicide rates increased in the four years after floods by 13.8 percent, from 12.1 to 13.8 per 100,000 (P<0.001); in the two years after hurricanes by 31.0 percent, from 12.0 to 15.7 per 100,000 (P<0.001); and in the first year after earthquakes by 62.9 percent, from 19.2 to 31.3 per 100,000 (P<0.001). The four-year increase of 19.7 percent after earthquakes was not statistically significant. Rates computed in a similar manner for the entire United States were stable. The increases in suicide rates were found for both sexes and for all age groups. The suicide rates did not change significantly after tornadoes or severe storms. Conclusions Our study shows that suicide rates increase after severe earthquakes, floods, and hurricanes and confirms the need for mental health support after severe disasters. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Krug, EG (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Injury Prevent & Control, Mailstop K-60,4770 Buford Hwy, Atlanta, GA 30341 USA.							ANDERSON RN, 1997, MON VITAL STAT RE S2, V45, P77; [Anonymous], 1997, PUBLIC HLTH CONSEQUE; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; Bolin R., 1985, DISASTERS MENTAL HLT, P3; BRAVO M, 1990, AM J COMMUN PSYCHOL, V18, P661, DOI 10.1007/BF00931236; BROMET E, 1995, EPIDEMIOL REV, V17, P113, DOI 10.1093/oxfordjournals.epirev.a036166; *CDC, 1989, CDC MON; *CTR MET HLTH SERV, 1994, DIS RESP REC HDB MEN, P2; FREEDY JR, 1994, J TRAUMA STRESS, V7, P257, DOI 10.1002/jts.2490070207; HAYNES MA, 1990, PREVENTING DIS RHETO, P129; IMAMURA K, 1995, LANCET, V346, P509, DOI 10.1016/S0140-6736(95)91360-2; KANIASTY KZ, 1990, J APPL SOC PSYCHOL, V20, P85, DOI 10.1111/j.1559-1816.1990.tb00401.x; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; LAUDISIO G, 1993, J ALLIANCE INF REFER, V15, P13; LESTER D, 1993, EUR ARCH PSY CLIN N, V242, P248, DOI 10.1007/BF02189971; Lew EO, 1996, J FORENSIC SCI, V41, P449; LIMA BR, 1993, J NERV MENT DIS, V181, P388, DOI 10.1097/00005053-199306000-00009; LOGUE JN, 1981, PUBLIC HEALTH REP, V96, P67; LOGUE JN, 1981, EPIDEMIOL REV, V3, P140, DOI 10.1093/oxfordjournals.epirev.a036231; Maida CA., 1989, J TRAUMA STRESS, V2, P37; MURPHY SA, 1986, RES NURS HEALTH, V9, P331, DOI 10.1002/nur.4770090410; *NAT I STAND TECHN, 1990, FED INF PROC STAND P; Noji Eric K., 1997, PUBLIC HLTH CONSEQUE, P101; OLLENDICK DG, 1982, J COMMUNITY PSYCHOL, V10, P157, DOI 10.1002/1520-6629(198204)10:2<157::AID-JCOP2290100209>3.0.CO;2-8; PERRY RW, 1978, MASS EMERGENCIES, V3, P105; QUARANTELLI EL, 1985, TRAUMA ITS WAKE, P173; ROBINS LN, 1986, DISASTER STRESS STUD, P21; Rossi P. H., 1983, INT J MASS EMERGENCI, V1, P467; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P171; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; SHORE JH, 1986, AM J PUBLIC HEALTH, V76, P76, DOI 10.2105/AJPH.76.Suppl.76; Solomon S.D., 1992, PTSD RES Q, V3, P1; SOMASUNDARAM DJ, 1995, ACTA PSYCHIAT SCAND, V91, P1, DOI 10.1111/j.1600-0447.1995.tb09733.x; STEINGLASS P, 1990, J APPL SOC PSYCHOL, V20, P1746, DOI 10.1111/j.1559-1816.1990.tb01509.x; Warheit GJ, 1996, J CHILD PSYCHOL PSYC, V37, P435, DOI 10.1111/j.1469-7610.1996.tb01424.x; WHO (World Health Organization), 1977, MAN INT STAT CLASS D	36	115	122	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					373	378		10.1056/NEJM199802053380607	http://dx.doi.org/10.1056/NEJM199802053380607			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YV426	9449732				2022-12-28	WOS:000071822200007
J	Saint, S; Saha, S; Tierney, LM				Saint, S; Saha, S; Tierney, LM			A square peg in a round hole	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-CELL CARCINOMA; NEPHRECTOMY; DIAGNOSIS		Univ Washington, Hlth Sci Ctr H220A, Robert Wood Johnson Clin Scholars Program, Dept Med, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Saint, S (corresponding author), Univ Washington, Hlth Sci Ctr H220A, Robert Wood Johnson Clin Scholars Program, Dept Med, 1959 Pacific Ave NE,Box 357183, Seattle, WA 98195 USA.		Saint, Sanjay/AAF-5126-2019					BENNETT RT, 1995, J UROLOGY, V154, P32, DOI 10.1016/S0022-5347(01)67217-3; Creevy CD, 1935, ARCH INTERN MED, V55, P895, DOI 10.1001/archinte.1935.00160240024002; Dennison DK, 1996, J PERIODONTOL, V67, P166; DURHAM JR, 1961, JAMA-J AM MED ASSOC, V175, P757, DOI 10.1001/jama.1961.03040090017003; FANTA CH, 1980, THORAX, V35, P794, DOI 10.1136/thx.35.10.794; FRANK W, 1994, J UROLOGY, V152, P1998, DOI 10.1016/S0022-5347(17)32289-9; Franklin J R, 1996, Semin Urol Oncol, V14, P230; Guinan P, 1997, J SURG ONCOL, V64, P295, DOI 10.1002/(SICI)1096-9098(199704)64:4<295::AID-JSO8>3.0.CO;2-4; Jobe B A, 1993, Nebr Med J, V78, P349; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KASSIRER JP, 1991, HOSP PRACT, V26, P29; KATZ PP, 1991, DIABETES CARE, V14, P375, DOI 10.2337/diacare.14.5.375; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEIFER D, 1991, NEW ENGL J MED, V325, P1723; MARCUS SG, 1993, J UROLOGY, V150, P463, DOI 10.1016/S0022-5347(17)35514-3; MARGOLIS ML, 1985, SOUTHERN MED J, V78, P757, DOI 10.1097/00007611-198506000-00040; MARINI JJ, 1980, WESTERN J MED, V132, P77; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; PALGON N, 1986, UROLOGY, V28, P516, DOI 10.1016/0090-4295(86)90156-1; WEINBERG BA, 1989, CLIN CARDIOL, V12, P289, DOI 10.1002/clc.4960120512; WOLF JS, 1994, J SURG ONCOL, V55, P7, DOI 10.1002/jso.2930550104	21	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					379	383		10.1056/NEJM199802053380608	http://dx.doi.org/10.1056/NEJM199802053380608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449733				2022-12-28	WOS:000071822200008
J	Bockarie, MJ; Alexander, NDE; Hyun, P; Dimber, Z; Bockarie, F; Ibam, E; Alpers, MP; Kazura, JW				Bockarie, MJ; Alexander, NDE; Hyun, P; Dimber, Z; Bockarie, F; Ibam, E; Alpers, MP; Kazura, JW			Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes	LANCET			English	Article							PAPUA-NEW-GUINEA; LYMPHATIC FILARIASIS; VECTOR CONTROL; MICROFILAREMIA; TRANSMISSION; FACILITATION; EFFICACY	Background WHO has targeted lymphatic filariasis for elimination. Studies of vector-parasite relations of Wuchereria bancrofti suggest that a reduction in the microfilarial reservoir by mass chemotherapy may interrupt transmission and thereby eliminate infection. However, no field data exist on the impact of chemotherapy alone on vector efficiency and transmission intensity of W bancrofti. We compared the impact of an annual community-wide single-dose treatment with diethylcarbamazine alone or with ivermectin on rate and intensity of microfilaraemia, and transmission intensity in an area of Papua New Guinea endemic for intense W bancrofti transmission. Methods We carried out clinical and parasitological surveys in 14 communities in matched pairs. People aged 5 years or older in seven communities received randomly assigned diethylcarbamazine 6 mg/kg and people in the other seven communities received diethylcarbamazine 6 mg/kg plus ivermectin 400 mu g/kg. We made physical examinations for hydroceles and leg oedema and investigated microfilarial densities by membrane filtration before and after treatment. We selected five communities for monthly entomological surveys between September, 1993, and September, 1995. Mosquitoes were collected in these communities by the all-night landing catch method and were individually dissected to identify rates of infection and infectiveness. Findings 2219 (87.6%) of 2534 eligible people received treatment. Microfilarial rate and density had decreased 1 year after treatment in all 14 communities; this decrease was significantly higher in communities given combined therapy than in those given diethylcarbamazine alone (mean decreases 57.5% and 30.6%, respectively; p=0.0013). Greater decreases were also seen in community-specific microfilarial intensity with combined therapy (mean reductions 91.1% and 69.8%, respectively;p=0.0047). The rate of leg oedema was not altered, but the frequency of advanced hydroceles decreased by 47% with combined therapy and 56% with diethylcarbamazine alone. 26641 Anopheles punctulatus mosquitoes were caught during 499 person-nights of landing catches. Exposure to infective third-stage larvae decreased in all monitored five communities. Annual transmission potential decreased by between 75.7% and 98.8% in combined-therapy communities and between 75.6% and 79.4% in communities given diethylcarbamazine alone, Transmission was almost interrupted in two communities treated with combined therapy. Interpretation Annual single-dose community-wide treatment with diethylcarbamazine alone or with ivermectin is effective for the control of lymphatic filariasis in highly endemic areas, but combination therapy brings about greater decreases in rates and intensity of microfilaraemia.	Case Western Reserve Univ, Sch Med, Div Geog Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Papua New Guinea Inst Med Res, Madang, Papua N Guinea; Papua New Guinea Inst Med Res, Goroka, Papua N Guinea; Univ Cambridge, Dept Zool, Cambridge, England	Case Western Reserve University; University Hospitals of Cleveland; PNG Institute Of Medical Research; PNG Institute Of Medical Research; University of Cambridge	Kazura, JW (corresponding author), Case Western Reserve Univ, Sch Med, Div Geog Med, 2109 Adelbert Rd, Cleveland, OH 44106 USA.		Bockarie, Moses/AAW-3130-2021; Bockarie, Moses/AAV-4578-2020					ADDISS DG, 1993, AM J TROP MED HYG, V48, P178, DOI 10.4269/ajtmh.1993.48.178; [Anonymous], 1996, TDR News, P1; [Anonymous], 1984, World Health Organ Tech Rep Ser, V702, P3; BAIN O, 1972, Annales de Parasitologie Humaine et Comparee, V47, P399; BAIN O, 1971, Annales de Parasitologie Humaine et Comparee, V46, P613; Balakrishnan N, 1992, J Commun Dis, V24, P87; BRENGUES J., 1969, Cahiers ORSTOM, Serie Entomologie Medicale et Parasiiologie, V7, P279; Brockarie M, 1996, AM J TROP MED HYG, V54, P577, DOI 10.4269/ajtmh.1996.54.577; CHARLWOOD DJ, 1987, ANN TROP MED PARASIT, V81, P429; DESOLE G, 1990, ACT LEIDENS, V59, P119; DESOWITZ RS, 1974, AM J TROP MED HYG, V23, P877, DOI 10.4269/ajtmh.1974.23.877; DREYER G, 1995, T ROY SOC TROP MED H, V89, P98, DOI 10.1016/0035-9203(95)90674-6; KAZURA J, 1993, AM J TROP MED HYG, V49, P804, DOI 10.4269/ajtmh.1993.49.804; Kazura JW, 1997, J INFECT DIS, V176, P242, DOI 10.1086/514030; MAXWELL CA, 1990, T ROY SOC TROP MED H, V84, P709, DOI 10.1016/0035-9203(90)90158-B; MEYERWITSCH DW, 1996, T R SOC TROP MED HYG, V90, P69; Michael E, 1996, PARASITOLOGY, V112, P409, DOI 10.1017/S0031182000066646; Moulia-Pelat J. P., 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P124; MOULIAPELAT JP, 1995, TROP MED PARASITOL, V46, P9; NELSON G S, 1958, Bull World Health Organ, V19, P204; Noroes J, 1997, T ROY SOC TROP MED H, V91, P78, DOI 10.1016/S0035-9203(97)90405-3; OTTESEN EA, 1990, NEW ENGL J MED, V322, P1113, DOI 10.1056/NEJM199004193221604; OTTESEN EA, 1995, PARASITOL TODAY, V11, P129, DOI 10.1016/0169-4758(95)80128-6; ROYSTON P, 1993, STATISTICIAN, V42, P37, DOI 10.2307/2348109; SCHUURKAMP GJ, 1994, PAPUA NEW GUINEA MED, V37, P65; SMITH PG, 1991, METHODS FIELD TRIALS; SOUTHGATE BA, 1992, T ROY SOC TROP MED H, V86, P523, DOI 10.1016/0035-9203(92)90096-U; SOUTHGATE BA, 1992, J TROP MED HYG, V95, P79; Turner J, 1997, LANCET, V349, P1639, DOI 10.1016/S0140-6736(05)62631-1; WADA Y, 1995, TROP MED PARASITOL, V46, P27; WALSH JF, 1978, T ROY SOC TROP MED H, V72, P675, DOI 10.1016/0035-9203(78)90039-1; WEBBER RH, 1991, J TROP MED HYG, V94, P241; WEBBER RH, 1979, T ROY SOC TROP MED H, V73, P722, DOI 10.1016/0035-9203(79)90031-2; Williams CB, 1937, ANN APPL BIOL, V24, P404, DOI 10.1111/j.1744-7348.1937.tb05042.x	34	86	89	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					162	168		10.1016/S0140-6736(97)07081-5	http://dx.doi.org/10.1016/S0140-6736(97)07081-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449870				2022-12-28	WOS:000071616300009
J	Mergener, K; Baillie, J				Mergener, K; Baillie, J			Fortnightly review - Acute pancreatitis	BRITISH MEDICAL JOURNAL			English	Review							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; CLASSIFICATION; PSEUDOCYSTS; PREVENTION; MANAGEMENT; TRIAL; TESTS		Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA	Duke University	Baillie, J (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA.							AGARWAL N, 1990, AM J GASTROENTEROL, V85, P356; AHEARNE PM, 1992, AM J SURG, V163, P111, DOI 10.1016/0002-9610(92)90262-P; Baillie J, 1997, NEW ENGL J MED, V336, P286, DOI 10.1056/NEJM199701233360409; BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; BANERJEE AK, 1995, POSTGRAD MED J, V71, P472, DOI 10.1136/pgmj.71.838.472; Banks PA, 1997, AM J GASTROENTEROL, V92, P377; BAXTER JN, 1991, LANCET, V338, P52; BLANEY SL, 1984, GUT, V25, P1340; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; Cavallini G, 1996, NEW ENGL J MED, V335, P919, DOI 10.1056/NEJM199609263351302; CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; DOMINGUEZMUNOZ JE, 1993, PANCREAS, V8, P682, DOI 10.1097/00006676-199311000-00003; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; Fitz RH, 1889, BOSTON MED SURG J, V120, P229; Fitz RH, 1889, BOSTON MED SURG J, V70, P181, DOI DOI 10.1056/NEJM188902211200801; GORELICK FS, 1995, TXB GASTROENTEROLOGY, P2064; HOWELL DA, 1993, GASTROINTEST ENDOSC, V39, P693, DOI 10.1016/S0016-5107(93)70225-4; Johnson CD, 1996, BRIT J SURG, V83, P883, DOI 10.1002/bjs.1800830703; Kemppainen EA, 1997, NEW ENGL J MED, V336, P1788, DOI 10.1056/NEJM199706193362504; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LUITEN EJT, 1995, ANN SURG, V222, P57, DOI 10.1097/00000658-199507000-00010; MARSHALL JB, 1993, ARCH INTERN MED, V153, P1185, DOI 10.1001/archinte.153.10.1185; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; Ranson J H, 1995, Adv Surg, V28, P93; RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SOERGEL KH, 1993, GASTROINTESTINAL DIS, P1628; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; TENNER S, 1994, AM J GASTROENTEROL, V89, P1863; VENTRUCCI M, 1987, PANCREAS, V2, P506, DOI 10.1097/00006676-198709000-00003; WANG SS, 1988, PANCREAS, V3, P153, DOI 10.1097/00006676-198804000-00007; WILSON C, 1990, BRIT J SURG, V77, P731, DOI 10.1002/bjs.1800770705	32	42	47	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					44	48		10.1136/bmj.316.7124.44	http://dx.doi.org/10.1136/bmj.316.7124.44			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451268	Green Published			2022-12-28	WOS:000071377900026
J	Zlokarnik, G; Negulescu, PA; Knapp, TE; Mere, L; Burres, N; Feng, LX; Whitney, M; Roemer, K; Tsien, RY				Zlokarnik, G; Negulescu, PA; Knapp, TE; Mere, L; Burres, N; Feng, LX; Whitney, M; Roemer, K; Tsien, RY			Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter	SCIENCE			English	Article							ESCHERICHIA-COLI; T-LYMPHOCYTES; GENE; PROTEINS; CEPHALOSPORIN; SECRETION; SEQUENCE; RECEPTOR; REAGENT; REVEALS	Gene expression was visualized in single living mammalian cells with beta-lactamase as a reporter that hydrolyzes a substrate loaded intracellularly as a membrane-permeant ester. Each enzyme molecule changed the fluorescence of many substrate molecules from green to blue by disrupting resonance energy transfer. This wavelength shift was detectable by eye or color film in individual cells containing less than 100 beta-lactamase molecules. The robust change in emission ratio reveals quantitative heterogeneity in real-time gene expression, enables clonal selection by flow cytometry, and forms a basis for high-throughput screening of pharmaceutical candidate drugs in living mammalian cells.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Saarland, D-66421 Homburg, Germany; Aurora Biosci, San Diego, CA 92121 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Saarland University	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.				NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; JONES RN, 1982, J CLIN MICROBIOL, V15, P677, DOI 10.1128/JCM.15.4.677-683.1982; JONES RN, 1982, J CLIN MICROBIOL, V15, P954, DOI 10.1128/JCM.15.5.954-958.1982; KADONAGA JT, 1984, J BIOL CHEM, V259, P2149; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MATAGNE A, 1990, BIOCHEM J, V265, P131, DOI 10.1042/bj2650131; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Moore JT, 1997, ANAL BIOCHEM, V247, P203, DOI 10.1006/abio.1997.2092; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PAGE MI, 1987, ADV PHYS ORG CHEM, V23, P165, DOI 10.1016/S0065-3160(08)60204-X; RAZ E, COMMUNICATION; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TSIEN RY, 1996, Patent No. 30540; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WINGENDER E, 1982, ANAL BIOCHEM, V127, P351, DOI 10.1016/0003-2697(82)90186-5	26	538	632	3	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					84	88		10.1126/science.279.5347.84	http://dx.doi.org/10.1126/science.279.5347.84			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417030				2022-12-28	WOS:000071323900045
J	Pignoni, F; Hu, BR; Zavitz, KH; Xiao, JA; Garrity, PA; Zipursky, SL				Pignoni, F; Hu, BR; Zavitz, KH; Xiao, JA; Garrity, PA; Zipursky, SL			The eye-specification proteins so and eya form a complex and regulate multiple steps in Drosophila eye development	CELL			English	Article							HOMEOBOX-CONTAINING GENE; SINE OCULIS GENE; 2-HYBRID SYSTEM; NERVOUS-SYSTEM; VISUAL-SYSTEM; EYELESS GENE; EXPRESSION; FAMILY; ANIRIDIA; HOMOLOG	sine oculis (so) and eyes absent (eya) are required for Drosophila eye development and are founding members of the mammalian Six and Eya gene families. These genes have been proposed to act with eyeless (Pax6) to regulate eye development in vertebrates and invertebrates. so encodes a highly diverged homeobox transcription factor and eya encodes a novel nuclear protein. We demonstrate that So and Eya (1) regulate common steps in eye development including cell proliferation, patterning, and neuronal development; (2) synergize in inducing ectopic eyes; and (3) interact in yeast and in vitro through evolutionarily conserved domains. We propose that an So/Eya complex regulates multiple steps in eye development and functions within the context of a network of genes to specify eye tissue identity.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zipursky, SL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Zipursky, Stephen/0000-0001-5630-7181; Garrity, Paul/0000-0002-8274-6564				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; Chanut F, 1997, DEVELOPMENT, V124, P559; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; Oliver G, 1995, DEVELOPMENT, V121, P4045; OLIVER G, 1995, DEVELOPMENT, V121, P693; Pignoni F, 1997, DEVELOPMENT, V124, P271; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SERIKAKU MA, 1994, GENETICS, V138, P1137; Shen WP, 1997, DEVELOPMENT, V124, P45; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; Tio M, 1997, DEVELOPMENT, V124, P343; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; Wolff Tanya, 1993, P1277; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; Xu PX, 1997, DEVELOPMENT, V124, P219; XU T, 1993, DEVELOPMENT, V117, P1223; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	40	471	479	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					881	891		10.1016/S0092-8674(00)80480-8	http://dx.doi.org/10.1016/S0092-8674(00)80480-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428512	Bronze			2022-12-28	WOS:000071281400006
J	Oppenheim, D; Simonds, C; Hartmann, O				Oppenheim, D; Simonds, C; Hartmann, O			Clowning on children's wards	LANCET			English	Article									Inst Gustave Roussy, Dept Paediat, Unit Psychiat & Psychooncol, F-94805 Villejuif, France; Le Rire Med, Paris, France	UNICANCER; Gustave Roussy	Oppenheim, D (corresponding author), Inst Gustave Roussy, Dept Paediat, Unit Psychiat & Psychooncol, Rue Camille Desmoulins, F-94805 Villejuif, France.							CAVELL S, 1979, WITTGENSTEIN SKEPTIC, P452; JAMISON RN, 1986, J ADOLESCENT HEALTH, V7, P162, DOI 10.1016/S0197-0070(86)80032-8; KUPST MJ, 1994, PEDIAT PSYCHOONCOLOG, P35; MALONEY MJ, 1982, J AM ACAD CHILD PSY, V21, P481, DOI 10.1016/S0002-7138(09)60798-6; MASERA G, 1993, MED PEDIATR ONCOL, V21, P627, DOI 10.1002/mpo.2950210903; Oppenheim D, 1996, ENFANT CANC TRAVERSE; PENDERGRASS TW, 1981, AM J PEDIAT HEMATOL, V3, P339; PFEFFERBAUM B, 1989, HDB PSYCHOONCOLOGY, P544; RAIMBAULT G, 1991, SER DEATH E, P177; SOURKES BM, 1995, ARMFULLS TIME PSYCHO; Winnicott D., 1971, PLAYING REALITY; WINNICOTT DW, 1968, INT J PSYCHOANAL, V49, P591	12	25	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1838	1840		10.1016/S0140-6736(97)07296-6	http://dx.doi.org/10.1016/S0140-6736(97)07296-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YM803	9428266				2022-12-28	WOS:000071102500045
J	Sharrack, B; Hughes, RAC				Sharrack, B; Hughes, RAC			Reliability of distance estimation by doctors and patients: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							DISABILITY LIVING ALLOWANCE; MULTIPLE-SCLEROSIS; DISEASE	Objective: To assess the reliability and accuracy of distance estimated by doctors and patients. Design: Comparison between estimated and measured distances of six familiar sites around Guy's Hospital, London. Subjects: 100 hospital consultants and 100 patients. Main outcome measures: Median (range) of estimated distances, and mean (SD) of the difference between estimated and measured distances. Results: Both doctors and patients gave a wide range of estimates of distance. The estimates differed by up to 14.6-fold from the measured distances, and the difference between minimum and maximum estimates was up to 62.5-fold. Conclusion: Doctors and patients were inaccurate at estimating distances, which implies that estimates of distances walked are not reliable indicators of a person's health.	United Med & Dent Sch Guys & St Thomas Hosp, Guys Hosp, Dept Neurol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Hughes, RAC (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Guys Hosp, Dept Neurol, London SE1 9RT, England.							BERNSTEIN ML, 1994, CHEST, V105, P163, DOI 10.1378/chest.105.1.163; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; FINE BJ, 1983, PERCEPT MOTOR SKILL, V57, P3, DOI 10.2466/pms.1983.57.1.3; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Sharrack B, 1996, J NEUROL SCI, V135, P1, DOI 10.1016/0022-510X(95)00261-Y; SINCLAIR DJM, 1980, BMJ-BRIT MED J, V280, P519, DOI 10.1136/bmj.280.6213.519; STEADMAN P, 1993, ARCH DIS CHILD, V68, P73, DOI 10.1136/adc.68.1.73; STEADMAN P, 1992, BRIT MED J, V305, P893, DOI 10.1136/bmj.305.6858.893-c	9	21	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1652	1654		10.1136/bmj.315.7123.1652	http://dx.doi.org/10.1136/bmj.315.7123.1652			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448528	Green Published			2022-12-28	WOS:000071149400011
J	Watanabe, T; Ashikaga, T; Nishizaki, M; Yamawake, N; Arita, M				Watanabe, T; Ashikaga, T; Nishizaki, M; Yamawake, N; Arita, M			Association of insulin with QTc dispersion	LANCET			English	Article							RISK		Yokohama Minaml Kyosai Hosp, Dept Endocrinol & Metab, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Yokohama Minaml Kyosai Hosp, Dept Cardiol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan		Watanabe, T (corresponding author), Yokohama Minaml Kyosai Hosp, Dept Endocrinol & Metab, Kanazawa Ku, Mutsuura Cho 500, Yokohama, Kanagawa 236, Japan.			Ashikaga, Takashi/0000-0003-2790-9436; Watanabe, Takayuki/0000-0003-2924-2022				ASHIKAGA T, 1995, CIRCULATION S1, V92, P1480; DAY CP, 1990, BRIT HEART J, V63, P342; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Suzuki U, 1996, J AM COLL CARDIOL, V27, P1458, DOI 10.1016/0735-1097(96)00011-3; WEI K, 1995, J AM COLL CARDIOL, V26, P859, DOI 10.1016/0735-1097(95)00279-8	5	29	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	1997	350	9094					1821	1822		10.1016/S0140-6736(05)63637-9	http://dx.doi.org/10.1016/S0140-6736(05)63637-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428258				2022-12-28	WOS:000071102500016
J	Adam, J				Adam, J			ABC of palliative care - The last 48 hours	BRITISH MEDICAL JOURNAL			English	Article									Hunter Hill Marie Curie Ctr, Glasgow, Lanark, Scotland		Adam, J (corresponding author), Hunter Hill Marie Curie Ctr, Glasgow, Lanark, Scotland.								0	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1600	1603		10.1136/bmj.315.7122.1600	http://dx.doi.org/10.1136/bmj.315.7122.1600			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437282	Green Published			2022-12-28	WOS:000071021900032
J	Thompson, NS; Henderson, SA				Thompson, NS; Henderson, SA			Lesson of the week - Long term sequelae of missed tendon injuries at the ankle	BRITISH MEDICAL JOURNAL			English	Review									QUEENS UNIV BELFAST,MUSGRAVE PK HOSP,BELFAST BT9 7JB,ANTRIM,NORTH IRELAND	Queens University Belfast								CITRON N, 1985, INJURY, V16, P610, DOI 10.1016/0020-1383(85)90009-9; JOHNSON KA, 1983, CLIN ORTHOP RELAT R, V177, P140; KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349, DOI 10.1177/107110079401500701; LICKSCHIFFER W, WIEN MED WOCHENSCHR, V146, P121; MASTERSON E, 1994, J BONE JOINT SURG BR, V76B, P444, DOI 10.1302/0301-620X.76B3.8175850; SOBEL M, 1990, FOOT ANKLE, V11, P124, DOI 10.1177/107110079001100302; SOUTER W. A., 1967, J BONE JOINT SURG B BRIT, V49, P710	7	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1528	1529		10.1136/bmj.315.7121.1528	http://dx.doi.org/10.1136/bmj.315.7121.1528			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420499	Green Published			2022-12-28	WOS:A1997YK98600031
